PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	HERWALDT, BL; NEVA, FA; BERMAN, JD				HERWALDT, BL; NEVA, FA; BERMAN, JD			ALLOPURINOL IN THE TREATMENT OF AMERICAN CUTANEOUS LEISHMANIASIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							EFFICACY		NIH,BETHESDA,MD 20892; WALTER REED ARMY MED CTR,WASHINGTON,DC 20307	National Institutes of Health (NIH) - USA; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	HERWALDT, BL (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							BALLOU WR, 1987, LANCET, V2, P13; BELAZZOUG S, 1986, T ROY SOC TROP MED H, V80, P670, DOI 10.1016/0035-9203(86)90176-8; CONVIT J, 1989, J INFECT DIS, V160, P104, DOI 10.1093/infdis/160.1.104; GUDERIAN RH, 1991, AM J TROP MED HYG, V45, P92, DOI 10.4269/ajtmh.1991.45.92; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; Saenz R E, 1987, Rev Med Panama, V12, P148; SAENZ RE, 1990, AM J MED, V89, P147, DOI 10.1016/0002-9343(90)90292-L	8	10	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					498	498						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625745				2022-12-28	WOS:A1992JH34000021
J	SAGAN, LA				SAGAN, LA			EPIDEMIOLOGIC AND LABORATORY STUDIES OF POWER FREQUENCY ELECTRIC AND MAGNETIC-FIELDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							60-HZ ELECTROMAGNETIC-FIELDS; HUMAN LYMPHOID-CELLS; 2 SEASONAL SOURCES; CHILDHOOD-CANCER; PERIPHERAL LYMPHOCYTES; WIRING CONFIGURATIONS; OVERHEAD POWERLINES; MAMMALIAN-CELLS; LOW-LEVEL; EXPOSURE				SAGAN, LA (corresponding author), ELECT POWER RES INST,DIV ENVIRONM,3412 HILLVIEW AVE,POB 10412,PALO ALTO,CA 94303, USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; BARIS D, 1990, BRIT J IND MED, V47, P788; BARNES F, 1989, BIOELECTROMAGNETICS, V10, P13, DOI 10.1002/bem.2250100103; BENIASHVILI DS, 1991, CANCER LETT, V61, P75, DOI 10.1016/0304-3835(91)90079-W; BLACKMAN CF, 1988, BIOELECTROMAGNETICS, V9, P215, DOI 10.1002/bem.2250090303; BLASK DE, 1990, EXTREMELY LOW FREQUE; BROADBENT DE, 1985, BRIT J IND MED, V42, P75; BUNIN GR, 1990, AM J EPIDEMIOL, V131, P776, DOI 10.1093/oxfordjournals.aje.a115568; BYUS CV, 1987, CARCINOGENESIS, V8, P1385, DOI 10.1093/carcin/8.10.1385; CHERNOFF N, IN PRESS TOXICOLOGY; COHEN MM, 1986, BIOELECTROMAGNETICS, V7, P415, DOI 10.1002/bem.2250070409; COHEN MM, 1986, MUTAT RES, V172, P177, DOI 10.1016/0165-1218(86)90073-X; COLEMAN MP, 1989, BRIT J CANCER, V60, P793, DOI 10.1038/bjc.1989.362; DAVIS MK, 1988, LANCET, V2, P365; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; GAMBERALE F, 1992, SCAND J WORK ENV HEA, V16, P51; GOODMAN R, 1990, 12TH ANN M BIOEL SOC; GRAHAM C, 1990, IMMUNOLOGICAL BIOCH; GUAGER JR, 1986, IEEE T POWER APPARAT, V140, P2436; JAUCHEM JR, 1991, J CLIN EPIDEMIOL, V44, P895, DOI 10.1016/0895-4356(91)90052-B; KIRSCHVINK J, IN PRESS P NATL ACAD; Kirschvink J. L., 1985, MAGNETITE BIOMINERAL, V1st; KLAUENBERG BJ, 1991, AM J EPIDEMIOL, V134, P913, DOI 10.1093/oxfordjournals.aje.a116166; KNAVE B, 1979, SCAND J WORK ENV HEA, V5, P115, DOI 10.5271/sjweh.2661; KOROBKOVA VP, 1972, AUG INT C LARG HIGH; LERCHL LA, 1991, J PINEAL RES, V10, P109; LIVINGSTON GK, 1991, ENVIRON MOL MUTAGEN, V17, P49, DOI 10.1002/em.2850170108; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; LOVSUND P, 1980, MED BIOL ENG COMPUT, V18, P326, DOI 10.1007/BF02443387; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; MCDOWALL ME, 1986, BRIT J CANCER, V53, P271, DOI 10.1038/bjc.1986.45; MCGIVERN RF, 1990, TERATOLOGY, V41, P1, DOI 10.1002/tera.1420410102; MCLEAN JR, 1991, 13TH ANN M BIOEL SOC; MYERS A, 1990, BRIT J CANCER, V62, P1008, DOI 10.1038/bjc.1990.428; NASCA PC, 1988, AM J EPIDEMIOL, V128, P1256, DOI 10.1093/oxfordjournals.aje.a115079; NORDENSON I, 1988, RADIAT ENVIRON BIOPH, V27, P39, DOI 10.1007/BF01211108; NORDSTROM S, 1983, BIOELECTROMAGNETICS, V4, P91, DOI 10.1002/bem.2250040109; PERRY FS, 1981, HEALTH PHYS, V41, P267, DOI 10.1097/00004032-198108000-00003; PITOT HC, 1991, FASEB J, V5, P2280, DOI 10.1096/fasebj.5.9.1860619; POOLE C, 1991, CANCER CAUSE CONTROL, V2, P267, DOI 10.1007/BF00052144; REESE JA, 1988, BIOELECTROMAGNETICS, V9, P237, DOI 10.1002/bem.2250090305; ROMMEREIM DN, 1990, FUND APPL TOXICOL, V14, P608, DOI 10.1016/0272-0590(90)90265-L; SALZINGER K, 1990, BIOELECTROMAGNETICS, V11, P105, DOI 10.1002/bem.2250110202; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360, DOI 10.5271/sjweh.1848; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SEVERSON RK, 1988, AM J EPIDEMIOL, V128, P10, DOI 10.1093/oxfordjournals.aje.a114932; SEVERSON RK, 1991, J NATL CANCER I, V83, P1028; SIKOV MR, 1987, BIOELECTROMAGNETICS, V8, P229, DOI 10.1002/bem.2250080303; SPITZ MR, 1985, AM J EPIDEMIOL, V121, P924, DOI 10.1093/oxfordjournals.aje.a114062; TENFORDE TS, 1989, BIOELECTROMAGNETICS, V10, P215, DOI 10.1002/bem.2250100302; TENFORDE TS, 1990, EXTREMELY LOW FREQUE, P291; THERIAULT G, 1991, DHHS NIOSH91111 US D; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1986, BIOELECTROMAGNETICS, V7, P13, DOI 10.1002/bem.2250070103; WERTHEIMER N, 1982, INT J EPIDEMIOL, V11, P345, DOI 10.1093/ije/11.4.345; WERTHEIMER N, 1980, AM J EPIDEMIOL, V111, P461, DOI 10.1093/oxfordjournals.aje.a112924; WERTHEIMER N, 1989, AM J EPIDEMIOL, V129, P220, DOI 10.1093/oxfordjournals.aje.a115112; WILSON BW, 1986, BIOELECTROMAGNETICS, V7, P239, DOI 10.1002/bem.2250070213; YOUNGSON JHAM, 1991, BRIT J CANCER, V63, P977, DOI 10.1038/bjc.1991.214; 1992, ELECTROMAGNETIC FIEL, P3; [No title captured]; 1992, BIOL EFFECTS POWER F	63	58	66	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					625	629		10.1001/jama.268.5.625	http://dx.doi.org/10.1001/jama.268.5.625			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629991				2022-12-28	WOS:A1992JF47300028
J	TEPPER, RI; COFFMAN, RL; LEDER, P				TEPPER, RI; COFFMAN, RL; LEDER, P			AN EOSINOPHIL-DEPENDENT MECHANISM FOR THE ANTITUMOR EFFECT OF INTERLEUKIN-4	SCIENCE			English	Article							LYMPHOCYTES	Murine interleukin-4 (IL-4) exhibits potent antitumor activity when present at the site of tumor cell challenge. Associated with tumor cell death is the appearance of an inflammatory infiltrate comprised predominantly of eosinophils and macrophages, but with few lymphocytes. Antibodies that specifically block the accumulation of granulocytes at the site of inflammation were injected in vivo to define the cell type responsible for the antitumor action of IL-4. These studies implicate eosinophils in IL-4-mediated tumor cytotoxicity. The lymphoid-independent nature of IL-4 action is supported by the analysis of mutant mouse strains with defined lymphocyte immunodeficiencies. The observed regression of established tumor masses by localized IL-4 action provides a rationale for exploring IL-4-mediated tumor killing as a potential therapy for human malignant disorders.	DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	TEPPER, RI (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02114, USA.							COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; COLEY DG, 1972, EXP PARASITOL, V32, P520; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; PENNLINE KJ, 1990, CYTOMETRY, V11, P823; SCHREIBER H, 1989, FUNDAMENTAL IMMUNOLO, P927; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2	8	505	514	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					548	551		10.1126/science.1636093	http://dx.doi.org/10.1126/science.1636093			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636093				2022-12-28	WOS:A1992JE75500035
J	FALK, RH				FALK, RH			PROARRHYTHMIA IN PATIENTS TREATED FOR ATRIAL-FIBRILLATION OR FLUTTER	ANNALS OF INTERNAL MEDICINE			English	Review						ARRHYTHMIA; ATRIAL FIBRILLATION; ANTIARRHYTHMIA AGENTS; TORSADES-DE-POINTES	PARKINSON-WHITE SYNDROME; POLYMORPHOUS VENTRICULAR-TACHYCARDIA; RECIPROCATING JUNCTIONAL TACHYCARDIA; SINUS NODE DYSFUNCTION; TORSADE-DE-POINTES; ANTIARRHYTHMIC DRUGS; FLECAINIDE ACETATE; INTRAVENOUS VERAPAMIL; RECENT-ONSET; THERAPY	Objective: To review data on the type, mechanism, and prevalence of the proarrhythmic effect of drugs used to treat atrial fibrillation or flutter. Data Sources: English-language literature from the early 1960s to the present was identified by manual search of the literature; relevant articles were reviewed. Pertinent earlier studies were identified from references in the articles reviewed and were included when relevant. Study Selection: All studies, controlled and uncontrolled, as well as individual case reports that contained data convincingly linking atrial antiarrhythmic therapy to a proarrhythmic side effect were included. Data Extraction: Key data were extracted from each article in studies in which a causal relationship between the use of a drug and a proarrhythmic response appeared likely. Data Synthesis: Antiarrhythmic therapy aimed at stabilizing the atrium may have adverse effects on the ventricle including torsade de pointes and, less commonly, sustained ventricular tachycardia. Different antiarrhythmic agents appear to have differing potentials for this proarrhythmic response, which is most common with class 1A agents. Other proarrhythmic responses to atrial antiarrhythmic agents include the acceleration of the ventricular response either by enhancing atrioventricular nodal or bypass tract conduction or by converting atrial fibrillation to flutter with 1:1 conduction. Calcium-channel blocking agents and, less commonly, digoxin may perpetuate the duration of paroxysmal atrial fibrillation, and virtually all agents can cause sinus node dysfunction or atrioventricular block. Conclusions: Although drug therapy for atrial fibrillation or flutter is generally well tolerated, the potential exists for uncommon but serious proarrhythmic effects. Knowledge of the risk factors and symptoms of these adverse reactions will help to further reduce this risk.			FALK, RH (corresponding author), BOSTON CITY HOSP, DIV CARDIOL, TALBOT 227W, 818 HARRISON AVE, BOSTON, MA 02118 USA.							ADAMSON AR, 1968, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.5599.223; AIZAWA Y, 1989, ANGIOLOGY, V40, P94, DOI 10.1177/000331978904000203; AKHTAR M, 1981, CIRCULATION, V63, P435, DOI 10.1161/01.CIR.63.2.435; ANASTASIOUNANA MI, 1987, AM HEART J, V113, P1071, DOI 10.1016/0002-8703(87)90914-8; ANDERSON JL, 1989, CIRCULATION, V80, P1557, DOI 10.1161/01.CIR.80.6.1557; BARRETT PA, 1980, AM HEART J, V100, P23, DOI 10.1016/0002-8703(80)90275-6; BEASLEY R, 1985, BRIT MED J, V290, P9, DOI 10.1136/bmj.290.6461.9; BELHASSEN B, 1988, CIRCULATION, V77, P795, DOI 10.1161/01.CIR.77.4.795; BELHASSEN B, 1988, AM J CARDIOL, V62, P835, DOI 10.1016/0002-9149(88)91240-4; BELLER GA, 1971, NEW ENGL J MED, V284, P989, DOI 10.1056/NEJM197105062841801; BIANCONI L, 1989, AM J CARDIOL, V64, P335, DOI 10.1016/0002-9149(89)90530-4; BINDER MJ, 1952, AM J MED, V12, P491, DOI 10.1016/0002-9343(52)90229-5; BROWN AK, 1978, BRIT HEART J, V40, P1149; BROWN MA, 1986, EUR HEART J, V7, P234, DOI 10.1093/oxfordjournals.eurheartj.a062057; BRUGADA P, 1991, CIRCULATION, V83, P1649, DOI 10.1161/01.CIR.83.5.1649; CAMM AJ, 1991, NEW ENGL J MED, V325, P1621, DOI 10.1056/NEJM199112053252306; CHENG TO, 1956, AM HEART J, V52, P273, DOI 10.1016/0002-8703(56)90265-4; CHENG TO, 1956, AM HEART J, V51, P417, DOI 10.1016/0002-8703(56)90068-0; CHOUTY F, 1988, AM J CARDIOL, V62, pD35; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COUMEL P, 1992, ATRIAL FIBRILLATION, P109; CRIJNS HJ, 1988, AM J CARDIOL, V62, P1303, DOI 10.1016/0002-9149(88)90282-2; DANAHY DT, 1978, AM HEART J, V95, P474, DOI 10.1016/0002-8703(78)90239-9; FALK RH, 1987, ANN INTERN MED, V106, P503, DOI 10.7326/0003-4819-106-4-503; FALK RH, 1989, ANN INTERN MED, V111, P107, DOI 10.7326/0003-4819-111-2-107; FALK RH, 1991, ANN INTERN MED, V114, P573, DOI 10.7326/0003-4819-114-7-573; FALK RH, 1988, NEW ENGL J MED, V318, P640; FELD GK, 1990, AM J CARDIOL, V66, P378, DOI 10.1016/0002-9149(90)90856-V; FISCH C, 1985, J AM COLL CARDIOL, V5, pA91, DOI 10.1016/S0735-1097(85)80467-8; FISCH C, 1983, BRIT HEART J, V50, P297; GARRATT C, 1989, LANCET, V2, P219; GARRATT C, 1989, AM J CARDIOL, V64, P1310, DOI 10.1016/0002-9149(89)90573-0; GARRATT C, 1989, LANCET, V1, P367; GRAYZEL J, 1972, J ELECTROCARDIOL, V5, P289, DOI 10.1016/S0022-0736(72)80010-4; GREER GS, 1989, AM J CARDIOL, V64, P339, DOI 10.1016/0002-9149(89)90531-6; GULAMHUSEIN S, 1983, AM HEART J, V106, P145, DOI 10.1016/0002-8703(83)90452-0; HERRE JM, 1985, AM J CARDIOL, V55, P227, DOI 10.1016/0002-9149(85)90337-6; HERRMANN GR, 1951, AM HEART J, V41, P182, DOI 10.1016/0002-8703(51)90098-1; HOROWITZ LN, 1987, AM J CARDIOL, V59, pE54, DOI 10.1016/0002-9149(87)90204-9; JACKMAN WM, 1988, PROG CARDIOVASC DIS, V31, P115, DOI 10.1016/0033-0620(88)90014-X; JUULMOLLER S, 1990, CIRCULATION, V82, P1932, DOI 10.1161/01.CIR.82.6.1932; KASANUKI H, 1986, CIRCULATION, V74, P105; KASTOR JA, 1967, ANN INTERN MED, V67, P1045, DOI 10.7326/0003-4819-67-5-1045; KEREN A, 1982, CHEST, V81, P384, DOI 10.1378/chest.81.3.384; Kerr WJ, 1922, HEART-J STUD CIRC, V9, P269; KHALSA A, 1979, ACTA MED SCAND, V205, P509; KLEIN GJ, 1979, NEW ENGL J MED, V301, P1080, DOI 10.1056/NEJM197911153012003; KOWEY PR, 1979, CIRCULATION, V60, P253; LABARRE A, 1979, CIRCULATION, V59, P226, DOI 10.1161/01.CIR.59.2.226; LEWIS GP, 1984, AM J CARDIOL, V53, pB52, DOI 10.1016/0002-9149(84)90502-2; LONDON F, 1954, AM HEART J, V48, P152, DOI 10.1016/0002-8703(54)90284-7; LOWN B, 1962, JAMA-J AM MED ASSOC, V182, P548; LOWN B, 1967, BRIT HEART J, V29, P469; MAHDYOON H, 1990, AM HEART J, V120, P1189, DOI 10.1016/0002-8703(90)90135-K; MARCUS FI, 1990, AM J CARDIOL, V66, P366, DOI 10.1016/0002-9149(90)90851-Q; MARGOLIS JR, 1975, CIRCULATION, V52, P162, DOI 10.1161/01.CIR.52.1.162; MARRIOTT HJ, 1972, CHEST, V61, P682, DOI 10.1378/chest.61.7.682; MCGOVERN B, 1986, ANN INTERN MED, V104, P791, DOI 10.7326/0003-4819-104-6-791; MCKIBBIN JK, 1984, BRIT HEART J, V51, P157; Miles W M, 1986, Cardiol Clin, V4, P429; MINARDO JD, 1988, NEW ENGL J MED, V319, P257, DOI 10.1056/NEJM198808043190501; MORADY F, 1987, PACE, V10, P492, DOI 10.1111/j.1540-8159.1987.tb04511.x; MORGANROTH J, 1986, J AM COLL CARDIOL, V8, P607, DOI 10.1016/S0735-1097(86)80190-5; MURDOCK CJ, 1990, AM J CARDIOL, V66, P755, DOI 10.1016/0002-9149(90)91144-U; MYERBURG RJ, 1989, CIRCULATION, V80, P1571, DOI 10.1161/01.CIR.80.6.1571; NEUVONEN PJ, 1981, EUR J CLIN PHARMACOL, V20, P85, DOI 10.1007/BF00607142; NGUYEN PT, 1986, CIRCULATION, V74, P340, DOI 10.1161/01.CIR.74.2.340; ORAM S, 1981, CLIN HEART DISEASE, P638; PIEPHO RW, 1987, CIRCULATION, V75, P181; PODRID PJ, 1980, NEW ENGL J MED, V302, P614, DOI 10.1056/NEJM198003133021106; POLLAK A, 1992, CIRCULATION, V85, P1955, DOI 10.1161/01.CIR.85.5.1955; POLLAK A, 1992, ATRIAL FIBRILLATION, P345; PORTERFIELD JG, 1989, AM J CARDIOL, V63, P114, DOI 10.1016/0002-9149(89)91091-6; PRITCHETT ELC, 1988, J CLIN EPIDEMIOL, V41, P851, DOI 10.1016/0895-4356(88)90101-1; RADFORD MD, 1968, BRIT HEART J, V30, P91; RANGER S, 1989, CIRCULATION, V79, P1000, DOI 10.1161/01.CIR.79.5.1000; RAWLES JM, 1990, BRIT HEART J, V63, P225; RICCIONI N, 1983, AM HEART J, V105, P870, DOI 10.1016/0002-8703(83)90259-4; ROBERTSON CE, 1980, BRIT HEART J, V44, P602; RODEN DM, 1986, AM HEART J, V111, P1088, DOI 10.1016/0002-8703(86)90010-4; RODEN DM, 1985, CIRC RES, V56, P857, DOI 10.1161/01.RES.56.6.857; ROSEN KM, 1972, AM J CARDIOL, V30, P801, DOI 10.1016/0002-9149(72)90003-3; ROSEN KM, 1970, AM J CARDIOL, V25, P1, DOI 10.1016/0002-9149(70)90807-6; SELLERS TD, 1977, CIRCULATION, V56, P260, DOI 10.1161/01.CIR.56.2.260; SELZER A, 1964, CIRCULATION, V30, P17, DOI 10.1161/01.CIR.30.1.17; SHEINMAN BD, 1982, BRIT MED J, V285, P999, DOI 10.1136/bmj.285.6347.999; SHENASA M, 1983, J AM COLL CARDIOL, V2, P545, DOI 10.1016/S0735-1097(83)80283-6; SHENASA M, 1988, AM J CARDIOL, V62, P403, DOI 10.1016/0002-9149(88)90967-8; SINGH BN, 1978, DRUGS, V15, P169, DOI 10.2165/00003495-197815030-00001; SMITH TW, 1984, PROG CARDIOVASC DIS, V26, P413, DOI 10.1016/0033-0620(84)90012-4; STANTON MS, 1989, J AM COLL CARDIOL, V14, P209, DOI 10.1016/0735-1097(89)90074-0; STRASBERG B, 1981, AM J CARDIOL, V47, P1309, DOI 10.1016/0002-9149(81)90264-2; STRATMANN HG, 1985, AM HEART J, V109, P375, DOI 10.1016/0002-8703(85)90615-5; STRAUSS HC, 1976, CIRCULATION, V54, P452, DOI 10.1161/01.CIR.54.3.452; TALLEY JD, 1989, CLIN CARDIOL, V12, P45, DOI 10.1002/clc.4960120109; TANDOWSKY RM, 1946, AM HEART J, V32, P617, DOI 10.1016/0002-8703(46)90670-9; TMM CT, 1989, J AM COLL CARDIOL, V13, P164; TOUBOUL P, 1979, BRIT HEART J, V42, P573; VANGELDER IC, 1989, AM J CARDIOL, V64, P1317, DOI 10.1016/0002-9149(89)90574-2; VELEBIT V, 1982, CIRCULATION, V65, P886, DOI 10.1161/01.CIR.65.5.886; VIKMO H, 1982, AM J CARDIOL, V50, P1090, DOI 10.1016/0002-9149(82)90423-4; WANG T, 1986, AM J CARDIOL, V57, P1160, DOI 10.1016/0002-9149(86)90692-2; WANG Y, 1991, J AM COLL CARDIOL, V18, P1711, DOI 10.1016/0735-1097(91)90508-7; WELLENS HJJ, 1992, ATRIAL FIBRILLATION, P333; WOOSLEY RL, 1988, NEW ENGL J MED, V318, P1107	105	146	149	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					141	150		10.7326/0003-4819-117-2-141	http://dx.doi.org/10.7326/0003-4819-117-2-141			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605429				2022-12-28	WOS:A1992JD12300009
J	FRANCES, R; FRANKLIN, JE				FRANCES, R; FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOPAMINE-D2 RECEPTOR GENE; ALCOHOLISM; ASSOCIATION; DISORDER				FRANCES, R (corresponding author), UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103, USA.							BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS AM, 1990, JAMA-J AM MED ASSOC, V264, P3156; BRADY K, 1990, AM J PSYCHIAT, V147, P1164; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS CE, 1991, JAMA-J AM MED ASSOC, V266, P1793; DULIT RA, 1990, AM J PSYCHIAT, V147, P1002; ELBASSEL N, 1991, PUBLIC HEALTH REP, V106, P586; GALANTER M, 1991, AM J DRUG ALCOHOL AB, V17, P1, DOI 10.3109/00952999108992805; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GEORGE DT, 1990, ACTA PSYCHIAT SCAND, V82, P1, DOI 10.1111/j.1600-0447.1990.tb01345.x; HUGHES JR, 1991, ARCH INTERN MED, V151, P1993, DOI 10.1001/archinte.151.10.1993; KUSHNER MG, 1990, AM J PSYCHIAT, V147, P685; METZGER D, 1991, AM J PSYCHIAT, V148, P636; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P655; ORFORD J, 1991, BRIT J MED PSYCHOL, V64, P189, DOI 10.1111/j.2044-8341.1991.tb01656.x; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P653; SCHRAGER L, 1991, PUBLIC HEALTH REP, V106, P78; SCHWAB S, 1991, AM J HUM GENET, V49, P203; UHL GR, 1992, ARCH GEN PSYCHIAT, V49, P157; WALSH DC, 1991, NEW ENGL J MED, V325, P775, DOI 10.1056/NEJM199109123251105; WILSNACK SC, 1991, AM J PUBLIC HEALTH, V81, P305, DOI 10.2105/AJPH.81.3.305; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1991, JAMA-J AM MED ASSOC, V266, P3133; 1991, AM J PSYCHIAT, V148, P1291	24	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					330	332						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613907				2022-12-28	WOS:A1992JC35200017
J	LIMBERG, B				LIMBERG, B			DIAGNOSIS AND STAGING OF COLONIC TUMORS BY CONVENTIONAL ABDOMINAL SONOGRAPHY AS COMPARED WITH HYDROCOLONIC SONOGRAPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLORECTAL-CANCER; CROHNS-DISEASE; CARCINOMA; ULTRASONOGRAPHY; APPENDICITIS; ULTRASOUND; POPULATION; BOWEL; RISK	Background. Ultrasonic examination has become increasingly important in the diagnosis of diseases of the gastrointestinal tract. In neoplastic diseases of the large intestine, however, the diagnostic value of conventional transabdominal sonography is limited. The purpose of this investigation was to determine whether the evaluation and staging of colonic tumors would be improved by the retrograde instillation of water into the colon in a procedure called hydrocolonic sonography. Methods. Three hundred patients were examined in a prospective study in which both conventional transabdominal sonography and transabdominal hydrocolonic sonography were performed before the diagnosis was verified by colonoscopy. The indication for the examinations was abdominal pain, diarrhea, weight loss, or the presence of occult blood in a stool specimen. Results. With the instillation of water into the colon, it was possible to display the colon sonographically from the rectosigmoid transition to the cecum in 97 percent of the patients examined. In addition to permitting the evaluation of the colonic lumen, the procedure allowed the five layers of the colonic wall and the connective tissue surrounding the colon to be examined in detail. Only 9 of 29 carcinomas were diagnosed by conventional abdominal sonography (31 percent), whereas hydrocolonic sonography permitted the diagnosis of 28 (97 percent). No polyps could be detected by conventional abdominal sonography, whereas hydrocolonic sonography permitted the diagnosis of 38 of 42 polyps greater-than-or-equal-to 7 mm (91 percent) and 3 of 12 polyps <7 mm (25 percent). In addition, detailed evaluation of the structure of the bowel wall with hydrocolonic sonography permitted a more precise staging of colonic tumors. Conclusions. Hydrocolonic sonography, a new diagnostic procedure, can facilitate the diagnosis and staging of colonic tumors.			LIMBERG, B (corresponding author), UNIV FRANKFURT,ACAD HOSP,KLINIKUM DARMSTADT,DEPT INTERNAL MED 2,GRAFENSTR 9,W-6100 DARMSTADT,GERMANY.							ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ATKIN W S, 1990, Gastroenterology, V98, pA650; BLUTH EI, 1979, RADIOLOGY, V133, P677, DOI 10.1148/133.3.677; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EIDE TJ, 1986, INT J CANCER, V38, P173, DOI 10.1002/ijc.2910380205; HERMANEK P, 1987, TNM CLASSIFICATOIN M; HILDEBRANDT U, 1985, DIS COLON RECTUM, V28, P42, DOI 10.1007/BF02553906; KIMMEY MB, 1989, GASTROENTEROLOGY, V96, P433, DOI 10.1016/0016-5085(89)91568-0; LIMBERG B, 1989, J CLIN ULTRASOUND, V17, P25, DOI 10.1002/jcu.1870170106; LIMBERG B, 1990, J CLIN ULTRASOUND, V18, P161, DOI 10.1002/jcu.1870180304; LIMBERG B, 1990, LANCET, V335, P144, DOI 10.1016/0140-6736(90)90012-T; Lutz H T, 1976, Ultrasound Med Biol, V2, P129, DOI 10.1016/0301-5629(76)90022-3; MAMAZZA J, 1982, DIS COLON RECTUM, V25, P558, DOI 10.1007/BF02564165; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEUGUT AI, 1988, AM J GASTROENTEROL, V83, P295; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; ROSATO FE, 1981, DIS COLON RECTUM, V24, P93, DOI 10.1007/BF02604295; SCHWERK WB, 1989, GASTROENTEROLOGY, V97, P630, DOI 10.1016/0016-5085(89)90634-3; SIANESI M, 1984, DIS COLON RECTUM, V27, P168, DOI 10.1007/BF02555665; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; TIO TL, 1989, GASTROENTEROLOGY, V96, P1478, DOI 10.1016/0016-5085(89)90515-5; 1980, CA-CANCER J CLIN, V30, P194; 1987, WORKING GUIDELINES E	26	86	92	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					65	69		10.1056/NEJM199207093270201	http://dx.doi.org/10.1056/NEJM199207093270201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603137	Bronze			2022-12-28	WOS:A1992JC21400001
J	OKELLY, B; BROWNER, WS; MASSIE, B; TUBAU, J; NGO, L; MANGANO, DT				OKELLY, B; BROWNER, WS; MASSIE, B; TUBAU, J; NGO, L; MANGANO, DT			VENTRICULAR ARRHYTHMIAS IN PATIENTS UNDERGOING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIARRHYTHMIC DRUG-THERAPY; NON-CARDIAC SURGERY; CIGARETTE-SMOKING; RISK; STRESS; INDEX	Objective.-To determine the incidence, clinical predictors and prognostic importance of perioperative ventricular arrhythmias. Design.-Prospective cohort study (Study of Perioperative Ischemia). Setting.-University-affiliated Department of Veterans Affairs Medical Center, San Francisco, Calif. Subjects.-A consecutive sample of 230 male patients, with known coronary artery disease (46%) or at high risk of coronary artery disease (54%), undergoing major noncardiac surgical procedures. Measurements.-We recorded cardiac rhythm throughout the preoperative (mean=21 hours), intraoperative (mean=6 hours), and postoperative (mean=38 hours) periods using continuous ambulatory electrocardiographic monitoring. Adverse cardiac outcomes were noted by physicians blinded to information about arrhythmias. Main Results.-Frequent or major ventricular arrhythmias (>30 ventricular ectopic beats per hour, ventricular tachycardia) occurred in 44% of our patients: 21% preoperatively, 16% intraoperatively, and 36% postoperatively. Compared with the preoperative baseline, the severity of arrhythmia increased in only 2% of patients intraoperatively but in 10% postoperatively. Preoperative ventricular arrhythmias were more common in smokers (odds ratio [OR], 4.1; 95% confidence interval [CI], 1.2 to 15.0), those with a history of congestive heart failure (OR, 4.1; 95% CI, 1.9 to 9.0), and those with electrocardiographic evidence of myocardial ischemia (OR, 2.2; 95% CI, 1. 1 to 4.7). Preoperative arrhythmias were associated with the occurrence of intraoperative and postoperative arrhythmias (OR, 7.3; 95% CI, 3.3 to 16.0, and OR, 6.4; 95% CI, 2.7 to 15.0, respectively). Nonfatal myocardial infarction or cardiac death occurred in nine men; these outcomes were not significantly more frequent in those with prior perioperative arrhythmias, albeit with wide CIs (OR, 1.6; 95% CI, 0.4 to 6.2). Conclusion.-Almost half of all high-risk patients undergoing noncardiac surgery have frequent ventricular ectopic beats or nonsustained ventricular tachycardia. Our results suggest that these arrhythmias, when they occur without other signs or symptoms of myocardial infarction, may not require aggressive monitoring or treatment during the perioperative period.	DEPT VET AFFAIRS MED CTR,DEPT MED,SAN FRANCISCO,CA 94121; DEPT VET AFFAIRS MED CTR,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,DEPT ANESTHESIA,SAN FRANCISCO,CA	University of California System; University of California San Francisco				Tice, Jeffrey/0000-0002-9857-2028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744, P01HL025847] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 25847, HL36744] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BERTRAND CA, 1971, J AMER MED ASSOC, V216, P1615, DOI 10.1001/jama.216.10.1615; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1984, HEART FAILURE, P1; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DAVIS MJE, 1984, AM J CARDIOL, V54, P282, DOI 10.1016/0002-9149(84)90183-8; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; DODD RB, 1962, SURGERY, V51, P440; Goldman L, 1987, J Cardiothorac Anesth, V1, P237, DOI 10.1016/S0888-6296(87)80011-X; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HALLSTROM AP, 1986, NEW ENGL J MED, V314, P271, DOI 10.1056/NEJM198601303140502; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; HENNEKENS CH, 1980, AM J EPIDEMIOL, V112, P93, DOI 10.1093/oxfordjournals.aje.a112980; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; HOLLIFIELD JW, 1989, AM J CARDIOL, V63, pG22, DOI 10.1016/0002-9149(89)90214-2; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; KIMBROUGH HM, 1975, J UROLOGY, V113, P846, DOI 10.1016/S0022-5347(17)59596-8; Kjekshus J, 1990, AM J CARDIOL, V65, P421, DOI DOI 10.1084/JEM.20051151; KNOEBEL SB, 1989, CIRCULATION, V79, P206, DOI 10.1161/01.CIR.79.1.206; KUNER J, 1967, DIS CHEST, V52, P580, DOI 10.1378/chest.52.5.580; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MASSIE B M, 1992, Journal of the American College of Cardiology, V19, p78A; MORGANROTH J, 1987, AM J CARDIOL, V59, pE32, DOI 10.1016/0002-9149(87)90199-8; MYERS MG, 1988, CHEST, V93, P14, DOI 10.1378/chest.93.1.14; NADEMANEE K, 1990, CIRCULATION, V82, P1054, DOI 10.1161/01.CIR.82.3.1054; PODRID PJ, 1989, EUR HEART J, V10, P66, DOI 10.1093/eurheartj/10.suppl_E.66; PRATT CM, 1985, NEW ENGL J MED, V313, P1444, DOI 10.1056/NEJM198512053132304; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; VANIK PE, 1968, ANESTH ANAL CURR RES, V47, P299; 1978, MANUAL OPERATIONS, V2	34	75	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					217	221		10.1001/jama.268.2.217	http://dx.doi.org/10.1001/jama.268.2.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608140				2022-12-28	WOS:A1992JB27900028
J	KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L				KRUMHOLZ, HM; PASTERNAK, RC; WEINSTEIN, MC; FRIESINGER, GC; RIDKER, PM; TOSTESON, ANA; GOLDMAN, L			COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH STREPTOKINASE IN ELDERLY PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WORCESTER HEART-ATTACK; MORTALITY; PROGNOSIS; RATES	Background. There is a lack of consensus among cardiologists about the potential benefit of thrombolytic therapy for suspected acute myocardial infarction in older patients. To investigate this issue, we constructed a decision-analytic model for patients 75 years of age or older who present with ST-segment elevation within six hours of the onset of symptoms suggesting acute myocardial infarction. Methods. The variables incorporated in this model were the probability that the patient has an acute myocardial infarction, the probability of in-hospital death among patients with acute myocardial infarction who do not receive thrombolytic therapy, the probability of a fatal or incapacitating complication resulting from thrombolytic therapy, and the expected relative reduction in the risk of death associated with thrombolytic therapy in patients with acute myocardial infarction. Our analyses were based primarily on the use of streptokinase as the thrombolytic agent. Results. Given our base-line assumptions, the probability of dying in the hospital was 21.4 percent if thrombolytic therapy was given and 24.4 percent if it was not given. In one-way sensitivity analyses, thrombolytic therapy decreased the risk of dying if the probability that the patient had an acute myocardial infarction was assumed to be greater than 9 percent, if the probability of dying in the hospital after an acute myocardial infarction without thrombolytic therapy was assumed to be greater than 3 percent, if the rate of fatal or incapacitating complications due to thrombolytic therapy was assumed to be 4 percent or less, or if the relative reduction in the risk of death associated with thrombolytic therapy was assumed to be greater than 1 percent. On the basis of our base-line assumptions, our estimate of the cost effectiveness of streptokinase therapy (the cost per year of life saved) for an 80-year-old patient with suspected acute myocardial infarction was $21,200. For a wide range of assumptions about risks, benefits, and costs, the cost per year of life saved remained less than $55,000. Conclusions. Within the limitations imposed by the assumptions used in our analysis, thrombolytic therapy with streptokinase was found to be a beneficial and cost-effective treatment for suspected acute myocardial infarction in elderly patients in a wide variety of clinical circumstances.	HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV CARDIOVASC, BOSTON, MA 02215 USA; HARVARD UNIV, BETH ISRAEL HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DIV CARDIOVASC, NASHVILLE, TN 37240 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Vanderbilt University			, Harlan/AAI-2875-2020		AHRQ HHS [1P01HS06341, 1R01HS06452, 1R01HS06258] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; CHAMBERLAIN DA, 1988, LANCET, V1, P545; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CRAGG DR, 1991, ANN INTERN MED, V115, P173, DOI 10.7326/0003-4819-115-3-173; GOLDBERG RJ, 1989, AM HEART J, V117, P543, DOI 10.1016/0002-8703(89)90727-8; GOLDBERG RJ, 1988, AM HEART J, V115, P761, DOI 10.1016/0002-8703(88)90876-9; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; GUNNAR RM, 1990, J AM COLL CARDIOL, V16, P249, DOI 10.1016/0735-1097(90)90575-A; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; Hodgson T A, 1984, Health Care Financ Rev, V5, P1; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; PASTERNAK RC, 1992, HEART DISEASE TXB CA, P1232; PFEFFER MA, 1991, JAMA-J AM MED ASSOC, V266, P528, DOI 10.1001/jama.266.4.528; ROIG E, 1987, CIRCULATION, V76, P280, DOI 10.1161/01.CIR.76.2.280; SHERRY S, 1991, J AM COLL CARDIOL, V17, P1237, DOI 10.1016/0735-1097(91)90859-8; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7; WEINSTEIN MC, 1987, AM J PUBLIC HEALTH, V77, P1417, DOI 10.2105/AJPH.77.11.1417; WILCOX RG, 1988, LANCET, V2, P525; 1988, AGING AM TRENDS PROJ; 1991, CIRCULATION S2, V84, P230	26	160	160	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					7	13		10.1056/NEJM199207023270102	http://dx.doi.org/10.1056/NEJM199207023270102			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598117				2022-12-28	WOS:A1992JA76100002
J	LEVINE, MN; GAFNI, A; MARKHAM, B; MACFARLANE, D				LEVINE, MN; GAFNI, A; MARKHAM, B; MACFARLANE, D			A BEDSIDE DECISION INSTRUMENT TO ELICIT A PATIENTS PREFERENCE CONCERNING ADJUVANT CHEMOTHERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						DECISION MAKING; BREAST NEOPLASMS; ANTINEOPLASTIC AGENTS; QUALITY OF LIFE PATIENT SATISFACTION	THERAPY; QUALITY; LIFE	The objective of this study was to develop an instrument to help clinicians inform patients with breast cancer of risks and benefits of adjuvant chemotherapy as derived from clinical trials and to help the informed patient decide whether she prefers treatment or no treatment. The instrument consists of a visual aid (called the decision board) and written material. It provides detailed information on a patient's choices (chemotherapy or no chemotherapy), outcomes (recurrence or not), probabilities of outcomes and their meaning, and quality of life associated with treatment choice and outcome. The validity and reliability of the instrument were evaluated in 30 healthy female volunteers. It was first administered using standard estimates of recurrence for node-negative breast cancer (15% risk of recurrence without treatment, which is reduced to 10% with chemotherapy). A preference for treatment (or no treatment) was then elicited. The validity was evaluated by changing the information provided on risks and benefits and determining whether the preference changed in a predictable manner. To test for reliability, the instrument was administered 2 weeks later. Seventeen women chose chemotherapy and 13 chose no chemotherapy. In the former group, 14 women (82%) switched preference when the magnitude of benefit was reduced, and 16 (94%) switched when the toxicity of treatment was increased. For those women who chose not to receive chemotherapy, 12 (92%) switched when the benefit was increased and 100% switched when toxicity was eliminated. The reliability was excellent (kappa = 0.86). The instrument has been used to elicit treatment preferences in 37 newly presenting patients with high-risk, node-negative breast cancer and has been found to be acceptable and helpful to the patient.	MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA	McMaster University	LEVINE, MN (corresponding author), HAMILTON REG CANC CTR, 699 CONCESS ST, HAMILTON L8V 5C3, ONTARIO, CANADA.							BONADONNA G, 1985, J CLIN ONCOL, V3, P259, DOI 10.1200/JCO.1985.3.2.259; BROCK DW, 1990, NEW ENGL J MED, V322, P1595, DOI 10.1056/NEJM199005313222209; BUDESCU DV, 1990, ORGAN BEHAV HUM DEC, V46, P240, DOI 10.1016/0749-5978(90)90031-4; CASSILETH BR, 1980, ANN INTERN MED, V92, P832, DOI 10.7326/0003-4819-92-6-832; DEVITA VT, 1989, NEW ENGL J MED, V320, P527, DOI 10.1056/NEJM198902233200812; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; GAFNI A, 1990, NEW ENGL J MED, V323, P1354; GOLDHIRSCH A, 1989, NEW ENGL J MED, V320, P491; HENDERSON IC, 1987, CURR PROB CANCER, V11, P127; HILLNER BE, 1991, NEW ENGL J MED, V324, P160, DOI 10.1056/NEJM199101173240305; HUGHES TE, 1991, MED CARE, V29, P297, DOI 10.1097/00005650-199103000-00011; LEVINE MN, 1988, J CLIN ONCOL, V6, P1798, DOI 10.1200/JCO.1988.6.12.1798; LEVINE MN, 1991, J CLIN ONCOL, V9, P348, DOI 10.1200/JCO.1991.9.2.348; LOOMES G, 1989, SOC SCI MED, V28, P299, DOI 10.1016/0277-9536(89)90030-0; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MEHREZ A, 1991, MED DECIS MAKING, V11, P140, DOI 10.1177/0272989X9101100212; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; MEHREZ A, 1990, SOC SCI MED, V31, P1281, DOI 10.1016/0277-9536(90)90137-H; NORMAN GR, 1986, PDQ STATISTICS; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; ROSE G, 1990, BRIT MED J, V301, P683, DOI 10.1136/bmj.301.6754.683; SIMINOFF LA, 1989, MED DECIS MAKING, V9, P262, DOI 10.1177/0272989X8900900406; SIMINOFF LA, 1989, J CLIN ONCOL, V7, P1192, DOI 10.1200/JCO.1989.7.9.1192	26	230	231	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					53	58		10.7326/0003-4819-117-1-53	http://dx.doi.org/10.7326/0003-4819-117-1-53			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596048				2022-12-28	WOS:A1992JA43500010
J	SCHWEISGUTH, F; POSAKONY, JW				SCHWEISGUTH, F; POSAKONY, JW			SUPPRESSOR OF HAIRLESS, THE DROSOPHILA HOMOLOG OF THE MOUSE RECOMBINATION SIGNAL BINDING-PROTEIN GENE, CONTROLS SENSORY ORGAN CELL FATES	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; ACTIVE-SITE TYROSINE; FLP RECOMBINASE; REGIONAL SIMILARITIES; SENSILLUM DEVELOPMENT; MELANOGASTER; DNA; LOCUS; MECHANISM; SEQUENCE	Suppressor of Hairless (Su(H)) is required at two stages of adult sensory organ development in Drosophila. Complete loss of Su(H) function results in a "neurogenic" phenotype in imaginal discs, in which too many cells adopt the sensory organ precursor cell fate. Su(H) is also involved in controlling the fates of sensillum accessory cells and is specifically expressed in two of these cells. Su(H) is the Drosophila homolog of the mouse J(kappa) RBP gene, whose product binds specifically to the recombination signal sequence of immunoglobulin J(kappa) segments. The Su(H) and J(kappa) RBP proteins are 82% identical over most of their length, and share with bacteriophage integrases and yeast recombinases a motif that includes residues directly involved in catalyzing recombination.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHWEISGUTH, F (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.							ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; ASHBURNER M, 1982, GENETICS, V101, P447; BANG AG, 1991, DEVELOPMENT, V111, P89; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1990, GENETIC REGULATORY H, P403; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DELACONCHA A, 1988, GENETICS, V118, P499; Dietrich U, 1984, J Neurogenet, V1, P315, DOI 10.3109/01677068409107094; EVANS BR, 1990, J BIOL CHEM, V265, P18504; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GORIELY A, 1991, DEVELOPMENT, V113, P1395; GRONOSTAJSKI RM, 1985, MOL CELL BIOL, V5, P3274, DOI 10.1128/MCB.5.11.3274; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1990, DEV BIOL, V138, P147, DOI 10.1016/0012-1606(90)90184-K; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HUANG F, 1991, DEVELOPMENT, V111, P1087; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; Lees AD, 1942, PROC R SOC SER B-BIO, V131, P87, DOI 10.1098/rspb.1942.0019; LEWIS S, 1989, CELL, V59, P585, DOI 10.1016/0092-8674(89)90002-0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LINDSLEY DL, 1968, CARNEGIE I WASH PUBL, V627; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MERCIER J, 1990, J BACTERIOL, V172, P3745, DOI 10.1128/jb.172.7.3745-3757.1990; NASH D, 1970, GENETICS, V64, P471; NASH D, 1965, GENET RES, V6, P175, DOI 10.1017/S0016672300004079; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; PRASAD PV, 1987, P NATL ACAD SCI USA, V84, P2189, DOI 10.1073/pnas.84.8.2189; ROBERTSON HM, 1988, GENETICS, V118, P461; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; UTATSU I, 1987, J BACTERIOL, V169, P5537, DOI 10.1128/jb.169.12.5537-5545.1987; VASSIN H, 1985, J NEUROGENET, V2, P291, DOI 10.3109/01677068509102325; VINCENT A, 1984, EMBO J, V3, P1003, DOI 10.1002/j.1460-2075.1984.tb01920.x; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3	54	248	251	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1199	1212		10.1016/0092-8674(92)90641-O	http://dx.doi.org/10.1016/0092-8674(92)90641-O			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617730				2022-12-28	WOS:A1992JA43100014
J	BRENNAN, P; SILMAN, A				BRENNAN, P; SILMAN, A			STATISTICAL-METHODS FOR ASSESSING OBSERVER VARIABILITY IN CLINICAL MEASURES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							KAPPA; AGREEMENT		UNIV MANCHESTER, ARTHRIT & RHEUMATISM COUNCIL, EPIDEMIOL RES UNIT, STOPFORD BLDG, MANCHESTER M13 9PL, LANCS, ENGLAND	University of Manchester								ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; ALTMAN DG, 1991, PRACTICAL STATISTICA; BISHOP YMN, 1978, DISCRETE MULTIVARIAT; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; COCHRANE AL, 1952, LANCET, V263, P505; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; FLEISS JL, 1969, PSYCHOL BULL, V72, P323, DOI 10.1037/h0028106; MACLURE M, 1987, AM J EPIDEMIOL, V126, P161, DOI 10.1093/aje/126.2.161; SCHILLING RSF, 1955, BMJ-BRIT MED J, V1, P65, DOI 10.1136/bmj.1.4905.65; Scott WA, 1955, PUBLIC OPIN QUART, V19, P321, DOI 10.1086/266577; THOMPSON WD, 1988, J CLIN EPIDEMIOL, V41, P949, DOI 10.1016/0895-4356(88)90031-5	13	781	795	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 6	1992	304	6840					1491	1494		10.1136/bmj.304.6840.1491	http://dx.doi.org/10.1136/bmj.304.6840.1491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611375	Green Published, Bronze			2022-12-28	WOS:A1992HY55300028
J	TYBULEWICZ, VLJ; TREMBLAY, ML; LAMARCA, ME; WILLEMSEN, R; STUBBLEFIELD, BK; WINFIELD, S; ZABLOCKA, B; SIDRANSKY, E; MARTIN, BM; HUANG, SP; MINTZER, KA; WESTPHAL, H; MULLIGAN, RC; GINNS, EI				TYBULEWICZ, VLJ; TREMBLAY, ML; LAMARCA, ME; WILLEMSEN, R; STUBBLEFIELD, BK; WINFIELD, S; ZABLOCKA, B; SIDRANSKY, E; MARTIN, BM; HUANG, SP; MINTZER, KA; WESTPHAL, H; MULLIGAN, RC; GINNS, EI			ANIMAL-MODEL OF GAUCHERS-DISEASE FROM TARGETED DISRUPTION OF THE MOUSE GLUCOCEREBROSIDASE GENE	NATURE			English	Article							CELLS; MUTATIONS	GAUCHER's disease is the most prevalent lysosomal storage disorder in humans and results from an autosomally inherited deficiency of the enzyme glucocerebrosidase (beta-D-glucosyl-N-acylsphingosine glucohydrolase) 1-6, which is responsible for degrading the sphingolipid glucocerebroside. An animal model for Gaucher's disease would be important for investigating its phenotypic diversity and pathogenesis and for evaluating therapeutic approaches. A naturally occurring canine model has been reported but not propagated 7. Attempts to mimic the disease in animals by inhibiting glucocerebrosidase have been inadequate 8. Here we generate an animal model for Gaucher's disease by creating a null allele in embryonic stem cells through gene targeting and using these genetically modified cells to establish a mouse strain carrying the mutation 9,10. Mice homozygous for this mutation have < 4% Of normal glucocerebrosidase activity, die within twenty-four hours of birth and store glucocerebroside in lysosomes of cells of the reticuloendothelial system.	NIMH,ALCOHOL DRUG ABUSE & MENTAL HLTH ADM,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; NICHHD,MAMMALIAN GENES & DEV LAB,BETHESDA,MD 20892; ERASMUS UNIV,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Erasmus University Rotterdam				Zablocka, Barbara/0000-0003-3116-7295				Barranger J. A., 1989, METABOLIC BASIS INHE, P1677; BEUTLER E, 1970, LANCET, V1, P612; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, TRENDS GENET, V5, P70, DOI 10.1016/0168-9525(89)90029-2; DEBRUIJN WC, 1976, HISTOCHEM J, V8, P121, DOI 10.1007/BF01007164; FREDRICKSON DS, 1978, METABOLIC BASIS INHE, P731; GRABOWSKI GA, 1990, CRIT REV BIOCHEM MOL, V25, P385, DOI 10.3109/10409239009090616; HARTLEY WJ, 1982, HDB ANIMAL MODELS HU; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Kanfer J N, 1982, Prog Clin Biol Res, V95, P627; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Kundu S K, 1981, Methods Enzymol, V72, P185, DOI 10.1016/S0076-6879(81)72012-3; Lee R E, 1982, Prog Clin Biol Res, V95, P177; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Martin B M, 1989, Adv Pediatr, V36, P277; ONEILL RR, 1989, P NATL ACAD SCI USA, V86, P5049, DOI 10.1073/pnas.86.13.5049; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SUN CC, 1984, PATHOL RES PRACT, V179, P101, DOI 10.1016/S0344-0338(84)80069-2; SVENNERHOLM L, 1982, GAUCHER DIS CENTURY, P231; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WILLEMSEN R, 1988, ULTRASTRUCT PATHOL, V12, P471, DOI 10.3109/01913128809032232	25	246	251	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					407	410		10.1038/357407a0	http://dx.doi.org/10.1038/357407a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594045				2022-12-28	WOS:A1992HX17200064
J	BLACK, RJ; URQUHART, JD; KENDRICK, SW; BUNCH, KJ; WARNER, J; JONES, DA				BLACK, RJ; URQUHART, JD; KENDRICK, SW; BUNCH, KJ; WARNER, J; JONES, DA			INCIDENCE OF LEUKEMIA AND OTHER CANCERS IN BIRTH AND SCHOOLS COHORTS IN THE DOUNREAY AREA	BRITISH MEDICAL JOURNAL			English	Article							WEST CUMBRIA; CHILDHOOD LEUKEMIA; CHILDREN BORN; YOUNG-PEOPLE; SEASCALE; FOLLOW	Objective - To determine whether a raised incidence of leukaemia in the Dounreay area occurred in children born to local mothers (birth cohort) or in those who moved to the area after birth (schools cohort) and also whether any cases of cancer have occurred in children born near Dounreay who may have moved elsewhere. Design - Follow up study. Setting - Dounreay area of Caithness, Scotland. Subjects - 4144 children born in the area in the period 1969-88 and 1641 children who attended local schools in the same period but who had been born elsewhere. Main outcome measures - Cancer registration records linked to birth and schools records with computerised probability matching methods. Results - Five cancer registrations were traced from the birth cohort compared with 5.8 expected on the basis of national rates (observed to expected ratio 0.9, 95% confidence interval 0.3 to 2.0). Atl five cases were of leukaemia (2.3, 0.7 to 5.4). In the schools cohort three cases were found (2.1, 0.4 to 6.2), all of which were of leukaemia (6.7, 1.4 to 19.5). All eight children were resident in the Dounreay area at the time of diagnosis; thus no cases were found in children who were born in or had attended school in the study area but who subsequently moved away. Conclusion - The raised incidence of leukaemia in both the birth and schools cohorts suggests that place of birth is not a more important factor than place of residence in the series of cases of leukaemia observed near Dounreay area.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	BLACK, RJ (corresponding author), SCOTTISH HLTH SERV,COMMON SERV AGCY,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,SCOTLAND.							Baldwin JA, 1987, TXB MED RECORD LINKA; BELL AG, 1989, REPORT DOUNREAY EDRP; BLACK D, 1984, INVESTIGATION POSSIB; Breslow NE, 1987, SCI PUBLICATIONS, VII; DRAPER GJ, 1988, SCI PUBLICATION, V87; GARDNER MJ, 1984, LANCET, V1, P216; GARDNER MJ, 1987, BRIT MED J, V295, P819, DOI 10.1136/bmj.295.6602.819; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GARDNER MJ, 1987, BRIT MED J, V295, P822, DOI 10.1136/bmj.295.6602.822; GLASS S, 1987, LEUKEMIA RES, V2, P881; HEASMAN M A, 1987, Health Bulletin (Edinburgh), V45, P147; HEASMAN MA, 1986, LANCET, V1, P266; KINLEN L, 1988, LANCET, V2, P1323; Newcombe H. B., 1988, HDB RECORD LINKAGE; STILLER CA, 1988, SCI PUBLICATION, V87; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1988, COMARE2ND COMM MED A	17	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1401	1405		10.1136/bmj.304.6839.1401	http://dx.doi.org/10.1136/bmj.304.6839.1401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628012	Green Published, Bronze			2022-12-28	WOS:A1992HX08200015
J	PARK, RHR; ALLISON, MC; LANG, J; SPENCE, E; MORRIS, AJ; DANESH, BJZ; RUSSELL, RI; MILLS, PR				PARK, RHR; ALLISON, MC; LANG, J; SPENCE, E; MORRIS, AJ; DANESH, BJZ; RUSSELL, RI; MILLS, PR			RANDOMIZED COMPARISON OF PERCUTANEOUS ENDOSCOPIC GASTROSTOMY AND NASOGASTRIC TUBE-FEEDING IN PATIENTS WITH PERSISTING NEUROLOGICAL DYSPHAGIA	BRITISH MEDICAL JOURNAL			English	Article							COMPLICATIONS; MORTALITY	Objective - To compare percutaneous endoscopic gastrostomy and nasogastric tube feeding in patients with persisting neurological dysphagia. Design - Randomised 28 day study of inpatients requiring long term enteral nutrition. Setting - Three Glasgow teaching hospitals. Subjects - 40 patients with dysphagia for at least four weeks secondary to neurological disorders: 20 patients (10 women) were randomised to nasogastric feeding and 20 (eight women) to endoscopic gastrostomy. Main outcome measures - Treatment failure (blocked or displaced tubes on three or more occasions or refusal to continue treatment); duration of feeding; intake of liquid diets; complications; nutritional status at end of trial. Results - One patient in each group died before starting feeding. Treatment failure occurred in 18 of the 19 nasogastric patients and in none of the gastrostomy group. The mean (SE) duration of feeding for the nasogastric group was 5.2 (1.5) days. No complications occurred in the nasogastric group but three (16%) of the gastrostomy group developed minor problems (aspiration pneumonia (two patients) wound infection (one)). Gastrostomy patients received a significantly greater proportion of their prescribed feed (93% (2%)) compared with the nasogastric group, (55% (4%); p < 0.001) and also gained significantly more weight after seven days of feeding (1.4 (0.5) kg v 0.6 (0.1) kg; p < 0.05). Analyses at days 14, 21, and 28 were not possible due to the small numbers remaining in the nasogastric group. Conclusion - Percutaneous endoscopic gastrostomy tube feeding is a safe and effective method of providing long term enteral nutrition to patients with neurological dysphagia and offers important advantages over nasogastric tube feeding.	GLASGOW ROYAL INFIRM,GASTROENTEROL UNIT,GLASGOW G4 0SF,SCOTLAND; WESTERN INFIRM & ASSOCIATED HOSP,GASTROENTEROL UNIT,GLASGOW G11 6NT,SCOTLAND; STOBHILL HOSP,GLASGOW,SCOTLAND	University of Glasgow								ALLISON MC, 1992, J ROY SOC MED, V85, P147; BENYA R, 1991, J AM COLL NUTR, V10, P209; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; COGEN R, 1989, AM J GASTROENTEROL, V84, P1509; FINUCANE P, 1991, POSTGRAD MED J, V67, P371, DOI 10.1136/pgmj.67.786.371; FOUTCH PG, 1988, AM J GASTROENTEROL, V83, P812; GUPTA T, 1989, GASTROENTEROLOGY, V96, pA1905; HOGAN RB, 1986, GASTROINTEST ENDOSC, V32, P253, DOI 10.1016/S0016-5107(86)71841-5; JONES M, 1990, JPEN-PARENTER ENTER, V14, P533, DOI 10.1177/0148607190014005533; Keohane P P, 1983, Clin Nutr, V2, P85, DOI 10.1016/0261-5614(83)90038-9; KIRBY DF, 1986, JPEN-PARENTER ENTER, V10, P155, DOI 10.1177/0148607186010002155; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; MORAN BJ, 1990, BRIT J SURG, V77, P858, DOI 10.1002/bjs.1800770805; PONSKY JL, 1985, AM J SURG, V149, P102, DOI 10.1016/S0002-9610(85)80017-9; PONSKY JL, 1981, GASTROINTEST ENDOSC, V27, P9, DOI 10.1016/S0016-5107(81)73133-X; REES RGP, 1988, JPEN-PARENTER ENTER, V12, P469, DOI 10.1177/0148607188012005469; RUGE J, 1986, SURG GYNECOL OBSTET, V162, P13; STEIGMANN GV, 1990, GASTROINTEST ENDOSC, V36, P1; WASILJEW BK, 1982, AM J SURG, V143, P194; WOLFSEN HC, 1990, AM J GASTROENTEROL, V85, P1120	20	271	283	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1406	1409		10.1136/bmj.304.6839.1406	http://dx.doi.org/10.1136/bmj.304.6839.1406			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628013	Green Published, Bronze			2022-12-28	WOS:A1992HX08200016
J	ENGEL, I; OTTENHOFF, THM; KLAUSNER, RD				ENGEL, I; OTTENHOFF, THM; KLAUSNER, RD			HIGH-EFFICIENCY EXPRESSION AND SOLUBILIZATION OF FUNCTIONAL T-CELL ANTIGEN RECEPTOR HETERODIMERS	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM; CYTOCHROME-C; DEGRADATION; RECOGNITION; IA; COMPLEX; CHAINS; GENE; ZETA; BETA	The T cell receptor (TCR) zeta-chain was attached to the TCR-alpha and beta-extracellular domains to induce efficient expression of alpha-beta-heterodimers that can recognize complexes of antigen with major histocompatibility complex (MHC) molecules. Chimeric constructs expressed in RBL-2H3 cells were efficiently transported to the cell surface uniquely as disulfide-linked heterodimers. Transfectants were activated by specific antigen-MHC complexes, which demonstrated that the expressed-alpha-beta was functional and that CD3 was not required for antigen-MHC binding. Constructs with thrombin cleavage sites were efficiently cleaved to soluble disulfide-linked heterodimers. Thus, attachment of TCR-zeta-domains and protease cleavage sites to TCR-alpha and beta induces expression of demonstrably functional heterodimers that can be solubilized.			ENGEL, I (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.							BECKER DM, 1985, NATURE, V317, P430, DOI 10.1038/317430a0; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HANSBURG D, 1983, J IMMUNOL, V131, P319; HEDRICK SM, 1982, CELL, V30, P141, DOI 10.1016/0092-8674(82)90020-4; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KRONENBERG M, 1986, ANNU REV IMMUNOL, V4, P529, DOI 10.1146/annurev.iy.04.040186.002525; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; SAITO T, 1987, NATURE, V325, P125, DOI 10.1038/325125a0; SAMELSON LE, 1985, CELL, V43, P223, DOI 10.1016/0092-8674(85)90027-3; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI C, UNPUB; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743	30	76	94	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1318	1321		10.1126/science.1598575	http://dx.doi.org/10.1126/science.1598575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598575				2022-12-28	WOS:A1992HW13500033
J	HENDEE, WR				HENDEE, WR			ESTIMATION OF RADIATION RISKS - BEIR-V AND ITS SIGNIFICANCE FOR MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATOMIC-BOMB SURVIVORS				HENDEE, WR (corresponding author), MED COLL WISCONSIN,OFF RES & TECHNOL,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							[Anonymous], 1990, HLTH EFFECTS EXPOSUR; BERGER ES, 1989, ARCH INTERN MED, V149, P1507, DOI 10.1001/archinte.149.7.1507; BOICE JD, 1990, JAMA-J AM MED ASSOC, V264, P622, DOI 10.1001/jama.264.5.622; DAVIS JP, 1990, NUCL NEWS        AUG, P35; HENDEE WR, 1990, HEALTH PHYS, V58, P251, DOI 10.1097/00004032-199003000-00002; HENDEE WR, 1991, RADIOGRAPHICS, V11, P1109, DOI 10.1148/radiographics.11.6.1749852; HENDEE WR, 1991, JAMA-J AM MED ASSOC, V265, P1437, DOI 10.1001/jama.265.11.1437; HENDEE WR, 1991, POSTGRAD RADIOL, V11, P162; ICRP, 1977, ICRP PUBL, V26, P1383; MOULDER JE, 1992, CURR OPIN RADIOL, V4, P1; NEEL JV, 1991, JAMA-J AM MED ASSOC, V266, P698, DOI 10.1001/jama.266.5.698; PRESTON DL, 1987, RADIAT RES, V111, P151, DOI 10.2307/3577030; SHIMIZU Y, 1990, JAMA-J AM MED ASSOC, V264, P601, DOI 10.1001/jama.264.5.601; VETTER RJ, 1990, HEALTH PHYS, V58, P557; YAMAZAKI JN, 1990, JAMA-J AM MED ASSOC, V264, P605, DOI 10.1001/jama.264.5.605; 1988, UNSCEAR E88IX7 UN SC; 1988, HLTH RISKS RADON OTH; 1982, UNSCEAR E82IX8 UN SC; 1977, UNSCEAR E77IX1 UN SC; [No title captured]; [No title captured]; 1977, CONSIDERATIONS HLTH; 1986, UNSCEAR A4116 UN SCI	23	51	52	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					620	624		10.1001/jama.268.5.620	http://dx.doi.org/10.1001/jama.268.5.620			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629990				2022-12-28	WOS:A1992JF47300027
J	EDWARDS, MJ; TOLLE, SW				EDWARDS, MJ; TOLLE, SW			DISCONNECTING A VENTILATOR AT THE REQUEST OF A PATIENT WHO KNOWS HE WILL THEN DIE - THE DOCTORS ANGUISH	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						ETHICS, MEDICAL; VENTILATORS; RIGHT TO DIE; DECISION MAKING; LIFE SUPPORT CARE		An awake ventilator-dependent patient asked to have the ventilator disconnected, knowing he would die. We share the conflicting feelings that arose from our respecting his wishes and our own emotional difficulties in sedating him, stopping the ventilator, and watching him die.	OREGON HLTH SCI UNIV, CTR ETH HLTH CARE, L101, 3181 SW SAM JACKSON PK RD, PORTLAND, OR 97201 USA	Oregon Health & Science University									0	62	63	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					254	256		10.7326/0003-4819-117-3-254	http://dx.doi.org/10.7326/0003-4819-117-3-254			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616221				2022-12-28	WOS:A1992JF30400014
J	GARCIA, KC; DESIDERIO, SV; RONCO, PM; VERROUST, PJ; AMZEL, LM				GARCIA, KC; DESIDERIO, SV; RONCO, PM; VERROUST, PJ; AMZEL, LM			RECOGNITION OF ANGIOTENSIN-II - ANTIBODIES AT DIFFERENT LEVELS OF AN IDIOTYPIC NETWORK ARE SUPERIMPOSABLE	SCIENCE			English	Article							HEAVY-CHAIN GENES; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; REGION GENE; DIVERSITY; COMPLEX; ANTIGEN; IDENTIFICATION; GENERATION; EXPRESSION	Genetic and sequence information are reported for an angiotensin II-reactive antibody (Ab1, MAb 110) and an anti-anti-idiotypic antibody (Ab3, MAb 131) that have identical antigen binding properties and that are related by an anti-idiotypic antibody (Ab2-beta) that satisfies accepted biochemical criteria for an internal image-bearing antibody. The sequences of the variable regions of the Ab3 and of the Abl are nearly identical, even though the Ab1 is an antibody to a peptide and the Ab3 is an antibody to a globular protein. Significantly, amino acid residues that make critical contacts with antigen in the crystal structure of the Ab3-antigen complex are highly conserved in Ab1, suggesting that the epitopes of the Ab2-beta recognized by the Ab3 do indeed resemble the bound structure of the antigen.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; HOP TENON,INSERM,U64,F-75790 PARIS 20,FRANCE; JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University			Ronco, Pierre/AAC-8390-2022	Amzel, L. Mario/0000-0002-0129-9572	PHS HHS [6M 44692] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIT AG, 1986, SCIENCE, V233, P747, DOI 10.1126/science.2426778; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CLAFLIN JL, 1987, J IMMUNOL, V138, P3060; CLARKE SH, 1990, J IMMUNOL, V144, P2795; COSENZA H, 1976, EUR J IMMUNOL, V6, P114, DOI 10.1002/eji.1830060208; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; GARCIA KC, 1989, J BIOL CHEM, V264, P20463; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GARCIA KC, UNPUB; GOUGH NM, 1981, P NATL ACAD SCI-BIOL, V78, P509, DOI 10.1073/pnas.78.1.509; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; JEMMERSON R, 1987, P NATL ACAD SCI USA, V84, P9180, DOI 10.1073/pnas.84.24.9180; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KOFLER R, 1988, J IMMUNOL, V140, P4031; KUROSAWA Y, 1981, NATURE, V290, P565, DOI 10.1038/290565a0; MARGET M, 1988, GENE, V74, P335, DOI 10.1016/0378-1119(88)90167-9; MARION TN, 1990, J IMMUNOL, V145, P2322; MAX EE, 1979, P NATL ACAD SCI USA, V76, P3450, DOI 10.1073/pnas.76.7.3450; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MITCHELL T J, 1990, Peptide Research, V3, P277; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PICARD C, 1986, IMMUNOLOGY, V57, P19; PONTILLON F, 1988, J IMMUNOL, V140, P3052; SAKANO H, 1981, NATURE, V290, P562, DOI 10.1038/290562a0; SAKANO H, 1979, NATURE, V280, P603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	36	47	48	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					528	531		10.1126/science.1636087	http://dx.doi.org/10.1126/science.1636087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636087				2022-12-28	WOS:A1992JE75500028
J	HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR				HWANG, SS; BOYLE, TJ; LYERLY, HK; CULLEN, BR			IDENTIFICATION OF ENVELOPE V3 LOOP AS THE MAJOR DETERMINANT OF CD4 NEUTRALIZATION SENSITIVITY OF HIV-1	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RECOMBINANT SOLUBLE CD4; AIDS-RELATED COMPLEX; MONONUCLEAR PHAGOCYTES; T4 ANTIGEN; ANTIBODIES; RECEPTOR; TYPE-1; GP120; RETROVIRUS	Laboratory isolates of human immunodeficiency virus type-1 (HIV-1) such as HTLV-IIIB are generally T cell line-tropic and highly sensitive to neutralization by soluble CD4 (sCD4), a potential antiviral agent that is undergoing clinical trial. However, many primary HIV-1 isolates are macrophage-tropic and sCD4-resistant. Envelope V3 loop sequences derived from primary HIV-1 isolates were sufficient to confer on HTLV-IIIB not only the tissue tropism but also the degree of sCD4 neutralization resistance characteristic of their HIV-1 strains of origin. Single amino acid changes in the V3 loop enhanced sCD4 resistance by up to tenfold. These observations suggest that the tissue tropism and sCD4 neutralization sensitivity of HIV-1 isolates are regulated by similar mechanisms.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Lyerly, Herbert K/B-6528-2014; Lyerly, Herbert Kim/AAX-4925-2020	Lyerly, Herbert K/0000-0002-0063-4770; Lyerly, Herbert Kim/0000-0002-0063-4770	NIAID NIH HHS [AI28662, AI28233] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI028233, P30AI028662] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; BRIGHTY DW, 1991, P NATL ACAD SCI USA, V88, P7802, DOI 10.1073/pnas.88.17.7802; BYRN RA, 1989, J VIROL, V63, P4370, DOI 10.1128/JVI.63.10.4370-4375.1989; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLAPHAM PR, 1991, VIROLOGY, V181, P703, DOI 10.1016/0042-6822(91)90904-P; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CLEMENTS GJ, 1991, AIDS RES HUM RETROV, V7, P3, DOI 10.1089/aid.1991.7.3; COLLMAN R, 1990, J VIROL, V64, P4468, DOI 10.1128/JVI.64.9.4468-4476.1990; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DEAN KC, 1988, NATURE, V331, P82; DEJONG JJ, 1992, J VIROL, V66, P757, DOI 10.1128/JVI.66.2.757-765.1992; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GAMATOS PJ, 1990, J IMMUNOL, V144, P4183; GARTNER S, 1990, AIDS RES HUM RETROV, V6, P1017, DOI 10.1089/aid.1990.6.1017; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HART TK, 1991, P NATL ACAD SCI USA, V88, P2189, DOI 10.1073/pnas.88.6.2189; HO DD, 1988, SCIENCE, V239, P1021, DOI 10.1126/science.2830667; HUSSEY RE, 1988, NATURE, V331, P80; HWANG S, UNPUB; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; KAHN JO, 1990, ANN INTERN MED, V112, P254, DOI 10.7326/0003-4819-112-4; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCDOUGAL JS, 1985, J IMMUNOL, V135, P3151; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBRIEN WA, 1992, J VIROL, V66, P3125, DOI 10.1128/JVI.66.5.3125-3130.1992; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RUSCHE JR, 1988, P NATL ACAD SCI USA, V85, P3198, DOI 10.1073/pnas.85.9.3198; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SCHUITEMAKER H, 1991, J VIROL, V65, P356, DOI 10.1128/JVI.65.1.356-363.1991; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; SMITH DH, 1987, SCIENCE, V238, P1704, DOI 10.1126/science.3500514; TAKEUCHI Y, 1991, J VIROL, V65, P1710, DOI 10.1128/JVI.65.4.1710-1718.1991; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WARD RHR, 1991, NATURE, V352, P434, DOI 10.1038/352434a0; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097	48	115	117	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					535	537		10.1126/science.1636088	http://dx.doi.org/10.1126/science.1636088			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636088				2022-12-28	WOS:A1992JE75500030
J	BAILEY, BJ				BAILEY, BJ			OTOLARYNGOLOGY HEAD AND NECK-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BAILEY, BJ (corresponding author), UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550, USA.							ABRAMSON AL, 1992, ARCH OTOLARYNGOL, V118, P25; AGUADO DL, 1991, INT J PEDIATR OTORHI, V21, P269, DOI 10.1016/0165-5876(91)90009-Z; ALLPHIN AL, 1991, LARYNGOSCOPE, V101, P815, DOI 10.1288/00005537-199108000-00003; EICHER SA, 1992, JAN SO SECT TRIOL SO; ELKASHLAN HK, 1991, OTOLARYNG HEAD NECK, V105, P533, DOI 10.1177/019459989110500405; HOFFMAN HT, 1991, ARCH OTOLARYNGOL, V117, P917; HOLINGER LD, 1991, LARYNGOSCOPE, V101, P596; KASHIMA HK, 1991, OTOLARYNG HEAD NECK, V104, P191, DOI 10.1177/019459989110400206; KAVANAGH KT, 1991, ANN OTO RHINOL LARYN, V100, P331, DOI 10.1177/000348949110000413; LUETJE CM, 1992, LARYNGOSCOPE, V102, P23; MCGEE TM, 1991, LARYNGOSCOPE, V101, P355; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; OROBELLO PW, 1991, ARCH OTOLARYNGOL, V117, P980; RICHARDS W, 1991, CLIN PEDIATR, V30, P88, DOI 10.1177/000992289103000205; SHOCKLEY WW, 1991, ARCH OTOLARYNGOL, V117, P745; TORIUMI DM, 1991, ARCH OTOLARYNGOL, V117, P1101; URKEN ML, 1991, ARCH OTOLARYNGOL, V117, P724; URKEN ML, 1991, ARCH OTOLARYNGOL, V117, P733; WIATRAK BJ, 1991, OTOLARYNG HEAD NECK, V105, P818, DOI 10.1177/019459989110500608	19	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					395	397						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613932				2022-12-28	WOS:A1992JC35200045
J	HAN, TM; RUNNEGAR, B				HAN, TM; RUNNEGAR, B			MEGASCOPIC EUKARYOTIC ALGAE FROM THE 2.1-BILLION-YEAR-OLD NEGAUNEE IRON-FORMATION, MICHIGAN	SCIENCE			English	Article							CARBONACEOUS MEGAFOSSILS; BACILLUS-SUBTILIS; RIBOSOMAL-RNA; ORIGIN; CHINA; EVOLUTION; BACTERIA	Hundreds of specimens of spirally coiled, megascopic, carbonaceous fossils resembling Grypania spiralis (Walcott), have been found in the 2.1 billion-year-old Negaunee Iron-Formation Formation at the Empire Mine, near Marquette, Michigan. This occurrence of Grypania is 700 million to 1 000 million years older than fossils from previously known sites in Montana, China, and India. As Grypania appears to have been a photosynthetic alga, this discovery places the origin of organelle-bearing eukaryotic cells prior to 2.1 billion years ago.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,DEPT EARTH & SPACE SCI,LOS ANGELES,CA 90024; CLIFFS MIN SERV CO MICHIGAN,ISHPEMING,MI 49849; UNIV CALIF LOS ANGELES,INST GEOPHYS & PLANETARY PHYS,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								Beer EJ., 1919, REC GEOL SURV INDIA, V50, P139; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P55, DOI 10.1111/j.1749-6632.1987.tb40597.x; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CLOUD P, 1979, PRECAMBRIAN RES, V10, P73, DOI 10.1016/0301-9268(79)90020-2; CRAWFORD AR, 1971, J GEOL SOC LONDON, V125, P351; DOOLITTLE RF, 1989, HIERARCHY LIFE, P73; DU RL, 1985, PRECAMBRIAN RES, V29, P5, DOI 10.1016/0301-9268(85)90055-5; DU RL, 1986, ACTA GEOL SINICA, P115; GALLARDO VA, 1977, NATURE, V268, P331, DOI 10.1038/268331a0; Gerlach DC., 1988, EOS, V69, P1515; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; HAN TM, 1975, 769 US GEOL SURV PRO, P76; Hayes JM., 1983, EARTHS EARLIEST BIOS, P291; HENDERSON E, 1984, SCIENCE, V225, P510, DOI 10.1126/science.6429855; HOFMANN HJ, 1981, CAN J EARTH SCI, V18, P443, DOI 10.1139/e81-038; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JANNASCH HW, 1989, NATURE, V342, P834, DOI 10.1038/342834a0; KABNICK S, 1991, AM SCI, V70, P34; KANDLER O, 1990, P NATL ACAD SCI USA, V87, P4576; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1991, MOL BIOL EVOL, V8, P378; MENDELSON NH, 1976, P NATL ACAD SCI USA, V73, P1740, DOI 10.1073/pnas.73.5.1740; MENDELSON NH, 1989, J BACTERIOL, V171, P1055, DOI 10.1128/jb.171.2.1055-1062.1989; Peel J.S., 1988, RAPP GRPHINLANDS GEO, V137, P5; RIDING R, 1984, GEOL MAG, V121, P205, DOI 10.1017/S0016756800028260; RIVERA MC, 1992, SCIENCE, V257, P74, DOI 10.1126/science.1621096; RUNNEGAR B, UNPUB; Runnegar B, 1991, PALAEOGEOGR PALAEOCL, V97, P97, DOI 10.1016/0031-0182(91)90186-U; SCHIDLOWSKI M, 1988, NATURE, V333, P313, DOI 10.1038/333313a0; SCHOPF JW, 1992, MAJOR EVENTS IN THE HISTORY OF LIFE, P29; SMITH CR, 1989, NATURE, V341, P27, DOI 10.1038/341027a0; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SONG XL, 1984, GEOL MAG, V121, P179; Starr M. P., 1981, PROKARYOTES; SUMMONS RE, 1988, GEOCHIM COSMOCHIM AC, V52, P1747, DOI 10.1016/0016-7037(88)90001-4; SUMMONS RE, 1990, AM J SCI, V290A, P212; TANDON K K, 1977, Geophytology, V7, P126; TANDON KK, 1977, CURR SCI INDIA, V46, P563; VIDAL G, 1989, LETHAIA, V22, P375, DOI 10.1111/j.1502-3931.1989.tb01437.x; WALTER MR, 1976, J PALEONTOL, V50, P872; WALTER MR, 1990, AM J SCI, V290A, P133; WANG F, 1981, NATURE, V294, P74; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; WOESE CR, 1977, P NATL ACAD SCI USA, V74, P5088, DOI 10.1073/pnas.74.11.5088	45	310	342	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 10	1992	257	5067					232	235		10.1126/science.1631544	http://dx.doi.org/10.1126/science.1631544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1631544				2022-12-28	WOS:A1992JC58500036
J	JILKA, RL; HANGOC, G; GIRASOLE, G; PASSERI, G; WILLIAMS, DC; ABRAMS, JS; BOYCE, B; BROXMEYER, H; MANOLAGAS, SC				JILKA, RL; HANGOC, G; GIRASOLE, G; PASSERI, G; WILLIAMS, DC; ABRAMS, JS; BOYCE, B; BROXMEYER, H; MANOLAGAS, SC			INCREASED OSTEOCLAST DEVELOPMENT AFTER ESTROGEN LOSS - MEDIATION BY INTERLEUKIN-6	SCIENCE			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CALCITONIN RECEPTORS; PARATHYROID-HORMONE; OSTEOBLASTIC CELLS; MARROW CULTURES; TRABECULAR BONE; PREVENTION; RATS; MICE	Osteoclasts, the cells that resorb bone, develop from hematopoietic precursors of the bone marrow under the control of factors produced in their microenvironment. The cytokine interleukin-6 can promote hematopoiesis and osteoclastogenesis. Interleukin-6 production by bone and marrow stromal cells is suppressed by 17-beta-estradiol in vitro. In mice, estrogen loss (ovariectomy) increased the number of colony-forming units for granulocytes and macrophages, enhanced osteoclast development in ex vivo cultures of marrow, and increased the number of osteoclasts in trabecular bone. These changes were prevented by 17-beta-estradiol or an antibody to interleukin-6. Thus, estrogen loss results in an interleukin-6-mediated stimulation of osteoclastogenesis, which suggests a mechanism for the increased bone resorption in postmenopausal osteoporosis.	DEPT VET AFFAIRS MED CTR,ENDOCRINOL & METAB SECT,INDIANAPOLIS,IN 46202; ELI LILLY & CO,LILLY RES LAB,INDIANAPOLIS,IN 46285; DNAX RES INST CELLULAR & MOLEC BIOL,PALO ALTO,CA 94304; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,CTR ONCOL,INDIANAPOLIS,IN 46202	Eli Lilly; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Texas System; University of Texas Health San Antonio; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis				Passeri, Giovanni/0000-0002-4039-1160	NATIONAL CANCER INSTITUTE [R01CA036464, R37CA036464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041313] Funding Source: NIH RePORTER; NCI NIH HHS [CA36464] Funding Source: Medline; NIAID NIH HHS [AI21761] Funding Source: Medline; NIAMS NIH HHS [AR41313] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARZEL US, 1988, AM J MED, V85, P847; BATAILLE, 1991, J CLIN INVEST, V88, P62; BROXMEYER HE, 1991, CANCER CELL-MON REV, V3, P480; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; ERNST M, 1989, ENDOCRINOLOGY, V125, P825, DOI 10.1210/endo-125-2-825; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GRAVES L, 1990, J CELL PHYSIOL, V145, P102, DOI 10.1002/jcp.1041450115; GRAY TK, 1989, BIOCHEM BIOPH RES CO, V158, P407, DOI 10.1016/S0006-291X(89)80062-2; HATTERSLEY G, 1989, ENDOCRINOLOGY, V125, P1606, DOI 10.1210/endo-125-3-1606; HATTERSLEY G, 1991, ENDOCRINOLOGY, V128, P259, DOI 10.1210/endo-128-1-259; HAWLEY TS, 1991, LEUKEMIA RES, V15, P659, DOI 10.1016/0145-2126(91)90068-5; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169-6009(91)90124-I; KLEIN B, 1991, BLOOD, V78, P1198; KURIHARA N, 1991, J BONE MINER RES, V6, P257; KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo-126-5-2733; LINDSAY R, 1976, LANCET, V1, P1038; LIU CC, 1991, ANAT REC, V229, P240, DOI 10.1002/ar.1092290211; OTSUKA T, 1991, EXP HEMATOL, V19, P1042; PACIFICI R, 1991, P NATL ACAD SCI USA, V88, P5134, DOI 10.1073/pnas.88.12.5134; POJDA Z, 1990, EXP HEMATOL, V18, P1034; ROODMAN GD, 1992, J CLIN INVEST, V89, P46, DOI 10.1172/JCI115584; STARNES HF, 1990, J IMMUNOL, V145, P4185; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P1504, DOI 10.1210/endo-123-3-1504; TAKANOYAMAMOTO T, 1990, P NATL ACAD SCI USA, V87, P2172, DOI 10.1073/pnas.87.6.2172; TURNER RT, 1988, ENDOCRINOLOGY, V122, P1146, DOI 10.1210/endo-122-3-1146; ULICH TR, 1991, J IMMUNOL, V146, P2316; WILLIAMS D, IN PRESS CONN TISS R; WONG GG, 1988, J IMMUNOL, V140, P3040	30	1209	1291	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					88	91		10.1126/science.1621100	http://dx.doi.org/10.1126/science.1621100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621100				2022-12-28	WOS:A1992JC16500036
J	DAVIS, SJ; SCHOCKMEL, GA; SOMOZA, C; BUCK, DW; HEALEY, DG; RIEBER, EP; REITER, C; WILLIAMS, AF				DAVIS, SJ; SCHOCKMEL, GA; SOMOZA, C; BUCK, DW; HEALEY, DG; RIEBER, EP; REITER, C; WILLIAMS, AF			ANTIBODY AND HIV-1 GP120 RECOGNITION OF CD4 UNDERMINES THE CONCEPT OF MIMICRY BETWEEN ANTIBODIES AND RECEPTORS	NATURE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; IDIOTYPIC ANTIBODIES; REOVIRUS RECEPTOR; MEMBRANE-PROTEIN; CELL-SURFACE; IDENTIFICATION; EXPRESSION; DIVERSITY; ANTIGEN; BINDING	IT has been proposed that antibodies can mimic the binding of a receptor to its ligand and that anti-idiotype antibodies raised against such antibodies can be used to identify the receptor 1-3. A large number of antibodies have been raised against CD4, the receptor on T cells for the envelope glycoprotein gp120 of the human immunodeficiency virus, and the site at which gp120 binds to CD4 has been delineated 4. It has therefore become possible to contrast the fine specificities of a natural ligand (gp120) and antibodies that interact with the receptor at the same site. Here we report that out of a panel of 225 anti-CD4 antibodies, only one showed fine binding specificity that was broadly like that of gp120, but the evidence was against this being an exact mimic. Thus the data indicate that the production of antibody mimics will occur very rarely or not at all and that the anti-idiotype approach is unlikely to be useful. This contention is supported by a review of the results of attempts to use this approach. Taking strict criteria for success, there is no example for which the anti-idiotype approach has led to the discovery of a previously undescribed receptor or other protein of interest.	BIOTECH RESOURCES INC,SAN ANTONIO,TX 78249; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND; UNIV MUNICH,INST IMMUNOL,W-8000 MUNICH 2,GERMANY	University of Cambridge; University of Munich	DAVIS, SJ (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,MRC,CELLULAR IMMUNOL UNIT,OXFORD OX1 3RE,ENGLAND.							BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; CHANH TC, 1987, P NATL ACAD SCI USA, V84, P3891, DOI 10.1073/pnas.84.11.3891; CHOI AHC, 1988, VIROLOGY, V163, P191, DOI 10.1016/0042-6822(88)90246-2; CO MS, 1985, P NATL ACAD SCI USA, V82, P5315, DOI 10.1073/pnas.82.16.5315; DALGLEISH AG, 1987, LANCET, V2, P1047; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; EICHMANN K, 1974, EUR J IMMUNOL, V4, P296, DOI 10.1002/eji.1830040413; Estess P, 1990, CURRENT RES PROTEIN, P499; FLUGGE UI, 1991, NATURE, V353, P364, DOI 10.1038/353364a0; GAULTON GN, 1986, ANNU REV IMMUNOL, V4, P253, DOI 10.1146/annurev.iy.04.040186.001345; GENTSCH JR, 1987, VIROLOGY, V161, P245, DOI 10.1016/0042-6822(87)90192-9; HEALEY DG, 1991, EUR J IMMUNOL, V21, P1491, DOI 10.1002/eji.1830210624; KRETH HW, 1973, EUR J IMMUNOL, V3, P141, DOI 10.1002/eji.1830030306; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; MASON DW, 1980, BIOCHEM J, V187, P1; PAIN D, 1990, NATURE, V347, P444, DOI 10.1038/347444a0; PAIN D, 1988, NATURE, V331, P232, DOI 10.1038/331232a0; PAUL RW, 1989, VIROLOGY, V172, P382, DOI 10.1016/0042-6822(89)90146-3; PAUL RW, 1987, VIROLOGY, V159, P94, DOI 10.1016/0042-6822(87)90351-5; REEVES JP, 1991, AIDS RES HUM RETROV, V7, P55, DOI 10.1089/aid.1991.7.55; SATTENTAU QJ, 1989, J EXP MED, V170, P1319, DOI 10.1084/jem.170.4.1319; SATTENTAU QJ, 1986, SCIENCE, V234, P1120, DOI 10.1126/science.2430333; SCHOCKMEL GA, 1992, J EXP MED, V175, P301, DOI 10.1084/jem.175.1.301; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEGE K, 1978, P NATL ACAD SCI USA, V75, P2443, DOI 10.1073/pnas.75.5.2443; STAUDT LM, 1983, J EXP MED, V157, P687, DOI 10.1084/jem.157.2.687; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; VAUX DJT, 1988, NATURE, V336, P36, DOI 10.1038/336036a0; WILKS D, 1991, J INFECT DIS, V163, P389, DOI 10.1093/infdis/163.2.389	31	66	73	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					76	79		10.1038/358076a0	http://dx.doi.org/10.1038/358076a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614536				2022-12-28	WOS:A1992JB34100058
J	KESSLER, DA; TAYLOR, MR; MARYANSKI, JH; FLAMM, EL; KAHL, LS				KESSLER, DA; TAYLOR, MR; MARYANSKI, JH; FLAMM, EL; KAHL, LS			THE SAFETY OF FOODS DEVELOPED BY BIOTECHNOLOGY	SCIENCE			English	Article							ENZYMES		US FDA,CTR FOOD SAFETY & APPL NUTR,DIV FOOD & COLOR ADDIT,ROCKVILLE,MD 20857; US FDA,OFF BIOTECHNOL,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	KESSLER, DA (corresponding author), US FDA,POLICY,5600 FISHERS LANE,ROCKVILLE,MD 20857, USA.							BERKOWITZ DB, 1990, BIO-TECHNOL, V8, P819, DOI 10.1038/nbt0990-819; HOPKINS DD, 1991, MUTABLE FEAST ASSURI; JAFFE WG, 1973, TOXICANTS OCCURRING, P106; PARIZA MW, 1983, J FOOD PROTECT, V46, P453, DOI 10.4315/0362-028X-46.5.453; VIHINEN M, 1989, CRIT REV BIOCHEM MOL, V24, P329, DOI 10.3109/10409238909082556; 1992, FED REG         0529, V57, P22984; 1989, APPROACHES ASSESSING; IN PRESS REPORT FOOD; 1990, REGUL TOXICOL PHAR 2, V12; 1991, FOOD NEW BIOTECHNOLO; 1991, STRATEGIES ASSESSING	11	82	84	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1747	&		10.1126/science.1615315	http://dx.doi.org/10.1126/science.1615315			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615315				2022-12-28	WOS:A1992JA43400011
J	REICH, CI; VANHOY, RW; PORTER, GL; WISE, JA				REICH, CI; VANHOY, RW; PORTER, GL; WISE, JA			MUTATIONS AT THE 3' SPLICE SITE CAN BE SUPPRESSED BY COMPENSATORY BASE CHANGES IN U1 SNRNA IN FISSION YEAST	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SIGNAL RECOGNITION PARTICLE; SCHIZOSACCHAROMYCES-POMBE; INTRON SEQUENCES; SACCHAROMYCES-CEREVISIAE; MAMMALIAN INTRONS; LARIAT FORMATION; GENE; BINDING	U1 snRNA is an essential splicing factor known to base pair with 5' splice sites of premessenger RNAs. We demonstrate that pairing between the universally conserved CU just downstream from the 5' junction interaction region and the 3' splice site AG contributes to efficient splicing of Schizosaccharomyces pombe introns that typify the AG-dependent class described in mammals. Strains carrying mutations in the 3' AG of an artificial intron accumulate linear precursor, indicative of a first step block. Lariat formation is partially restored in these mutants by compensatory changes in nucleotides C-7 and U8 of U1 snRNA. ConsiStent with a general role in fission yeast splicing, mutations at C-7 are lethal, while U8 mutants are growth impaired and accumulate linear, unspliced precursor to U6 snRNA. U1 RNA-mediated recognition of the 3' splice site may have origins in analogous intramolecular interactions in an ancestral self-splicing RNA.			REICH, CI (corresponding author), UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA.							AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BACH ML, 1987, CURR GENET, V12, P527, DOI 10.1007/BF00419562; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P841, DOI 10.1093/nar/9.4.841; BRENNWALD P, 1988, MOL CELL BIOL, V8, P1580, DOI 10.1128/MCB.8.4.1580; BURKE JM, 1990, NATURE, V344, P80, DOI 10.1038/344080a0; DUCHENE M, 1988, NUCLEIC ACIDS RES, V16, P7233, DOI 10.1093/nar/16.15.7233; FOUSER LA, 1987, MOL CELL BIOL, V7, P225, DOI 10.1128/MCB.7.1.225; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; GATERMANN KB, 1989, MOL CELL BIOL, V9, P1526, DOI 10.1128/MCB.9.4.1526; GOGUEL V, 1991, GENE DEV, V5, P1430, DOI 10.1101/gad.5.8.1430; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANN BC, 1989, J CELL BIOL, V109, P3223, DOI 10.1083/jcb.109.6.3223; HIMMELSPACH M, 1991, MOL CELL BIOL, V11, P1258, DOI 10.1128/MCB.11.3.1258; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KROL A, 1990, NUCLEIC ACIDS RES, V18, P3803, DOI 10.1093/nar/18.13.3803; LANG KM, 1990, MOL CELL BIOL, V10, P4942, DOI 10.1128/MCB.10.9.4942; LAZAR E, 1982, NUCLEIC ACIDS RES, V10, P1193, DOI 10.1093/nar/10.4.1193; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MOUNT SM, 1981, NUCLEIC ACIDS RES, V9, P6351, DOI 10.1093/nar/9.23.6351; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PORTER G, 1990, MOL CELL BIOL, V10, P2874, DOI 10.1128/MCB.10.6.2874; POTASHKIN J, 1989, NUCLEIC ACIDS RES, V17, P7821, DOI 10.1093/nar/17.19.7821; POTASHKIN J, 1989, EMBO J, V8, P551, DOI 10.1002/j.1460-2075.1989.tb03409.x; REDDY R, 1989, METHOD ENZYMOL, V180, P521; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; REICH C, 1990, MOL CELL BIOL, V10, P5548, DOI 10.1128/MCB.10.10.5548; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, NATURE, V317, P732, DOI 10.1038/317732a0; RYMOND BC, 1986, EMBO J, V5, P3517, DOI 10.1002/j.1460-2075.1986.tb04677.x; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; RYMOND BC, 1987, GENE DEV, V1, P238, DOI 10.1101/gad.1.3.238; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOGIN ML, 1989, INT CONGR SER, V824, P133; STEITZ JA, 1988, STRUCTURE FUNCTION M, P71; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TATEI K, 1987, J BIOL CHEM, V262, P11667; TODA T, 1984, CELL, V37, P233, DOI 10.1016/0092-8674(84)90319-2; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WISE JA, 1991, METHOD ENZYMOL, V194, P405; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZILLMANN M, 1988, MOL CELL BIOL, V8, P814, DOI 10.1128/MCB.8.2.814; ZILLMANN M, 1987, MOL CELL BIOL, V7, P2877, DOI 10.1128/MCB.7.8.2877	65	102	102	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1159	1169		10.1016/0092-8674(92)90637-R	http://dx.doi.org/10.1016/0092-8674(92)90637-R			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617727				2022-12-28	WOS:A1992JA43100010
J	BIGGWITHER, GW; HO, KKY; GRUNSTEIN, RR; SULLIVAN, CE; DOUST, BD				BIGGWITHER, GW; HO, KKY; GRUNSTEIN, RR; SULLIVAN, CE; DOUST, BD			EFFECTS OF LONG-TERM OCTREOTIDE ON GALL STONE FORMATION AND GALL-BLADDER FUNCTION	BRITISH MEDICAL JOURNAL			English	Article							SOMATOSTATIN		ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,CTR SLEEP DISORDERS,CAMPERDOWN,NSW 2050,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney	BIGGWITHER, GW (corresponding author), ST VINCENTS HOSP,DEPT RADIOL,DARLINGHURST,NSW 2010,AUSTRALIA.		Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011	Ho, Ken/0000-0002-2508-9588; 				AHRENDT SA, 1991, AM J SURG, V161, P177, DOI 10.1016/0002-9610(91)90381-M; DODDS WJ, 1985, AM J ROENTGENOL, V145, P1009, DOI 10.2214/ajr.145.5.1009; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; LIESSUM PA, 1989, J CLIN ENDOCR METAB, V69, P557; SASSOLAS G, 1990, J CLIN ENDOCR METAB, V71, P391, DOI 10.1210/jcem-71-2-391	5	33	34	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1611	1612		10.1136/bmj.304.6842.1611	http://dx.doi.org/10.1136/bmj.304.6842.1611			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628089	Green Published, Bronze			2022-12-28	WOS:A1992JA43600024
J	NOVELLO, AC; ROSENBERG, M; SALTZMAN, L; SHOSKY, J				NOVELLO, AC; ROSENBERG, M; SALTZMAN, L; SHOSKY, J			A MEDICAL RESPONSE TO DOMESTIC VIOLENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CTR DIS CONTROL,NATL CTR ENVIRONM HLTH & INJURY CONTROL,ATLANTA,GA 30333; US PHS,WASHINGTON,DC	Centers for Disease Control & Prevention - USA; United States Public Health Service								1991, AM J EPIDEMIOL, V134, P59	1	74	74	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3132	3132		10.1001/jama.267.23.3132	http://dx.doi.org/10.1001/jama.267.23.3132			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593724				2022-12-28	WOS:A1992HX91800004
J	MILLER, AD				MILLER, AD			HUMAN GENE-THERAPY COMES OF AGE	NATURE			English	Review							RETROVIRAL VECTORS; CELLS; EXPRESSION; VIRUS; IMMUNITY; POTENT; INVIVO; MODEL	Advances in the understanding of molecular biology of human disease and the development of efficient gene transfer techniques have resulted in practical approaches to human gene therapy, with new techniques being developed at an increasing rate. The first trials have now begun in humans and initial results are positive.			MILLER, AD (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Miller, Dusty/0000-0002-3736-3660				ASHER AL, 1991, J IMMUNOL, V146, P3227; BARR E, 1991, SCIENCE, V254, P1507, DOI 10.1126/science.1962212; BODINE DM, 1990, P NATL ACAD SCI USA, V87, P3738, DOI 10.1073/pnas.87.10.3738; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; COLOMBO MP, 1991, J EXP MED, V173, P889, DOI 10.1084/jem.173.4.889; CORNETTA K, 1991, HUM GENE THER, V2, P215, DOI 10.1089/hum.1991.2.3-215; CORNETTA K, 1990, HUM GENE THER, V1, P15, DOI 10.1089/hum.1990.1.1-15; CURIEL DT, 1991, P NATL ACAD SCI USA, V88, P8850, DOI 10.1073/pnas.88.19.8850; DHAWAN J, 1991, SCIENCE, V254, P1509, DOI 10.1126/science.1962213; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FRASER CC, 1992, P NATL ACAD SCI USA, V89, P1968, DOI 10.1073/pnas.89.5.1968; GANSBACHER B, 1990, CANCER RES, V50, P7820; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; JIAO SS, 1992, HUM GENE THER, V3, P21, DOI 10.1089/hum.1992.3.1-21; KANTOFF PW, 1987, J EXP MED, V166, P219, DOI 10.1084/jem.166.1.219; KANTOFF PW, 1989, BLOOD, V73, P1066; KOLBERG R, 1992, J NIH RES, V4, P43; KOTIN RM, 1990, P NATL ACAD SCI USA, V87, P2211, DOI 10.1073/pnas.87.6.2211; LOTHROP CD, 1991, BLOOD, V78, P237; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; LYNCH CM, 1992, P NATL ACAD SCI USA, V89, P1138, DOI 10.1073/pnas.89.3.1138; LYNCH CM, 1991, J VIROL, V65, P3887, DOI 10.1128/JVI.65.7.3887-3890.1991; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MILLER AD, 1990, BLOOD, V76, P271; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; PALMER TD, 1989, BLOOD, V73, P438; PALMER TD, 1991, P NATL ACAD SCI USA, V88, P1330, DOI 10.1073/pnas.88.4.1330; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SCADDEN DT, 1990, J VIROL, V64, P424, DOI 10.1128/JVI.64.1.424-427.1990; SCHUENING FG, 1991, BLOOD, V78, P2568; STEAD RB, 1988, BLOOD, V71, P742; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9456, DOI 10.1073/pnas.86.23.9456; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFF JA, 1991, BIOTECHNIQUES, V11, P474; WU GY, 1991, J BIOL CHEM, V266, P14338; ZENKE M, 1990, P NATL ACAD SCI USA, V87, P3655, DOI 10.1073/pnas.87.10.3655; 1991, HUM GENE THER, V2, P331; 1990, HUM GENE THER, V1, P93; 1991, HUM GENE THER, V2, P251	47	824	1180	3	66	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					455	460		10.1038/357455a0	http://dx.doi.org/10.1038/357455a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608446				2022-12-28	WOS:A1992HY05200050
J	CHAPLIN, JE; LASSO, RY; SHORVON, SD; FLOYD, M				CHAPLIN, JE; LASSO, RY; SHORVON, SD; FLOYD, M			NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY - THE SOCIAL AND PSYCHOLOGICAL EFFECTS OF A RECENT DIAGNOSIS OF EPILEPSY	BRITISH MEDICAL JOURNAL			English	Article							PROGNOSIS; SEIZURES	Objectives - To determine the nature and extent of psychosocial problems in epilepsy and their associations. Design - A postal survey was used drawing data from prospective consecutive cases. Data on demographic, medical, and social backgrounds were collected. A specially designed, validated attitude questionnaire examined 14 areas of psychosocial adjustment to epilepsy. Setting - 124 primary care general practices. Subjects - Adults (aged over 17) with a recent diagnosis of epilepsy (within previous 36 months). They were registered with the national general practice study of epilepsy and had a confirmed diagnosis according to the usual criteria. 216 subjects were approached for the survey by their general practitioners; 192 returned questionnaires. Results - Problems in at least one area were experienced by 175 (91%) of the 192 subjects. Problems were generally mild, which contrasts strongly with findings in chronic cases. The areas of greatest concern were fear of seizures (80% of cases; 72% moderate or severe) and fear of stigma in employment (69% of cases; 40% moderate or severe). A highly significant relation was found between psychosocial effects and the frequency and recency of seizures. Conclusions-In the early stages of epilepsy psychosocial effects are closely related to the severity of the medical condition, suggesting that the argument for the stigmatising effect of the diagnosis by itself is less important than previously thought. The findings also suggest that problems may evolve as the condition becomes chronic.	INST NEUROL,LONDON WC1N 3BG,ENGLAND	University of London; University College London	CHAPLIN, JE (corresponding author), CITY UNIV LONDON,CTR REHABIL RESOURCE,DEPT SYST SCI,LONDON EC1V 0HB,ENGLAND.		Shorvon, Simon D/A-2019-2009; Chaplin, John/AAI-8584-2020	Chaplin, John/0000-0001-8128-4225				CHAPLIN JE, 1990, NEUROEPIDEMIOLOGY, V9, P151, DOI 10.1159/000110765; DODRILL CB, 1984, EPILEPSIA, V25, P168, DOI 10.1111/j.1528-1157.1984.tb04173.x; HART YM, 1989, NEUROEPIDEMIOLOGY, V8, P221; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; LEVIN R, 1988, EPILEPSIA, V29, P805, DOI 10.1111/j.1528-1157.1988.tb04238.x; Nunnally J. C, 1981, PSYCHOMETRIC THEORY; RODIN EA, 1972, EPILEPSIA, V13, P121, DOI 10.1111/j.1528-1157.1972.tb04559.x; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SHORVON SD, 1984, J NEUROL NEUROSUR PS, V47, P1157, DOI 10.1136/jnnp.47.11.1157; WRIGHT GN, 1978, NEW DIMENSIONS REHAB, P492	10	61	61	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1416	1418		10.1136/bmj.304.6839.1416	http://dx.doi.org/10.1136/bmj.304.6839.1416			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628019	Green Published, Bronze			2022-12-28	WOS:A1992HX08200023
J	DELAMOTHE, T				DELAMOTHE, T			HEALTH-CARE IN RUSSIA - HELPING RUSSIA	BRITISH MEDICAL JOURNAL			English	Article																			0	7	7	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1432	1434		10.1136/bmj.304.6839.1432	http://dx.doi.org/10.1136/bmj.304.6839.1432			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628025	Bronze, Green Published			2022-12-28	WOS:A1992HX08200030
J	FENG, Q; PARK, TK; REBEK, J				FENG, Q; PARK, TK; REBEK, J			CROSSOVER REACTIONS BETWEEN SYNTHETIC REPLICATORS YIELD ACTIVE AND INACTIVE RECOMBINANTS	SCIENCE			English	Article								Self-replicating molecules can be synthesized through the covalent linkage of two complementary subunits to give a self-complementary structure. Complementarity refers to sizes, shapes, and the weak intermolecular forces involved in molecular recognition between the two subunits. In order to provide a model system for evolution at the molecular level, "crossover" or recombination experiments were staged with synthetic replicators. These reactions gave rise to new structural types. The ability (or inability) of the new recombinants to catalyze their own formation is shown to be a consequence of their molecular shapes.			FENG, Q (corresponding author), MIT,DEPT CHEM,CAMBRIDGE,MA 02139, USA.							BACHMANN PA, 1991, J AM CHEM SOC, V113, P8204, DOI 10.1021/ja00022a002; BARR RG, 1986, J PHYS CHEM-US, V90, P328, DOI 10.1021/j100274a026; ETTER MC, 1986, J AM CHEM SOC, V108, P5871, DOI 10.1021/ja00279a035; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; KEMP DS, 1981, J ORG CHEM, V46, P5140, DOI 10.1021/jo00338a014; NOWICK JS, 1991, J AM CHEM SOC, V113, P8831, DOI 10.1021/ja00023a036; NOWICK JS, 1990, J AM CHEM SOC, V112, P8902, DOI 10.1021/ja00180a038; PARK TK, IN PRESS J AM CHEM S; ROTELLO V, 1991, J AM CHEM SOC, V113, P9422, DOI 10.1021/ja00024a089; SIMARD M, 1991, J AM CHEM SOC, V113, P4696, DOI 10.1021/ja00012a057; von Kiedrowski G. A, 1986, ANGEW CHEM, V98, P932; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; ZIELINSKI WS, 1987, NATURE, V327, P346, DOI 10.1038/327346a0	13	59	59	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1179	1180		10.1126/science.256.5060.1179	http://dx.doi.org/10.1126/science.256.5060.1179			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589798				2022-12-28	WOS:A1992HV19200027
J	KIM, SG; MANNINO, MM; CHOU, R; ROTH, S; ROTH, JA; DESAI, B; FERRICK, KJ; FISHER, JD				KIM, SG; MANNINO, MM; CHOU, R; ROTH, S; ROTH, JA; DESAI, B; FERRICK, KJ; FISHER, JD			RAPID SUPPRESSION OF SPONTANEOUS VENTRICULAR ARRHYTHMIAS DURING ORAL AMIODARONE LOADING	ANNALS OF INTERNAL MEDICINE			English	Article						AMIODARONE; ARRHYTHMIA; VENTRICULAR FIBRILLATION; TACHYCARDIA; EXTRASYSTOLE	CLASS-1A ANTIARRHYTHMIC AGENT; PROGRAMMED STIMULATION; MYOCARDIAL CONCENTRATIONS; TACHYCARDIA INDUCTION; CARDIAC-ARRHYTHMIAS; CLINICAL EFFICACY; THERAPY; COMBINATION; SAFETY; PLASMA	Objective: To determine the time course of effects of amiodarone during an oral loading period. Design: A prospective, nonrandomized study. Setting: Arrhythmia referral center at a university hospital. Patients: Fifty patients with refractory sustained ventricular tachycardia (n = 44) or ventricular fibrillation (n = 6) and frequent (greater-than-or-equal-to 30/h) ventricular premature complexes. Intervention: Oral amiodarone, 1200 mg/d for 14 days and 400 mg/d thereafter. Measurements: Ambulatory electrocardiographic monitorings, 12-lead electrocardiograms, and amiodarone blood levels on days 3, 5, 7, 9, 11, 13, and 28. Results: Dramatic reductions of ventricular arrhythmias were noted during the first 72 hours of the therapy. Average ventricular premature complexes/h, couplets/h, and nonsustained ventricular tachycardias/24 h were 524 +/- 1224/h, 16 +/- 61 /h, and 167 +/- 611/24 h, respectively, at baseline, and reduced to 140 +/- 243/h, 11 +/- 50/h, and 33 +/- 117/24 h, respectively, on day 3 (P < 0.05 for all). Subsequent reductions of ventricular arrhythmias from day 3 to day 13 were more gradual but were still significant (P < 0.05). A significant reduction of ventricular arrhythmias (greater-than-or-equal-to 70% reduction of ventricular premature complexes and greater-than-or-equal-to 90% reduction of nonsustained ventricular tachycardias) was noted in 50% of patients on day 3, in 65% on day 7, and in 83% on day 13. Prolongation of the OT interval exhibited a similar time course. There were no further differences in reduction of ventricular premature complexes or OT intervals between day 13 and day 28. Conclusions: Oral amiodarone given in loading doses produces rapid and dramatic reductions in spontaneous ventricular arrhythmias within 72 hours. Subsequent reductions of spontaneous arrhythmia were gradual and less dramatic.	MONTEFIORE MED CTR, DEPT MED, BRONX, NY 10467 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	KIM, SG (corresponding author), MONTEFIORE MED CTR, DIV CARDIOL, 111 E 210TH ST, BRONX, NY 10467 USA.			Fisher, John/0000-0003-2748-8715				[Anonymous], 1986, Am J Cardiol, V57, P91; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BORBOLA J, 1988, AM HEART J, V115, P1202, DOI 10.1016/0002-8703(88)90009-9; DEBBAS NMG, 1984, BRIT HEART J, V51, P316; ESCOUBET B, 1985, AM J CARDIOL, V55, P696, DOI 10.1016/0002-9149(85)90139-0; GREENSPON AJ, 1988, J AM COLL CARDIOL, V11, P117, DOI 10.1016/0735-1097(88)90176-3; HAFFAJEE CI, 1983, AM HEART J, V106, P935, DOI 10.1016/0002-8703(83)90019-4; KIM SG, 1987, AM J CARDIOL, V60, P288, DOI 10.1016/0002-9149(87)90229-3; KIM SG, 1988, AM J CARDIOL, V62, P7; KIM SG, 1987, CIRCULATION, V76, P1, DOI 10.1161/01.CIR.76.1.1; KIM SG, 1985, AM J CARDIOL, V56, P84, DOI 10.1016/0002-9149(85)90571-5; KIM SG, 1987, J AM COLL CARDIOL, V9, P398, DOI 10.1016/S0735-1097(87)80395-9; KIM SG, 1987, AM J CARDIOL, V59, P1314, DOI 10.1016/0002-9149(87)90911-8; MARCHLINSKI FE, 1985, AM J CARDIOL, V55, P709, DOI 10.1016/0002-9149(85)90141-9; MASON JW, 1991, CIRCULATION, V84, P348; MITCHELL LB, 1989, CIRCULATION, V80, P34, DOI 10.1161/01.CIR.80.1.34; MITCHELL LB, 1987, NEW ENGL J MED, V317, P1681, DOI 10.1056/NEJM198712313172701; MORADY F, 1986, J AM COLL CARDIOL, V7, P148, DOI 10.1016/S0735-1097(86)80273-X; MORGANROTH J, 1978, CIRCULATION, V58, P408, DOI 10.1161/01.CIR.58.3.408; MOSTOW ND, 1984, AM J CARDIOL, V54, P569, DOI 10.1016/0002-9149(84)90250-9; MOSTOW ND, 1986, CIRCULATION, V73, P1231, DOI 10.1161/01.CIR.73.6.1231; NADEMANEE K, 1982, CIRCULATION, V66, P200; RAKITA L, 1983, JAMA-J AM MED ASSOC, V250, P1293, DOI 10.1001/jama.250.10.1293; ROSENBAUM MB, 1976, AM J CARDIOL, V38, P934, DOI 10.1016/0002-9149(76)90807-9; ROSENFELD LE, 1987, AM HEART J, V114, P1367, DOI 10.1016/0002-8703(87)90538-2; SIDDOWAY LA, 1983, AM HEART J, V106, P951, DOI 10.1016/0002-8703(83)90021-2; SINGH BN, 1984, PACE, V7, P109, DOI 10.1111/j.1540-8159.1984.tb04867.x; VELTRI EP, 1985, J AM COLL CARDIOL, V6, P806, DOI 10.1016/S0735-1097(85)80487-3; VELTRI EP, 1985, AM J CARDIOL, V55, P375, DOI 10.1016/0002-9149(85)90379-0; WELLENS HJJ, 1984, CIRCULATION, V69, P120, DOI 10.1161/01.CIR.69.1.120; WINKLE RA, 1978, CIRCULATION, V57, P1116, DOI 10.1161/01.CIR.57.6.1116	31	7	7	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					197	201		10.7326/0003-4819-117-3-197	http://dx.doi.org/10.7326/0003-4819-117-3-197			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616213				2022-12-28	WOS:A1992JF30400004
J	RASKIN, P; ARAUZPACHECO, C				RASKIN, P; ARAUZPACHECO, C			THE TREATMENT OF DIABETIC-RETINOPATHY - A VIEW FOR THE INTERNIST	ANNALS OF INTERNAL MEDICINE			English	Review						DIABETIC RETINOPATHY; LIGHT COAGULATION; VITRECTOMY; INSULIN; MACULAR DEGENERATION	BLOOD-GLUCOSE CONTROL; GLYCEMIC CONTROL; MACULAR EDEMA; MEXICAN-AMERICANS; ALDOSE REDUCTASE; LONG-TERM; PROGRESSION; RISK; PRESSURE; COMPLICATIONS	Purpose: To review the status of surgical and medical therapy for diabetic retinopathy from the perspective of the non-ophthalmologist. Data Sources: Relevant English-language articles published from January 1981 to July 1991 were identified through MEDLINE. Other relevant articles were obtained from the authors' personal database. Study Selection: For the review of surgical treatment, large randomized, controlled trials were selected. For the review of medical treatment, randomized studies comparing intensive insulin treatment with conventional insulin therapy were selected, as were double-blind, randomized, controlled trials of aldose-reductase inhibitor therapy and antiplatelet therapy in patients with diabetic retinopathy. Data Extraction: Emphasis is on findings from large, multicenter, randomized, controlled studies. Data Synthesis: Surgery is effective in three clinical situations: Panretinal (scatter) photocoagulation is effective treatment for proliferative retinopathy that is likely to progress to severe visual loss, with such therapy resulting in a 50% to 60% decrease in the main outcome (visual acuity of 5/200 or less; focal photocoagulation decreases the incidence of deterioration of visual acuity by 60% in patients with clinically significant macular edema, but no benefit of photocoagulation has been shown in patients with mild-to-moderate background diabetic retinopathy; and vitrectomy is effective in improving visual acuity only in patients with severe, complicated proliferative retinopathy. Intensive insulin therapy has not been consistently effective in short-term studies with small numbers of subjects. Results of the Diabetes Control and Complications Trial should show whether intensive insulin therapy affects the course of diabetic complications. Aldose-reductase inhibitors have not shown efficacy in changing the course of diabetic retinopathy. Results of trials using antiplatelet agents are controversial. Conclusions. Current therapy of diabetic retinopathy is based on detection and surgical treatment of advanced lesions. Medical interventions that effectively halt the progression or prevent the development of diabetic retinopathy are needed.			RASKIN, P (corresponding author), UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.							AKAGI Y, 1983, INVEST OPHTH VIS SCI, V24, P1516; [Anonymous], 1988, OPHTHALMOLOGY, V95, P1307; [Anonymous], 1985, Arch Ophthalmol, V103, P1644; Arauz-Pacheco Carlos, 1992, Journal of Diabetes and its Complications, V6, P131, DOI 10.1016/1056-8727(92)90024-F; BAUDOIN C, 1989, DIABETES, V38, P491; BLACKENSHIP GW, 1985, OPHTHALMOLOGY, V92, P503; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; BRINCHMANNHANSEN O, 1988, OPHTHALMOLOGY, V95, P1358; CERUTTI F, 1989, OPHTHALMOLOGICA, V198, P116, DOI 10.1159/000309971; CHAHAL P, 1985, HYPERTENSION, V7, P79; CHASE HP, 1990, OPHTHALMOLOGY, V97, P155; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; DAHLJORGENSEN K, 1986, BRIT MED J, V293, P1195, DOI 10.1136/bmj.293.6556.1195; DCCT Res Grp, 1986, DIABETES, V35, P530; DOFT BH, 1984, OPHTHALMOLOGY, V91, P1453; ELMAN KD, 1990, OBSTET GYNECOL, V75, P119; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FRIBERG TR, 1985, OPHTHALMOLOGY, V92, P1051; GARDNER LI, 1984, DIABETES, V33, P86, DOI 10.2337/diabetes.33.1.86; HAFFNER SM, 1988, DIABETES, V37, P878, DOI 10.2337/diabetes.37.7.878; HOTTA N, 1990, DIABETES S1, V39, pA61; JANKA HU, 1989, DIABETES, V38, P460, DOI 10.2337/diabetes.38.4.460; JAVITT JC, 1989, OPHTHALMOLOGY, V96, P255; JOHNSSON S, 1960, DIABETES, V9, P1; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KAUFMAN SC, 1989, INVEST OPHTH VIS SCI, V30, P23; KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746; KLEIN BE, 1982, DIABETES CARE, V13, P34; KLEIN R, 1985, DIABETES CARE, V8, P311, DOI 10.2337/diacare.8.4.311; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1780, DOI 10.1001/archopht.1989.01070020862028; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1988, ARCH INTERN MED, V148, P181, DOI 10.1001/archinte.148.1.181; KLEIN R, 1988, MED CLIN N AM, V72, P1415, DOI 10.1016/S0025-7125(16)30715-5; KLEIN R, 1984, OPHTHALMOLOGY, V91, P1464; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1989, ARCH INTERN MED, V149, P2427, DOI 10.1001/archinte.149.11.2427; KLEIN R, 1989, OPHTHALMOLOGY, V96, P1501; KLEIN R, 1986, DIABETIC RENAL RETIN, V3, P245; KNOWLER WC, 1980, NEW ENGL J MED, V302, P645, DOI 10.1056/NEJM198003203021201; KOHNER M, 1990, DIABETES S1, V39, pA62; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LAURITZEN T, 1983, LANCET, V1, P200; LESPERANCE FA, 1990, DIABETES MELLITUS TH, P661; LESPERANCE FA, 1989, OPHTHALMIC LASERS, P159; MERIMEE TJ, 1990, NEW ENGL J MED, V322, P978, DOI 10.1056/NEJM199004053221406; MOLONEY JBM, 1982, AM J OPHTHALMOL, V93, P745, DOI 10.1016/0002-9394(82)90471-8; NATHAN DM, 1991, DIABETES CARE, V14, P26, DOI 10.2337/diacare.14.1.26; NORGAARD K, 1989, DIABETIC MED, V6, P325, DOI 10.1111/j.1464-5491.1989.tb01173.x; PIRART J, 1977, DIABETES METAB, V3, P97; RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302; RASKIN P, 1987, AM J MED, V83, P298, DOI 10.1016/0002-9343(87)90702-9; RICE TA, 1983, AM J OPHTHALMOL, V95, P22, DOI 10.1016/0002-9394(83)90330-6; ROSENSTOCK J, 1986, AM J MED, V81, P1012, DOI 10.1016/0002-9343(86)90398-0; ROSENSTOCK J, 1988, DIABETES METAB REV, V4, P417, DOI 10.1002/dmr.5610040502; SHERWIN RS, 1988, JAMA-J AM MED ASSOC, V260, P37; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; STARUP K, 1980, ACTA OPHTHALMOL, V58, P347; STERN MP, 1983, DIABETOLOGIA, V24, P272, DOI 10.1007/BF00282712; TEUSCHER A, 1988, DIABETES CARE, V11, P246, DOI 10.2337/diacare.11.3.246; 1983, OPHTHALMOLOGY, V88, P583; 1987, ARCH OPHTHALMOL-CHIC, V103, P1976; 1990, ARCH OPHTHALMOL-CHIC, V108, P1577; 1990, ARCH OPHTHALMOL-CHIC, V108, P1234; 1991, OPHTHALMOLOGY S5, V98, P739; 1991, OPHTHAL S, V98, P757	69	14	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					226	233		10.7326/0003-4819-117-3-226	http://dx.doi.org/10.7326/0003-4819-117-3-226			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616217				2022-12-28	WOS:A1992JF30400010
J	BARRALNETTO, M; BARRAL, A; BROWNELL, CE; SKEIKY, YAW; ELLINGSWORTH, LR; TWARDZIK, DR; REED, SG				BARRALNETTO, M; BARRAL, A; BROWNELL, CE; SKEIKY, YAW; ELLINGSWORTH, LR; TWARDZIK, DR; REED, SG			TRANSFORMING GROWTH-FACTOR-BETA IN LEISHMANIAL INFECTION - A PARASITE ESCAPE MECHANISM	SCIENCE			English	Article							INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; IFN-GAMMA; EXPRESSION; FACTOR-BETA-1; MACROPHAGES; LYMPHOKINE; ANTIGENS; SUBSETS; CELLS	The course of infection with the protozoan parasite Leishmania is determined in part by their early replication in macrophages, the exclusive host cells for these organisms. Although factors contributing to the survival of Leishmania are not well understood, cytokines influence the course of infection. Transforming growth factor-beta (TGF-beta) is a multipotential cytokine with diverse effects on cells of the immune system, including down-regulation of certain macrophage functions. Leishmanial infection induced the production of active TGF-beta, both in vitro and in vivo. TGF-beta was important for determining in vivo susceptibility to experimental leishmanial infection.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; FED UNIV BAHIA,SCH MED,BR-40140 SALVADOR,BA,BRAZIL; CELTRIX LABS INC,PALO ALTO,CA 94303; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021	Center for Infectious Disease Research; Bristol-Myers Squibb; Cornell University			Barral-Netto, Manoel/B-3904-2009; Barral, Aldina/B-4191-2009	Barral-Netto, Manoel/0000-0002-5823-7903; Barral, Aldina/0000-0002-7177-464X	FIC NIH HHS [TW-00018] Funding Source: Medline; NIAID NIH HHS [AI-25038, AI-16282] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025038, P01AI016282] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASSOIAN RK, 1987, P NATL ACAD SCI USA, V84, P6020, DOI 10.1073/pnas.84.17.6020; BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; DING A, 1990, J IMMUNOL, V145, P940; HARMS G, 1989, LANCET, V1, P1287; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEHRL JH, 1986, J IMMUNOL, V137, P3855; MULE JJ, 1988, CANCER IMMUNOL IMMUN, V26, P95; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; NELSON BJ, 1991, J IMMUNOL, V146, P1849; SADICK MD, 1991, INFECT IMMUN, V59, P4710, DOI 10.1128/IAI.59.12.4710-4714.1991; SAMUELSON J, 1991, J EXP MED, V173, P49, DOI 10.1084/jem.173.1.49; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; SILVA JS, 1991, J EXP MED, V174, P539, DOI 10.1084/jem.174.3.539; SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169; TITUS RG, 1988, SCIENCE, V239, P1306, DOI 10.1126/science.3344436; TSUNAWAKI S, 1988, NATURE, V334, P260, DOI 10.1038/334260a0; WAHL SM, 1988, J IMMUNOL, V140, P3026	21	395	406	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					545	548		10.1126/science.1636092	http://dx.doi.org/10.1126/science.1636092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636092				2022-12-28	WOS:A1992JE75500034
J	TAKESHITA, T; ASAO, H; OHTANI, K; ISHII, N; KUMAKI, S; TANAKA, N; MUNAKATA, H; NAKAMURA, M; SUGAMURA, K				TAKESHITA, T; ASAO, H; OHTANI, K; ISHII, N; KUMAKI, S; TANAKA, N; MUNAKATA, H; NAKAMURA, M; SUGAMURA, K			CLONING OF THE GAMMA-CHAIN OF THE HUMAN IL-2 RECEPTOR	SCIENCE			English	Article							HUMAN INTERLEUKIN-2 RECEPTOR; COLONY-STIMULATING FACTOR; NATURAL-KILLER-CELLS; HUMAN T-CELLS; BETA-CHAIN; MOLECULAR-CLONING; SIGNAL TRANSDUCTION; LIGAND-BINDING; EXPRESSION; PROTEINS	A third subunit, the gamma-chain, of the human interleukin-2 receptor (IL-2R) was identified, and a complementary DNA clone encoding this member of the cytokine receptor family was isolated. The gamma-chain is necessary for the formation of the high- and intermediate-affinity receptors, which consist of alpha-beta-gamma-heterotrimers and beta-gamma-heterodimers, respectively. The IL-2R on murine fibroblastoid cells can be internalized after binding IL-2 only if the gamma-chain is present; alpha and beta are insufficient for internalization. Thus, the gamma-chain is an indispensable component of the functional IL-2R.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; TOHOKU UNIV,SCH MED,DEPT BIOCHEM 2,SENDAI,MIYAGI 980,JAPAN	Tohoku University; Tohoku University			Takeshita, Toshikazu/AAL-1382-2021	Ishii, Naoto/0000-0002-0549-8245				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HATAKEYAMA M, 1985, NATURE, V317, P467; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERRMANN F, 1985, J EXP MED, V162, P1111, DOI 10.1084/jem.162.3.1111; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ISHII T, 1987, BIOCHEM J, V242, P211, DOI 10.1042/bj2420211; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MINAMOTO S, 1990, J IMMUNOL, V145, P2177; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; Suzuki J, 1989, Int Immunol, V1, P373, DOI 10.1093/intimm/1.4.373; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TAKESHITA T, 1992, J IMMUNOL, V148, P2157; TANAKA Y, 1985, MICROBIOL IMMUNOL, V29, P959, DOI 10.1111/j.1348-0421.1985.tb02960.x; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TRINCHIERI G, 1984, J EXP MED, V160, P1147, DOI 10.1084/jem.160.4.1147; TSUDO M, 1990, J IMMUNOL, V145, P599; VOSS SD, 1990, J EXP MED, V172, P1101, DOI 10.1084/jem.172.4.1101; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZURAWSKI SM, 1990, EMBO J, V9, P3899, DOI 10.1002/j.1460-2075.1990.tb07610.x	35	877	924	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					379	382		10.1126/science.1631559	http://dx.doi.org/10.1126/science.1631559			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631559				2022-12-28	WOS:A1992JD67400032
J	FEDER, J; ROWLAND, D				FEDER, J; ROWLAND, D			GOVERNMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FEDER, J (corresponding author), KAISER COMMISS FUTURE MEDICAID,BALTIMORE,MD, USA.							Blendon R J, 1992, J Am Health Policy, V2, P21; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2509, DOI 10.1001/jama.267.18.2509; ROCKEFELLER JD, 1990, NEW ENGL J MED, V323, P1005, DOI 10.1056/NEJM199010043231429; ROWLAND D, 1991, JAMA-J AM MED ASSOC, V265, P3127; 1990, CALL ACTION FINAL RE; 1992, SOURCES HLTH INSURAN	6	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					362	364						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613921				2022-12-28	WOS:A1992JC35200032
J	JOYNT, RJ				JOYNT, RJ			NEUROLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											JOYNT, RJ (corresponding author), UNIV ROCHESTER,SCH MED & DENT,ROCHESTER,NY 14642, USA.							ADLER J, 1991, ARCH NEUROL-CHICAGO, V48, P133, DOI 10.1001/archneur.1991.00530140025013; Barnett H. J. M., 1991, NEW ENGL J MED, V325, P445; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CADY RK, 1991, JAMA-J AM MED ASSOC, V265, P2831, DOI 10.1001/jama.265.21.2831; FENICHEL GM, 1991, ARCH NEUROL-CHICAGO, V48, P575, DOI 10.1001/archneur.1991.00530180027012; KRUMHOLZ A, 1991, JAMA-J AM MED ASSOC, V265, P622, DOI 10.1001/jama.265.5.622; KUMAR A, 1991, ARCH NEUROL-CHICAGO, V48, P160, DOI 10.1001/archneur.1991.00530140052017; MARX J, 1992, SCIENCE, V255, P1200, DOI 10.1126/science.1312259; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SOFRONIEW MV, 1991, TINS, V12, P513; TUSZYNSKI MH, 1991, ANN NEUROL, V30, P625, DOI 10.1002/ana.410300502	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					380	382						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613927				2022-12-28	WOS:A1992JC35200039
J	RANDALL, LL				RANDALL, LL			PEPTIDE BINDING BY CHAPERONE SECB - IMPLICATIONS FOR RECOGNITION OF NONNATIVE STRUCTURE	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN EXPORT; TRANSLOCATION; PREPROTEIN; MEMBRANE; INVITRO	The molecular basis for recognition of nonnative proteins by the molecular chaperone SecB was investigated with an in vitro assay based on the protection of SecB from proteolysis when a ligand is bound. The SecB tetramer has multiple binding sites for positively charged peptides. When the peptide binding sites are occupied, the complex undergoes a conformational change to expose hydrophobic sites that bind the fluorescent probe 1-anilino-naphthalene-8-sulfonate. A model is proposed for interaction of nonnative polypeptides with both hydrophilic and hydrophobic sites on SecB.			RANDALL, LL (corresponding author), WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, R01GM029798] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DAVIDSON B, 1967, BIOCHEMISTRY-US, V6, P1616, DOI 10.1021/bi00858a008; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIERASCH LM, 1992, ANTON LEEUW INT J G, V61, P93, DOI 10.1007/BF00580613; HARDY SJS, 1991, SCIENCE, V251, P439, DOI 10.1126/science.1989077; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; ICHIMURA S, 1977, BIOPOLYMERS, V16, P1449, DOI 10.1002/bip.1977.360160706; KUMAMOTO CA, 1985, J BACTERIOL, V163, P267, DOI 10.1128/JB.163.1.267-274.1985; KUMAMOTO CA, 1989, J BIOL CHEM, V264, P2242; LYNN J, 1968, BIOCHEM BIOPH RES CO, V33, P327, DOI 10.1016/0006-291X(68)90788-2; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; Park K.- Y., UNPUB; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; RANDALL LL, 1990, SCIENCE, V248, P860, DOI 10.1126/science.2188362; WATANABE M, 1989, P NATL ACAD SCI USA, V86, P2728, DOI 10.1073/pnas.86.8.2728; WEISS JB, 1988, P NATL ACAD SCI USA, V85, P8978, DOI 10.1073/pnas.85.23.8978	16	110	114	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	1992	257	5067					241	245		10.1126/science.1631545	http://dx.doi.org/10.1126/science.1631545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC585	1631545				2022-12-28	WOS:A1992JC58500039
J	MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LI, J; TATEO, IM				MANGANO, DT; BROWNER, WS; HOLLENBERG, M; LI, J; TATEO, IM			LONG-TERM CARDIAC PROGNOSIS FOLLOWING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERIPHERAL VASCULAR-DISEASE; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; MORTALITY; RISK; INDEX	Objective.-To determine the long-term (2-year) cardiac prognosis of high-risk patients undergoing noncardiac surgery and to determine the predictors of long-term adverse cardiac outcome. Design.-Prospective cohort study. Historical, clinical, and laboratory data were collected during the in-hospital period, and at 6 months, 1 year, and 2 years following surgery. Data were analyzed using proportional hazards models. Setting.-University-affiliated Veterans Affairs medical center. Population.-A consecutive sample of 444 patients with or at high risk for coronary artery disease who had undergone elective noncardiac surgery and were discharged from the hospital in stable condition. Main Outcome Measures.-Cardiac death, myocardial infarction, unstable angina, progressive angina requiring coronary artery bypass graft surgery or coronary angioplasty, and new unstable angina requiring hospitalization. Results.-Forty-seven patients (11%) had major cardiovascular complications during a 728-day (median) follow-up period: 24 had cardiac death; 11, nonfatal myocardial infarction; six, progressive angina requiring coronary artery bypass graft surgery or coronary angioplasty; and six, new unstable angina requiring hospitalization. Thirty percent of outcomes occurred within 6 months of surgery and 64% within 1 year. Five independent predictors of long-term outcome were identified. Three predictors reflected the preexisting chronic disease state: (1) the presence of known vascular disease (hazard ratio, 6.1; 95% confidence interval [CI], 2.5 to 15.0; P<.0001); (2) a history of congestive heart failure (hazard ratio, 5.0; 95% CI, 2.0 to 12.0; P<.0005); and (3) known coronary artery disease (hazard ratio, 3.7; 95% CI, 1.7 to 8.0; P<.0007). Two predictors reflected acute postoperative ischemic events: (1) myocardial infarction/unstable angina (hazard ratio, 20; 95% CI, 7.5 to 53.0; P<.0001) and (2) myocardial ischemia (hazard ratio, 2.2; 95% CI, 1.1 to 4.3; P<.03). Patients surviving a postoperative in-hospital myocardial infarction had a 28-fold increase in the rate of subsequent cardiac complications within 6 months following surgery, a 15-fold increase within 1 year, and a 14-fold increase within 2 years (95% CI, 5.8 to 32; P<.00001). Seventy percent of all long-term adverse outcomes were preceded by in-hospital postoperative ischemia that occurred at least 30 days (median, 282 days) before the long-term event. The development of congestive heart failure or ventricular tachycardia (without ischemia) during hospitalization was not associated with adverse long-term outcome. Conclusions.-The incidence of long-term adverse cardiac outcomes following noncardiac surgery is substantial. At increased risk are patients with chronic cardiovascular disease; at highest risk are patients with acute perioperative ischemic events. We conclude that survivors of in-hospital perioperative ischemic events, specifically myocardial infarction, unstable angina, and postoperative ischemia, warrant more aggressive long-term follow-up and treatment than is currently practiced.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; DEPT VET AFFAIRS MED CTR,SAN FRANCISCO,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	MANGANO, DT (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT VET AFFAIRS MED CTR 129,DEPT ANESTHESIA,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.			Tice, Jeffrey/0000-0002-9857-2028	NHLBI NIH HHS [R01-HL36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; ASHBURN WL, 1980, RADIOL CLIN N AM, V18, P467; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BRAUNWALD E, 1984, HEART FAILURE, P1; CHAITMAN BR, 1979, CIRCULATION, V59, P560, DOI 10.1161/01.CIR.59.3.560; CRAWFORD ES, 1981, SURGERY, V90, P1055; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; FORSTER ED, 1986, ANN THORAC SURG, V41, P42; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P156; HARRISON DC, 1985, AM J CARDIOL, V56, pC10, DOI 10.1016/S0002-9149(85)80003-5; HERTZER NR, 1980, ANN SURG, V192, P667; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; HERTZER NR, 1982, CLEVELAND CLIN Q, V49, P1; HERTZER NR, 1981, ANN SURG, V193, P493; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KANNEL WB, 1984, CIRCULATION, V70, P331, DOI 10.1161/01.CIR.70.3.331; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; MACKEY WC, 1990, J VASC SURG, V11, P226, DOI 10.1067/mva.1990.17574; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1990, NEW ENGL J MED, V323, P1171; MEHTA J, 1985, J LAB CLIN MED, V106, P661; RABY KE, 1990, AM J CARDIOL, V66, P1309, DOI 10.1016/0002-9149(90)91159-4; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROCCO MB, 1988, CIRCULATION, V78, P877, DOI 10.1161/01.CIR.78.4.877; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SEVERI S, 1989, AM J CARDIOL, V64, P889, DOI 10.1016/0002-9149(89)90837-0; SILICIANO D, 1990, OPIOIDS ANESTHESIA, V2, P164; STONE PH, 1986, J AM COLL CARDIOL, V8, P1007, DOI 10.1016/S0735-1097(86)80374-6; TOMATIS LA, 1972, SURGERY, V71, P429; TZIVONI D, 1988, AM J CARDIOL, V62, P661, DOI 10.1016/0002-9149(88)91198-8; UDELSMAN R, 1987, J CLIN ENDOCR METAB, V64, P986, DOI 10.1210/jcem-64-5-986; YOUNIS LT, 1990, AM HEART J, V119, P1287, DOI 10.1016/S0002-8703(05)80177-2; 1989, PHS891232 US DEP HLT; 1978, MANUAL OPERATIONS, V2; 1983, NEW ENGL J MED, V309, P331	38	249	256	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					233	239		10.1001/jama.268.2.233	http://dx.doi.org/10.1001/jama.268.2.233			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608143				2022-12-28	WOS:A1992JB27900031
J	EDDY, DM; EDDY, MH				EDDY, DM; EDDY, MH			COST-EFFECTIVENESS ANALYSIS - IS IT UP TO THE TASK .20.	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion									DUKE UNIV,DURHAM,NC 27706	Duke University								[Anonymous], 1992, MANUAL ASSESSING HLT; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2439, DOI 10.1001/jama.266.17.2439; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2505; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2498; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2501; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055	10	51	52	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3342	3348		10.1001/jama.267.24.3342	http://dx.doi.org/10.1001/jama.267.24.3342			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597918				2022-12-28	WOS:A1992HY94400039
J	WALLACE, A; SALUZ, H				WALLACE, A; SALUZ, H			BEYOND SILVER STAINING	NATURE			English	Article							POLYACRYLAMIDE GELS; PROTEINS; DNA				WALLACE, A (corresponding author), IST RIC BIOL MOLEC,VIA PONTINA KM 30600,I-00040 POMEZIA,ITALY.							ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; ASKINS BS, 1976, APPL OPTICS, V15, P2860, DOI 10.1364/AO.15.002860; DEMPSTER DT, 1978, THESIS ROCHESTER I T; FYSON JR, 1980, J PHOTOGR SCI, V28, P194; GLAFKIDES P, 1987, CHIMIE PHYSIQUE PHOT, V2; GLAFKIDES P, 1987, CHIMIE PHYSIQUE PHOT, V1; IRIE S, 1982, ANAL BIOCHEM, V126, P350, DOI 10.1016/0003-2697(82)90526-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; MERRIL CR, 1990, NATURE, V343, P779, DOI 10.1038/343779a0; OWUNWANNE A, 1982, J APPL PHOTOGR ENG, V8, P104; SMITH AG, 1985, J IMAGING TECHNOL, V11, P27; SMITHYMAN K, 1985, LANDFALL, V39, P8; SUZUKI S, 1952, J SOC SCI PHOTO 1109; THACKRAY M, 1974, AUTORADIOGRAPHY RADI; VACHON D, 1980, J APPL PHOTOGR ENG, V6, P141; WALLACE A, 1992, ANAL BIOCHEM, V203, P27, DOI 10.1016/0003-2697(92)90038-9	17	4	4	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					608	609		10.1038/357608a0	http://dx.doi.org/10.1038/357608a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608474				2022-12-28	WOS:A1992HZ11200064
J	DURFEE, MJ; GELLERT, GA; TILTONDURFEE, D				DURFEE, MJ; GELLERT, GA; TILTONDURFEE, D			ORIGINS AND CLINICAL RELEVANCE OF CHILD-DEATH REVIEW TEAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABUSE; INJURIES	Interagency child death review teams have emerged in response to the increasing awareness of severe violence against children in the United States. Since 1978, when the first team originated in Los Angeles, Calif, child death review teams have been established across the nation. Approximately 100 million Americans or 40% of the nation's population now live in counties or states served by such teams; most have been formed since 1988. Multiagency child death review involves a systematic, multidisciplinary, and multiagency process to coordinate and integrate data and resources from coroners, law enforcement, courts, child protective services, and health care providers. This article provides an introduction to the unique factors and magnitude of suspicious child deaths, and to the concept and process of interagency child death review. Future expansion of this process should lead to more effective multiagency case management and prevention of future deaths and serious injuries to children from child abuse and neglect.	ORANGE CTY HLTH CARE AGCY,SANTA ANA,CA; LOS ANGELES CTY INTERAGENCY COUNCIL CHILD ABUSE & NEGLECT,LOS ANGELES,CA		DURFEE, MJ (corresponding author), LOS ANGELES CTY DEPT HLTH SERV,313 N FIGUEROA ST,LOS ANGELES,CA 90012, USA.							ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ANDERSON TL, 1992, DATA COLLECTION CHIL; APOLO JU, 1987, PEDIATR EMERG CARE, V2, P93; CHRISTOFFEL KK, 1990, AM J DIS CHILD, V144, P697, DOI 10.1001/archpedi.1990.02150300095025; DARO D, 1992, CURRENT TRENDS CHILD; DURFEE M, 1989, PROTECT CHILD    SPR, P9; FOSSUM RM, 1991, J FORENSIC SCI, V36, P47; GRANIK LA, 1992, CHILD DEATH REV TEAM; GRIEST KJ, 1989, PEDIATRICS, V83, P41; KAPLAN SR, 1992, CHILD FATALITIES INV; KLEINMAN PK, 1989, NEW ENGL J MED, V320, P507, DOI 10.1056/NEJM198902233200807; KRAVITZ RM, 1990, CLIN PEDIATR, V29, P587, DOI 10.1177/000992289002901008; Levin AV, 1990, OPHTHALMOL CLIN N AM, V3, P249; LUNDSTROM M, 1991, PUBLIC WELFARE   SUM, P18; MARGOLIN L, 1990, CHILD WELFARE, V4, P309; MCLOUGHLIN E, 1990, AM J DIS CHILD, V144, P677, DOI 10.1001/archpedi.1990.02150300075020; MEADOW R, 1990, J PEDIATR-US, V117, P351, DOI 10.1016/S0022-3476(05)81072-8; REECE RM, 1990, PEDIATR CLIN N AM, V37, P905; RIFFENBURGH RS, 1991, J FORENSIC SCI, V36, P741; SAUNDERS E, 1989, PUBLIC HEALTH REP, V104, P368; SMITH P, 1991, CHILD DEATH REV REV; SPAIDE RF, 1990, AM FAM PHYSICIAN, V41, P1145; STRANGLER GJ, 1991, PUBLIC WELFARE   FAL, P5; SULLIVAN CA, 1990, CLIN PEDIATR, V29, P587; 1988, CALIFORNIA PROTOCOL; 1990, HLTH PEOPLE 2000 NAT; 1991, CREATING CARING COMM; 1991, CHILD DEATH REV TEAM; 1990, CHILD DEATH REV TEAM; 1990, AJDC, V144, P627; 1990, REPORT OREGON FATALI; 1991, COLORADO CHILD FATAL	32	65	65	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3172	3175		10.1001/jama.267.23.3172	http://dx.doi.org/10.1001/jama.267.23.3172			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593738				2022-12-28	WOS:A1992HX91800026
J	BEWLEY, S				BEWLEY, S			THE LAW, MEDICAL-STUDENTS, AND ASSAULT	BRITISH MEDICAL JOURNAL			English	Article											BEWLEY, S (corresponding author), UNIV COLL HOSP LONDON,DEPT OBSTET & GYNAECOL,LONDON WC1E 6AU,ENGLAND.			bewley, susan/0000-0001-8064-652X				BEWLEY S, 1992, IN PRESS 26TH P BRIT; BRAZIER M, 1987, MED PATIENTS LAW, P55; CHAMBERLAIN G, 1990, AVOID MEDICOLEGAL PR, P16; Corbett J., 1990, METRO            JUL, p54e71; CORBETT J, 1990, METRO            SEP, P124; Dyer C, 1991, GUARDIAN        0916, P2; PHILLIPS A, 1991, GUARDIAN        0122, P34; ROBINSON J, 1985, J MED ETHICS, V11, P15; SKEGG PDG, 1984, LAW ETHICS MED, P95; WINKLER F, 1988, NEEDLE           JUN, P10; 1981, LAW SOC GAZETTE, V78, P1341; 1986, WOMEN MED        MAY, P8	12	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1551	1553		10.1136/bmj.304.6841.1551	http://dx.doi.org/10.1136/bmj.304.6841.1551			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628058	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800029
J	SCHOFIELD, PF; JONES, DJ				SCHOFIELD, PF; JONES, DJ			ABC OF COLORECTAL DISEASES - COLORECTAL NEOPLASIA .2. LARGE-BOWEL CANCER	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		SCHOFIELD, PF (corresponding author), WITHINGTON HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1561	1563		10.1136/bmj.304.6841.1561	http://dx.doi.org/10.1136/bmj.304.6841.1561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628061	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800033
J	PETSKO, GA				PETSKO, GA			ON THE OTHER HAND	SCIENCE			English	Editorial Material									BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT CHEM,WALTHAM,MA 02254	Brandeis University	PETSKO, GA (corresponding author), BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,DEPT BIOCHEM,WALTHAM,MA 02254, USA.		Petsko, Gregory/AAO-7962-2020					BONNER WA, 1975, NATURE, V258, P419, DOI 10.1038/258419a0; BROCK CP, 1991, J AM CHEM SOC, V113, P9811, DOI 10.1021/ja00026a015; FLOURET G, 1965, J AM CHEM SOC, V87, P3775, DOI 10.1021/ja01094a045; KOEPPE RE, 1992, PROTEINS, V12, P49, DOI 10.1002/prot.340120107; MILTON RCD, 1992, SCIENCE, V256, P1445, DOI 10.1126/science.1604320; MOFFAT AS, 1992, SCIENCE, V256, P309, DOI 10.1126/science.256.5055.309; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; WADE D, 1990, P NATL ACAD SCI USA, V87, P4761, DOI 10.1073/pnas.87.12.4761; ZAWADZKE LE, IN PRESS J AM CHEM S	9	23	27	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1403	1404		10.1126/science.1604313	http://dx.doi.org/10.1126/science.1604313			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604313				2022-12-28	WOS:A1992HX33700023
J	LI, TY; ETLER, DA				LI, TY; ETLER, DA			NEW MIDDLE PLEISTOCENE HOMINID CRANIA FROM YUNXIAN IN CHINA	NATURE			English	Article							HOMO-SAPIENS; ORIGIN; SKULL	Two fossil human crania have been found in Middle Pleistocene terrace deposits of the Han River in Yun county (Yunxian), Hubei province, China (Figs 1 and 2) 1. These damaged but relatively complete adult specimens show a mixture of features associated both with Homo erectus and with 'archaic H. sapiens'. The Yunxian crania (Figs 3 and 4), although crushed and distorted to varying degrees, are unusual in having major elements of the basicranium, palate, face and cranial vault preserved together. The specimens reveal many details of facial and basicranial anatomy rarely seen in hominid crania of comparable antiquity. Moreover, they are the most complete crania of such great age discovered on the Asian mainland. They consequently throw new light on Middle Pleistocene hominid diversity and the relationships among regionally disparate Middle Pleistocene hominids.	UNIV CALIF BERKELEY,DEPT ANTHROPOL,HUMAN EVOLUT STUDIES LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley	LI, TY (corresponding author), HUBEI INST ARCHEOL,67 DONGHU RD,WUHAN 430077,PEOPLES R CHINA.							Aiello L, 1990, INTRO HUMAN EVOLUTIO; BLACK DAVIDSON, 1931, PALAEONTOLOGIA SINICA SER D, V7, P1; Brauer G., 1990, Acta Anthropologica Sinica, V9, P350; CLARKE RJ, 1990, J HUM EVOL, V19, P699, DOI 10.1016/0047-2484(90)90004-U; CONTROY GC, 1978, NATURE, V276, P67; DAY MH, 1980, NATURE, V284, P55, DOI 10.1038/284055a0; Dong X., 1989, EARLY HUMANKIND CHIN, P9; Howell F.C., 1978, P154; HUBLIN JJ, 1984, ANTHROPOS BRNO, V23, P175; KENNEDY GE, 1991, J HUM EVOL, V20, P375, DOI 10.1016/0047-2484(91)90006-H; Maier W., 1984, Courier Forschungsinstitut Senckenberg, V69, P123; Murrill R.I., 1975, Zeitschrift Morph Anthrop, V66, P176; POPE GG, 1991, J HUM EVOL, V21, P189, DOI 10.1016/0047-2484(91)90061-Y; RAK Y, 1986, J HUM EVOL, V15, P151, DOI 10.1016/S0047-2484(86)80042-2; RIGHTMIRE GP, 1990, EVOLUTION H ERECTUS; Sartono S., 1975, P327; SOHN S, 1990, ACTA ANTHR SINICA, V9, P359; Stringer C.B., 1984, Courier Forschungsinstitut Senckenberg, V69, P131; STRINGER CB, 1979, J ARCHAEOL SCI, V6, P235, DOI 10.1016/0305-4403(79)90002-5; STRINGER CB, 1988, SCIENCE, V239, P1263, DOI 10.1126/science.3125610; Wang Z., 1991, JIANGHAN KAOGU, V39, P1; Weidenreich F., 1943, Palaeontologia Sinica, VD 10, P1; WEIDENREICH F, 1937, PALAEONTOL SINICA D, V1, P1; WEIDENREICH F, 1936, PALAEONTOLOGICA SI D, V7, P1; Weidenreich F., 1951, ANTHROPOLOGICAL PAPE, V43, P205; Woo J., 1959, PALEOVERTEBR PALEOAN, V1, P159; WOO JK, 1965, SCI SINICA, V14, P1032; Wu, 1990, ACTA ANTHR SINICA, V9, P312; Wu RK., 1988, ACTA ANTHROPOL SIN, V7, P97; Wu RK, 1982, ACTA ANTHR SIN, V1, P2; WU XZ, 1981, SCI SINICA, V24, P530; Xinzhi W., 1988, ACTA ANTHROPOL SIN, V7, P287	32	81	98	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					404	407						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HX172	1594044				2022-12-28	WOS:A1992HX17200063
J	HJORTDAHL, P; LAERUM, E				HJORTDAHL, P; LAERUM, E			CONTINUITY OF CARE IN GENERAL-PRACTICE - EFFECT ON PATIENT SATISFACTION	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; META-ANALYSIS; DIMENSIONS	Objective-To evaluate the influence of continuity of care on patient satisfaction with consultations. Design-Directed and episodic specific evaluation of patient satisfaction with recent consultation. Setting and subjects-A representative sample of 3918 Norwegian primary care patients were asked to evaluate their consultations by filling in a questionnaire. The response rate was 78%. Main outcome measures-The patient's overall satisfaction with the consultation was rated on a six point scale. Continuity of care was recorded as the duration and intensity of the present patient-doctor relationship and as patients' perception of the present doctor being their personal doctor or not. Results-The multivariate analysis indicated that an overall personal patient-doctor relationship increased the odds of the patient being satisfied with the consultation sevenfold (95% confidence interval 4.9 to 9.9) as compared with consultations where no such relationships existed. The duration of the patient-doctor relationship had a weak but significant association with patient satisfaction, while the intensity of contacts showed no such association. Conclusion-Personal, continuous care is linked with patient satisfaction. If patient satisfaction is accepted as an integral part of quality health care, reinforcing personal care may be one way of increasing this quality.			HJORTDAHL, P (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY.							[Anonymous], 1970, EXIT VOICE LOYALTY R, DOI DOI 10.3917/RCE.002.0244; BANAHAN BF, 1981, J FAM PRACTICE, V12, P767; FITZPATRICK R, 1991, BMJ-BRIT MED J, V302, P1129, DOI 10.1136/bmj.302.6785.1129; FITZPATRICK R, 1991, BRIT MED J, V302, P887, DOI 10.1136/bmj.302.6781.887; FITZPATRICK RM, 1983, SOC SCI MED, V17, P501, DOI 10.1016/0277-9536(83)90057-6; FREEMAN G, 1984, FAM PRACT, V1, P245, DOI 10.1093/fampra/1.4.245; HALL JA, 1988, SOC SCI MED, V27, P637, DOI 10.1016/0277-9536(88)90012-3; HALL JA, 1988, SOC SCI MED, V27, P935, DOI 10.1016/0277-9536(88)90284-5; HARRIS RT, 1978, J APPL BEHAV SCI, V14, P382, DOI 10.1177/002188637801400313; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HJORTDAHL P, 1989, FAM PRACT, V6, P292, DOI 10.1093/fampra/6.4.292; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; Lamberts H., 1987, ICPC INT CLASSIFICAT; MARQUIS MS, 1983, MED CARE, V21, P821, DOI 10.1097/00005650-198308000-00006; McWhinney IR, 1989, TXB FAMILY MED; MURPHY M, 1989, BRIT MED J, V298, P1331, DOI 10.1136/bmj.298.6684.1331; Pascoe G C, 1983, Eval Program Plann, V6, P185, DOI 10.1016/0149-7189(83)90002-2; PENDLETON D, 1984, CONSULTATON APPROACH; ROTER DL, 1987, MED CARE, V25, P437, DOI 10.1097/00005650-198705000-00007; RUTLE O, 1983, 11983 STAT I FOLK RE; WARE JE, 1975, MED CARE, V13, P669, DOI 10.1097/00005650-197508000-00006	22	263	268	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1287	1290		10.1136/bmj.304.6837.1287	http://dx.doi.org/10.1136/bmj.304.6837.1287			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606434	Green Published, Bronze			2022-12-28	WOS:A1992HV08600026
J	ZATORRE, RJ; EVANS, AC; MEYER, E; GJEDDE, A				ZATORRE, RJ; EVANS, AC; MEYER, E; GJEDDE, A			LATERALIZATION OF PHONETIC AND PITCH DISCRIMINATION IN SPEECH PROCESSING	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN AUDITORY-CORTEX; CORTICAL AREAS; ORGANIZATION; PERCEPTION; LOCALIZATION; LANGUAGE; MEMORY; BRAIN	Cerebral activation was measured with positron emission tomography in ten human volunteers. The primary auditory cortex showed increased activity in response to noise bursts, whereas acoustically matched speech syllables activated secondary auditory cortices bilaterally. Instructions to make judgments about different attributes of the same speech signal resulted in activation of specific lateralized neural systems. Discrimination of phonetic structure led to increased activity in part of Broca's area of the left hemisphere, suggesting a role for articulatory recoding in phonetic perception. Processing changes in pitch produced activation of the right prefrontal cortex, consistent with the importance of right-hemisphere mechanisms in pitch perception.			ZATORRE, RJ (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,MCCONNELL BRAIN IMAGING CTR,MONTREAL H3A 2B4,QUEBEC,CANADA.		Gjedde, Albert/I-2452-2019; Gjedde, Albert/U-3751-2019	Gjedde, Albert/0000-0002-3756-7401				Alajouanine T., 1939, SYNDROME DESINTEGRAT; BLUMSTEIN SE, 1977, NEUROPSYCHOLOGIA, V15, P19, DOI 10.1016/0028-3932(77)90111-7; BLUMSTEIN SE, 1987, MOTOR SENSORY PROCES, P257; BRUGGE JF, 1985, CEREB CORTEX, V4, P229; BUB D, 1991, J CEREBRAL BLOOD S2, V11, pS850; CELESIA GG, 1976, BRAIN, V99, P403, DOI 10.1093/brain/99.3.403; CHAVIS DA, 1976, BRAIN RES, V117, P379; CHERTKOW H, 1991, Neurology, V41, P300; COLOMBO M, 1990, SCIENCE, V247, P336, DOI 10.1126/science.2296723; EVANS AC, 1991, J CEREBR BLOOD F MET, V11, pA69, DOI 10.1038/jcbfm.1991.40; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; EVANS AC, IN PRESS NEUROLMAGE; FITZPATRICK KA, 1982, CORTICAL SENSORY ORG, V3, P71; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312; GESCHWIN.N, 1970, SCIENCE, V170, P940, DOI 10.1126/science.170.3961.940; LAUTER JL, 1985, HEARING RES, V20, P199, DOI 10.1016/0378-5955(85)90024-3; LECOURS AR, 1976, BRAIN LANG, V3, P88, DOI 10.1016/0093-934X(76)90008-0; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; LIBERMAN AM, 1967, PSYCHOL REV, V74, P431, DOI 10.1037/h0020279; LIEGEOISCHAUVEL C, 1991, BRAIN, V114, P139; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MEYER E, 1988, Society for Neuroscience Abstracts, V14, P917; MILNER B, 1962, INTERHEMISPHER RELAT, P177; OJEMANN G, 1979, SCIENCE, V205, P1401, DOI 10.1126/science.472757; Ombredane A, 1951, SURFACE DYSLEXIA; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PAUS T, UNPUB; Penfield W., 1959, SPEECH BRAIN MECHANI; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; SHALLICE T, 1990, NEUROPSYCHOLOGICAL I, pCH1; Tailarach J., 1988, COPLANAR STEREOTAXIC; Taylor L. B, 1979, FUNCTIONAL NEUROSURG, P165; WHITFIELD IC, 1985, CEREB CORTEX, P329; WISE R, 1991, BRAIN, V114, P1803, DOI 10.1093/brain/114.4.1803; WOOD CC, 1971, SCIENCE, V173, P1248, DOI 10.1126/science.173.4003.1248; WORSLEY KJ, IN PRESS J CEREB BLO; ZATORRE RJ, 1991, BRAIN, V114, P2403, DOI 10.1093/brain/114.6.2403; ZATORRE RJ, 1988, J ACOUST SOC AM, V84, P566, DOI 10.1121/1.396834	43	1170	1189	3	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					846	849		10.1126/science.1589767	http://dx.doi.org/10.1126/science.1589767			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589767				2022-12-28	WOS:A1992HT23500048
J	BROWN, J; MACKINNON, D; KING, A; VANDERBUSH, E				BROWN, J; MACKINNON, D; KING, A; VANDERBUSH, E			ELEVATED ARTERIAL BLOOD-PRESSURE IN CARDIAC-TAMPONADE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VENTRICULAR DIASTOLIC COLLAPSE; VASCULAR SMOOTH-MUSCLE; ECHOCARDIOGRAPHIC SIGN; PERICARDIAL TAMPONADE; PULSUS PARADOXUS; MEDICAL PATIENTS; HYPERTENSION; COMPRESSION; RESISTANCE	Background. In cardiac tamponade cardiac output falls, but peripheral vascular resistance increases, so that systemic blood pressure may be maintained at normal or near-normal levels. We recently observed a patient with cardiac tamponade whose blood pressure was markedly elevated. Methods. To determine the frequency of elevated blood pressure in patients with cardiac tamponade and their hemodynamic characteristics, we studied 18 consecutive patients with cardiac tamponade from a variety of causes using right heart catheterization. Results. Six of the 18 patients had systolic arterial blood pressures ranging from 150 to 210 mm Hg (mean [+/-SD], 176+/-26) and diastolic pressures ranging from 100 to 130 mm Hg (mean, 113+/-14). All six had previously been hypertensive. After pericardiocentesis there was a significant decrease in blood pressure (to 139+/-13 mm Hg systolic, P<0.05; and 83+/-6 mm Hg diastolic, P<0.01) and peripheral vascular resistance (from 2150+/-588 to 1207+/-345 dyn . sec . cm-5, P<0.01). Cardiac output increased in all six. The other 12 patients, 3 of whom had a history of hypertension, had significant increases in cardiac output and systolic blood pressure (from 119+/-13 to 127+/-7 mm Hg, P<0.05) after pericardiocentesis, whereas peripheral vascular resistance decreased. Both groups had similar degrees of cardiac tamponade, as indicated by measurements of cardiac output and intrapericardial, right atrial, and pulmonary-artery wedge pressures. Conclusions. Elevated blood pressure may occur in some patients with cardiac tamponade who have preexisting hypertension. Moreover, blood pressure may fall after pericardiocentesis in patients who have elevated blood pressure associated with tamponade.			BROWN, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HARLEM HOSP CTR,DEPT MED,DIV CARDIOL,506 LENOX AVE,NEW YORK,NY 10032, USA.							ARMSTRONG WF, 1982, CIRCULATION, V65, P1491, DOI 10.1161/01.CIR.65.7.1491; Beck CS, 1935, J AMER MED ASSOC, V104, P714, DOI 10.1001/jama.1935.02760090018005; BOHR DF, 1984, AM J MED, V77, P3, DOI 10.1016/S0002-9343(84)80032-7; COGSWELL TL, 1985, CIRCULATION, V72, P1076, DOI 10.1161/01.CIR.72.5.1076; COGSWELL TL, 1986, AM J PHYSIOL, V251, pR916, DOI 10.1152/ajpregu.1986.251.5.R916; ENGEL PJ, 1982, AM J CARDIOL, V50, P1018, DOI 10.1016/0002-9149(82)90411-8; FOWLER NO, 1969, J CLIN INVEST, V48, P502, DOI 10.1172/JCI106007; FOWLER NO, 1978, MOD CONC CARDIOV DIS, V47, P115; FOWLER NO, 1978, CIRCULATION, V57, P563, DOI 10.1161/01.CIR.57.3.563; GASCHO JA, 1981, AM J PHYSIOL, V240, pH49, DOI 10.1152/ajpheart.1981.240.1.H49; GEER M, 1984, CLIN RES, V32, pA331; GILLAM LD, 1983, CIRCULATION, V68, P294, DOI 10.1161/01.CIR.68.2.294; GUBERMAN BA, 1981, CIRCULATION, V64, P633, DOI 10.1161/01.CIR.64.3.633; HANCOCK EW, 1971, CIRCULATION, V43, P183, DOI 10.1161/01.CIR.43.2.183; HOLLOWAY ET, 1973, CIRC RES, V33, P678, DOI 10.1161/01.RES.33.6.678; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M, P105; KERBER RE, 1982, NEW ENGL J MED, V307, P929, DOI 10.1056/NEJM198210073071506; KRONZON I, 1983, J AM COLL CARDIOL, V2, P770, DOI 10.1016/S0735-1097(83)80318-0; KULKARNI P, 1986, CHEST, V89, pS496; LEIMGRUBER PP, 1983, CIRCULATION, V68, P612, DOI 10.1161/01.CIR.68.3.612; LEVINE MJ, 1991, J AM COLL CARDIOL, V17, P59, DOI 10.1016/0735-1097(91)90704-D; LORELL BH, 1988, HEART DISEASE TXB CA, P1497; MILLER SW, 1982, AM J CARDIOL, V50, P1287, DOI 10.1016/0002-9149(82)90465-9; NYBORG NCB, 1988, HYPERTENSION, V11, P635, DOI 10.1161/01.HYP.11.6.635; PEGRAM BL, 1975, CARDIOVASC RES, V9, P707, DOI 10.1093/cvr/9.6.707; REDDY PS, 1978, CIRCULATION, V58, P265, DOI 10.1161/01.CIR.58.2.265; SCHILLER NB, 1977, CIRCULATION, V56, P774, DOI 10.1161/01.CIR.56.5.774; SCHULTE KL, 1988, HYPERTENSION, V11, P320, DOI 10.1161/01.HYP.11.4.320; SHABETAI R, 1979, PROG CARDIOVASC DIS, V22, P107, DOI 10.1016/0033-0620(79)90017-3; SHARP JT, 1960, AM J MED, V29, P640, DOI 10.1016/0002-9343(60)90097-8; SHEBATAI R, 1970, AM J CARDIOL, V26, P480; SINGH S, 1984, CIRCULATION, V70, P966, DOI 10.1161/01.CIR.70.6.966; SINGH S, 1986, AM J CARDIOL, V57, P652, DOI 10.1016/0002-9149(86)90853-2; SIVERTSSON R, 1968, LIFE SCI PT 1 PHYSI, V7, P1291, DOI 10.1016/0024-3205(68)90244-0; SPODICK DH, 1968, DIS CHEST, V54, P62, DOI 10.1378/chest.54.1.62	35	34	35	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					463	466		10.1056/NEJM199208133270704	http://dx.doi.org/10.1056/NEJM199208133270704			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625736				2022-12-28	WOS:A1992JH34000004
J	KOIKE, T; TATEWAKI, W; AOKI, A; YOSHIMOTO, H; YAGISAWA, K; HASHIMOTO, S; FURUKAWA, T; SAITOH, H; TAKAHASHI, M; YANG, LB; WANG, Y; SHIBATA, A				KOIKE, T; TATEWAKI, W; AOKI, A; YOSHIMOTO, H; YAGISAWA, K; HASHIMOTO, S; FURUKAWA, T; SAITOH, H; TAKAHASHI, M; YANG, LB; WANG, Y; SHIBATA, A			SEVERE SYMPTOMS OF HYPERHISTAMINEMIA AFTER THE TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH TRETINOIN (ALL-TRANS-RETINOIC ACID)	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CHRONIC GRANULOCYTIC LEUKEMIA; DIFFERENTIATION THERAPY				KOIKE, T (corresponding author), NIIGATA UNIV,SCH MED,DEPT INTERNAL MED 1,1-754 ASAHI MACHI,NIIGATA 951,JAPAN.							ANDERSON W, 1988, GASTROENTEROLOGY, V95, P195, DOI 10.1016/0016-5085(88)90311-3; CASTAIGNE S, 1990, BLOOD, V76, P1704; Frankel S, 1991, BLOOD S, V78, p380a; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KUBONISHI I, 1985, ACTA HAEMATOL JAPON, V48, P1390; LISO V, 1975, BLUT, V30, P261, DOI 10.1007/BF01635358; ROSENTHAL S, 1977, BRIT J HAEMATOL, V36, P367, DOI 10.1111/j.1365-2141.1977.tb00660.x; TOMONAGA M, 1985, BLOOD, V66, P350; Umeda M, 1987, Rinsho Ketsueki, V28, P2004; UNDRITZ E, 1972, PLANCHES HEMATOLOGIE; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; YOUMAN JD, 1973, ARCH INTERN MED, V131, P560, DOI 10.1001/archinte.1973.00320100088012	13	42	42	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					385	387		10.1056/NEJM199208063270604	http://dx.doi.org/10.1056/NEJM199208063270604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625712	Bronze			2022-12-28	WOS:A1992JG35600004
J	METTLER, FA; WILLIAMSON, MR; ROYAL, HD; HURLEY, JR; KHAFAGI, F; SHEPPARD, MC; BERAL, V; REEVES, G; SAENGER, EL; YOKOYAMA, N; PARSHIN, V; GRIAZNOVA, EA; TARANENKO, M; CHESIN, V; CHEBAN, A				METTLER, FA; WILLIAMSON, MR; ROYAL, HD; HURLEY, JR; KHAFAGI, F; SHEPPARD, MC; BERAL, V; REEVES, G; SAENGER, EL; YOKOYAMA, N; PARSHIN, V; GRIAZNOVA, EA; TARANENKO, M; CHESIN, V; CHEBAN, A			THYROID-NODULES IN THE POPULATION LIVING AROUND CHERNOBYL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; ULTRASONOGRAPHY; NODULARITY; RADIATION; IRRADIATION; MANAGEMENT; CHILDHOOD; CHILDREN	Objective.-To determine the baseline incidence, prevalence, and characteristics of thyroid nodules in the population living around the Chernobyl nuclear power plant and to compare the findings with unexposed populations. Design.-Prevalence study. Population samples from seven highly contaminated villages were compared with six nearby control villages of the same size and type. The data were obtained as part of the International Chernobyl Project conducted in 1990. Setting.-The study was conducted 4.5 years after the Chernobyl reactor accident that released large quantities of radionuclides, including radioiodine. Patients or Other Participants.-Population samples of approximately 100 persons residing in both highly contaminated villages and control villages since the accident were compared. Individuals were selected on the basis of birth date as being 5, 10, 40, or 60 years old at the time of the study. All persons selected underwent a thyroid examination. Interventions.-None. Main Outcome Measures.-Two main outcome measures were used, both for thyroid nodularity: clinical palpation and high-resolution ultrasonography. Results.-There was no significant difference in thyroid nodularity between the study groups. Nodules were palpated in 0.7% of children and 2.9% of adults. Discrete nodules were found by ultrasonography in 0.5% of children and 14.9% of adults. Multinodular goiter was found in 3% of adults. Nodules were more common in females. Conclusions.-Four and a half years after the Chernobyl accident, the incidence, prevalence, and characteristics of thyroid nodules were the same in population samples from both highly contaminated and control settlements and similar to results reported for unexposed populations in other countries.	WASHINGTON UNIV,SCH MED,DEPT RADIOL,ST LOUIS,MO 63110; CORNELL UNIV,MED CTR,NEW YORK HOSP,SCH MED,DEPT NUCL MED,NEW YORK,NY 10021; ROYAL BRISBANE HOSP,SCH MED,DEPT NUCL MED,BRISBANE,QLD 4029,AUSTRALIA; UNIV BIRMINGHAM,SCH MED,DEPT MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; RADCLIFFE INFIRM,CANC EPIDEMIOL UNIT,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND; UNIV CINCINNATI HOSP,MED CTR RADIOISOTOPE LAB,CINCINNATI,OH; RADIAT EFFECT RES FDN,NAGASAKI,JAPAN; ACAD MED SCI OBINSK,INST MED RADIOL,OBNINSK,USSR; MINIST PUBL HLTH USSR,INST BIOPHYS,MOSCOW,USSR; KIEV UNION SCI CTR RADIAT MED,KIEV,UKRAINE,USSR	Washington University (WUSTL); Cornell University; NewYork-Presbyterian Hospital; Royal Brisbane & Women's Hospital; University of Birmingham; Radcliffe Infirmary; University of Oxford; University System of Ohio; University of Cincinnati; Radiation Effects Research Foundation - Japan; National Academy of Medical Sciences of Ukraine; National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine	METTLER, FA (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT RADIOL,ALBUQUERQUE,NM 87131, USA.							ASHCRAFT MW, 1981, HEAD NECK SURG, V3, P216, DOI 10.1002/hed.2890030309; BANDER A, 1991, RADIOLOGY, V181, P683; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; CARROLL BA, 1982, AM J ROENTGENOL, V133, P499; HAY ID, 1984, LANCET, V1, P916; HAY ID, 1988, CURR MED, V5, P22; HAYASHI N, 1986, Acta Radiologica Diagnosis, V27, P403; HORLOCKER T, 1986, THYROIDOLOGY, P1309; ILYIN L A, 1990, Journal of Radiological Protection, V10, P3, DOI 10.1088/0952-4746/10/1/001; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KATZ JF, 1984, RADIOLOGY, V151, P741, DOI 10.1148/radiology.151.3.6718735; MAXON HR, 1977, AM J MED, V63, P967, DOI 10.1016/0002-9343(77)90552-6; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; NAGATAKI S, 1989, RAD THYROID, P1; POTTERN LM, 1990, J CLIN EPIDEMIOL, V43, P449, DOI 10.1016/0895-4356(90)90133-A; RALLISON ML, 1974, AM J MED, V56, P457, DOI 10.1016/0002-9343(74)90476-8; RALLISON ML, 1975, JAMA-J AM MED ASSOC, V233, P1069, DOI 10.1001/jama.233.10.1069; ROBBINS J, 1989, RAD THYROID, P11; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; RON E, 1989, RADIAT RES, V120, P516, DOI 10.2307/3577801; SCHIBLE W, 1979, RADIOLOGY, V133, P413; SHORE R, 1984, J NATL CANCER I, V74, P1177; STARK DD, 1983, SURGERY, V94, P863; VANDER JB, 1968, ANN INTERN MED, V69, P537, DOI 10.7326/0003-4819-69-3-537; WANG ZY, 1990, JNCI-J NATL CANCER I, V82, P478, DOI 10.1093/jnci/82.6.478; WOESTYN J, 1985, BRIT J RADIOL, V58, P1179, DOI 10.1259/0007-1285-58-696-1179; 1991, TECHNICAL REPORT INT	27	59	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					616	619		10.1001/jama.268.5.616	http://dx.doi.org/10.1001/jama.268.5.616			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629989				2022-12-28	WOS:A1992JF47300026
J	FOEGE, WH				FOEGE, WH			PREVENTIVE MEDICINE AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FOEGE, WH (corresponding author), EMORY UNIV,CARTER CTR,ATLANTA,GA 30322, USA.							BAKER SP, 1987, NEW ENGL J MED, V316, P1384, DOI 10.1056/NEJM198705283162206; MARWICK C, 1992, JAMA-J AM MED ASSOC, V267, P1174; RICE DP, 1991, WESTERN J MED, V154, P294; 1991, MMWR, V39, P3; 1992, MMWR, V41, P81; 1984, MAR P BELL C NEW YOR; 1989, MMWR, V38, P269; 1988, 3RD P INT CHILD SURV; 1991, 1991 WORLD BANK WORL; 1990, 4TH P INT CHILD SURV; 1987, JAMA-J AM MED ASSOC, V257, P790; 1992, STATE WORLDS CHILDRE	12	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					401	403		10.1001/jama.268.3.401	http://dx.doi.org/10.1001/jama.268.3.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613935				2022-12-28	WOS:A1992JC35200048
J	LARREY, D; VIAL, T; PAUWELS, A; CASTOT, A; BIOUR, M; DAVID, M; MICHEL, H				LARREY, D; VIAL, T; PAUWELS, A; CASTOT, A; BIOUR, M; DAVID, M; MICHEL, H			HEPATITIS AFTER GERMANDER (TEUCRIUM-CHAMAEDRYS) ADMINISTRATION - ANOTHER INSTANCE OF HERBAL MEDICINE HEPATOTOXICITY	ANNALS OF INTERNAL MEDICINE			English	Article						GERMANDER; HEPATITIS, TOXIC; MEDICINE, HERBAL; WEIGHT LOSS; JAUNDICE	VENO-OCCLUSIVE DISEASE; SECONDARY; COMFREY; LIVER	Objective: To show that germander (Teucrium chamaedrys), an herbal medicine used to facilitate weight loss, may be hepatotoxic and to delineate the nature of the injury. Design: Retrospective study. Setting: Liver units of several centers in the French Network of Pharmacovigilance. Patients: Seven patients who developed hepatitis after germander administration and who had no other cause of liver injury. Measurements: Clinical examination, liver function tests, various serologic tests, ultrasonography, and histologic study. Results: Hepatitis characterized by jaundice and a marked increase in serum aminotransferase levels occurred 3 to 18 weeks after germander administration. Liver biopsy specimens in three patients showed hepatocyte necrosis. After discontinuing treatment with germander, jaundice disappeared within 8 weeks and recovery was complete in 1.5 to 6 months. In three cases, germander readministration was followed by the prompt recurrence of hepatitis. Conclusion: Germander may be hepatotoxic, which supports the view that herbal medicines are not always as safe as generally assumed.	HOP EDOUARD HERRIOT, SERV PHARMACOTOXICOVIGILANCE, F-69000 LYONS, FRANCE; HOP ST ANTOINE, SERV HEPATOGASTROENTEROL, F-75571 PARIS 12, FRANCE; HOP FERNAND WIDAL, F-75475 PARIS 10, FRANCE	CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	LARREY, D (corresponding author), HOP ST ELOI, SERV MALAD APPAREIL DIGEST, F-34059 MONTPELLIER, FRANCE.			Vial, Thierry/0000-0003-3786-581X				BACH N, 1989, AM J MED, V87, P97, DOI 10.1016/S0002-9343(89)80492-9; BEUERS U, 1991, LANCET, V337, P372, DOI 10.1016/0140-6736(91)91012-J; CARLSSON C, 1990, LANCET, V336, P1068, DOI 10.1016/0140-6736(90)92538-S; DAVIES EG, 1990, LANCET, V336, P177; HARVEY J, 1981, BRIT MED J, V282, P186, DOI 10.1136/bmj.282.6259.186; KATZ M, 1990, J CLIN GASTROENTEROL, V12, P203, DOI 10.1097/00004836-199004000-00021; KUMANA CR, 1985, GUT, V26, P101, DOI 10.1136/gut.26.1.101; MACGREGOR FB, 1989, BRIT MED J, V299, P1156, DOI 10.1136/bmj.299.6708.1156; MOHABBAT O, 1976, LANCET, V2, P269; MOORE N, 1985, LANCET, V2, P1056; RIDKER PM, 1989, LANCET, V1, P657, DOI 10.1016/S0140-6736(89)92154-5; TANDON BN, 1976, LANCET, V2, P271; VALLA D, 1988, BAILLIERE CLIN GASTR, V2, P481, DOI 10.1016/0950-3528(88)90013-9; WESTON CFM, 1987, BRIT MED J, V295, P183, DOI 10.1136/bmj.295.6591.183	14	221	222	1	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					129	132		10.7326/0003-4819-117-2-129	http://dx.doi.org/10.7326/0003-4819-117-2-129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605427				2022-12-28	WOS:A1992JD12300006
J	RICH, S; KAUFMANN, E; LEVY, PS				RICH, S; KAUFMANN, E; LEVY, PS			THE EFFECT OF HIGH-DOSES OF CALCIUM-CHANNEL BLOCKERS ON SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-HISTORY; THROMBOSIS; THERAPY	Background. Primary pulmonary hypertension is a progressive, fatal disease of unknown cause. Vasodilator drugs have been used as a treatment, but their efficacy is uncertain. Methods. We treated 64 patients with primary pulmonary hypertension with high doses of calcium-channel blockers. Patients who responded to treatment (defined as those whose pulmonary-artery pressure and pulmonary vascular resistance immediately fell by more than 20 percent after challenge) were treated for up to five years. Their survival was compared with that of the patients who did not respond and with patients enrolled in the National Institutes of Health (NIH) Registry on Primary Pulmonary Hypertension. Warfarin was given to 55 percent of the patients as concurrent therapy, on the basis of a lung scan showing nonuniformity of pulmonary blood flow (47 percent of patients who responded and 57 percent of those who did not respond). Results. Seventeen patients (26 percent) responded to treatment, as indicated by a 39 percent fall in pulmonary-artery pressure and a 53 percent fall in the pulmonary-vascular-resistance index (P<0.001). Nifedipine (mean [+/-SD] daily dose, 172+/-41 mg) was given to 13 patients, and diltiazem (mean daily dose, 720+/-208 mg) was given to 4 patients. After five years, 94 percent of the patients who responded (16 of 17) were alive, as compared with 55 percent of the patients who did not respond (26 of 47, P = 0.003). The survival of the patients who responded was also significantly better than that of the NIH registry cohort (P = 0.002) and patients from the NIH registry who were treated at the University of Illinois (P = 0.001). The use of warfarin was associated with improved survival (P = 0.025), particularly in the patients who did not respond. Conclusions. This study suggests that high doses of calcium-channel blockers in patients with primary pulmonary hypertension who respond with reductions in pulmonary-artery pressure and pulmonary vascular resistance may improve survival over a five-year period.	UNIV ILLINOIS,COLL MED,SCH PUBL HLTH,EPIDEMIOL & BIOMETRY PROGRAM,CHICAGO,IL 60680	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	RICH, S (corresponding author), UNIV ILLINOIS,COLL MED,DEPT MED,CARDIOL SECT,POB 6998,M-C 787,CHICAGO,IL 60680, USA.							DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; DRESDALE DT, 1951, AM J MED, V11, P686, DOI 10.1016/0002-9343(51)90020-4; EISENBERG PR, 1990, CIRCULATION, V82, P841, DOI 10.1161/01.CIR.82.3.841; FUSTER V, 1981, AM J CARDIOL, V47, P422, DOI 10.1016/0002-9149(81)90761-X; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; GATEWOOD RP, 1979, PROG CARDIOL, V8, P305; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; LEVINE SM, 1990, CHEST, V98, P1107, DOI 10.1378/chest.98.5.1107; LONG WA, 1987, AM REV RESPIR DIS, V136, P773, DOI 10.1164/ajrccm/136.3.773; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Pocock SJ., 2013, CLIN TRIALS PRACTICA; RICH S, 1991, J AM COLL CARDIOL, V18, P1323, DOI 10.1016/0735-1097(91)90556-O; RICH S, 1988, PROG CARDIOVASC DIS, V31, P205, DOI 10.1016/0033-0620(88)90016-3; RICH S, 1987, ANN INTERN MED, V107, P216, DOI 10.7326/0003-4819-107-2-216; RICH S, 1984, AM J MED, V76, P573, DOI 10.1016/0002-9343(84)90279-1; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RICH S, 1985, CIRCULATION, V71, P1191, DOI 10.1161/01.CIR.71.6.1191; ROSNER B, 1990, ESSENTIALS BIOSTATIS; THILENIUS OG, 1965, PEDIATRICS, V36, P75; WALCOTT G, 1970, AM J MED, V49, P70, DOI 10.1016/S0002-9343(70)80115-2; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; WOOD P, 1958, BRIT HEART J, V20, P557	22	1115	1180	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					76	81		10.1056/NEJM199207093270203	http://dx.doi.org/10.1056/NEJM199207093270203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603139				2022-12-28	WOS:A1992JC21400003
J	RIVERA, MC; LAKE, JA				RIVERA, MC; LAKE, JA			EVIDENCE THAT EUKARYOTES AND EOCYTE PROKARYOTES ARE IMMEDIATE RELATIVES	SCIENCE			English	Article							ARCHAEBACTERIA; EVOLUTION; SEQUENCES; NUCLEUS; ORIGIN; TU	The phylogenetic origin of eukaryotes has been unclear because eukaryotic nuclear genes have diverged substantially from prokaryotic ones. The genes coding for elongation factor EF-1-alpha were compared among various organisms. The EF-1-alpha sequences of eukaryotes contained an 11-amino acid segment that was also found in eocytes (extremely thermophilic, sulfur-metabolizing bacteria) but that was absent in all other bacteria. The related (paralogous) genes encoding elongation factor EF-2 and initiation factor IF-2 also lacked the 11-amino acid insert. These data imply that the eocytes are the closest surviving relatives (sister taxon) of the eukaryotes.	UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	RIVERA, MC (corresponding author), UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024, USA.		Rivera, Maria/GYU-2150-2022					BALDAUF SL, 1990, NATURE, V344, P262, DOI 10.1038/344262a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FITCH WM, 1977, AM NAT, V111, P223, DOI 10.1086/283157; Gerbi S. A., 1985, MOL EVOLUTIONARY GEN, P419, DOI DOI 10.1007/978-1-4684-4988-4_7; GOGARTEN JP, 1989, P NATL ACAD SCI USA, V86, P6661, DOI 10.1073/pnas.86.17.6661; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; HERRMANN BG, 1987, METHOD ENZYMOL, V152, P180; Hill WE., 1990, RIBOSOME STRUCTURE F; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAMEKURA M, 1988, HALOPHILIC BACTERIA, P25; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAKE JA, 1984, P NATL ACAD SCI-BIOL, V81, P3786, DOI 10.1073/pnas.81.12.3786; LAKE JA, 1991, MOL BIOL EVOL, V8, P378; LAKE JA, 1991, TRENDS BIOCHEM SCI, V16, P46, DOI 10.1016/0968-0004(91)90020-V; LANZOTTI V, 1989, BIOCHIM BIOPHYS ACTA, V1004, P44, DOI 10.1016/0005-2760(89)90210-5; LARSEN N, 1986, SYST APPL MICROBIOL, V7, P49, DOI 10.1016/S0723-2020(86)80123-0; Margulis L., 1993, SYMBIOSIS CELL EVOLU; MATHESON AT, 1990, RIBOSOME, P617; MINDEL DP, 1991, PHYLOGENETIC ANAL DN, P119; PATTERSON C, 1990, NATURE, V344, P199, DOI 10.1038/344199a0; Saiki R. K., 1990, PCR PROTOCOLS GUIDE, P13; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WATERMAN MS, 1987, J MOL BIOL, V197, P723, DOI 10.1016/0022-2836(87)90478-5; Wiley E.O., 1981, PHYLOGENETICS; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	30	279	283	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					74	76		10.1126/science.1621096	http://dx.doi.org/10.1126/science.1621096			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621096				2022-12-28	WOS:A1992JC16500032
J	THIBAULT, GE				THIBAULT, GE			FAILURE TO RESOLVE A DIAGNOSTIC INCONSISTENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PULMONARY-EMBOLISM											[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; COME PC, 1987, J AM COLL CARDIOL, V10, P971, DOI 10.1016/S0735-1097(87)80333-9; EAGLE KA, 1992, HEART DISEASE, P1528; ERBEL R, 1989, LANCET, V1, P457; GRAY HH, 1988, LANCET, V1, P1441; KASSIRER JP, 1978, ANN INTERN MED, V89, P245, DOI 10.7326/0003-4819-89-2-245; SHARMA G V R K, 1988, Journal of the American College of Cardiology, V11, p53A; SHARMA GVR, 1976, DIS MON, V22; The urokinase pulmonary embolism trial, 1973, CIRCULATION, V47, pII1; Topol E J, 1989, Cardiol Clin, V7, P827; VOYTOVICH AE, 1985, J MED EDUC, V60, P302	12	6	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					36	39		10.1056/NEJM199207023270107	http://dx.doi.org/10.1056/NEJM199207023270107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598099				2022-12-28	WOS:A1992JA76100007
J	LI, JM; SHORE, GC				LI, JM; SHORE, GC			REVERSAL OF THE ORIENTATION OF AN INTEGRAL PROTEIN OF THE MITOCHONDRIAL OUTER-MEMBRANE	SCIENCE			English	Article							INNER MEMBRANE; PRECURSOR PROTEINS; SIGNAL SEQUENCE; IMPORT; INSERTION; POLYPEPTIDE; RESIDUES; INVITRO; DOMAIN; PORIN	The NH2-terminus of the signal-anchor sequence of an integral, bitopic protein of the outer mitochondrial membrane was extended both in amino acid length (from 11 to 38 amino acids) and net charge (from +4 to +8)-changes that confer on the NH2-terminus characteristics of a strong matrix-targeting signal. The protein was inserted into the outer membrane but in an inverted orientation (N(cyto)-C(in)). These findings suggest that, in common with other membrane systems, the orientation of a protein in the outer mitochondrial membrane can be determined by a signal that causes retention of the NH2-terminus on the cytosolic side of the membrane.			LI, JM (corresponding author), MCGILL UNIV,DEPT BIOCHEM,MCINTYRE MED SCI BLDG,MONTREAL H3G 1Y6,QUEBEC,CANADA.							BAKKER EP, 1978, BIOCHEMISTRY-US, V17, P2899, DOI 10.1021/bi00607a031; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; FREITAG H, 1982, EUR J BIOCHEM, V126, P197, DOI 10.1111/j.1432-1033.1982.tb06766.x; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLICK B, 1991, ANNU REV GENET, V25, P21; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; Li J. P. H., UNPUB; MCBRIDE H, UNPUB; MIHARA K, 1982, P NATL ACAD SCI-BIOL, V79, P7102, DOI 10.1073/pnas.79.23.7102; NGUYEN M, 1987, J CELL BIOL, V104, P1193, DOI 10.1083/jcb.104.5.1193; NGUYEN M, 1986, J BIOL CHEM, V261, P800; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NGUYEN M, 1987, J BIOL CHEM, V262, P3929; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; SINGER SJ, 1990, ANNU REV CELL BIOL, V6, P247, DOI 10.1146/annurev.cb.06.110190.001335; SKERJANC IS, 1988, J BIOL CHEM, V263, P17233; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938	24	52	52	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1815	1817		10.1126/science.1615327	http://dx.doi.org/10.1126/science.1615327			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615327				2022-12-28	WOS:A1992JA43400035
J	BIJUR, PE; KURZON, M; OVERPECK, MD; SCHEIDT, PC				BIJUR, PE; KURZON, M; OVERPECK, MD; SCHEIDT, PC			PARENTAL ALCOHOL-USE, PROBLEM DRINKING, AND CHILDRENS INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective. - Millions of US children are exposed to parents who are problem drinkers, yet there is little evidence about the effect of parental alcohol consumption on children's health. The aim of this study was to assess the association between children's injuries and parental drinking. Design. - Survey of a nationally representative sample of the US population by household interview. Participants. - 12360 children and parents from single-family households, with data from the Alcohol and Child Health supplements to the 1988 National Health Interview Survey. Main Outcome Measure. - Serious injuries-injuries resulting in hospitalization, surgical treatment, missed school, one half day or more in bed. Results. - Children of mothers categorized as problem drinkers had 2.1 times the risk of serious injury as children of mothers who were nondrinkers (95% CI, 1.3 to 3.5). Other measures of mothers' alcohol consumption (ie, average, maximum, and self-rated consumption) were unrelated to child injuries, as were all measures of fathers' drinking. Children of women who were problem drinkers married to men rated as moderate or heavy drinkers had a relative risk of serious injury of 2.7 (95% CI, 0.8 to 8.6) compared with children of nondrinkers. Conclusion. - Children of women who are problem drinkers have an elevated injury risk; children with two parents who are problem drinkers are at higher risk. Further research is needed on potential mechanisms and interventions. Primary prevention might be enhanced if physicians elicited information about parental drinking, helped secure appropriate treatment, and participated in public health efforts to reduce the deleterious effects of alcohol.	NICHHD, ROCKVILLE, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	BIJUR, PE (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PEDIAT, ROOM 920, ROSE F KENNEDY CTR, BRONX, NY 10461 USA.				NICHD NIH HHS [R01-HD25416-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025416] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAMS PF, 1989, VITAL HLTH STAT, V10, P173; BEYER JM, 1981, J DRUG ISSUES, V11, P233, DOI 10.1177/002204268101100205; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; CHAFETZ ME, 1971, Q J STUD ALCOHOL, V32, P687; CLAIR D, 1987, J STUD ALCOHOL, V48, P345, DOI 10.15288/jsa.1987.48.345; DAWSON DA, 1991, J MARRIAGE FAM, V53, P573, DOI 10.2307/352734; ELGUEBALY N, 1977, AM J PSYCHIAT, V134, P357; FAMULARO R, 1986, AM J ORTHOPSYCHIAT, V56, P481, DOI 10.1111/j.1939-0025.1986.tb03480.x; KAMMEIER SM, 1971, Q J STUD ALCOHOL, V32, P364; KAPLAN SJ, 1983, J AM ACAD CHILD PSY, V22, P238, DOI 10.1016/S0002-7138(09)60371-X; KATZ D, 1978, BIOMETRICS, V34, P469, DOI 10.2307/2530610; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P298; LINDEN W, 1986, J CONSULT CLIN PSYCH, V54, P309, DOI 10.1037/0022-006X.54.3.309; LOWENFELS AB, 1984, ANN EMERG MED, V13, P1056, DOI 10.1016/S0196-0644(84)80070-0; MARGOLIS LH, 1986, PEDIATRICS, V77, P870; Obuchowska I., 1974, INT MENTAL HLTH RES, V16, P2; ORFORD J, 1990, RES ADV ALCOHOL DRUG, V10, P81; PUTNAM S, 1987, NOV AM MED C UN INJ; Reilly E L, 1986, Adv Psychosom Med, V16, P17; RIVARA FP, 1982, AM J DIS CHILD, V136, P502, DOI 10.1001/archpedi.1982.03970420026004; SCHOENBORN CA, 1991, ADV DATA, V205; SHAH BV, 1989, SUDAAN PROCEDURES DE; WALLER JA, 1985, INJURY CONTROL GUIDE, P467; WILLIAMS GD, 1986, PUBLIC HEALTH REP, V101, P593; 1987, DIAGNOSTIC STATISTIC; 1972, US DHEW HSM721050 NA; [No title captured]; 1984, ALCOHOL HLTH RES WOR, V8, P1	28	77	77	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3166	3171		10.1001/jama.267.23.3166	http://dx.doi.org/10.1001/jama.267.23.3166			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX918	1593737				2022-12-28	WOS:A1992HX91800025
J	MCCORMICK, KF				MCCORMICK, KF			ATTITUDES OF PRIMARY CARE PHYSICIANS TOWARD CORPORAL PUNISHMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FAMILY VIOLENCE; CHILD-ABUSE; DISCIPLINE; PEDIATRICIAN; AGGRESSION	Objective. - The purpose of this study was to determine whether or not family physicians and pediatricians support the use of corporal punishment. The frequency with which these physicians offer anticipatory guidance on discipline was also studied. Design. - Self-report survey, mailed to study participants. Participants. - The sample for this study was 800 family physicians and 400 pediatricians, randomly selected from the Ohio State Medical Board's roster of family physicians and pediatricians. Physicians with a subspecialty were excluded. Participants who did not return their surveys received a second, and if necessary, a third mailing of the survey. After three mailings, a total of 619 physicians (61%) completed a survey. Main Outcome Measure. - Participants were considered to support corporal punishment if they would tell a parent in their medical practice that spanking would be an appropriate response to any one of a series of childhood misbehaviors presented in the survey. Results. - Of family physicians, 70% (95% confidence interval [CI], 66% to 75%) support use of corporal punishment. Of pediatricians, 59% (95% CI, 52% to 66%) support corporal punishment. Of pediatricians, 90% (95% CI, 86% to 94%) indicated that they include discipline issues either always or most of the time when providing anticipatory guidance to parents. Significantly fewer family physicians (52%; 95% CI, 47% to 57%) indicated that they discuss discipline either always or most of the time when providing anticipatory guidance (P < .01). Conclusions. - Most family physicians and pediatricians support the use of corporal punishment in spite of evidence that it is neither effective nor necessary, and can be harmful. Pediatricians offer anticipatory guidance on discipline more often than family physicians.	SOC TEACHERS FAMILY MED,VIOLENCE EDUC TASK FORCE,KANSAS CITY,MO		MCCORMICK, KF (corresponding author), BARBERTON CITIZENS HOSP,FAMILY PRACTICE RESIDENCY,155 5TH ST NE,BARBERTON,OH 44203, USA.			McCormick, Kenelm/0000-0002-6088-6347				ALEVIZOS KJ, 1975, J BEHAV THER EXP PSY, V6, P253, DOI 10.1016/0005-7916(75)90113-5; ANDERSON KA, 1976, J CLIN CHILD PSY FAL, P46; BANDURA A, 1961, J ABNORM SOC PSYCH, V63, P575, DOI 10.1037/h0045925; BANDURA A, 1961, J ABNORM SOC PSYCHOL, V1, P311; BERGER AM, 1988, CHILD ABUSE NEGLECT, V12, P251, DOI 10.1016/0145-2134(88)90033-6; BERKOWITZ L, 1981, J PERS SOC PSYCHOL, V40, P687, DOI 10.1037/0022-3514.40.4.687; BERNAL ME, 1969, J NERV MENT DIS, V148, P375, DOI 10.1097/00005053-196904000-00005; Bongiovanni A. F., 1979, CORPORAL PUNISHMENT, P351; CARLSON BE, 1986, AM J ORTHOPSYCHIAT, V56, P308, DOI 10.1111/j.1939-0025.1986.tb02731.x; CHRISTOPHERSEN ER, 1986, PEDIATR CLIN N AM, V33, P789; CHRISTOPHERSEN ER, 1980, PEDIATRICS, V66, P641; DEAN AG, 1990, EPIINFO VERSION 5 WO; DRABMAN R, 1973, J EXP CHILD PSYCHOL, V16, P236, DOI 10.1016/0022-0965(73)90164-1; DRABMAN RS, 1987, PEDIATRICS, V59, P78; EMERY RE, 1989, AM PSYCHOL, V44, P321, DOI 10.1037/0003-066X.44.2.321; ERICKSON MT, 1980, CHILD DEV DEV DISABI, P411; FARLEY AC, 1978, INEQUALITY ED, V23, P57; FLANDERS JP, 1968, PSYCHOL BULL, V69, P316, DOI 10.1037/h0025721; FOREHAND R, 1976, J EXP CHILD PSYCHOL, V21, P109, DOI 10.1016/0022-0965(76)90061-8; GARDNER HL, 1976, J ABNORM CHILD PSYCH, V4, P277, DOI 10.1007/BF00917764; Gelles R.J., 1983, DARK SIDE FAMILIES C, P151; GOODWIN J, 1985, HOSP COMMUNITY PSYCH, V36, P1074; GREEN JL, 1987, PRIMARY PEDIATRIC CA, P606; Greenblat C., 1983, DARK SIDE FAMILIES C, P235; HENDRICKSMATTHE.M, 1989, OHIO FAM PHYSICIAN N, V41, P22; Herzberger S., 1983, DARK SIDE FAMILIES, P317; HOFFMAN ML, 1967, J PERS SOC PSYCHOL, V5, P45, DOI 10.1037/h0024189; HULLEY SB, 1988, CECIL TXB MED, V1, P40; Hyman I A, 1977, Child Today, V6, P17; JOHNSTON JM, 1972, AM PSYCHOL, V27, P1033, DOI 10.1037/h0033887; Keller K, 1975, J Fam Pract, V2, P449; Kelly P C, 1987, Tex Med, V83, P40; KORSCH BM, 1965, AM J PUBLIC HEALTH N, V55, P1880, DOI 10.2105/AJPH.55.12.1880; LEFKOWITZ MM, 1978, ARCH GEN PSYCHIAT, V35, P186; MCCORD J, 1988, PSYCHIATRY, V51, P14, DOI 10.1080/00332747.1988.11024376; MERZ B, 1992, AM MED NEWS     0106, P3; MORRIS JL, 1985, AM J DIS CHILD, V139, P194, DOI 10.1001/archpedi.1985.02140040096037; Namaste, 1990, J INTERPERS VIOLENCE, V5, P43, DOI [10.1177/088626090005004002, DOI 10.1177/088626090005004002]; OWENS DJ, 1979, CORPORAL PUNISHMENT, P107; POOLE SR, 1991, PEDIATRICS, V88, P162; POOLE SR, 1983, J FAM PRACTICE, V16, P365; STRAUS MA, 1971, J MARRIAGE FAM, V33, P658, DOI 10.2307/349438; Straus MA, 1983, DARK SIDE FAMILIES C, P213; Sullivan L, 1991, JAMA, V265, P2778, DOI 10.1001/jama.265.21.2778; THYER BA, 1987, PSYCHOL REP, V60, P129, DOI 10.2466/pr0.1987.60.1.129; WESSEL MA, 1980, PEDIATRICS, V66, P639; WILLIAMS CD, 1959, J ABNORM SOC PSYCH, V59, P269, DOI 10.1037/h0046688; 1975, AM PSYCHOL, V30, P632; 1980, AM J PUBLIC HEALTH, V70, P308; 1991, DEMOGRAPHIC CHARACTE; 1989, AM J PSYCHIAT, V146, P1524; 1991, PEDIATRICS, V88, P173; 1983, PEDIATRICS, V72, P373; 1972, REPORT TASK FORCE CO; 1985, HRSDMC861 US DEP HLT; 1988, BMDP STATISTICAL SOF; 1990, ROSTER REGISTERED PH; 1984, PEDIATRICS, V73, P258; 1991, ACTIVE MEMBER PRACTI; 1989, STATISTICAL ABSTRACT	60	65	67	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3161	3165		10.1001/jama.267.23.3161	http://dx.doi.org/10.1001/jama.267.23.3161			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593736				2022-12-28	WOS:A1992HX91800024
J	SUGG, NK; INUI, T				SUGG, NK; INUI, T			PRIMARY CARE PHYSICIANS RESPONSE TO DOMESTIC VIOLENCE - OPENING PANDORA BOX	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BATTERED WOMEN; EMERGENCY	Objective. - To explore primary care physicians'experiences with domestic violence victims to determine the barriers to problem recognition and intervention in the primary care setting. Design. - Ethnography, a qualitative research method involving the use of open-ended, semistructured interviews. Setting. - An urban health maintenance organization serving a predominantly white, middle-income population. Participants. - Thirty-eight physicians, predominantly family practitioners (89%), were interviewed. Results. - Analysis of the interviews revealed that physicians found exploring domestic violence in the clinical setting analogous to "opening Pandora's box." Their issues include lack of comfort, fear of offending, powerlessness, loss of control, and time constraints. Conclusion. - This study revealed several barriers that physicians perceived as preventing them from comfortably intervening with domestic violence victims. These issues need to be addressed in training programs. Further studies should be done to assess generalizability of these findings to other groups of physicians.	UNIV WASHINGTON,DIV GEN INTERNAL MED,SEATTLE,WA 98195; ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SEATTLE,WA	University of Washington; University of Washington Seattle								GOLDBERG WG, 1984, JAMA-J AM MED ASSOC, V251, P3259, DOI 10.1001/jama.251.24.3259; Graves Robert, 1986, GREEK MYTHS; KURZ D, 1987, SOC PROBL, V34, P69, DOI 10.1525/sp.1987.34.1.03a00050; Lincoln Y, 1985, NATURALISTIC ENQUIRY; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; RANDALL T, 1990, JAMA-J AM MED ASSOC, V264, P939, DOI 10.1001/jama.264.8.939; STARK E, 1979, INT J HEALTH SERV, V9, P461, DOI 10.2190/KTLU-CCU7-BMNQ-V2KY; STARK E, 1981, MONOGRAPH OFFICE DOM, V7; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; Warshaw C, 1989, GENDER SOC, V3, P506, DOI 10.1177/089124389003004008	10	450	465	1	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3157	3160		10.1001/jama.267.23.3157	http://dx.doi.org/10.1001/jama.267.23.3157			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593735				2022-12-28	WOS:A1992HX91800023
J	MURRAY, JE				MURRAY, JE			HUMAN ORGAN-TRANSPLANTATION - BACKGROUND AND CONSEQUENCES	SCIENCE			English	Article								The story of the renal transplant program of the Peter Bent Brigham Hospital (now the Brigham and Women's Hospital) in Boston weaves together three distinct threads: the study of renal disease, the phenomenon of skin grafting in twins, and the development of surgical procedures ultimately leading to the use of chemical immunosuppression. The common leitmotiv is one of a single event or report proving to be decisive. Unanticipated consequences of successful human organ transplantation include the reorganization of clinical and nonclinical disciplines, national and international cooperation in organ preservation and distribution, tissue-typing as a marker for disease, redefinition of death in terms of brain function, better understanding of disease processes, and new health care quandaries that result from the scarcity of organ donors.	BRIGHAM & WOMENS HOSP,PLAST SURG,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,PLAST SURG,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital	MURRAY, JE (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							ANDERSON D, 1951, HEREDITY, V5, P379, DOI 10.1038/hdy.1951.38; BELZER FO, 1967, LANCET, V2, P536; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Brown JB, 1937, SURGERY, V1, P558; CALNE RY, 1969, NATURE, V223, P472, DOI 10.1038/223472a0; CALNE RY, 1962, ANN NY ACAD SCI, V99, P743, DOI 10.1111/j.1749-6632.1962.tb45358.x; CALNE RY, 1968, BMJ-BRIT MED J, V4, P535, DOI 10.1136/bmj.4.5630.535; CALNE RY, 1960, LANCET, V1, P417; Carrel A, 1906, SCIENCE, V23, P394, DOI 10.1126/science.23.584.394; DAMMIN GJ, 1957, ANN NY ACAD SCI, V64, P967, DOI 10.1111/j.1749-6632.1957.tb52488.x; DAVIES HFS, 1991, TRANSPLANT P, V23, P2248; DEMPSTER WJ, 1953, BRIT J SURG, V40, P477; DONG E, 1972, ANN SURG, V176, P503; Gibson T, 1943, J ANAT, V77, P299; GOODWIN WE, 1963, J UROLOGY, V89, P13, DOI 10.1016/S0022-5347(17)64491-4; GROTH CG, 1972, SURG GYNECOL OBSTETR, V134, P323; Hamburger J, 1991, HIST TRANSPLANTATION, P61; HUME DM, 1955, J CLIN INVEST, V34, P327, DOI 10.1172/JCI103085; Hunter J., 1779, PHILOS T ROY SOC LON, V69, P279, DOI 10.1098/rstl.1779.0020; KOLFF W, 1944, ACTA MED SCAND, V117, P120; KOLFF WJ, 1965, ANN INTERN MED, V62, P608, DOI 10.7326/0003-4819-62-3-608; KUSS R, 1962, POSTGRAD MED J, V38, P528, DOI 10.1136/pgmj.38.443.528; KUSS R, 1951, Mem Acad Chir (Paris), V77, P755; LAND W, 1991, ORGAN REPLACEMENT TH; LANG S, 1956, Plast Reconstr Surg (1946), V17, P211, DOI 10.1097/00006534-195603000-00004; LAWLER RH, 1951, JAMA-J AM MED ASSOC, V147, P45, DOI 10.1001/jama.1951.73670180006010d; Lille FR, 1916, SCIENCE, V43, P611, DOI 10.1126/science.43.1113.611; Loeb Leo, 1945, BIOL BASIS INDIVIDUA; LOWER R R, 1960, Surg Forum, V11, P18; Medawar P. B., 1957, UNIQUENESS INDIVIDUA; MEDAWAR PB, 1965, BRIT MED BULL, V21, P97, DOI 10.1093/oxfordjournals.bmb.a070392; Merrill John P, 1955, SURG FORUM, V6, P432; MERRILL JP, 1956, JAMA-J AM MED ASSOC, V160, P277, DOI 10.1001/jama.1956.02960390027008; MERRILL JP, 1963, JAMA-J AM MED ASSOC, V185, P347, DOI 10.1001/jama.1963.03060050025015; MERRILL JP, 1960, NEW ENGL J MED, V262, P1251, DOI 10.1056/NEJM196006232622501; MICHON L, 1953, LAPRESSE MED, V61, P1419; MOORE FD, 1959, TRANSPLAN B, V6, P103; MOORE FD, 1972, TRANSPLANT GIVE TAKE, P66; Murray J E, 1967, Transplantation, V5, P752, DOI 10.1097/00007890-196707000-00044; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; MURRAY JE, 1962, ANN NY ACAD SCI, V99, P768, DOI 10.1111/j.1749-6632.1962.tb45360.x; MURRAY JE, 1962, ANN SURG, V156, P337, DOI 10.1097/00000658-196209000-00002; MURRAY JE, 1956, SURG GYNECOL OBSTET, V103, P15; MURRAY JE, 1964, ANN SURG, V160, P449, DOI 10.1097/00000658-196409000-00009; MURRAY JE, 1960, SURGERY, V48, P272; MURRAY JE, 1958, ANN SURG, V148, P343, DOI 10.1097/00000658-195809000-00004; MURRAY JE, 1990, PRIX NOBEL, P207; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PADGETT EC, 1932, SOUTH MED J, V25, P895; PENN I, 1988, TRANSPLANT P, V20, P885; PORTER KA, 1958, ARCH SURG-CHICAGO, V76, P908; Quinby WC, 1916, J EXP MED, V23, P535, DOI 10.1084/jem.23.4.535; QUINTON W, 1960, T AM SOC ART INT ORG, V6, P104; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SIMONSEN M, 1953, ACTA PATHOL MIC SC, V32, P1; STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STERIOFF S, 1987, MAYO CLIN PROC, V62, P1051, DOI 10.1016/S0025-6196(12)65078-2; Williamson CS, 1926, J UROLOGY, V16, P231, DOI 10.1016/S0022-5347(17)73405-2; WILSON RE, 1959, SURGERY, V46, P261; WOODRUFF MFA, 1959, LANCET, V2, P476; ZUKOSKI C F, 1960, Surg Forum, V11, P470; 1968, JAMA-J AM MED ASSOC, V205, P337	63	26	27	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1411	1416		10.1126/science.1604314	http://dx.doi.org/10.1126/science.1604314			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604314				2022-12-28	WOS:A1992HX33700025
J	YOUNG, MP; YAMANE, S				YOUNG, MP; YAMANE, S			SPARSE POPULATION CODING OF FACES IN THE INFEROTEMPORAL CORTEX	SCIENCE			English	Article							TEMPORAL CORTEX; NEURONS; MONKEY; PERCEPTION; RESPONSES; DIRECTION; IDENTITY; FEATURES	How does the brain represent objects in the world? A proportion of cells in the temporal cortex of monkeys responds specifically to objects, such as faces, but the type of coding used by these cells is not known. Population analysis of two sets of such cells showed that information is carried at the level of the population and that this information relates, in the anterior inferotemporal cortex, to the physical properties of face stimuli and, in the superior temporal polysensory area, to other aspects of the faces, such as their familiarity. There was often sufficient information in small populations of neurons to identify particular faces. These results suggest that representations of complex stimuli in the higher visual areas may take the form of a sparse population code.	INST PHYS & CHEM RES,FRONTIER RES PROGRAM,NEURAL INFORMAT PROC LAB,WAKO,SAITAMA 351,JAPAN; ELECTROTECH LAB,DIV NEUROSCI,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; National Institute of Advanced Industrial Science & Technology (AIST)	YOUNG, MP (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							Barlow H B, 1972, Perception, V1, P371, DOI 10.1068/p010371; BARLOW HB, 1985, Q J EXP PSYCHOL-A, V37, P121, DOI 10.1080/14640748508400927; BAYLIS GC, 1985, BRAIN RES, V342, P91, DOI 10.1016/0006-8993(85)91356-3; Dasser V., 1988, MACHIAVELLIAN INTELL, P85; Edgington E. S., 1980, RANDOMIZATION TESTS; FREE WJ, 1975, MASS ACTION NERVOUS; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GEORGOPOULOS AP, 1984, DYNAMIC ASPECTS NEOC; Gower J.C., 1971, MATH ARCHAEOLOGICAL, P138; HASSELMO ME, 1989, BEHAV BRAIN RES, V32, P203, DOI 10.1016/S0166-4328(89)80054-3; Konorski J., 1967, INTEGRATIVE ACTIVITY; LEHKY SR, 1990, J NEUROSCI, V10, P2281; PERRETT DI, 1984, HUM NEUROBIOL, V3, P197; PERRETT DI, 1987, TRENDS NEUROSCI, V10, P358, DOI 10.1016/0166-2236(87)90071-3; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; RHODES G, 1988, PERCEPTION, V17, P43, DOI 10.1068/p170043; SCHONEMANN PH, 1970, PSYCHOMETRIKA, V35, P245, DOI 10.1007/BF02291266; SHEPARD RN, 1980, SCIENCE, V210, P390, DOI 10.1126/science.210.4468.390; YAMANE S, 1988, EXP BRAIN RES, V73, P209, DOI 10.1007/BF00279674; YOUNG MP, 1990, THESIS U ST ANDREWS	22	418	421	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1327	1331		10.1126/science.1598577	http://dx.doi.org/10.1126/science.1598577			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	HW135	1598577				2022-12-28	WOS:A1992HW13500036
J	BERNERSEN, B; JOHNSEN, R; BOSTAD, L; STRAUME, B; SOMMER, AI; BURHOL, PG				BERNERSEN, B; JOHNSEN, R; BOSTAD, L; STRAUME, B; SOMMER, AI; BURHOL, PG			IS HELICOBACTER-PYLORI THE CAUSE OF DYSPEPSIA	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-LIKE ORGANISMS; UPPER GASTROINTESTINAL SYMPTOMS; FOLLOW-UP EXAMINATIONS; NON-ULCER DYSPEPSIA; CHRONIC GASTRITIS; MUCOSAL HISTOLOGY; BIOPSY SPECIMENS; PREVALENCE; INFECTION; DIAGNOSIS	Objective-To determine the association between infection with Helicobacter pylori and dyspepsia. Design-Cross sectional study of dyspeptic subjects and age and sex matched controls identified by a questionnaire survey of all inhabitants aged 20-69. (Endoscopy, histological examination, and microbiological examinations of biopsies from the gastric mucosa were performed blind.) Setting-Population based survey in Sorreisa, Norway. Subjects-All 782 dyspeptic subjects (excluding those with a previous history of peptic ulcer, gall stones or kidney stones, and coronary heart disease) and controls were offered an endoscopy, of whom 309 dyspeptic subjects and 310 controls attended. Main outcome measures-Prevalences of endoscopic and histological diagnoses and of cultures positive for H pylori. Results-A high prevalence of positive cultures, increasing with age, was found in both dyspeptic subjects (48%) and non-dyspeptic controls (36%) (p = 0.004). Positive cultures in both dyspeptic subjects and controls were strongly associated with histological gastritis (70%, 95% confidence interval 65.5 to 85.3; 60%, 52.7 to 67.7, respectively) and peptic ulcer (92%, 61.5 to 99.8; 64.1, 9.4 to 99.2, respectively). Only 3% of subjects with a histologically non-inflamed gastric mucosa had this infection (dyspeptic subjects 2%, 0.2 to 7.0; controls 4%; 1.2 to 8.8). Conclusions-The relation between dyspeptic symptoms and H pylori is dubious; H pylori seems to have a pathogenetic role in gastritis and may be a contributing factor but not a cause of peptic ulcer.	UNIV TROMSO,INST COMMUNITY MED,N-9001 TROMSO,NORWAY; UNIV TROMSO HOSP,GASTROENTEROL,N-9012 TROMSO,NORWAY	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso; University Hospital of North Norway								ALMOAGEL MA, 1990, AM J GASTROENTEROL, V85, P944; BARTHEL JS, 1988, ARCH INTERN MED, V148, P1149, DOI 10.1001/archinte.148.5.1149; BARTLETT JG, 1988, GASTROENTEROLOGY, V94, P229, DOI 10.1016/0016-5085(88)90634-8; BERNERSEN B, 1990, GUT, V31, P989, DOI 10.1136/gut.31.9.989; COGHLAN JG, 1987, LANCET, V2, P1109; COLINJONES DG, 1988, LANCET, V1, P576; Doenges JL, 1938, P SOC EXP BIOL MED, V38, P536; DOOLEY CP, 1988, ANN INTERN MED, V108, P70, DOI 10.7326/0003-4819-108-1-70; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; Fleiss JL, 1981, STAT METHODS RATES P; Freedberg A. S., 1940, AM J DIG DIS, V7, P443, DOI DOI 10.1007/BF02997393; GOODWIN CS, 1986, J CLIN PATHOL, V39, P353, DOI 10.1136/jcp.39.4.353; HEATLEY RV, 1987, LANCET, V2, P779; JOHNSEN R, 1991, BRIT MED J, V302, P749, DOI 10.1136/bmj.302.6779.749; JOHNSSON F, 1987, SCAND J GASTROENTERO, V22, P714, DOI 10.3109/00365528709011148; JONES DM, 1984, J CLIN PATHOL, V37, P1002, DOI 10.1136/jcp.37.9.1002; LANGENBERG ML, 1984, LANCET, V1, P1348; LAWSON HH, 1964, LANCET, V1, P469; LOFFELD RJLF, 1989, GUT, V30, P1206, DOI 10.1136/gut.30.9.1206; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P436, DOI 10.5694/j.1326-5377.1985.tb113443.x; MORRIS A, 1987, AM J GASTROENTEROL, V82, P192; MYREN J, 1974, SCAND J GASTROENTERO, V9, P457; NESLAND AA, 1985, SCAND J GASTROENTERO, V20, P222, DOI 10.3109/00365528509089661; OWEN DA, 1979, PATHOL ANNU, V1, P247; PETERSON WL, 1986, GASTROENTEROLOGY, V90, P1585; PETTROSS CW, 1988, DIGEST DIS SCI, V33, P649, DOI 10.1007/BF01540425; RAUWS EA, 1988, GASTROENTEROLOGY, V94, P33, DOI 10.1016/0016-5085(88)90606-3; SAVARY M, 1977, OESOPHAGUS LEHRBUCH; SIURALA M, 1988, GUT, V29, P909, DOI 10.1136/gut.29.7.909; TALLEY NJ, 1988, ANN INTERN MED, V108, P865, DOI 10.7326/0003-4819-108-6-865; TATSUTA M, 1986, DIGEST DIS SCI, V31, P7, DOI 10.1007/BF01347902; VENABLES CW, 1985, SCAND J GASTROENTERO, V20, P91, DOI 10.3109/00365528509103941; VILLAKO K, 1990, ENDOSCOPY, V22, P114, DOI 10.1055/s-2007-1012814; WARREN JR, 1983, LANCET, V1, P1273; WHITEHEAD R, 1972, J CLIN PATHOL, V25, P1, DOI 10.1136/jcp.25.1.1; WHITEHEAD R, 1975, DIGESTION, V13, P129, DOI 10.1159/000197701	37	142	142	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1276	1279		10.1136/bmj.304.6837.1276	http://dx.doi.org/10.1136/bmj.304.6837.1276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606428	Green Published, Bronze			2022-12-28	WOS:A1992HV08600019
J	CROSSLEY, M; LUDWIG, M; STOWELL, KM; DEVOS, P; OLEK, K; BROWNLEE, GG				CROSSLEY, M; LUDWIG, M; STOWELL, KM; DEVOS, P; OLEK, K; BROWNLEE, GG			RECOVERY FROM HEMOPHILIA-B LEYDEN - AN ANDROGEN-RESPONSIVE ELEMENT IN THE FACTOR-IX PROMOTER	SCIENCE			English	Article							INVITRO TRANSCRIPTION; GENE	One form of the inherited, X-linked, bleeding disorder, hemophilia B, resolves after puberty. Mutations at -20 and -26 in the clotting factor IX promoter impair transcription by disrupting the binding site for the liver-enriched transcription factor LF-A1/HNF4. The -26 but not the -20 mutation also disrupts an androgen-responsive element, which overlaps the LF-A1/HNF4 site. This explains the improvement seen in patients with the -20 mutation and the failure of the -26 patient to recover.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,CHEM PATHOL UNIT,S PARKS RD,OXFORD OX1 3RE,ENGLAND; UNIV BONN,INST EXPTL HEMATOL & BLOOD TRANSFUS,W-5300 BONN 1,GERMANY; CATHOLIC UNIV LEUVEN,EXPTL MED & ENDOCRINOL LAB,B-3000 LOUVAIN,BELGIUM; UNIV BONN,INST CLIN BIOCHEM,W-5300 BONN 1,GERMANY	University of Oxford; University of Bonn; KU Leuven; University of Bonn			Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRIET E, 1985, ANN INTERN MED, V103, P225, DOI 10.7326/0003-4819-103-2-225; BRIET E, 1982, NEW ENGL J MED, V306, P788, DOI 10.1056/NEJM198204013061306; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; CROSSLEY ML, UNPUB; DEVOS P, 1991, J BIOL CHEM, V266, P3439; GIANNELLI F, 1991, NUCLEIC ACIDS RES, V19, P2193, DOI 10.1093/nar/19.suppl.2193; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HIROSAWA S, 1990, P NATL ACAD SCI USA, V87, P4421, DOI 10.1073/pnas.87.12.4421; Lubhan DB, 1988, SCIENCE, V240, P327; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUDWIG M, UNPUB; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MONACI P, 1988, EMBO J, V7, P2075, DOI 10.1002/j.1460-2075.1988.tb03047.x; RAMJI DP, 1991, NUCLEIC ACIDS RES, V19, P1139, DOI 10.1093/nar/19.5.1139; REITSMA PH, 1988, BLOOD, V72, P1074; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAKEDA H, 1990, J ENDOCRINOL, V126, P17, DOI 10.1677/joe.0.1260017; WESTLEY B, 1980, CELL, V20, P353, DOI 10.1016/0092-8674(80)90621-2	22	127	130	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					377	379		10.1126/science.1631558	http://dx.doi.org/10.1126/science.1631558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631558				2022-12-28	WOS:A1992JD67400031
J	ORGEL, LE				ORGEL, LE			MOLECULAR REPLICATION	NATURE			English	Review							TEMPLATE-DIRECTED SYNTHESIS; RNA RANDOM COPOLYMERS; SYSTEM; MODEL; HEXADEOXYNUCLEOTIDE; OLIGOMERIZATION; MACROMOLECULES; POLYMERIZATION; DERIVATIVES; MICELLES	Simple replicating molecules are likely to have played a critical role in the origin of life. Recent experiments show that non-enzymatic replication is conceivable in a wide range of synthetic chemical systems. The challenge now facing these studies is how to develop information-coding systems from simple prebiotic precursors.			ORGEL, LE (corresponding author), SALK INST BIOL STUDIES, POB 85800, SAN DIEGO, CA 92186 USA.							ACEVEDO OL, 1987, J MOL BIOL, V197, P187, DOI 10.1016/0022-2836(87)90117-3; BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0; BACHMANN PA, 1990, J AM CHEM SOC, V112, P8200, DOI 10.1021/ja00178a073; BALLARD DGH, 1956, PROC R SOC LON SER-A, V236, P384, DOI 10.1098/rspa.1956.0143; BAMFORD CH, 1973, P NATO ADV STUDY I, P54; BIEBRICHER CK, 1983, EVOLUTIONARY BIOL, V16; BONNER WA, 1991, ORIGINS LIFE EVOL B, V21, P59, DOI 10.1007/BF01809580; BOSSCHER F, 1982, MACROMOLECULES, V15, P1442, DOI 10.1021/ma00233a045; BRACK A, 1976, J MOL EVOL, V8, P307, DOI 10.1007/BF01739255; Cairns-Smith AG, 1977, ENCY IGNORANCE, P391; CAIRNSSMITH AG, 1982, GENETIC TAKEOVER; CHALLA G, 1981, PURE APPL CHEM, V53, P627, DOI 10.1351/pac198153030627; de Duve C, 1991, BLUEPRINT CELL NATUR; DOUDNA JA, 1991, SCIENCE, V251, P1605, DOI 10.1126/science.1707185; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; FENG Q, IN PRESS SCIENCE; HARADA K, 1990, ORIGINS LIFE EVOL B, V20, P151, DOI 10.1007/BF01808276; HARADA K, 1991, J MOL EVOL, V32, P358, DOI 10.1007/BF02101274; HILL AR, 1988, J MOL EVOL, V28, P170, DOI 10.1007/BF02143509; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; INOUE T, 1981, J AM CHEM SOC, V103, P7666, DOI 10.1021/ja00415a051; INOUE T, 1983, SCIENCE, V219, P859, DOI 10.1126/science.6186026; JOYCE GF, 1986, J MOL BIOL, V188, P433, DOI 10.1016/0022-2836(86)90166-X; JOYCE GF, 1984, NATURE, V310, P602, DOI 10.1038/310602a0; JOYCE GF, 1987, COLD SPRING HARB SYM, V52, P41, DOI 10.1101/SQB.1987.052.01.008; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; JOYCE GF, 1984, J MOL BIOL, V176, P279, DOI 10.1016/0022-2836(84)90425-X; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KAUFFMAN SA, 1986, J THEOR BIOL, V119, P1, DOI 10.1016/S0022-5193(86)80047-9; KONDEPUDI DK, 1990, SCIENCE, V250, P975, DOI 10.1126/science.250.4983.975; LUISI PL, 1989, ORIGINS LIFE EVOL B, V19, P633, DOI 10.1007/BF01808123; Mizuno T., 1974, Advances in Carbohydrate Chemistry and Biochemistry, V29, P173; MOROWITZ HJ, 1988, ORIGINS LIFE EVOL B, V18, P281, DOI 10.1007/BF01804674; MULLER D, 1990, HELV CHIM ACTA, V73, P1410, DOI 10.1002/hlca.19900730526; NELSESTUEN GL, 1980, J MOL EVOL, V15, P59, DOI 10.1007/BF01732583; NOWICK JS, 1991, J AM CHEM SOC, V113, P8831, DOI 10.1021/ja00023a036; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; REBEK J, 1992, CHEM IND-LONDON, P171; ROTELLO V, 1991, J AM CHEM SOC, V113, P9422, DOI 10.1021/ja00024a089; SCHWARTZ AW, 1985, SCIENCE, V228, P585, DOI 10.1126/science.228.4699.585; Shapiro Robert, 1986, ORIGINS SKEPTICS GUI; SPIEGELMAN S, 1971, Quarterly Reviews of Biophysics, V4, P213; TERFORT A, IN PRESS ANGEW CHEM, V31; TJIVIKUA T, 1990, J AM CHEM SOC, V112, P1249, DOI 10.1021/ja00159a057; VANDEGRAMPEL HT, 1992, MACROMOLECULES, V25, P1049, DOI 10.1021/ma00029a006; VISSCHER J, 1987, J MOL EVOL, V26, P291, DOI 10.1007/BF02101146; von Kiedrowski G., 1990, 40 JAHRE FONDS CHEM, P197; VONKIEDROWSKI G, 1991, ANGEW CHEM INT EDIT, V30, P423, DOI 10.1002/anie.199104231; VONKIEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P932, DOI 10.1002/anie.198609322; VONKIEDROWSKI G, 1989, ANGEW CHEM INT EDIT, V28, P1235, DOI 10.1002/anie.198912351; VONKIEDROWSKI G, IN PRESS ORIGINS LIF, V22; VONKIEDROWSKI G, IN PRESS NACHR CHEM; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WEBER AL, 1989, ORIGINS LIFE EVOL B, V19, P179, DOI 10.1007/BF01808151; WEBER AL, 1987, ORIGINS LIFE EVOL B, V17, P107, DOI 10.1007/BF01808239; Wilen HS., 1991, ENANTIOMERS RACEMATE; WU T, IN PRESS J AM CHEM S, V114	58	403	407	5	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 16	1992	358	6383					203	209		10.1038/358203a0	http://dx.doi.org/10.1038/358203a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630488				2022-12-28	WOS:A1992JD58700044
J	VOELKER, TA; WORRELL, AC; ANDERSON, L; BLEIBAUM, J; FAN, C; HAWKINS, DJ; RADKE, SE; DAVIES, HM				VOELKER, TA; WORRELL, AC; ANDERSON, L; BLEIBAUM, J; FAN, C; HAWKINS, DJ; RADKE, SE; DAVIES, HM			FATTY-ACID BIOSYNTHESIS REDIRECTED TO MEDIUM CHAINS IN TRANSGENIC OILSEED PLANTS	SCIENCE			English	Article							ARABIDOPSIS; TRANSFORMATION; TRANSPORT; CLONING; PROTEIN; MUTANTS	Medium-chain fatty acids (FAs), found in storage lipids of certain plants, are an important renewable resource. Seeds of undomesticated California bay accumulate laurate (12:0), and a 12:0-acyl-carrier protein thioesterase (BTE) has been purified from this tissue. Sequencing of BTE enabled the cloning of a complementary DNA coding for a plastid-targeted preprotein. Expression of the complementary DNA in the seeds of Arabidopsis thaliana resulted in BTE activity, and medium chains accumulated at the expense of long-chain (greater-than-or-equal-to 16) FAs. Laurate became the most abundant FA species and was deposited in the storage triacylglycerols. These results demonstrate a mechanism for medium-chain FA synthesis in plants.			VOELKER, TA (corresponding author), CALGENE INC,1920 5TH ST,DAVIS,CA 95616, USA.							AEBERSOLD R, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P71; ALEXANDER DC, 1987, METHOD ENZYMOL, V154, P41; BATTEY JF, 1989, TRENDS BIOTECHNOL, V7, P122, DOI 10.1016/0167-7799(89)90088-7; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; DAVIES H, UNPUB; DAVIES HM, 1991, ARCH BIOCHEM BIOPHYS, V290, P37, DOI 10.1016/0003-9861(91)90588-A; HARWOOD JL, 1988, ANNU REV PLANT PHYS, V39, P101, DOI 10.1146/annurev.arplant.39.1.101; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; JAMES DW, 1990, THEOR APPL GENET, V80, P241, DOI 10.1007/BF00224393; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KNUTZON DS, 1992, P NATL ACAD SCI USA, V89, P2624, DOI 10.1073/pnas.89.7.2624; KNUTZON DS, COMMUNICATION; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; LEMIEUX B, 1990, THEOR APPL GENET, V80, P234, DOI 10.1007/BF00224392; LUTCKE HA, 1987, EMBO J, V6, P44; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; OHLROGGE JB, 1979, P NATL ACAD SCI USA, V76, P1194, DOI 10.1073/pnas.76.3.1194; POLLARD MR, 1991, ARCH BIOCHEM BIOPHYS, V284, P1; ROSNER MR, 1982, J CELL BIOCHEM, V18, P37, DOI 10.1002/jcb.1982.240180105; SMEEKENS S, 1990, TRENDS BIOCHEM SCI, V15, P73, DOI 10.1016/0968-0004(90)90180-J; TURPEN T H, 1986, Biotechniques, V4, P14; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536	23	314	369	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					72	74		10.1126/science.1621095	http://dx.doi.org/10.1126/science.1621095			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621095				2022-12-28	WOS:A1992JC16500031
J	MAGGIONI, AP; FRANZOSI, MG; SANTORO, E; WHITE, H; VANDEWERF, F; TOGNONI, G				MAGGIONI, AP; FRANZOSI, MG; SANTORO, E; WHITE, H; VANDEWERF, F; TOGNONI, G			THE RISK OF STROKE IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION AFTER THROMBOLYTIC AND ANTITHROMBOTIC TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECHOCARDIOGRAPHY	Background. Many trials in patients with acute myocardial infarction have demonstrated that thrombolytic therapy is not associated with an excessive risk of stroke, as compared with conventional treatment. However, the incidence of various forms of stroke in patients treated,with different thrombolytic and antithrombotic regimens and the associated effect of risk factors for stroke are largely unknown. Methods. Strokes occurring in patients hospitalized with acute myocardial infarction who were enrolled in either of two large trials were analyzed. The patients were randomly assigned to receive streptokinase (1.5 million units) or recombinant tissue plasminogen activator (t-PA) (100 mg) and also randomly assigned to receive subcutaneous heparin or no heparin. Ninety-one percent of the patients also received aspirin. Results. Complete data were available on 20,768 patients. A total of 236 (1.14 percent) had strokes in the hospital; 0.36 percent had hemorrhagic strokes, 0.48 percent ischemic strokes, and 0.30 percent strokes of undefined cause. Patients treated with t-PA had a small but significant excess of stroke as compared with those who received streptokinase (1.33 vs. 0.94 percent; adjusted odds ratio, 1.42; 95 percent confidence interval, 1.09 to 1.84). The administration of subcutaneous heparin in addition to a thrombolytic agent did not increase the risk of stroke (risk with heparin, 1.13 percent; without heparin, 1.14 percent). Older age, a higher Killip class, and the occurrence of anterior infarction significantly increased the risk of stroke, whereas a higher body-mass index or a history of hypertension, diabetes, or smoking did not. Conclusions. Patients with acute myocardial infarction who receive thrombolytic therapy have a small risk of stroke. Treatment with t-PA as compared with streptokinase resulted in a small but significant excess of stroke. Subcutaneous heparin, given together with t-PA or streptokinase and aspirin, did not result in an increased risk of stroke.	UNIV HOSP GASTHUISBERG, DIV CARDIOL, INT STUDY GRP, B-3000 LOUVAIN, BELGIUM	KU Leuven; University Hospital Leuven	MAGGIONI, AP (corresponding author), GRP ITALIANO STUDIO SOPRAVVIVENZA INFARTO MIOCARDI, COORDINATING CTR, VIA ERITREA 62, I-20157 MILAN, ITALY.		santoro, eugenio/ABG-7901-2020; Leonardi, Giuseppe/AAY-1205-2020; Simes, Robert John/P-1497-2014; Maggioni, Aldo Pietro/AAL-5334-2020	santoro, eugenio/0000-0002-5719-9896; Maggioni, Aldo Pietro/0000-0003-2764-6779				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1988, BRIT MED J, V296, P320; ASINGER RW, 1981, NEW ENGL J MED, V305, P297, DOI 10.1056/NEJM198108063050601; CALIFF RM, 1988, ACUTE CORONARY CARE, P539; CHAMBERLAIN DA, 1990, LANCET, V335, P427; DEBONO DP, 1992, BRIT HEART J, V67, P122; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRINES CL, 1990, J AM COLL CARDIOL, V16, P223, DOI 10.1016/0735-1097(90)90482-5; HUNT D, 1992, LANCET, V339, P753; KOMRAD MS, 1984, NEUROLOGY, V34, P1403, DOI 10.1212/WNL.34.11.1403; MAGGIONI A, 1991, BMJ-BRIT MED J, V302, P1428, DOI 10.1136/bmj.302.6790.1428; OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P; ODONNELL M, 1991, BRIT MED J, V302, P1259, DOI 10.1136/bmj.302.6787.1259; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P227; THOMPSON PL, 1978, BRIT MED J, V2, P457, DOI 10.1136/bmj.2.6135.457; VANDEWERF F, 1990, LANCET, V336, P71; WEINREICH DJ, 1984, ANN INTERN MED, V100, P789, DOI 10.7326/0003-4819-100-6-789; WILCOX RG, 1988, LANCET, V2, P525	24	213	214	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					1	6		10.1056/NEJM199207023270101	http://dx.doi.org/10.1056/NEJM199207023270101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598096	Bronze			2022-12-28	WOS:A1992JA76100001
J	TOPOL, EJ; CALIFF, RM				TOPOL, EJ; CALIFF, RM			THROMBOLYTIC THERAPY FOR ELDERLY PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION		DUKE UNIV, SCH MED, DURHAM, NC 27710 USA	Duke University	TOPOL, EJ (corresponding author), CLEVELAND CLIN FDN, CLEVELAND, OH 44195 USA.							[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; CRAVER JM, 1990, CIRCULATION, V82, P360; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; FEIT F, 1990, CIRCULATION, V82, P666; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; HUNT D, 1992, LANCET, V339, P753; KAPANTAIS G, 1989, ADV VITAL HLTH STATI, V172; KOLATA G, 1992, NY TIMES        0216, P6; KRUMHOLZ HM, 1992, NEW ENGL J MED, V327, P7, DOI 10.1056/NEJM199207023270102; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MULLER DWM, 1990, ANN INTERN MED, V113, P949, DOI 10.7326/0003-4819-113-12-949; SOLDO BJ, 1988, GERIATRIC MED, P12; TOPOL EJ, 1992, J AM COLL CARDIOL, V19, P1123, DOI 10.1016/0735-1097(92)90312-B; WEAVER WD, 1991, J AM COLL CARDIOL, V18, P657, DOI 10.1016/0735-1097(91)90784-7	17	54	55	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					45	47		10.1056/NEJM199207023270109	http://dx.doi.org/10.1056/NEJM199207023270109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598101				2022-12-28	WOS:A1992JA76100009
J	MANSON, JE; NATHAN, DM; KROLEWSKI, AS; STAMPFER, MJ; WILLETT, WC; HENNEKENS, CH				MANSON, JE; NATHAN, DM; KROLEWSKI, AS; STAMPFER, MJ; WILLETT, WC; HENNEKENS, CH			A PROSPECTIVE-STUDY OF EXERCISE AND INCIDENCE OF DIABETES AMONG UNITED-STATES MALE PHYSICIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLUCOSE-TOLERANCE; POLYNESIAN POPULATION; PREVALENCE; MELLITUS; PACIFIC; RISK	Objective.-To examine prospectively the association between regular exercise and the subsequent development of non-insulin-dependent diabetes mellitus (NIDDM). Design.-Prospective cohort study including 5 years of follow-up. Participants.-21 271 US male physicians participating in the Physicians' Health Study, aged 40 to 84 years and free of diagnosed diabetes mellitus, myocardial infarction, cerebrovascular disease, and cancer at baseline. Morbidity follow-up was 99.7% complete. Main Outcome Measure.-Incidence of NIDDM. Results.-At baseline, information was obtained about frequency of vigorous exercise and other risk indicators. During 105 141 person-years of follow-up, 285 new cases of NIDDM were reported. The age-adjusted incidence of NIDDM ranged from 369 cases per 1 00 000 person-years in men who engaged in vigorous exercise less than once weekly to 214 cases per 1 00 000 person-years in those exercising at least five times per week (P, trend, <.001). Men who exercised at least once per week had an age-adjusted relative risk (RR) of NIDDM of 0.64 (95% Cl, 0.51 to 0.82; P=.0003) compared with those who exercised less frequently. The age-adjusted RR of NIDDM decreased with increasing frequency of exercise: 0.77 for once weekly, 0.62 for two to four times per week, and 0.58 for five or more times per week (P, trend, .0002). A significant reduction in risk of NIDDM persisted after adjustment for both age and body-mass index: RR, 0.71 (95% Cl, 0.56 to 0.91; P=.006) for at least once per week compared with less than once weekly, and P, trend, .009, for increasing frequency of exercise. Further control for smoking, hypertension, and other coronary risk factors did not materially alter these associations. The inverse relation of exercise to risk of NIDDM was particularly pronounced among overweight men. Conclusions.-Exercise appears to reduce the development of NIDDM even after adjusting for body-mass index. Increased physical activity may be a promising approach to the primary prevention of NIDDM.	HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DIABET RES CTR,BOSTON,MA 02114; BRIGHAM & WOMENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,JOSLIN DIABET CTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Joslin Diabetes Center, Inc.; Harvard University; Harvard T.H. Chan School of Public Health					NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 36798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BECKNIELSEN H, 1989, DIABETES METAB REV, V5, P487, DOI 10.1002/dmr.5610050602; BJORNTORP P, 1982, RECENT TREND DIABETE, P115; BURSTEIN R, 1985, DIABETES, V34, P756, DOI 10.2337/diabetes.34.8.756; CEDERHOLM J, 1985, ACTA MED SCAND, V217, P373; DAHM GL, 1987, AM J PHYSIOL, V252, pE170; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; FRISCH RE, 1986, DIABETES, V35, P1101, DOI 10.2337/diabetes.35.10.1101; HARRIS MI, 1985, DIABETES AM DIABETES, V6, P1; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLLOSZY JO, 1986, ACTA MED SCAND S, V711, P55; HUGHES T, 1987, MMWR-MORBID MORTAL W, V36, P195; JARRETT RJ, 1986, DIABETIC MED, V3, P549, DOI 10.1111/j.1464-5491.1986.tb00813.x; KING H, 1986, MED J AUSTRALIA, V145, P505, DOI 10.5694/j.1326-5377.1986.tb139452.x; KING H, 1984, AM J EPIDEMIOL, V119, P396, DOI 10.1093/oxfordjournals.aje.a113758; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; KOIVISTO V A, 1986, Diabetes Metabolism Reviews, V1, P445; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MONDON CE, 1980, AM J PHYSIOL, V239, pE169, DOI 10.1152/ajpendo.1980.239.3.E169; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; RUDERMAN N, 1990, DIABETES CARE, V13, P1163, DOI 10.2337/diacare.13.11.1163; SCHNEIDER SH, 1984, DIABETOLOGIA, V26, P355, DOI 10.1007/BF00266036; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; STERN JS, 1987, RECENT ADV OBESITY R, P337; TAYLOR R, 1984, DIABETOLOGIA, V27, P578, DOI 10.1007/BF00276971; TAYLOR RJ, 1983, DIABETES CARE, V6, P334, DOI 10.2337/diacare.6.4.334; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WASHBURN RA, 1987, PREV MED, V16, P636, DOI 10.1016/0091-7435(87)90047-8; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45; ZIMMET P, 1990, DIABETES METAB REV, V6, P91, DOI 10.1002/dmr.5610060203; 1985, NIH851468 US DEP HLT	35	500	515	3	34	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					63	67		10.1001/jama.268.1.63	http://dx.doi.org/10.1001/jama.268.1.63			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608115				2022-12-28	WOS:A1992JA16500024
J	GERSHON, D				GERSHON, D			NEW BIOTECHNOLOGY INSTITUTE AT RICE PROMOTES INTERDISCIPLINARY STUDIES	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					630	630		10.1038/357630a0	http://dx.doi.org/10.1038/357630a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614508				2022-12-28	WOS:A1992JA43000025
J	CHOPIN, K				CHOPIN, K			LETTER FROM POLAND .3. POSTTOTALITARIAN MEDICINE	BRITISH MEDICAL JOURNAL			English	Article																		FOSTER DP, 1990, LANCET, V335, P458	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1557	1560		10.1136/bmj.304.6841.1557	http://dx.doi.org/10.1136/bmj.304.6841.1557			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628060	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800032
J	LEWIS, JD; MEEHAN, RR; HENZEL, WJ; MAURERFOGY, I; JEPPESEN, P; KLEIN, F; BIRD, A				LEWIS, JD; MEEHAN, RR; HENZEL, WJ; MAURERFOGY, I; JEPPESEN, P; KLEIN, F; BIRD, A			PURIFICATION, SEQUENCE, AND CELLULAR-LOCALIZATION OF A NOVEL CHROMOSOMAL PROTEIN THAT BINDS TO METHYLATED DNA	CELL			English	Article							MOUSE SATELLITE DNA; GENE-EXPRESSION; CHROMATIN STRUCTURE; DENOVO METHYLATION; PROMOTER; CELLS; 5-METHYLCYTOSINE; IDENTIFICATION; DEMETHYLATION; ORGANIZATION	Methylation of mammalian DNA can lead to repression of transcription and alteration of chromatin structure. Recent evidence suggests that both effects are the result of an interaction between the methylated sites and methyl-CpG-binding proteins (MeCPs). MeCP1 has previously been detected in crude nuclear extracts. Here we report the identification, purification, and cDNA cloning of a novel MeCP called MeCP2. Unlike MeCP1, the new protein is able to bind to DNA that contains a single methyl-CpG pair. By staining with an antibody, we show that the distribution of MeCP2 along the chromosomes parallels that of methyl-CpG. In mouse, for example, MeCP2 is concentrated in pericentromeric heterochromatin, which contains a large fraction (about 40%) of all genomic 5-methylcytosine.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; GENENTECH INC,S SAN FRANCISCO,CA 94080; ERNST BOEHRINGER INST ARZNEIMITTELFORSCH,A-1121 VIENNA,AUSTRIA; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; UNIV VIENNA,INST BOT,A-1010 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Roche Holding; Genentech; University of Edinburgh; University of Vienna	LEWIS, JD (corresponding author), UNIV EDINBURGH,INST CELL & MOLEC BIOL,KINGS BLDG,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND.			Bird, Adrian/0000-0002-8600-0372; Henzel, William/0000-0003-2940-3797; Meehan, Richard/0000-0001-6471-6882	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; ASHLEY CT, 1989, J BIOL CHEM, V264, P8394; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BUSCHHAUSEN G, 1985, NUCLEIC ACIDS RES, V13, P5503, DOI 10.1093/nar/13.15.5503; CHURCHILL MEA, 1989, EMBO J, V8, P4189, DOI 10.1002/j.1460-2075.1989.tb08604.x; COMINGS DE, 1973, EXP CELL RES, V77, P469, DOI 10.1016/0014-4827(73)90601-0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GROUDINE M, 1981, NATURE, V292, P311, DOI 10.1038/292311a0; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOJOH H, 1990, NUCLEIC ACIDS RES, V18, P4099; HORZ W, 1981, NUCLEIC ACIDS RES, V9, P683, DOI 10.1093/nar/9.3.683; HUBSCHER U, 1987, NUCLEIC ACIDS RES, V15, P5486, DOI 10.1093/nar/15.13.5486; JEPPESEN PN, 1991, CHROMOSOMA, V101, P322; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JONES KW, 1970, NATURE, V225, P912, DOI 10.1038/225912a0; JOSEPH A, 1989, EXP CELL RES, V183, P494, DOI 10.1016/0014-4827(89)90408-4; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; KIT S, 1961, J MOL BIOL, V3, P711, DOI 10.1016/S0022-2836(61)80075-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE A, 1991, P NATL ACAD SCI USA, V88, P6515, DOI 10.1073/pnas.88.15.6515; MANSON MM, 1981, CARCINOGENESIS, V2, P661, DOI 10.1093/carcin/2.7.661; MANUELIDIS L, 1981, FEBS LETT, V129, P25, DOI 10.1016/0014-5793(81)80746-6; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; MISKIMINS WK, 1985, P NATL ACAD SCI USA, V82, P6741, DOI 10.1073/pnas.82.20.6741; MURRAY EJ, 1987, EMBO J, V6, P2329, DOI 10.1002/j.1460-2075.1987.tb02508.x; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PARDUE ML, 1970, SCIENCE, V168, P1356, DOI 10.1126/science.168.3937.1356; PAWLAK A, 1991, NUCLEIC ACIDS RES, V19, P1029; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; REEVES R, 1990, J BIOL CHEM, V265, P8573; RENBAUM P, 1990, NUCLEIC ACIDS RES, V18, P1145, DOI 10.1093/nar/18.5.1145; RICKWOOD D, 1975, EUR J BIOCHEM, V51, P593, DOI 10.1111/j.1432-1033.1975.tb03961.x; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID M, 1984, HUM GENET, V67, P257, DOI 10.1007/BF00291352; SOLAGE A, 1978, BIOCHEMISTRY-US, V17, P2934, DOI 10.1021/bi00607a036; STANLEY KK, 1984, EMBO J, V3, P1429, DOI 10.1002/j.1460-2075.1984.tb01988.x; STEIN R, 1982, P NATL ACAD SCI USA, V79, P4418; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; SUTTER D, 1980, P NATL ACAD SCI-BIOL, V77, P253, DOI 10.1073/pnas.77.1.253; VANDERPLOEG LHT, 1980, CELL, V19, P947, DOI 10.1016/0092-8674(80)90086-0; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG RYH, 1986, NUCLEIC ACIDS RES, V14, P9843, DOI 10.1093/nar/14.24.9843; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; WILKS AF, 1982, P NATL ACAD SCI-BIOL, V79, P4252, DOI 10.1073/pnas.79.14.4252	52	1041	1077	3	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					905	914		10.1016/0092-8674(92)90610-O	http://dx.doi.org/10.1016/0092-8674(92)90610-O			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606614				2022-12-28	WOS:A1992HY79200003
J	NAGLICH, JG; METHERALL, JE; RUSSELL, DW; EIDELS, L				NAGLICH, JG; METHERALL, JE; RUSSELL, DW; EIDELS, L			EXPRESSION CLONING OF A DIPHTHERIA-TOXIN RECEPTOR - IDENTITY WITH A HEPARIN-BINDING EGF-LIKE GROWTH-FACTOR PRECURSOR	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; BACTERIAL TOXINS; SIGNAL SEQUENCE; FACTOR-ALPHA; B-FRAGMENT; ZETA-CHAIN; LOW PH; CELLS	A monkey cDNA (pDTS) encoding a diphtheria toxin (DT) sensitivity determinant was isolated by expression cloning in mouse L-M cells. Mouse cells are naturally resistant to DT, because they lack functional cell surface receptors for the toxin. Unlike wild-type L-M cells, pDTS-transfected mouse cells are extremely toxin sensitive and specifically bind radioiodinated DT. Intoxication of the transfected cells requires receptor-mediated endocytosis of the bound toxin. The cDNA is predicted to encode an integral membrane protein that is identical to the precursor of a heparin-binding EGF-like growth factor. The DT sensitivity protein is thus a growth factor precursor that DT exploits as a receptor.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	NAGLICH, JG (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Russell, David/0000-0002-0277-403X	NATIONAL CANCER INSTITUTE [F32CA008398] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016805] Funding Source: NIH RePORTER; NCI NIH HHS [CA 08398] Funding Source: Medline; NIAID NIH HHS [AI-16805] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CIEPLAK W, 1987, J BIOL CHEM, V262, P13246; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; EBERLE W, 1991, CELL, V67, P1203, DOI 10.1016/0092-8674(91)90296-B; EIDELS L, 1982, INFECT IMMUN, V37, P1054, DOI 10.1128/IAI.37.3.1054-1058.1982; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GRAHAM FL, 1980, INTRO MACROMOLECULES, V1, P3; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; IWAMOTO R, 1991, J BIOL CHEM, V266, P20463; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KLEIN R, 1989, EMBO J, V8, P3701, DOI 10.1002/j.1460-2075.1989.tb08545.x; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATTHEWS LS, 1991, CELL, V65, P973; MEKADA E, 1991, J BIOL CHEM, V266, P20457; MEKADA E, 1985, J BIOL CHEM, V260, P2148; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MOEHRING TJ, 1974, BIOCHEM BIOPH RES CO, V60, P1446, DOI 10.1016/0006-291X(74)90360-X; MOSKAUG JO, 1987, J BIOL CHEM, V262, P10339; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; NAGLICH JG, 1990, P NATL ACAD SCI USA, V87, P7250, DOI 10.1073/pnas.87.18.7250; NAGLICH JG, 1992, P NATL ACAD SCI USA, V89, P2170, DOI 10.1073/pnas.89.6.2170; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NEF P, 1988, EMBO J, V7, P595, DOI 10.1002/j.1460-2075.1988.tb02852.x; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PROIA RL, 1981, J BIOL CHEM, V256, P4991; PROIA RL, 1980, J BIOL CHEM, V255, P2025; RAETZ CRH, 1982, P NATL ACAD SCI-BIOL, V79, P3223, DOI 10.1073/pnas.79.10.3223; ROBBINS AR, 1987, METHOD ENZYMOL, V138, P458; ROLF JM, 1990, J BIOL CHEM, V265, P7331; ROLF JM, 1989, P NATL ACAD SCI USA, V86, P2036, DOI 10.1073/pnas.86.6.2036; RYSER HJP, 1991, J BIOL CHEM, V266, P18439; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; Sambrook J, 1989, MOL CLONING LABORATO; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; STENMARK H, 1988, J BIOL CHEM, V263, P13449; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WEISSMAN AM, 1988, P NATL ACAD SCI USA, V85, P9709, DOI 10.1073/pnas.85.24.9709; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; WRIGHT HT, 1984, J BIOL CHEM, V259, P1649	67	470	492	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					1051	1061		10.1016/0092-8674(92)90623-K	http://dx.doi.org/10.1016/0092-8674(92)90623-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606612				2022-12-28	WOS:A1992HY79200016
J	ZWI, AB; UGALDE, A				ZWI, AB; UGALDE, A			MILITARY EXPENDITURE AND FOREIGN-AID - SHOULD THEY BE LINKED	BRITISH MEDICAL JOURNAL			English	Article									UNIV TEXAS,SOCIOL,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	ZWI, AB (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH POLICY UNIT,LONDON WC1E 7HT,ENGLAND.		Zwi, Anthony/AAP-8731-2020; Zwi, Anthony/AAP-7026-2021	Zwi, Anthony/0000-0001-6902-6602				[Anonymous], 1991, HUMAN DEV REPORT; CLIFF J, 1988, SOC SCI MED, V27, P717, DOI 10.1016/0277-9536(87)90331-5; GALBRAITH JK, 1991, GUARDIAN        0806, P17; LOONEY RE, 1990, J SOC POLIT ECON ST, V15, P213; SIVARD R, 1989, WORLD MILITARY SOCIA; TANSEY G, 1990, REAL SECURITY E W N; Thee M., 1980, PROBLEMS CONT MILITA; THORSSON I, 1982, DEVELOPMENT, V1, P12; ZWI A, 1991, HEALTH POLICY PLANN, V6, P203, DOI 10.1093/heapol/6.3.203; 1991, STOCKHOLM INITIATIVE	10	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1421	1422		10.1136/bmj.304.6839.1421	http://dx.doi.org/10.1136/bmj.304.6839.1421			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628021	Green Published, Bronze			2022-12-28	WOS:A1992HX08200026
J	HERENDEEN, DR; KASSAVETIS, GA; GEIDUSCHEK, EP				HERENDEEN, DR; KASSAVETIS, GA; GEIDUSCHEK, EP			A TRANSCRIPTIONAL ENHANCER WHOSE FUNCTION IMPOSES A REQUIREMENT THAT PROTEINS TRACK ALONG DNA	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; BINDING PROTEIN; REPLICATION APPARATUS; PROMOTER SEARCH; GENE; EXPRESSION; ACTIVATOR; DISTANCE; SITE	Transcriptional regulation of the bacteriophage T4 late genes requires the participation of three DNA polymerase accessory proteins that are encoded by T4 genes 44, 62, and 45, and that act at an enhancer-like site. Transcriptional activation by these DNA replication proteins also requires the function of an RNA polymerase-bound coactivator protein that is encoded by T4 gene 33 and a promoter recognition protein that is encoded by T4 gene 55. Transcriptional activation in DNA constructs, in which the enhancer and a T4 late promoter can be segregated on two rings of a DNA catenane, has now been analyzed. The ability of an interposed DNA-binding protein to affect communication between the enhancer and the promoter was also examined. Together, these experiments demonstrate that this transcription-activating signal is conveyed between its enhancer and a T4 late promoter by a DNA-tracking mechanism. Alternative activation mechanisms relying entirely on through-space interactions of enhancer-bound and promoter-bound proteins are excluded.	UNIV CALIF SAN DIEGO,DEPT BIOL,9500 GILMAN DR,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego								ADHYA S, 1989, ANNU REV GENET, V23, P207; ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BEDINGER P, 1983, J BIOL CHEM, V258, P9649; BEDINGER P, 1983, CELL, V34, P115, DOI 10.1016/0092-8674(83)90141-1; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; ELLIOTT T, 1984, CELL, V36, P211, DOI 10.1016/0092-8674(84)90091-6; GEIDUSCHEK EP, 1983, BACTERIOPHAGE T, V4, P189; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREENSTEIN D, 1908, J MOL BIOL, V197, P157; GRUIDL ME, 1991, VIROLOGY, V184, P359, DOI 10.1016/0042-6822(91)90852-3; HERENDEEN DR, 1989, SCIENCE, V245, P952, DOI 10.1126/science.2672335; HERENDEEN DR, 1990, SCIENCE, V248, P573, DOI 10.1126/science.2185541; Hochschild A., 1990, DNA TOPOLOGY ITS BIO, P107; JARVIS TC, 1991, J BIOL CHEM, V266, P1830; JARVIS TC, 1989, J BIOL CHEM, V264, P12717; KASSAVETIS GA, 1986, J BIOL CHEM, V261, P14256; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P3977; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAGASANIK B, 1989, New Biologist, V1, P247; Maniatis T., 1982, MOL CLONING; MCPHEETERS DS, 1986, NUCLEIC ACIDS RES, V14, P5813, DOI 10.1093/nar/14.14.5813; MULLER HP, 1989, CELL, V58, P767, DOI 10.1016/0092-8674(89)90110-4; MUNN MM, 1991, J BIOL CHEM, V266, P20034; NOSSAL NG, 1983, BACTERIOPHAGE T, V4, P71; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; PEEBLES CL, 1979, CELL, V18, P27, DOI 10.1016/0092-8674(79)90350-7; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; REED RR, 1981, P NATL ACAD SCI-BIOL, V78, P3428, DOI 10.1073/pnas.78.6.3428; REED RR, 1981, CELL, V25, P713, DOI 10.1016/0092-8674(81)90178-1; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; SCARLATO V, 1989, VIROLOGY, V171, P475, DOI 10.1016/0042-6822(89)90617-X; SCHNEIDER GJ, 1990, J BIOL CHEM, V265, P10198; SELICK HE, 1987, UCLA S MOL CELL BIOL, V26, P183; SINGER P, 1987, J BIOL CHEM, V262, P14178; SINGER PT, 1988, J BIOL CHEM, V263, P4208; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; VENKATESAN M, 1982, J BIOL CHEM, V257, P2435; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WEDEL A, 1990, SCIENCE, V248, P486, DOI 10.1126/science.1970441; WILLIAMS KJ, 1991, THESIS U CALIFORNIA; WRIGHT DJ, 1989, J BIOL CHEM, V264, P11816	51	116	117	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1298	1303		10.1126/science.1598572	http://dx.doi.org/10.1126/science.1598572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598572				2022-12-28	WOS:A1992HW13500026
J	VYAS, P; VICKERS, MA; SIMMONS, DL; AYYUB, H; CRADDOCK, CF; HIGGS, DR				VYAS, P; VICKERS, MA; SIMMONS, DL; AYYUB, H; CRADDOCK, CF; HIGGS, DR			CIS-ACTING SEQUENCES REGULATING EXPRESSION OF THE HUMAN ALPHA-GLOBIN CLUSTER LIE WITHIN CONSTITUTIVELY OPEN CHROMATIN	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; LOCUS ACTIVATION REGION; CPG-RICH ISLANDS; CELL-SPECIFIC ENHANCER; I SENSITIVE DOMAIN; GENE-CLUSTER; TRANSGENIC MICE; HYPERSENSITIVE SITES; CHICKEN LYSOZYME; MESSENGER-RNAS	Current models suggest that tissue-specific genes are arranged in discrete, independently controlled segments of chromatin referred to as regulatory domains. Transition from a closed to open chromatin structure may be an important step in the regulation of gene expression. To determine whether the human alpha-globin cluster, like the beta-globin cluster, lies within a discrete, erythroid-specific domain, we have examined the long-range genomic organization and chromatin structure around this region. The alpha-genes lie adjacent to at least four widely expressed genes. The major alpha-globin regulatory element lies 40 kb away from the cluster within an intron of one of these genes. Therefore, unlike the beta-cluster, cis-acting sequences controlling alpha-gene expression are dispersed within a region of chromatin that is open in both erythroid and nonerythroid cells. This implies a difference in the hierarchical control of alpha- and beta-globin expression.	JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND	University of Oxford	VYAS, P (corresponding author), JOHN RADCLIFFE HOSP,MRC,MOLEC HAEMATOL UNIT,OXFORD OX3 9DU,ENGLAND.		Vyas, Paresh/B-5708-2009	Vyas, Paresh/0000-0003-3931-0914	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; ALBITAR M, 1989, BLOOD, V74, P629; ALEVY MC, 1984, BIOCHEMISTRY-US, V23, P2309, DOI 10.1021/bi00305a034; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BICKMORE WA, 1989, TRENDS GENET, V5, P144, DOI 10.1016/0168-9525(89)90055-3; BIRD AP, 1987, EMBO J, V6, P999, DOI 10.1002/j.1460-2075.1987.tb04851.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BODNAR JW, 1988, J THEOR BIOL, V132, P479, DOI 10.1016/S0022-5193(88)80086-9; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHENSOLAL MM, 1982, DNA-J MOLEC CELL BIO, V1, P355, DOI 10.1089/dna.1982.1.355; COMINGS DE, 1978, ANNU REV GENET, V12, P25, DOI 10.1146/annurev.ge.12.120178.000325; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; ECCLES S, 1990, New Biologist, V2, P801; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; Elgin SCR, 1990, CURR OPIN CELL BIOL, V2, P437, DOI 10.1016/0955-0674(90)90125-X; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P6197, DOI 10.1093/nar/15.15.6197; FISCHELGHODSIAN N, 1987, NUCLEIC ACIDS RES, V15, P9215, DOI 10.1093/nar/15.22.9215; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRAME MC, 1984, BRIT J CANCER, V49, P269, DOI 10.1038/bjc.1984.44; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GEY GO, 1952, CANCER RES, V12, P264; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HAGMAN J, 1990, GENE DEV, V4, P978, DOI 10.1101/gad.4.6.978; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HANSON IM, 1991, GENOMICS, V10, P417, DOI 10.1016/0888-7543(91)90327-B; HATTON CSR, 1990, BLOOD, V76, P221; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HIGGS DR, 1989, BLOOD, V73, P1081; HIGGS DR, 1990, GENE DEV, V4, P1588, DOI 10.1101/gad.4.9.1588; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; HSU SL, 1988, NATURE, V331, P94, DOI 10.1038/331094a0; HUXLEY C, 1990, MOL CELL BIOL, V10, P605, DOI 10.1128/MCB.10.2.605; JACKSON DA, 1991, BIOESSAYS, V13, P1, DOI 10.1002/bies.950130102; JANTZEN K, 1986, NUCLEIC ACIDS RES, V14, P6085, DOI 10.1093/nar/14.15.6085; JARMAN AP, 1991, MOL CELL BIOL, V11, P4679, DOI 10.1128/MCB.11.9.4679; JARMAN AP, 1988, EMBO J, V7, P3337, DOI 10.1002/j.1460-2075.1988.tb03205.x; JARMAN AP, 1988, AM J HUM GENET, V43, P249; JARMAN AP, 1989, HEMOGLOBIN SWITCHI B, P33; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; KLEIN E, 1967, LANCET, V2, P1068; LAUER J, 1980, CELL, V20, P119, DOI 10.1016/0092-8674(80)90240-8; LAWSON GM, 1982, J BIOL CHEM, V257, P1501; LAWSON GM, 1980, BIOCHEMISTRY-US, V19, P4403, DOI 10.1021/bi00560a004; LEIBOVITZ A, 1973, JNCI-J NATL CANCER I, V51, P691; LEUNG SO, 1989, NUCLEIC ACIDS RES, V17, P8283, DOI 10.1093/nar/17.20.8283; LEVINSON B, 1990, GENOMICS, V7, P1, DOI 10.1016/0888-7543(90)90512-S; LIEBHABER SA, 1990, P NATL ACAD SCI USA, V87, P9431, DOI 10.1073/pnas.87.23.9431; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MCCORMICK D, 1983, BRIT J EXP PATHOL, V64, P103; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; NICHOLLS RD, 1987, CELL, V49, P369, DOI 10.1016/0092-8674(87)90289-3; Old JM., 1983, METHODS HEMATOLOGY T, V6, P74; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; PETTERSSON S, 1990, NATURE, V344, P165, DOI 10.1038/344165a0; ROMAO L, 1991, BLOOD, V78, P1589; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT CA, 1989, EMBO J, V8, P2305, DOI 10.1002/j.1460-2075.1989.tb08357.x; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P8573; SPIES T, 1989, P NATL ACAD SCI USA, V86, P8955, DOI 10.1073/pnas.86.22.8955; SPIES T, 1989, SCIENCE, V243, P214, DOI 10.1126/science.2911734; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THOMPSON S, 1984, J CELL SCI, V72, P37; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; VANASSENDELFT GB, 1989, CELL, V56, P969, DOI 10.1016/0092-8674(89)90630-2; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; WILKIE AOM, 1990, NATURE, V346, P868, DOI 10.1038/346868a0; WILLIAMS T, 1986, NATURE, V322, P275, DOI 10.1038/322275a0; WILSON JT, 1980, J BIOL CHEM, V255, P2807; YAGI M, 1986, MOL CELL BIOL, V6, P1108, DOI 10.1128/MCB.6.4.1108	92	155	155	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					781	793		10.1016/0092-8674(92)90290-S	http://dx.doi.org/10.1016/0092-8674(92)90290-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591777				2022-12-28	WOS:A1992HW83800009
J	BRADA, M; FORD, D; ASHLEY, S; BLISS, JM; CROWLEY, S; MASON, M; RAJAN, B; TRAISH, D				BRADA, M; FORD, D; ASHLEY, S; BLISS, JM; CROWLEY, S; MASON, M; RAJAN, B; TRAISH, D			RISK OF 2ND BRAIN-TUMOR AFTER CONSERVATIVE SURGERY AND RADIOTHERAPY FOR PITUITARY-ADENOMA	BRITISH MEDICAL JOURNAL			English	Article							NERVOUS-SYSTEM; IRRADIATION; CANCER; CHILDHOOD; COMPLICATIONS	Objective-To assess the risk of second brain tumour in patients with pituitary adenoma treated with conservative surgery and external beam radiotherapy. Design-Long term follow up of a cohort of patients with pituitary adenoma and comparison of tumour occurrence with population incidence rates. Setting-The Royal Marsden Hospital. Subjects-334 patients with pituitary adenoma treated with conservative surgery and radiotherapy (median dose 45 Gy) and followed up for 3760 person years. Main outcome measures-Second intracranial tumour and systemic malignancy. Results-Five patients developed a second brain tumour: two had astrocytoma, two meningioma, and one meningeal sarcoma. The cumulative risk of developing a second brain tumour over the first 10 years after treatment was 1.3% (95% confidence interval 0.4% to 3.9%) and over 20 years 1.9% (0.7% to 5.0%). The relative risk of a second brain tumour compared with the incidence in the normal population was 9.38 (3.05 to 21.89). There was no excess risk of any other type of second primary malignancy. Conclusions-There is an increased risk of second intracranial tumour in patients with pituitary adenoma treated with surgery and radiotherapy. Although radiation is likely to be the most important factor contributing to the excess risk, further study is required in a cohort of similar patients not receiving radiation.	INST CANC RES,ACAD UNIT RADIOTHERAPY & ONCOL,SUTTON SM2 5PX,SURREY,ENGLAND; INST CANC RES,EPIDEMIOL SECT,SUTTON SM2 5PX,SURREY,ENGLAND; ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	BRADA, M (corresponding author), INST CANC RES,NEUROONCOL UNIT,SUTTON SM2 5PX,SURREY,ENGLAND.			Bliss, Judith/0000-0001-7957-7424				Albo V, 1985, P AN M AM SOC CLIN, V4, P172; AMENDOLA BE, 1985, CANCER INVEST, V3, P507, DOI 10.3109/07357908509039812; ARISTIZABAL S, 1977, INT J RADIAT ONCOL, V2, P667, DOI 10.1016/0360-3016(77)90046-3; BERNSTEIN M, 1991, RAD INJURY NERVOUS, P480; BRESLOW NE, 1987, DESIGN ANAL COHORT S, V2, P69; COLEMAN MP, 1989, PERSON YEARS USER MA; DOWSETT RJ, 1990, INT J RADIAT ONCOL, V19, P453, DOI 10.1016/0360-3016(90)90557-Z; EBERSOLD MJ, 1986, J NEUROSURG, V64, P713, DOI 10.3171/jns.1986.64.5.0713; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; FEEK CM, 1984, CLIN ENDOCRINOL, V20, P401, DOI 10.1111/j.1365-2265.1984.tb03435.x; FLICKINGER JC, 1989, CANCER, V63, P2409, DOI 10.1002/1097-0142(19890615)63:12<2409::AID-CNCR2820631206>3.0.CO;2-M; GRIGSBY PW, 1989, INT J RADIAT ONCOL, V16, P1411, DOI 10.1016/0360-3016(89)90942-5; HALBERG FE, 1987, ENDOCRIN METAB CLIN, V16, P667, DOI 10.1016/S0889-8529(18)30468-7; HARRIS JR, 1976, RADIOLOGY, V120, P167, DOI 10.1148/120.1.167; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KAPLAN EL, 1978, J AM STAT ASSOC, V54, P457; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; KLIBANSKI A, 1991, NEW ENGL J MED, V324, P822; PARKER RG, 1990, INT J RADIAT ONCOL, V18, P993, DOI 10.1016/0360-3016(90)90432-J; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; ROSS DA, 1988, J NEUROSURG, V68, P854, DOI 10.3171/jns.1988.68.6.0854; SOFFER D, 1983, J NEUROSURG, V59, P1048, DOI 10.3171/jns.1983.59.6.1048; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203	24	329	332	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1343	1346		10.1136/bmj.304.6838.1343	http://dx.doi.org/10.1136/bmj.304.6838.1343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611331	Bronze, Green Published			2022-12-28	WOS:A1992HW41700021
J	OU, CY; CIESIELSKI, CA; MYERS, G; BANDEA, CI; LUO, CC; KORBER, BTM; MULLINS, JI; SCHOCHETMAN, G; BERKELMAN, RL; ECONOMOU, AN; WITTE, JJ; FURMAN, LJ; SATTEN, GA; MACINNES, KA; CURRAN, JW; JAFFE, HW				OU, CY; CIESIELSKI, CA; MYERS, G; BANDEA, CI; LUO, CC; KORBER, BTM; MULLINS, JI; SCHOCHETMAN, G; BERKELMAN, RL; ECONOMOU, AN; WITTE, JJ; FURMAN, LJ; SATTEN, GA; MACINNES, KA; CURRAN, JW; JAFFE, HW			MOLECULAR EPIDEMIOLOGY OF HIV TRANSMISSION IN A DENTAL PRACTICE	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-B; TYPE-1; AIDS; SENSITIVITY; PHYLOGENIES; INFECTION; SEQUENCES; THERAPY; RISK	Human immunodeficiency virus type 1 (HIV-1) transmission from infected patients to health-care workers has been well documented, but transmission from an infected health-care worker to a patient has not been reported. After identification of an acquired immunodeficiency syndrome (AIDS) patient who had no known risk factors for HIV infection but who had undergone an invasive procedure performed by a dentist with AIDS, six other patients of this dentist were found to be HIV-infected. Molecular biologic studies were conducted to complement the epidemiologic investigation. Portions of the HIV proviral envelope gene from each of the seven patients, the dentist, and 35 HIV-infected persons from the local geographic area were amplified by polymerase chain reaction and sequenced. Three separate comparative genetic analyses-genetic distance measurements, phylogenetic tree analysis, and amino acid signature pattern analysis-showed that the viruses from the dentist and five dental patients were closely related. These data, together with the epidemiologic investigation, indicated that these patients became infected with HIV while receiving care from a dentist with AIDS.	LOS ALAMOS NATL LAB,DIV THEORET,LOS ALAMOS,NM 87545; STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; FLORIDA DEPT HLTH & REHAB SERV,TALLAHASSEE,FL; CTR DIS CONTROL,NATL CTR PREVENT SERV,DIV ORAL HLTH,ATLANTA,GA 30333	United States Department of Energy (DOE); Los Alamos National Laboratory; Stanford University; Florida Department of Health; Centers for Disease Control & Prevention - USA	OU, CY (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333, USA.		Scott, Rodney/B-2827-2013	Scott, Rodney/0000-0001-7724-3404; Korber, Bette/0000-0002-2026-5757				AHTONE J, 1983, J AM DENT ASSOC, V106, P219, DOI 10.14219/jada.archive.1983.0416; ALIZON M, 1986, CELL, V46, P63, DOI 10.1016/0092-8674(86)90860-3; BALFE P, 1990, J VIROL, V64, P6221, DOI 10.1128/JVI.64.12.6221-6233.1990; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; BURGER H, 1991, P NATL ACAD SCI USA, V88, P11236, DOI 10.1073/pnas.88.24.11236; BURGER H, 1990, LANCET, V336, P134, DOI 10.1016/0140-6736(90)91657-V; CICHUTEK K, 1991, AIDS, V5, P1185, DOI 10.1097/00002030-199110000-00005; CIESIELSKI C, 1992, ANN INTERN MED, V116, P798, DOI 10.7326/0003-4819-116-10-798; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DELASSUS S, 1991, J VIROL, V65, P225, DOI 10.1128/JVI.65.1.225-231.1991; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; GIBBS RA, 1989, PCR TECHNOLOGY PRINC, P171; GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HALL P, 1991, BIOMETRICS, V47, P757, DOI 10.2307/2532163; HETTMANSPERGER TP, 1984, STATISTICAL INFERENC; HILLIS D, UNPUB; HO DD, 1989, NEW ENGL J MED, V321, P1625; HOLMES GP, 1990, ANN INTERN MED, V112, P833, DOI 10.7326/0003-4819-112-11-833; KANE MA, 1985, J AM DENT ASSOC, V110, P834; KORBER B, UNPUB; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; KWOK S, 1989, AMPLIFICATIONS, V2, P4; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LAROSA GJ, 1991, SCIENCE, V251, P811, DOI 10.1126/science.1990444; LI WH, 1991, FUNDAMENTALS MOL EVO, P111; LIN HJ, 1991, J INFECT DIS, V164, P284, DOI 10.1093/infdis/164.2.284; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCKEATING JA, 1989, AIDS, V3, P777, DOI 10.1097/00002030-198912000-00001; MYERHANS A, 1989, CELL, V58, P901; MYERS G, 1991, HUMAN RETROVIRUSES A; NARA PL, 1989, RETROVIRUSES HUMAN A, P203; OU CY, 1991, BIOTECHNIQUES, V10, P442; OU CY, IN PRESS AIDS RES HU; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SARKAR G, 1990, NATURE, V343, P27, DOI 10.1038/343027a0; SHAW FE, 1986, JAMA-J AM MED ASSOC, V255, P3260, DOI 10.1001/jama.255.23.3260; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; SMITH JS, 1991, NEW ENGL J MED, V324, P205, DOI 10.1056/NEJM199101243240401; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; SRINVASAN A, 1986, BLOOD, V232, P1548; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; STEULER H, 1992, AIDS RES HUM RETROV, V8, P53, DOI 10.1089/aid.1992.8.53; Stuart A, 1983, ENCY STAT SCI, V4, P367; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WELCH J, 1989, LANCET, V1, P205; WOLLINSKY SM, 1992, SCIENCE, V255, P1134; 1986, MORBID MORTAL WKLY R, V35, P221; 1991, MORBID MORTAL WKLY R, V40, P377; 1990, MORBID MORTAL WKLY R, V39, P489; 1991, MORBID MORTAL WKLY R, V40, P21; 1987, MORBID MORTAL WKLY R, V36, pS2	57	390	409	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1165	1171		10.1126/science.256.5060.1165	http://dx.doi.org/10.1126/science.256.5060.1165			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589796				2022-12-28	WOS:A1992HV19200025
J	FOLLAND, ED; KRIEGEL, BJ; HENDERSON, WG; HAMMERMEISTER, KE; SETHI, GK				FOLLAND, ED; KRIEGEL, BJ; HENDERSON, WG; HAMMERMEISTER, KE; SETHI, GK			IMPLICATIONS OF 3RD HEART SOUNDS IN PATIENTS WITH VALVULAR HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR VOLUME; ORIGIN; FAILURE; DOGS	Background. The presence of third heart sounds in patients with valvular heart disease is often regarded as a sign of heart failure, but it may also depend on the type of valvular disease. Methods. We assessed the prevalence of third heart sounds and the relation between third heart sounds and cardiac function in 1281 patients with six types of valvular heart disease. Results. The prevalence of third heart sounds was higher in patients with mitral regurgitation (46 percent) or aortic regurgitation (28 percent) than in those with aortic stenosis (11 percent) or mitral stenosis (8 percent). The left ventricular ejection fraction was significantly lower (P<0.001) when a third heart sound was detected in patients with aortic stenosis (0.38, vs. 0.56 in those without third heart sounds) or mixed aortic valve disease (0.40 vs. 0.55). However, the ejection fraction was only slightly lower in patients with mitral regurgitation and third heart sounds (0.51 vs. 0.57, P = 0.03). The pulmonary-capillary wedge pressure was higher (P<0.001) when a third heart sound was detected in patients with aortic stenosis (18.6 mm Hg, vs. 12.1 mm Hg in those without third heart sounds). There was no association between the wedge pressure and third heart sounds in patients with mitral regurgitation. The prevalence of third heart sounds increased with the severity of mitral regurgitation. Conclusions. In patients with mitral regurgitation, third heart sounds are common but do not necessarily reflect left ventricular systolic dysfunction or increased filling pressure. In patients with aortic stenosis, third heart sounds are uncommon but usually indicate the presence of systolic dysfunction and elevated filling pressure.	VET AFFAIRS MED CTR,RES SERV,BOSTON,MA; VET AFFAIRS MED CTR,RES SERV,HINES,IL; VET AFFAIRS MED CTR,RES SERV,DENVER,CO; VET AFFAIRS MED CTR,RES SERV,TUCSON,AZ	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System								ABDULLA AM, 1981, CIRCULATION, V64, P464, DOI 10.1161/01.CIR.64.3.464; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P1040; DODGE HT, 1960, AM HEART J, V60, P762, DOI 10.1016/0002-8703(60)90359-8; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRAYZEL J, 1960, AM J MED, V28, P578, DOI 10.1016/0002-9343(60)90152-2; HAMMERMEISTER KE, 1974, CIRCULATION, V49, P739; ISHIMITSU T, 1985, J AM COLL CARDIOL, V5, P268, DOI 10.1016/S0735-1097(85)80046-2; ISHMAIL AA, 1987, CHEST, V91, P870, DOI 10.1378/chest.91.6.870; KENNEDY JW, 1970, AM HEART J, V80, P343, DOI 10.1016/0002-8703(70)90099-2; KUO PT, 1957, J CLIN INVEST, V36, P1035, DOI 10.1172/JCI103499; LEE DCS, 1982, NEW ENGL J MED, V306, P699, DOI 10.1056/NEJM198203253061202; NIXON PG, 1961, BRIT HEART J, V23, P677; OZAWA Y, 1983, CIRCULATION, V67, P399, DOI 10.1161/01.CIR.67.2.399; OZAWA Y, 1983, CIRCULATION, V67, P393, DOI 10.1161/01.CIR.67.2.393; SHAH PM, 1968, NEW ENGL J MED, V278, P753, DOI 10.1056/NEJM196804042781402; SHAH PM, 1969, AM HEART J, V78, P823, DOI 10.1016/0002-8703(69)90450-5; VANDEWERF F, 1984, J CLIN INVEST, V73, P1400, DOI 10.1172/JCI111344; VANDEWERF F, 1984, CIRCULATION, V69, P1070, DOI 10.1161/01.CIR.69.6.1070; 1985, CONTROLLED CLIN TRIA, V6, P51	19	34	35	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					458	462		10.1056/NEJM199208133270703	http://dx.doi.org/10.1056/NEJM199208133270703			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625735				2022-12-28	WOS:A1992JH34000003
J	BENJAMIN, EJ; PLEHN, JF; DAGOSTINO, RB; BELANGER, AJ; COMAI, K; FULLER, DL; WOLF, PA; LEVY, D				BENJAMIN, EJ; PLEHN, JF; DAGOSTINO, RB; BELANGER, AJ; COMAI, K; FULLER, DL; WOLF, PA; LEVY, D			MITRAL ANNULAR CALCIFICATION AND THE RISK OF STROKE IN AN ELDERLY COHORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATCHED CONTROL SUBJECTS; ANULAR CALCIUM; CARDIAC ABNORMALITIES; ISCHEMIC ATTACKS; ECHOCARDIOGRAPHY; DISEASE; FIBROSUS; VALVE	Background. Previous clinical studies have suggested that there is an association between mitral annular calcification and the risk of stroke, but it is unclear whether this association is independent of the traditional risk factors for stroke. We examined the relation between mitral annular calcification and the incidence of stroke in a population-based study. Methods. Subjects in the Framingham Study receiving a routine examination underwent M-mode echocardiography to determine the presence and severity (thickness in millimeters) of mitral annular calcification. The incidence of stroke during eight years of follow-up was analyzed with a proportional-hazards model adjusting for the calcification, age, sex, systolic blood pressure, diabetes mellitus, cigarette smoking, atrial fibrillation, and coronary heart disease or congestive heart failure. Results. Among 1159 subjects whose echocardiograms could be assessed for mitral annular calcification and who had no history or current evidence of stroke at the index examination (51 percent of all subjects), the prevalence of mitral annular calcification was 10.3 percent in the men and 15.8 percent in the women. Multivariate analysis demonstrated that the presence of mitral annular calcification was associated with a relative risk of stroke of 2.10 (95 percent confidence interval, 1.24 to 3.57; P = 0.006). There was a continuous relation between the incidence of stroke and the severity of mitral annular calcification; each millimeter of thickening as shown on the echocardiogram represented a relative risk of stroke of 1.24 (95 percent confidence interval, 1.1 2 to 1.37; P<0.001). Furthermore, even when subjects with coronary heart disease or congestive heart failure were excluded from the analysis, subjects with mitral annular calcification still had twice the risk of stroke. Conclusions. In an elderly, longitudinally followed population-based cohort, mitral annular calcification was associated with a doubled risk of stroke, independently of traditional risk factors for stroke. Whether such calcification contributes causally to the risk of stroke or is merely a marker of increased risk because of its association with other precursors of stroke remains unknown.	BOSTON CITY HOSP,DEPT CARDIOL,BOSTON,MA 02118; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; NHLBI,BETHESDA,MD 20892; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PREVENT MED,BOSTON,MA 02118; BETH ISRAEL HOSP,DIV CARDIOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DIV CLIN EPIDEMIOL,BOSTON,MA 02215; DARTMOUTH HITCHCOCK MED CTR,CARDIOL SECT,LEBANON,NH	Boston Medical Center; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	BENJAMIN, EJ (corresponding author), FRAMINGHAM HEART DIS EPIDEMIOL STUDY,5 THURBER ST,FRAMINGHAM,MA 01701, USA.		Benjamin, Emelia/E-7103-2011; Levy, Daniel/ABB-2752-2021; Levy, Daniel/ABF-6873-2021	Benjamin, Emelia/0000-0003-4076-2336; Levy, Daniel/0000-0003-1843-8724; Wolf, Philip/0000-0002-3628-301X	NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [2-R01-NS-17950-09] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALWLESS JF, 1982, STATISTICAL MODELS M, P359; Barnett H J, 1983, Neurol Clin, V1, P291; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; Bonniger M, 1908, DEUT MED WOCHENSCHR, V34, P2292; BONNIGER M, 1908, DTSCH MED WCHNSCHR, V34, P2293; BURNSIDE JW, 1972, ANN INTERN MED, V76, P615, DOI 10.7326/0003-4819-76-4-615; CUPPLES LA, 1988, NIH882969 PUBL; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEBONO DP, 1979, LANCET, V2, P383; FULKERSON PK, 1979, AM J MED, V66, P967, DOI 10.1016/0002-9343(79)90452-2; FURLAN AJ, 1984, STROKE, V15, P801, DOI 10.1161/01.STR.15.5.801; GOOD DC, 1986, STROKE, V17, P6, DOI 10.1161/01.STR.17.1.6; GREENLAND P, 1981, ANN INTERN MED, V95, P51, DOI 10.7326/0003-4819-95-1-51; GUTHRIE J, 1963, BRIT HEART J, V25, P137; JESPERSEN CM, 1987, ACTA MED SCAND, V222, P37; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P70; KANNEL WB, 1983, JAMA-J AM MED ASSOC, V250, P2942, DOI 10.1001/jama.250.21.2942; KIRK RS, 1969, BRIT HEART J, V31, P684; KORN D, 1962, NEW ENGL J MED, V267, P900, DOI 10.1056/NEJM196211012671802; LIN CS, 1987, ARCH PATHOL LAB MED, V111, P411; MELLINO M, 1982, AM HEART J, V103, P222, DOI 10.1016/0002-8703(82)90495-1; NAIR CK, 1989, AM J CARDIOL, V63, P465, DOI 10.1016/0002-9149(89)90321-4; NAIR CK, 1984, AM J CARDIOL, V54, P1286, DOI 10.1016/S0002-9149(84)80082-X; NISHIDE M, 1983, STROKE, V14, P541, DOI 10.1161/01.STR.14.4.541; POMERANCE A, 1970, J CLIN PATHOL, V23, P354, DOI 10.1136/jcp.23.4.354; REM JA, 1985, STROKE, V16, P950, DOI 10.1161/01.STR.16.6.950; RIDOLFI RL, 1976, ARCH PATHOL LAB MED, V100, P117; ROBERTS WC, 1972, ANN INTERN MED, V77, P939, DOI 10.7326/0003-4819-77-6-939; RYTAND DA, 1946, ARCH INTERN MED, V78, P544, DOI 10.1001/archinte.1946.00220050049003; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SAVAGE DD, 1983, AM J CARDIOL, V51, P1375, DOI 10.1016/0002-9149(83)90315-6; SAVAGE DD, 1987, HYPERTENSION, V9, P40; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; TODNEM K, 1986, ACTA NEUROL SCAND, V74, P323; ZAK FG, 1949, AM J MED SCI, V218, P510, DOI 10.1097/00000441-194911000-00004; 1992, ANN INTERN MED, V116, P6; 1988, APPLIED REGRESSION A, P297; 1990, NEW ENGL J MED, V323, P1505	39	300	305	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					374	379		10.1056/NEJM199208063270602	http://dx.doi.org/10.1056/NEJM199208063270602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625711				2022-12-28	WOS:A1992JG35600002
J	BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M				BLEICH, A; DYCIAN, A; KOSLOWSKY, M; SOLOMON, Z; WIENER, M			PSYCHIATRIC IMPLICATIONS OF MISSILE ATTACKS ON A CIVILIAN POPULATION - ISRAELI LESSONS FROM THE PERSIAN-GULF-WAR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEBANON WAR	Objective.-To determine the proportion of hospitalized patients who had stress reactions as a result of missile attacks during the Persian Gulf War and evaluate the factors that influenced their evacuation. Design.-Review of medical records of patients hospitalized as a result of missile attacks. Setting.-During the Persian Gulf War in the winter of 1991, Israel received 18 missile attacks involving 39 surface-to-surface Scud missiles. The uncertainty in time, place, and type of warhead, conventional or chemical, was a source of chronic stress and the immediate cause for many traumatic stress reactions at or near the missile attack sites. Participants.-Data from victims who were injured after each missile attack were available through a central hookup between 12 local hospitals and the Medical Corps of the Israeli Defence Force. Main Outcome Measure.-The number of persons diagnosed in the hospital as psychological casualties after each missile attack. Results.-Approximately 43% of the 773 casualties evacuated to hospitals were diagnosed as psychological casualties, and an additional 27% had mistakenly injected themselves with atropine. Data also indicated that triage of psychological casualties to hospitals was more a function of the rescue team's training and preparation than the severity or extent of injury or damage. Conclusions.-Optimal treatment during events that cause mass casualties requires proper preparation of rescue teams as well as reorganization of the hospital' s psychiatric services. The threat of chemical warfare affected the number and nature of stress reactions.	TEL AVIV UNIV,SACKLER SCH MED,TEL AVIV,ISRAEL; TEL AVIV UNIV,SHAPEL SCH SOCIAL WORK,IL-69978 TEL AVIV,ISRAEL; BAR ILAN UNIV,DEPT PSYCHOL,RAMAT GAN,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Bar Ilan University	BLEICH, A (corresponding author), ISRAEL DEF FORCES,MED CORPS,DEPT MENTAL HLTH,MIL POB 02149,JERUSALEM,ISRAEL.							BELENKY GL, 1987, PSYCHIAT ANN, V17, P528, DOI 10.3928/0048-5713-19870801-06; BURKLE F M JR, 1991, Emergency Medicine Clinics of North America, V9, P87; BUYDENSBRANCHEY L, 1990, J NERV MENT DIS, V178, P582, DOI 10.1097/00005053-199009000-00005; DUNN CL, 1952, EMERGENCY MED SERVIC, V1, P170; HISS J, 1992, BRIT MED J, V304, P92, DOI 10.1136/bmj.304.6819.92; KARSENTY E, 1991, ISRAEL J MED SCI, V27, P603; Kormos HR, 1978, STRESS DISORDERS VIE, P3; NEWHOUSE P, 1987, CONT STUDIES COMBAT, P185; NOY S, 1984, ISRAEL J MED SCI, V20, P360; OBALLANCE E, 1988, GULF WAR, P103; RACHMAN SJ, 1990, FEAR COURAGE, P25; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; SOLOMON Z, 1986, AM J PSYCHIAT, V143, P613	13	67	67	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					613	615		10.1001/jama.268.5.613	http://dx.doi.org/10.1001/jama.268.5.613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JF473	1629988				2022-12-28	WOS:A1992JF47300025
J	ISEMAN, MD				ISEMAN, MD			A LEAP OF FAITH - WHAT CAN WE DO TO CURTAIL INTRAINSTITUTIONAL TRANSMISSION OF TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; INFECTION CONTROL; ULTRAVIOLET RAYS; CROSS INFECTION	ULTRAVIOLET AIR DISINFECTION	Large-scale, epidemic transmission of tuberculosis to patients, nonprofessional staff, nurses, and physicians has been documented recently in hospitals, clinics, acquired immunodeficiency syndrome (AIDS) residencies, and correctional facilities. Prominent factors in these outbreaks have included human immunodeficiency virus (HIV) infection and AIDS, delayed diagnosis of tuberculosis, multidrug-resistant strains of tuberculosis that resulted in protracted shedding of mycobacteria, and ventilation patterns in buildings that resulted in the accumulation of infectious particles. Multiple deaths from tuberculosis have resulted. Various strategies, including vaccines, masks, augmented ventilation, air filters, and ultraviolet irradiation have been proposed to control this situation. Although no well-controlled studies exist to document the utility of any of these modalities, ultraviolet germicidal irradiation seems both the best theoretical model and the most practical tactic. Ultraviolet systems should be widely deployed throughout high-risk institutions.	UNIV COLORADO, SCH MED, DENVER, CO 80202 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	ISEMAN, MD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DIV INFECT DIS, CLIN MYCOBACTERIOL SERV, 1400 JACKSON ST, DENVER, CO 80206 USA.							CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; Riley R.L., 1961, MOL MED MICROBIOLOGY, P1; RILEY RL, 1989, AM REV RESPIR DIS, V139, P1286, DOI 10.1164/ajrccm/139.5.1286; STEAD WW, 1989, AM REV RESPIR DIS, V140, P1832, DOI 10.1164/ajrccm/140.6.1832a; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; 1991, MMWR, V40, P585; 1991, MMWR, V40, P129; 1980, B INT UNION TUBERC, V55, P14; 1990, MMWR, V39, P1	16	52	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					251	253		10.7326/0003-4819-117-3-251	http://dx.doi.org/10.7326/0003-4819-117-3-251			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616220				2022-12-28	WOS:A1992JF30400013
J	LAURENCE, J; HODTSEV, AS; POSNETT, DN				LAURENCE, J; HODTSEV, AS; POSNETT, DN			SUPERANTIGEN IMPLICATED IN DEPENDENCE OF HIV-1 REPLICATION IN T-CELLS ON TCR V-BETA EXPRESSION	NATURE			English	Article							MOLECULAR ANALYSIS; CLONAL ANERGY; LYMPHOCYTES-T; ENTEROTOXIN-B; INFECTION; INDUCTION; MICE	IN the pathogenesis of AIDS it is not yet understood whether the small fraction of CD4+ T cells (approximately 1%) infected with the human immunodeficiency virus (HIV) are randomly targeted or not. Here we present evidence that human CD4 T-cell lines expressing selected T-cell antigen receptor V-beta gene products can all be infected in vitro with HIV-1, but give markedly different titres of HIV-1 virion production. For example, V-beta-12 T-cell lines from several unrelated donors reproducibly yielded up to 100-fold more gag gene product (p24gag antigen) than V-beta-6.7a lines. This is consistent with a superantigen effect, because the V-beta selectivity was observed with several divergent HIV-1 isolates, was dependent on antigen-presenting cells and on major histocompatibility complex (MHC) class II but was not MHC class II-restricted. The in vivo significance of these findings is supported by the preferential stimulation of V-beta-12+ T cells by freshly obtained irradiated antigen-presenting cells from some HIV-1-seropositive but not HIV-1-negative donors. Moreover, cells from patients positive for viral antigen (gp120) were enriched in the V-beta-12 subpopulation. V-beta-12+ T cells were not deleted in AIDS patients, however, raising the possibility that a variety of mechanisms contribute to T-cell depletion. Our results indicate that a superantigen targets a subpopulation of CD4+ cells for viral replication.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,1300 YORK AVE,BOX 56,NEW YORK,NY 10021	Cornell University								ACUTO O, 1985, J EXP MED, V161, P1326, DOI 10.1084/jem.161.6.1326; BIGLER RD, 1983, J EXP MED, V158, P1000, DOI 10.1084/jem.158.3.1000; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; COFFIN JM, 1992, SCIENCE, V255, P411, DOI 10.1126/science.1310360; FRIEDMAN SM, 1991, J EXP MED, V174, P891, DOI 10.1084/jem.174.4.891; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; IGNATOWICZ L, 1992, J EXP MED, V175, P917, DOI 10.1084/jem.175.4.917; IMBERTI L, 1991, SCIENCE, V254, P860, DOI 10.1126/science.1948066; JANEWAY C, 1991, NATURE, V349, P459, DOI 10.1038/349459a0; KAPPLER J, 1989, SCIENCE, V244, P811, DOI 10.1126/science.2524876; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; LAURENCE J, 1991, J VIROL, V65, P213, DOI 10.1128/JVI.65.1.213-219.1991; LAURENCE J, 1989, J CLIN INVEST, V83, P1843, DOI 10.1172/JCI114090; MARRACK P, 1991, NATURE, V349, P524, DOI 10.1038/349524a0; OHEHIR RE, 1990, P NATL ACAD SCI USA, V87, P8884, DOI 10.1073/pnas.87.22.8884; ONEILL H, 1991, CELL IMMUNOL, V6136, P54; PRASHAR Y, 1991, J IMMUNOL, V147, P3441; RAMMENSEE HG, 1989, NATURE, V339, P541, DOI 10.1038/339541a0; RELLAHAN BL, 1990, J EXP MED, V172, P1091, DOI 10.1084/jem.172.4.1091; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	28	164	170	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					255	259		10.1038/358255a0	http://dx.doi.org/10.1038/358255a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630494				2022-12-28	WOS:A1992JD58700060
J	STAESSEN, JA; LAUWERYS, RR; BUCHET, JP; BULPITT, CJ; RONDIA, D; VANRENTERGHEM, Y; AMERY, A				STAESSEN, JA; LAUWERYS, RR; BUCHET, JP; BULPITT, CJ; RONDIA, D; VANRENTERGHEM, Y; AMERY, A			IMPAIRMENT OF RENAL-FUNCTION WITH INCREASING BLOOD LEAD CONCENTRATIONS IN THE GENERAL-POPULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SERUM CREATININE; EXPOSURE; CADMIUM; PRESSURE; HYPERTENSION; WORKERS	Background. Nephropathy is known to occur in persons with heavy exposure to lead. Whether exposure to lead in the general population leads to impaired renal function is not known. Methods. We studied renal function and indexes ot lead exposure in a random population sample of 965 men and 1016 women (age range, 20 to 88 years). In all the subjects we measured creatinine clearance and blood concentrations of lead and zinc protoporphyrin (an indirect measure of blood lead level). Results. The mean (+/-SD) creatinine clearance rate was 99+/-30 ml per minute in the men and 80+/-25 ml per minute in the women. In the men the geometric mean blood lead concentration was 114-mu-g per liter (0.55-mu-mol per liter) (range, 23 to 725-mu-g per liter [0.11 to 3.5-mu-mol per liter]), and in the women 75-mu-g per liter (0.36-mu-mol per liter) (range, 17 to 603-mu-g per liter [0.08 to 2.9-mu-mol per liter]); the zinc protoporphyrin values in blood averaged 1.0 and 1.1-mu-g per gram ot hemoglobin, respectively. The creatinine clearance rate was inversely correlated with blood lead and zinc protoporphyrin values in the men and the women both before and after adjustments for age, body-mass index, and diuretic treatment. A 10-fold increase in blood lead concentration was associated with a reduction of 10 to 13 ml per minute in creatinine clearance. We also found a positive correlation between serum beta-2-microglobulin (which is inversely related to the glomerular filtration rate) and blood lead in men, between serum beta-2-microglobulin and zinc protoporphyrin in both sexes, and between serum creatinine and zinc protoporphyrin in men. Conclusions. Exposure to lead may impair renal function in the general population. The alternative hypothesis that renal impairment may lead to an increase in the blood lead concentration cannot be excluded. however.	CATHOLIC UNIV LEUVEN,HYPERTENS & CARDIOVASC REHABIL UNIT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,DEPT PATHOPHYSIOL,NEPHROL UNIT,B-3000 LOUVAIN,BELGIUM; CATHOLIC UNIV LEUVEN,IND TOXICOL & OCCUPAT MED UNIT,B-3000 LOUVAIN,BELGIUM; STATE UNIV LIEGE,ENVIRONM TOXICOL UNIT,B-4000 LIEGE,BELGIUM	KU Leuven; KU Leuven; KU Leuven; University of Liege			Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				[Anonymous], 1988, BMJ, V297, P319; BARTELS H, 1971, CLIN CHIM ACTA, V32, P81, DOI 10.1016/0009-8981(71)90467-0; BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BERNARD A, 1984, EXPERIENTIA, V40, P143, DOI 10.1007/BF01963577; BERNARD AM, 1983, CLIN CHEM, V29, P1007; BUCHET JP, 1980, J OCCUP ENVIRON MED, V22, P741; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; CAMPBELL BC, 1981, TOXICOL LETT, V9, P121, DOI 10.1016/0378-4274(81)90027-8; CHISOLM JJ, 1962, J PEDIATR-US, V60, P1, DOI 10.1016/S0022-3476(62)80002-X; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; CRAMER K, 1974, BRIT J IND MED, V31, P113; EMMERSON BT, 1991, NEPHRON, V58, P233, DOI 10.1159/000186421; EMMERSON BT, 1963, AUSTRALAS ANN MED, V12, P139, DOI 10.1111/imj.1963.12.2.139; EMMERSON BT, 1971, AUST NZ J MED, V1, P353, DOI 10.1111/j.1445-5994.1971.tb02545.x; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; GRAZIANO JH, 1991, ARCH ENVIRON HEALTH, V46, P347, DOI 10.1080/00039896.1991.9934401; HILBRANDS LB, 1991, KIDNEY INT, V40, P1171, DOI 10.1038/ki.1991.331; KARLSSON FA, 1980, SCAND J CLIN LAB INV, V40, P27; LAUWERYS R, 1990, ENVIRON HEALTH PERSP, V87, P283, DOI 10.2307/3431036; LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.me.39.020188.002341; PERSIJN JP, 1976, J CLIN CHEM CLIN BIO, V14, P421; POCOCK SJ, 1984, BRIT MED J, V289, P872, DOI 10.1136/bmj.289.6449.872; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN J, 1991, J HUM HYPERTENS, V5, P485; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7; 1987, WORLD HLTH ORG REGIO, V23, P242; 1934, MED J AUSTRALIA, V1, P600	29	175	180	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					151	156		10.1056/NEJM199207163270303	http://dx.doi.org/10.1056/NEJM199207163270303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608406	Green Published			2022-12-28	WOS:A1992JD31900003
J	MCGUIRE, WL; CLARK, GM				MCGUIRE, WL; CLARK, GM			PROGNOSTIC FACTORS AND TREATMENT DECISIONS IN AXILLARY-NODE-NEGATIVE BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							S-PHASE FRACTION; DNA FLOW-CYTOMETRY; STAGE-I T1N0M0; CATHEPSIN-D; ADJUVANT THERAPY; FOLLOW-UP; SURVIVAL; PLOIDY; INDEX; CARCINOMA		UNIV TEXAS,HLTH SCI CTR,DEPT MED ONCOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA30195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA030195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; CLARK GM, 1992, J CLIN ONCOL, V10, P428, DOI 10.1200/JCO.1992.10.3.428; CORNELISSE CJ, 1987, CYTOMETRY, V8, P225, DOI 10.1002/cyto.990080217; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; FISHER B, 1991, CANCER-AM CANCER SOC, V68, P1465, DOI 10.1002/1097-0142(19911001)68:7<1465::AID-CNCR2820680702>3.0.CO;2-I; FORNANDER T, 1989, LANCET, V1, P117; HATSCHEK T, 1989, CANCER, V64, P1074, DOI 10.1002/1097-0142(19890901)64:5<1074::AID-CNCR2820640519>3.0.CO;2-M; HEDLEY DW, 1987, CANCER RES, V47, P4729; HENRY JA, 1990, CANCER, V65, P265, DOI 10.1002/1097-0142(19900115)65:2<265::AID-CNCR2820650214>3.0.CO;2-1; JOENSUU H, 1990, CANCER, V66, P331, DOI 10.1002/1097-0142(19900715)66:2<331::AID-CNCR2820660222>3.0.CO;2-6; KALLIONIEMI OP, 1987, BRIT J CANCER, V56, P637, DOI 10.1038/bjc.1987.258; KALLIONIEMI OP, 1988, CANCER, V62, P2183, DOI 10.1002/1097-0142(19881115)62:10<2183::AID-CNCR2820621019>3.0.CO;2-B; KEYHANIROFAGHA S, 1990, CANCER-AM CANCER SOC, V65, P1577, DOI 10.1002/1097-0142(19900401)65:7<1577::AID-CNCR2820650721>3.0.CO;2-D; LEWIS WE, 1990, CANCER-AM CANCER SOC, V65, P2315; LYKKESFELDT AE, 1988, ACTA ONCOL, V27, P749, DOI 10.3109/02841868809091780; MCGUIRE WL, 1988, J NATL CANCER I, V80, P1075, DOI 10.1093/jnci/80.13.1075; MCGUIRE WL, 1990, J NATL CANCER I, V82, P1006, DOI 10.1093/jnci/82.12.1006; MCGUIRE WL, 1991, J NATL CANCER I, V83, P154, DOI 10.1093/jnci/83.3.154; MCGUIRE WL, 1988, J CLIN ONCOL, V6, P1071, DOI 10.1200/JCO.1988.6.7.1071; MCGUIRE WL, 1989, NEW ENGL J MED, V320, P525, DOI 10.1056/NEJM198902233200811; MOE RE, 1991, AM J SURG, V161, P580, DOI 10.1016/0002-9610(91)90904-R; MUSS HB, 1989, CANCER, V64, P1894, DOI 10.1002/1097-0142(19891101)64:9<1894::AID-CNCR2820640923>3.0.CO;2-K; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; OREILLY SM, 1990, BRIT J CANCER, V61, P671, DOI 10.1038/bjc.1990.152; ROCHEFORT H, 1990, CANCER CELL-MON REV, V2, P383; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; ROSEN PP, 1989, J CLIN ONCOL, V7, P1239, DOI 10.1200/JCO.1989.7.9.1239; ROSNER D, 1990, CANCER, V66, P199, DOI 10.1002/1097-0142(19900715)66:2<199::AID-CNCR2820660202>3.0.CO;2-L; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SPYRATOS F, 1989, LANCET, V2, P1115; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; WINCHESTER DJ, 1990, ARCH SURG-CHICAGO, V125, P886; 1992, J NCI MONOGRAPHS, V11, P1; 1992, LANCET, V339, P71	37	354	360	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1756	1761						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1594018				2022-12-28	WOS:A1992HZ89400007
J	HADORN, DC; MCCORMICK, K; DIOKNO, A				HADORN, DC; MCCORMICK, K; DIOKNO, A			AN ANNOTATED ALGORITHM APPROACH TO CLINICAL GUIDELINE DEVELOPMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT-CARE; MEDICINE	The Urinary Incontinence in Adults Guideline Panel facilitated the ready elucidation of its guideline's management recommendations through the use of an annotated algorithm approach. The algorithms created as part of this guideline differ from previous algorithms in two ways: (1) they employ systematic annotation to link explicitly the algorithms' recommendations to the literature, and (2) they contain patient counseling and decision nodes to depict the major preference-dependent decision or branch points in the algorithm. We believe that these two innovations can help ensure the clinical validity of guidelines' algorithms while preserving appropriate clinical flexibility and respecting patient preferences.	WILLIAM BEAUMONT HOSP, ROYAL OAK, MI 48072 USA; RAND CORP, SANTA MONICA, CA 90406 USA; NIA, GERIATR RES CTR, BETHESDA, MD 20892 USA	Beaumont Health; RAND Corporation; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)					AHRQ HHS [T32 HS 00007] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1982, CRITERIA STANDARDS Q; Field MJ, 1990, CLIN PRACTICE GUIDEL; Gottlieb L K, 1990, QRB Qual Rev Bull, V16, P80; GREENFIELD S, 1981, MED CARE, V19, P255, DOI 10.1097/00005650-198103000-00002; GREENFIELD S, 1990, PROVIDING QUALITY CA; GRIMM RH, 1975, NEW ENGL J MED, V292, P507, DOI 10.1056/NEJM197503062921005; KASSIRER JP, 1990, HOSP PRACT, P23; KOMAROFF AL, 1982, AM J PUBLIC HEALTH, V72, P10, DOI 10.2105/AJPH.72.1.10; KOMAROFF AL, 1974, NEW ENGL J MED, V290, P307, DOI 10.1056/NEJM197402072900605; MARGOLIS CZ, 1983, JAMA-J AM MED ASSOC, V249, P627, DOI 10.1001/jama.249.5.627; PALMER RH, 1984, MED CARE, V22, P632, DOI 10.1097/00005650-198407000-00005; SOX HC, 1973, NEW ENGL J MED, V288, P818, DOI 10.1056/NEJM197304192881605; 1992, AHCPR920038 AG HLTH	13	44	44	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3311	3314		10.1001/jama.267.24.3311	http://dx.doi.org/10.1001/jama.267.24.3311			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597913				2022-12-28	WOS:A1992HY94400030
J	ENGLANDER, SW; ENGLANDER, JJ; MCKINNIE, RE; ACKERS, GK; TURNER, GJ; WESTRICK, JA; GILL, SJ				ENGLANDER, SW; ENGLANDER, JJ; MCKINNIE, RE; ACKERS, GK; TURNER, GJ; WESTRICK, JA; GILL, SJ			HYDROGEN-EXCHANGE MEASUREMENT OF THE FREE-ENERGY OF STRUCTURAL AND ALLOSTERIC CHANGE IN HEMOGLOBIN	SCIENCE			English	Article							DIMER-TETRAMER ASSOCIATION; TEMPERATURE-DEPENDENCE; RIBONUCLEASE-S; RESOLUTION; PROTEINS; HELIX	The inability to localize and measure the free energy of protein structure and structure change severely limits protein structure-function investigations. The local unfolding model for protein hydrogen exchange quantitatively relates the free energy of local structural stability with the hydrogen exchange rate of concerted sets of structurally related protons. In tests with a number of modified hemoglobin forms, the loss in structural free energy obtained locally from hydrogen exchange results matches the loss in allosteric free energy measured globally by oxygen-binding and subunit dissociation experiments.	UNIV COLORADO,DEPT BIOCHEM,BOULDER,CO 80309; WASHINGTON UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110	University of Colorado System; University of Colorado Boulder; Washington University (WUSTL)	ENGLANDER, SW (corresponding author), UNIV PENN,JOHNSON RES FDN,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104, USA.				NIGMS NIH HHS [R01 GM031847] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031847] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ALLEWELL NM, 1983, J BIOCHEM BIOPH METH, V7, P345, DOI 10.1016/0165-022X(83)90060-X; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BERGER ARIEH, 1957, ARCH BIOCHEM AND BIOPHYS, V69, P106, DOI 10.1016/0003-9861(57)90478-2; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; ENGLANDER JJ, 1983, J MOL BIOL, V169, P325, DOI 10.1016/S0022-2836(83)80186-7; ENGLANDER JJ, 1985, ANAL BIOCHEM, V147, P234, DOI 10.1016/0003-2697(85)90033-8; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; ENGLANDER SW, 1975, ANN NY ACAD SCI, V244, P10, DOI 10.1111/j.1749-6632.1975.tb41518.x; ENGLANDER SW, 1980, BIOPHYS J, V32, P577, DOI 10.1016/S0006-3495(80)84991-5; ENGLANDER SW, 1983, STRUCTURE DYNAMICS N, P421; HVIDT AASE, 1966, ADVANCE PROTEIN CHEM, V21, P287, DOI 10.1016/S0065-3233(08)60129-1; IP SHC, 1977, J BIOL CHEM, V252, P82; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; KUWAJIMA K, 1983, J MOL BIOL, V169, P299, DOI 10.1016/S0022-2836(83)80185-5; LOUIE G, 1988, J MOL BIOL, V201, P755, DOI 10.1016/0022-2836(88)90472-X; LOUIE G, 1988, J MOL BIOL, V201, P765, DOI 10.1016/0022-2836(88)90473-1; MAIN EL, 1980, J BIOL CHEM, V255, P10695; MCKINNIE RE, 1991, CHEM PHYS, V158, P283, DOI 10.1016/0301-0104(91)87072-4; MILLS FC, 1979, J BIOL CHEM, V254, P2881; MONOD J, 1965, J MOL BIOL, V12, P33; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RAY J, 1986, BIOCHEMISTRY-US, V25, P3000, DOI 10.1021/bi00358a040; ROGERO JR, 1986, METHOD ENZYMOL, V131, pL508; ROSA JJ, 1979, J MOL BIOL, V133, P399, DOI 10.1016/0022-2836(79)90400-5; TURNER GL, 1989, THESIS J HOPKINS U B; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; WAND AJ, 1986, BIOCHEMISTRY-US, V25, P1107, DOI 10.1021/bi00353a025; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	29	83	83	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1684	1687		10.1126/science.256.5064.1684	http://dx.doi.org/10.1126/science.256.5064.1684			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609279	Green Accepted			2022-12-28	WOS:A1992HZ17400046
J	MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L				MCFARLANE, J; PARKER, B; SOEKEN, K; BULLOCK, L			ASSESSING FOR ABUSE DURING PREGNANCY - SEVERITY AND FREQUENCY OF INJURIES AND ASSOCIATED ENTRY INTO PRENATAL-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHYSICAL ABUSE; VIOLENCE; CONFLICT; WOMEN	Objective. - To assess the occurrence, frequency, and severity of physical abuse during pregnancy and associated initiation of prenatal care. Design. - Stratified, prospective cohort analysis. Setting. - Public prenatal clinics in Houston, Tex, and Baltimore, Md. Participants. - Total population-based sample of 691 black, Hispanic, and white pregnant women. All of the women were urban residents and most of the Hispanic women were Mexican American. All participants were invited into the study at the first prenatal visit and were followed up until delivery. Main Outcome Measure. - Identification of abuse status. Results. - A three-question Abuse Assessment Screen detected a 17% (1/6) prevalence of physical or sexual abuse during pregnancy, which is more than double all previous published reports. When evaluated against nationally tested research instruments, the three-question screen that was asked at the first prenatal visit was sensitive and specific to abuse status. Abuse was recurrent, with 60% of abused women reporting two or more episodes of assault. Location of abuse focused on the head. Frequency and severity of abuse and potential danger of homicide was appreciably worse for white women. Abused women were twice as likely as nonabused women to begin prenatal care during the third trimester. Conclusions. - A simple clinical assessment screen completed by the health care provider in a private setting and with the male partner absent is as effective as research instruments in identifying abused women. Straightforward, routine clinical assessment is recommended as essential in preventing potential trauma, interrupting existing abuse, and protecting health.	UNIV MARYLAND,BALTIMORE,MD 21201; UNIV OTAGO,DUNEDIN,NEW ZEALAND	University System of Maryland; University of Maryland Baltimore; University of Otago	MCFARLANE, J (corresponding author), TEXAS WOMANS UNIV,1130 MD ANDERSON BLVD,HOUSTON,TX 77030, USA.				PHS HHS [R49/CCR603514-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; BERENSON A, 1991, AM J OBSTET GYNECOL, V164, P491; CAMPBELL J, IN PRESS RES NURS HL; CAMPBELL JC, 1986, ADV NURS SCI, V8, P36, DOI 10.1097/00012272-198607000-00006; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; HILLARD PJA, 1985, OBSTET GYNECOL, V66, P185; HUDSON WW, 1981, J MARRIAGE FAM, V43, P873, DOI 10.2307/351344; JORGENSEN SR, 1977, J MARRIAGE FAM, V39, P653, DOI 10.2307/350472; LAZARRO M, 1991, J NURS ADMIN, V21, P24; MCFARLANE J, 1989, WOMEN HEALTH, V15, P69, DOI 10.1300/J013v15n03_06; MCFARLANE J, 1991, PUBLIC HEALTH NURS, V8, P245, DOI 10.1111/j.1525-1446.1991.tb00664.x; MCFARLANE J, 1991, VIOLENCE WOMEN NURSI; MCFARLANE J, 1991, DATING VIOLENCE YOUN; Parker B, 1991, MCN Am J Matern Child Nurs, V16, P161, DOI 10.1097/00005721-199105000-00013; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; Steinmetz S., 1977, CYCLE VIOLENCE ASSER; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; STRAUS MA, 1986, J MARRIAGE FAM, V48, P465, DOI 10.2307/352033; STRAUS MA, 1981, CLOSED DOORS VIOLENC; 1988, ABUSED WOMAN; 1986, SURGEON GENERALS WOR; 1989, BATTERED WOMAN	22	715	727	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3176	3178		10.1001/jama.267.23.3176	http://dx.doi.org/10.1001/jama.267.23.3176			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593739				2022-12-28	WOS:A1992HX91800027
J	DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S				DICK, PH; CROMBIE, IK; DURHAM, T; MCFEE, C; PRIMROSE, M; MITCHELL, S			UNNECESSARY HOSPITALIZATION IN A PSYCHIATRIC REHABILITATION UNIT	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND	University of Dundee	DICK, PH (corresponding author), ROYAL LIFF HOSP,DUNDEE PSYCHIAT REHABIL SERV,DUNDEE DD2 5NF,SCOTLAND.							AFFLECK JW, 1984, BRIT J PSYCHIAT, V145, P517, DOI 10.1192/bjp.145.5.517; Dick P H, 1990, Int J Rehabil Res, V13, P119, DOI 10.1097/00004356-199006000-00003; MCCREADIE RG, 1983, BRIT J PSYCHIAT, V143, P564, DOI 10.1192/bjp.143.6.564; MCCREADIE RG, 1991, BRIT J PSYCHIAT, V158, P398, DOI 10.1192/bjp.158.3.398; 1989, CARING PEOPLE COMMUN	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1544	1544		10.1136/bmj.304.6841.1544	http://dx.doi.org/10.1136/bmj.304.6841.1544			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HZ178	1628055	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800026
J	HORWICH, A				HORWICH, A			CURRENT ISSUES IN CANCER .6. RADIOTHERAPY UPDATE	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-TUMORS; RADIATION-THERAPY; BREAST-CANCER; ACCELERATED RADIOTHERAPY; BLOOD-FLOW; CARCINOMA; FRACTIONATION; CHEMOTHERAPY; PROGNOSIS; RATES				HORWICH, A (corresponding author), ROYAL MARSDEN HOSP,DEPT RADIOTHERAPY & ONCOL,ACAD UNIT,SUTTON SM2 5PT,SURREY,ENGLAND.							BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHAPLIN DJ, 1987, CANCER RES, V47, P597; COLEMAN CN, 1990, INT J RADIAT ONCOL, V18, P389, DOI 10.1016/0360-3016(90)90105-S; COX R, 1986, MOL BIOL MED, V3, P229; CUMMINGS B, 1984, CANCER-AM CANCER SOC, V54, P2062, DOI 10.1002/1097-0142(19841115)54:10<2062::AID-CNCR2820541004>3.0.CO;2-T; DEACON J, 1984, RADIOTHER ONCOL, V2, P317, DOI 10.1016/S0167-8140(84)80074-2; DISCHE S, 1985, RADIOTHER ONCOL, V3, P97, DOI 10.1016/S0167-8140(85)80015-3; DOBBS HJ, 1984, APPL RADIOL, V13, P51; EMAMI B, 1991, INT J RADIAT ONCOL, V21, P109, DOI 10.1016/0360-3016(91)90171-Y; GLAHOLM J, 1989, LANCET, V1, P1326; HENK JM, 1981, INT J RADIAT ONCOL, V7, P1125, DOI 10.1016/0360-3016(81)90173-5; HORWICH A, 1990, RADIOTHER ONCOL, V19, P353, DOI 10.1016/0167-8140(90)90036-V; HORWICH A, 1989, BIOL BASIS RADIOTHER, P279; HORWICH A, 1987, HODGKINS DISEASE, P250; MOYNIHAN C, 1987, CANCER SURV, V6, P477; OCONNELL MEA, IN PRESS RADIOTHER C; OTT RJ, 1991, BRIT J CANCER, V63, P343, DOI 10.1038/bjc.1991.81; PARKINS CS, 1989, BIOL BASIS RADIOTHER, P305; POWELL S, 1990, RADIOTHER ONCOL, V19, P95, DOI 10.1016/0167-8140(90)90123-E; Rees G J, 1991, Clin Oncol (R Coll Radiol), V3, P41; ROWELL NP, 1989, BRIT J CANCER, V59, P135, DOI 10.1038/bjc.1989.27; SAUNDERS MI, 1989, INT J RADIAT ONCOL, V17, P1287, DOI 10.1016/0360-3016(89)90538-5; SAUNDERS MI, 1990, INT J RADIAT ONCOL, V19, P1211, DOI 10.1016/0360-3016(90)90231-8; STEEL GG, 1988, RADIOTHER ONCOL, V11, P31, DOI 10.1016/0167-8140(88)90044-8; STEEL GG, 1989, RADIOTHER ONCOL, V15, P63, DOI 10.1016/0167-8140(89)90119-9; SUIT HD, 1982, CANCER-AM CANCER SOC, V50, P1227, DOI 10.1002/1097-0142(19821001)50:7<1227::AID-CNCR2820500702>3.0.CO;2-J; TAIT D, 1990, BRIT J CANCER, V62, P702, DOI 10.1038/bjc.1990.362; TAIT D, 1988, RADIOTHER ONCOL, V13, P23, DOI 10.1016/0167-8140(88)90294-0; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; THOMLINSON RH, 1955, BRIT J CANCER, V9, P539, DOI 10.1038/bjc.1955.55; THORPE SM, 1989, CANCER RES, V49, P6008; TROTT KR, 1985, RADIOTHER ONCOL, V3, P1, DOI 10.1016/S0167-8140(85)80002-5; WILLIAMS MV, 1984, INT J RADIAT ONCOL, V10, P1703, DOI 10.1016/0360-3016(84)90532-7; WILSON GD, 1988, BRIT J CANCER, V58, P423, DOI 10.1038/bjc.1988.234; WITHERS HR, 1985, CANCER, V55, P2086, DOI 10.1002/1097-0142(19850501)55:9+<2086::AID-CNCR2820551409>3.0.CO;2-1; 1983, BMJ, V2, P381; 1989, REV PROVISION CANCER	37	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1554	1557		10.1136/bmj.304.6841.1554	http://dx.doi.org/10.1136/bmj.304.6841.1554			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628059	Bronze, Green Published			2022-12-28	WOS:A1992HZ17800031
J	SMITH, TF; WATERMAN, MS				SMITH, TF; WATERMAN, MS			THE CONTINUING CASE OF THE FLORIDA DENTIST	SCIENCE			English	Editorial Material									UNIV SO CALIF,DEPT MATH,LOS ANGELES,CA 90089	University of Southern California	SMITH, TF (corresponding author), BOSTON UNIV,BIOMOLEC ENGN RES CTR,BOSTON,MA 02215, USA.							[Anonymous], 1992, DNA TECHNOLOGY FOREN; BARINAGA M, 1992, SCIENCE, V255, P686, DOI 10.1126/science.1738842; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; LANDER ES, 1989, NATURE, V339, P501, DOI 10.1038/339501a0; MCCABE ERB, 1992, J PEDIATR-US, V120, P499, DOI 10.1016/S0022-3476(05)82475-8; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PALCA J, 1992, SCIENCE, V255, P392, DOI 10.1126/science.1734515; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; 1990, MORB MORTAL WKLY REP, V39, P489	9	32	32	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1155	1156		10.1126/science.256.5060.1155	http://dx.doi.org/10.1126/science.256.5060.1155			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589795				2022-12-28	WOS:A1992HV19200023
J	STEEL, JM; ALLWINKLE, J; MOFFAT, R; CARRINGTON, DJ				STEEL, JM; ALLWINKLE, J; MOFFAT, R; CARRINGTON, DJ			USE OF LUCOZADE AND GLUCAGON BY AMBULANCE STAFF FOR TREATING HYPOGLYCEMIA	BMJ-BRITISH MEDICAL JOURNAL			English	Article									SCOTTISH AMBULANCE SERV, EDINBURGH EH10 5SA, SCOTLAND		STEEL, JM (corresponding author), ROYAL INFIRM, DEPT DIABET, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND.							COLLIER A, 1987, DIABETES CARE, V10, P712, DOI 10.2337/diacare.10.6.712; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; MULHAUSER I, 1985, DIABETES CARE S1, V8, P39; WESTON C, 1990, BRIT MED J, V300, P908, DOI 10.1136/bmj.300.6729.908-a; YAXLEY L, 1991, DIABETIC MED S1, V8, P71	5	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 16	1992	304	6837					1283	1284		10.1136/bmj.304.6837.1283	http://dx.doi.org/10.1136/bmj.304.6837.1283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606430	Green Published, Bronze			2022-12-28	WOS:A1992HV08600022
J	BROSE, N; PETRENKO, AG; SUDHOF, TC; JAHN, R				BROSE, N; PETRENKO, AG; SUDHOF, TC; JAHN, R			SYNAPTOTAGMIN - A CALCIUM SENSOR ON THE SYNAPTIC VESICLE SURFACE	SCIENCE			English	Article							PROTEIN-KINASE-C; MEMBRANE-PROTEIN; PHASE-SEPARATION; BINDING PROTEIN; POLYLYSINE; CELLS	Neurons release neurotransmitters by calcium-dependent exocytosis of synaptic vesicles. However, the molecular steps transducing the calcium signal into membrane fusion are still an enigma. It is reported here that synaptotagmin, a highly conserved synaptic vesicle protein, binds calcium at physiological concentrations in a complex with negatively charged phospholipids. This binding is specific for calcium and involves the cytoplasmic domain of synaptotagmin. Calcium binding is dependent on the intact oligomeric structure of synaptotagmin (it is abolished by proteolytic cleavage at a single site). These results suggest that synaptotagmin acts as a cooperative calcium receptor in exocytosis.	MAX PLANCK INST PSYCHIAT,DEPT NEUROCHEM,W-8033 MARTINSRIED,GERMANY; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Petrenko, Alexander/0000-0002-6689-6546; Jahn, Reinhard/0000-0003-1542-3498				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7961, DOI 10.1021/bi00246a013; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BIRRELL GB, 1976, BIOCHEMISTRY-US, V15, P2925, DOI 10.1021/bi00658a035; BOGGS JM, 1976, BIOCHEMISTRY-US, V15, P5420; CARRIER D, 1986, BIOCHEMISTRY-US, V25, P4167, DOI 10.1021/bi00362a027; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; FOHR KJ, IN PRESS METHODS ENZ; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; HARTMANN W, 1978, BIOCHIM BIOPHYS ACTA, V509, P474, DOI 10.1016/0005-2736(78)90241-9; IKEDA T, 1990, BIOCHIM BIOPHYS ACTA, V1026, P105, DOI 10.1016/0005-2736(90)90339-P; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LLINAS R, 1981, BIOPHYS J, V33, P289, DOI 10.1016/S0006-3495(81)84898-9; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PERIN MS, 1991, J BIOL CHEM, V266, P615; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; REICHARDT LF, 1983, ANNU REV BIOCHEM, V52, P871, DOI 10.1146/annurev.bi.52.070183.004255; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; TRIFARO JM, 1989, NEUROSCIENCE, V29, P1, DOI 10.1016/0306-4522(89)90327-8; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V	27	795	802	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1021	1025		10.1126/science.1589771	http://dx.doi.org/10.1126/science.1589771			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589771				2022-12-28	WOS:A1992HU22400039
J	BODENHEIMER, T				BODENHEIMER, T			UNDERINSURANCE IN AMERICA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-INSURANCE; MEDICAL-CARE; HYPERTENSION; SERVICES; ACCESS; ADULTS; COSTS											BASTANI R, 1991, PREV MED, V20, P350, DOI 10.1016/0091-7435(91)90034-2; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; BLENDON RJ, 1991, HEALTH AFFAIR, V10, P170, DOI 10.1377/hlthaff.10.4.170; BRANCH LG, 1988, GERONTOLOGIST, V28, P648, DOI 10.1093/geront/28.5.648; BRAVEMAN P, 1988, WESTERN J MED, V149, P708; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; CANTOR JC, 1990, J HEALTH POLIT POLIC, V15, P755, DOI 10.1215/03616878-15-4-755; CHRISTENSEN S, 1987, MILBANK Q, V65, P397, DOI 10.2307/3349945; COTTON P, 1991, JAMA-J AM MED ASSOC, V265, P2451; DiCarlo Steven, 1989, Health Care Financ Rev, V10, P77; ECKHOLM E, 1991, NY TIMES        0926, P12; Eckholm Erik, 1991, N Y Times Web, P24; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; EVANS RG, 1989, HLTH CARE FINANC R S, P72; FARLEY PJ, 1985, MILBANK FUND Q, V63, P476, DOI 10.2307/3349844; FEDER J, 1987, HEALTH AFFAIR, V6, P5, DOI 10.1377/hlthaff.6.4.5; FIHN SD, 1988, J GEN INTERN MED, V3, P356, DOI 10.1007/BF02595794; FREUDENHEIM M, 1992, NY TIMES        0329, P14; FRIEDMAN E, 1991, JAMA-J AM MED ASSOC, V265, P2491, DOI 10.1001/jama.265.19.2491; Friedman E, 1991, Health Manage Q, V13, P23; GLASER W, 1991, HLTH INSURANCE PRACT; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; KEELER EB, 1985, JAMA-J AM MED ASSOC, V254, P1926; LEVIT KR, 1991, HEALTH AFFAIR, V10, P117, DOI 10.1377/hlthaff.10.1.117; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1987, AM J PUBLIC HEALTH, V77, P801, DOI 10.2105/AJPH.77.7.801; REINHARDT UE, 1989, HLTH CARE FINANC R S, P97; Rice T, 1986, Health Aff (Millwood), V5, P5, DOI 10.1377/hlthaff.5.3.5; ROSENTHAL E, 1991, NY TIMES        0424, pC23; Rosenthal Elisabeth, 1991, N Y Times Web, P26; SHULMAN NB, 1986, AM J PUBLIC HEALTH, V76, P1105, DOI 10.2105/AJPH.76.9.1105; SKOLNICK A, 1991, JAMA-J AM MED ASSOC, V265, P2453, DOI 10.1001/jama.265.19.2453; SULLIVAN CB, 1991, HEALTH AFFAIR, V10, P104, DOI 10.1377/hlthaff.10.2.104; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; ZAPKA JG, 1991, MED CARE, V29, P697, DOI 10.1097/00005650-199108000-00003; 1989, HLTH BENEFITS SURVEY; 1991, SSA0510043 SOC SEC A; 1990, CALL ACTION; 1990, AM HLTH CARE CRISIS; 1987, INSURING CATASTROPHI; 1990, HLTH BENEFITS SURVEY; 1988, MED TESTING HLTH INS; [No title captured]; 1991, 7 WARNING SIGNS HLTH; 1991, DHHS PHS911232 DEP H	48	40	40	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					274	278		10.1056/NEJM199207233270412	http://dx.doi.org/10.1056/NEJM199207233270412			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JE381	1614471				2022-12-28	WOS:A1992JE38100012
J	ZUGER, A				ZUGER, A			MONDAY MORNING CLINIC	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					468	468						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619737				2022-12-28	WOS:A1992JD47200009
J	FREEDMAN, DX; STAHL, SM				FREEDMAN, DX; STAHL, SM			PSYCHIATRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSESSIVE-COMPULSIVE DISORDER; GLUCOSE METABOLIC RATES; AKATHISIA		UNIV CALIF SAN DIEGO,SCH MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego	FREEDMAN, DX (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024, USA.							ALTEMUS M, 1992, ARCH GEN PSYCHIAT, V49, P9; BAXTER LR, 1988, AM J PSYCHIAT, V145, P1560; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; COHN JB, 1992, PSYCHOPHATOLOGY S1, V25, P10; GELERNTER CS, 1991, ARCH GEN PSYCHIAT, V48, P938; GRINDLINGER HM, 1991, ARCH GEN PSYCHIAT, V48, P857; HALARIS AE, 1975, BIOL MAJOR PSYCHOSES; HOLLANDER E, 1992, ARCH GEN PSYCHIAT, V49, P21; KARNO M, 1988, ARCH GEN PSYCHIAT, V45, P1094, DOI 10.1001/archpsyc.1988.01800360042006; LEONARD HL, 1991, ARCH GEN PSYCHIAT, V48, P821; LEONARD HL, 1991, ARCH GEN PSYCHIAT, V48, P922; LESCH KP, 1991, ARCH GEN PSYCHIAT, V48, P540; LIPINSKI JF, 1989, J CLIN PSYCHIAT, V50, P339; MANN JJ, 1991, ARCH GEN PSYCHIAT, V48, P1027; NORDAHL TE, 1989, NEUROPSYCHOPHARMACOL, V2, P23, DOI 10.1016/0893-133X(89)90003-1; RAPOPORT JL, IN PRESS ARCH GEN PS; RICKELS K, 1982, J CLIN PSYCHIAT, V43, P81; STAHL SM, 1992, SEROTONIN 1A RECEPTO; STAHL SM, IN PRESS PSYCHOL MED; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P518; SWEDO SE, 1991, ARCH GEN PSYCHIAT, V48, P828; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P29; ZUBENKO GS, 1987, J CLIN PSYCHOPHARM, V7, P254; 1991, ARCH GEN PSYCHIAT, V48, P730; 1992, ARCH GEN PSYCHIAT, V49, P139	25	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					403	405						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613936				2022-12-28	WOS:A1992JC35200049
J	MITCHELL, JM; SCOTT, E				MITCHELL, JM; SCOTT, E			NEW EVIDENCE OF THE PREVALENCE AND SCOPE OF PHYSICIAN JOINT VENTURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONFLICTS	Physician ownership of health care businesses (outside their own practice) to which they refer patients has attracted considerable attention in the medical literature, in the media, and from federal and state policymakers. Despite the concerns raised about these ownership arrangements, known as joint ventures, the prevalence and scope of joint ventures involving physicians is not well documented. This report examines the prevalence and scope of physician joint ventures in Florida based on data collected under a legislative mandate. Our results indicate that physician ownership of health care businesses providing diagnostic testing or other ancillary services is common in Florida. While this conclusion is based on our comprehensive survey of health care businesses in Florida, it is at least indicative that such arrangements are likely to occur elsewhere. We find that at least 40% of Florida physicians involved in direct patient care have an investment interest in a health care business to which they may refer their patients for services; over 91% of the physician owners are concentrated in specialties that may refer patients for services. About 40% of the physician investors have a financial interest in diagnostic imaging centers. The estimates reported here indicate that the proportion of referring physicians involved in direct patient care who participate in joint ventures is much higher than previous estimates suggest.	FLORIDA STATE UNIV,DEPT FINANCE,TALLAHASSEE,FL 32306	State University System of Florida; Florida State University	MITCHELL, JM (corresponding author), FLORIDA STATE UNIV,DEPT ECON,R-128,TALLAHASSEE,FL 32306, USA.							DOBSON R, 1986, NEW ENGL J MED, V314, P250; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HYMAN DA, 1989, NEW ENGL J MED, V320, P1275, DOI 10.1056/NEJM198905113201911; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1682, DOI 10.1056/NEJM199006073222327; MORGENSON G, 1991, FORBES          0415, P38; PEAR R, 1991, NY TIMES        0924, pA26; PEAR R, 1991, NY TIMES        1118, pA1; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; RODWIN MA, 1989, NEW ENGL J MED, V321, P1405, DOI 10.1056/NEJM198911163212010; Rosenfeld R.H., 1984, MOD HEATHCARE, V14, P60; SOUHRADA L, 1988, HOSPITALS, V62, P76; Waldholz Michael, 1989, WALL STREET J   0301, pA1; 1989, FINANCIAL ARRANGEMEN; 1991, PHYSICIAN MARKETPLAC, V2, P1; 1992, JAMA-J AM MED ASSOC, V267, P2366; 1986, PROFIT ENTERPRISE HL, P151	18	49	49	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					80	84		10.1001/jama.268.1.80	http://dx.doi.org/10.1001/jama.268.1.80			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608117				2022-12-28	WOS:A1992JA16500027
J	GALINSKI, MR; MEDINA, CC; INGRAVALLO, P; BARNWELL, JW				GALINSKI, MR; MEDINA, CC; INGRAVALLO, P; BARNWELL, JW			A RETICULOCYTE-BINDING PROTEIN COMPLEX OF PLASMODIUM-VIVAX MEROZOITES	CELL			English	Article							DUFFY-BLOOD-GROUP; MALARIA PARASITES; CIRCUMSPOROZOITE PROTEIN; ERYTHROCYTE INVASION; KNOWLESI; CELL; RECEPTOR; SEQUENCE; INVITRO; SIGNAL	Plasmodium vivax merozoites primarily invade reticulocytes. The basis of this restricted host cell preference has been debated. Here we introduce two novel P. vivax proteins that comigrate on reducing SDS-polyacrylamide gels, colocalize at the apical pole of merozoites, and adhere specifically to reticulocytes. The genes encoding these proteins, P. vivax reticulocyte-binding proteins 1 and 2 (PvRBP-1 and PvRBP-2), have been cloned and analyzed. Homologous genes are evident in the closely related simian malaria parasite, P. cynomolgi, which also prefers to invade reticulocytes, but are not evident in the genome of another related simian malaria parasite, P. knowlesi, which invades all red blood cell subpopulations. Native PvRBP-1 is likely a transmembrane-anchored disulfide-linked protein, and along with PvRBP-2 may function as an adhesive protein complex. We propose that the RBPs of P. vivax, and homologous proteins of P. cynomolgi, function to target the reticulocyte subpopulation of red blood cells for invasion.			GALINSKI, MR (corresponding author), NYU,MED CTR,DEPT MED & MOLEC PARASITOL,NEW YORK,NY 10010, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024710, R22AI024710] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24710] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS JH, 1990, CELL, V63, P141, DOI 10.1016/0092-8674(90)90295-P; AIKAWA M, 1978, J CELL BIOL, V77, P72, DOI 10.1083/jcb.77.1.72; AUSUBEL EM, 1989, CURRENT PROTOCOLS MO; AUSUBEL EM, 1989, CURRENT PROTOCOLS S; BANNISTER LH, 1975, PARASITOLOGY, V71, P483, DOI 10.1017/S0031182000047247; BARNWELL JW, 1989, J EXP MED, V169, P1795, DOI 10.1084/jem.169.5.1795; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BROWN HJ, 1991, MOL BIOCHEM PARASIT, V49, P99, DOI 10.1016/0166-6851(91)90133-Q; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Darnell JE, 1986, MOL CELL BIOL; DELPORTILLO HA, 1991, P NATL ACAD SCI USA, V88, P4030, DOI 10.1073/pnas.88.9.4030; DIGIOVANNI L, 1990, EXP PARASITOL, V70, P373, DOI 10.1016/0014-4894(90)90120-2; DVORAK JA, 1975, SCIENCE, V187, P748, DOI 10.1126/science.803712; FANG XD, 1991, MOL BIOCHEM PARASIT, V44, P125, DOI 10.1016/0166-6851(91)90228-X; FINE E, 1984, AM J TROP MED HYG, V33, P220, DOI 10.4269/ajtmh.1984.33.220; GABIUS HJ, 1985, CELL, V42, P449, DOI 10.1016/0092-8674(85)90102-3; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; HADLEY TJ, 1988, PROG ALLERGY, V41, P49; HUYNH TV, 1985, DNA CLONING, V1; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KEMP DJ, 1987, ANNU REV MICROBIOL, V41, P181, DOI 10.1146/annurev.mi.41.100187.001145; KITCHEN S. F., 1938, AMER JOUR TROP MED, V18, P347; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUMAR MA, 1992, BIOTECHNIQUES, V72, P198; LAZARIDES E, 1987, CELL, V51, P345, DOI 10.1016/0092-8674(87)90631-3; MCCUTCHAN TF, 1984, SCIENCE, V225, P808, DOI 10.1126/science.6382604; MILLER LH, 1979, J EXP MED, V149, P172, DOI 10.1084/jem.149.1.172; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MITCHELL GH, 1988, CRIT REV ONCOL HEMAT, V8, P255, DOI 10.1016/S1040-8428(88)80011-8; MONS B, 1988, EXP PARASITOL, V66, P183, DOI 10.1016/0014-4894(88)90089-6; MONS B, 1990, BLOOD CELLS, V16, P299; OZAKI LS, 1983, CELL, V34, P815, DOI 10.1016/0092-8674(83)90538-X; PATEL VP, 1985, P NATL ACAD SCI USA, V82, P440, DOI 10.1073/pnas.82.2.440; PERKINS ME, 1992, PARASITOL TODAY, V8, P28, DOI 10.1016/0169-4758(92)90308-O; PERKINS ME, 1989, EXP PARASITOL, V69, P94, DOI 10.1016/0014-4894(89)90175-6; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; PETERSON MG, 1990, MOL BIOCHEM PARASIT, V39, P279, DOI 10.1016/0166-6851(90)90067-V; RAPOPORT SM, 1986, RETICULOCYTE; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUL A, 1990, MOL BIOCHEM PARASIT, V42, P55, DOI 10.1016/0166-6851(90)90112-Y; STEWART MJ, 1991, J PROTOZOOL, V38, P411, DOI 10.1111/j.1550-7408.1991.tb01379.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VERNICK KD, 1988, NUCLEIC ACIDS RES, V16, P6883, DOI 10.1093/nar/16.14.6883; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WARREN M, 1966, J PARASITOL, V52, P14, DOI 10.2307/3276382; WATERS AP, 1990, J BIOL CHEM, V265, P17974; WEBER JL, 1988, EXP PARASITOL, V66, P143, DOI 10.1016/0014-4894(88)90087-2; WERTHEIMER SP, 1989, EXP PARASITOL, V69, P340, DOI 10.1016/0014-4894(89)90083-0; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	54	301	306	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1213	1226		10.1016/0092-8674(92)90642-P	http://dx.doi.org/10.1016/0092-8674(92)90642-P			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617731				2022-12-28	WOS:A1992JA43100015
J	NOLLER, HF; HOFFARTH, V; ZIMNIAK, L				NOLLER, HF; HOFFARTH, V; ZIMNIAK, L			UNUSUAL RESISTANCE OF PEPTIDYL TRANSFERASE TO PROTEIN EXTRACTION PROCEDURES	SCIENCE			English	Article							23S RIBOSOMAL-RNA; ESCHERICHIA-COLI RIBOSOMES; PEPTIDYLTRANSFERASE ACTIVITY; A-SITES; P-SITES; SUBUNITS; CHLORAMPHENICOL; RECONSTITUTION; IDENTIFICATION; NUCLEOTIDES	Peptidyl transferase, the ribosomal activity responsible for catalysis of peptide bond formation, is resistant to vigorous procedures that are conventionally employed to remove proteins from protein-nucleic acid complexes. When the "fragment reaction" was used as a model assay for peptide bond formation, Escherichia coli ribosomes or 50S subunits retained 20 to 40 percent activity after extensive treatment with proteinase K and SDS, but lost activity after extraction with phenol or exposure to EDTA. Ribosomes from the thermophilic eubacterium Thermus aquaticus remained more than 80 percent active after treatment with proteinase K and SDS, which was followed by vigorous extraction with phenol. This activity is attributable to peptidyl transferase, as judged by specific inhibition by the peptidyl transferase-specific antibiotics chloramphenicol and carbomycin. In contrast, activity is abolished by treatment with ribonuclease T1. These findings support the possibility that 23S ribosomal RNA participates in the peptidyl transferase function.			NOLLER, HF (corresponding author), UNIV CALIF SANTA CRUZ, SINSHEIMER LABS, SANTA CRUZ, CA 95064 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017129, R37GM017129] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM17129] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATCHISON RE, UNPUB; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BURMA DP, 1985, ARCH BIOCHEM BIOPHYS, V239, P427, DOI 10.1016/0003-9861(85)90708-8; CECH TR, 1981, CELL, V27, P487, DOI 10.1016/0092-8674(81)90390-1; CERNA J, 1973, EUR J BIOCHEM, V34, P551, DOI 10.1111/j.1432-1033.1973.tb02794.x; Chambliss G., 1980, RIBOSOMES STRUCTURE, P357; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAMPL H, 1981, J BIOL CHEM, V256, P2284; HELD WA, 1973, J BIOL CHEM, V248, P5720; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADEN BEH, 1968, J MOL BIOL, V35, P333, DOI 10.1016/S0022-2836(68)80028-2; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MONRO RE, 1967, J MOL BIOL, V25, P347, DOI 10.1016/0022-2836(67)90146-5; MONRO RE, 1967, J MOL BIOL, V28, P161, DOI 10.1016/S0022-2836(67)80085-8; MOORE VG, 1975, P NATL ACAD SCI USA, V72, P844, DOI 10.1073/pnas.72.3.844; NIERHAUS KH, 1973, P NATL ACAD SCI USA, V70, P1931, DOI 10.1073/pnas.70.7.1931; NIERHAUS KH, 1982, CURR TOP MICROBIOL, V97, P81; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; PARISH JH, 1966, BIOCHIM BIOPHYS ACTA, V129, P554, DOI 10.1016/0005-2787(66)90070-0; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; SIEGMANN M, 1987, METHOD ENZYMOL, V146, P362; STAEHELIN T, 1969, COLD SPRING HARB SYM, V34, P39, DOI 10.1101/SQB.1969.034.01.008; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TERAOKA H, 1978, FEBS LETT, V88, P223, DOI 10.1016/0014-5793(78)80179-3; VESTER B, 1988, EMBO J, V7, P3577, DOI 10.1002/j.1460-2075.1988.tb03235.x; 1989, CATALOGUE BACTERIA B	33	608	629	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1992	256	5062					1416	1419		10.1126/science.1604315	http://dx.doi.org/10.1126/science.1604315			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604315				2022-12-28	WOS:A1992HX33700026
J	WADA, A				WADA, A			WHAT FRONTIERS FOR FRONTIER	NATURE			English	Editorial Material											WADA, A (corresponding author), SAGAMI CHEM RES CTR,NISHI-OHNUMA 4-4-1,SAGAMIHARA,KANAGAWA 229,JAPAN.							1977, NATURE, V16, P44; 1904, NATURE, V71, P150	2	5	5	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					356	356		10.1038/357356a0	http://dx.doi.org/10.1038/357356a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594037				2022-12-28	WOS:A1992HX17200022
J	MCCULLOCH, P				MCCULLOCH, P			GASTRIC-CANCER	BRITISH MEDICAL JOURNAL			English	Article											MCCULLOCH, P (corresponding author), NATL CANC CTR,5-1-1 TSUKIJI,CHUO KU,TOKYO 104,JAPAN.			McCulloch, Peter/0000-0002-3210-8273					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1372	1373		10.1136/bmj.304.6838.1372	http://dx.doi.org/10.1136/bmj.304.6838.1372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611340	Green Published, Bronze			2022-12-28	WOS:A1992HW41700033
J	TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA				TUNSTALLPEDOE, H; BAILEY, L; CHAMBERLAIN, DA; MARSDEN, AK; WARD, ME; ZIDEMAN, DA			SURVEY OF 3765 CARDIOPULMONARY RESUSCITATIONS IN BRITISH HOSPITALS (THE BRESUS STUDY) - METHODS AND OVERALL RESULTS	BRITISH MEDICAL JOURNAL			English	Article							BASIC LIFE SUPPORT; CARDIAC-ARREST; INTENSIVE-CARE; EMERGENCY; SURVIVAL; ACCIDENT; GUIDELINES	Objective-To determine the circumstances, incidence, and outcome of cardiopulmonary resuscitation in British hospitals. Design-Hospitals registered all cardiopulmonary resuscitation attempts for 12 months or longer and followed survival to one year. Setting-12 metropolitan, provincial, teaching, and non-teaching hospitals across Britain. Subjects-3765 patients in whom a resuscitation attempt was performed, including 927 in whom the onset of arrest was outside the hospital. Main outcome measure-Survival after initial resuscitation, at 24 hours, at discharge from hospital, and at one year, calculated by the life table method. Results-There were 417 known survivors at one year, with 214 lost to follow up. By life table analysis for every eight attempted resuscitations there were three immediate survivors, two at 24 hours, 1.5 leaving hospital alive, and one alive at one year. Survival at one year was 12.5% including out of hospital cases and 15.0% not including these cases. Each hospital year averaged 30 survivors at one year: three who had an arrest outside hospital, seven who had one in the accident and emergency department, seven in the cardiac care unit, 10 in the general wards, and three in other, non-ward areas. Within the hospitals survival rates were best in those who had an arrest in the accident and emergency department, the cardiac care unit, or other specialised units. Outcome varied 12-fold in subgroups defined by age, type of arrest, and place of arrest. Conclusion-71% of the mortality at one year in patients undergoing attempted resuscitation occurred during the initial arrest. Hospital resuscitation is life saving and cost effective and warrants appropriate attention, training, coordination, and equipment.	UNIV SUSSEX,BRIGHTON BN1 9RH,E SUSSEX,ENGLAND; ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND; PINDERFIELDS HOSP,ACCID & EMERGENCY MED,WAKEFIELD,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; HAMMERSMITH HOSP,LONDON W12 0HS,ENGLAND	University of Sussex; University of Brighton; Pinderfields Hospital; University of Oxford; Imperial College London	TUNSTALLPEDOE, H (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,CARDIOVASC EPIDEMIOL UNIT,DUNDEE DD1 9SY,SCOTLAND.							BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; CHAMBERLAIN DA, 1989, BRIT MED J, V299, P446, DOI 10.1136/bmj.299.6696.446; COBBE SM, 1991, BRIT MED J, V302, P1517, DOI 10.1136/bmj.302.6791.1517; COPE AR, 1987, J ROY SOC MED, V80, P746, DOI 10.1177/014107688708001207; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DEBARD ML, 1981, ANN EMERG MED, V10, P408, DOI 10.1016/S0196-0644(81)80307-1; DELOOZ HH, 1989, RESUSCITATION, V17, pS1, DOI 10.1016/0300-9572(89)90085-3; EVANS TR, 1990, ABC RESUSCITATION; GEORGE AL, 1989, AM J MED, V87, P28; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; KAYE W, 1981, HEART LUNG, V10, P860; MARSDEN AK, 1989, BRIT MED J, V299, P442, DOI 10.1136/bmj.299.6696.442; MCGRATH RB, 1987, ANN EMERG MED, V16, P1365, DOI 10.1016/S0196-0644(87)80420-1; ROBERTSON CE, 1984, ARCH EMERG MED, V1, P17; ROSER LA, 1967, ARCH SURG-CHICAGO, V95, P658; SCOTT RPF, 1981, ANAESTHESIA, V36, P526, DOI 10.1111/j.1365-2044.1981.tb10290.x; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; SMITH GB, 1987, INTENS CARE MED, V13, P260, DOI 10.1007/BF00265115; SULJAGAPECHTEL K, 1984, RESUSCITATION, V12, P77, DOI 10.1016/0300-9572(84)90061-3; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; WARDROPE J, 1986, ARCH EMERG MED, V3, P183; WILDSMITH JA, 1972, BRIT J ANAESTH, V44, P716; WYNNE G, 1987, BRIT MED J, V294, P1198, DOI 10.1136/bmj.294.6581.1198; ZIDEMAN DA, 1985, J WORLD ASS EMERGENC, V1, P291; 1980, JAMA-J AM MED ASSOC, V244, P453; 1987, J R COLL PHYSICIANS, V21, P1	28	233	237	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1347	1351		10.1136/bmj.304.6838.1347	http://dx.doi.org/10.1136/bmj.304.6838.1347			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611332	Green Published, Bronze			2022-12-28	WOS:A1992HW41700022
J	NICOLAOU, KC; DAI, WM; TSAY, SC; ESTEVEZ, VA; WRASIDLO, W				NICOLAOU, KC; DAI, WM; TSAY, SC; ESTEVEZ, VA; WRASIDLO, W			DESIGNED ENEDIYNES - A NEW CLASS OF DNA-CLEAVING MOLECULES WITH POTENT AND SELECTIVE ANTICANCER ACTIVITY	SCIENCE			English	Article							NEOCARZINOSTATIN CHROMOPHORE ANALOGS; ESPERAMICIN-CALICHEMICIN CLASS; CHROMIUM-MEDIATED CLOSURES; 10-MEMBERED RING ANALOGS; DIELS-ALDER ROUTE; ANTITUMOR ANTIBIOTICS; CALICHEAMICIN-ESPERAMICIN; BICYCLIC CORE; DYNEMICIN-A; GENERAL METHODOLOGY	The rational design and biological actions of a new class of DNA-cleaving molecules with potent and selective anticancer activity are reported. These relatively simple enediyne-type compounds were designed from basic chemical principles to mimic the actions of the rather complex naturally occurring enediyne anticancer antibiotics, particularly dynemicin A. Equipped with locking and triggering devices, these compounds damage DNA in vitro and in vivo on activation by chemical or biological means. Their damaging effects are manifested in potent anticancer activity with remarkable selectivities. Their mechanism of action involves intracellular unlocking and triggering of a Bergman reaction, leading to highly reactive benzenoid diradicals that cause severe DNA damage. The results of these studies demonstrate the potential of these de novo designed molecules as biotechnology tools and anticancer agents.	UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	NICOLAOU, KC (corresponding author), Scripps Res Inst, RES INST, DEPT CHEM, LA JOLLA, CA 92037 USA.		Dai, Wei-Min/B-6981-2008	Dai, Wei-Min/0000-0001-5688-7606				BERGMAN RG, 1973, ACCOUNTS CHEM RES, V6, P25, DOI 10.1021/ar50061a004; BIRNBOIM HC, 1981, CANCER RES, V41, P1889; BORMAN S, 1991, CHEM ENG NEWS, V69, P11, DOI 10.1021/cen-v069n035.p011; CABAL MP, 1990, J AM CHEM SOC, V112, P3253, DOI 10.1021/ja00164a079; CHIKASHITA H, 1991, J ORG CHEM, V56, P1962; DANISHEFSKY SJ, 1988, TETRAHEDRON LETT, V29, P4681, DOI 10.1016/S0040-4039(00)80579-1; DANISHEFSKY SJ, 1988, J AM CHEM SOC, V110, P6890, DOI 10.1021/ja00228a051; DARBY N, 1971, J CHEM SOC CHEM COMM, P1516, DOI 10.1039/c29710001516; DOI T, 1991, J ORG CHEM, V56, P3465, DOI 10.1021/jo00011a002; DOYLE TW, 22ND P ANN CANC S AN, V1; DRAK J, 1991, P NATL ACAD SCI USA, V88, P7464, DOI 10.1073/pnas.88.17.7464; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GOLIK J, 1987, J AM CHEM SOC, V109, P3462, DOI 10.1021/ja00245a049; HASELTINE JN, 1989, J AM CHEM SOC, V111, P7638, DOI 10.1021/ja00201a068; HASELTINE JN, 1991, J AM CHEM SOC, V113, P3850, DOI 10.1021/ja00010a030; HASELTINE JN, 1990, J ORG CHEM, V55, P2576, DOI 10.1021/jo00296a007; HIRAMA M, 1989, J AM CHEM SOC, V111, P4120, DOI 10.1021/ja00193a065; HIRAMA M, 1991, J AM CHEM SOC, V113, P9851, DOI 10.1021/ja00026a022; JONES RR, 1972, J AM CHEM SOC, V94, P660, DOI 10.1021/ja00757a071; KONISHI M, 1990, J AM CHEM SOC, V112, P3715, DOI 10.1021/ja00165a097; KREBS A, 1990, TETRAHEDRON LETT, V31, P3533, DOI 10.1016/S0040-4039(00)94435-6; LEE MD, 1987, J AM CHEM SOC, V109, P3464, DOI 10.1021/ja00245a050; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P235, DOI 10.1021/ar00008a003; LEE MD, 1987, J AM CHEM SOC, V109, P3466, DOI 10.1021/ja00245a051; LOCKHART TP, 1981, J AM CHEM SOC, V103, P4082, DOI 10.1021/ja00404a018; LOCKHART TP, 1981, J AM CHEM SOC, V103, P4091, DOI 10.1021/ja00404a019; MAGNUS P, 1989, J CHEM SOC CHEM COMM, P916, DOI 10.1039/c39890000916; MAGNUS P, 1989, TETRAHEDRON LETT, V30, P1905, DOI 10.1016/S0040-4039(00)99609-6; MAGNUS P, 1990, J ORG CHEM, V55, P1709, DOI 10.1021/jo00293a009; MAGNUS P, 1988, J AM CHEM SOC, V110, P6921, DOI 10.1021/ja00228a071; MAGNUS P, 1990, J AM CHEM SOC, V112, P4986, DOI 10.1021/ja00168a068; MAGNUS P, 1991, J CHEM SOC CHEM COMM, P544, DOI 10.1039/c39910000544; MAGNUS P, 1991, J CHEM SOC CHEM COMM, P541, DOI 10.1039/c39910000541; MANTLO NB, 1989, J ORG CHEM, V54, P2781, DOI 10.1021/jo00273a002; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MYERS AG, 1989, J AM CHEM SOC, V111, P9130, DOI 10.1021/ja00207a036; MYERS AG, 1991, J AM CHEM SOC, V113, P694, DOI 10.1021/ja00002a059; MYERS AG, 1989, J AM CHEM SOC, V111, P8057, DOI 10.1021/ja00202a079; NAGATA R, 1989, TETRAHEDRON LETT, V30, P4995, DOI 10.1016/S0040-4039(01)80564-5; NAGATA R, 1990, TETRAHEDRON LETT, V31, P2907, DOI 10.1016/0040-4039(90)80181-K; NICOLAOU KC, 1992, ANGEW CHEM INT EDIT, V31, P340, DOI 10.1002/anie.199203401; NICOLAOU KC, 1990, ANGEW CHEM INT EDIT, V29, P1064, DOI 10.1002/anie.199010641; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P7247, DOI 10.1021/ja00229a068; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1032, DOI 10.1002/anie.199110321; NICOLAOU KC, 1991, J AM CHEM SOC, V113, P3106, DOI 10.1021/ja00008a045; NICOLAOU KC, 1988, J AM CHEM SOC, V110, P4866, DOI 10.1021/ja00222a077; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P7416, DOI 10.1021/ja00176a064; NICOLAOU KC, 1991, J AM CHEM SOC, V113, P9878, DOI 10.1021/ja00026a039; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P1387, DOI 10.1002/anie.199113873; NICOLAOU KC, 1989, ANGEW CHEM INT EDIT, V28, P1272, DOI 10.1002/anie.198912721; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P7825, DOI 10.1021/ja00177a070; NICOLAOU KC, IN PRESS ANGEW CHEM; NICOLAOU KC, UNPUB; NISHIKAWA T, 1991, CHEM LETT, P1271, DOI 10.1246/cl.1991.1271; NISHIKAWA T, 1991, SYNLETT, P393; PORCO JA, 1990, J AM CHEM SOC, V112, P7410, DOI 10.1021/ja00176a060; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; SAKAI Y, 1991, TETRAHEDRON LETT, V32, P4363, DOI 10.1016/S0040-4039(00)92171-3; SCHOENEN FJ, 1989, TETRAHEDRON LETT, V30, P3765, DOI 10.1016/S0040-4039(01)80649-3; SCHREIBER SL, 1988, J AM CHEM SOC, V110, P631, DOI 10.1021/ja00210a071; SCHREIBER SL, 1989, TETRAHEDRON LETT, V30, P433, DOI 10.1016/S0040-4039(00)95220-1; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SMITH AL, 1992, J AM CHEM SOC, V114, P3134, DOI 10.1021/ja00034a068; TOMIOKA K, 1989, TETRAHEDRON LETT, V30, P851, DOI 10.1016/S0040-4039(01)80634-1; TOSHIMA K, 1991, TETRAHEDRON LETT, V32, P391, DOI 10.1016/S0040-4039(00)92636-4; WEHLAGE T, 1990, TETRAHEDRON LETT, V31, P6625, DOI 10.1016/S0040-4039(00)97131-4; WENDER PA, 1990, J AM CHEM SOC, V112, P5369, DOI 10.1021/ja00169a065; WENDER PA, 1988, TETRAHEDRON LETT, V29, P909, DOI 10.1016/S0040-4039(00)82479-X; WENDER PA, 1991, J AM CHEM SOC, V113, P2311, DOI 10.1021/ja00006a065	69	331	348	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1172	1178		10.1126/science.256.5060.1172	http://dx.doi.org/10.1126/science.256.5060.1172			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589797				2022-12-28	WOS:A1992HV19200026
J	KOCH, C; ZADOR, A; BROWN, TH				KOCH, C; ZADOR, A; BROWN, TH			DENDRITIC SPINES - CONVERGENCE OF THEORY AND EXPERIMENT	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; PYRAMIDAL CELLS; CALCIUM; STIMULATION; ENHANCEMENT; MECHANISM; NEURONS		YALE UNIV,NEUROSCI PROGRAM,NEW HAVEN,CT 06520; YALE UNIV,DEPT PSYCHOL,NEW HAVEN,CT 06520	Yale University; Yale University	KOCH, C (corresponding author), CALTECH,COMP & NEURAL SYST PROGRAM,PASADENA,CA 91125, USA.			Zador, Anthony/0000-0002-8431-9136; Koch, Christof/0000-0001-6482-8067				BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BRADLEY P, 1979, BRAIN RES, V162, P148, DOI 10.1016/0006-8993(79)90764-9; BROWN T H, 1988, P201; BROWN TH, 1988, SCIENCE, V242, P724, DOI 10.1126/science.2903551; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COSS RG, 1985, BEHAV NEURAL BIOL, V44, P151, DOI 10.1016/S0163-1047(85)90170-0; COSS RG, 1978, SCIENCE, V200, P787, DOI 10.1126/science.644322; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DESMOND N L, 1988, P265; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; GREENOUGH WT, 1985, SYNAPTIC PLASTICITY, P335; GUTHRIE PB, 1991, NATURE, V354, P76, DOI 10.1038/354076a0; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1989, HIPPOCAMPUS NEW VIST, P32; HOLMES WR, 1990, J NEUROPHYSIOL, V63, P1148, DOI 10.1152/jn.1990.63.5.1148; KOCH C, 1983, PROC R SOC SER B-BIO, V218, P455, DOI 10.1098/rspb.1983.0051; LARKMAN AU, 1991, J COMP NEUROL, V306, P320, DOI 10.1002/cne.903060208; LEE KS, 1980, J NEUROPHYSIOL, V44, P247, DOI 10.1152/jn.1980.44.2.247; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; PERKEL DH, 1985, BRAIN RES, V325, P331, DOI 10.1016/0006-8993(85)90334-8; PURPURA DP, 1974, SCIENCE, V186, P1126, DOI 10.1126/science.186.4169.1126; Rall W., 1974, CELLULAR MECH SUBSER, P13; Rall W., 1978, STUDIES NEUROPHYSIOL, P203; REGEHR WG, 1989, NATURE, V341, P533, DOI 10.1038/341533a0; RINZEL J, 1982, SOME MATH QUESTIONS, P7; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499, DOI 10.1152/jn.1988.60.2.499; SHEPHERD GM, 1985, P NATL ACAD SCI USA, V82, P2192, DOI 10.1073/pnas.82.7.2192; VANHARREVELD A, 1975, EXP NEUROL, V49, P736, DOI 10.1016/0014-4886(75)90055-2; WILSON CJ, 1984, J NEUROSCI, V4, P281; WILSON CJ, 1983, J NEUROSCI, V3, P383; XIANG Z, 1991, Society for Neuroscience Abstracts, V17, P1330; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	35	80	81	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					973	974		10.1126/science.1589781	http://dx.doi.org/10.1126/science.1589781			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589781				2022-12-28	WOS:A1992HU22400025
J	HUMPHRIES, P; KENNA, P; FARRAR, GJ				HUMPHRIES, P; KENNA, P; FARRAR, GJ			ON THE MOLECULAR-GENETICS OF RETINITIS-PIGMENTOSA	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; RETINAL DEGENERATION; USHER SYNDROME; DNA-SEQUENCES; RD MOUSE; LINKAGE; RHODOPSIN; ADRP; POLYMORPHISMS; HETEROGENEITY	The human retina carries specialized neurons, the rod and cone photoreceptors, which absorb and transduce light energy and transmit impulses through the optic nerve to the brain. The most prevalent group of inherited retinopathies, affecting approximately 1.5 million people, is collectively termed retinitis pigmentosa (RP). Mutations responsible for RP have now been found in two genes encoding transmembrane proteins of the rod photoreceptor outer segment disc, and a number of additional causative genes have been localized. It is likely that characterization of the majority of such genes over the next few years will lead to a substantial elucidation of the molecular pathology of this debilitating group of hereditary conditions.			HUMPHRIES, P (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT GENET,DUBLIN 2,IRELAND.		Bateson, Jane Farrar/AAO-6147-2020; Farrar, G Jane/B-9832-2011		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BELLEWHITE M, 1992, GENOMICS, V12, P301; BHATTACHARYA SS, 1984, NATURE, V309, P253, DOI 10.1038/309253a0; BLANTON SH, 1990, GENOMICS, V8, P179, DOI 10.1016/0888-7543(90)90243-N; BLEEKERWAGEMAKE.L, UNPUB; BOWES C, 1989, P NATL ACAD SCI USA, V86, P9722, DOI 10.1073/pnas.86.24.9722; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BUNDEY S, 1984, J MED GENET, V21, P417, DOI 10.1136/jmg.21.6.417; BUNKER CH, 1984, AM J OPHTHALMOL, V97, P357, DOI 10.1016/0002-9394(84)90636-6; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; FARRAR GJ, 1990, GENOMICS, V8, P35; FARRAR GJ, 1990, AM J HUM GENET, V47, P941; FARRAR GJ, 1991, GENOMICS, V11, P870, DOI 10.1016/0888-7543(91)90009-4; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; Heckenlively J. R., 1988, RETINITIS PIGMENTOSA; Holmgren F., 1870, UPPSALA LAKAREFORENI, V6, P419; HUMPHRIES P, 1990, CLIN GENET, V38, P1; HUMPHRIES P, IN PRESS PROG RET RE; HUMPHRIES P, UNPUB; INGLE C, 1985, AM J HUM GENET, V37, P451; INGLEHEARN CF, 1990, GENOMICS, V6, P168, DOI 10.1016/0888-7543(90)90462-4; JORDAN SA, 1992, AM J HUM GENET, V50, P634; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Karpe G., 1945, ACTA OPHTHALMOL SUPPL [COPENHAGEN], V24, P1; KIMBERLING WJ, 1989, LARYNGOSCOPE, V99, P66; MCWILLIAM P, 1989, GENOMICS, V5, P619, DOI 10.1016/0888-7543(89)90031-1; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTT J, 1990, P NATL ACAD SCI USA, V87, P701, DOI 10.1073/pnas.87.2.701; PAGON RA, 1988, SURV OPHTHALMOL, V33, P137, DOI 10.1016/0039-6257(88)90085-9; PELIAS MZ, 1988, CYTOGENET CELL GENET, V47, P111, DOI 10.1159/000132524; ROSENFELD PJ, 1992, INVEST OPHTH VIS SCI, V33, P1397; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; STRYER L, 1988, COLD SPRING HARB SYM, V53, P283, DOI 10.1101/SQB.1988.053.01.035; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; TRAVIS GH, 1991, GENOMICS, V10, P733, DOI 10.1016/0888-7543(91)90457-P; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; WIEACKER P, 1984, AM J HUM GENET, V36, P265; YANDELL DW, 1989, AM J HUM GENET, V45, P547	40	151	157	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					804	808		10.1126/science.1589761	http://dx.doi.org/10.1126/science.1589761			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589761				2022-12-28	WOS:A1992HT23500034
J	BLAIR, P; ROWLANDS, BJ; WEBB, H; LOWRY, K				BLAIR, P; ROWLANDS, BJ; WEBB, H; LOWRY, K			SELECTIVE DECONTAMINATION OF THE DIGESTIVE-TRACT	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							INTENSIVE-CARE				BLAIR, P (corresponding author), QUEENS UNIV BELFAST,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND.							BLAIR P, 1991, SURGERY, V110, P303; GASTINNE H, 1992, NEW ENGL J MED, V326, P594, DOI 10.1056/NEJM199202273260903; GODARD J, 1990, INTENS CARE MED, V16, P307, DOI 10.1007/BF01706355; LEDINGHAM IM, 1988, LANCET, V1, P785; REIDY JJ, 1990, CRIT CARE MED, V18, P1449, DOI 10.1097/00003246-199012000-00028	5	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					361	362						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1620185				2022-12-28	WOS:A1992JF65500031
J	PYZDROWSKI, KL; KENDALL, DM; HALTER, JB; NAKHLEH, RE; SUTHERLAND, DER; ROBERTSON, RP				PYZDROWSKI, KL; KENDALL, DM; HALTER, JB; NAKHLEH, RE; SUTHERLAND, DER; ROBERTSON, RP			PRESERVED INSULIN-SECRETION AND INSULIN INDEPENDENCE IN RECIPIENTS OF ISLET AUTOGRAFTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							I DIABETIC RECIPIENTS; PANCREATIC-POLYPEPTIDE; AUTO-TRANSPLANTATION; INDUCED HYPOGLYCEMIA; ADRENERGIC-BLOCKADE; GLUCAGON-RELEASE; CANINE PANCREAS; NERVOUS-SYSTEM; CYCLOSPORIN; PLASMA	Background. Transplantation of pancreatic islets, rather than whole pancreas, has been introduced as a treatment for diabetes mellitus. We studied five patients ranging in age from 12 to 37 years who had severe chronic pancreatitis for which they underwent total pancreatectomy followed by isolation and hepatic transplantation of their own islets. Methods. All patients had remained insulin-independent for 1 to 7 1/2 years after transplantation. The numbers of islets transplanted ranged from 110,000 to 412,000. Islet function was assessed by measuring the plasma insulin responses to intravenous glucose and arginine and the plasma glucagon responses to hypoglycemia and arginine. In one patient, islet function was studied during catheterization of the hepatic vein, portal vein, and splenic artery and by analysis of a liver-biopsy specimen. Results. After transplantation, the mean (+/-SD)fasting plasma glucose concentration was 122+/-47 mg per deciliter (6.8+/-2.6 mmol per liter) and the hemoglobin A1c concentration was 6.0+/-0.8 percent in the five patients. The values were most abnormal - 214 mg per deciliter (11.9 mmol per liter) and 7.3 percent, respectively - in the patient who received only 110,000 islets. The acute plasma insulin responses to glucose and to arginine in the five patients were 23+/-13 and 26+/-10-mu-U per milliliter (168+/-94 and 184+/-70 pmol per liter), respectively, as compared with 58+/-6 and 37+/-8-mu-U per milliliter (416+/-44 and 267+/-61 pmol per liter) in the normal subjects. The peak plasma glucagon responses to insulin and arginine were 21+/-4 and 65+/-36 pg per millilter, respectively, as compared with 125+/-28 and 156+/-99 pg per milliliter in the normal subjects. All five patients had plasma epinephrine but not pancreatic polypeptide responses to hypoglycemia. The results of the hepatic-vein catheterization in one patient indicated that the transplanted islets released insulin and glucagon in response to arginine. Immunoperoxidase staining of this patient's liver-biopsy specimen showed that the islets contained insulin, glucagon, and somatostatin but not pancreatic polypeptide. Conclusions. Intrahepatic transplantation of as few as 265,000 islets can result in the release of insulin and glucagon at appropriate times and in prolonged periods of insulin independence.	UNIV MINNESOTA, CTR DIABET, BOX 101 UMHC, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT MED, DIV ENDOCRINOL & METAB, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT SURG, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT LAB MED & PATHOL, MINNEAPOLIS, MN 55455 USA; UNIV MICHIGAN, DEPT MED, ANN ARBOR, MI 48109 USA; VET AFFAIRS MED CTR, ANN ARBOR, MI USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Roberston, R Paul/AAX-5613-2021		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000400] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039994, T32DK007203] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR 00400] Funding Source: Medline; NIDDK NIH HHS [R01 DK 39994, 5T32 DK 07203] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAMERON JL, 1980, SURGERY, V87, P397; CHESNEY TMC, 1969, DIABETES, V18, P627, DOI 10.2337/diab.18.9.627; DIEM P, 1990, J CLIN INVEST, V86, P2008, DOI 10.1172/JCI114936; DIEM P, 1990, DIABETES, V39, P534, DOI 10.2337/diabetes.39.5.534; DUNNING BE, 1990, AM J PHYSIOL, V258, pE436, DOI 10.1152/ajpendo.1990.258.3.E436; FARNEY AC, 1991, SURGERY, V110, P427; GERSELL DJ, 1979, DIABETES, V28, P11, DOI 10.2337/diabetes.28.1.11; GILLISON SL, 1989, DIABETES, V38, P465, DOI 10.2337/diabetes.38.4.465; GLASER B, 1983, METABOLISM, V32, P57, DOI 10.1016/0026-0495(83)90156-7; GUNNARSSON R, 1983, LANCET, V2, P571; HARRIS M, 1979, DIABETES, V28, P1039; HAVEL PJ, 1989, ENDOCR REV, V10, P332, DOI 10.1210/edrv-10-3-332; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVERSEN J, 1971, J CLIN INVEST, V50, P2123, DOI 10.1172/JCI106706; LARGIADER F, 1980, TRANSPLANTATION, V29, P76, DOI 10.1097/00007890-198001000-00017; LYGREN I, 1983, SCAND J GASTROENTERO, V18, P155, DOI 10.3109/00365528309181576; MARLISS EB, 1973, EUR J CLIN INVEST, V3, P16; MIRALLES P, 1990, DIABETES, V39, P996, DOI 10.2337/diabetes.39.8.996; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NAJARIAN JS, 1980, ANN SURG, V192, P526, DOI 10.1097/00000658-198010000-00011; NIELSEN JH, 1986, DIABETES, V35, P1049, DOI 10.2337/diabetes.35.9.1049; PALMER JP, 1979, METABOLISM, V28, P549, DOI 10.1016/0026-0495(79)90196-3; PALMER JP, 1976, J CLIN INVEST, V57, P522, DOI 10.1172/JCI108305; RIZZA RA, 1979, J CLIN INVEST, V64, P62, DOI 10.1172/JCI109464; RIZZA RA, 1982, J CLIN ENDOCR METAB, V54, P131, DOI 10.1210/jcem-54-1-131; ROBERTSON RP, 1986, DIABETES, V35, P1016, DOI 10.2337/diabetes.35.9.1016; RUSSELL AE, 1989, J AUTONOM NERV SYST, V26, P85, DOI 10.1016/0165-1838(89)90111-2; SCHARP DW, 1990, DIABETES, V39, P515, DOI 10.2337/diabetes.39.4.515; SCHARP DW, 1991, TRANSPLANTATION, V51, P76, DOI 10.1097/00007890-199101000-00012; SUTHERLAND DER, 1981, DIABETOLOGIA, V20, P435; TRIMBLE ER, 1980, DIABETES, V29, P341, DOI 10.2337/diabetes.29.5.341; TZAKIS AG, 1990, LANCET, V336, P402, DOI 10.1016/0140-6736(90)91946-8; WALTER RM, 1974, J CLIN INVEST, V54, P1214, DOI 10.1172/JCI107864; WARNOCK GL, 1992, DIABETOLOGIA, V35, P89, DOI 10.1007/BF00400857; WEIR GC, 1990, DIABETES, V39, P401, DOI 10.2337/diabetes.39.4.401	35	133	139	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					220	226		10.1056/NEJM199207233270402	http://dx.doi.org/10.1056/NEJM199207233270402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614463	Bronze			2022-12-28	WOS:A1992JE38100002
J	GERTZ, EW				GERTZ, EW			HIGH-OSMOLALITY AND LOW-OSMOLALITY CONTRAST AGENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							CORONARY ARTERIOGRAPHY; IOXAGLATE				GERTZ, EW (corresponding author), UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94921 USA.							BARRETT BJ, 1992, NEW ENGL J MED, V326, P431, DOI 10.1056/NEJM199202133260702; BETTMANN MA, 1985, INVEST RADIOL, V20, pS70, DOI 10.1097/00004424-198501002-00017; CORCOS T, 1984, J CAN ASSOC RADIOL, V35, P354; FOLKE K, 1985, BRIT J RADIOL, V58, P319, DOI 10.1259/0007-1285-58-688-319; GERTZ EW, 1992, J AM COLL CARDIOL, V19, P899, DOI 10.1016/0735-1097(92)90268-R; Higgins C B, 1983, Acta Radiol Suppl, V366, P111; HIRSHFELD JW, 1992, NEW ENGL J MED, V326, P482, DOI 10.1056/NEJM199202133260709; Levorstad K, 1983, Acta Radiol Suppl, V366, P101; NOTO TJ, 1991, CATHETER CARDIO DIAG, V24, P75, DOI 10.1002/ccd.1810240202; PALMER F J, 1988, Australasian Radiology, V32, P426, DOI 10.1111/j.1440-1673.1988.tb02770.x; SCHOLTZ ME, 1988, S AFR MED J, V73, P168; STEINBERG EP, 1992, NEW ENGL J MED, V326, P425, DOI 10.1056/NEJM199202133260701	12	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					203	203						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608419				2022-12-28	WOS:A1992JD31900022
J	BARNESS, LA				BARNESS, LA			PEDIATRICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BARNESS, LA (corresponding author), UNIV WISCONSIN, MADISON, WI 53706 USA.							BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BEUTLER E, 1991, NEW ENGL J MED, V325, P1809; BOS AP, 1991, LANCET, V338, P1279, DOI 10.1016/0140-6736(91)92151-Q; CORBET A, 1991, J PEDIATR-US, V118, P277, DOI 10.1016/S0022-3476(05)80502-5; DUNN MS, 1991, PEDIATRICS, V87, P377; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; GIBSON A, 1991, LANCET, V338, P1595, DOI 10.1016/0140-6736(91)92417-Z; GILBERTBARNESS EF, 1991, ARCH PATHOL LAB MED, V115, P226; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; KENDIG JW, 1991, NEW ENGL J MED, V324, P865, DOI 10.1056/NEJM199103283241301; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SHAPIRO LR, 1991, NEW ENGL J MED, V325, P1736, DOI 10.1056/NEJM199112123252409; SUTHERLAND GR, 1991, NEW ENGL J MED, V325, P1720, DOI 10.1056/NEJM199112123252407; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H	14	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					399	401						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613934				2022-12-28	WOS:A1992JC35200047
J	WILKINS, RH				WILKINS, RH			NEUROLOGICAL SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WILKINS, RH (corresponding author), DUKE UNIV,MED CTR,DURHAM,NC 27710, USA.							BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CARSON BS, 1990, JAMA-J AM MED ASSOC, V263, P2658; EYSTER EF, 1992, CLIN NEUR, V38, P252; GUGLIELMI G, 1991, J NEUROSURG, V75, P8, DOI 10.3171/jns.1991.75.1.0008; GUTHRIE BL, 1992, CLIN NEUR, V38, P112; HAID RW, 1992, CLIN NEUR, V38, P213; HIGASHIDA RT, 1990, AM J NEURORADIOL, V11, P633; KATO A, 1991, J NEUROSURG, V74, P845, DOI 10.3171/jns.1991.74.5.0845; KELLY PJ, 1991, NEUROSURGERY UPDATE, V2, P379; LUNSFORD LD, 1992, CLIN NEUR, V38, P405; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; SAUNDERS RL, 1991, CLIN NEUR, V37, P682; SISTI MB, 1991, J NEUROSURG, V75, P40, DOI 10.3171/jns.1991.75.1.0040; 1991, STROKE, V22, P1229; 1991, NEW ENGL J MED, V325, P445	15	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					379	380						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613926				2022-12-28	WOS:A1992JC35200038
J	THOM, DH; GRAYSTON, JT; SISCOVICK, DS; WANG, SP; WEISS, NS; DALING, JR				THOM, DH; GRAYSTON, JT; SISCOVICK, DS; WANG, SP; WEISS, NS; DALING, JR			ASSOCIATION OF PRIOR INFECTION WITH CHLAMYDIA-PNEUMONIAE AND ANGIOGRAPHICALLY DEMONSTRATED CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; ATHEROSCLEROSIS; PATHOGENESIS; TWAR; HERPESVIRUS; FINLAND; CELLS	Objective.-To evaluate the association between prior infection with Chlamydia Pneumoniae, as measured by IgG antibody, and coronary artery disease. Design.-A population-based, case-control study. Setting.-Group Health Cooperative of Puget Sound, a Seattle-based health maintenance organization. Participants.-Men 55 years of age and younger and women 65 years of age and younger. Cases (n=171) were members of Group Health Cooperative undergoing diagnostic coronary angiography who had at least one coronary artery lesion occupying 50% or more of the luminal diameter. The population controls (n=120) were Group Health Cooperative members without known coronary heart disease. Main Outcome Measure.-The adjusted odds ratio (OR) for coronary artery disease associated with prior C pneumoniae infection as measured by the presence of IgG antibody. Results.-After adjusting for age, gender, and calendar quarter of blood drawing, the OR for coronary artery disease associated with the presence of antibody was 2.6 (95% confidence interval, 1.4 to 4.8). The association was limited to cigarette smokers, in whom the OR was 3.5 (95% confidence interval, 1.7 to 7.0). Among never-smokers, the OR was 0.8 (95% confidence interval, 0.3 to 1.9). When cases and controls were restricted to those assayed concurrently, the adjusted OR (smokers and nonsmokers combined) was 4.2 (95% confidence interval, 1.8 to 10.0). Adjustment for serum cholesterol, hypertension, alcohol use, diabetes, and socioeconomic status did not change these results. Only a weak association was found when cases were compared with 63 subjects whose angiographic results were normal (OR, 1.2; 95% confidence interval, 0.6 to 2.2). Conclusions.-These results generally support the previously reported association between C pneumoniae infection and coronary heart disease. However, caution should be used in interpreting the basis for this association.	UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	THOM, DH (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DIV FAMILY & COMMUNITY MED,703 WELCH RD,SUITE G-1,STANFORD,CA 94305, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021885] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-F32-HL-08194-01] Funding Source: Medline; NIAID NIH HHS [AI-21885] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAILLIE EE, 1979, CLIN CHEM, V25, P817; BOOZE CF, 1987, AVIAT SPACE ENVIR MD, V58, P297; Breslow N, 1980, STATISTICAL METHODS, V32; CHIRGWIN K, 1991, J INFECT DIS, V163, P757, DOI 10.1093/infdis/163.4.757; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FABRICANT CG, 1981, AM J PATHOL, V105, P176; GRAYSTON JT, 1985, REV INFECT DIS, V7, P717; GRAYSTON JT, 1990, J INFECT DIS, V161, P618, DOI 10.1093/infdis/161.4.618; HAJJAR DP, 1987, J CLIN INVEST, V80, P1317, DOI 10.1172/JCI113208; KLEEMOLA M, 1988, J INFECT DIS, V157, P230, DOI 10.1093/infdis/157.2.230; KRON J, 1983, ARCH INTERN MED, V143, P1466; LOPESVIRELLA MF, 1985, CLIN IMMUNOL IMMUNOP, V37, P377, DOI 10.1016/0090-1229(85)90107-2; MATTILA KJ, 1989, J INTERN MED, V225, P293, DOI 10.1111/j.1365-2796.1989.tb00084.x; MIKLOZEK CL, 1988, AM HEART J, V115, P768, DOI 10.1016/0002-8703(88)90877-0; Osler W, 1908, MODERN MED ITS PRACT, P429; Patnode D, 1990, CHLAMYDIAL INFECTION, P406; PATTON DL, 1987, J INFECT DIS, V155, P1292, DOI 10.1093/infdis/155.6.1292; PUOLAKKAINEN M, 1989, EPIDEMIOL INFECT, V102, P287, DOI 10.1017/S0950268800029964; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMMALKORPI K, 1988, METABOLISM, V37, P859, DOI 10.1016/0026-0495(88)90120-5; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; VISSER MR, 1988, P NATL ACAD SCI USA, V85, P8227, DOI 10.1073/pnas.85.21.8227; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WANG SP, 1984, 1983 INT S MED VIR, P87; Warnick G R, 1986, Methods Enzymol, V129, P101; YAMAZAKI T, 1990, J INFECT DIS, V162, P1390, DOI 10.1093/infdis/162.6.1390	29	369	388	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					68	72		10.1001/jama.268.1.68	http://dx.doi.org/10.1001/jama.268.1.68			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608116				2022-12-28	WOS:A1992JA16500025
J	LOWNDES, NF; JOHNSON, AL; BREEDEN, L; JOHNSTON, LH				LOWNDES, NF; JOHNSON, AL; BREEDEN, L; JOHNSTON, LH			SWI6 PROTEIN IS REQUIRED FOR TRANSCRIPTION OF THE PERIODICALLY EXPRESSED DNA-SYNTHESIS GENES IN BUDDING YEAST	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; REGULATORS	IN budding yeast many genes are expressed under cell-cycle control in late G1. These include a large group of DNA synthesis genes 1, the HO gene 2 involved in mating-type switching, CTS1 (chitinase) 3 and also CLN1 and CLN2 (ref. 4) encoding G1 cyclins. Two factors, encoded by the SWI4 and SWI6 genes, are required for HO (ref. 5), CLN (refs 6, 7) and CTS1 (ref. 3) gene expression and, at least in the HO promoter, bind to CACGA4 upstream sequences 5,7-9 (CCBs). This motif is not found upstream of the DNA synthesis genes, which instead have a hexamer element, ACGCGT 1 (MCB), an MluI restriction site, that is recognized by a cell-cycle regulated transcription complex DSC1 (ref. 1). This MluI-activation system consisting of the MCBs and DSC1 is conserved in fission yeast where a DSC1-like complex controls the cdc22+ ribonucleotide reductase gene 10. The Schizosaccharomyces pombe cdc10+ gene encodes a component of DSC1 (ref. 10) and, significantly, this has homology with both the Swi4 and Swi6 proteins 8,11. Here we show that Swi6 is an essential component of DSC1 and that deletion of SWI6 impairs the cell-cycle regulation of the DNA synthesis genes, as well as CLN1 and CLN2. Thus Swi6 is the common factor in regulation of all the above genes and may therefore be responsible for the timing of their expression in late G1.	NATL INST MED RES,YEAST GENET LAB,RIDGEWAY,MILL HILL,LONDON NW7 1AA,ENGLAND; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	MRC National Institute for Medical Research; Fred Hutchinson Cancer Center			Lowndes, Noel F/B-9084-2008	Lowndes, Noel F/0000-0002-3216-4427; Breeden, Linda/0000-0001-7337-5434				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BARKER DG, 1985, NUCLEIC ACIDS RES, V13, P8323, DOI 10.1093/nar/13.23.8323; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; DOHRMANN PR, IN PRESS GENES DEV; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; JOHNSTON LH, IN PRESS COLD SPRING; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1992, TRENDS GENET, V8, P79, DOI 10.1016/0168-9525(92)90183-5; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; NASMYTH K, 1987, CELL, V49, P549, DOI 10.1016/0092-8674(87)90457-0; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; SIMANIS V, 1989, J CELL SCI, V92, P51; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	23	148	148	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					505	508		10.1038/357505a0	http://dx.doi.org/10.1038/357505a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608450				2022-12-28	WOS:A1992HY05200066
J	HAWTON, K; FAGG, J				HAWTON, K; FAGG, J			TRENDS IN DELIBERATE SELF POISONING AND SELF INJURY IN OXFORD, 1976-90	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; PARASUICIDE; EDINBURGH	Objective - To review trends in deliberate self poisoning and self injury (attempted suicide) over 15 years (1976-90) on the basis of general hospital referrals. Design - Prospective data collection by computerised monitoring system. Setting - Teaching general hospital. Subjects - All patients aged 15 and over (n = 9605) referred to the hospital after episodes (n = 13 340) of deliberate self poisoning or self injury. Main outcome measures - Rates based on population of Oxford city; changes in substances used for self poisoning; history and repetition of attempts; and rates of admission to the hospital and of referral to the psychiatric service. Results - Attempted suicide rates for women declined during the late 1970s and early 1980s but increased again during the late 1980s. Those for men remained relatively steady throughout the period. Highest mean annual rates occurred in women aged 15-19 (711/100 000) and in 20-34 year old men (334/100 000). The proportion of overdoses with paracetamol increased from 14.3% (125/873) in 1976 to 42% (365/869) in 1990 (chi-2 for trend = 481, p < 0.01). Throughout the period the proportions of referred patients admitted to hospital and of those attempting suicide for the first time (over two thirds) did not decrease. Annual rates of repetition of attempts by women declined from 15.1% (257/1700) in 1976-8 to 11.9% (161/1356) in 1987-9 (chi-2 for trend = 7.8, p < 0.01). Lower repetition rates occurred in women admitted to hospital and referred to the psychiatric service (431/4585, 9.4%) than in those not referred (42/235, 17.9%; chi-2 = 17.2, p < 0.0001). Conclusions - Rates of attempted suicide declined in the 1970s and early 1980s, in women, but there are probably at least 100 000 hospital referrals a year in England and Wales because of this problem. Prevention of paracetamol self poisoning requires urgent attention, and psychosocial assessment should be conducted with as many of those who attempt suicide as possible.			HAWTON, K (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.							ALDERSON MR, 1974, LANCET, V1, P1040; [Anonymous], 1984, MANAGEMENT DELIBERAT; BANCROFT JHJ, 1975, BRIT J PREV SOC MED, V29, P170; BLACK D, 1988, J ROY SOC MED, V81, P97, DOI 10.1177/014107688808100216; BLAKE DR, 1978, BRIT MED J, V1, P1032, DOI 10.1136/bmj.1.6119.1032; BREWER C, 1985, BRIT MED J, V290, P391, DOI 10.1136/bmj.290.6465.391; FORSTER DP, 1985, ACTA PSYCHIAT SCAND, V71, P657; HAWTON K, 1979, BRIT MED J, V2, P1040, DOI 10.1136/bmj.2.6197.1040; HAWTON K, 1987, ATTEMPTED SUICIDE; HAWTON K, 1989, CURRENT RES SUICIDE, P180; KREITMAN N, 1979, PSYCHOL MED, V9, P469, DOI 10.1017/S0033291700032013; OWENS DW, 1988, BRIT J PSYCHIAT, V152, P830, DOI 10.1192/bjp.152.6.830; PLATT S, 1988, PSYCHOL MED, V18, P405, DOI 10.1017/S0033291700007959; SKRIMSHIRE AM, 1976, J BIOSOC SCI, V8, P85, DOI 10.1017/S0021932000010531	14	130	131	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1409	1411		10.1136/bmj.304.6839.1409	http://dx.doi.org/10.1136/bmj.304.6839.1409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628014	Bronze, Green Published			2022-12-28	WOS:A1992HX08200017
J	WONG, J; BLACK, P				WONG, J; BLACK, P			ACUTE ADRENAL INSUFFICIENCY ASSOCIATED WITH HIGH-DOSE INHALED STEROIDS	BRITISH MEDICAL JOURNAL			English	Letter											WONG, J (corresponding author), AUCKLAND HOSP,AUCKLAND 3,NEW ZEALAND.							GORDON ACH, 1987, EUR J RESPIR DIS, V71, P10	1	52	53	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1415	1415		10.1136/bmj.304.6839.1415-a	http://dx.doi.org/10.1136/bmj.304.6839.1415-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628017	Green Published, Bronze			2022-12-28	WOS:A1992HX08200021
J	PETTIT, S; IRVING, MH				PETTIT, S; IRVING, MH			ABC OF COLORECTAL DISEASES - NONSPECIFIC INFLAMMATORY BOWEL-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,GEN SURG,SALFORD M6 8HD,LANCS,ENGLAND		PETTIT, S (corresponding author), VICTORIA HOSP,BLACKPOOL,ENGLAND.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1367	1371		10.1136/bmj.304.6838.1367	http://dx.doi.org/10.1136/bmj.304.6838.1367			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611339	Bronze, Green Published			2022-12-28	WOS:A1992HW41700032
J	PELED, N; DAGAN, O; BABYN, P; SILVER, MM; BARKER, G; HELLMANN, J; SCOLNIK, D; KOREN, G				PELED, N; DAGAN, O; BABYN, P; SILVER, MM; BARKER, G; HELLMANN, J; SCOLNIK, D; KOREN, G			GASTRIC-OUTLET OBSTRUCTION INDUCED BY PROSTAGLANDIN THERAPY IN NEONATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL HEART-DISEASE; RAT GASTROINTESTINAL MUCOSA; INFANTS; MISOPROSTOL; ULCERS	Background. An infusion of prostaglandin E1 is widely used to maintain patency of the ductus arteriosus in neonates with congenital heart disease. After gastric-outlet obstruction was recognized in several infants who received prostaglandin E1, we studied the association between the drug and this complication. Methods. We evaluated all neonates who received prostaglandin E1 in our hospital between October 1, 1989, and September 30, 1991, for clinical, radiologic, or pathological evidence of acute gastric-outlet obstruction. Results. Of the 74 neonates evaluated, 65 had no signs of gastric obstruction and were considered normal; 5 had clinical and radiologic or pathological evidence of gastric obstruction consistent with the presence of antral mucosal hyperplasia. The remaining four neonates had clinical signs of gastric obstruction, but no radiologic or pathological examinations were performed. The 5 neonates with antral hyperplasia had received prostaglandin E1 for longer periods (mean [+/-SD] duration, 569+/-341 hours) than the 65 normal neonates (54+/-58 hours, P<0.001) or the 4 neonates with clinical signs of gastric obstruction (119+/-60 hours, P<0.05). The cumulative dose of prostaglandin E1 was higher in the neonates with antral hyperplasia (2982+/-1392-mu-g per kilogram of body weight) than in the normal neonates (279+/-270-mu-g per kilogram, P<0.001) or the neonates with signs of gastric obstruction (528+/-306-mu-g per kilogram, P<0.01). In two neonates with antral hyperplasia, the cessation of therapy lessened the gastric-outlet obstruction. Conclusions. The administration of prostaglandin E1 to neonates can cause gastric-outlet obstruction due to antral hyperplasia. Neonates who receive prostaglandin E1 at recommended doses for more than 120 hours should be closely monitored for evidence of antral hyperplasia.	HOSP SICK CHILDREN,RES INST,DIV CLIN PHARMACOL,555 UNIV AVE,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT RADIOL,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT CRIT CARE,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT PATHOL,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DIV CLIN PHARMACOL & TOXICOL,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DIV NEONATOL,TORONTO M5G 1X8,ONTARIO,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV TORONTO,DEPT RADIOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO M5S 1A1,ONTARIO,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto								CHOURAQUI JP, 1981, GASTROENTEROLOGY, V80, P1042; CULLINANE C, IN PRESS PEDIATR PAT; FELDMAN M, 1990, AM J MED SCI, V300, P116, DOI 10.1097/00000441-199008000-00008; GILGER M, 1990, SCI PRACTICE PEDIATR, P2358; GOODLAD RA, 1989, GUT, V30, P316, DOI 10.1136/gut.30.3.316; HELANDER HF, 1985, GASTROENTEROLOGY, V89, P1393, DOI 10.1016/0016-5085(85)90660-2; HEYMANN MA, 1981, AM HEART J, V101, P837, DOI 10.1016/0002-8703(81)90622-0; KATZ ME, 1985, PEDIATR RADIOL, V15, P136, DOI 10.1007/BF02388723; LANGE IR, 1984, AM J OBSTET GYNECOL, V148, P621, DOI 10.1016/0002-9378(84)90762-2; LEUNG MP, 1988, J PEDIATR, V133, P1044; LEWIS AB, 1981, CIRCULATION, V64, P893, DOI 10.1161/01.CIR.64.5.893; LOCK JE, 1979, LANCET, V1, P1343; MCALISTER WH, 1988, PEDIATR RADIOL, V18, P79, DOI 10.1007/BF02395770; MILLER MJS, 1989, J PEDIATR-US, V115, P335, DOI 10.1016/S0022-3476(89)80108-8; OKEEFFE FN, 1991, RADIOLOGY, V178, P827, DOI 10.1148/radiology.178.3.1994426; REINHART WH, 1983, GASTROENTEROLOGY, V85, P1003; Swischuk L E, 1989, Radiographics, V9, P437; THANOPOULOS BD, 1987, EUR J PEDIATR, V146, P279, DOI 10.1007/BF00716473; TYTGAT GNJ, 1986, GASTROENTEROLOGY, V90, P1111, DOI 10.1016/0016-5085(86)90375-6; WHITEHEAD R, 1990, MENETRIERS DISEASE M, P112; ZINNER MJ, 1989, ANN SURG, V210, P590, DOI 10.1097/00000658-198911000-00004	21	63	63	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					505	510		10.1056/NEJM199208203270801	http://dx.doi.org/10.1056/NEJM199208203270801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635565				2022-12-28	WOS:A1992JJ45700001
J	RUNYON, BA; MONTANO, AA; AKRIVIADIS, EA; ANTILLON, MR; IRVING, MA; MCHUTCHISON, JG				RUNYON, BA; MONTANO, AA; AKRIVIADIS, EA; ANTILLON, MR; IRVING, MA; MCHUTCHISON, JG			THE SERUM-ASCITES ALBUMIN GRADIENT IS SUPERIOR TO THE EXUDATE-TRANSUDATE CONCEPT IN THE DIFFERENTIAL-DIAGNOSIS OF ASCITES	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	SPONTANEOUS BACTERIAL PERITONITIS; CHRONIC LIVER-DISEASE; PROTEIN-CONCENTRATION; CIRRHOTIC ASCITES; OPSONIC ACTIVITY; MENSTRUAL-CYCLE; FLUID; DIURESIS; BACTERASCITES; SPECTRUM	Objective: To compare the serum-ascites albumin gradient to the exudate-transudate concept in the classification of ascites. Design: Prospective collection of ascitic fluid data from patients with well-characterized causes of ascites. Setting. Hepatology inpatient and outpatient ward and consult service of a large, urban hospital. Patients: A total of 901 paired serum and ascitic fluid samples were collected from consecutive patients with all forms of ascites. Interventions: None. Main Outcome Measures: The utility of the serum-ascites albumin gradient and the old exudate-transudate concept (as defined by ascitic fluid total protein concentration [AFTP]) were compared for their ability in discriminating the cause for ascites formation. Results: The albumin gradient correctly differentiated causes of ascites due to portal hypertension from those that were not due to portal hypertension 96.7% of the time. The AFTP, when used as defined in the old exudate-transudate concept, classified the causes of ascites correctly only 55.6% of the time. This resulted in part because the AFTP of most spontaneously infected samples (traditionally expected to be exudates) was low, and the AFTP of most cardiac ascites samples (traditionally expected to be transudates) was high. Conclusions: The exudate-transudate concept should be discarded in the classification of ascites. The serum-ascites albumin gradient is far more useful than the AFTP as a marker for portal hypertension, but the latter remains a useful adjunct in the differential diagnosis of ascites.	UNIV IOWA, IOWA CITY, IA 52242 USA; UNIV SO CALIF, LIVER UNIT, LOS ANGELES, CA 90089 USA	University of Iowa; University of Southern California								AKRIVIADIS EA, 1990, GASTROENTEROLOGY, V98, P127, DOI 10.1016/0016-5085(90)91300-U; BOUCKAERT PXJM, 1986, J REPROD FERTIL, V77, P329; BOYER TD, 1978, ARCH INTERN MED, V138, P1103, DOI 10.1001/archinte.138.7.1103; BURACK WR, 1960, AM J MED, V28, P510, DOI 10.1016/0002-9343(60)90145-5; CHESON BD, 1985, CLIN LAB MED, V5, P195, DOI 10.1016/S0272-2712(18)30865-5; DOUMAS BT, 1971, CLIN CHIM ACTA, V31, P87, DOI 10.1016/0009-8981(71)90365-2; HOEFS JC, 1985, DM-DIS MON, V31, P1, DOI 10.1016/0011-5029(85)90002-1; HOEFS JC, 1983, J LAB CLIN MED, V102, P260; HOEFS JC, 1981, HEPATOLOGY, V1, P249, DOI 10.1002/hep.1840010310; KAJANI MA, 1990, DIGEST DIS SCI, V35, P33, DOI 10.1007/BF01537219; MAATHUIS JB, 1978, J ENDOCRINOL, V76, P123, DOI 10.1677/joe.0.0760123; MAUER K, 1988, DIGEST DIS SCI, V33, P1208, DOI 10.1007/BF01536667; MAUK PM, 1988, ARCH INTERN MED, V148, P1577, DOI 10.1001/archinte.148.7.1577; PARE P, 1983, GASTROENTEROLOGY, V85, P240; POCKROS PJ, 1988, HEPATOLOGY, V8, P1450; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RECTOR WG, 1984, AM J MED, V77, P83, DOI 10.1016/0002-9343(84)90440-6; ROCCO VK, 1986, ANN INTERN MED, V105, P573, DOI 10.7326/0003-4819-105-4-573; ROVELSTAD RA, 1958, GASTROENTEROLOGY, V34, P436; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; RUNYON BA, 1988, J CLIN GASTROENTEROL, V10, P410, DOI 10.1097/00004836-198808000-00013; RUNYON BA, 1986, ARCH INTERN MED, V146, P2173, DOI 10.1001/archinte.146.11.2173; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; RUNYON BA, 1985, HEPATOLOGY, V5, P257, DOI 10.1002/hep.1840050217; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; RUNYON BA, 1984, HEPATOLOGY, V4, P1209, DOI 10.1002/hep.1840040619; RUNYON BA, 1986, HEPATOLOGY, V6, P396, DOI 10.1002/hep.1840060311; RUNYON BA, 1989, GASTROENTEROLOGY, V97, P158, DOI 10.1016/0016-5085(89)91430-3; RUNYON BA, 1987, J CLIN GASTROENTEROL, V9, P172, DOI 10.1097/00004836-198704000-00012; RUNYON BA, 1990, HEPATOLOGY, V12, P710, DOI 10.1002/hep.1840120415; RUNYON BA, 1991, TXB GASTROENTEROLOGY, P846; SAMPLINER RE, 1974, AM J MED SCI, V267, P275, DOI 10.1097/00000441-197405000-00003; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; SPAK I, 1960, ACTA CHIR SCAND    S, V261, P7; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403	35	382	403	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					215	220		10.7326/0003-4819-117-3-215	http://dx.doi.org/10.7326/0003-4819-117-3-215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616215				2022-12-28	WOS:A1992JF30400007
J	HALL, SS				HALL, SS			HOW TECHNIQUE IS CHANGING SCIENCE	SCIENCE			English	Editorial Material																			0	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					344	349		10.1126/science.1631556	http://dx.doi.org/10.1126/science.1631556			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631556				2022-12-28	WOS:A1992JD67400020
J	BROWNER, WS; LI, J; MANGANO, DT				BROWNER, WS; LI, J; MANGANO, DT			IN-HOSPITAL AND LONG-TERM MORTALITY IN MALE VETERANS FOLLOWING NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY SURGERY; PERIPHERAL VASCULAR-SURGERY; BYPASS-SURGERY; CARDIAC RISK; ANESTHESIA; EPIDEMIOLOGY; DISEASE; INDEX; CASS	Objectives.-To determine the causes of and risk factors for mortality following noncardiac surgery. Design.-Prospective cohort study. Setting.-A university-affiliated Veterans Affairs medical center. Patients.-Consecutive series of 474 men between the ages of 38 and 89 years (mean age, 68 years) who were undergoing major noncardiac surgery involving general anesthesia. All subjects had known coronary artery disease or were at high risk for coronary artery disease. Measurements and Results.-During the initial hospitalization, 26 patients (5%) died, most commonly from sepsis (n=6) or cardiac diseases (n=6). Deaths occurred from postoperative days 2 to 69; half occurred more than 3 weeks after surgery. Multivariable analysis disclosed that a history of hypertension (odds ratio [OR]=3.8; 95% confidence interval [CI], 1.1 to 13), a severely limited activity level (OR=9.7; 95% CI, 2.5 to 37), and a creatinine clearance of less than 0.83 mL/s (OR=6.8; 95% CI, 2.8 to 16) were all independently associated with an increased risk of postoperative mortality. The mortality rate in patients with two or more of these risk factors was 20%, nearly eight times higher (95% CI, 3.6 to 16) than those with one or no risk factors. An additional 82 patients died within the next 2 years; cancer, renal dysfunction, congestive heart failure, and obstructive pulmonary disease were independently associated with long-term mortality. Conclusions.-Even in patients at high risk of cardiac complications following surgery, noncardiac causes of death are more common. Patients with a history of hypertension, severely limited activity, and reduced renal function appear to be at especially high risk of in-hospital mortality after noncardiac surgery.	UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR 111A1,DEPT ANESTHESIA,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,DEPT SURG,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	BROWNER, WS (corresponding author), UNIV CALIF SAN FRANCISCO,VET AFFAIRS MED CTR 111A1,DEPT MED,SAN FRANCISCO,CA 94121, USA.				NHLBI NIH HHS [R01-HL 36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DEUTSCH E, 1989, ANN INTERN MED, V110, P369, DOI 10.7326/0003-4819-110-5-369; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FARROW SC, 1982, BRIT J ANAESTH, V54, P811, DOI 10.1093/bja/54.8.811; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; FOWKES FGR, 1982, BRIT J ANAESTH, V54, P819, DOI 10.1093/bja/54.8.819; GERSH BJ, 1983, CIRCULATION, V67, P483, DOI 10.1161/01.CIR.67.3.483; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; KAUKINEN L, 1982, ANN CHIR GYNAECOL FE, V71, P283; KENNEDY JW, 1980, J THORAC CARDIOV SUR, V80, P876; KOUCHOUKOS NT, 1980, CIRCULATION, V62, P84; LAWRENCE VA, 1989, ARCH INTERN MED, V149, P280, DOI 10.1001/archinte.149.2.280; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MARX GF, 1973, ANESTHESIOLOGY, V39, P54, DOI 10.1097/00000542-197307000-00010; POTGIETER PD, 1981, S AFR MED J, V59, P412; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; SANDLER RS, 1987, J GEN INTERN MED, V2, P149, DOI 10.1007/BF02596141; SHAH DM, 1980, SURG CLIN N AM, V60, P1359; STEEN PA, 1978, JAMA-J AM MED ASSOC, V239, P2566, DOI 10.1001/jama.239.24.2566; VACANTI CJ, 1970, ANESTH ANALG, V49, P654; VONKNORRING J, 1981, SURGERY, V90, P55; WAKEFIELD TW, 1982, SURGERY, V91, P586; WHITE GH, 1988, AM J SURG, V156, P103, DOI 10.1016/S0002-9610(88)80365-9; WILSON RF, 1979, ARCH SURG-CHICAGO, V114, P461; 1984, LANCET, V2, P1079; 1989, PHS891232 NAT CTR HU; 1978, MANUAL OPERATIONS, V2	31	153	157	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					228	232		10.1001/jama.268.2.228	http://dx.doi.org/10.1001/jama.268.2.228			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608142				2022-12-28	WOS:A1992JB27900030
J	IP, NY; NYE, SH; BOULTON, TG; DAVIS, S; TAGA, T; LI, YP; BIRREN, SJ; YASUKAWA, K; KISHIMOTO, T; ANDERSON, DJ; STAHL, N; YANCOPOULOS, GD				IP, NY; NYE, SH; BOULTON, TG; DAVIS, S; TAGA, T; LI, YP; BIRREN, SJ; YASUKAWA, K; KISHIMOTO, T; ANDERSON, DJ; STAHL, N; YANCOPOULOS, GD			CNTF AND LIF ACT ON NEURONAL CELLS VIA SHARED SIGNALING PATHWAYS THAT INVOLVE THE IL-6 SIGNAL TRANSDUCING RECEPTOR COMPONENT GP130	CELL			English	Article							CILIARY NEUROTROPHIC FACTOR; DIFFERENTIATION FACTOR; SYMPATHETIC NEURONS; SPINAL-CORD; EXPRESSION; CLONING; PROTEINS; CULTURE	Ciliary neurotrophic factor (CNTF) has a variety of actions within the nervous system. While some of the actions of leukemia inhibitory factor (LIF) on neurons resemble those of CNTF, LIF also has broad actions outside of the nervous system that in many cases mimic those of interleukin-6 (IL-6). Comparison of the tyrosine phosphorylations and gene activations induced by CNTF and LIF in neuron cell lines reveals that they are indistinguishable and also very similar to signaling events that characterize LIF and IL-6 responses in hematopoietic cells. We provide a basis for the overlapping actions of these three factors by demonstrating that the shared CNTF and LIF signaling pathways involve the IL-6 signal transducing receptor component gp130. Thus, the receptor system for CNTF is surprisingly unlike those used by the nerve growth factor family of neurotrophic factors, but is instead related to those used by a subclass of hematopoietic cytokines.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; CALTECH, HOWARD HUGHES MED INST, PASADENA, CA 91125 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA; TOSOH CORP, BIOTECHNOL RES LAB, KANAGAWA, JAPAN	Osaka University; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; Tosoh Corporation	IP, NY (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Kishimoto, Tadamitsu/C-8470-2009	Ip, Nancy Yuk-Yu/0000-0002-2763-8907				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BLOTTNER D, 1989, NEUROSCI LETT, V105, P316, DOI 10.1016/0304-3940(89)90640-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DARLING TL, 1983, METHODS CELL CULTURE; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GEARING DP, 1991, CELL, V66, P9, DOI 10.1016/0092-8674(91)90131-H; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GODARD A, 1992, J BIOL CHEM, V267, P3214; HALL AK, 1992, TRENDS NEUROSCI, V15, P35, DOI 10.1016/0166-2236(92)90022-Z; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IP NY, 1991, J NEUROSCI, V11, P3124; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MANTHORPE M, 1986, DEV BRAIN RES, V25, P191, DOI 10.1016/0165-3806(86)90208-7; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MIYAJIMA A, 1992, IN PRESS ANN REV IMM; MUGGLETONHARRIS AL, 1989, GROWTH CONTROL CELL; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NYE SH, 1992, IN PRESS MOL BIOL CE; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; RAO MS, 1990, DEV BIOL, V139, P65, DOI 10.1016/0012-1606(90)90279-R; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKAPER SD, 1986, DEV BRAIN RES, V24, P39, DOI 10.1016/0165-3806(86)90171-9; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VANDENBERGH DJ, 1991, DEV BIOL, V148, P10, DOI 10.1016/0012-1606(91)90313-R; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	47	683	700	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1121	1132		10.1016/0092-8674(92)90634-O	http://dx.doi.org/10.1016/0092-8674(92)90634-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617725				2022-12-28	WOS:A1992JA43100007
J	LI, E; BESTOR, TH; JAENISCH, R				LI, E; BESTOR, TH; JAENISCH, R			TARGETED MUTATION OF THE DNA METHYLTRANSFERASE GENE RESULTS IN EMBRYONIC LETHALITY	CELL			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; DENOVO METHYLATION; RETROVIRAL GENOMES; STEM-CELLS; HOMOLOGOUS RECOMBINATION; DETERMINES METHYLATION; SEQUENCE SPECIFICITY; TRANSGENIC MICE; EXPRESSION; MOUSE	Gene targeting in embryonic stem (ES) cells has been used to mutate the murine DNA methyltransferase gene. ES cell lines homozygous for the mutation were generated by consecutive targeting of both wild-type alleles; the mutant cells were viable and showed no obvious abnormalities with respect to growth rate or morphology, and had only trace levels of DNA methyltransferase activity. A quantitative end-labeling assay showed that the level of m5C in the DNA of homozygous mutant cells was about one-third that of wild-type cells, and Southern blot analysis after cleavage of the DNA with a methylation-sensitive restriction endonuclease revealed substantial demethylation of endogenous retroviral DNA. The mutation was introduced into the germline of mice and found to cause a recessive lethal phenotype. Homozygous embryos were stunted, delayed in development, and did not survive past midgestation. The DNA of homozygous embryos showed a reduction of the level of m5C similar to that of homozygous ES cells. These results indicate that while a 3-fold reduction in levels of genomic m5C has no detectable effect on the viability or proliferation of ES cells in culture, a similar reduction of DNA methylation in embryos causes abnormal development and embryonic lethality.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,HUMAN REPROD & REPROD BIOL LAB,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School	LI, E (corresponding author), WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043565] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 44339-05] Funding Source: Medline; NIGMS NIH HHS [GM43565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2; BESTOR TH, 1985, P NATL ACAD SCI USA, V82, P2674, DOI 10.1073/pnas.82.9.2674; BESTOR TH, 1990, PHILOS T ROY SOC B, V326, P179, DOI 10.1098/rstb.1990.0002; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHAILLET JR, 1991, CELL, V66, P77, DOI 10.1016/0092-8674(91)90140-T; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; GILLESPIE PG, 1991, P NATL ACAD SCI USA, V88, P2536; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HADCHOUEL M, 1987, NATURE, V329, P454, DOI 10.1038/329454a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWLETT SK, 1991, DEVELOPMENT, V113, P119; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JAENISCH R, 1985, P NATL ACAD SCI USA, V82, P1451, DOI 10.1073/pnas.82.5.1451; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; Jahner D., 1984, DNA METHYLATION BIOC, P189; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JONES PA, 1983, RECENT RES CANCER, V84, P202; Kaufman M. H, 1990, POSTIMPLANTATION MAM, P81; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; MANN JR, 1988, DEVELOPMENT, V103, P129; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MONK M, 1991, DEVELOPMENT, V112, P189; MONK M, 1987, DEVELOPMENT, V99, P371; PEDRALINOY G, 1986, J BIOL CHEM, V261, P7600; PFEIFER GP, 1986, BIOCHIM BIOPHYS ACTA, V868, P238, DOI 10.1016/0167-4781(86)90059-X; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SAPIENZA C, 1987, NATURE, V328, P251, DOI 10.1038/328251a0; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHWARZ MB, 1962, J BIOL CHEM, V237, P1961; SHEMER R, 1991, P NATL ACAD SCI USA, V88, P11300, DOI 10.1073/pnas.88.24.11300; SIMPSON VJ, 1986, NUCLEIC ACIDS RES, V14, P6711, DOI 10.1093/nar/14.16.6711; STEVENS LC, 1973, J NATL CANCER I, V50, P235, DOI 10.1093/jnci/50.1.235; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; STUHLMANN H, 1981, CELL, V26, P221, DOI 10.1016/0092-8674(81)90305-6; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URIELISHOVAL S, 1982, FEBS LETT, V146, P148, DOI 10.1016/0014-5793(82)80723-0; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIGLER M, 1981, CELL, V24, P33, DOI 10.1016/0092-8674(81)90498-0; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	58	3116	3353	8	212	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					915	926		10.1016/0092-8674(92)90611-F	http://dx.doi.org/10.1016/0092-8674(92)90611-F			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606615				2022-12-28	WOS:A1992HY79200004
J	PRINGLE, M				PRINGLE, M			MANAGING CHANGE IN PRIMARY CARE .1. MANAGING CHANGE IN GENERAL-PRACTICE - INTRODUCTION	BRITISH MEDICAL JOURNAL			English	Article																			0	1	1	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1357	1358		10.1136/bmj.304.6838.1357	http://dx.doi.org/10.1136/bmj.304.6838.1357			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611336	Green Published, Bronze			2022-12-28	WOS:A1992HW41700028
J	RADECKI, SE; GINSBURG, PB; LASKER, RD				RADECKI, SE; GINSBURG, PB; LASKER, RD			RBRVS - OBJECTIONS TO MALONEY .2.	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PHYSICIAN PAYMENT REVIEW COMMISS,2120 L ST NW,SUITE 510,WASHINGTON,DC 20037; LONG BEACH MEM MED CTR,LONG BEACH,CA									GIRARD RA, 1979, ANN INTERN MED, V90, P965, DOI 10.7326/0003-4819-90-6-965; GONZALEZ ML, 1991, SOCIOECONOMIC CHARAC; LLOYD JS, 1979, ARCH OTOLARYNGOL, V105, P610; MALONEY JV, 1991, JAMA-J AM MED ASSOC, V266, P3453; MENDENHALL R, 1981, MED PRACTICE US SPEC; MENDENHALL RC, 1981, NEUROSURGERY, V8, P267, DOI 10.1227/00006123-198102000-00022; OWENS A, 1989, MED ECON, V66, P131	7	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1992	267	13					1824	1825		10.1001/jama.267.13.1824	http://dx.doi.org/10.1001/jama.267.13.1824			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HK672	1622470				2022-12-28	WOS:A1992HK67200036
J	BARASH, P				BARASH, P			ANESTHESIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BARASH, P (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							ANAND KJS, 1992, NEW ENGL J MED, V326, P1092; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; COHEN CB, 1991, NEW ENGL J MED, V325, P1879, DOI 10.1056/NEJM199112263252611; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; HACKMANN T, 1991, ANESTHESIOLOGY, V75, P27, DOI 10.1097/00000542-199107000-00006; LUTNER RE, 1991, ANESTHESIOLOGY, V75, P394, DOI 10.1097/00000542-199109000-00003; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MARTIN RL, 1991, ANESTH ANALG, V73, P321; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; POHOST GM, 1991, CIRCULATION, V84, P931, DOI 10.1161/01.CIR.84.2.931; ROY WL, 1991, CAN J ANAESTH, V38, P700, DOI 10.1007/BF03008445; TROUG RD, 1991, ANESTHESIOLOGY, V74, P606; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; VELANOVICH V, 1991, SURGERY, V109, P236; WALKER RM, 1991, JAMA-J AM MED ASSOC, V266, P2407, DOI 10.1001/jama.266.17.2407; WELBORN LG, 1991, ANESTHESIOLOGY, V74, P1003, DOI 10.1097/00000542-199106000-00006; YOUNGNER SJ, 1991, JAMA-J AM MED ASSOC, V266, P2433, DOI 10.1001/jama.266.17.2433	18	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					335	337						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613910				2022-12-28	WOS:A1992JC35200020
J	EISENBERG, JM				EISENBERG, JM			ECONOMICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											EISENBERG, JM (corresponding author), GEORGETOWN UNIV,MED CTR,WASHINGTON,DC 20007, USA.							American College of Physicians, 1990, ANN INTERN MED, V112, P641; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; KASS NE, 1991, INQUIRY-J HEALTH CAR, V28, P249; KILPATRICK KE, 1991, HEALTH SERV RES, V26, P277; KRONICK R, 1991, INQUIRY-J HEALTH CAR, V28, P318; LEWINEPSTEIN N, 1991, MED CARE, V29, P543, DOI 10.1097/00005650-199106000-00013; MONHEIT AC, 1989, HLTH AFFAIRS     WIN, P23; NELSON C, 1990, CURRENT POPULATI P70, V17; RICE DP, 1991, WESTERN J MED, V154, P294; SHORT P, 1990, PHS903469 US DEP HLT; Short P F, 1990, J Health Care Poor Underserved, V1, P9; THORPE KE, 1992, JAMA-J AM MED ASSOC, V267, P945, DOI 10.1001/jama.267.7.945; YOUNG GJ, 1991, INQUIRY-J HEALTH CAR, V28, P255; 1990, CALL ACTION FINAL RE; 1991, PHYSICIAN MARKETPLAC, P1	15	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					344	345						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JC352	1613914				2022-12-28	WOS:A1992JC35200025
J	OBRIEN, TP; GOLDBERG, MF				OBRIEN, TP; GOLDBERG, MF			OPHTHALMOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPTIC NEURITIS; DEFICIENCY; LASER				OBRIEN, TP (corresponding author), JOHNS HOPKINS UNIV,SCH MED,WILMER EYE INST,BALTIMORE,MD 21205, USA.							BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; EBERS GC, 1985, ARCH NEUROL-CHICAGO, V42, P702, DOI 10.1001/archneur.1985.04060070096025; FLEISHMAN JA, 1987, OPHTHALMOLOGY, V94, P1029; GOLDSTEIN H, 1980, AM F BLIN RES SERIES, V26; HOLLAND GN, 1983, OPHTHALMOLOGY, V90, P859; JABS DA, 1989, ARCH OPHTHALMOL-CHIC, V107, P75, DOI 10.1001/archopht.1989.01070010077031; JENNINGS T, 1990, OPHTHALMIC SURG LAS, V21, P492; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; SHAFFER RN, 1992, HIST AM BOARD OPHTHA; SOMMER A, 1983, LANCET, V2, P585; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; SOMMER A, 1981, LANCET, V1, P1407; TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048; TROKEL SL, 1983, AM J OPHTHALMOL, V96, P710, DOI 10.1016/S0002-9394(14)71911-7; WEST KP, 1991, LANCET, V338, P67, DOI 10.1016/0140-6736(91)90070-6; 1992, NEW ENGL J MED, V326, P213	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					393	395						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613931				2022-12-28	WOS:A1992JC35200044
J	RIVLIN, RS				RIVLIN, RS			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER		CORNELL UNIV,MED CTR,NEW YORK HOSP,NEW YORK,NY 10021	Cornell University; NewYork-Presbyterian Hospital	RIVLIN, RS (corresponding author), MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA029502, P30CA029502] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUNK MJ, 1989, P SOC EXP BIOL MED, V190, P379; COWDEN WB, 1987, T ROY SOC TROP MED H, V81, P533, DOI 10.1016/0035-9203(87)90395-6; DOWLING HJ, 1991, CLIN RES, V39, pA645; DUTTA P, 1991, J PROTOZOOL, V38, P479, DOI 10.1111/j.1550-7408.1991.tb04820.x; GOODWIN PJ, 1990, BREAST CANCER RES TR, V16, P205, DOI 10.1007/BF01806329; HOUMARD JA, 1991, INT J OBESITY, V15, P181; NEWMARK HL, 1991, AM J CLIN NUTR, V54, pS209, DOI 10.1093/ajcn/54.1.209S; RIVLIN RS, 1991, AM J CLIN NUTR, V54, pS177; SCHAPIRA DV, 1991, CANCER, V67, P2215, DOI 10.1002/1097-0142(19910415)67:8<2215::AID-CNCR2820670836>3.0.CO;2-Q; SCHAPIRA DV, 1990, ANN INTERN MED, V112, P182, DOI 10.7326/0003-4819-112-3-182; SERES DS, 1991, NUTR RES, V11, P337, DOI 10.1016/S0271-5317(05)80309-4; WEINHOUSE S, 1991, CA-CANCER J CLIN, V41, P334, DOI 10.3322/canjclin.41.6.334	12	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					382	383		10.1001/jama.268.3.382	http://dx.doi.org/10.1001/jama.268.3.382			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613928				2022-12-28	WOS:A1992JC35200040
J	YOUNG, MP				YOUNG, MP			OBJECTIVE ANALYSIS OF THE TOPOLOGICAL ORGANIZATION OF THE PRIMATE CORTICAL VISUAL-SYSTEM	NATURE			English	Article							RHESUS-MONKEY; CORTEX; CONNECTIONS; MACAQUE; PATHWAYS; AREAS	THE primate cortical visual system is composed Of many structurally and functionally distinct areas 1-3, each receiving and sending about 10 projections from and to other cortical areas 1. The visual cortex is thus served by many cortico-cortical connections to form a network of considerable complexity. Thus the gross organization of this cortical processing system presents a formidable topological problem: although the spatial Position of the areas in the brain is reasonably well established, the gross 'processing architecture' defined by the connections, is less well understood. Here I report an optimization approach that gives both qualitative and quantitative insight into the connectional topology of the primate cortical visual system. This approach supports suggestions that the system is divided into a dorsal 'stream' and a ventral 'stream' with limited cross-talk, that these two streams reconverge in the region of the principal sulcus (area 46) and in the superior temporal polysensory areas, that the system is hierarchically organized, and that the majority of the connections are from 'nearest-neighbour' and 'next-door-but-one' areas.			YOUNG, MP (corresponding author), UNIV OXFORD,PHYSIOL LAB,PARKS RD,OXFORD OX1 3PT,ENGLAND.							BAIZER JS, 1991, J NEUROSCI, V11, P168; BOUSSAOUD D, 1990, J COMP NEUROL, V296, P462, DOI 10.1002/cne.902960311; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; COWEY A, 1979, Q J EXP PSYCHOL, V31, P1, DOI 10.1080/14640747908400703; CROCK F, 1991, COLD SPRING HARB SYM, V55, P953; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; Edgington E. S., 1980, RANDOMIZATION TESTS; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GOWER JC, 1975, PSYCHOMETRIKA, V40, P33, DOI 10.1007/BF02291478; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; MITCHISON G, 1991, P ROY SOC B-BIOL SCI, V245, P151, DOI 10.1098/rspb.1991.0102; MIYASHITA Y, 1988, NATURE, V335, P817, DOI 10.1038/335817a0; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; Norusis M.J., 1990, SPSS BASE SYSTEM USE; PETERS A, 1985, CEREBRAL CORTEX; SCHILLER PH, 1991, SCIENCE, V251, P1251, DOI 10.1126/science.2006413; SCHONEMAN P, 1970, PSYCHOMETRIKA, V31, P1; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; SHEPARD RN, 1962, PSYCHOMETRIKA, V27, P125, DOI 10.1007/BF02289630; TANAKA K, 1991, J NEUROPHYSIOL, V66, P170, DOI 10.1152/jn.1991.66.1.170; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; Young F. W., 1990, SPSS BASE SYSTEM USE, P396; YOUNG FW, 1979, MULTIDIMENSIONAL SCA; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; YOUNG MP, 1990, THESIS ST ANDREWS U; YOUNG MP, 1991, SOC NEUR ABS, V17; YOUNG MP, IN PRESS J NEUROPHYS; YOUNG MP, IN PRESS BRAIN MECHA; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	30	337	346	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					152	155		10.1038/358152a0	http://dx.doi.org/10.1038/358152a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614547				2022-12-28	WOS:A1992JC58300052
J	NAKAYAMA, T; UEDA, Y; YAMADA, H; SHORES, EW; SINGER, A; JUNE, CH				NAKAYAMA, T; UEDA, Y; YAMADA, H; SHORES, EW; SINGER, A; JUNE, CH			INVIVO CALCIUM ELEVATIONS IN THYMOCYTES WITH T-CELL RECEPTORS THAT ARE SPECIFIC FOR SELF LIGANDS	SCIENCE			English	Article							TRANSGENIC MICE; CD4+8+ THYMOCYTES; ANTIGEN RECEPTOR; TOLERANCE; EXPRESSION; REACTIVITY; SELECTION; PRODUCTS; DELETION; IMMATURE	Selection of the T cell receptor (TCR) repertoire in the thymus probably involves TCR-mediated signals transduced in developing thymocytes after interaction with thymic stromal cells bearing self ligands. TCR-transduced signals should have identifiable consequences that would distinguish thymocytes whose TCRs have been engaged by self ligands from those whose TCRs have not. Among thymocytes expressing a transgenic TCR of defined specificity, a large number had elevated intracellular calcium concentrations but only when resident in a negatively selecting thymus in which their self ligand was expressed. Thus, developing thymocytes are stimulated by endogenous ligands in vivo to mobilize intracellular calcium, and increased intracellular calcium concentrations may reflect the consequences of intrathymic signaling associated with thymic negative selection.	NCI,EXPTL IMMUNOL BRANCH,BLDG 10 ROOM 4B-17,BETHESDA,MD 20892; USN,MED RES INST,IMMUNE CELL BIOL PROGRAM,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Naval Medical Research Center (NMRC); United States Department of Defense; United States Navy			Nakayama, Toshinori/E-1067-2017	Nakayama, Toshinori/0000-0002-1434-2007				ABE R, 1988, NATURE, V335, P827, DOI 10.1038/335827a0; BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; FINKEL TH, 1987, NATURE, V330, P179, DOI 10.1038/330179a0; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MACDONALD HR, 1988, NATURE, V336, P471, DOI 10.1038/336471a0; MACDONALD HR, 1988, NATURE, V332, P40, DOI 10.1038/332040a0; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; NAKAYAMA T, 1991, P NATL ACAD SCI USA, V88, P9949, DOI 10.1073/pnas.88.22.9949; Nakayama T, UNPUB; PULLEN AM, 1988, NATURE, V335, P796, DOI 10.1038/335796a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; Singer A., 1986, PROG IMMUNOL, V6, P60; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z	20	68	70	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					96	99		10.1126/science.1621102	http://dx.doi.org/10.1126/science.1621102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621102				2022-12-28	WOS:A1992JC16500039
J	BRENNAN, TA; KIRSCHNER, R				BRENNAN, TA; KIRSCHNER, R			MEDICAL-ETHICS AND HUMAN-RIGHTS VIOLATIONS - THE IRAQI OCCUPATION OF KUWAIT AND ITS AFTERMATH	ANNALS OF INTERNAL MEDICINE			English	Article						ETHICS, MEDICAL; HUMAN RIGHTS; IRAQ; KUWAIT; DELIVERY OF HEALTH CARE	PHYSICIANS; IMPERIALISM	Immediately after the liberation of Kuwait by a coalition of allied forces in March 1991, representatives of Physicians for Human Rights traveled to Kuwait and conducted an inquiry into human rights violations allegedly perpetrated by Iraqi forces. The inquiry focused on the abuses that were said to have occurred in health care institutions. Human rights abuses by the Iraqis in Kuwaiti hospitals were documented, but certain allegations proved to be unfounded. However, Kuwaiti abuses of those accused of collaborating with the Iraqi invaders, in particular Palestinian citizens of Kuwait, were also observed. The trip and inquiry generated questions about the scope and applicability of medical ethical principles to physicians in different cultures and in situations unlike those in which medicine is normally practiced. In light of the Kuwait experience, Physicians for Human Rights has drawn tentative conclusions about the universal nature of medical ethics.			BRENNAN, TA (corresponding author), PHYSICIANS HUMAN RIGHTS, 100 BOYLSTON ST, SUITE 702, BOSTON, MA 02116 USA.							AHTISAARI M, 1991, COMMUNICATION   0328; ALMUTAWA M, 1989, HASTINGS CENT REP, V19, pS11; ANGELL M, 1988, NEW ENGL J MED, V319, P1081, DOI 10.1056/NEJM198810203191608; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BRENNAN TA, 1991, JUST DOCTORING MED E; CARTER J, 1986, JAMA-J AM MED ASSOC, V255, P2798, DOI 10.1001/jama.1986.03370200100036; CASSEL CK, 1985, JAMA-J AM MED ASSOC, V254, P652, DOI 10.1001/jama.254.5.652; DANIELS N, 1979, J MED PHILOS, V4, P174, DOI 10.1093/jmp/4.2.174; ESPERSON O, 1987, DAN MED B, V34, P198; GELLHORN A, 1977, WHO B, V17, P194; GILKS CF, 1990, NEW ENGL J MED, V322, P200; Goffman E., 1961, ENCOUNTERS; JONSEN AR, 1985, BREAKING BODIES MIND; Newton Lisa H, 1990, IRB, V12, P10, DOI 10.2307/3564110; NIGHTINGALE EO, 1986, JAMA-J AM MED ASSOC, V255, P2794, DOI 10.1001/jama.255.20.2794; OUTKA G, 1974, PERSPECTIVES BIOL ME, V18, P187; RISPLERCHAIM V, 1989, J MED ETHICS, V15, P203, DOI 10.1136/jme.15.4.203; Sandel M., 1982, LIBERALISM LIMITS JU; YOUNG QD, 1990, JAMA-J AM MED ASSOC, V264, P3127; 1981, ISLAMIC CODE MED ETH, P26; 1991, VICTORY TURNED SOUR; 1992, IN PRESS PHYSICIANS; 1990, DETERIORATING HUMAN; 1991, J MED ETHICS S, V17, P35; 1990, IRAQ OCCUPIED KUWAIT; 1991, AMNESTY INT CALLS EM; 1987, DAN MED B, V34, P321	27	6	6	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					78	82		10.7326/0003-4819-117-1-78	http://dx.doi.org/10.7326/0003-4819-117-1-78			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596050				2022-12-28	WOS:A1992JA43500013
J	ELDAR, M; SIEVNER, Z; GOLDBOURT, U; REICHERREISS, H; KAPLINSKY, E; BEHAR, S				ELDAR, M; SIEVNER, Z; GOLDBOURT, U; REICHERREISS, H; KAPLINSKY, E; BEHAR, S			PRIMARY VENTRICULAR-TACHYCARDIA IN ACUTE MYOCARDIAL-INFARCTION - CLINICAL CHARACTERISTICS AND MORTALITY	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; TACHYCARDIA; HEART VENTRICLE; DEATH, SUDDEN; HEMODYNAMICS	FIBRILLATION; PROGNOSIS; ARRHYTHMIAS; REPERFUSION	Objective: To examine the immediate and long-term clinical and prognostic significance of primary ventricular tachycardia, defined as tachycardia of ventricular origin occurring within 48 hours of acute myocardial infarction in patients without hemodynamic compromise (Killip class I). Design: Prospective cohort study. Setting: Intensive coronary care units in eight regional, referral, and university hospitals. Patients: A total of 162 patients with primary ventricular tachycardia, both sustained and nonsustained (study group), and 2578 counterparts without ventricular tachycardia (reference group). Measurements: In-hospital rates of atrial fibrillation, atrioventricular block, congestive heart failure, cardiogenic shock, and cardiac arrest. In-hospital and 1-year follow-up rates of sudden death, nonsudden cardiac death, and noncardiac death. Results: The study and reference groups had similar mortality (in-hospital, 6.8% and 9.6%, P > 0.2 and at 1 year after discharge, 3.7% and 5.4%, P > 0.2, respectively) and in-hospital complication rates (atrioventricular block, 13.0% and 9.7%, P > 0.2; cardiogenic shock, 3.7% and 3.0%, P > 0.2; cardiac arrest, 1.8% and 4.4%, P > 0.2, respectively). Patients with sustained ventricular tachycardia (28 patients) compared with those with nonsustained ventricular tachycardia (134 patients) had higher rates of polymorphic tachycardia (50% compared with 6%, P = 0.001), in-hospital total cardiac mortality (21 % compared with 4%, P = 0.003) and sudden-death mortality (14% compared with 2%, P = 0.001); they also showed a trend toward a higher in-hospital mortality than the reference group (21.4% compared with 9.6%, P = 0.15) but had no increased mortality 1 year after discharge (4.6% compared with 5.4%, P > 0.2). Conclusions: As a group, patients with primary ventricular tachycardia do not differ from counterparts without primary ventricular tachycardia in their in-hospital clinical course and 1-year prognosis. Primary sustained ventricular tachycardia is often polymorphic and carries worse in-hospital prognosis than nonsustained tachycardia. However, it does not predict recurrent ventricular tachycardia or increased sudden-death rates during the next year.			ELDAR, M (corresponding author), CHAIM SHEBA MED CTR, NEUFELD CARDIAC RES CTR, NEUFELD CARDIAC RES INST, IL-52621 TEL HASHOMER, ISRAEL.							[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BEHAR S, 1990, AM J CARDIOL, V66, P1208, DOI 10.1016/0002-9149(90)91101-B; BEHAR S, 1988, EUR HEART J, V9, P354; Bishop YM., 2007, DISCRETE MULTIVARIAT; CAMPBELL RWF, 1981, BRIT HEART J, V46, P351; DUBOIS C, 1986, EUR HEART J, V7, P945, DOI 10.1093/oxfordjournals.eurheartj.a061999; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOROWITZ LN, 1981, CIRCULATION, V63, P1120, DOI 10.1161/01.CIR.63.5.1120; KERSSCHOT IE, 1986, J AM COLL CARDIOL, V7, P1234, DOI 10.1016/S0735-1097(86)80141-3; LAWRIE DM, 1968, LANCET, V2, P523; LIE K I, 1974, European Journal of Cardiology, V1, P379; MILLER FC, 1986, AM HEART J, V112, P928, DOI 10.1016/0002-8703(86)90302-9; NICOD P, 1988, J AM COLL CARDIOL, V11, P464, DOI 10.1016/0735-1097(88)91518-5; TCHOU P, 1989, Journal of the American College of Cardiology, V13, p21A; TOFLER GH, 1987, AM J CARDIOL, V60, P755, DOI 10.1016/0002-9149(87)91018-6; TYE KH, 1979, AM J CARDIOL, V44, P632, DOI 10.1016/0002-9149(79)90280-7; VOLPI A, 1987, NEW ENGL J MED, V317, P257, DOI 10.1056/NEJM198707303170501; VOLPI A, 1989, AM J CARDIOL, V63, P1174, DOI 10.1016/0002-9149(89)90174-4; 1985, SAS USERS GUIDE STAT, P403; 1985, SAS USERS GUIDE STAT, P171	22	38	39	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					31	36		10.7326/0003-4819-117-1-31	http://dx.doi.org/10.7326/0003-4819-117-1-31			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596045				2022-12-28	WOS:A1992JA43500005
J	MAIN, J; WARD, MK				MAIN, J; WARD, MK			POTENTIATION OF ALUMINUM ABSORPTION BY EFFERVESCENT ANALGESIC TABLETS IN A HEMODIALYSIS PATIENT	BRITISH MEDICAL JOURNAL			English	Article							TOXICITY; CITRATE				MAIN, J (corresponding author), ROYAL VICTORIA INFIRM,RENAL OFF,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND.							KIRSCHBAUM BB, 1989, AM J MED SCI, V297, P9, DOI 10.1097/00000441-198901000-00003; MOLITORIS BA, 1989, KIDNEY INT, V36, P949, DOI 10.1038/ki.1989.286; NOLIN CR, 1990, KIDNEY INT, V38, P937; PARTRIDGE NA, 1989, KIDNEY INT, V35, P1413, DOI 10.1038/ki.1989.142	4	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1686	1686		10.1136/bmj.304.6843.1686	http://dx.doi.org/10.1136/bmj.304.6843.1686			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633526	Bronze, Green Published			2022-12-28	WOS:A1992JB93900031
J	CURTIS, RE; BOICE, JD; STOVALL, M; BERNSTEIN, L; GREENBERG, RS; FLANNERY, JT; SCHWARTZ, AG; WEYER, P; MOLONEY, WC; HOOVER, RN				CURTIS, RE; BOICE, JD; STOVALL, M; BERNSTEIN, L; GREENBERG, RS; FLANNERY, JT; SCHWARTZ, AG; WEYER, P; MOLONEY, WC; HOOVER, RN			RISK OF LEUKEMIA AFTER CHEMOTHERAPY AND RADIATION TREATMENT FOR BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HODGKINS-DISEASE; ADJUVANT CHEMOTHERAPY; OVARIAN-CANCER; CYCLOPHOSPHAMIDE; RADIOTHERAPY; MALIGNANCIES; MELPHALAN; NEOPLASMS; CERVIX	Background. Few studies have evaluated the late effects of adjuvant chemotherapy for breast cancer. Moreover, the relation between the risk of leukemia and the amount of drug given and the interaction of chemotherapy with radiotherapy have not been described in detail. Methods. We conducted a case-control study in a cohort of 82,700 women given a diagnosis of breast cancer from 1973 to 1985 in five areas of the United States. Detailed information about therapy was obtained for 90 patients with leukemia and 264 matched controls. The dose of radiation to the active marrow was estimated from individual radiotherapy records (mean dose, 7.5 Gy). Results. The risk of acute nonlymphocytic leukemia was significantly increased after regional radiotherapy alone (relative risk, 2.4), alkylating agents alone (relative risk, 10.0), and combined radiation and drug therapy (relative risk, 17.4). Dose-dependent risks were observed after radiotherapy and treatment with melphalan and cyclophosphamide. Melphalan was 10 times more leukemogenic than cyclophosphamide (relative risk, 31.4 vs. 3.1). There was little increase in the risk associated with total cyclophosphamide doses of less than 20,000 mg. Conclusions. Although leukemia occurs in few patients with breast cancer, significantly elevated risks were linked to treatments with regional radiation and alkylating agents. Melphalan is a more potent leukemogen than cyclophosphamide or radiotherapy. Low risks were associated with the levels of cyclophosphamide in common use today. Systemic drug therapy combined with radiotherapy that delivers high doses to the marrow appears to enhance the risk of leukemia.	NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT RADIAT PHYS,HOUSTON,TX 77025; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA 30322; DEPT HLTH SERV,CONNECTICUT TUMOR REGISTRY,HARTFORD,CT; MICHIGAN CANC FDN,DETROIT,MI 48201; STATE HLTH REGISTRY IOWA,IOWA CITY,IA; HARVARD UNIV,SCH MED,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center; University of Southern California; Emory University; Harvard University; Harvard Medical School	CURTIS, RE (corresponding author), NCI,EPIDEMIOL & BIOSTAT PROGRAM,RADIAT EPIDEMIOL BRANCH,EXECUT PLAZA N,SUITE 408,BETHESDA,MD 20892, USA.							ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BLAYNEY DW, 1990, NEW ENGL J MED, V322, P1818; BOICE JD, 1987, J NATL CANCER I, V79, P1295; BRESLOW NE, 1980, IARC SCI PUBLICAT 32, V1; CURTIS RE, 1990, CANCER RES, V50, P2741; CURTIS RE, 1989, J CLIN ONCOL, V7, P21, DOI 10.1200/JCO.1989.7.1.21; CUZICK J, 1987, BRIT J CANCER, V55, P523, DOI 10.1038/bjc.1987.107; FISHER B, 1985, J CLIN ONCOL, V3, P1640, DOI 10.1200/JCO.1985.3.12.1640; GREENE MH, 1986, ANN INTERN MED, V105, P360, DOI 10.7326/0003-4819-105-3-360; HAAS JF, 1987, BRIT J CANCER, V55, P213, DOI 10.1038/bjc.1987.40; HENDERSON IC, 1987, BREAST DISEASES, P324; HERRING MK, 1986, AM J CLIN ONCOL-CANC, V9, P269, DOI 10.1097/00000421-198606000-00018; HOLDENER EE, 1984, RECENT RESULTS CANC, V96, P188; KALDOR JM, 1990, NEW ENGL J MED, V322, P1, DOI 10.1056/NEJM199001043220101; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; LUBIN JH, 1981, COMPUT BIOMED RES, V14, P138, DOI 10.1016/0010-4809(81)90031-8; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; STOVALL M, 1989, MED PHYS, V16, P726, DOI 10.1118/1.596331; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1987, J CLIN ONCOL, V5, P1138, DOI 10.1200/JCO.1987.5.8.1138; VALAGUSSA P, 1986, J CLIN ONCOL, V4, P830, DOI 10.1200/JCO.1986.4.6.830; VANKAICK G, 1989, RISKS RADIUM THOROTR, P98	23	329	335	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1745	1751		10.1056/NEJM199206253262605	http://dx.doi.org/10.1056/NEJM199206253262605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1594016	Bronze			2022-12-28	WOS:A1992HZ89400005
J	GOSSELINK, ATM; CRIJNS, HJGM; VANGELDER, IC; HILLIGE, H; WIESFELD, ACP; LIE, KI				GOSSELINK, ATM; CRIJNS, HJGM; VANGELDER, IC; HILLIGE, H; WIESFELD, ACP; LIE, KI			LOW-DOSE AMIODARONE FOR MAINTENANCE OF SINUS RHYTHM AFTER CARDIOVERSION OF ATRIAL-FIBRILLATION OR FLUTTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LEFT-VENTRICULAR FUNCTION; HISTORICAL DEVELOPMENT; QUINIDINE THERAPY; CLINICAL EFFICACY; ELECTROCONVERSION; TACHYARRHYTHMIAS; DISOPYRAMIDE; ARRHYTHMIAS; CONVERSION; TOXICITY	Objective.-To study efficacy and safety of low-dose amiodarone for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation or flutter. Design.-Nonrandomized trial; mean duration of follow-up, 20.7 months. Setting.-Referral center; institutional practice; both hospitalized and ambulatory care. Patients.-Eighty-nine consecutive patients having chronic atrial fibrillation or flutter and eligible for cardioversion. Patients had failed previous treatment aimed at maintaining sinus rhythm. During follow-up one patient was withdrawn because of side effects; all patients were available for follow-up. Intervention.-Before cardioversion, patients received 600 mg of amiodarone daily during a 4-week loading period. After conversion, the daily maintenance dose was 204+/-66 mg (mean+/-SD). Main Outcome Measures.-Arrhythmia recurrence and adverse effects causing drug discontinuation. Results.-During loading, 15 patients (16%) converted, and after electrical cardioconversion, 90% of all patients had sinus rhythm. Actuarially, 53% of these patients were still in sinus rhythm after 3 years. In patients with compromised left ventricular function, 93% maintained sinus rhythm after 6 months. One patient died due to congestive heart failure. Intolerable side effects occurred in one patient. No proarrhythmia was observed. Logistic regression analysis revealed that amiodarone was ineffective in patients with mitral stenosis or chronic arrhythmia. Conclusions.-Low-dose amiodarone is effective for maintaining sinus rhythm in patients with difficult to treat chronic atrial fibrillation or flutter and is associated with a low incidence of serious side effects.			GOSSELINK, ATM (corresponding author), UNIV GRONINGEN HOSP, DEPT CARDIOL, THORAXCTR, POB 30001, 9700 RB GRONINGEN, NETHERLANDS.							ANTMAN EM, 1988, J AM COLL CARDIOL, V12, P1005, DOI 10.1016/0735-1097(88)90468-8; BLEVINS RD, 1987, ARCH INTERN MED, V147, P1401, DOI 10.1001/archinte.147.8.1401; BRODSKY MA, 1987, AM J CARDIOL, V60, P572, DOI 10.1016/0002-9149(87)90307-9; BYRNEQUINN E, 1970, BRIT HEART J, V32, P370; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; CRIJNS HJ, 1991, AM J CARDIOL, V68, P335, DOI 10.1016/0002-9149(91)90828-9; DEPAOLA AAV, 1987, AM J CARDIOL, V60, P276, DOI 10.1016/0002-9149(87)90227-X; ELLENBOGEN KA, 1985, AM HEART J, V110, P376, DOI 10.1016/0002-8703(85)90159-0; FOGOROS RN, 1983, CIRCULATION, V68, P88, DOI 10.1161/01.CIR.68.1.88; GOLD RL, 1986, AM J CARDIOL, V57, P124, DOI 10.1016/0002-9149(86)90964-1; GRABOYS TB, 1983, AM HEART J, V106, P870, DOI 10.1016/0002-8703(83)90009-1; GREENE HL, 1989, PROG CARDIOVASC DIS, V31, P319, DOI 10.1016/0033-0620(89)90029-7; HAFFAJEE CI, 1983, CIRCULATION, V67, P1347, DOI 10.1161/01.CIR.67.6.1347; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HARTEL G, 1970, BRIT HEART J, V32, P57; HARTEL G, 1974, CLIN PHARMACOL THER, V15, P551; HILLESTAD L, 1971, BRIT HEART J, V33, P518; HOROWITZ LN, 1985, J AM COLL CARDIOL, V6, P1402, DOI 10.1016/S0735-1097(85)80232-1; KARLSON BW, 1988, EUR HEART J, V9, P284, DOI 10.1093/oxfordjournals.eurheartj.a062498; KERIN NZ, 1989, J CLIN PHARMACOL, V29, P418, DOI 10.1002/j.1552-4604.1989.tb03354.x; KERIN NZ, 1988, J ELECTROPHYSIOL, V2, P289; KOPELMAN HA, 1989, PROG CARDIOVASC DIS, V31, P355, DOI 10.1016/0033-0620(89)90030-3; KOWEY PR, 1988, CHEST, V93, P54, DOI 10.1378/chest.93.1.54; LLOYD EA, 1984, S AFR MED J, V65, P367; MCCOMB JM, 1980, EUR J CARDIOL, V11, P381; NADEMANEE K, 1983, ANN INTERN MED, V98, P577, DOI 10.7326/0003-4819-98-5-577; RASMUSSEN K, 1981, ACTA MED SCAND, P23; ROSENBAUM MB, 1976, AM J CARDIOL, V38, P934, DOI 10.1016/0002-9149(76)90807-9; SCHWARTZ PJ, 1983, ANN INTERN MED, V99, P561, DOI 10.7326/0003-4819-99-4-561; SHELDON RS, 1988, AM J CARDIOL, V62, P736, DOI 10.1016/0002-9149(88)91213-1; SINGH BN, 1989, PROG CARDIOVASC DIS, V31, P249, DOI 10.1016/0033-0620(89)90033-9; SINGH BN, 1983, AM HEART J, V106, P788, DOI 10.1016/0002-8703(83)90002-9; SINGH BN, 1984, PACE, V7, P109, DOI 10.1111/j.1540-8159.1984.tb04867.x; SODERMARK T, 1975, BRIT HEART J, V37, P486; STANTON MS, 1989, J AM COLL CARDIOL, V14, P209, DOI 10.1016/0735-1097(89)90074-0; TROBAUGH GB, 1984, AM J CARDIOL, V54, P1263, DOI 10.1016/S0002-9149(84)80077-6; VANGELDER IC, 1989, AM J CARDIOL, V64, P1317, DOI 10.1016/0002-9149(89)90574-2; VITOLO E, 1981, ACTA CARDIOL, V36, P431; WARD DE, 1980, BRIT HEART J, V44, P91; WILLIAMS EMV, 1982, BRIT HEART J, V47, P513	40	232	239	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3289	3293		10.1001/jama.267.24.3289	http://dx.doi.org/10.1001/jama.267.24.3289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597910				2022-12-28	WOS:A1992HY94400026
J	PHILPOTT, A; LENO, GH				PHILPOTT, A; LENO, GH			NUCLEOPLASMIN REMODELS SPERM CHROMATIN IN XENOPUS EGG EXTRACTS	CELL			English	Article							NUCLEOSOME ASSEMBLY INVITRO; HISTONE COMPLEXES; LAEVIS OOCYTES; ACIDIC PROTEIN; NUCLEI; FERTILIZATION; DNA; REPLICATION; TRANSITIONS; CLEAVAGE	Nucleoplasmin is necessary and sufficient for the initial stage of Xenopus sperm decondensation in egg extracts. In this article we show that sperm decondensation is accompanied by loss of two sperm-specific basic proteins (X and Y) and gain of histones H2A and H2B, resulting in nucleosome formation. Purified nucleoplasmin alone removes X and Y and assembles purified H2A and H2B on decondensing sperm chromatin, forming nucleosome cores. Immunodepletion of nucleoplasmin from extract prevents removal of X and Y and addition of H2A and H2B, while adding back nucleoplasmin restores decondensation and X and Y removal. Thus, nucleoplasmin acts as both an assembly and a disassembly factor for remodeling sperm chromatin at fertilization.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST CANC & DEV BIOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge				Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; BOLS NC, 1972, CAN J ZOOLOG, V50, P171, DOI 10.1139/z72-026; BOLS NC, 1973, CAN J ZOOL, V51, P203, DOI 10.1139/z73-029; DEAN J, 1983, DEV BIOL, V99, P210, DOI 10.1016/0012-1606(83)90269-5; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; EARNSHAW WC, 1980, CELL, V21, P373, DOI 10.1016/0092-8674(80)90474-2; GORDON K, 1985, EXP CELL RES, V157, P409, DOI 10.1016/0014-4827(85)90126-0; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KLEINSCHMIDT JA, 1991, EMBO J, V10, P3043, DOI 10.1002/j.1460-2075.1991.tb07855.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1983, EXP CELL RES, V148, P481, DOI 10.1016/0014-4827(83)90169-6; Longo F.J., 1978, Current Topics in Developmental Biology, V12, P149, DOI 10.1016/S0070-2153(08)60596-7; MANN M, 1982, J EXP ZOOL, V222, P173, DOI 10.1002/jez.1402220209; MILLS AD, 1980, J MOL BIOL, V139, P561, DOI 10.1016/0022-2836(80)90148-5; NOLL M, 1974, NATURE, V251, P249, DOI 10.1038/251249a0; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; PHILPOTT A, 1991, CELL, V65, P569, DOI 10.1016/0092-8674(91)90089-H; POCCIA D, 1986, INT REV CYTOL, V105, P1, DOI 10.1016/S0074-7696(08)61061-X; POCCIA D, 1984, DEV BIOL, V104, P274, DOI 10.1016/0012-1606(84)90083-6; POCCIA D, 1981, DEV BIOL, V82, P287, DOI 10.1016/0012-1606(81)90452-8; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; STICK R, 1985, CELL, V41, P191, DOI 10.1016/0092-8674(85)90073-X; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; WOLFFE AP, 1989, NUCLEIC ACIDS RES, V17, P769; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	32	203	211	1	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					759	767		10.1016/0092-8674(92)90288-N	http://dx.doi.org/10.1016/0092-8674(92)90288-N			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591776				2022-12-28	WOS:A1992HW83800007
J	HIBBERD, AD; PEARSON, IY; MCCOSKER, CJ; CHAPMAN, JR; MACDONALD, GJ; THOMPSON, JF; OCONNELL, DL; MOHACSI, PJ; MCLOUGHLIN, MP; SPRATT, PM; COMPTON, JS; BROWN, MA				HIBBERD, AD; PEARSON, IY; MCCOSKER, CJ; CHAPMAN, JR; MACDONALD, GJ; THOMPSON, JF; OCONNELL, DL; MOHACSI, PJ; MCLOUGHLIN, MP; SPRATT, PM; COMPTON, JS; BROWN, MA			POTENTIAL FOR CADAVERIC ORGAN RETRIEVAL IN NEW-SOUTH-WALES	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DONATION	Objectives-To measure the potential for cadaver organ retrieval in New South Wales and to determine the reasons for potential donors failing to become actual donors. Design-Prospective audit of all patients dying in five hospitals in New South Wales between 1 December 1989 and 30 November 1990; quality assurance of the data by independent medical specialist and if disagreement by study committee. Patients-2879 patients (100% of all deaths) yielding 364 patients with coma and 181 potential donors. Outcome measures-Realistic medically suitable potential donor rate, missed potential donor rate, rate of potential donors with permission refused, donor rate, reasons for realistic medically suitable potential donors failing to become actual donors. Results -2879 deaths yielded 73 medically suitable potential donors, resulting in 19 actual donors, 30 missed potential donors, 19 potential donors with permission refused, and five in whom adequate resuscitation failed. The most common reason for a potential donor failing to become an actual donor was a decision by the senior medical practitioner to withdraw or not to institute ventilatory or haemodynamic support (26/73). The second major obstacle was refusal of permission by the next of kin (17/73). Assuming that the potential donor rate was that implied by the observed donor rate (13/million population/year) the projected missed potential donor rate was 9/million population/year (95% confidence interval 4 to 15) and the projected rate of potential donors with permission refused was 13/million population/year (95% confidence interval 5 to 22). Assuming that the rate of potential donors in the study hospitals was the same as in the other New South Wales hospitals, the projected donor rate for New South Wales was 18/million population/year (10 to 26); the projected missed potential donor rate was 15/million population/year (7 to 23); and the projected rate of potential donors with permission refused was 18/million population/year (10 to 27). Conclusions-The donor rate could be increased 70%-80% by overcoming the reluctance of medical practitioners to resuscitate missed potential donors and increased further by gaining permission for organ retrieval from the next of kin.	WESTMEAD HOSP, WESTMEAD, NSW, AUSTRALIA; RED CROSS, BLOOD TRANSFUS SERV, SYDNEY, NSW, AUSTRALIA; PRINCE HENRY HOSP, LITTLE BAY, NSW 2036, AUSTRALIA; ROYAL PRINCE ALFRED HOSP, CAMPERDOWN, NSW 2050, AUSTRALIA; ROYAL NEWCASTLE HOSP, CTR CLIN EPIDEMIOL & BIOSTAT, NEWCASTLE, NSW 2300, AUSTRALIA; ST VINCENTS HOSP, DARLINGHURST, NSW 2010, AUSTRALIA; ST GEORGE HOSP, KOGARAH, NSW 2217, AUSTRALIA	University of Sydney; Australian Red Cross Blood Service; University of Sydney; University of Newcastle; St Vincents Hospital Sydney; St George Hospital	HIBBERD, AD (corresponding author), JOHN HUNTER HOSP, NEWCASTLE TRANSPLANT UNIT, LOCKED BAG 1, NEWCASTLE MAIL CTR, NEWCASTLE, NSW 2310, AUSTRALIA.			Thompson, John/0000-0002-2816-2496				[Anonymous], 1976, BMJ-BRIT MED J, V2, P1187; CHISHOLM GD, 1988, BRIT MED J, V296, P1419, DOI 10.1136/bmj.296.6634.1419; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS; DISNEY APS, 1991, AUSTR NZ DIALYSIS TR; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; GENTLEMAN D, 1990, BMJ-BRIT MED J, V301, P1203, DOI 10.1136/bmj.301.6762.1203; GORE SM, 1991, BRIT MED J, V302, P149, DOI 10.1136/bmj.302.6769.149; GORE SM, 1989, BRIT MED J, V299, P1193, DOI 10.1136/bmj.299.6709.1193; MORTON JB, 1979, BRIT MED J, V1, P239, DOI 10.1136/bmj.1.6158.239; SALIH MAM, 1991, BRIT MED J, V302, P1053, DOI 10.1136/bmj.302.6784.1053; 1989, EUROTRANSPLANT NEWSL, V65, P1	11	34	34	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 23	1992	304	6838					1339	1343		10.1136/bmj.304.6838.1339	http://dx.doi.org/10.1136/bmj.304.6838.1339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611330	Green Published, Bronze			2022-12-28	WOS:A1992HW41700020
J	JONES, KP; CHARLTON, IH; MIDDLETON, M; PREECE, WJ; HILL, AP				JONES, KP; CHARLTON, IH; MIDDLETON, M; PREECE, WJ; HILL, AP			TARGETING ASTHMA CARE IN GENERAL-PRACTICE USING A MORBIDITY INDEX	BRITISH MEDICAL JOURNAL			English	Article							PRESSURIZED AEROSOL INHALERS; MANAGEMENT; MORTALITY; PATIENT; TRENDS; RATES; AUDIT	Objectives-To evaluate a morbidity index as a postal surveillance tool in defining previously diagnosed asthmatic patients needing extra education or management; to determine the accuracy of a computerised asthma register in general practice. Design-Postal questionnaire survey of asthmatic patients identified from a computer register. Questionnaire comprised three morbidity questions, two questions about current asthma status, and one about treatments. Setting-Urban general practice of 8400 patients linked to academic unit. Subjects-853 asthmatic patients of all ages. Main outcome measures-Numbers of patients with low, medium, and high morbidity; associations of these groups with age, asthma status, and drugs taken. Results-Two mailings yielded 621 replies (73%); 28 patients (5%) had moved away, leaving 593 for analysis. Attempts were subsequently made to contact 20% sample of non-respondents. 234 respondents (40%) were in the "low morbidity" group, 149 (25%) in the "medium morbidity" group, and 210 (35%) in the "high morbidity" category. 53% of patients perceiving themselves as currently asthmatic (193/362) were in the high morbidity group, but 7% (11/153) who said they were no longer asthmatic and 8% (6/78) who did not believe they had ever been asthmatic were also in that group. High morbidity was also found in 10% (18/185) of those on no treatment, 38% (59/154) of those on bronchodilators alone, and 54% (119/220) of those on inhaled corticosteroids. 25 patients (4%) were wrongly identified as asthmatic; when combined with returns marked "gone away" this gave a disease register accuracy of 91%. Conclusions-This exercise identified subgroups of previously diagnosed asthmatic patients with high morbidity in general practice who might benefit from extra education and management and revealed some misclassification on the asthma disease register.			JONES, KP (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,PRIMARY MED CARE GRP,SOUTHAMPTON SO1 6ST,ENGLAND.							ALLEN SC, 1986, BRIT J DIS CHEST, V80, P45, DOI 10.1016/0007-0971(86)90008-2; ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; [Anonymous], 1990, BMJ, V301, P651; ASTHMA, 1992, ARCH DIS CHILD, V67, P240; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806, DOI 10.1164/ajrccm/139.3.806; BURNEY PGJ, 1986, LANCET, V2, P323; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURNEY PGJ, 1991, THORAX, V46, P574, DOI 10.1136/thx.46.8.574; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P256; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; EVANS R, 1987, CHEST S, V91, P65; HILTON S, 1990, BRIT J GEN PRACT, V40, P505; HILTON S, 1986, LANCET, V1, P26; HORN CR, 1990, RESP MED, V84, P67, DOI 10.1016/S0954-6111(08)80097-2; HORN CR, 1989, RESP MED, V83, P71, DOI 10.1016/S0954-6111(89)80063-0; HORSLEY MG, 1988, J CLIN PHARM THER, V13, P139, DOI 10.1111/j.1365-2710.1988.tb00170.x; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; JOHNSON N, 1991, BRIT MED J, V302, P763, DOI 10.1136/bmj.302.6779.763; JONES K, 1991, BRIT J GEN PRACT, V41, P224; JONES K, 1989, J ROY COLL GEN PRACT, V39, P254; JONES KP, 1992, BRIT MED J, V304, P361, DOI 10.1136/bmj.304.6823.361; JONES KP, 1991, THORAX, V46; MAO Y, 1987, CAN MED ASSOC J, V137, P620; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; STANLEY PH, 1991, BRIT MED J, V303, P971, DOI 10.1136/bmj.303.6808.971; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; WARNER JO, 1989, ARCH DIS CHILD, V64, P1065, DOI 10.1136/adc.64.7.1065; WHITE PT, 1989, J ROY COLL GEN PRACT, V39, P182; 1989, LANCET, V2, P199; 1990, BMJ, V301, P797	34	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1353	1356		10.1136/bmj.304.6838.1353	http://dx.doi.org/10.1136/bmj.304.6838.1353			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611335	Green Published, Bronze			2022-12-28	WOS:A1992HW41700026
J	MATUSCHKA, FR; SPIELMAN, A				MATUSCHKA, FR; SPIELMAN, A			THE VECTOR OF THE LYME-DISEASE SPIROCHETE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	MATUSCHKA, FR (corresponding author), FREE UNIV BERLIN,W-1000 BERLIN 33,GERMANY.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					542	542						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635568				2022-12-28	WOS:A1992JJ45700007
J	CATES, W; HINMAN, AR				CATES, W; HINMAN, AR			AIDS AND ABSOLUTISM - THE DEMAND FOR PERFECTION IN PREVENTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; METHADONE TREATMENT; HIV INFECTION; NOTIFICATION; RISK				CATES, W (corresponding author), CTR DIS CONTROL,ATLANTA,GA 30333, USA.							ADLER MW, 1988, BRIT MED J, V296, P1420, DOI 10.1136/bmj.296.6634.1420; ANGELL M, 1991, NEW ENGL J MED, V325, P811; BRANDT EN, 1988, PUBLIC HEALTH REP, V103, P339; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; EVANS L, 1986, ACCIDENT ANAL PREV, V18, P229, DOI 10.1016/0001-4575(86)90007-2; Francois-Marie Arouet, 1764, DICT PHILOS; Gerstein D., 1990, TREATING DRUG PROBLE; HOUSTON S, 1991, NEW ENGL J MED, V325, P810; LAMBERT B, 1990, NY TIMES, P1; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; MARKS G, 1991, AM J PUBLIC HEALTH, V81, P1321, DOI 10.2105/AJPH.81.10.1321; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; NEWMEYER JA, 1988, J PSYCHOACTIVE DRUGS, V20, P159, DOI 10.1080/02791072.1988.10524488; NOBLE RC, 1991, NEWSWEEK        0401, P8; OHI G, 1988, LANCET, V2, P947; PERRY S, 1989, HOSP COMMUNITY PSYCH, V40, P158; RAMSTEDT K, 1990, SEX TRANSM DIS, V17, P37, DOI 10.1097/00007435-199017010-00008; ROTHENBERG RB, 1990, SEXUALLY TRANSMITTED, P1081; RUTHERFORD GW, 1988, JAMA-J AM MED ASSOC, V259, P3609, DOI 10.1001/jama.259.24.3609; SCHLESINGER AM, 1989, BROWN ALUMNI MONTHLY, V42, P37; SIEGEL JE, 1991, AM J PUBLIC HEALTH, V81, P1273, DOI 10.2105/AJPH.81.10.1273; TOOMEY KE, 1988, NEW ENGL J MED, V319, P442; TOOMEY KE, 1989, AIDS, V3, pS57, DOI 10.1097/00002030-198901001-00009; VANDENHOEK JAR, 1989, AM J PUBLIC HEALTH, V79, P1355, DOI 10.2105/AJPH.79.10.1355; VLAHOV D, 1991, EPIDEMIOLOGY, V2, P444, DOI 10.1097/00001648-199111000-00010; WYKOFF RF, 1991, SEX TRANSM DIS, V18, P217, DOI 10.1097/00007435-199110000-00004; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185; 1990, METHADONE MAINTENANC, P30; 1991, MMWR MORB MORTAL WKL, V40	29	43	44	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					492	494		10.1056/NEJM199208133270711	http://dx.doi.org/10.1056/NEJM199208133270711			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JH340	1625740				2022-12-28	WOS:A1992JH34000011
J	MELDRUM, FC; HEYWOOD, BR; MANN, S				MELDRUM, FC; HEYWOOD, BR; MANN, S			MAGNETOFERRITIN - INVITRO SYNTHESIS OF A NOVEL MAGNETIC PROTEIN	SCIENCE			English	Article							FE(OH)2 SUSPENSIONS; AIR OXIDATION; IRON(II) ION; FERRITIN; FE3O4	The iron storage protein ferritin consists of a spherical polypeptide shell (apoferritin) surrounding a 6-nanometer inorganic core of the hydrated iron oxide ferrihydrite (5Fe2O3.9H2O). Previous studies have shown that the in vitro reconstitution of apoferritin yields mineral cores essentially identical to those of the native proteins. A magnetic mineral was synthesized within the nanodimensional cavity of horse spleen ferritin by the use of controlled reconstitution conditions. Transmission electron microscopy and electron diffraction analysis indicate that the entrapped mineral particles are discrete 6-nanometer spherical single crystals of the ferrimagnetic iron oxide magnetite (Fe3O4). The resulting magnetic protein, "magnetoferritin," could have uses in biomedical imaging, cell labeling, and separation procedures.	UNIV BATH,SCH CHEM,BATH BA2 7AY,AVON,ENGLAND	University of Bath			Mann, Stephen/D-1332-2012; Meldrum, Fiona C/E-2726-2014	Mann, Stephen/0000-0003-3012-8964; Meldrum, Fiona/0000-0001-9243-8517				BUTLER RF, 1975, J GEOPHYS RES, V80, P4049, DOI 10.1029/JB080i029p04049; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; KEMP W, 1986, NMR CHEM MULTINUCLEA, P154; KIYAMA M, 1974, B CHEM SOC JPN, V47, P1646, DOI 10.1246/bcsj.47.1646; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1988, J BIOL CHEM, V263, P18086; LIVNE E, 1986, J HISTOCHEM CYTOCHEM, V34, P167, DOI 10.1177/34.2.3944455; MANN S, 1987, J MOL BIOL, V198, P405, DOI 10.1016/0022-2836(87)90290-7; MANN S, 1989, J CHEM SOC FARAD T 1, V85, P3033, DOI 10.1039/f19898503033; Mann S., 1989, BIOMINERALIZATION CH; MELDRUM FC, 1991, NATURE, V349, P684, DOI 10.1038/349684a0; MELDRUM FC, UNPUB; MOLDAY RS, 1977, NATURE, V268, P437, DOI 10.1038/268437a0; OZAKI M, 1985, J COLLOID INTERF SCI, V107, P199, DOI 10.1016/0021-9797(85)90162-6; TAMAURA Y, 1983, J CHEM SOC DALTON, P189, DOI 10.1039/dt9830000189; TAMAURA Y, 1981, J CHEM SOC DALTON, P1807, DOI 10.1039/dt9810001807; TAYLOR RM, 1984, CLAY CLAY MINER, V32, P167, DOI 10.1346/CCMN.1984.0320302; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; ZHAO XK, 1990, J PHYS CHEM-US, V94, P2373	20	504	531	3	142	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					522	523		10.1126/science.1636086	http://dx.doi.org/10.1126/science.1636086			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636086				2022-12-28	WOS:A1992JE75500025
J	CLYNE, CA; ESTES, NAM; WANG, PJ				CLYNE, CA; ESTES, NAM; WANG, PJ			DRUG-THERAPY - MORICIZINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CONGESTIVE HEART-FAILURE; COMPLEX VENTRICULAR ARRHYTHMIAS; ANTIARRHYTHMIC EFFICACY; LONG-TERM; PREMATURE COMPLEXES; PURKINJE-FIBERS; ETHMOZINE; HCL; TACHYCARDIA; HYDROCHLORIDE		NEW ENGLAND MED CTR, BOSTON, MA USA; TUFTS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University								[Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1986, Am J Cardiol, V57, P91; BIGGER JT, 1990, AM J CARDIOL, V65, pD15; BIOLLAZ J, 1983, CLIN PPHARM THER, V37, P665; BURTON JR, 1976, AM J MED, V61, P215, DOI 10.1016/0002-9343(76)90172-8; BUTMAN SM, 1987, AM J CARDIOL, V60, P603, DOI 10.1016/0002-9149(87)90313-4; COHEN IS, 1977, PROG CARDIOVASC DIS, V20, P151, DOI 10.1016/0033-0620(77)90004-4; DANGMAN KH, 1983, J PHARMACOL EXP THER, V227, P578; DANILO P, 1977, EUR J PHARMACOL, V45, P127, DOI 10.1016/0014-2999(77)90082-6; DORIAN P, 1986, AM HEART J, V112, P327, DOI 10.1016/0002-8703(86)90270-X; DREMIN SA, 1986, KARDIOLOGIYA, V26, P10; EVANS VL, 1987, AM J CARDIOL, V60, pF83; GREENE HL, 1989, AM J CARDIOL, V63, P393, DOI 10.1016/0002-9149(89)90306-8; GRITSENKO AN, 1971, CHEM PHARM J, V6, P17; HESSION MJ, 1987, AM J CARDIOL, V60, pF59; HEWETT K, 1983, EUR J PHARMACOL, V96, P21, DOI 10.1016/0014-2999(83)90524-1; HODESS AB, 1979, J CARDIOVASC PHARM, V1, P427, DOI 10.1097/00005344-197907000-00005; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; HOROWITZ LN, 1990, AM J CARDIOL, V65, pD41; HOWRIE DL, 1987, EUR J CLIN PHARMACOL, V32, P607, DOI 10.1007/BF02455996; JANUARY CT, 1988, CIRC RES, V62, P563, DOI 10.1161/01.RES.62.3.563; KAVERINA N V, 1970, Farmakologiya i Toksikologiya (Moscow), V33, P693; KENNEDY H L, 1988, American Journal of Noninvasive Cardiology, V2, P98; KENNEDY HL, 1986, AM HEART J, V111, P667, DOI 10.1016/0002-8703(86)90096-7; KENNEDY HL, 1990, AM J CARDIOL, V65, pD47; KVAM DC, 1984, AM J CARDIOL, V53, pB22, DOI 10.1016/0002-9149(84)90497-1; MACFARLAND RT, 1985, J CLIN PHARMACOL, V25, P138, DOI 10.1002/j.1552-4604.1985.tb02814.x; MAHLER SA, 1990, AM J CARDIOL, V65, pD11; MAKIELSKI JC, 1988, J MOL CELL CARDIOL, V20, P255, DOI 10.1016/S0022-2828(88)80058-0; MANN DE, 1984, AM HEART J, V107, P674, DOI 10.1016/0002-8703(84)90314-4; MIURA DS, 1986, AM HEART J, V111, P661, DOI 10.1016/0002-8703(86)90095-5; MORGANROTH J, 1985, AM HEART J, V110, P1188, DOI 10.1016/0002-8703(85)90010-9; MORGANROTH J, 1987, AM J CARDIOL, V60, pF48; MORGANROTH J, 1990, AM J CARDIOL, V65, pD26; MORGANROTH J, 1979, AM HEART J, V98, P621, DOI 10.1016/0002-8703(79)90288-6; MORGANROTH J, 1989, AM J CARDIOL, V63, P172, DOI 10.1016/0002-9149(89)90280-4; NESTERENKO VV, 1982, B EXP BIOL MED+, V94, P1248, DOI 10.1007/BF00835636; OLSHANSKY B, 1991, CIRCULATION S2, V84, P713; PODRID PJ, 1990, AM J CARDIOL, V65, pD56; PODRID PJ, 1980, CIRCULATION, V61, P450, DOI 10.1161/01.CIR.61.2.450; PODRID PJ, 1980, NEW ENGL J MED, V302, P614, DOI 10.1056/NEJM198003133021106; POWELL JR, 1984, AM J MED, V77, P57; PRATT CM, 1987, AM J CARDIOL, V60, pF73; PRATT CM, 1987, AM J CARDIOL, V60, pF52; PRATT CM, 1984, CIRCULATION, V69, P288, DOI 10.1161/01.CIR.69.2.288; PRATT CM, 1983, AM HEART J, V106, P85, DOI 10.1016/0002-8703(83)90444-1; PRATT CM, 1986, CIRCULATION, V73, P718, DOI 10.1161/01.CIR.73.4.718; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; ROSEN MR, 1976, AM HEART J, V91, P191, DOI 10.1016/S0002-8703(76)80574-1; ROSENSHTRAUKH LV, 1987, AM J CARDIOL, V60, pF27; ROZENSHTRAUKH L V, 1979, Kardiologiya, V19, P63; ROZENSHTRAUKH LV, 1980, NIH812101 DEP HLTH H, P119; ROZENSHTRAUKH LV, 1978, DHEW NIH781470 PUBL, P291; SALERNO D M, 1991, Journal of the American College of Cardiology, V17, p56A; SHAND DG, 1984, CLIN PHARMACOKINET, V9, P27, DOI 10.2165/00003088-198400091-00004; SIDDOWAY LA, 1990, AM J CARDIOL, V65, pD21; SINGH SN, 1984, AM J CARDIOL, V53, P745, DOI 10.1016/0002-9149(84)90397-7; SMETNEV AS, 1987, AM J CARDIOL, V60, pF40; SOMBERG JC, 1986, AM HEART J, V112, P1358, DOI 10.1016/0002-8703(86)90407-2; TSCHAIDSE P, 1991, CIRCULATION S2, V84, P125; WAXMAN HL, 1983, CIRCULATION, V67, P30, DOI 10.1161/01.CIR.67.1.30; WILLIAMS EMV, 1991, J CLIN PHARMACOL, V31, P123, DOI 10.1002/j.1552-4604.1991.tb03695.x; WILLIAMS EMV, 1984, J CLIN PHARMACOL, V24, P129, DOI 10.1002/j.1552-4604.1984.tb01822.x; WOOSLEY RL, 1987, AM J CARDIOL, V60, pF35; 1989, 1989 P FDA CARD REN	65	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					255	260						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614466				2022-12-28	WOS:A1992JE38100007
J	LORIAUX, DL				LORIAUX, DL			ENDOCRINOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WOMEN; THERAPY; RISK; LOCALIZATION; ESTROGENS; FRACTURE; CANCER; TUMORS				LORIAUX, DL (corresponding author), OREGON HLTH SCI UNIV,PORTLAND,OR 97201, USA.							Albright F, 1937, NEW ENGL J MED, V216, P727, DOI 10.1056/NEJM193704292161701; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; FOSTER CM, 1984, J CLIN ENDOCR METAB, V58, P1161, DOI 10.1210/jcem-58-6-1161; LAMBERTS SWJ, 1990, J CLIN ENDOCR METAB, V71, P566, DOI 10.1210/jcem-71-3-566; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; McCune DJ, 1937, AM J DIS CHILD, V54, P806, DOI 10.1001/archpedi.1937.01980040110009; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; PERSSON I, 1989, BRIT MED J, V298, P147, DOI 10.1136/bmj.298.6667.147; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403	13	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					352	354						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613916				2022-12-28	WOS:A1992JC35200027
J	BRADLEY, DJ; KJELLBOM, P; LAMB, CJ				BRADLEY, DJ; KJELLBOM, P; LAMB, CJ			ELICITOR-INDUCED AND WOUND-INDUCED OXIDATIVE CROSS-LINKING OF A PROLINE-RICH PLANT-CELL WALL PROTEIN - A NOVEL, RAPID DEFENSE RESPONSE	CELL			English	Article							NODULIN TRANSCRIPT ENOD2; PARENCHYMA INNER CORTEX; SOYBEAN ROOT-NODULES; MONOCLONAL-ANTIBODIES; POLYACRYLAMIDE GELS; PHASEOLUS-VULGARIS; GLYCOPROTEIN GENE; SALICYLIC-ACID; EXPRESSION; PEA	Treatment of bean or soybean cells with fungal elicitor or glutathione causes a rapid insolubilization of preexisting (hydroxy)proline-rich structural proteins in the cell wall. This insolubilization, which involves H2O2-mediated oxidative cross-linking, is initiated within 2 min and is complete within 10 min under optimal conditions, and hence, precedes the expression of transcription-dependent defenses. Cross-linking is also under developmental control during hypocotyl growth and in tissues subject to mechanical stress such as the stem-petiole junction. Stimulus-dependent oxidative cross-linking of wall structural proteins is a novel site of cellular regulation with potentially important functions in cell maturation and toughening of cell walls in the initial stages of plant defense.	SALK INST BIOL STUDIES,PLANT BIOL LAB,LA JOLLA,CA 92037	Salk Institute			poinssot, benoit/B-2569-2009	poinssot, benoit/0000-0001-5890-4318				APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; AYERS AR, 1976, PLANT PHYSIOL, V57, P760, DOI 10.1104/pp.57.5.760; BIGGS KJ, 1990, PLANT PHYSIOL, V92, P197, DOI 10.1104/pp.92.1.197; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BRADLEY DJ, 1988, PLANTA, V173, P149, DOI 10.1007/BF00403006; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHEONG JJ, 1991, PLANT CELL, V3, P137, DOI 10.1105/tpc.3.2.137; CORBIN DR, 1987, MOL CELL BIOL, V7, P4337, DOI 10.1128/MCB.7.12.4337; COSIO EG, 1990, FEBS LETT, V271, P223, DOI 10.1016/0014-5793(90)80411-B; CRAMER CL, 1985, EMBO J, V4, P285, DOI 10.1002/j.1460-2075.1985.tb03627.x; DEOLIVEIRA DE, 1990, PLANT CELL, V2, P427, DOI 10.1105/tpc.2.5.427; Dixon R A, 1990, Adv Genet, V28, P165; DIXON RA, 1990, ANNU REV PLANT PHYS, V41, P339, DOI 10.1146/annurev.pp.41.060190.002011; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; GUEVARA J, 1982, ELECTROPHORESIS, V3, P197, DOI 10.1002/elps.1150030404; HONG JC, 1989, PLANT CELL, V1, P937, DOI 10.1105/tpc.1.9.937; HONG JC, 1990, J BIOL CHEM, V265, P2470; Hurn B A, 1980, Methods Enzymol, V70, P104; KELLER B, 1989, P NATL ACAD SCI USA, V86, P1529, DOI 10.1073/pnas.86.5.1529; KELLER B, 1989, GENE DEV, V3, P1639, DOI 10.1101/gad.3.10.1639; KELLER B, 1988, EMBO J, V7, P3625, DOI 10.1002/j.1460-2075.1988.tb03243.x; KELLER B, 1989, EMBO J, V8, P1309, DOI 10.1002/j.1460-2075.1989.tb03510.x; KJELLBOM P, 1984, PHYSIOL PLANTARUM, V62, P501, DOI 10.1111/j.1399-3054.1984.tb02791.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB CJ, 1989, CELL, V56, P215, DOI 10.1016/0092-8674(89)90894-5; LAWTON MA, 1987, MOL CELL BIOL, V7, P335, DOI 10.1128/MCB.7.1.335; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; NORMAN PM, 1986, PLANTA, V167, P452, DOI 10.1007/BF00391220; Roberts K, 1990, CURR OPIN CELL BIOL, V2, P920, DOI 10.1016/0955-0674(90)90093-T; SAUER N, 1990, PLANT CELL ENVIRON, V13, P257, DOI 10.1111/j.1365-3040.1990.tb01310.x; SCHEEL D, 1991, ADV MOL GENETICS PLA, V1, P373; SEQUEIRA L, 1983, ANNU REV MICROBIOL, V37, P51, DOI 10.1146/annurev.mi.37.100183.000411; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; SHENG J, 1991, PLANT J, V3, P345; SMITH JA, 1991, PHYSIOL MOL PLANT P, V38, P232; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBOSCH KA, 1989, EMBO J, V8, P335, DOI 10.1002/j.1460-2075.1989.tb03382.x; VANDEWIEL C, 1990, EMBO J, V9, P1; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WALBOT V, 1985, TRENDS GENET, V1, P165, DOI 10.1016/0168-9525(85)90071-X; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WINGATE VPM, 1988, PLANT PHYSIOL, V87, P206, DOI 10.1104/pp.87.1.206	47	981	1053	2	120	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					21	30		10.1016/0092-8674(92)90530-P	http://dx.doi.org/10.1016/0092-8674(92)90530-P			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623521				2022-12-28	WOS:A1992JC95700005
J	SERGENT, J; ZUCK, E; TERRIAH, S; MACDONALD, B				SERGENT, J; ZUCK, E; TERRIAH, S; MACDONALD, B			DISTRIBUTED NEURAL NETWORK UNDERLYING MUSICAL SIGHT-READING AND KEYBOARD PERFORMANCE	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN-BRAIN; AGRAPHIA; ALEXIA; LOCALIZATION; ACTIVATION; COMPOSER; APHASIA	Music, like other forms of expression, requires specific skills for its production, and the organization and representation of these skills in the human brain are not well understood. With the use of positron emission tomography and magnetic resonance imaging, the functional neuroanatomy of musical sight-reading and keyboard performance was studied in ten professional pianists. Reading musical notations and translating these notations into movement patterns on a keyboard resulted in activation of cortical areas distinct from, but adjacent to, those underlying similar verbal operations. These findings help explain why brain damage in musicians may or may not affect both verbal and musical functions depending on the size and location of the damaged area.			SERGENT, J (corresponding author), MCGILL UNIV,MONTREAL NEUROL INST,COGNIT NEUROSCI LAB,MONTREAL H3A 2B4,QUEBEC,CANADA.							ALAJOUANINE T, 1948, BRAIN, V71, P229, DOI 10.1093/brain/71.3.229; [Anonymous], 1977, MUSIC BRAIN; BASSO A, 1985, J NEUROL NEUROSUR PS, V48, P407, DOI 10.1136/jnnp.48.5.407; Benton AL, 1977, MUSIC AND THE BRAIN, P378; BERNSTEIN L., 1976, UNANSWERED QUESTION; BRUST JCM, 1980, BRAIN, V103, P367, DOI 10.1093/brain/103.2.367; Damasio H, 1989, LESION ANAL NEUROPSY; DELIEGE C, 1984, FONDEMENTS MUSIQUE T; Evans A.C., 1989, PROC SPIE, V1092, P264, DOI [10.1117/12.953267, DOI 10.1117/12.953267]; EVANS AC, 1988, J CEREBR BLOOD F MET, V8, P513, DOI 10.1038/jcbfm.1988.92; EVANS AC, 1991, IEEE T MED IMAGING, V10, P90, DOI 10.1109/42.75615; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FOX PT, 1991, J CEREBR BLOOD F MET, V11, pA79, DOI 10.1038/jcbfm.1991.41; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JUDD T, 1983, BRAIN, V106, P435, DOI 10.1093/brain/106.2.435; Lerdahl F., 1983, GENERATIVE GRAMMAR T; LURIA AL, 1965, J NEUROL SCI, P288; Marin O., 1982, PSYCHOL MUSIC, P453; MARIN OSM, 1980, DEEP DYSLEXIA, P407; Marnat Marcel, 1986, RAVEL; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MINTUN MA, 1989, J CEREBR BLOOD F MET, V9, P96, DOI 10.1038/jcbfm.1989.13; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; POSNER MI, 1988, SCIENCE, V240, P1627, DOI 10.1126/science.3289116; RAICHLE ME, 1983, J NUCL MED, V24, P790; ROELTGEN DP, 1984, BRAIN, V107, P811, DOI 10.1093/brain/107.3.811; ROSENTHAL M, 1987, MONDE MUS, V103, P114; SERGENT J, 1992, CEREB CORTEX, V2, P68, DOI 10.1093/cercor/2.1.68; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; SERGENT J, 1989, HDB NEUROPSYCHOLOGY, P69; Shallice T., 1988, NEUROPSYCHOLOGY MENT, DOI DOI 10.1017/IPM.2020.45; SIGNORET JL, 1987, REV NEUROL-FRANCE, V143, P172; SLOBODA J, 1978, PSYCHOL MUSIC, V9, P1; Sloboda J. A., 1985, MUSICAL MIND COGNITI; TAIRA M, 1990, EXP BRAIN RES, V83, P29; Talairach J., 1988, COPLANAR STEREOTAXIC; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; Weiskrantz L., 1968, ANAL BEHAV CHANGE, P400	41	197	198	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					106	109		10.1126/science.1621084	http://dx.doi.org/10.1126/science.1621084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	JC165	1621084				2022-12-28	WOS:A1992JC16500042
J	USHKARYOV, YA; PETRENKO, AG; GEPPERT, M; SUDHOF, TC				USHKARYOV, YA; PETRENKO, AG; GEPPERT, M; SUDHOF, TC			NEUREXINS - SYNAPTIC CELL-SURFACE PROTEINS RELATED TO THE ALPHA-LATROTOXIN RECEPTOR AND LAMININ	SCIENCE			English	Article							WIDOW SPIDER VENOM; EGF-LIKE REPEATS; NEUROMUSCULAR-JUNCTIONS; DROSOPHILA-MELANOGASTER; SYNAPSIN-I; GENE; MEMBRANE; PURIFICATION; PRECURSOR; MOLECULES	A family of highly polymorphic neuronal cell surface proteins, the neurexins, has been identified. At least two genes for neurexins exist. Each gene uses alternative promoters and multiple variably spliced exons to potentially generate more than a 100 different neurexin transcripts. The neurexins were discovered by the identification of one member of the family as the receptor for alpha-latrotoxin. This toxin is a component of the venom from black widow spiders; it binds to presynaptic nerve terminals and triggers massive neurotransmitter release. Neurexins contain single transmembrane regions and extracellular domains with repeated sequences similar to sequences in laminin A, slit, and agrin, proteins that have been implicated in axon guidance and synaptogenesis. An antibody to neurexin I showed highly concentrated immunoreactivity at the synapse. The polymorphic structure of the neurexins, their neural localization, and their sequence similarity to proteins associated with neurogenesis suggest a function as cell recognition molecules in the nerve terminal.	MOSCOW BIOORGAN CHEM INST,MOSCOW 117871,USSR; UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	USHKARYOV, YA (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.		Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Petrenko, Alexander/0000-0002-6689-6546				CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; FERNS M, IN PRESS NEURON; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIDD S, 1983, CELL, V34, P421, DOI 10.1016/0092-8674(83)90376-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LONGENEC.HE, 1970, NATURE, V225, P701, DOI 10.1038/225701a0; MALGAROLI A, 1989, NEUROSCIENCE, V32, P393, DOI 10.1016/0306-4522(89)90088-2; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; MCMAHAN UJ, 1989, DEV NEUROSCI-BASEL, V11, P227, DOI 10.1159/000111903; NOONAN DM, 1991, J BIOL CHEM, V266, P22939; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PERIN MS, 1988, EMBO J, V7, P2697, DOI 10.1002/j.1460-2075.1988.tb03123.x; PETERS A, 1991, WEBSTER FINE STRUCTU; PETR P, 1985, BIOCHIM BIOPHYS ACTA, V815, P46; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; REICHARDT LF, 1989, MOL NEUROBIOL, P110; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHEER H, 1985, EMBO J, V4, P323, DOI 10.1002/j.1460-2075.1985.tb03632.x; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; SKUBITZ APN, 1991, J CELL BIOL, V115, P1137, DOI 10.1083/jcb.115.4.1137; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TZENG MC, 1979, J NEUROCHEM, V33, P263, DOI 10.1111/j.1471-4159.1979.tb11728.x; VALTORTA F, 1984, J CELL BIOL, V99, P124, DOI 10.1083/jcb.99.1.124; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981	40	556	578	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					50	56		10.1126/science.1621094	http://dx.doi.org/10.1126/science.1621094			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621094				2022-12-28	WOS:A1992JC16500025
J	FURUKAWA, T; MARUYAMA, S; KAWAICHI, M; HONJO, T				FURUKAWA, T; MARUYAMA, S; KAWAICHI, M; HONJO, T			THE DROSOPHILA HOMOLOG OF THE IMMUNOGLOBULIN RECOMBINATION SIGNAL BINDING-PROTEIN REGULATES PERIPHERAL NERVOUS-SYSTEM DEVELOPMENT	CELL			English	Article							SMALL AUTOSOMAL REGION; LARGE TRANSPOSING ELEMENT; SCUTE GENE-COMPLEX; LOOP-HELIX PROTEINS; ALCOHOL-DEHYDROGENASE; STRUCTURAL GENE; NEGATIVE REGULATOR; MELANOGASTER; DNA; MUTATIONS	The J(kappa) RBP binds to the immunoglobulin recombination signal sequence flanking the kappa-type J segment. We previously isolated the highly conserved homolog of the J(kappa) RBP gene from D. melanogaster, which is not thought to have immunoglobulin molecules. Using many deficiency mutants and in situ hybridization, we mapped the Drosophila J(kappa) RBP gene in a region containing two recessive lethal mutations, i.e., br26 and br7, which shows the dominant Suppressor of Hairless (Su(H)) phenotype in heterozygotes. All six Su(H) alleles analyzed at the DNA level contained mutations in the Drosophila J(kappa) RBP gene. Since the Su(H) mutation affects peripheral nervous system development, the Drosophila J(kappa) RBP gene product is involved in gene regulation of peripheral nervous system development. The results also imply that the immunoglobulin recombination signal sequence and the target sequence of the Drosophila J(kappa) RBP protein might have a common evolutionary origin.			FURUKAWA, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ASHBURNER M, 1982, GENETICS, V102, P401; ASHBURNER M, 1990, GENETICS, V126, P679; ASHBURNER M, 1982, GENETICS, V101, P447; ASHBURNER M, 1983, GENETICS, V104, P405; ASHBURNER M, 1982, GENETICS, V102, P421; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANG AG, 1991, DEVELOPMENT, V111, P89; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CRAIG NL, 1988, ANNU REV GENET, V22, P77; DELPRADO JM, 1984, W ROUX ARCH DEV BIOL, V193, P242; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA T, 1991, J BIOL CHEM, V266, P23334; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GUBB D, 1986, GENETICS, V112, P551; GUBB D, 1985, CHROMOSOMA, V92, P116, DOI 10.1007/BF00328463; GUBB D, 1984, CHROMOSOMA, V91, P54, DOI 10.1007/BF00286485; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; JAN YN, 1990, TRENDS NEUROSCI, V13, P493, DOI 10.1016/0166-2236(90)90083-M; KAWAICHI M, 1991, J BIOL CHEM, V266, P18387; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P844, DOI 10.1073/pnas.82.3.844; LITMAN GW, 1985, P NATL ACAD SCI USA, V82, P2082, DOI 10.1073/pnas.82.7.2082; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MOHLER J, 1984, GENETICS, V106, P249; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NASH D, 1990, GENETICS, V64, P471; NISHIDA Y, 1986, BIOCHEM BIOPH RES CO, V141, P474, DOI 10.1016/S0006-291X(86)80197-8; ODONNELL JD, 1977, GENETICS, V86, P533; Plunkett CR, 1926, J EXP ZOOL, V46, P181, DOI 10.1002/jez.1400460204; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAGER J, 1988, EMBO J, V7, P2409, DOI 10.1002/j.1460-2075.1988.tb03086.x; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TREACY MN, 1991, NATURE, V350, P577, DOI 10.1038/350577a0; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WOODRUFF RC, 1979, GENETICS, V92, P133; WOODRUFF RC, 1979, GENETICS, V92, P117	50	114	117	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1191	1197		10.1016/0092-8674(92)90640-X	http://dx.doi.org/10.1016/0092-8674(92)90640-X			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617729				2022-12-28	WOS:A1992JA43100013
J	MCENERY, PT; STABLEIN, DM; ARBUS, G; TEJANI, A				MCENERY, PT; STABLEIN, DM; ARBUS, G; TEJANI, A			RENAL-TRANSPLANTATION IN CHILDREN - A REPORT OF THE NORTH-AMERICAN-PEDIATRIC-RENAL-TRANSPLANT-COOPERATIVE-STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Previous studies of renal transplantation in children have focused on the survival of grafts and patients. Little information is available about the cause of renal disease, the sources of donated organs, or children's growth after transplantation. The North American Pediatric Renal Transplant Cooperative Study was organized to identify the diseases that require transplantation and to analyze factors that affect the success of transplantation in children. Methods. We collected data from 73 pediatric transplantation centers from 1987 through 1990. These data included information about demographic characteristics of patients, graft function, and therapy one month after transplantation and every six months thereafter for each patient 17 years of age or younger. Results. Altogether, 1550 children received 1667 renal allografts during this period; 31 percent of the children were five years of age or younger. Forty-three percent of the transplanted kidneys came from a living related donor, and 57 percent from a cadaver. The two most common causes of renal disease leading to transplantation were congenital malformations of the kidneys and urinary tract (42 percent of the patients) and focal segmental glomerulosclerosis (12 percent). One year after transplantation, the rate of graft survival in recipients of a kidney from a living related donor was 89 percent; it was 80 percent after three years. For recipients of cadaver kidneys, the comparable rates were 74 percent and 62 percent, respectively (P<0.001). The best growth was observed in patients who were no more than five years old at the time of transplantation. During follow-up, 79 patients died, and cancer developed in 12 patients. Conclusions. The most common causes of end-stage renal disease in children and adolescents are congenital malformations of the kidneys and urinary tract and focal segmental glomerulosclerosis. The rates of graft survival at one and three years are better in children and adolescents who receive a kidney from a living related donor than in those who receive a kidney from a cadaver.	SUNY HLTH SCI CTR,CTR NAPRTCS CLIN COORDINATING,450 CLARKSON AVE,BOX 49,BROOKLYN,NY 11203; CHILDRENS HOSP MED CTR,CINCINNATI,OH 45229; EMMES CORP,POTOMAC,MD; HOSP SICK CHILDREN,TORONTO M5G 1X8,ONTARIO,CANADA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Cincinnati Children's Hospital Medical Center; Emmes Corporation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)								ALEXANDER SR, 1990, PEDIATR NEPHROL, V4, P542, DOI 10.1007/BF00869842; BROYER M, 1989, TRANSPLANT P, V21, P1985; FINE RN, 1985, KIDNEY INT S, V29, pS7; HARMON WE, 1991, TRANSPLANTATION, V51, P406, DOI 10.1097/00007890-199102000-00026; TRACHTMAN H, 1985, KIDNEY INT, V29, pS15; 1991, NIH913176 NAT I DIAB; 1990, UNOS UPDATE, V8, P10; 1989, FED REGISTER, V54, P36452	8	169	172	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1727	1732		10.1056/NEJM199206253262602	http://dx.doi.org/10.1056/NEJM199206253262602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1594014	Bronze			2022-12-28	WOS:A1992HZ89400002
J	SCHOFIELD, PF; JONES, DJ				SCHOFIELD, PF; JONES, DJ			ABC OF COLORECTAL DISEASES - COLORECTAL NEOPLASIA .3. TREATMENT AND PREVENTION	BRITISH MEDICAL JOURNAL			English	Article									HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND		SCHOFIELD, PF (corresponding author), WITHINGTON HOSP,MANCHESTER M20 8LR,LANCS,ENGLAND.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1624	1627		10.1136/bmj.304.6842.1624	http://dx.doi.org/10.1136/bmj.304.6842.1624			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628094	Green Published, Bronze			2022-12-28	WOS:A1992JA43600032
J	POWERS, R; GARRETT, DS; MARCH, CJ; FRIEDEN, EA; GRONENBORN, AM; CLORE, GM				POWERS, R; GARRETT, DS; MARCH, CJ; FRIEDEN, EA; GRONENBORN, AM; CLORE, GM			3-DIMENSIONAL SOLUTION STRUCTURE OF HUMAN INTERLEUKIN-4 BY MULTIDIMENSIONAL HETERONUCLEAR MAGNETIC-RESONANCE SPECTROSCOPY	SCIENCE			English	Article							RESTRAINED MOLECULAR-DYNAMICS; CYTOKINE RECEPTOR SUPERFAMILY; CELL-STIMULATING FACTOR; 2D NMR-SPECTRA; DISTANCE GEOMETRY; FACTOR-I; COUPLING-CONSTANTS; HYDROGEN-EXCHANGE; PROTEINS; ASSIGNMENT	The three-dimensional solution structure of recombinant human interleukin-4, a protein of 133 residues and 15.4 kilodaltons that plays a key role in the immune and inflammatory systems, has been solved by multidimensional heteronuclear magnetic resonance spectroscopy. The structure is dominated by a left-handed four-helix bundle with an unusual topology comprising two overhand connections. The linker elements between the helices are formed by either long loops, small helical turns, or short strands. The overall topology is remarkably similar to that of growth hormone and granulocyte-macrophage colony stimulating factor, despite the absence of any sequence homology, and substantial differences in the relative lengths of the helices, the length and nature of the various connecting elements, and the pattern of disulfide bridges. These three proteins, however, bind to cell surface receptors belonging to the same hematopoietic superfamily, which suggests that interleukin-4 may interact with its receptor in an analogous manner to that observed in the crystal structure of the growth hormone-extracellular receptor complex.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA; IMMUNEX CORP, SEATTLE, WA 98101 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Immunex Corporation			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008; Powers, Robert/AAK-3431-2020	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Powers, Robert/0000-0001-9948-6837; Gronenborn, Angela M/0000-0001-9072-3525				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; ARAI KI, 1990, ANNU REV BIOCHEM, V59, P7983; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; BRUNGER AT, 1992, XPLOR VERSION 3 MANU; CARR C, 1991, BIOCHEMISTRY-US, V30, P1515, DOI 10.1021/bi00220a011; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHICHE L, 1990, P NATL ACAD SCI USA, V87, P3240, DOI 10.1073/pnas.87.8.3240; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CURTIS BM, 1991, PROTEINS, V11, P111, DOI 10.1002/prot.340110204; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; DIEDERICHS K, 1991, J MOL BIOL, V221, P55, DOI 10.1016/0022-2836(91)90803-E; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FORMANKAY JD, 1990, BIOCHEMISTRY-US, V29, P1566, DOI 10.1021/bi00458a030; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GARRETT DS, 1992, BIOCHEMISTRY-US, V31, P4347, DOI 10.1021/bi00132a027; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRABSTEIN K, 1986, J EXP MED, V163, P1405, DOI 10.1084/jem.163.6.1405; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PARK LS, 1987, P NATL ACAD SCI USA, V84, P1669, DOI 10.1073/pnas.84.6.1669; PARK LS, 1987, J EXP MED, V166, P476, DOI 10.1084/jem.166.2.476; PAUL WE, 1987, ANNU REV IMMUNOL, V5, P429, DOI 10.1146/annurev.iy.05.040187.002241; POWERS R, 1992, BIOCHEMISTRY-US, V31, P4334, DOI 10.1021/bi00132a026; REDFIELD C, 1991, BIOCHEMISTRY-US, V30, P11029, DOI 10.1021/bi00110a004; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	50	150	164	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1992	256	5064					1673	1677		10.1126/science.256.5064.1673	http://dx.doi.org/10.1126/science.256.5064.1673			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609277	Green Published			2022-12-28	WOS:A1992HZ17400043
J	DEVRIESSMITS, AMM; BURGERING, BMT; LEEVERS, SJ; MARSHALL, CJ; BOS, JL				DEVRIESSMITS, AMM; BURGERING, BMT; LEEVERS, SJ; MARSHALL, CJ; BOS, JL			INVOLVEMENT OF P21RAS IN ACTIVATION OF EXTRACELLULAR SIGNAL-REGULATED KINASE-2	NATURE			English	Article							INSULIN; PHOSPHORYLATES; STIMULATION	MANY growth factors upon stimulation of their receptors induce the activity of extracellular signal-regulated kinases, ERKs, also known as MAP kinases 1,2. Several of these growth factors also activate the ras proto-oncogene product, p21ras (Ras), by stimulating the conversion of the inactive GDP-bound form of Ras to the active GTP-bound form 3-6. We have shown that direct introduction of p21ras oncoprotein into cells in the absence of growth factors activates ERKs within five minutes 7, which indicates that normal p21ras may be involved in the activation of ERKs by growth factors. Here we use a recombinant vaccinia virus expressing an interfering mutant of p21ras, Ras(Asn17), to investigate this question. In NIH3T3 cells that overexpress the insulin receptor, this recombinant virus inhibits insulin-induced activation of ERK2 completely, but there is no inhibition of insulin-induced activation of phosphatidyl-inositol-3-kinase. In rat-1 cells the recombinant virus inhibited ERK2 activity induced by platelet-derived growth factor (PDGF) but not by phorbol ester. We conclude that p21ras mediates insulin- and PDGF-induced activation of ERK2.	CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK	DEVRIESSMITS, AMM (corresponding author), UNIV UTRECHT,PHYSIOL CHEM LAB,VONDELLAAN 24A,3521 GG UTRECHT,NETHERLANDS.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACKSHEAR PJ, 1991, J BIOL CHEM, V266, P10946; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVISON AJ, 1989, J MOL BIOL, V210, P749, DOI 10.1016/0022-2836(89)90107-1; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Mackett M., 1985, DNA CLONING PRACTICA, P191; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; OSTEROP APR, IN PRESS J BIOL CHEM; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; STACEY DW, 1991, ONCOGENE, V6, P2297; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0	23	387	388	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					602	604		10.1038/357602a0	http://dx.doi.org/10.1038/357602a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608472				2022-12-28	WOS:A1992HZ11200058
J	RICE, WR				RICE, WR			SEXUALLY ANTAGONISTIC GENES - EXPERIMENTAL-EVIDENCE	SCIENCE			English	Article								When selection differs between the sexes, a mutation beneficial to one sex may be harmful to the other (sexually antagonistic). Because the sexes share a common gene pool, selection in one sex can interfere with the other's adaptive evolution. Theory predicts that sexually antagonistic mutations should accumulate in tight linkage with a new sex-determining gene, even when the harm to benefit ratio is high. Genetic markers and artificial selection were used to make a pair of autosomal genes segregate like a new pair of sex-determining genes in a Drosophila melanogaster model system. A 29-generation study provides experimental evidence that sexually antagonistic genes may be common in nature and will accumulate in response to a new sex-determining gene.			RICE, WR (corresponding author), UNIV CALIF SANTA CRUZ,BIOL BOARD STUDIES,SANTA CRUZ,CA 95064, USA.							Bull J.J., 1983, EVOLUTION SEX DETERM; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1987, AM NAT, V130, P113, DOI 10.1086/284701; CHARLESWORTH D, 1980, GENET RES, V35, P205, DOI 10.1017/S0016672300014051; Fisher RA, 1931, BIOL REV BIOL P CAMB, V6, P345, DOI 10.1111/j.1469-185X.1931.tb01030.x; KIDWELL JF, 1973, GENETICS, V85, P171; Lindsley D.L., 1968, GENETIC VARIATIONS D; MANDEL SPH, 1971, HEREDITY, V26, P49, DOI 10.1038/hdy.1971.5; RICE WR, 1984, EVOLUTION, V38, P735, DOI 10.1111/j.1558-5646.1984.tb00346.x; SPEITH HT, 1983, GENETICS BIOL DROSOP, V3, pCH23	10	239	240	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1436	1439		10.1126/science.1604317	http://dx.doi.org/10.1126/science.1604317			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604317				2022-12-28	WOS:A1992HX33700033
J	POSSELT, AM; BARKER, CF; FRIEDMAN, AL; NAJI, A				POSSELT, AM; BARKER, CF; FRIEDMAN, AL; NAJI, A			PREVENTION OF AUTOIMMUNE DIABETES IN THE BB RAT BY INTRATHYMIC ISLET TRANSPLANTATION AT BIRTH	SCIENCE			English	Article							LYMPHOCYTES-T; MONOCLONAL-ANTIBODIES; SELF-TOLERANCE; CELLS; EXPRESSION; RECEPTOR; SUBSETS	Spontaneous diabetes in the BioBreeding (BB) rat, like human type I diabetes, results from the destruction of pancreatic islets by autoreactive T lymphocytes recognizing beta-cell-specific antigens. T cell tolerance is in part mediated by interactions of maturing thymocytes with antigens expressed in the thymic microenvironment; islets were therefore implanted into the thymus of neonatal diabetes-prone BB rats to determine whether exposure of T cell precursors to beta-cell antigens could influence the development of diabetes. This treatment completely prevented diabetes and insulitis in the native pancreas. The effect may be the result of specific modulation of diabetogenic T cells maturing in an islet-bearing thymus.	HOSP UNIV PENN,DEPT SURG,4 SILVERSTEIN,3400 SPRUCE ST,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034878, R01DK026007, R37DK026007, R01DK034878] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34878, DK26007] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPEL MC, 1989, DIABETOLOGIA, V32, pA461; DEAN BM, 1985, DIABETOLOGIA, V28, P464, DOI 10.1007/BF00280892; GEORGIOU HM, 1988, J EXP MED, V167, P132, DOI 10.1084/jem.167.1.132; GOTFREDSEN CF, 1985, DIABETOLOGIA, V28, P933, DOI 10.1007/BF00703140; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; JAWORSKI MA, 1986, DIABETES RES CLIN EX, V3, P1; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LIKE AA, 1986, DIABETES, V35, pA74; LIKE AA, 1986, J EXP MED, V164, P1145, DOI 10.1084/jem.164.4.1145; LIKE AA, 1979, SCIENCE, V206, P1421, DOI 10.1126/science.388619; MASON DW, 1983, IMMUNOL REV, V74, P57, DOI 10.1111/j.1600-065X.1983.tb01084.x; MCKEEVER U, 1990, P NATL ACAD SCI USA, V87, P7618, DOI 10.1073/pnas.87.19.7618; MORDES JP, 1987, DIABETES METAB REV, V3, P725, DOI 10.1002/dmr.5610030307; MORDES JP, 1987, DIABETOLOGIA, V30, P22, DOI 10.1007/BF01788902; MURASE N, 1990, DIABETES, V39, P1584, DOI 10.2337/diabetes.39.12.1584; NAJI A, 1983, J IMMUNOL, V130, P2168; NAJI A, 1981, SCIENCE, V213, P1390, DOI 10.1126/science.6791286; NAKHOODA AF, 1977, DIABETES, V26, P100, DOI 10.2337/diabetes.26.2.100; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; POSSELT AM, 1990, SCIENCE, V249, P1293, DOI 10.1126/science.2119056; POSSELT AM, 1991, ANN SURG, V214, P363, DOI 10.1097/00000658-199110000-00001; RAMSDELL F, 1989, SCIENCE, V246, P1038, DOI 10.1126/science.2511629; ROSSINI AA, 1984, J CLIN INVEST, V74, P36; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5	24	133	136	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1321	1324		10.1126/science.1598576	http://dx.doi.org/10.1126/science.1598576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598576				2022-12-28	WOS:A1992HW13500034
J	ZHANG, JP; STEPHENS, RS				ZHANG, JP; STEPHENS, RS			MECHANISM OF C-TRACHOMATIS ATTACHMENT TO EUKARYOTIC HOST-CELLS	CELL			English	Article							CHLAMYDIA-TRACHOMATIS; HEPARAN-SULFATE; LEISHMANIA-DONOVANI; BINDING PROTEINS; MCCOY CELLS; PSITTACI; GLYCOSAMINOGLYCAN; BIOSYNTHESIS; SEQUENCE; HELA	A novel trimolecular mechanism of microbial attachment to mammalian host cells was characterized for the obligate intracellular pathogen Chlamydia trachomatis. Using purified glycosaminoglycans (GAGs) and specific GAG lyases, we demonstrated that a heparan sulfate-like GAG present on the surface of chlamydia organisms is required for attachment to host cells. These observations were supported by inhibition of attachment following binding of heparan sulfate receptor analogs to chlamydiae and by demonstrating that chlamydiae synthesize a unique heparan sulfate-like GAG. Furthermore, exogenous heparan sulfate, as an adhesin analog, restored attachment and infectivity to organisms that had lost these attributes following treatment with heparan sulfate lyase. These data suggest that a GAG adhesin ligand mediates attachment by bridging mutual GAG receptors on the host cell surface and on the chlamydial outer membrane surface.	UNIV CALIF SAN FRANCISCO,FRANCIS I PROCTOR FDN,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	ZHANG, JP (corresponding author), UNIV CALIF BERKELEY,DEPT BIOMED & ENVIRONM HLTH SCI,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY007757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029432] Funding Source: NIH RePORTER; NEI NIH HHS [EY07757] Funding Source: Medline; NIAID NIH HHS [AI29432] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN J, 1988, J BACTERIOL, V171, P285; BARZU T, 1985, BIOCHIM BIOPHYS ACTA, V845, P196, DOI 10.1016/0167-4889(85)90177-6; BEACHEY EH, 1981, J INFECT DIS, V143, P325, DOI 10.1093/infdis/143.3.325; BECKER Y, 1969, ISRAEL J MED SCI, V5, P121; BILOZUR ME, 1990, J BIOL CHEM, V265, P19697; BUTCHER BA, 1990, EXP PARASITOL, V71, P49, DOI 10.1016/0014-4894(90)90007-Y; BYRNE GI, 1976, INFECT IMMUN, V14, P645, DOI 10.1128/IAI.14.3.645-651.1976; BYRNE GI, 1978, INFECT IMMUN, V19, P598, DOI 10.1128/IAI.19.2.598-606.1978; CARDIN AD, 1984, ANAL BIOCHEM, V137, P368, DOI 10.1016/0003-2697(84)90099-X; CERI H, 1986, INFECT IMMUN, V51, P1; DAWSON CR, 1985, REV INFECT DIS, V7, P768; EISSENBERG LG, 1983, INFECT IMMUN, V40, P741, DOI 10.1128/IAI.40.2.741-751.1983; ESKO JD, 1986, J BIOL CHEM, V261, P5725; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; HATCH TP, 1981, J GEN MICROBIOL, V125, P273; HODINKA RL, 1986, INFECT IMMUN, V54, P885; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHNSON AP, 1983, BRIT J VENER DIS, V59, P369; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KOEHLER JE, 1990, J BIOL CHEM, V265, P13206; KOHNKEGODT B, 1991, BIOCHEMISTRY-US, V30, P55, DOI 10.1021/bi00215a009; KUO CC, 1976, INFECT IMMUN, V13, P1103, DOI 10.1128/IAI.13.4.1103-1109.1976; KURE S, 1986, J IMMUNOL, V137, P3900; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; MENOZZI FD, 1991, FEMS MICROBIOL LETT, V78, P59; METTENLEITER TC, 1990, J VIROL, V64, P278, DOI 10.1128/JVI.64.1.278-286.1990; MOULDER JW, 1988, MICROBIOLOGY CHLAMYD, P3; MUKHOPADHYAY NK, 1989, BIOCHEM J, V264, P517, DOI 10.1042/bj2640517; OFEK I, 1982, J BACTERIOL, V149, P426, DOI 10.1128/JB.149.2.426-433.1982; OKAZAKI K, 1991, VIROLOGY, V181, P666, DOI 10.1016/0042-6822(91)90900-V; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PAUL G, 1987, J BIOL CHEM, V262, P9587; SCHACHTER J, 1988, MICROBIOLOGY CHLAMYD, P153; SODERLUND G, 1983, INFECT IMMUN, V40, P534; STEPHENS RS, 1986, J BACTERIOL, V168, P1277, DOI 10.1128/jb.168.3.1277-1282.1986; STEPHENS RS, 1982, J CLIN MICROBIOL, V16, P4, DOI 10.1128/JCM.16.1.4-7.1982; STEPHENS RS, 1989, INTRACELLULAR PARASI, P51; STORZ J, 1989, MICROBIOLOGY CHLAMYD, P167; TROY FA, 1979, ANNU REV MICROBIOL, V33, P519, DOI 10.1146/annurev.mi.33.100179.002511; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; VANN WF, 1981, EUR J BIOCHEM, V116, P359, DOI 10.1111/j.1432-1033.1981.tb05343.x; VRETOU E, 1989, J GEN MICROBIOL, V135, P3229; WIELAND F, 1980, FEBS LETT, V120, P110, DOI 10.1016/0014-5793(80)81058-1; WINER MA, 1989, J REPROD FERTIL, V87, P337, DOI 10.1530/jrf.0.0870337; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; WYRICK PB, 1989, INFECT IMMUN, V57, P2378, DOI 10.1128/IAI.57.8.2378-2389.1989	52	206	211	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					861	869		10.1016/0092-8674(92)90296-O	http://dx.doi.org/10.1016/0092-8674(92)90296-O			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591780				2022-12-28	WOS:A1992HW83800015
J	CORAZZA, GR; FRISONI, M; FILIPPONI, C; GULLO, L; POGGI, VM; GASBARRINI, G				CORAZZA, GR; FRISONI, M; FILIPPONI, C; GULLO, L; POGGI, VM; GASBARRINI, G			INVESTIGATION OF QT INTERVAL IN ADULT CELIAC-DISEASE	BRITISH MEDICAL JOURNAL			English	Article									S ORSOLA UNIV HOSP,DEPT MED PATHOL & CLIN MED 1,I-40138 BOLOGNA,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna	CORAZZA, GR (corresponding author), UNIV LAQUILA,DEPT MED,I-67100 LAQUILA,ITALY.		Corazza, Gino Roberto/K-8500-2016	Corazza, Gino Roberto/0000-0001-9532-0573				CHAMBERS JB, 1985, LANCET, V2, P1308; GREEN PA, 1960, GASTROENTEROLOGY, V38, P399; ISNER JM, 1985, ANN INTERN MED, V102, P49, DOI 10.7326/0003-4819-102-1-49; MOSS AJ, 1986, JAMA-J AM MED ASSOC, V256, P2985; VINCENT G M, 1974, Progress in Cardiovascular Diseases, V16, P523	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1285	1285		10.1136/bmj.304.6837.1285	http://dx.doi.org/10.1136/bmj.304.6837.1285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606432	Bronze, Green Published			2022-12-28	WOS:A1992HV08600024
J	BLANAR, MA; RUTTER, WJ				BLANAR, MA; RUTTER, WJ			INTERACTION CLONING - IDENTIFICATION OF A HELIX-LOOP-HELIX ZIPPER PROTEIN THAT INTERACTS WITH C-FOS	SCIENCE			English	Article							MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR BINDS; DNA-BINDING; LEUCINE ZIPPER; RNA-POLYMERASE; NUCLEOTIDE-SEQUENCE; NEGATIVE REGULATION; IMMUNE INTERFERON; UPSTREAM ELEMENT; MYC-ONCOGENE	A facile method for isolating genes that encode interacting proteins has been developed with a polypeptide probe that contains an amino-terminal extension with recognition sites for a monoclonal antibody, a specific endopeptidase, and a site-specific protein kinase. This probe, containing the basic region-leucine zipper dimerization motif of c-Fos, was used to screen a complementary DNA library. A complementary DNA that encoded a member of the basic-helix-loop-helix-zipper (bHLH-Zip) family of proteins was isolated. The complementary DNA-encoded polypeptide FIP (Fos interacting protein) bound to oligonucleotide probes that contained DNA binding motifs for other HLH proteins. When cotransfected with c-Fos, FIP stimulated transcription of an AP-1-responsive promoter.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	BLANAR, MA (corresponding author), UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041822, R01DK021344, R56DK021344, R37DK021344] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41822, DK-21344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1989, New Biologist, V1, P35; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, UNPUB; BOHMANN D, 1988, NATURE, V332, P166; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; CURRAN T, 1987, ONCOGENE, V2, P79; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUNG HF, 1986, METHOD ENZYMOL, V119, P296; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PRICE V, 1987, GENE, V55, P287, DOI 10.1016/0378-1119(87)90288-5; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCOTTO KW, 1989, GENE DEV, V3, P651, DOI 10.1101/gad.3.5.651; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VOGT P, 1990, ADV CANCER RES, V85, P1; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	59	337	373	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1014	1018		10.1126/science.1589769	http://dx.doi.org/10.1126/science.1589769			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589769				2022-12-28	WOS:A1992HU22400037
J	WIERTELAK, EP; MAIER, SF; WATKINS, LR				WIERTELAK, EP; MAIER, SF; WATKINS, LR			CHOLECYSTOKININ ANTIANALGESIA - SAFETY CUES ABOLISH MORPHINE ANALGESIA	SCIENCE			English	Article							SPINAL-CORD; OPIATE ANALGESIA; BINDING-SITES; ANTAGONIST; PAIN; CCK; NEUROPEPTIDE; NOCICEPTION; INHIBITION; L-365,260	Environmental stimuli that signal the occurrence of aversive or dangerous events activate endogenous opiate analgesia systems. Signals for safety (the nonoccurrence of aversive events) produce the opposite and inhibit environmentally produced analgesia. Stimuli that signal safety are now shown to abolish the analgesic effect of morphine, even when morphine is applied directly to spinal cord. Further, this antiopiate effect occurs because the environmental stimulus leads to release of the neuropeptide cholecystokinin in the spinal cord. This process may contribute to the regulation of pain and the development of opiate tolerance.			WIERTELAK, EP (corresponding author), UNIV COLORADO, DEPT PSYCHOL, BOULDER, CO 80309 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014617] Funding Source: NIH RePORTER; NIMH NIH HHS [5T32MH14617-15] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLARD M, 1991, NEUROSCIENCE, V40, P81, DOI 10.1016/0306-4522(91)90176-O; ALLARD M, 1989, BRAIN RES, V500, P169, DOI 10.1016/0006-8993(89)90311-9; BABER NS, 1989, PAIN, V39, P307, DOI 10.1016/0304-3959(89)90045-6; BELL JA, 1977, EUR J PHARMACOL, V42, P147, DOI 10.1016/0014-2999(77)90354-5; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; CHANG RSL, 1986, P NATL ACAD SCI USA, V83, P4923, DOI 10.1073/pnas.83.13.4923; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; FARIS PL, 1983, SCIENCE, V219, P310, DOI 10.1126/science.6294831; HARRO J, 1991, EUR J PHARMACOL, V193, P379, DOI 10.1016/0014-2999(91)90156-K; HILL DR, 1990, BRAIN RES, V526, P276, DOI 10.1016/0006-8993(90)91232-6; HILL DR, 1988, NEUROSCI LETT, V89, P133, DOI 10.1016/0304-3940(88)90369-2; KELLY DD, 1986, ANN NY ACAD SCI, V467; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; MAIER SF, 1976, ANIM LEARN BEHAV, V4, P217, DOI 10.3758/BF03214039; MELZACK R, 1988, 5TH P WORLD C PAIN, P4; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; PASTERNAK GW, 1988, JAMA-J AM MED ASSOC, V259, P1362, DOI 10.1001/jama.259.9.1362; RATAUD J, 1991, BRAIN RES, V548, P315, DOI 10.1016/0006-8993(91)91139-R; SIEGEL S, 1979, PSYCHOPATHOLOGY ANIM, P143; SOLOMON RL, 1974, PSYCHOL REV, V81, P119, DOI 10.1037/h0036128; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; TWYCROSS RG, 1984, TXB PAIN, P516; WATKINS LR, 1986, BRAIN RES, V362, P308, DOI 10.1016/0006-8993(86)90455-5; WATKINS LR, 1984, SCIENCE, V224, P395, DOI 10.1126/science.6546809; WESTBROOK RF, 1990, Q J EXP PSYCHOL-B, V42, P1; WIERTELAK E P, 1991, Society for Neuroscience Abstracts, V17, P109; WIERTELAK EP, UNPUB; YAKSH TL, 1977, J PHARMACOL EXP THER, V202, P411; YAKSH TL, 1985, ANNU REV PHARMACOL, V25, P433, DOI 10.1146/annurev.pa.25.040185.002245; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; ZADINA JE, 1987, BRAIN RES, V409, P10, DOI 10.1016/0006-8993(87)90736-0; ZINBERG NE, 1984, DRUG SET SETTING, P12	32	127	128	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					830	833		10.1126/science.1589765	http://dx.doi.org/10.1126/science.1589765			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589765				2022-12-28	WOS:A1992HT23500043
J	IFUDU, O; KOLASINSKI, SL; FRIEDMAN, EA				IFUDU, O; KOLASINSKI, SL; FRIEDMAN, EA			KIDNEY-RELATED MUNCHAUSEN-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											IFUDU, O (corresponding author), SUNY HLTH SCI CTR, DEPT MED, BOX 52, 450 CLARKSON AVE, BROOKLYN, NY 11203 USA.							ASHER R, 1951, LANCET, V260, P339; ATKINSON RL, 1974, JAMA-J AM MED ASSOC, V230, P89, DOI 10.1001/jama.230.1.89; COHEN AH, 1989, AM J NEPHROL, V9, P309, DOI 10.1159/000167986; DIAZBUXO JA, 1975, CLIN NEPHROL, V4, P23; IRELAND P, 1967, AM J MED, V43, P579, DOI 10.1016/0002-9343(67)90181-7; KARK RM, 1958, ARCH INTERN MED, V101, P439, DOI 10.1001/archinte.1958.00260140271038; LEVY NB, 1977, INT J PSYCHIAT MED, V7, P257, DOI 10.2190/W4X3-KPX2-384D-4J7U; LIDNENBAUM J, 1974, JAMA-J AM MED ASSOC, V228, P498; MORELMAROGER L, 1982, AM J KIDNEY DIS, V1, P244, DOI 10.1016/S0272-6386(82)80062-0; MUTH RG, 1965, J UROLOGY, V94, P1; PANNBACKER M, 1990, Ear Nose and Throat Journal, V69, P656; PETERSDORF RG, 1957, ANN INTERN MED, V46, P1039, DOI 10.7326/0003-4819-46-6-1039; ROSENBLUM M, 1977, ARCH INTERN MED, V137, P1244, DOI 10.1001/archinte.137.9.1244; SHAFER N, 1980, NEW YORK STATE J MED, V80, P594; SLOTKIN EA, 1962, J UROLOGY, V87, P13, DOI 10.1016/S0022-5347(17)64898-5; SPIRO HR, 1968, ARCH GEN PSYCHIAT, V18, P569, DOI 10.1001/archpsyc.1968.01740050057010; TUNBRIDGE WM, 1969, NEW ENGL J MED, V280, P1130	17	29	30	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					388	389		10.1056/NEJM199208063270605	http://dx.doi.org/10.1056/NEJM199208063270605			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625713	Bronze			2022-12-28	WOS:A1992JG35600005
J	AMITAI, Y; ALMOG, S; SINGER, R; HAMMER, R; BENTUR, Y; DANON, YL				AMITAI, Y; ALMOG, S; SINGER, R; HAMMER, R; BENTUR, Y; DANON, YL			ATROPINE POISONING IN CHILDREN DURING THE PERSIAN GULF CRISIS - A NATIONAL SURVEY IN ISRAEL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PHARMACOKINETICS	Objective.-To evaluate the effects of high doses of atropine in children accidentally injected with automatic atropine injectors. These were distributed in Israel during the Persian Gulf Crisis as an antidote for chemical warfare agents. Design and Setting.-A national survey in pediatric emergency departments in Israel, involving 22 medical centers, with prospective data collection in 14 centers. Patients.-Children (n=268) presenting to emergency departments following misuse of automatic atropine injectors. Main Outcome Measures.-Documentation of atropine dose and clinical manifestations; determination of a clinical severity score and its correlation with atropine dose; measurements of serum atropine levels in six patients. Results.-Over a period of 4 months, 268 cases were reported, of which 240 were clinically evaluated. The most common site of injection (75%) was the finger or palm. Doses were up to 17-fold higher than standard doses for age. In 116 children (48%), systemic effects of atropine were observed, and 20 (8%) had severe atropinization. Seizures and life-threatening arrhythmias were not reported, and there were no fatalities. The severity of atropinization was correlated with the dose following a classic nonlinear, dose-response relationship. Serum atropine levels (6.2 to 61.0 ng/mL) were much higher than those observed after administration of therapeutic doses. Conclusions.-The high incidence of injection in the hand implies accidental use of automatic atropine injectors among children. The lack of mortality or life-threatening complications from injection of large doses of atropine attests to its relative safety in children. The low risk from atropine injections weighed against expected benefit as a lifesaving antidote justifies the distribution of personal atropine injectors to children at risk of organophosphorus nerve agent attack.	CHAIM SHEBA MED CTR, INST CLIN PHARMACOL & TOXICOL, IL-52621 TEL HASHOMER, ISRAEL; SOROKA MED CTR, IL-84101 BEER SHEVA, ISRAEL; ISRAELS NATL POISON INFORMAT CTR, HAIFA, ISRAEL; CHILDRENS MED CTR ISRAEL, PETAH TIQWA, ISRAEL	Chaim Sheba Medical Center; Ben Gurion University; Soroka Medical Center	AMITAI, Y (corresponding author), HADASSAH UNIV HOSP, DEPT PEDIAT, MT SCOPUS, IL-91240 JERUSALEM, ISRAEL.							ADAMS RG, 1982, J CLIN PHARMACOL, V22, P477, DOI 10.1002/j.1552-4604.1982.tb02638.x; BERGHEM L, 1980, BRIT J ANAESTH, V52, P597, DOI 10.1093/bja/52.6.597; Brown JH, 1990, PHARM BASIS THERAPEU, V8th, P150; FASTH A, 1975, ACTA PHARM SUEC, V12, P311; HEATH WE, 1950, BRIT MED J, V2, P608, DOI 10.1136/bmj.2.4679.608; HINDERLING PH, 1985, J PHARM SCI-US, V74, P703, DOI 10.1002/jps.2600740702; HOLFORD NHG, 1982, PHARMACOL THERAPEUT, V16, P143, DOI 10.1016/0163-7258(82)90051-1; KETCHUM JS, 1973, PSYCHOPHARMACOLOGIA, V28, P121, DOI 10.1007/BF00421398; Morton HG, 1939, J PEDIATR-US, V14, P755, DOI 10.1016/S0022-3476(39)80097-X; Munns GF, 1929, J AMER MED ASSOC, V96, P171; OLSSON GL, 1983, ANAESTHESIA, V38, P1179, DOI 10.1111/j.1365-2044.1983.tb12521.x; Owens SM, 1890, LANCET, Vii, P443; Pilcher JD, 1934, J PHARMACOL EXP THER, V52, P196; SECORD E, 1991, AM J DIS CHILD, V145, P724	14	28	28	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					630	632		10.1001/jama.268.5.630	http://dx.doi.org/10.1001/jama.268.5.630			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF473	1629992				2022-12-28	WOS:A1992JF47300029
J	FISCHL, MA; UTTAMCHANDANI, RB; DAIKOS, GL; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; LAI, SH				FISCHL, MA; UTTAMCHANDANI, RB; DAIKOS, GL; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; LAI, SH			AN OUTBREAK OF TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT TUBERCLE-BACILLI AMONG PATIENTS WITH HIV-INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS; DRUG RESISTANCE, MICROBIAL; CROSS INFECTION; MYCOBACTERIUM-TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED IMMUNODEFICIENCY SYNDROME; NON-HAITIAN PATIENTS; FLORIDA	Objective: To evaluate a nosocomial outbreak of tuberculosis caused by multiple-drug-resistant bacilli among patients with tuberculosis and HIV infection. Design: A case-control study. Patients: Patients with HIV infection and culture-proven tuberculosis. Measurements: Patient characteristics, date of diagnoses of HIV infection and disease, date of diagnosis of tuberculosis, Mycobacterium tuberculosis susceptibility results, and medical center contact. Results: Sixty-two patients who had tuberculosis caused by multiple-drug-resistant bacilli (cases) and 55 patients who had tuberculosis caused by susceptible or single-drug-resistant bacilli (controls) were identified. Controls were more likely to be black (odds ratio, 0.4; 95% Cl, 0.2 to 0.9) or Haitian (odds ratio, 0.2; Cl, 0.1 to 0.6) compared with cases, who were more likely to be homosexual men (odds ratio, 2.9; Cl, 1.3 to 6.4). Forty-four cases (71%) had previous contact with an HIV clinic compared with 15 controls (27%) (P < 0.0001). Cases were more likely to have had AIDS (odds ratio, 7.7; Cl, 1.5 to 53.7), to have been hospitalized on an HIV ward (odds ratio, 8.3; Cl, 2.3 to 29.7), to have been seen in an HIV clinic (odds ratio, 7.8; Cl, 3.4 to 18.1), to have received intravenous therapy in an HIV clinic (odds ratio, 13.0; Cl, 4.6 to 37.0), or to have received inhalation pentamidine in an HIV clinic before a diagnosis of tuberculosis was made. Multiple logistic regression analysis showed that a diagnosis of AIDS (odds ratio, 11.2; Cl, 3.1 to 40.6) and HIV clinic visits (odds ratio, 13.0; Cl, 2.7 to 63.7) before a diagnosis of tuberculosis were significantly associated with tuberculosis caused by multiple-drug-resistant bacilli. Using susceptibility patterns and appointment dates, we found that 22 cases had previous contact with a person who had tuberculosis caused by multiple-drug-resistant bacilli in the HIV clinic. Conclusions: Nosocomial transmission of M. tuberculosis from other HIV-infected patients with tuberculosis caused by multiple-drug-resistant bacilli can occur. These findings have serious public health implications and demand strict adherence to acid-fast bacilli isolation precautions.	F KEVIN MURPHY & ASSOCIATES, DALLAS, TX 75218 USA; CLEVELAND CLIN FLORIDA, FT LAUDERDALE, FL 33109 USA; UNIV MIAMI, SCH MED, DEPT MED, AIDS CLIN RES UNIT, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, COMPREHENS AIDS PROGRAM, MIAMI, FL 33101 USA	Cleveland Clinic Foundation; University of Miami; University of Miami; University of Miami	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Daikos, George L./ABD-8378-2021					BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; PITCHENIK AE, 1982, NEW ENGL J MED, V307, P162, DOI 10.1056/NEJM198207153070306; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; 1986, MMWR, V35, P587; 1991, MMWR, V40, P649; 1989, MMWR, V36, P795; 1989, MMWR, V36, P785; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1987, MMWR, V36, P133; 1990, MMWR, V39, P1	19	342	354	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					177	183		10.7326/0003-4819-117-3-177	http://dx.doi.org/10.7326/0003-4819-117-3-177			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616211				2022-12-28	WOS:A1992JF30400001
J	BAKER, CJ; MELISH, ME; HALL, RT; CASTO, DT; VASAN, U; GIVNER, LB				BAKER, CJ; MELISH, ME; HALL, RT; CASTO, DT; VASAN, U; GIVNER, LB			INTRAVENOUS IMMUNE GLOBULIN FOR THE PREVENTION OF NOSOCOMIAL INFECTION IN LOW-BIRTH-WEIGHT NEONATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNOGLOBULIN; INFANTS; PHARMACOKINETICS; OPSONIZATION; ANTIBODY	Background. Nosocomial infection is a major risk for premature infants with very low birth weights. One reason for their susceptibility to infection may be antibody deficiency, since there is little transfer of maternal IgG to the fetus before 32 weeks' gestation. Methods. We conducted a multicenter, double-blind study of neonates weighing 500 to 1750 g at birth. A total of 588 neonates were randomly assigned, with stratification for birth weight, to receive periodic intravenous infusions of either immune globulin (500 mg per kilogram of body weight per day) or a placebo. Mortality, morbidity, and nosocomial infection during the next 56 days were assessed. Results. The infusions were well tolerated; mild, reversible adverse reactions occurred in five infants in each group. There was a significant reduction in the risk of a first nosocomial infection in the recipients of immune globulin as compared with the placebo recipients (relative risk, 0.7; 95 percent confidence interval, 0.5 to 0.9). About 85 percent of the nosocomial infections were bacterial; the majority of these were caused by coagulase-negative staphylococci or Staphylococcus aureus. The neonates who received immune globulin had fewer mean days of hospitalization than the controls (62 vs. 68, P = 0.15); among the infants with infections, the difference in the mean length of the hospital stay was even greater (80 days vs. 101 days, P = 0.02). Conclusions. For premature infants weighing between 500 and 1750 g at birth, treatment with intravenous infusions of immune globulin is safe and reduces the risk of nosocomial infection.	JEFFERSON DAVIS HOSP,HOUSTON,TX 77019; UNIV HAWAII,JOHN A BURNS SCH MED,HONOLULU,HI 96822; KAPIOLANI MED CTR,HONOLULU,HI; UNIV MISSOURI,SCH MED,KANSAS CITY,MO 64108; CHILDRENS MERCY HOSP,KANSAS CITY,MO 64108; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,WINSTON SALEM,NC 27103; BRENNER CHILDRENS HOSP,WINSTON SALEM,NC	Baylor College of Medicine; University of Hawaii System; University of Missouri System; University of Missouri Kansas City; Children's Mercy Hospital; University of Texas System; University of Texas Health San Antonio; Rush University; Wake Forest University; Wake Forest Baptist Medical Center	BAKER, CJ (corresponding author), BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030, USA.							ALLAN WC, 1980, AM J DIS CHILD, V134, P1028, DOI 10.1001/archpedi.1980.02130230008003; BALLOW M, 1986, PEDIATR RES, V20, P899, DOI 10.1203/00006450-198609000-00019; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; BUSSEL JB, 1990, REV INFECT DIS, V12, pS457; CATES KL, 1988, PEDIATR RES, V23, P14, DOI 10.1203/00006450-198801000-00005; CHRISTENSEN RD, 1991, J PEDIATR-US, V118, P606, DOI 10.1016/S0022-3476(05)83389-X; CLAPP DW, 1989, J PEDIATR-US, V115, P973, DOI 10.1016/S0022-3476(89)80753-X; CLARK LA, 1986, J MED MICROBIOL, V22, P1, DOI 10.1099/00222615-22-1-1; COX DR, 1972, J R STAT SOC B, V34, P187; DUNN OJ, 1987, APPLIED STATISTICS A; Goldmann D A, 1989, Infect Dis Clin North Am, V3, P779; HERNANDEZ JA, 1986, CLIN PERINATOL, V13, P461, DOI 10.1016/S0095-5108(18)30832-7; HILL HR, 1986, REV INFECT DIS, V8, pS396; HOBBS JR, 1967, LANCET, V1, P757, DOI 10.1016/S0140-6736(67)91369-4; JARVIS WR, 1987, PEDIATR INFECT DIS J, V6, P344, DOI 10.1097/00006454-198704000-00003; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KIM KS, 1989, J ALLERGY CLIN IMMUN, V84, P579, DOI 10.1016/0091-6749(89)90194-2; KINNEY J, 1991, AM J DIS CHILD, V145, P1233, DOI 10.1001/archpedi.1991.02160110025013; KOJIMA Y, 1990, J INFECT DIS, V162, P435, DOI 10.1093/infdis/162.2.435; KYLLONEN KS, 1989, J PEDIATR-US, V115, P1013, DOI 10.1016/S0022-3476(89)80761-9; LASSITER HA, 1991, PEDIATR INFECT DIS J, V10, P663; MONTANARO A, 1984, AM J MED, V76, P67, DOI 10.1016/0002-9343(84)90322-X; NOYA FJD, 1988, J PEDIATR-US, V112, P278, DOI 10.1016/S0022-3476(88)80070-2; NOYA FJD, 1989, PEDIATR INFECT DIS J, V8, P759, DOI 10.1097/00006454-198911000-00006; POLLACK M, 1983, J INFECT DIS, V147, P1090, DOI 10.1093/infdis/147.6.1090; Rothman K, 1986, MODERN EPIDEMIOLOGY; SASIDHARAN P, 1988, CLIN PEDIATR, V27, P271, DOI 10.1177/000992288802700601; SCHUTZE GE, 1991, INFECT IMMUN, V59, P2573, DOI 10.1128/IAI.59.8.2573-2578.1991; SHAIO MF, 1989, PEDIATR RES, V25, P634, DOI 10.1203/00006450-198906000-00016; STIEHM ER, 1990, REV INFECT DIS, V12, pS439; WEISMAN LE, 1989, VOX SANG, V57, P243, DOI 10.1111/j.1423-0410.1989.tb00836.x; YANG KD, 1989, J INFECT DIS, V159, P701, DOI 10.1093/infdis/159.4.701; YODER MC, 1990, PEDIATR CLIN N AM, V33, P481; 1988, NEW ENGL J MED, V319, P902; 1991, NEW ENGL J MED, V325, P73	35	111	116	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					213	219		10.1056/NEJM199207233270401	http://dx.doi.org/10.1056/NEJM199207233270401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614462				2022-12-28	WOS:A1992JE38100001
J	DANTZKER, DR; STEINBERG, H				DANTZKER, DR; STEINBERG, H			PULMONARY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											DANTZKER, DR (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461, USA.							BACH JR, 1990, CHEST, V97, P52, DOI 10.1378/chest.97.1.52; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CALHOON JH, 1991, J THORAC CARDIOV SUR, V101, P816; CARERE R, 1991, J THORAC CARDIOVASC, V401, P115; CAREY J, 1990, CHEST, V97, P150; CHAPMAN KR, 1991, NEW ENGL J MED, V324, P788, DOI 10.1056/NEJM199103213241202; DALY CL, 1992, NEW ENGL J MED, V326, P231; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434, DOI 10.1164/ajrccm/142.2.434; KAISER LR, 1991, J THORAC CARDIOV SUR, V102, P333; REED CE, 1990, AM REV RESPIR DIS, V141, P582; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; STRUMPF DA, 1991, AM REV RESPIR DIS, V144, P1234, DOI 10.1164/ajrccm/144.6.1234; TRULOCK EP, 1991, JAMA-J AM MED ASSOC, V266, P1943, DOI 10.1001/jama.266.14.1943; WEISS R, 1992, SCIENCE, V255, P148, DOI 10.1126/science.1553538; 1991, MMWR, V40, P585	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					405	407						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613937				2022-12-28	WOS:A1992JC35200050
J	GOLDFRANK, LR				GOLDFRANK, LR			MEDICAL TOXICOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							2,3-DIMERCAPTOSUCCINIC ACID; BENZODIAZEPINES; FLUMAZENIL; ANTIBODIES; REVERSAL		NYU MED CTR,NEW YORK,NY 10016	New York University	GOLDFRANK, LR (corresponding author), BELLEVUE HOSP CTR,NEW YORK,NY 10016, USA.							BASILE AS, 1991, NEW ENGL J MED, V325, P473, DOI 10.1056/NEJM199108153250705; BOSMAN DK, 1991, GASTROENTEROLOGY, V101, P772, DOI 10.1016/0016-5085(91)90538-V; BOWYER K, 1980, CHEST, V77, P232, DOI 10.1378/chest.77.2.232; BRUNN GJ, 1991, INT J IMMUNOPHARMACO, V13, P841, DOI 10.1016/0192-0561(91)90035-6; BURR W, 1989, BRIT MED J, V298, P1713, DOI 10.1136/bmj.298.6689.1713-a; GRAZIANO JH, 1986, MED TOXICOL ADV DRUG, V1, P155, DOI 10.1007/BF03259834; GRAZIANO JH, 1988, J PEDIATR-US, V113, P751, DOI 10.1016/S0022-3476(88)80396-2; HUNKELER W, 1981, NATURE, V290, P514, DOI 10.1038/290514a0; LITOVITZ TL, 1991, AM J EMERG MED, V9, P461, DOI 10.1016/0735-6757(91)90216-7; LOPEZ A, 1990, CRIT CARE MED, V18, P1480, DOI 10.1097/00003246-199012000-00032; OBOYLE C, 1983, BRIT J ANAESTH, V55, P349, DOI 10.1093/bja/55.4.349; OSULLIVAN GF, 1987, CLIN PHARMACOL THER, V42, P254, DOI 10.1038/clpt.1987.143; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; POLLOCK DA, 1991, JAMA-J AM MED ASSOC, V266, P2233, DOI 10.1001/jama.266.16.2233; PRISCHL F, 1988, MED TOXICOL ADV DRUG, V3, P334, DOI 10.1007/BF03259944; SCANLON JW, 1991, REPROD TOXICOL, V5, P89, DOI 10.1016/0890-6238(91)90037-G; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; TERRIEN N, 1990, TOXICOL APPL PHARM, V104, P504, DOI 10.1016/0041-008X(90)90172-Q; WEISMAN RS, 1991, J TOXICOL-CLIN TOXIC, V29, P553, DOI 10.3109/15563659109025754; 1991, STRATEGIC PLAN ELIMI; 1988, ROLE PRIMARY CARE PH	21	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					375	376						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613924				2022-12-28	WOS:A1992JC35200036
J	LU, X; PARK, SH; THOMPSON, TC; LANE, DP				LU, X; PARK, SH; THOMPSON, TC; LANE, DP			RAS-INDUCED HYPERPLASIA OCCURS WITH MUTATION OF P53, BUT ACTIVATED RAS AND MYC TOGETHER CAN INDUCE CARCINOMA WITHOUT P53 MUTATION	CELL			English	Article							CELLULAR TUMOR-ANTIGEN; TRANSFORMED-CELLS; SACCHAROMYCES-CEREVISIAE; MONOCLONAL-ANTIBODIES; DNA DAMAGE; RAD9 GENE; ONCOGENES; EXPRESSION; SEQUENCE; PROTEIN	Using a reconstituted mouse prostate organ, the effects on endogenous p53 expression of the ras oncogene or of the ras+myc oncogenes were investigated. In this system the ras gene alone causes mild hyperplasia, but the combination of ras and myc leads to the formation of carcinomas. Surprisingly, while p53 mutations were found in cells derived from the reconstituted organs containing ras alone, no such mutations were found in the ras+myc-transformed cells. Their growth, unlike that of the cells containing ras alone, was not inhibited by transfection with plasmids encoding wild-type human p53. We suggest that expression of both activated ras and myc genes bypasses the need for p53 mutation by neutralizing the tumor suppressor activity of normal p53.	BAYLOR COLL MED,SCOTT DEPT UROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	LU, X (corresponding author), UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN LABS,CELL TRANSFORMAT RES GRP,DUNDEE DD1 4HN,SCOTLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545; Lu, Xin/0000-0002-6587-1152	NATIONAL CANCER INSTITUTE [R01CA050588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043523] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50588] Funding Source: Medline; NIDDK NIH HHS [DK-43523] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, ONCOGENE, V5, P893; BENNETT WP, 1991, ONCOGENE, V6, P1779; BRAITHWAITE AW, 1989, J VIROL, V63, P1792, DOI 10.1128/JVI.63.4.1792-1799.1989; CASEY G, 1991, ONCOGENE, V6, P1791; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1991, CANCER RES, V51, P6304; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1986, CANCER CELL, V4, P387; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAZARS R, 1991, ONCOGENE, V6, P1685; MERZ VW, 1991, MOL ENDOCRINOL, V5, P503, DOI 10.1210/mend-5-4-503; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1986, VIROLOGY, V150, P265, DOI 10.1016/0042-6822(86)90286-2; MOORE JP, 1987, ONCOGENE RES, V2, P65; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; REIHSAUS E, 1990, ONCOGENE, V5, P137; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	40	163	167	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					153	161		10.1016/0092-8674(92)90541-J	http://dx.doi.org/10.1016/0092-8674(92)90541-J			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623518				2022-12-28	WOS:A1992JC95700016
J	BRUNO, S; BORZIO, M; ROMAGNONI, M; BATTEZZATI, PM; ROSSI, S; CHIESA, A; PODDA, M				BRUNO, S; BORZIO, M; ROMAGNONI, M; BATTEZZATI, PM; ROSSI, S; CHIESA, A; PODDA, M			COMPARISON OF SPONTANEOUS ASCITES FILTRATION AND REINFUSION WITH TOTAL PARACENTESIS WITH INTRAVENOUS ALBUMIN INFUSION IN CIRRHOTIC-PATIENTS WITH TENSE ASCITES	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC PARACENTESIS; RECIRCULATION; SAFE	Objective-To compare the effectiveness and safety of spontaneous ascites filtration and reinfusion and total paracentesis plus intravenous albumin infusion in cirrhotic patients with tense ascites. Design-Randomised trial of the two treatments. Setting-Teaching hospital and district general hospital in Milan. Patients-45 consecutive cirrhotic patients with recurrent tense ascites and urinary sodium excretion rate <20 mmol/day. 35 fulfilled admission criteria and completed the study. 17 received spontaneous ascites filtration and 18 paracentesis plus albumin infusion. Main outcome measures-Body weight; urinary volume; serum and urinary electrolyte, serum fibrinogen, and plasma aldosterone concentrations; and plasma renin activity before the procedure and 24 hours and eight days afterwards. Results-Both procedures were effective in all patients. Weight decreased in both groups and showed no substantial increase after eight days. In patients receiving ascites filtration, values decreased significantly (p<0.01) after 24 hours for platelet count (mean relative change 0.92; 99% confidence interval 0.86 to 0.98) and serum fibrinogen concentration (0.92; 0.88 to 0.98) but returned to pretreatment values after eight days; no laboratory and clinical signs of disseminated intravascular coagulation were noted. Three patients in this group had fever, which receded spontaneously. One patient in each group had dilutional hyponatraemia. Conclusions-Spontaneous ascites filtration and reinfusion is an effective treatment for tense ascites. Reinfusion of the patient's concentrated proteins provides savings without compromising safety.	UNIV MILAN,ST PAOLO HOSP,SCH MED,DEPT INTERNAL MED,I-20122 MILAN,ITALY; FATEBENEFRATELLI HOSP,DEPT MED 1,MILAN,ITALY; FATEBENEFRATELLI HOSP,NEPHROL UNIT,MILAN,ITALY	University of Milan				Battezzati, Pier Maria/0000-0003-1344-3452; Bruno, Savino/0000-0002-3887-864X				ANSLEY JD, 1987, SURGERY, V83, P181; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; Huynh H, 1976, J EDUC STATIST, V1, P69, DOI DOI 10.3102/10769986001001069; LANDINI S, 1985, INT J ARTIF ORGANS, V8, P227; MORTENSON RA, 1968, AM J SURG, V116, P929, DOI 10.1016/0002-9610(68)90469-8; PLANAS R, 1990, GASTROENTEROLOGY, V99, P1736, DOI 10.1016/0016-5085(90)90481-F; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; SALERNO F, 1987, J HEPATOL, V5, P102, DOI 10.1016/S0168-8278(87)80067-3; SCHIFF ER, 1987, HEPATOLOGY, V7, P591, DOI 10.1002/hep.1840070330; SIMON DM, 1987, HEPATOLOGY, V7, P423, DOI 10.1002/hep.1840070302; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; SOLERNO F, 1991, HEPATOLOGY, V13, P707; TAWES RL, 1981, AM J SURG, V142, P51, DOI 10.1016/S0002-9610(81)80011-6; TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N; WILDE JT, 1990, J HEPATOL, V10, P217, DOI 10.1016/0168-8278(90)90055-V; WILKINSONSP, 1975, POSTGRAD MED J, V51, P583; WINER BJ, 1971, STATISTICAL PRINCIPL, P518	18	43	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1655	1658		10.1136/bmj.304.6843.1655	http://dx.doi.org/10.1136/bmj.304.6843.1655			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633517	Bronze, Green Published			2022-12-28	WOS:A1992JB93900019
J	STANLEY, FJ; WATSON, L				STANLEY, FJ; WATSON, L			TRENDS IN PERINATAL-MORTALITY AND CEREBRAL-PALSY IN WESTERN-AUSTRALIA, 1967 TO 1985	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT INFANTS; WHITE MATTER NECROSIS; CHANGING PANORAMA; INTRAPARTUM ASPHYXIA; GESTATIONAL-AGE; SWEDEN; PERIOD; DAMAGE	Objective-To analyse the trends in stillbirths, neonatal deaths, and cerebral palsy in all infants born in Western Australia from 1967 to 1985. To relate these trends to changes in perinatal care, particularly in relation to avoidance of intrapartum asphyxia in term infants and the increased survival of low birthweight infants. Design-Descriptive epidemiological study calculating population rates for perinatal deaths and cerebral palsy according to year of birth and birth weight. Setting-Western Australia. Subjects-All infants born after 20 weeks' gestation or weighing at least 400 g (live and stillborn). Main Outcome Measures-Stillbirths, neonatal deaths (from perinatal death certificates), and cerebral palsy (from a population based register). Results-Overall stillbirth rates fell from 12.1/1000 total births in 1967-70 to 8.1 in 1983-5. Early neonatal mortality fell from 13.0/1000 live births to 4-4 over the same period whereas total cerebral palsy rates remained at around 2-2.5/1000 live births. Death rates fell in all birth weight categories, particularly in low birthweight infants between 1975 and 1985, the period when birthweight data were available. In contrast, cerebral palsy rates in infants under 1500 g rose significantly over this period (from 12.1 in 1968 to 64.9 in 1985). The rise was seen in all spastic categories, including severely and multiply handicapped children. Conclusions-Large increases in the use of interventions aimed at reducing birth asphyxia and handicaps had not (by 1985) resulted in lower rates of cerebral palsy. This suggests that birth asphyxia is not a major cause. The increased survival of low birthweight infants has resulted in more cerebral palsy in this group, due either to postnatal complications of immaturity or prenatal damage to the fetal brain. These findings have implications for planning perinatal care and for litigation for putative obstetric malpractice in cerebral palsy cases.			STANLEY, FJ (corresponding author), PRINCESS MARGARET HOSP,WESTERN AUSTRALIAN RES INST CHILD HLTH,GPO BOX D184,PERTH,WA 6001,AUSTRALIA.							ALBERMAN E, 1963, Dev Med Child Neurol, V5, P388; ARMSTRONG DL, 1987, AM J DIS CHILD, V141, P617, DOI 10.1001/archpedi.1987.04460060035027; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BAX M C, 1964, Dev Med Child Neurol, V6, P295; BEJAR R, 1986, ANN NEUROL, V20, P436; BERNFIELD M, 1990, PEDIATR RES, V27, P21; BLAIR E, 1988, J PEDIATR-US, V112, P515, DOI 10.1016/S0022-3476(88)80161-6; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; BLAIR E, 1985, DEV MED CHILD NEUROL, V27, P615; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; COOKE RWI, 1987, ARCH DIS CHILD, V62, P931, DOI 10.1136/adc.62.9.931; DOWDING VM, 1988, IRISH MED J, V81, P25; FISHER CC, 1990, MED J AUSTRALIA, V153, P639, DOI 10.5694/j.1326-5377.1990.tb126307.x; FREEMAN JM, 1988, PEDIATRICS, V82, P240; GEE V, 1989, PERINATAL STATISTICS; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; HAGBERG B, 1984, ACTA PAEDIATR SCAND, V73, P433, DOI 10.1111/j.1651-2227.1984.tb09951.x; HAGBERG B, 1989, BRAIN DEV-JPN, V11, P368, DOI 10.1016/S0387-7604(89)80018-X; HILL C, 1987, VALIDATION STUDY W A; KITCHEN WH, 1987, AM J PERINAT, V4, P29, DOI 10.1055/s-2007-999733; LARROCHE JC, 1986, BIOL NEONATE, V50, P61; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; MCDONALD AD, 1963, ARCH DIS CHILD, V38, P579, DOI 10.1136/adc.38.202.579; MOORE DJ, 1987, PERINATAL STATISTICS; NAEYE RL, 1989, AM J DIS CHILD, V143, P1154, DOI 10.1001/archpedi.1989.02150220044018; NELSON KB, 1988, J PEDIATR-US, V112, P572, DOI 10.1016/S0022-3476(88)80169-0; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; PANETH N, 1990, J PEDIATR-US, V116, P975, DOI 10.1016/S0022-3476(05)80664-X; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PHAROAH POD, 1971, LANCET, V1, P308; RIIKONEN R, 1989, ACTA PAEDIATR SCAND, V78, P581, DOI 10.1111/j.1651-2227.1989.tb17940.x; SARNAT HB, 1987, AM J DIS CHILD, V141, P969, DOI 10.1001/archpedi.1987.04460090046022; SHEARER MH, 1986, BIRTHS, V12, P151; STANLEY F J, 1985, Neuroepidemiology, V4, P146, DOI 10.1159/000110226; STANLEY FJ, 1991, MED J AUSTRALIA, V154, P623, DOI 10.5694/j.1326-5377.1991.tb121226.x; STANLEY FJ, 1986, AM J PUBLIC HEALTH, V76, P35, DOI 10.2105/AJPH.76.1.35; STANLEY FJ, 1988, AM J OBSTET GYNECOL, V158, P89, DOI 10.1016/0002-9378(88)90784-3; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; 1989, LANCET, V2, P1251	39	174	175	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1658	1663		10.1136/bmj.304.6843.1658	http://dx.doi.org/10.1136/bmj.304.6843.1658			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633518	Green Published, Bronze			2022-12-28	WOS:A1992JB93900020
J	CITOVSKY, V; ZUPAN, J; WARNICK, D; ZAMBRYSKI, P				CITOVSKY, V; ZUPAN, J; WARNICK, D; ZAMBRYSKI, P			NUCLEAR-LOCALIZATION OF AGROBACTERIUM VIRE2 PROTEIN IN PLANT-CELLS	SCIENCE			English	Article							SINGLE-STRANDED-DNA; TOBACCO MOSAIC-VIRUS; BINDING-PROTEIN; T-DNA; VIRD2 PROTEIN; 5' END; TUMEFACIENS; PLASMID; COMPLEX; ASSOCIATION	The Agrobacterium single-stranded DNA (ssDNA) intermediate T-strand is likely transferred to the plant cell nucleus as a complex with a single VirD2 molecule at its 5' end and multiple VirE2 molecules along its length. VirD2 contains a nuclear localization signal (NLS); however, because the T-strand is principally coated with VirE2 molecules, VirE2 also might assist in nuclear uptake. Indeed, VirE2 fused to a reporter protein localizes to plant cell nuclei, a process mediated by two amino acid sequences with homology to the bipartite NLS of Xenopus nucleoplasmin. Moreover, tumorigenicity of an avirulent virE2 mutant is restored when inoculated on transgenic plants expressing VirE2, supporting in planta function of VirE2.	UNIV CALIF BERKELEY,DEPT PLANT BIOL,GENET & PLANT BIOL BLDG,BERKELEY,CA 94720; SANDOZ CROP PROTECT CORP,PALO ALTO,CA 94304	University of California System; University of California Berkeley; Novartis; Sandoz				Citovsky, Vitaly/0000-0003-2024-6844	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM045244, R01GM045244] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45244-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CHRISTIE PJ, 1988, J BACTERIOL, V170, P2659, DOI 10.1128/jb.170.6.2659-2667.1988; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; CITOVSKY V, 1989, P NATL ACAD SCI USA, V86, P1193, DOI 10.1073/pnas.86.4.1193; CITOVSKY V, 1992, PLANT CELL, V4, P397, DOI 10.1105/tpc.4.4.397; CITOVSKY V, 1988, SCIENCE, V240, P501, DOI 10.1126/science.240.4851.501; DAS A, 1988, P NATL ACAD SCI USA, V85, P2909, DOI 10.1073/pnas.85.9.2909; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; GERACE L, 1988, ANN REV CELL BIOL, V4, P355; GIETL C, 1987, P NATL ACAD SCI USA, V84, P9006, DOI 10.1073/pnas.84.24.9006; HERRERAESTRELLA A, 1988, EMBO J, V7, P4055, DOI 10.1002/j.1460-2075.1988.tb03299.x; HIROOKA T, 1987, J BACTERIOL, V169, P1529, DOI 10.1128/jb.169.4.1529-1536.1987; HODGES LM, UNPUB; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; HOWARD E, 1990, BIOESSAYS, V12, P103, DOI 10.1002/bies.950120302; HOWARD E, 1990, UCLA SYM BI, V129, P1; HOWARD EA, 1989, P NATL ACAD SCI USA, V86, P4017, DOI 10.1073/pnas.86.11.4017; HOWARD EA, 1992, BIOESSAYS, V68, P109; KNORR DA, 1988, P NATL ACAD SCI USA, V85, P170, DOI 10.1073/pnas.85.1.170; LEHTO K, 1990, VIROLOGY, V174, P290, DOI 10.1016/0042-6822(90)90077-5; LOHMAN TM, 1986, J MOL BIOL, V187, P603, DOI 10.1016/0022-2836(86)90338-4; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCDONNELL RE, 1987, PLANT MOL BIOL REP, V5, P380; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; STACHEL SE, 1986, EMBO J, V5, P1445, DOI 10.1002/j.1460-2075.1986.tb04381.x; WARD ER, 1988, SCIENCE, V242, P927, DOI 10.1126/science.242.4880.927; WINANS SC, 1987, NUCLEIC ACIDS RES, V15, P825, DOI 10.1093/nar/15.2.825; YOUNG C, 1988, J BACTERIOL, V170, P3367, DOI 10.1128/jb.170.8.3367-3374.1988; ZAMBRYSKI PC, 1992, ANNU REV PLANT PHYS, V43, P465, DOI 10.1146/annurev.pp.43.060192.002341	35	217	244	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1802	1805		10.1126/science.1615325	http://dx.doi.org/10.1126/science.1615325			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615325				2022-12-28	WOS:A1992JA43400031
J	ALEXANDER, SF; LYON, LJ; NEVINS, MA; YCRE, LR; THAYER, HS				ALEXANDER, SF; LYON, LJ; NEVINS, MA; YCRE, LR; THAYER, HS			10 YEARS OF ORIENTING COLLEGE-STUDENTS TO CAREERS IN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PASCACK VALLEY HOSP,DEPT MED EDUC,OLD HOOD RD,WESTWOOD,NJ 07675; PASCACK VALLEY HOSP,DEPT MED,WESTWOOD,NJ; PASCACK VALLEY HOSP,OFF PRESIDENT & CHIEF EXECUT OFFICER,WESTWOOD,NJ; PASCACK VALLEY HOSP,DEPT VOLUNTEER SERV,WESTWOOD,NJ; UNIV MED & DENT NEW JERSEY,DEPT MED,NEWARK,NJ	Rutgers State University New Brunswick; Rutgers State University Medical Center								Alexander S F, 1983, J Med Soc N J, V80, P421; ORZAC ES, 1981, J MED EDUC, V56, P620	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3330	3331						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HY944	1597915				2022-12-28	WOS:A1992HY94400034
J	GEORGOPOULOS, AP; ASHE, J; SMYRNIS, N; TAIRA, M				GEORGOPOULOS, AP; ASHE, J; SMYRNIS, N; TAIRA, M			THE MOTOR CORTEX AND THE CODING OF FORCE	SCIENCE			English	Article							FREE ARM MOVEMENTS; NEURONAL POPULATION; 3-DIMENSIONAL SPACE; VISUAL TARGETS; CELL DISCHARGE; DIRECTION; MONKEY; DYNAMICS; PATTERN; MUSCLE	The relation of cellular activity in the motor cortex to the direction of two-dimensional isometric force was investigated under dynamic conditions in monkeys. A task was designed so that three force variables were dissociated: the force exerted by the subject, the net force, and the change in force. Recordings of neuronal activity in the motor cortex revealed that the activity of single cells was directionally tuned and that this tuning was invariant across different directions of a bias force. Cell activity was not related to the direction of force exerted by the subject, which changed drastically as the bias force changed. In contrast, the direction of net force, the direction of force change, and the visually instructed direction all remained quite invariant and congruent and could be the directional variables, alone or in combination, to which cell activity might relate.	UNIV MINNESOTA,SCH MED,DEPT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PHYSIOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	GEORGOPOULOS, AP (corresponding author), VET AFFAIRS MED CTR,CTR BRAIN SCI,MINNEAPOLIS,MN 55455, USA.		SMYRNIS, NIKOLAOS/B-9822-2011; Smyrnis, Nikolaos/AAA-3783-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS007226, R01NS017413] Funding Source: NIH RePORTER; NINDS NIH HHS [NS07226, NS17413] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALEXANDER GE, 1990, J NEUROPHYSIOL, V64, P133, DOI 10.1152/jn.1990.64.1.133; Bernstein N, 1967, COORDINATION REGULAT; BIZZI E, 1991, SCIENCE, V253, P287, DOI 10.1126/science.1857964; CAMINITI R, 1990, J NEUROSCI, V10, P2039; CHENEY PD, 1980, J NEUROPHYSIOL, V44, P773, DOI 10.1152/jn.1980.44.4.773; CONRAD B, 1977, EXP BRAIN RES, V29, P85; CRUTCHER MD, 1990, J NEUROPHYSIOL, V64, P151, DOI 10.1152/jn.1990.64.1.151; Evarts E. V., 1967, NEUROPHYSIOLOGICAL B, P215; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; EVARTS EV, 1983, J NEUROPHYSIOL, V49, P1199, DOI 10.1152/jn.1983.49.5.1199; EVARTS EV, 1969, J NEUROPHYSIOL, V32, P375, DOI 10.1152/jn.1969.32.3.375; FLANDERS M, 1992, J NEUROPHYSIOL, V67, P931, DOI 10.1152/jn.1992.67.4.931; FROMM C, 1983, PFLUG ARCH EUR J PHY, V398, P318, DOI 10.1007/BF00657241; Georgopoulos A. P., 1984, DYNAMIC ASPECTS NEOC, P501; GEORGOPOULOS AP, 1985, BEHAV BRAIN RES, V18, P159, DOI 10.1016/0166-4328(85)90071-3; GEORGOPOULOS AP, 1991, ANNU REV NEUROSCI, V14, P361, DOI 10.1146/annurev.ne.14.030191.002045; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; GHEZ C, 1979, INTEGRATION NERVOUS, P307; GIBSON AR, 1985, J PHYSIOL-LONDON, V358, P551, DOI 10.1113/jphysiol.1985.sp015566; GROBSTEIN P, 1988, BRAIN BEHAV EVOLUT, V31, P34, DOI 10.1159/000116574; HEPPREYMOND MC, 1978, J PHYSIOL-PARIS, V74, P287; HOCHERMAN S, 1991, EXP BRAIN RES, V83, P285; HOLLERBACH JM, 1982, BIOL CYBERN, V44, P67, DOI 10.1007/BF00353957; Humphrey D R, 1983, Adv Neurol, V39, P347; KALASKA JF, 1990, EXP BRAIN RES, V80, P351; KALASKA JF, 1989, J NEUROSCI, V9, P2080; KALASKA JF, 1991, MOTOR CONTROL CONCEP, P307; LURITO J T, 1991, Society for Neuroscience Abstracts, V17, P1226; LURITO J T, 1990, Society for Neuroscience Abstracts, V16, P1087; MARTIN JH, 1985, EXP BRAIN RES, V57, P427; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; MASSEY JT, 1991, EXP BRAIN RES, V83, P439, DOI 10.1007/BF00231170; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; RIEHLE A, 1989, J NEUROPHYSIOL, V61, P534, DOI 10.1152/jn.1989.61.3.534; SCHWARTZ AB, 1988, J NEUROSCI, V8, P2913; SMITH AM, 1975, EXP BRAIN RES, V23, P315; SNEDECOR GW, 1980, STATISTICAL METHODS, P288; SOECHTING JF, 1987, NEUROSCIENCE, V23, P39, DOI 10.1016/0306-4522(87)90269-7; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; VIVIANI P, 1982, NEUROSCIENCE, V7, P431, DOI 10.1016/0306-4522(82)90277-9; [No title captured]	45	281	287	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1692	1695		10.1126/science.256.5064.1692	http://dx.doi.org/10.1126/science.256.5064.1692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609282				2022-12-28	WOS:A1992HZ17400049
J	MCLAUGHLIN, SK; MCKINNON, PJ; MARGOLSKEE, RF				MCLAUGHLIN, SK; MCKINNON, PJ; MARGOLSKEE, RF			GUSTDUCIN IS A TASTE-CELL-SPECIFIC G-PROTEIN CLOSELY RELATED TO THE TRANSDUCINS	NATURE			English	Article							AMINO-ACID SEQUENCE; CYCLIC-GMP PHOSPHODIESTERASE; GTP-BINDING PROTEIN; ROD OUTER SEGMENTS; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; INHIBITORY SUBUNIT; ADENOSINE RECEPTOR; ELONGATION-FACTORS; PERTUSSIS TOXIN	A novel G protein alpha-subunit (alpha-gustducin) has been identified and cloned from taste tissue. Alpha-gustducin messenger RNA is expressed in taste buds of all taste papillae (circumvallate, foliate and fungiform); it is not expressed in non-sensory portions of the tongue, nor is it expressed in the other tissues examined. Alpha-gustducin most closely resembles the transducins (the rod and cone photoreceptor G proteins), suggesting that gustducin's role in taste transduction is analogous to that of transducin in light transduction.	ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	Roche Holding				Margolskee, Robert/0000-0002-9572-2887				AKABAS MH, 1988, SCIENCE, V242, P1047, DOI 10.1126/science.3194756; Ausubel FM, 1988, MOL REPROD DEV; AVENET P, 1987, J MEMBRANE BIOL, V97, P223, DOI 10.1007/BF01869225; AVENET P, 1989, J MEMBRANE BIOL, V112, P1, DOI 10.1007/BF01871158; AVENET P, 1988, NATURE, V331, P351, DOI 10.1038/331351a0; BEIDLER LM, 1970, CIBA F S, P51; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIADEI PPC, 1970, 2ND S OR SENS PERC, P5; GROVERJOHNSON N, 1976, CELL TISSUE RES, V169, P395; GUTH L, 1963, EXP NEUROL, V8, P336, DOI 10.1016/0014-4886(63)90085-2; HALLIDAY KR, 1984, J CYCLIC NUCL PROT, V9, P435; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; KINNAMON SC, 1988, P NATL ACAD SCI USA, V85, P7023, DOI 10.1073/pnas.85.18.7023; KINNAMON SC, 1988, J GEN PHYSIOL, V91, P351, DOI 10.1085/jgp.91.3.351; KINNAMON SC, 1988, TRENDS NEUROSCI, V11, P491, DOI 10.1016/0166-2236(88)90010-0; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KURIHARA K, 1972, BIOCHEM BIOPH RES CO, V48, P30, DOI 10.1016/0006-291X(72)90339-7; LAW JS, 1982, RES COMMUN CHEM PATH, V38, P439; LEREA CL, 1986, SCIENCE, V234, P77, DOI 10.1126/science.3529395; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LUGO DI, 1989, MOL ENDOCRINOL, V3, P1313, DOI 10.1210/mend-3-8-1313; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NAVON SE, 1988, J BIOL CHEM, V263, P489; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PANG IH, 1990, J BIOL CHEM, V265, P18707; PRICE S, 1973, NATURE, V241, P54, DOI 10.1038/241054a0; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; REUTTER K, 1971, Z ZELLFORSCH MIK ANA, V120, P280, DOI 10.1007/BF00335540; ROPER SD, 1989, ANNU REV NEUROSCI, V12, P329, DOI 10.1146/annurev.ne.12.030189.001553; Sambrook J, 1989, MOL CLONING; SCHIFFMAN SS, 1983, P NATL ACAD SCI-BIOL, V80, P6136, DOI 10.1073/pnas.80.19.6136; SCHIFFMAN SS, 1985, PHARMACOL BIOCHEM BE, V22, P195, DOI 10.1016/0091-3057(85)90377-6; SCHIFFMAN SS, 1986, PHARMACOL BIOCHEM BE, V24, P429, DOI 10.1016/0091-3057(86)90536-8; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPICKOFSKY N, 1992, ASS CHEMORECEPTION S, V14, P192; SPIELMAN AI, 1989, CHEM SENSES, V14, P841, DOI 10.1093/chemse/14.6.841; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRIEM BJ, 1989, BIOCHEM J, V260, P121, DOI 10.1042/bj2600121; STRIEM BJ, 1990, CHEM SENSES, V15, P529, DOI 10.1093/chemse/15.5.529; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TONOSAKI K, 1988, NATURE, V331, P354, DOI 10.1038/331354a0; UI M, 1984, ADV CYCLIC NUCL PROT, V17, P145; VANDOP C, 1984, J BIOL CHEM, V259, P23; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; Whiteside B, 1926, J COMP NEUROL, V40, P33, DOI 10.1002/cne.900400105; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316	60	538	565	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					563	569		10.1038/357563a0	http://dx.doi.org/10.1038/357563a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608467				2022-12-28	WOS:A1992HZ11200044
J	ALLEN, J; WILSON, A				ALLEN, J; WILSON, A			MANAGING CHANGE IN PRIMARY CARE .2. LEARNING FROM THE PAST	BRITISH MEDICAL JOURNAL			English	Article									UNIV LEICESTER,DEPT GEN PRACTICE,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND	University of Leicester									0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1418	1420		10.1136/bmj.304.6839.1418	http://dx.doi.org/10.1136/bmj.304.6839.1418			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX082	1628020	Green Published, Bronze			2022-12-28	WOS:A1992HX08200024
J	KOLESKE, AJ; BURATOWSKI, S; NONET, M; YOUNG, RA				KOLESKE, AJ; BURATOWSKI, S; NONET, M; YOUNG, RA			A NOVEL TRANSCRIPTION FACTOR REVEALS A FUNCTIONAL LINK BETWEEN THE RNA POLYMERASE-II CTD AND TFIID	CELL			English	Article							C-TERMINAL DOMAIN; LARGEST SUBUNIT; REPEAT DOMAIN; SACCHAROMYCES-CEREVISIAE; HEPTAPEPTIDE REPEAT; INITIATION; YEAST; PHOSPHORYLATION; PROMOTER; PROTEIN	The RNA polymerase II large subunit carboxy-terminal domain (CTD) plays a role in transcription initiation, but its mechanism of action is not well understood. We have investigated the function of the SRB2 gene, which was isolated as a dominant suppressor of CTD truncation mutations. The allele specificity of this suppressor indicates that SRB2 and the CTD are involved in the same function. Indeed, cells lacking SRB2 and cells lacking a large portion of the CTD exhibit the same set of conditional growth phenotypes and exhibit very similar defects in gene expression in vivo. The SRB2 protein is a novel transcription factor that has an important role in basal and activated transcription in vitro and is essential for efficient establishment of the transcription initiation apparatus. Template commitment experiments suggest that SRB2 becomes physically associated with the transcription initiation complex. We f ind that SRB2 binds specifically to TFIID. As SRB2 and the RNA polymerase II CTD are involved in the same function, these results reveal a functional link between the CTD and the TATA-binding factor. This study implicates the CTD in recruitment of RNA polymerase II to the transcription initiation complex.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	KOLESKE, AJ (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARIAS JA, 1991, J BIOL CHEM, V266, P8055; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; DAHMUS ME, 1992, IN PRESS TRANSCRIPTI; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EDLER RT, 1983, P NATL ACAD SCI USA, V80, P2432; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HARLOW E, 1988, ANTIBODIES LABORATOR; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGFORD CJ, 1984, CELL, V36, P645, DOI 10.1016/0092-8674(84)90344-1; LANGFORD CJ, 1983, CELL, V33, P519, DOI 10.1016/0092-8674(83)90433-6; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; Parker R, 1987, MOL BIOL RNA NEW PER, P133; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PIKIELNY CW, 1983, CELL, V34, P395, DOI 10.1016/0092-8674(83)90373-2; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROSBASH M, 1981, CELL, V24, P679, DOI 10.1016/0092-8674(81)90094-5; Sambrook J, 1989, MOL CLONING LABORATO; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; ZAWEL L, 1992, IN PRESS PROG NUCL A; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	65	153	155	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					883	894		10.1016/0092-8674(92)90298-Q	http://dx.doi.org/10.1016/0092-8674(92)90298-Q			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591782				2022-12-28	WOS:A1992HW83800017
J	PELOSI, AJ; APPLEBY, L				PELOSI, AJ; APPLEBY, L			PSYCHOLOGICAL INFLUENCES ON CANCER AND ISCHEMIC-HEART-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							PERSONALITY; PREDICTORS		UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	PELOSI, AJ (corresponding author), HAIRMYRES HOSP,E KILBRIDE G75 8RG,SCOTLAND.			Pelosi, Anthony/0000-0002-5501-2661				BINIK YM, 1991, BEHAV RES THER, V29, P33, DOI 10.1016/S0005-7967(09)80004-1; Eysenck H.J., 1991, ADULT EPQ R; EYSENCK HJ, 1989, J SOC POLIT ECON ST, V14, P25; EYSENCK HJ, 1985, PERS INDIV DIFFER, V6, P535, DOI 10.1016/0191-8869(85)90003-0; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1986, SMOKING SOC MORE BAL; FOX BH, 1988, TOPICS HLTH PSYCHOL, P37; GROSSARTHMATICE.R, 1988, PRIMARY PREVENTION C, P199; GROSSARTHMATICE.R, 1980, PSYCHOTHER PSYCHOSOM, V33, P120; GROSSARTHMATICE.R, 1988, TOPICS HLTH PSYCHOL, P57; GROSSARTHMATICEK R, 1984, CANCER DETECT PREV, V7, P201; GROSSARTHMATICEK R, 1990, J BEHAV THER EXP PSY, V21, P91, DOI 10.1016/0005-7916(90)90014-C; GROSSARTHMATICEK R, 1983, PSYCHOTHER PSYCHOSOM, V40, P191, DOI 10.1159/000287767; GROSSARTHMATICEK R, 1985, J PSYCHOSOM RES, V29, P167, DOI 10.1016/0022-3999(85)90038-8; GROSSARTHMATICEK R, 1982, SOC SCI MED, V16, P493, DOI 10.1016/0277-9536(82)90058-2; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P1; GROSSARTHMATICEK R, 1980, PSYCHOTHER PSYCHOSOM, V33, P129, DOI 10.1159/000287423; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSARTHMATICEK R, 1990, PSYCHOL REP, V66, P355, DOI 10.2466/PR0.66.2.355-373; GROSSARTHMATICEK R, 1989, PSYCHOL REP, V65, P177, DOI 10.2466/pr0.1989.65.1.177; GROSSARTHMATICK R, 1985, PERS INDIV DIFFER, V6, P313, DOI 10.1016/0191-8869(85)90055-8	21	29	29	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1295	1298		10.1136/bmj.304.6837.1295	http://dx.doi.org/10.1136/bmj.304.6837.1295			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606436	Bronze, Green Published			2022-12-28	WOS:A1992HV08600029
J	POGGIO, T; FAHLE, M; EDELMAN, S				POGGIO, T; FAHLE, M; EDELMAN, S			FAST PERCEPTUAL-LEARNING IN VISUAL HYPERACUITY	SCIENCE			English	Article							ORIENTATION; IMPROVEMENT	In many different spatial discrimination tasks, such as in determining the sign of the offset in a vernier stimulus, the human visual system exhibits hyperacuity by evaluating spatial relations with the precision of a fraction of a photoreceptor's diameter. It is proposed that this impressive performance depends in part on a fast learning process that uses relatively few examples and that occurs at an early processing stage in the visual pathway. This hypothesis is given support by the demonstration that it is possible to synthesize, from a small number of examples of a given task, a simple network that attains the required performance level. Psychophysical experiments agree with some of the key predictions of the model. In particular, fast stimulus-specific learning is found to take place in the human visual system, and this learning does not transfer between two slightly different hyperacuity tasks.	WEIZMANN INST SCI, DEPT APPL MATH & COMP SCI, IL-76100 REHOVOT, ISRAEL; UNIV TUBINGEN, EYE CLIN, DEPT NEUROOPHTHALMOL, W-7400 TUBINGEN 1, GERMANY	Weizmann Institute of Science; Eberhard Karls University of Tubingen	POGGIO, T (corresponding author), MIT, CTR BIOL INFORMAT PROC, ARTIFICIAL INTELLIGENCE LAB, CAMBRIDGE, MA 02139 USA.							BALL K, 1982, SCIENCE, V218, P697, DOI 10.1126/science.7134968; BARLOW HB, 1979, NATURE, V279, P189, DOI 10.1038/279189a0; BENNETT RG, 1991, PERCEPT PSYCHOPHYS, V49, P541, DOI 10.3758/BF03212188; Black H. S., 1953, MODULATION THEORY; BRUNELLI R, 1991, IRST9111004 I RIC SC; BRUNELLI R, 1991, 12TH P INT JOINT C A; CRICK FHC, 1980, ORG CEREBRAL CORTEX, P505; Duda R. O., 1973, PATTERN CLASSIFICATI; EDELMAN S, 1991, BIOL CYBERN, V64, P209, DOI 10.1007/BF00201981; EDELMAN S, IN PRESS INT J PATTE; EDELMAN S, 1990, AI MEMO MIT ARTIFICI, V1181; EDELMAN S, IN PRESS IMAGE PRO B; EDELMAN S, 1991, CSTR9120 WEIZM I DEP; FAHLE M, UNPUB; FIORENTINI A, 1980, NATURE, V287, P43, DOI 10.1038/287043a0; FREGNAC Y, 1988, NATURE, V333, P367, DOI 10.1038/333367a0; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; MARUYAMA M, 1992, AI MEMO MIT ARTIFICI, V1291; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097; Omohundro S. M., 1987, Complex Systems, V1, P273; POGGIO T, 1990, P IEEE, V78, P1481, DOI 10.1109/5.58326; POGGIO T, 1990, COLD SPRING HARB SYM, V55, P899; POGGIO T, 1990, NATURE, V343, P263, DOI 10.1038/343263a0; POGGIO T, 1989, AI MEMO MIT ARTIFICI, V1140; RAMACHANDRAN VS, 1973, PERCEPTION, V2, P371, DOI 10.1068/p020371; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; WATT R J, 1985, Spatial Vision, V1, P31, DOI 10.1163/156856885X00053; WEISS Y, 1991, CSTR9121 WEIZM I DEP; WESTHEIMER G, 1977, VISION RES, V17, P941, DOI 10.1016/0042-6989(77)90069-4	29	438	444	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					1018	1021		10.1126/science.1589770	http://dx.doi.org/10.1126/science.1589770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589770	Green Submitted			2022-12-28	WOS:A1992HU22400038
J	MACLENNAN, DH; PHILLIPS, MS				MACLENNAN, DH; PHILLIPS, MS			MALIGNANT HYPERTHERMIA	SCIENCE			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; RYANODINE RECEPTOR GENE; INDUCED CA-2+ RELEASE; SKELETAL-MUSCLE; HALOTHANE SENSITIVITY; MOLECULAR-CLONING; LOCUS; CONTRACTURE; MECHANISM	In humans genetically predisposed to malignant hyperthermia, anesthesia can induce skeletal muscle rigidity, hypermetabolism, and high fever, which, if not immediately reversed, can lead to tissue damage or death. The corresponding condition in swine leads to stress-induced deaths and devalued meat products. Abnormalities in the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum (the ryanodine receptor) have been implicated in the cause of both the porcine and human syndromes by physiological and biochemical studies and genetic linkage analysis. In swine, a single founder mutation in the ryanodine receptor gene (RYR1) can account for all cases of malignant hyperthermia in all breeds, but a series of different RYR1 mutations are likely to be uncovered in human families with MH. Moreover, lack of linkage between malignant hyperthermia and RYR1 in some families indicates a heterogenous genetic basis for the human syndrome.			MACLENNAN, DH (corresponding author), UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO M5G 1L6, ONTARIO, CANADA.							ARCHIBALD AL, 1985, ANIM BLOOD GROUPS BI, V16, P253; ARCHIBALD AL, 1991, BREEDING FOR DISEASE RESISTANCE IN FARM ANIMALS, P449; BRITT BA, 1991, THERMOREGULATION PAT, P179; BROWNELL AKW, 1988, BRIT J ANAESTH, V60, P303, DOI 10.1093/bja/60.3.303; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CARRIER L, 1991, BIOCHIM BIOPHYS ACTA, V1064, P175, DOI 10.1016/0005-2736(91)90299-N; DENBOROUGH MA, 1960, LANCET, V2, P45; DEUFEL T, 1992, IN PRESS AM J HUM GE; Eikelenboom G., 1974, Tijdschrift voor Diergeneeskunde, V99, P421; ELLIS FR, 1971, BRIT J ANAESTH, V43, P721; ENDO M, 1983, BIOMED RES-TOKYO, V4, P83, DOI 10.2220/biomedres.4.83; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FILL M, 1990, BIOPHYS J, V57, P471, DOI 10.1016/S0006-3495(90)82563-7; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FLETCHER JE, 1990, BIOCHEM CELL BIOL, V68, P1195, DOI 10.1139/o90-177; FOSTER PS, 1989, LANCET, V2, P124, DOI 10.1016/S0140-6736(89)90182-7; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLARD EF, 1991, GENOMICS, V11, P751, DOI 10.1016/0888-7543(91)90084-R; GILLARD EF, IN PRESS GENOMICS; HARBITZ I, 1990, GENOMICS, V8, P243, DOI 10.1016/0888-7543(90)90278-3; HEALY JMS, 1991, BRIT MED J, V303, P1225, DOI 10.1136/bmj.303.6812.1225; HEIMANPATTERSON TD, 1988, MUSCLE NERVE, V11, P453, DOI 10.1002/mus.880110507; INUI M, 1987, J BIOL CHEM, V262, P1740; KALOW W, 1970, LANCET, V2, P895, DOI 10.1016/S0140-6736(70)92069-6; KNUDSON CM, 1990, J BIOL CHEM, V265, P2421; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LARACH MG, 1989, ANESTH ANALG, V69, P511; LARACH MG, 1990, ANESTHESIOLOGY, V73, pA1013; LEVITT RC, 1991, GENOMICS, V11, P543, DOI 10.1016/0888-7543(91)90061-I; LUDVIGSEN J, 1953, 15TH INT VET C STOCK, V1, P602; LUSIS AJ, 1986, P NATL ACAD SCI USA, V83, P3929, DOI 10.1073/pnas.83.11.3929; LYTTON J, 1992, HEART CARDIOVASCULAR, V2, P1203; MACKENZIE AE, 1990, AM J HUM GENET, V46, P1082; MACKENZIE AE, 1991, ANESTHESIOLOGY, V75, P4, DOI 10.1097/00000542-199107000-00002; MACLENNAN DH, 1990, NATURE, V343, P559, DOI 10.1038/343559a0; MCCARTHY TV, 1990, NATURE, V343, P562, DOI 10.1038/343562a0; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MICKELSON JR, 1988, J BIOL CHEM, V263, P9310; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MULLEY JC, 1991, CYTOGENET CELL GENET, V58, P2022; NELSON TE, 1988, CELL CALCIUM, V9, P257, DOI 10.1016/0143-4160(88)90006-1; OBRIEN PJ, 1987, VET RES COMMUN, V11, P527, DOI 10.1007/BF00396370; OBRIEN PJ, 1986, CAN J VET RES, V50, P318; OHNISHI ST, 1983, FEBS LETT, V161, P103; OHTA T, 1990, EUR J PHARMACOL, V178, P11; OTSU K, 1991, GENOMICS, V11, P744, DOI 10.1016/0888-7543(91)90083-Q; OTSU K, 1990, J BIOL CHEM, V265, P13472; OTSU K, IN PRESS GENOMICS; PHILLIPS M, UNPUB; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; SEELER DC, 1983, CAN J COMP MED, V47, P284; SIMPSON SP, 1989, ANIM PROD, V49, P503, DOI 10.1017/S0003356100032712; SMITH JS, 1988, J GEN PHYSIOL, V92, P1, DOI 10.1085/jgp.92.1.1; SMITH JS, 1985, NATURE, V316, P446, DOI 10.1038/316446a0; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; WAGENKNECHT T, 1989, NATURE, V338, P167, DOI 10.1038/338167a0; WEBB AJ, 1986, ANIM PROD, V43, P493, DOI 10.1017/S0003356100002713; ZORZATO F, 1990, J BIOL CHEM, V265, P2244; 1984, BR J ANESTH, V56, P1267	61	398	405	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					789	794		10.1126/science.1589759	http://dx.doi.org/10.1126/science.1589759			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589759				2022-12-28	WOS:A1992HT23500031
J	SETARO, JF; BLACK, HR				SETARO, JF; BLACK, HR			CURRENT CONCEPTS - REFRACTORY HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BLOOD-PRESSURE; ALCOHOL-CONSUMPTION; ARTERIAL-PRESSURE; RESISTANT HYPERTENSION; INSULIN RESISTANCE; OSLERS MANEUVER; DRUG-THERAPY; TRIAL; DIAGNOSIS; HYPERINSULINEMIA		YALE UNIV, SCH MED,YALE VASC CTR,DEPT INTERNAL MED, NEW HAVEN, CT 06510 USA	Yale University								ALDERMAN MH, 1988, HYPERTENSION, V11, pS71, DOI 10.1161/01.HYP.11.3_Pt_2.II71; ANDERSSON O, 1977, ACTA MED SCAND, P1; [Anonymous], 1988, ARCH INTERN MED, V148, P1023; BECKER MH, 1985, MED CARE, V23, P539, DOI 10.1097/00005650-198505000-00014; BLACK HR, 1982, DEV CARDIOVASC MED, V16, P692; BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1988, HYPERTENSION S2, V11, P7; CHALMERS JP, 1989, LANCET, V1, P399; CHOBANIAN AV, 1987, AM J CARDIOL, V59, pF1, DOI 10.1016/0002-9149(87)90032-4; DUSTAN HP, 1972, NEW ENGL J MED, V286, P861, DOI 10.1056/NEJM197204202861603; ESCHBACH JW, 1989, KIDNEY INT, V35, P134, DOI 10.1038/ki.1989.18; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRANNINI E, 1991, HYPERTENSION, V18, P636, DOI 10.1161/01.HYP.18.5.636; FLORAS JS, 1981, LANCET, V2, P107; FRANCIS CK, 1991, AMJ MED S1A, V91; FROHLICH ED, 1988, HYPERTENSION S2, V11, P67; GIFFORD RW, 1978, ANN INTERN MED, V88, P661, DOI 10.7326/0003-4819-88-5-661; GIFFORD RW, 1988, HYPERTENSION, V11, pS101, DOI 10.1161/01.HYP.11.3_Pt_2.II101; HAYNES RB, 1982, HYPERTENSION, V4, P415; HLA KM, 1991, J CLIN EPIDEMIOL, V44, P513, DOI 10.1016/0895-4356(91)90214-T; HOFFSTEIN V, 1991, AM J MED, V91, P190, DOI 10.1016/0002-9343(91)90014-O; JOHNS DW, 1988, HYPERTENSION, V11, pS88; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; LANGFORD HG, 1991, HYPERTENSION, V17, P210, DOI 10.1161/01.HYP.17.2.210; LEVINSON PD, 1991, ARCH INTERN MED, V151, P455, DOI 10.1001/archinte.151.3.455; LITTLER WA, 1975, CIRCULATION, V51, P1101, DOI 10.1161/01.CIR.51.6.1101; LOWENTHAL DT, 1983, CLIN EXP HYPERTENS A, V5, P297, DOI 10.3109/10641968309048828; MACMAHON S, 1987, HYPERTENSION, V9, P111, DOI 10.1161/01.HYP.9.2.111; MCAREAVEY D, 1984, BRIT MED J, V288, P106, DOI 10.1136/bmj.288.6411.106; MEJIA AD, 1990, ANN INTERN MED, V112, P270, DOI 10.7326/0003-4819-112-4-270; MESSERLI FH, 1985, NEW ENGL J MED, V312, P1548, DOI 10.1056/NEJM198506133122405; MODAN M, 1991, HYPERTENSION, V17, P565, DOI 10.1161/01.HYP.17.4.565; NICHOLSON JP, 1987, ANN INTERN MED, V107, P329, DOI 10.7326/0003-4819-107-2-329; OATES JA, 1988, HYPERTENSION S2, V11, P4; PICKERING TG, 1988, JAMA-J AM MED ASSOC, V259, P225, DOI 10.1001/jama.259.2.225; PICKERING TG, 1988, HYPERTENSION, V11, pS96; PRINEAS RJ, 1991, HYPERTENSION, V17, pI143, DOI 10.1161/01.HYP.17.1_Suppl.I143; PUDDEY IB, 1987, LANCET, V1, P647; RADACK KL, 1987, ANN INTERN MED, V107, P628, DOI 10.7326/0003-4819-107-5-628; RAM CVS, 1981, ARCH INTERN MED, V141, P1015, DOI 10.1001/archinte.141.8.1015; REAVEN GM, 1991, AM HEART J, V121, P1283, DOI 10.1016/0002-8703(91)90434-J; ROCCELLA EJ, 1991, ARCH INTERN MED, V151, P1280; SACKETT DL, 1975, LANCET, V1, P1205; SETARO JF, 1991, HYPERTENSION, V18, P289, DOI 10.1161/01.HYP.18.3.289; STAIR DC, 1990, PROG CARDIOVASC DIS, V33, P185, DOI 10.1016/0033-0620(90)90008-P; STEIN PP, 1991, MEDICINE, V70, P46, DOI 10.1097/00005792-199101000-00004; STROGATZ DS, 1991, AM J EPIDEMIOL, V133, P442, DOI 10.1093/oxfordjournals.aje.a115911; SWALES JD, 1982, LANCET, V1, P894; TARAZI RC, 1970, ARCH INTERN MED, V125, P835; TSAPATSARIS NP, 1991, ARCH INTERN MED, V151, P2209, DOI 10.1001/archinte.151.11.2209; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; Wood AJ, 1988, HYPERTENSION S2, V11, pII1; WOODS JW, 1988, HYPERTENSION, V11, pS11; YAKOVLEVITCH M, 1991, ARCH INTERN MED, V151, P1786, DOI 10.1001/archinte.151.9.1786	55	119	123	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					543	547						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635569				2022-12-28	WOS:A1992JJ45700008
J	SELWYN, PA; SCKELL, BM; ALCABES, P; FRIEDLAND, GH; KLEIN, RS; SCHOENBAUM, EE				SELWYN, PA; SCKELL, BM; ALCABES, P; FRIEDLAND, GH; KLEIN, RS; SCHOENBAUM, EE			HIGH-RISK OF ACTIVE TUBERCULOSIS IN HIV-INFECTED DRUG-USERS WITH CUTANEOUS ANERGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY VIRUS-INFECTION; AIDS EPIDEMIC; PROGRAM	Objectives.-To determine the incidence of active tuberculosis in human immunodeficiency virus (HIV)-seropositive and HIV-seronegative drug injectors with cutaneous anergy and to examine the effectiveness of isoniazid chemoprophylaxis in preventing tuberculosis among drug injectors with positive tuberculin test results. Design and Setting.-Prospective observational study linked to an ongoing study of HIV infection within a New York City (NY) methadone program; subjects also underwent routine intradermal tuberculin testing and multiple-antigen delayed-type hypersensitivity skin testing. The 31 -month study period ended December 31, 1990. Methods.-Anergic subjects and tuberculin reactors who were HIV seropositive were compared by HIV disease status and CD4+ T-lymphocyte levels. Tuberculosis incidence was calculated for anergics (none treated with isoniazid) and for treated and untreated tuberculin reactors, by HIV serological status. Results.-Among those seropositive for HIV, anergic subjects had more advanced HIV disease and fewer CD4+ cells (median 0.33 vs 0.56 x 10(9)/L, P<.01) compared with tuberculin reactors, although neither clinical status nor CD4+ cell counts consistently predicted anergy. Five (7.6%) of 68 anergic subjects who were HIV seropositive and none of 52 anergic subjects who were HIV seronegative (n=18) or of unknown (n=34) HIV serological status developed active tuberculosis during the study period (P<.05). The tuberculosis incidence rate among anergic subjects who were HIV seropositive was 6.6 cases per 100 person-years (95% confidence interval [CI], 2.1 to 15.3). Of 25 HIV-seropositive tuberculin reactors who did not receive or complete 12 months of isoniazid prophylaxis, tuberculosis incidence was 9.7 cases per 1 00 person-years (95% CI, 2.6 to 24.7; P=0.56, compared with the rate among anergic HIV seropositives); there were no cases of tuberculosis in 53.4 person-years of follow-up for 27 HIV-seropositive tuberculin reactors who received 12 months of prophylaxis (rate difference between treated and untreated groups, 9.7 cases per 100 person-years, 95% CI, 1.3 to 18.0). Conclusion.-Drug injectors with cutaneous anergy who are seropositive for HIV are at high risk of active tuberculosis, similar to that among untreated HIV-seropositive tuberculin reactors. A decreased incidence of active tuberculosis was seen in HIV-seropositive tuberculin reactors receiving 12 months of isoniazid chemoprophylaxis, compared with untreated or partially treated subjects. These results support the routine use of delayed-type hypersensitivity testing to accompany tuberculin testing for drug injectors with known or suspected HIV infection, and consideration of isoniazid prophylaxis for anergic as well as tuberculin-reactive subjects who are HIV seropositive, in populations with a high prevalence of coexisting HIV and Mycobacterium tuberculosis infection.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT EPIDEMIOL & SOCIAL MED,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,MONTEFIORE MED CTR,DEPT MED,DIV INFECT DIS,BRONX,NY 10461	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine				Schoenbaum, Ellie/0000-0002-0878-284X	NIDA NIH HHS [R01DA04347] Funding Source: Medline; PHS HHS [U62/CCU200714] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004347] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BIRX D, 1989, 5 INT C AIDS MONTR; BLATT SP, 1991, 7TH INT C AIDS FLOR; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96; COHEN J, 1990, 6TH INT C AIDS SAN F; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DIPERRI G, 1989, LANCET, V2, P1502; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; JORDAN TJ, 1991, JAMA-J AM MED ASSOC, V265, P2987, DOI 10.1001/jama.265.22.2987; MARKOWITZ N, 1991, 7 INT C AIDS FLOR; NARDELL EA, 1990, AM REV RESPIR DIS, V142, P501, DOI 10.1164/ajrccm/142.3.501; PITCHENIK AE, 1990, ANN INTERN MED, V113, P89, DOI 10.7326/0003-4819-113-2-89; PITCHENIK AE, 1990, MMWR, V39, P718; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; ROBERT CF, 1989, NEW ENGL J MED, V321, P1268; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P214; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; SELWYN PA, 1988, AIDS, V2, P267, DOI 10.1097/00002030-198808000-00005; SELWYN PA, 1991, NEW YORK STATE J MED, V91, P233; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1989, ANN INTERN MED, V111, P761, DOI 10.7326/0003-4819-111-9-761; SELWYN PA, 1989, AM J PUBLIC HEALTH, V79, P1358, DOI 10.2105/AJPH.79.10.1358; SELWYN PA, 1990, 6TH INT C AIDS SAN F; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; WADHAWAN D, 1990, 6TH INT C AIDS SAN F; WIERZBA TP, 1991, 7TH INT C AIDS FLOR; 1991, MMWR, V40, P649; 1990, MMWR SRR17, V39, P1; 1987, MMWR, V36, P785; 1989, MMWR, V38, P236; 1991, MMWR, V40, P585; 1990, MMWR SRR8, V39, P1; 1991, MMWR SRR5, V40, P27; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1990, TUBERCULOSIS NEW YOR; 1990, MMWR, V39, P638	39	261	265	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					504	509		10.1001/jama.268.4.504	http://dx.doi.org/10.1001/jama.268.4.504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619742				2022-12-28	WOS:A1992JD47200025
J	LANE, TA; ANDERSON, KC; GOODNOUGH, LT; KURTZ, S; MOROFF, G; PISCIOTTO, PT; SAYERS, M; SILBERSTEIN, LE				LANE, TA; ANDERSON, KC; GOODNOUGH, LT; KURTZ, S; MOROFF, G; PISCIOTTO, PT; SAYERS, M; SILBERSTEIN, LE			LEUKOCYTE REDUCTION IN BLOOD COMPONENT THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						LEUKOCYTES; BLOOD COMPONENT TRANSFUSION; HLA ANTIGENS; ALLOIMMUNIZATION	CYTOMEGALO-VIRUS INFECTION; VERSUS-HOST DISEASE; DONOR PLATELET TRANSFUSIONS; POOR BLOOD; RED-CELLS; LYMPHOCYTOTOXIC ANTIBODY; MULTITRANSFUSED PATIENTS; ULTRAVIOLET-IRRADIATION; DEPLETED BLOOD; HLA ANTIGENS	Purpose: To review methods of preventing or minimizing the adverse effects associated with the transfusion of passenger leukocytes present in cellular blood components and to define groups of patients who are at risk for adverse effects. Data Sources: English-language articles on transfusion medicine. Study Selection: Original reports describing the pathogenesis of leukocyte-induced adverse effects in transfusion recipients and the influence of leukocyte-reduced blood components on these effects. Data Extraction: Evaluation of the diagnosis, transfusion history, and treatment of the study patients; the methods and results of leukocyte reduction; and specific outcomes, including development of alloimmunization to leukocytes, febrile reactions to transfusion, and platelet refractoriness. Data Synthesis: Passenger leukocytes are the chief cause of alloimmunization to human leukocyte antigen (HLA) and leukocyte-specific antigens in transfusion recipients. Alloimmunization may result in febrile transfusion reactions, platelet refractoriness, and acute lung injury. Leukocytes are also the vector for transfusion-associated cytomegalovirus infection. Technologic advances in the leukocyte reduction of cellular blood components have made it possible to reduce the number of leukocytes to fewer than 10(7) per transfusion. Findings suggest that the use of leukocyte-reduced cellular blood components may minimize or prevent recurrent febrile reactions and alloimmunization to leukocyte antigens. Cytomegalovirus may not be transmitted by blood components containing fewer than 10(7) leukocytes. Conclusions: Leukocyte reduction in red blood cell and platelet transfusions using third-generation filters is indicated for selected patients who are likely to receive long-term transfusion support, to prevent recurrent febrile reactions and to prevent or delay alloimmunization to leukocyte antigens. Leukocyte-depleted transfusions may also be indicated to delay or prevent refractoriness to platelet transfusion.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; UNIV HOSP CLEVELAND, DEPT MED, CLEVELAND, OH 44106 USA; LAHEY CLIN FDN, BURLINGTON, MA 01805 USA; AMER RED CROSS, JEROME HOLLAND LAB, ROCKVILLE, MD 20855 USA; UNIV CONNECTICUT, CTR HLTH, DEPT LAB MED, FARMINGTON, CT 06030 USA; PUGET SOUND BLOOD CTR & PROGRAM, SEATTLE, WA 98104 USA; HOSP UNIV PENN, BLOOD BANK, PHILADELPHIA, PA 19104 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University Hospitals of Cleveland; Lahey Hospital & Medical Center; American Red Cross; University of Connecticut; Puget Sound Blood Center; University of Pennsylvania; Pennsylvania Medicine	LANE, TA (corresponding author), UNIV CALIF SAN DIEGO, SCH MED, DEPT PATHOL 0612, 9500 GILMAN DR, LA JOLLA, CA 92093 USA.							Adler S P, 1988, Transfus Med Rev, V2, P235, DOI 10.1016/S0887-7963(88)70051-6; ADLER SP, 1983, REV INFECT DIS, V5, P977; ADLER SP, 1988, TRANSFUSION, V28, P604, DOI 10.1046/j.1537-2995.1988.28689059044.x; AKAHOSHI M, 1992, TRANSFUSION, V32, P169, DOI 10.1046/j.1537-2995.1992.32292180149.x; ALEXANDER JW, 1991, TRANSFUSION, V31, P195, DOI 10.1046/j.1537-2995.1991.31391165165.x; ANDERSON KC, 1990, NEW ENGL J MED, V323, P315; ANDERSON KC, 1991, TRANSFUS SCI, V12, P163, DOI 10.1016/0955-3886(91)90125-M; ANDREU G, 1990, TRANSFUSION, V30, P401, DOI 10.1046/j.1537-2995.1990.30590296370.x; ANDREU G, 1988, BLOOD, V72, P964; ASTER RH, 1964, J CLIN INVEST, V43, P856, DOI 10.1172/JCI104971; BAIRD MA, 1986, TRANSPLANTATION, V42, P1, DOI 10.1097/00007890-198607000-00001; BERTHOLF MF, 1989, TRANSFUSION, V29, P521, DOI 10.1046/j.1537-2995.1989.29689318451.x; BETTS RF, 1979, J MED VIROL, V4, P89, DOI 10.1002/jmv.1890040203; BLAJCHMAN MA, 1992, BLOOD, V79, P1371; Bonacossa I A, 1990, Transfus Med Rev, V4, P144, DOI 10.1016/S0887-7963(90)70259-3; BOWDEN R, 1990, TRANSFUSION, V30, P762, DOI 10.1046/j.1537-2995.1990.30891020340.x; Bowden R.A., 1989, TRANSFUSION S, V29, P57; BOWDEN RA, 1991, BLOOD, V78, P246; BRADY MT, 1984, J INFECT DIS, V150, P334, DOI 10.1093/infdis/150.3.334; BRAND A, 1988, VOX SANG, V54, P160, DOI 10.1111/j.1423-0410.1988.tb03892.x; CHOU SW, 1987, J INFECT DIS, V155, P565, DOI 10.1093/infdis/155.3.565; CLAAS FHJ, 1981, EXP HEMATOL, V9, P84; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DAUSSET J., 1966, TRANSPLANTATION, V4, P182, DOI 10.1097/00007890-196603000-00008; Dausset Jean, 1954, VOX SANG BASEL, V4, P190; DEEG HJ, 1989, BLOOD, V74, P2592; DEGRAANHENTZEN YCE, 1989, TRANSFUSION, V29, P757; DEMMLER GJ, 1986, J PEDIATR-US, V108, P762, DOI 10.1016/S0022-3476(86)81062-9; DEWITTE T, 1990, TRANSPLANTATION, V50, P964, DOI 10.1097/00007890-199012000-00013; DUTCHER JP, 1981, BLOOD, V57, P395; DUTCHER JP, 1981, BLOOD, V58, P1007; DZIK WH, 1990, VOX SANG, V59, P153, DOI 10.1111/j.1423-0410.1990.tb00850.x; EERNISSE JG, 1981, EXP HEMATOL, V9, P77; FISHER M, 1985, VOX SANG, V49, P331, DOI 10.1111/j.1423-0410.1985.tb00807.x; FRIEDMAN LI, 1990, TRANSFUSION, V30, P387, DOI 10.1046/j.1537-2995.1990.30590296368.x; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOGGE DE, 1983, AM J HEMATOL, V14, P363, DOI 10.1002/ajh.2830140407; HOWARD JE, 1978, TRANSFUSION, V18, P496, DOI 10.1046/j.1537-2995.1978.18478251250.x; HUGHES ASB, 1982, BRIT J HAEMATOL, V50, P381, DOI 10.1111/j.1365-2141.1982.tb01933.x; KAO KJ, 1988, HUM IMMUNOL, V21, P115, DOI 10.1016/0198-8859(88)90086-9; KICKLER TS, 1989, TRANSFUSION, V29, P411, DOI 10.1046/j.1537-2995.1989.29589284140.x; KLINGEMANN HG, 1987, BRIT J HAEMATOL, V66, P115, DOI 10.1111/j.1365-2141.1987.tb06900.x; KOERNER K, 1991, VOX SANG, V60, P61, DOI 10.1111/j.1423-0410.1991.tb00873.x; KOOY MV, 1991, BLOOD, V77, P201; KOOY MV, 1990, TRANSFUSION, V30, P34; KOSKIMIES S, 1986, TRANSPLANT P, V18, P20; LANG DJ, 1977, TRANSFUSION, V17, P391, DOI 10.1046/j.1537-2995.1977.17477216868.x; LEE EJ, 1987, BLOOD, V70, P1727; LUBAN NLC, 1987, AM J DIS CHILD, V141, P416, DOI 10.1001/archpedi.1987.04460040074018; MANGANO MM, 1991, AM J CLIN PATHOL, V95, P733, DOI 10.1093/ajcp/95.5.733; MCCULLOUGH J, 1981, BLOOD, V58, P164; MENITOVE JE, 1982, VOX SANG, V42, P318, DOI 10.1111/j.1423-0410.1982.tb01106.x; Meryman H T, 1989, Transfus Med Rev, V3, P180, DOI 10.1016/S0887-7963(89)70078-X; MERYMAN HT, 1986, TRANSFUSION, V26, P101, DOI 10.1046/j.1537-2995.1986.26186124010.x; MINTZ PD, 1991, AM J CLIN PATHOL, V95, P609, DOI 10.1093/ajcp/95.5.609; MIYAMOTO M, 1989, VOX SANG, V57, P164, DOI 10.1111/j.1423-0410.1989.tb00815.x; MURPHY MF, 1987, BRIT J HAEMATOL, V67, P255, DOI 10.1111/j.1365-2141.1987.tb02344.x; MURPHY MF, 1986, BRIT J HAEMATOL, V62, P529, DOI 10.1111/j.1365-2141.1986.tb02965.x; OKOCHI K, 1986, AIDS RES, V2, P5157; PAMPHILON DH, 1990, BRIT J HAEMATOL, V75, P240, DOI 10.1111/j.1365-2141.1990.tb02656.x; PELLEGRINO MA, 1982, TRANSPLANTATION, V33, P530, DOI 10.1097/00007890-198205000-00013; PERKINS HA, 1966, VOX SANG, V11, P578, DOI 10.1111/j.1423-0410.1966.tb04256.x; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; RAPAPORT FT, 1965, TRANSPLANTATION, V4, P490; REVERBERI R, 1989, HAEMATOLOGICA, V74, P283; RICE GPA, 1984, P NATL ACAD SCI-BIOL, V81, P6134, DOI 10.1073/pnas.81.19.6134; SAARINEN UM, 1990, BLOOD, V75, P512; SAYERS MH, 1992, ANN INTERN MED, V116, P55, DOI 10.7326/0003-4819-116-1-55; SCHIFFER CA, 1987, TRANSFUSION, V27, P162, DOI 10.1046/j.1537-2995.1987.27287150190.x; SCHIFFER CA, 1991, BLOOD, V77, P1; SCHIFFER CA, 1987, PROG HEMATOL, V15, P91; SCHIFFER CA, 1983, BLOOD, V62, P815; SCHRIER RD, 1985, SCIENCE, V230, P1048, DOI 10.1126/science.2997930; SIRCHIA G, 1983, VOX SANG, V44, P115, DOI 10.1111/j.1423-0410.1983.tb04112.x; SIRCHIA G, 1990, TRANSFUSION, V30, P30, DOI 10.1046/j.1537-2995.1990.30190117625.x; SIRCHIA G, 1982, VOX SANG, V42, P190, DOI 10.1111/j.1423-0410.1982.tb01094.x; SIRCHIA G, 1987, TRANSFUSION, V27, P402, DOI 10.1046/j.1537-2995.1987.27587320533.x; SLICHTER SJ, 1990, HEMATOL ONCOL CLIN N, V4, P291; SLICHTER SJ, 1987, BLOOD, V69, P414; SNIECINSKI I, 1988, BLOOD, V71, P1402; SNYDER EL, 1989, TRANSFUSION, V29, P568, DOI 10.1046/j.1537-2995.1989.29789369671.x; TAYLOR BJ, 1986, PEDIATR INFECT DIS J, V5, P188, DOI 10.1097/00006454-198603000-00005; THALER M, 1989, NEW ENGL J MED, V321, P25, DOI 10.1056/NEJM198907063210105; TOLKOFFRUBIN NE, 1978, ANN INTERN MED, V89, P625, DOI 10.7326/0003-4819-89-5-625; TUCKER J, 1989, BRIT J HAEMATOL, V73, P572, DOI 10.1111/j.1365-2141.1989.tb00304.x; VANBEKKUM DW, 1965, ISRAEL J MED SCI, V1, P879; VERDONCK LF, 1987, BONE MARROW TRANSPL, V2, P73; WALKER RH, 1987, AM J CLIN PATHOL, V88, P374, DOI 10.1093/ajcp/88.3.374; WELCH HG, 1989, TRANSFUSION, V29, P193, DOI 10.1046/j.1537-2995.1989.29389162721.x; WELSH KI, 1977, EUR J IMMUNOL, V7, P267, DOI 10.1002/eji.1830070505; WENZ B, 1983, TRANSFUSION, V23, P95, DOI 10.1046/j.1537-2995.1983.23283172868.x; WENZ B, 1990, Transfusion Medicine Reviews, V4, P3, DOI 10.1016/S0887-7963(90)70236-2; WENZ B, 1980, VOX SANG, V39, P282, DOI 10.1111/j.1423-0410.1980.tb01872.x; WENZ B, 1984, TRANSFUSION, V24, P88, DOI 10.1046/j.1537-2995.1984.24184122576.x	95	102	103	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					151	162		10.7326/0003-4819-117-2-151	http://dx.doi.org/10.7326/0003-4819-117-2-151			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605430				2022-12-28	WOS:A1992JD12300010
J	WIECH, H; BUCHNER, J; ZIMMERMANN, R; JAKOB, U				WIECH, H; BUCHNER, J; ZIMMERMANN, R; JAKOB, U			HSP90 CHAPERONES PROTEIN FOLDING INVITRO	NATURE			English	Article							HEAT-SHOCK PROTEINS; LIGHT-CHAIN	THE heat-shock protein Hsp90 is the most abundant constitutively expressed stress protein in the cytosol of eukaryotic cells 1,2, where it participates in the maturation of other proteins, modulation of protein activity in the case of hormone-free steroid receptors, and intracellular transport of some newly synthesized kinases 3-5. A feature of all these processes could be their dependence on the formation of protein structure. If Hsp90 is a molecular chaperone involved in maintaining a certain subset of cellular proteins in an inactive form, it should also be able to recognize and bind non-native proteins, thereby influencing their folding to the native state. Here we investigate whether Hsp90 can influence protein folding in vitro and show that Hsp90 suppresses the formation of protein aggregates by binding to the target proteins at a stoichiometry of one Hsp90 dimer to one or two substrate molecule(s). Furthermore, the yield of correctly folded and functional protein is increased significantly. The action of Hsp90 does not depend on the presence of nucleoside triphosphates, so it may be that Hsp90 uses a novel molecular mechanism to assist protein folding in vivo.	UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,UNIV STR 31,W-8400 REGENSBURG,GERMANY; UNIV GOTTINGEN,ZENTRUM BIOCHEM,BIOCHEM ABT 2,W-3400 GOTTINGEN,GERMANY	University of Regensburg; University of Gottingen			Buchner, Johannes/A-2651-2010	Buchner, Johannes/0000-0003-1282-7737				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; BUCKEL P, 1987, GENE, V51, P13, DOI 10.1016/0378-1119(87)90469-0; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTO Y, 1982, J MOL BIOL, V156, P891, DOI 10.1016/0022-2836(82)90146-2; JOHNSTONE A, 1987, IMMUNOCHEMISTRY PRAC, P55; KAWATA Y, 1991, BIOCHEMISTRY-US, V30, P4367, DOI 10.1021/bi00232a001; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SCHMIDT M, IN PRESS J BIOL CHEM; SRERE PA, 1963, ACTA CHEM SCAND, V17, pS129; TSUNENAGA M, 1987, BIOCHEMISTRY-US, V26, P4367; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WEST SM, 1988, BIOCHEM J, V251, P135, DOI 10.1042/bj2510135; WETLAUFER DB, 1962, ADV PROTEIN CHEM, V17, P303	18	441	452	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					169	170		10.1038/358169a0	http://dx.doi.org/10.1038/358169a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614549				2022-12-28	WOS:A1992JC58300059
J	ZYCHLINSKY, A; PREVOST, MC; SANSONETTI, PJ				ZYCHLINSKY, A; PREVOST, MC; SANSONETTI, PJ			SHIGELLA-FLEXNERI INDUCES APOPTOSIS IN INFECTED MACROPHAGES	NATURE			English	Article							LISTERIA-MONOCYTOGENES; PLASMID; SPREAD; GROWTH; CELLS; ACTIN	THE Gram-negative bacterial pathogen Shigella flexneri causes dysentery by invading the human colonic mucosa 1. Bacteria are phagocytosed by enterocytes 2, escape from the phagosome into the cytoplasm 3 and spread to adjacent cells 4. After crossing the epithelium, Shigella reaches the lamina propria of intestinal villi, the first line of defence. This tissue is densely populated with phagocytes that are killed in great numbers, resulting in abscesses 5,6. The genes required for cell invasion 7 and macrophage killing 2 are located on a 220-kilobase plasmid. We report here on the mechanism of cytotoxicity used by S. flexneri to kill macrophages. Each of four different strains was tested for its capacity to induce cell death. An invasive strain induced programmed cell death (apoptosis 8,9), whereas its non-invasive, plasmid-cured isogenic strain was not toxic; neither was a mutant in ipa B (ref. 10) (invasion protein antigen), a gene necessary for entry. A non-invasive strain expressing the haemolysin operon of Escherichia coli 11 induced accidental cell death (necrosis), demonstrating that other bacterial cytotoxic mechanisms do not lead to apoptosis. This is the first evidence that an invasive bacterial pathogen can induce suicide in its host cells.	INST PASTEUR, INSERM,U199,UNITE PATHOGENIE MICROBIENNE MOLEC, 25-28 RUE DOCTEUR ROUX, F-75724 PARIS 15, FRANCE; INST PASTEUR, CENT MICROSCOPIE ELECTR STN, F-75724 PARIS 15, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ANAND BS, 1986, GASTROENTEROLOGY, V90, P654, DOI 10.1016/0016-5085(86)91120-0; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERNARDINI ML, 1989, P NATL ACAD SCI USA, V86, P3867, DOI 10.1073/pnas.86.10.3867; CLERC PL, 1987, INFECT IMMUN, V55, P521, DOI 10.1128/IAI.55.3.521-527.1987; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GAILLARD JL, 1987, INFECT IMMUN, V55, P2822, DOI 10.1128/IAI.55.11.2822-2829.1987; HIGH N, 1992, EMBO J, V11, P1991, DOI 10.1002/j.1460-2075.1992.tb05253.x; LABREC EH, 1964, J BACTERIOL, V88, P1503, DOI 10.1128/JB.88.5.1503-1518.1964; MANGAN DF, 1991, J IMMUNOL, V146, P1541; MATHAN MM, 1991, REV INFECT DIS, V13, pS314; NOEGEL A, 1979, MOL GEN GENET, V175, P343, DOI 10.1007/BF00397234; SANSONETTI PJ, 1986, INFECT IMMUN, V51, P461, DOI 10.1128/IAI.51.2.461-469.1986; SANSONETTI PJ, 1982, INFECT IMMUN, V35, P852, DOI 10.1128/IAI.35.3.852-860.1982; Tanenbaum SW, 1978, CYTOCHALASINS BIOCH; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; WARING P, 1990, J BIOL CHEM, V265, P14476; WELCH RA, 1991, MOL MICROBIOL, V5, P521, DOI 10.1111/j.1365-2958.1991.tb00723.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279	18	758	809	10	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 9	1992	358	6382					167	169		10.1038/358167a0	http://dx.doi.org/10.1038/358167a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614548				2022-12-28	WOS:A1992JC58300058
J	KUO, CJ; CHUNG, JK; FIORENTINO, DF; FLANAGAN, WM; BLENIS, J; CRABTREE, GR				KUO, CJ; CHUNG, JK; FIORENTINO, DF; FLANAGAN, WM; BLENIS, J; CRABTREE, GR			RAPAMYCIN SELECTIVELY INHIBITS INTERLEUKIN-2 ACTIVATION OF P70 S6 KINASE	NATURE			English	Article							PEPTIDYL-PROLYL ISOMERASE; IMMUNOSUPPRESSANT FK506; MACROLIDES FK-506; DISTINCT; PROTEIN; CLONING; ENZYME; CELLS	THE macrolide rapamycin induces cell cycle G1 arrest in yeast and in mammalian cells 1-3, which suggests that an evolutionarily conserved, rapamycin-sensitive pathway may regulate entry into S phase. In mammals, rapamycin inhibits interleukin-2 receptor-induced S phase entry and subsequent T-cell proliferation 4-6, resulting in immunosuppression. Here we show that interleukin-2 selectively stimulates the phosphorylation and activation of p70 S6 kinase but not the erk-encoded MAP kinases and rsk-encoded S6 kinases 7,8. Rapamycin completely and rapidly inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase at concentrations comparable to those blocking S phase entry of T cells (0.05-0.2 nM). The structurally related macrolide FK506 competitively antagonizes the actions of rapamycin, indicating that these effects are mediated by FKBP, which binds the transition-state mimic structure common to both rapamycin and FK506 (refs 4, 6, 9-11). The selective blockade of the p70 S6 kinase activation cascade by the rapamycin-FKBP complex implicates this signalling pathway in the regulation of T cell entry into S phase.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	KUO, CJ (corresponding author), STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,HOWARD HUGHES MED INST,MOLEC & GENET MED UNIT,STANFORD,CA 94305, USA.			Fiorentino, David/0000-0001-7951-3674; Kuo, Calvin/0000-0002-7427-5985				BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLENIS J, 1991, CANCER CELL, V3, P1; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CHUNG J, IN PRESS CELL; CHUNG JK, 1991, MOL CELL BIOL, V11, P1868, DOI 10.1128/MCB.11.4.1868; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MORRIS RE, 1991, IMMUNOL TODAY, V12, P137; PELECH SL, 1986, P NATL ACAD SCI USA, V83, P5968, DOI 10.1073/pnas.83.16.5968; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0	23	582	596	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					70	73		10.1038/358070a0	http://dx.doi.org/10.1038/358070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614535				2022-12-28	WOS:A1992JB34100056
J	GERSHON, D				GERSHON, D			BIOTECHNOLOGY LEADS THE WAY AS STATE MOVES BEYOND GROUND-BASED ECONOMY	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					626	627		10.1038/357626a0	http://dx.doi.org/10.1038/357626a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JA430	1614505				2022-12-28	WOS:A1992JA43000022
J	RUBIN, GP				RUBIN, GP			ENDOSCOPY FACILITIES IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article											RUBIN, GP (corresponding author), HLTH CTR,THORNABY TS17 0BZ,CLEVELAND,ENGLAND.							EVANS P, 1988, PULSE, V48, P80; HENNIGAN TW, 1990, BRIT MED J, V301, P478, DOI 10.1136/bmj.301.6750.478; NEVILLE RG, 1988, UPDATE, V36, P2311	3	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1542	1543		10.1136/bmj.304.6841.1542	http://dx.doi.org/10.1136/bmj.304.6841.1542			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628053	Bronze, Green Published			2022-12-28	WOS:A1992HZ17800024
J	SCOTT, MGB; MARINKER, M				SCOTT, MGB; MARINKER, M			MANAGING CHANGE IN PRIMARY CARE .4. IMPOSED CHANGE IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article									MSD FDN,LONDON E14 9WA,ENGLAND		SCOTT, MGB (corresponding author), CAIRNTOUL PRACTICE,GLASGOW G14 0XT,SCOTLAND.							Halmos P., 1965, FAITH COUNSELLORS; KLEIN R, 1991, HEALTHCARE PROVISION; MORRELL DC, 1991, BMJ-BRIT MED J, V302, P1313, DOI 10.1136/bmj.302.6788.1313	3	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1548	1550		10.1136/bmj.304.6841.1548	http://dx.doi.org/10.1136/bmj.304.6841.1548			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628057	Bronze, Green Published			2022-12-28	WOS:A1992HZ17800028
J	BEUTLER, E				BEUTLER, E			GAUCHER DISEASE - NEW MOLECULAR APPROACHES TO DIAGNOSIS AND TREATMENT	SCIENCE			English	Article							ACID BETA-GLUCOSIDASE; HUMAN GLUCOCEREBROSIDASE GENE; HEMATOPOIETIC PROGENITOR CELLS; SPODOPTERA-FRUGIPERDA CELLS; BONE-MARROW TRANSPLANTATION; TAY-SACHS DISEASE; NUCLEOTIDE-SEQUENCE; REPLACEMENT THERAPY; CARRIER STATE; DEFICIENCY	Gaucher disease is characterized by the accumulation at glucocerebroside, leading to enlargement of the liver and spleen and lesions in the bones. It is caused by an inherited deficiency of the enzyme glucocerebrosidase. Many mutations exist, but four of these account for over 97% of the mutations in Ashkenazi Jews, the population group in which Gaucher disease is the most common. Although there is a strong relation between the mutations and disease manifestations, genetic counseling is made difficult by the fact that within each genotype there is considerable variability in the severity of the disease. Intravenous infusion of glucocerebrosidase is an effective treatment, but the availability of enzyme replacement therapy is limited by its high cost. Marrow transplantation is also effective in treating the disease, but is rarely performed because of the risks involved. In the future gene transfer may become the treatment of choice.			BEUTLER, E (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCRR NIH HHS [RR00833] Funding Source: Medline; NIDDK NIH HHS [DK36639] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036639] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHORD DT, 1978, CELL, V15, P269, DOI 10.1016/0092-8674(78)90102-2; AERTS JMFG, 1990, BIOCHEM J, V269, P93, DOI 10.1042/bj2690093; BARNEVELD RA, 1983, HUM GENET, V64, P227, DOI 10.1007/BF00279398; BARTON NW, 1991, NEW ENGL J MED, V325, P1811; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; BELCHETZ PE, 1977, LANCET, V2, P116; BEUTLER E, 1970, J LAB CLIN MED, V76, P747; BEUTLER E, 1990, EXP HEMATOL, V18, P857; BEUTLER E, 1990, BLOOD, V76, P646; BEUTLER E, 1981, TRENDS BIOCHEM SCI, V6, P95, DOI 10.1016/0968-0004(81)90035-9; BEUTLER E, 1984, P NATL ACAD SCI-BIOL, V81, P6506, DOI 10.1073/pnas.81.20.6506; BEUTLER E, 1977, P NATL ACAD SCI USA, V74, P4620, DOI 10.1073/pnas.74.10.4620; BEUTLER E, 1992, BLOOD, V79, P1662; BEUTLER E, 1970, LANCET, V1, P612; BEUTLER E, 1986, P NATL ACAD SCI USA, V83, P7472, DOI 10.1073/pnas.83.19.7472; BEUTLER E, 1991, P NATL ACAD SCI USA, V88, P10544, DOI 10.1073/pnas.88.23.10544; BEUTLER E, 1991, BLOOD, V78, P1183; BEUTLER E, 1990, ANN HUM GENET, V54, P149, DOI 10.1111/j.1469-1809.1990.tb00371.x; BEUTLER E, 1991, NEW ENGL J MED, V325, P1809; BEUTLER E, UNPUB; BEUTLER E, 1992, GENOMICS, V12, P7995; BEUTLER E, 1988, LIPID STORAGE DISORD, P19; BEUTLER E, 1982, GAUCHER DISEASE CENT, P573; BRADY RO, 1974, NEW ENGL J MED, V291, P989, DOI 10.1056/NEJM197411072911901; BUTCHER BA, 1989, CLIN CHIM ACTA, V184, P235, DOI 10.1016/0009-8981(89)90056-9; CAO A, 1981, AM J HUM GENET, V33, P592; CONZELMANN E, 1983, AM J HUM GENET, V35, P900; CORRELL PH, 1989, P NATL ACAD SCI USA, V86, P8912, DOI 10.1073/pnas.86.22.8912; DAHL N, 1990, AM J HUM GENET, V47, P275; DALE GL, 1980, ENZYME THERAPY GENET, V2, P33; DEDUVE C, 1964, FED PROC, V23, P1045; DESNICK RJ, 1982, GAUCHER DISEASE CENT, P1; DIAMOND J, 1991, DISCOVER, V12, P60; DINUR T, 1986, P NATL ACAD SCI USA, V83, P1660, DOI 10.1073/pnas.83.6.1660; DOEBBER TW, 1982, J BIOL CHEM, V257, P2193; ERIKSON A, 1986, ACTA PAEDIATR SCAND, V326, P7; EYAL N, 1990, GENE, V96, P277, DOI 10.1016/0378-1119(90)90264-R; EYAL N, 1991, HUM GENET, V87, P328; FIGUEROA ML, IN PRESS CLIN RES; FINK JK, 1990, P NATL ACAD SCI USA, V87, P2334, DOI 10.1073/pnas.87.6.2334; FURBISH FS, 1978, BIOCHEM BIOPH RES CO, V81, P1047, DOI 10.1016/0006-291X(78)91456-0; FURBISH FS, 1981, BIOCHIM BIOPHYS ACTA, V673, P425, DOI 10.1016/0304-4165(81)90474-8; GINNS EI, 1985, P NATL ACAD SCI USA, V82, P7101, DOI 10.1073/pnas.82.20.7101; GOLDMAN DP, IN PRESS INT J TECH; GRABOWSKI GA, 1989, ENZYME, V41, P131, DOI 10.1159/000469068; GRABOWSKI GA, 1985, AM J HUM GENET, V37, P499; GRACE ME, 1990, J BIOL CHEM, V265, P6827; GRACE ME, 1991, AM J HUM GENET, V49, P646; GRAVES PN, 1988, DNA-J MOLEC CELL BIO, V7, P521, DOI 10.1089/dna.1.1988.7.521; HARADA F, 1987, P NATL ACAD SCI USA, V84, P8091, DOI 10.1073/pnas.84.22.8091; HOBBS JR, 1987, ENZYME, V38, P194, DOI 10.1159/000469205; HONG CM, 1990, DNA CELL BIOL, V9, P233, DOI 10.1089/dna.1990.9.233; HOROWITZ M, 1989, GENOMICS, V4, P87, DOI 10.1016/0888-7543(89)90319-4; JANSEN RW, 1991, J BIOL CHEM, V266, P3343; KARLSSON S, 1991, BLOOD, V78, P2481; KAWAME H, 1991, AM J HUM GENET, V49, P1378; KAY AC, 1991, T ASSOC AM PHYSICIAN, V104, P258; KOHN DB, 1991, HUM GENE THER, V2, P101, DOI 10.1089/hum.1991.2.2-101; LATHAM T, 1990, AM J HUM GENET, V47, P79; LATHAM TE, 1991, DNA CELL BIOL, V10, P15, DOI 10.1089/dna.1991.10.15; LENNARTZ MR, 1987, BIOCHEM J, V245, P705, DOI 10.1042/bj2450705; MARTIN BM, 1988, DNA-J MOLEC CELL BIO, V7, P99, DOI 10.1089/dna.1988.7.99; MORNET E, 1991, AM J HUM GENET, V48, P79; NAVON R, 1986, AM J MED GENET, V24, P179, DOI 10.1002/ajmg.1320240123; NAVON R, 1976, AM J HUM GENET, V28, P339; NAVON R, 1973, AM J HUM GENET, V25, P287; OBRIEN JS, 1970, NEW ENGL J MED, V283, P15, DOI 10.1056/NEJM197007022830104; OCKERMAN PA, 1968, SCAND J CLIN LAB INV, V22, P62, DOI 10.3109/00365516809160739; OHASHI T, 1991, J BIOL CHEM, V266, P3661; PENTCHEV PG, 1983, AM J HUM GENET, V35, P621; PENTCHEV PG, 1978, P NATL ACAD SCI USA, V75, P3970, DOI 10.1073/pnas.75.8.3970; RAPPEPORT JM, 1984, NEW ENGL J MED, V311, P84, DOI 10.1056/NEJM198407123110203; REINER O, 1988, GENE, V73, P469, DOI 10.1016/0378-1119(88)90511-2; ROTTER JI, 1987, NATURE, V329, P289, DOI 10.1038/329289a0; SCHNABEL D, 1991, FEBS LETT, V284, P57, DOI 10.1016/0014-5793(91)80760-Z; SHAFITZAGARDO B, 1981, AM J HUM GENET, V33, P564; SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345; SORGE J, 1990, J CLIN INVEST, V86, P1137, DOI 10.1172/JCI114818; SORGE J, 1985, P NATL ACAD SCI USA, V82, P7289, DOI 10.1073/pnas.82.21.7289; SORGE J, 1985, P NATL ACAD SCI USA, V82, P5442, DOI 10.1073/pnas.82.16.5442; SORGE J, 1987, P NATL ACAD SCI USA, V84, P906, DOI 10.1073/pnas.84.4.906; SORGE J, 1986, COLD SPRING HARB SYM, V60, P1041; SORGE JA, 1987, AM J HUM GENET, V41, P1016; STEER CJ, 1978, FEBS LETT, V91, P202, DOI 10.1016/0014-5793(78)81172-7; THEOPHILUS BDM, 1989, NUCLEIC ACIDS RES, V17, P7707, DOI 10.1093/nar/17.19.7707; TSUJI S, 1988, P NATL ACAD SCI USA, V85, P2349, DOI 10.1073/pnas.85.7.2349; TSUJI S, 1986, J BIOL CHEM, V261, P50; TSUJI S, 1987, NEW ENGL J MED, V316, P570, DOI 10.1056/NEJM198703053161002; VIDGOFF J, 1973, AM J HUM GENET, V25, P372; WIGDERSON M, 1989, AM J HUM GENET, V44, P365; ZIMRAN A, 1991, NEW ENGL J MED, V325, P1810; ZIMRAN A, 1989, LANCET, V2, P349; ZIMRAN A, 1990, AM J HUM GENET, V46, P902; ZIMRAN A, 1990, J CLIN INVEST, V85, P219, DOI 10.1172/JCI114415; ZIMRAN A, 1991, AM J HUM GENET, V49, P855; ZIMRAN A, COMMUNICATION; 1991, WALL STREET J   1223, pB1; 1991, WALL STREET J   1224, pA2; 1992, NY TIMES        0122, pC19	99	194	212	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					794	799		10.1126/science.1589760	http://dx.doi.org/10.1126/science.1589760			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589760				2022-12-28	WOS:A1992HT23500032
J	COCCONI, G; BELLA, M; CALABRESI, F; TONATO, M; CANALETTI, R; BONI, C; BUZZI, F; CECI, G; CORGNA, E; COSTA, P; LOTTICI, R; PAPADIA, F; SOFRA, MC; BACCHI, M				COCCONI, G; BELLA, M; CALABRESI, F; TONATO, M; CANALETTI, R; BONI, C; BUZZI, F; CECI, G; CORGNA, E; COSTA, P; LOTTICI, R; PAPADIA, F; SOFRA, MC; BACCHI, M			TREATMENT OF METASTATIC MALIGNANT-MELANOMA WITH DACARBAZINE PLUS TAMOXIFEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR-BETA; ADVANCED BREAST-CANCER; KILLER CELL-ACTIVITY; HUMAN LYMPHOCYTES-T; ESTROGEN-RECEPTORS; COMBINATION CHEMOTHERAPY; TRANSFORMED PHENOTYPE; ENDOCRINE THERAPY; IMMUNE-RESPONSE; NK ACTIVITY	Background. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. Methods and Results. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P<0.001). Conclusions. In the treatment of metastatic malignant melanoma, dacarbazine plus tamoxifen is more effective than dacarbazine alone, as indicated by both the response rate and the median survival; the difference in efficacy occurs mainly among women.	OSPED MAGGIORE PARMA,ITALIAN ONCOL GRP CLIN RES,ONCOL SERV,PARMA UNIT,PARMA,ITALY; IST REGINA ELENA,I-00161 ROME,ITALY; POLICLIN MONTELUCE,DIV MED ONCOL,PERUGIA UNIT,PERUGIA,ITALY; OSPED S MARIA,ONCOL SERV,TERNI UNIT,TERNI,ITALY; OSPED CIVILE,ONCOL SERV,PIACENZA UNIT,PIACENZA,ITALY; UNIV PARMA,DIV PLAST SURG,I-43100 PARMA,ITALY	University of Parma; University Hospital of Parma; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Parma								ADAMI HO, 1990, JAMA-J AM MED ASSOC, V263, P2189, DOI 10.1001/jama.263.16.2189; BALCH CM, 1983, J CLIN ONCOL, V1, P126, DOI 10.1200/JCO.1983.1.2.126; BALCH CM, 1991, CUTANEOUS MELANOMA, P40; BEHL C, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P59; BENASSAYAG C, 1986, ENDOCRINOLOGY, V118, P1; BERD D, 1991, P AN M AM SOC CLIN, V10, P291; BLATT J, 1984, BRIT J CANCER, V50, P837, DOI 10.1038/bjc.1984.264; BLATT J, 1984, P AM SOC CLIN ONCOL, V3, P77; BONMASSAR A, 1979, EUR J CANCER, V15, P933, DOI 10.1016/0014-2964(79)90276-7; BROWN TJ, 1987, J IMMUNOL, V139, P2977; CECI G, 1988, CANCER, V61, P1988, DOI 10.1002/1097-0142(19880515)61:10<1988::AID-CNCR2820611010>3.0.CO;2-5; COCCONI G, 1983, CANCER, V51, P581, DOI 10.1002/1097-0142(19830215)51:4<581::AID-CNCR2820510404>3.0.CO;2-G; COHEN JHM, 1983, J IMMUNOL, V131, P2767; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; CREAGAN ET, 1980, CANCER, V46, P1785, DOI 10.1002/1097-0142(19801015)46:8<1785::AID-CNCR2820460815>3.0.CO;2-0; DELARCO JE, 1985, P NATL ACAD SCI USA, V82, P5015; DELPRETE SA, 1984, CANCER TREAT REP, V68, P1403; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DESLYPERE JP, 1985, J CLIN ENDOCR METAB, V61, P564, DOI 10.1210/jcem-61-3-564; FEUCHT KA, 1988, CANCER RES, V48, P7093; FIORETTI MC, 1975, PHARMACOL RES COMMUN, V7, P481, DOI 10.1016/0031-6989(75)90009-0; FISHER RI, 1976, LANCET, V2, P337; FOLKERD EJ, 1983, J STEROID BIOCHEM, V19, P687, DOI 10.1016/0022-4731(83)90236-4; GULINO A, 1985, J LEUKOCYTE BIOL, V38, P159; HANNA N, 1983, J IMMUNOL, V130, P974; HERSEY P, 1982, CANCER RES, V42, P363; HRUSHESKY WJM, 1988, J NATL CANCER I, V80, P1232, DOI 10.1093/jnci/80.15.1232; KALLAND T, 1980, J IMMUNOL, V124, P194; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARAKOUSIS CP, 1980, CANCER TREAT REP, V64, P819; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LEGHA SS, 1989, SEMIN ONCOL, V16, P34; LUIKART SD, 1984, J CLIN ONCOL, V2, P164, DOI 10.1200/JCO.1984.2.3.164; LUSTER MI, 1981, BIOL RELEVANCE IMMUN, P153; MANDEVILLE R, 1984, EUR J CANCER CLIN ON, V20, P983, DOI 10.1016/0277-5379(84)90174-3; MARELLI O, 1988, BRIT J CANCER, V58, P171, DOI 10.1038/bjc.1988.186; MCCARTY KS, 1986, CANCER RES, V46, P4244; MCCLAY EF, 1987, CANCER TREAT REP, V71, P465; MCCLAY EF, 1988, SEMIN ONCOL, V15, P569; MCCLAY EF, 1989, CANCER, V63, P1292, DOI 10.1002/1097-0142(19890401)63:7<1292::AID-CNCR2820630711>3.0.CO;2-I; MEYSKENS FL, 1980, CANCER TREAT REP, V64, P171; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOURIDSEN HT, 1985, EUR J CANCER CLIN ON, V21, P291, DOI 10.1016/0277-5379(85)90128-2; NESBIT RA, 1979, NEW ENGL J MED, V301, P1241; PAAVONEN T, 1981, J EXP MED, V154, P1935, DOI 10.1084/jem.154.6.1935; PARMIANI G, 1990, J NATL CANCER I, V82, P361, DOI 10.1093/jnci/82.5.361; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTS AB, 1990, ADV CLIN ONCOL, V1, P283; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; TORMEY DC, 1982, AM J CLIN ONCOL-CANC, V5, P33; VILADIU P, 1985, CANCER, V56, P2745, DOI 10.1002/1097-0142(19851215)56:12<2745::AID-CNCR2820561204>3.0.CO;2-G; WALKER MJ, 1988, SEMIN ONCOL, V15, P512; WALKER MJ, 1987, J CLIN ONCOL, V5, P1256, DOI 10.1200/JCO.1987.5.8.1256; WIELAND I, 1986, CELL, V47, P675, DOI 10.1016/0092-8674(86)90510-6; ZAVA DT, 1983, EUR J CANCER CLIN ON, V19, P1151, DOI 10.1016/0277-5379(83)90041-X; 1985, SAS USERS GUIDE STAT; 1984, J CLIN ONCOL, V2, P131	58	221	231	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					516	523		10.1056/NEJM199208203270803	http://dx.doi.org/10.1056/NEJM199208203270803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635566				2022-12-28	WOS:A1992JJ45700003
J	ISRAILI, ZH; HALL, WD				ISRAILI, ZH; HALL, WD			COUGH AND ANGIONEUROTIC-EDEMA ASSOCIATED WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR THERAPY - A REVIEW OF THE LITERATURE AND PATHOPHYSIOLOGY	ANNALS OF INTERNAL MEDICINE			English	Review						ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COUGH; ANGIONEUROTIC EDEMA; KININS; PROSTAGLANDINS	CONGESTIVE HEART-FAILURE; ENALAPRIL-INDUCED COUGH; BRADYKININ-INDUCED BRONCHOCONSTRICTION; POST-MARKETING SURVEILLANCE; SEVERE CUTANEOUS REACTIONS; C1 ESTERASE INHIBITOR; SUBSTANCE-P; ESSENTIAL-HYPERTENSION; BRONCHIAL HYPERREACTIVITY; ACE-INHIBITORS	Objective: To review available information on cough and angioneurotic edema associated with angiotensin-converting enzyme (ACE) inhibitors. Data Sources: All relevant articles from 1966 through 1991 were identified mainly through MEDLINE search and article bibliographies. Study Selection: More than 400 articles were identified; 200 reporting incidence or possible mechanisms for the side effects or both were selected. Data Extraction and Synthesis: All pertinent information, including incidence and mechanisms of ACE inhibitor-induced cough and angioedema, was reviewed and collated. Conclusions: Cough occurs in 5% to 20% of patients treated with ACE inhibitors, recurring with reintroduction of the same or another ACE inhibitor. It is more common in women. The mechanism may involve accumulation of prostaglandins, kinins (such as bradykinin), or substance P (neurotransmitter present in respiratory tract C-fibers); both bradykinin and substance P are degraded by ACE. A 4-day trial of withdrawal of the ACE inhibitor or temporary substitution of another class of antihypertensive agent inexpensively and easily ascertains if the ACE inhibitor caused the cough. Change to another ACE inhibitor or additive therapy with nonsteroidal anti-inflammatory drugs is not recommended. Prompt recognition of ACE inhibitor-related cough can prevent unnecessary diagnostic testing and treatment. Angioedema occurs in 0.1% to 0.2% of patients receiving ACE inhibitors. The onset usually occurs within hours or, at most, 1 week after starting therapy. The mechanism may involve autoantibodies, bradykinin, or complement-system components. Treatment involves first protecting the airway, followed by epinephrine, antihistamines, and corticosteroids if needed. Therapy is then resumed with an alternate class of antihypertensive agent.	EMORY UNIV, SCH MED, DEPT MED, 69 BUTLER ST, ATLANTA, GA 30303 USA	Emory University								ABRAMS WB, 1984, FED PROC, V43, P1314; AGOSTONI A, 1991, AM J MED, V90, P278; ANDERSON MW, 1990, J ALLERGY CLIN IMMUN, V85, P856, DOI 10.1016/0091-6749(90)90068-F; ARMAYOR GM, 1988, DRUG INTEL CLIN PHAR, V22, P365, DOI 10.1177/106002808802200501; ARR SM, 1985, BRIT J CLIN PHARMACO, V20, pP279; AUCHINCLOSS JH, 1986, AM J MED, V81, P260, DOI 10.1016/0002-9343(86)90261-5; BARNA JS, 1990, OTOLARYNG HEAD NECK, V103, P795, DOI 10.1177/019459989010300521; BARNES PJ, 1987, AM REV RESPIR DIS, V136, pS77, DOI 10.1164/ajrccm/136.6_Pt_2.S77; BARROW SE, 1986, BRIT J PHARMACOL, V87, P243, DOI 10.1111/j.1476-5381.1986.tb10177.x; BASRAN GS, 1982, LANCET, V1, P935; BENCHIMOL H, 1987, PRESSE MED, V16, P1432; BERKIN KE, 1989, EUR RESPIR J, V2, P198; BERTOLI L, 1986, POSTGRAD MED J, V62, P47; BI CK, 1987, CLIN RES, V35, pA922; BIOUR M, 1988, THERAPIE, V43, P122; BOLZANO K, 1987, J CARDIOVASC PHARM, V9, pS43, DOI 10.1097/00005344-198700003-00011; BORK K, 1984, ARCH DERMATOL RES, V276, P375, DOI 10.1007/BF00413358; BOULET LP, 1989, JAMA-J AM MED ASSOC, V261, P413, DOI 10.1001/jama.261.3.413; BROGDEN RN, 1988, DRUGS, V36, P540, DOI 10.2165/00003495-198836050-00003; BROWN CL, 1990, J HUM HYPERTENS, V4, P51; BUCK SH, 1986, PHARMACOL REV, V38, P179; BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; CAMERON DI, 1990, CAN J CARDIOL, V6, P265; CAMERON HA, 1989, J HUM HYPERTENS, V3, P177; CANESSA PA, 1990, MED-RIV ENC MED ITAL, V10, P296; CAPELLA D, 1991, MED CLIN-BARCELONA, V96, P126; CASCIERI MA, 1984, MOL PHARMACOL, V25, P287; CASPRITZ G, 1986, ARZNEIMITTELFORSCH, V36-2, P1605; CHALMERS D, 1987, BRIT J CLIN PHARMACO, V24, P343, DOI 10.1111/j.1365-2125.1987.tb03179.x; CHAMPION RH, 1979, TXB DERMATOLOGY, P971; CHIN HL, 1990, ANN INTERN MED, V112, P312, DOI 10.7326/0003-4819-112-4-312_2; COLEMAN JW, 1986, BRIT J CLIN PHARMACO, V22, P161, DOI 10.1111/j.1365-2125.1986.tb05244.x; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; COLLIER JG, 1984, BRIT J PHARMACOL, V81, P113, DOI 10.1111/j.1476-5381.1984.tb10750.x; COOPER WD, 1987, J ROY COLL GEN PRACT, V37, P346; COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; COX JP, 1989, J HYPERTENS, V7, P299; CREISSON C, 1986, POSTGRAD MED J, V62, P139; DAVIES RO, 1984, AM J MED, V77, P23, DOI 10.1016/S0002-9343(84)80055-8; DIBIANCO R, 1986, MED TOXICOL ADV DRUG, V1, P122, DOI 10.1007/BF03259832; DIXON CMS, 1987, BRIT J CLIN PHARMACO, V23, P91, DOI 10.1111/j.1365-2125.1987.tb03015.x; DOERING W, 1987, AM J CARDIOL, V59, pD60, DOI 10.1016/0002-9149(87)90055-5; DONALDSON VH, 1969, J CLIN INVEST, V48, P642, DOI 10.1172/JCI106022; DONOHOE JF, 1988, AM J MED, V85, P31, DOI 10.1016/0002-9343(88)90347-6; Dzau V J, 1989, Cardiol Clin, V7, P119; DZAU VJ, 1987, PRACT CARDIOL, V13, P40; EDWARDS CRW, 1985, LANCET, V1, P30; FERNER RE, 1987, BRIT MED J, V294, P1119, DOI 10.1136/bmj.294.6580.1119; FERNER RE, 1989, BRIT J CLIN PHARMACO, V27, P337, DOI 10.1111/j.1365-2125.1989.tb05374.x; FRANK MM, 1986, J ALLERGY CLIN IMMUN, V78, P848, DOI 10.1016/0091-6749(86)90228-9; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; FROHLICH ED, 1984, ARCH INTERN MED, V144, P1441, DOI 10.1001/archinte.144.7.1441; FUJIMURA M, 1990, THORAX, V45, P633, DOI 10.1136/thx.45.8.633; FUJITA T, 1981, CLIN EXP HYPERTENS, V3, P939, DOI 10.3109/10641968109033714; FULLER RW, 1987, BRIT J CLIN PHARMACO, V23, P88, DOI 10.1111/j.1365-2125.1987.tb03014.x; FULLER RW, 1985, J APPL PHYSIOL, V58, P1080, DOI 10.1152/jappl.1985.58.4.1080; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; FULLER RW, 1987, BMJ-BRIT MED J, V295, P1025, DOI 10.1136/bmj.295.6605.1025-a; FURBERG CD, 1985, AM J CARDIOL, V55, P1110, DOI 10.1016/0002-9149(85)90756-8; FURNESS PN, 1986, J CLIN PATHOL, V39, P902, DOI 10.1136/jcp.39.8.902; FYHRQUIST F, 1983, CLIN EXP HYPERTENS A, V5, P1319, DOI 10.3109/10641968309048860; FYHRQUIST F, 1987, J CARDIOVASC PHARM, V9, pS61, DOI 10.1097/00005344-198700003-00015; GAVRAS H, 1986, CLIN THER, V9, P24; GAVRAS I, 1983, ANN INTERN MED, V98, P556, DOI 10.7326/0003-4819-98-4-556_2; GELFAND JA, 1979, MEDICINE, V58, P321, DOI 10.1097/00005792-197907000-00004; GIANOS ME, 1990, AM J EMERG MED, V8, P124, DOI 10.1016/0735-6757(90)90198-9; GIBSON GR, 1989, ARCH INTERN MED, V149, P2701, DOI 10.1001/archinte.149.12.2701; GILCHRIST NL, 1989, J HUM HYPERTENS, V3, P451; GOETZL EJ, 1984, NEW ENGL J MED, V311, P252, DOI 10.1056/NEJM198407263110409; GOLDSZER RC, 1988, AM J MED, V85, P887; GOODFIELD MJ, 1985, BRIT MED J, V290, P1111, DOI 10.1136/bmj.290.6475.1111; GREENBERG R, 1979, EUR J PHARMACOL, V57, P287, DOI 10.1016/0014-2999(79)90491-6; HAKAS JF, 1990, ANN ALLERGY, V65, P322; HARTUNG HP, 1988, FASEB J, V2, P48, DOI 10.1096/fasebj.2.1.2446942; HAVELKA J, 1982, BRIT J CLIN PHARMACO, V14, pS71, DOI 10.1111/j.1365-2125.1982.tb02060.x; HENTGES F, 1986, J ALLERGY CLIN IMMUN, V78, P860, DOI 10.1016/0091-6749(86)90231-9; HIGENBOTTAM T, 1987, B EUR PHYSIOPATH RES, V23, pS25; HINOJOSA M, 1990, J ALLERGY CLIN IMMUN, V85, P818, DOI 10.1016/0091-6749(90)90206-J; HOOD S, 1987, NEW ZEAL MED J, V100, P6; HUME AL, 1989, PHARMACOTHERAPY, V9, P88; INMAN WHW, 1988, BRIT MED J, V297, P826, DOI 10.1136/bmj.297.6652.826; INMAN WHW, 1986, LANCET, V2, P1218; IRVIN JD, 1986, AM J MED, V81, P46, DOI 10.1016/0002-9343(86)90945-9; IRWIN RS, 1977, ARCH INTERN MED, V137, P1186, DOI 10.1001/archinte.137.9.1186; JACKSON J, 1988, NEW ENGL J MED, V318, P122; JENKINS AC, 1985, ARCH INTERN MED, V145, P2029, DOI 10.1001/archinte.145.11.2029; JENKINS AC, 1985, J CARDIOVASC PHARM, V7, pS96, DOI 10.1097/00005344-198507001-00019; JOHNSTON CI, 1982, AM J CARDIOL, V49, P1401, DOI 10.1016/0002-9149(82)90350-2; JOHNSTON CI, 1981, ANGIOTENSIN CONVERTI, P123; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; KALLENBERG CGM, 1985, ARTHRITIS RHEUM, V28, P597, DOI 10.1002/art.1780280528; KALLENBERG CGM, 1985, BRIT MED J, V290, P1829; KAUFMAN J, 1989, CHEST, V95, P544, DOI 10.1378/chest.95.3.544; KAUFMAN MP, 1980, J APPL PHYSIOL, V48, P511, DOI 10.1152/jappl.1980.48.3.511; KELLSTEIN DE, 1990, BRAIN RES, V526, P291, DOI 10.1016/0006-8993(90)91234-8; Knoben J M, 1983, Ned Tijdschr Geneeskd, V127, P1306; KOOPMANS PP, 1989, J INTERN MED, V226, P139, DOI 10.1111/j.1365-2796.1989.tb01370.x; KOSTIS JB, 1988, AM HEART J, V116, P1591, DOI 10.1016/0002-8703(88)90748-X; LACOURCIERE Y, 1991, BRIT J CLIN PHARMACO, V32, P115, DOI 10.1111/j.1365-2125.1991.tb05622.x; LAHER MS, 1987, J CARDIOVASC PHARM, V9, pS69, DOI 10.1097/00005344-198700003-00017; Lanting P J, 1991, Ned Tijdschr Geneeskd, V135, P335; LAROCHELLE P, 1979, CAN MED ASSOC J, V121, P309; Le Menn G, 1990, Rev Prat, V40, P48; LEIER CV, 1983, CIRCULATION, V67, P155, DOI 10.1161/01.CIR.67.1.155; LEJEUNNE C, 1988, REV MAL RESPIR, V5, P645; LENHARDT EB, 1988, AM J MED SCI, V296, P119; LINDGREN BR, 1989, MED TOXICOL ADV DRUG, V4, P369, DOI 10.1007/BF03259918; LINDGREN BR, 1987, EUR J PHARMACOL, V135, P383, DOI 10.1016/0014-2999(87)90688-1; LINDGREN BR, 1989, CHEST, V95, P1225, DOI 10.1378/chest.95.6.1225; LIU MC, 1988, FASEB J, V2, pA1698; LUNDBERG JM, 1983, ACTA PHYSIOL SCAND, V119, P49, DOI 10.1111/j.1748-1716.1983.tb07304.x; MACLEAN D, 1990, BRIT J CLIN PHARMACO, V30, P203, DOI 10.1111/j.1365-2125.1990.tb03766.x; MATERSON BJ, 1984, ARCH INTERN MED, V144, P1947; MATHEWS KP, 1980, ANN INTERN MED, V93, P443, DOI 10.7326/0003-4819-93-3-443; MCCOOL FD, 1987, CLIN CHEST MED, V8, P189; MCEWAN JR, 1989, BMJ-BRIT MED J, V299, P13, DOI 10.1136/bmj.299.6690.13; MCEWAN JR, 1990, J PHARMACOL EXP THER, V255, P161; MCNALLY EM, 1987, WESTERN J MED, V146, P226; MITCHELL A, 1986, ARCH INTERN MED, V146, P1017, DOI 10.1001/archinte.1986.00360170275038; MORICE AH, 1987, LANCET, V2, P1116; MORICE AH, 1989, J CARDIOVASC PHARM, V13, pS59, DOI 10.1097/00005344-198900133-00015; MURPHY PJ, 1986, BRIT MED J, V293, P239, DOI 10.1136/bmj.293.6541.239; NASH DT, 1986, POSTGRAD MED, V80, P46; NASH DT, 1986, POSTGRAD MED, V80, P40, DOI 10.1080/00325481.1986.11699450; NAVIS GJ, 1984, LANCET, V1, P1017; NEWBALL HH, 1973, J APPL PHYSIOL, V35, P552, DOI 10.1152/jappl.1973.35.4.552; Newman T J, 1988, Am J Med, V84, P140, DOI 10.1016/0002-9343(88)90221-5; NICHOLLS MG, 1987, CLIN EXP HYPERTENS A, V9, P653, DOI 10.3109/10641968709164238; OGIHARA T, 1991, AM J HYPERTENS, V4, pS42, DOI 10.1093/ajh/4.1.42S; OGIHARA T, 1991, AM J HYPERTENS, V4, pS46, DOI 10.1093/ajh/4.1.46S; OLLIVIER JP, 1987, PRESSE MED, V16, P759; OMAE T, 1987, CLIN EXP HYPERTENS A, V9, P635, DOI 10.3109/10641968709164236; ORFAN N, 1990, JAMA-J AM MED ASSOC, V264, P1287, DOI 10.1001/jama.264.10.1287; OYVIN IA, 1972, BIOCHEM PHARMACOL, V21, P89, DOI 10.1016/0006-2952(72)90253-5; POOLE MD, 1991, OTOLARYNG HEAD NECK, V105, P714, DOI 10.1177/019459989110500513; PREDEL HG, 1987, AM J CARDIOL, V59, pD143, DOI 10.1016/0002-9149(87)90069-5; PUOLIJOKI H, 1989, EUR RESPIR J, V2, P289; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; RATNOFF OD, 1969, J EXP MED, V129, P315, DOI 10.1084/jem.129.2.315; REGOLI D, 1980, PHARMACOL REV, V32, P1; REID JL, 1987, BMJ-BRIT MED J, V295, P943, DOI 10.1136/bmj.295.6604.943; RICHARDSON D, 1984, 10TH SCI M INT SOC H; RICHARDSON PS, 1981, CLIN RES PROC, V17, P979; ROBERTS JR, 1991, ANN EMERG MED, V20, P555, DOI 10.1016/S0196-0644(05)81616-6; RODRIGUEZ FJ, 1986, POSTGRAD MED J, V62, P94; ROSSETTO BJ, 1987, WESTERN J MED, V146, P102; ROSSONI G, 1980, PROSTAGLANDINS, V20, P547, DOI 10.1016/0090-6980(80)90042-8; RUMBOLDT Z, 1988, INT J CLIN PHARM RES, V8, P181; RUSH JE, 1987, J CARDIOVASC PHARM, V9, pS99, DOI 10.1097/00005344-198700003-00023; SALA H, 1986, POSTGRAD MED J, V62, P76; SANTAMBROGIO G, 1987, B EUR PHYSIOPATH RES, V23, pS19; SARUTA T, 1991, AM J HYPERTENS, V4, pS23, DOI 10.1093/ajh/4.1.23S; SCHNAPER HW, 1990, AM J HYPERTENS, V3, pS278, DOI 10.1093/ajh/3.11S.278S; SCHREIBER AD, 1976, BLOOD, V48, P567; SEBASTIAN JL, 1991, CHEST, V99, P36, DOI 10.1378/chest.99.1.36; SEIDMAN MD, 1990, OTOLARYNG HEAD NECK, V102, P727, DOI 10.1177/019459989010200617; SEMPLE PF, 1986, NEW ENGL J MED, V314, P61; SESOKO S, 1985, ARCH INTERN MED, V145, P1524, DOI 10.1001/archinte.145.8.1524; SHEPHERD GM, 1990, AM J MED, V88, P446, DOI 10.1016/0002-9343(90)90514-E; SHORE SA, 1988, AM REV RESPIR DIS, V137, P331, DOI 10.1164/ajrccm/137.2.331; SINGER DRJ, 1986, BRIT MED J, V293, P1243, DOI 10.1136/bmj.293.6556.1243-c; Skidgel R A, 1987, Agents Actions Suppl, V22, P289; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; SMITH WM, 1984, J HYPERTENS       S5, V2, pS113; SPATH PJ, 1989, ARCH INTERN MED, V149, P1213, DOI 10.1001/archinte.149.5.1213; STANZIOLA L, 1989, HYPERTENSION, V13, P515; STARK RD, 1986, ARCH INTERN MED, V146, P1227, DOI 10.1001/archinte.1986.00360180247045; Stokes G S, 1988, Aust Fam Physician, V17, P275; STROCCHI E, 1989, J HYPERTENS, V7, pS308, DOI 10.1097/00004872-198900076-00150; SUAREZ M, 1986, AM J MED, V81, P336, DOI 10.1016/0002-9343(86)90274-3; SWARTZ SL, 1982, AM J CARDIOL, V49, P1405, DOI 10.1016/0002-9149(82)90351-4; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; THYSELL H, 1988, EUR J CLIN PHARMACOL, V34, P649, DOI 10.1007/BF00615232; TODD PA, 1986, DRUGS, V31, P198, DOI 10.2165/00003495-198631030-00002; TOWN GI, 1987, NEW ZEAL MED J, V100, P161; TUGWELL S, 1987, MED J AUSTRALIA, V147, P263, DOI 10.5694/j.1326-5377.1987.tb133444.x; ULM EH, 1982, LIFE SCI, V30, P1225, DOI 10.1016/0024-3205(82)90667-1; UMEKI S, 1986, ARCH INTERN MED, V146, P1956, DOI 10.1001/archinte.146.10.1956; UMEKI S, 1987, LANCET, V2, P1526; UMEKI S, 1988, ANGIOLOGY, V39, P58, DOI 10.1177/000331978803900110; UNGER T, 1981, EUR J PHARMACOL, V72, P255, DOI 10.1016/0014-2999(81)90282-X; VAITH P, 1991, IMMUN INFEKT, V19, P27; VARONIER HS, 1968, INT ARCH ALLER A IMM, V34, P293, DOI 10.1159/000230120; WARNER NJ, 1988, DRUGS, V35, P89, DOI 10.2165/00003495-198800355-00016; WARNER NJ, 1989, AM J CARDIOL, V63, pD33, DOI 10.1016/0002-9149(89)90415-3; WEBB D, 1986, LANCET, V2, P1094; WEBER M A, 1988, American Journal of Medicine, V84, P16; WEBER MA, 1986, DRUG THER, V16, P43; WERNZE H, 1988, Z KARDIOL, V77, P61; WHALEN J, 1989, AM J HYPERTENS, V2, pA45; WILKIN JK, 1980, ARCH DERMATOL, V116, P902; WINNING AJ, 1986, CLIN SCI, V71, P519, DOI 10.1042/cs0710519; WOOD SM, 1987, BRIT MED J, V294, P91, DOI 10.1136/bmj.294.6564.91; YEO WW, 1991, LANCET, V337, P187, DOI 10.1016/0140-6736(91)90861-I; YEUNG JHK, 1985, BIOCHEM PHARMACOL, V34, P4005, DOI 10.1016/0006-2952(85)90380-6; 1987, NZ MED J, V100, P137	196	739	769	1	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					234	242		10.7326/0003-4819-117-3-234	http://dx.doi.org/10.7326/0003-4819-117-3-234			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616218				2022-12-28	WOS:A1992JF30400011
J	HE, XM; CARTER, DC				HE, XM; CARTER, DC			ATOMIC-STRUCTURE AND CHEMISTRY OF HUMAN SERUM-ALBUMIN	NATURE			English	Article							AMINO-ACID SEQUENCE; DRUG-BINDING-SITES; ALPHA-FETOPROTEIN; MACROMOLECULAR CRYSTALLOGRAPHY; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; VARIANTS; GENE; POPULATIONS; EXPRESSION	The three-dimensional structure of human serum albumin has been determined crystallographically to a resolution of 2.8 angstrom. It comprises three homologous domains that assemble to form a heart-shaped molecule. Each domain is a product of two subdomains that possess common structural motifs. The principal regions of ligand binding to human serum albumin are located in hydrophobic cavities in subdomains IIA and IIIA, which exhibit similar chemistry. The structure explains numerous physical phenomena and should provide insight into future pharmacokinetic and genetically engineered therapeutic applications of serum albumin.	NASA,GEORGE C MARSHALL SPACE FLIGHT CTR,SPACE SCI LAB,ES76 BIOPHYS,HUNTSVILLE,AL 35812	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center								AOKI K, 1973, BIOCHIM BIOPHYS ACTA, V328, P323, DOI 10.1016/0005-2795(73)90265-1; ARAI K, 1989, P NATL ACAD SCI USA, V86, P434, DOI 10.1073/pnas.86.2.434; BOS OJM, 1988, BIOCHEM PHARMACOL, V37, P3905, DOI 10.1016/0006-2952(88)90072-X; BROWN JR, 1976, FED PROC, V35, P2141; BROWN JR, 1982, LIPID PROTEIN INTERA, V1, P25; BROWN WM, 1989, NUCLEIC ACIDS RES, V17, P10495, DOI 10.1093/nar/17.24.10495; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BYRNES L, 1990, DNA CELL BIOL, V9, P647, DOI 10.1089/dna.1990.9.647; CARTER DC, 1989, SCIENCE, V244, P1195, DOI 10.1126/science.2727704; CARTER DC, 1990, SCIENCE, V249, P302, DOI 10.1126/science.2374930; COOKE NE, 1985, J CLIN INVEST, V76, P2420, DOI 10.1172/JCI112256; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; DIXON JW, 1974, J BIOL CHEM, V249, P5872; Dugiaczyk A, 1982, P NATL ACAD SCI USA, V79, P71; FEHSKE KJ, 1981, BIOCHEM PHARMACOL, V30, P687, DOI 10.1016/0006-2952(81)90151-9; FELDHOFF RC, 1983, BIOCHEM BIOPH RES CO, V114, P20, DOI 10.1016/0006-291X(83)91588-7; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GALLIANO M, 1990, P NATL ACAD SCI USA, V87, P8721, DOI 10.1073/pnas.87.22.8721; GORIN MB, 1980, P NATL ACAD SCI-BIOL, V77, P1351, DOI 10.1073/pnas.77.3.1351; GRAY JE, 1992, PROTEIN SCI, V1, P289; HAGAG N, 1983, BIOCHEMISTRY-US, V22, P2420, DOI 10.1021/bi00279a018; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JAGDODZINSKI LL, 1981, P NATL ACAD SCI USA, V78, P3521; JONES TA, 1987, J APPL CRYSTALLOGR, V20, P383; KING TP, 1973, ARCH BIOCHEM BIOPHYS, V156, P509, DOI 10.1016/0003-9861(73)90300-7; KRAGHHANSEN U, 1981, PHARMACOL REV, V33, P17; KURONO Y, 1987, CHEM PHARM BULL, V35, P734; LUFT AJ, 1983, BIOCHEMISTRY-US, V22, P5978, DOI 10.1021/bi00294a043; MINGHETTI PP, 1985, MOL BIOL EVOL, V2, P347; MORINAGA T, 1983, P NATL ACAD SCI-BIOL, V80, P4604, DOI 10.1073/pnas.80.15.4604; MOSKAITIS JE, 1989, MOL ENDOCRINOL, V3, P464, DOI 10.1210/mend-3-3-464; OZEKI Y, 1980, CHEM PHARM BULL, V28, P535; PARDRIDGE WM, 1987, AM J PHYSIOL, V252, P157; PEDERSEN SM, 1987, BIOCHEM PHARMACOL, V35, P2661; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PUTNAM FW, 1984, PLSMA PROTEINS, V4; QUIRK AV, 1989, BIOTECHNOL APPL BIOC, V11, P273; ROSSMANN MG, 1962, ACTA CRYSTALLOGR, V15, P24, DOI 10.1107/S0365110X62000067; SARGENT TD, 1981, P NATL ACAD SCI-BIOL, V78, P243, DOI 10.1073/pnas.78.1.243; SCHNITZER JE, 1988, P NATL ACAD SCI USA, V85, P6773, DOI 10.1073/pnas.85.18.6773; SCHOENTGEN F, 1986, BIOCHIM BIOPHYS ACTA, V871, P189, DOI 10.1016/0167-4838(86)90173-1; SOLLENE NP, 1979, MOL PHARMACOL, V14, P754; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; TAKAHASHI N, 1987, P NATL ACAD SCI USA, V84, P8001, DOI 10.1073/pnas.84.22.8001; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEINSTOCK J, 1988, NUCLEIC ACIDS RES, V16, P9045, DOI 10.1093/nar/16.18.9045; YANG F, 1990, GENOMICS, V7, P509, DOI 10.1016/0888-7543(90)90193-X	48	3277	3434	13	515	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					209	215		10.1038/358209a0	http://dx.doi.org/10.1038/358209a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630489	Green Published			2022-12-28	WOS:A1992JD58700045
J	ORGAN, CH; FRY, WR				ORGAN, CH; FRY, WR			SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											ORGAN, CH (corresponding author), UNIV CALIF DAVIS E BAY,OAKLAND,CA, USA.							CHEADLE WG, 1991, AM J SURG, V161, P639, DOI 10.1016/0002-9610(91)91247-G; ESPOSITO TJ, 1991, ARCH SURG-CHICAGO, V126, P292; GOSEKI N, 1991, ANN SURG, V214, P83; MUELLER CB, 1991, ANN SURG, V214, P206, DOI 10.1097/00000658-199109000-00003; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; PAREKH D, 1991, AM J SURG, V161, P84, DOI 10.1016/0002-9610(91)90365-K; PATTERSON GA, 1991, MAY AM ASS THOR SURG; RICHARDSON JD, 1991, 51ST ANN M AM ASS SU; STALLION A, 1991, Surgical Forum (Chicago), V42, P441; STREITZ JM, 1991, ANN SURG, V213, P122, DOI 10.1097/00000658-199102000-00005; WOLFE BM, 1991, ARCH SURG-CHICAGO, V126, P1192; 1991, LANCET, V337, P1235; 1991, NEW ENGL J MED, V325, P445	13	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					413	414						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613941				2022-12-28	WOS:A1992JC35200054
J	BARRES, BA; HART, IK; COLES, HSR; BURNE, JF; VOYYODIC, JT; RICHARDSON, WD; RAFF, MC				BARRES, BA; HART, IK; COLES, HSR; BURNE, JF; VOYYODIC, JT; RICHARDSON, WD; RAFF, MC			CELL-DEATH AND CONTROL OF CELL-SURVIVAL IN THE OLIGODENDROCYTE LINEAGE	CELL			English	Article							GROWTH FACTOR-I; RAT OPTIC-NERVE; GLIAL PROGENITOR-CELL; TYPE-2 ASTROCYTE DEVELOPMENT; FREE SUPPLEMENTED MEDIUM; MONOCLONAL-ANTIBODY; NEURONAL DEATH; CHICK-EMBRYO; NEUROTROPHIC FACTOR; PROTEIN-SYNTHESIS	Dead cells are observed in many developing animal tissues, but the causes of these normal cell deaths are mostly unknown. We show that about 50% of oligodendrocytes normally die in the developing rat optic nerve, apparently as a result of a competition for limiting amounts of survival signals. Both platelet-derived growth factor and insulin-like growth factors are survival factors for newly formed oligodendrocytes and their precursors in culture. Increasing platelet-derived growth factor in the developing optic nerve decreases normal oligodendrocyte death by up to 90% and doubles the number of oligodendrocytes in 4 days. These results suggest that a requirement for survival signals is more general than previously thought and that some normal cell deaths in nonneural tissues may also reflect competition for survival factors.			BARRES, BA (corresponding author), UNIV LONDON UNIV COLL, DEPT BIOL, MRC, DEV NEUROBIOL PROGRAMME, MEDAWAR BLDG, LONDON WC1E 6BT, ENGLAND.		Richardson, William/C-1762-2008	Richardson, William/0000-0001-7261-2485				AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; ALOISI F, 1990, J NEUROSCI RES, V27, P16, DOI 10.1002/jnr.490270104; [Anonymous], [No title captured]; ARONVANEVERCOOR.A, 1991, J NEUROSCI RES, V28, P244; BALLOTTI R, 1987, EMBO J, V6, P3633, DOI 10.1002/j.1460-2075.1987.tb02695.x; BANNON MJ, 1984, BRAIN RES, V301, P184, DOI 10.1016/0006-8993(84)90421-9; BARDE YA, 1983, ANNU REV PHYSIOL, V45, P601, DOI 10.1146/annurev.ph.45.030183.003125; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1988, TRENDS NEUROSCI, V11, P343, DOI 10.1016/0166-2236(88)90055-0; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BARTLETT PF, 1981, BRAIN RES, V204, P339, DOI 10.1016/0006-8993(81)90593-X; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1980, EXP CELL RES, V125, P183, DOI 10.1016/0014-4827(80)90202-5; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CARSON MJ, 1990, THESIS U PENNSYLVANI; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEMMONS DR, 1985, CIRC RES, V56, P418, DOI 10.1161/01.RES.56.3.418; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; Cope FO., 1991, APOPTOSIS MOL BASIS, P47; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; DAVID S, 1984, J NEUROCYTOL, V13, P961, DOI 10.1007/BF01148596; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; DRAGO J, 1991, P NATL ACAD SCI USA, V88, P2199, DOI 10.1073/pnas.88.6.2199; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; DUTLY F, 1991, GLIA, V4, P559, DOI 10.1002/glia.440040603; ECCLESTON PA, 1985, DEV BRAIN RES, V21, P315, DOI 10.1016/0165-3806(85)90221-4; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRIEDMAN B, 1989, GLIA, V2, P380, DOI 10.1002/glia.440020510; FULTON BP, 1992, IN PRESS J NEUROSCI; GARD AL, 1989, DEVELOPMENT, V106, P119; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HABU S, 1977, EUR J IMMUNOL, V7, P451, DOI 10.1002/eji.1830070710; HAMBURGER V, 1981, J NEUROSCI, V1, P60, DOI 10.1523/JNEUROSCI.01-01-00060.1981; HAMBURGER V, 1949, J EXP ZOOL, V111, P457, DOI 10.1002/jez.1401110308; HANSSON HA, 1989, EXP EYE RES, V48, P411, DOI 10.1016/S0014-4835(89)80009-0; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HILDEBRAND C, 1971, ACTA PHYSL SCAND S, V354, P109; HOFER MM, 1988, NATURE, V331, P261, DOI 10.1038/331261a0; HUETTNER JE, 1986, J NEUROSCI, V6, P3044; HYNES RO, 1978, CELL, V13, P151, DOI 10.1016/0092-8674(78)90146-0; JACKSON KF, 1988, J NEUROCYTOL, V17, P657, DOI 10.1007/BF01260993; Kerr J. F., 1991, APOPTOSIS MOL BASIS, V3, P5; KNAPP PE, 1986, J NEUROSCI, V6, P2813; Korr H, 1980, Adv Anat Embryol Cell Biol, V61, P1; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYPIANOU N, 1988, ENDOCRINOLOGY, V122, P552; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LIEVRE C, 1991, DEVELOPMENT, V111, P105; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V4, P525, DOI 10.1016/0896-6273(90)90110-2; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MAGE MG, 1977, J IMMUNOL METHODS, V15, P47, DOI 10.1016/0022-1759(77)90016-3; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MCMORRIS FA, 1988, J NEUROSCI RES, V21, P199, DOI 10.1002/jnr.490210212; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MCMORRIS FA, 1990, CELLULAR MOL BIOL MY, P281; MESSNER PW, 1991, ABST SOC NEUR, V17, P1124; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; MORI S, 1970, J COMP NEUROL, V139, P1, DOI 10.1002/cne.901390102; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MOZELL RL, 1991, J NEUROSCI RES, V30, P382, DOI 10.1002/jnr.490300214; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; NOBLE M, 1984, EMBO J, V3, P2243, DOI 10.1002/j.1460-2075.1984.tb02122.x; NOBLE M, 1991, IN PRESS ANN NY ACAD; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANNESE E, 1967, ACTA NEUROPATHOL, V8, P309, DOI 10.1007/BF00688831; PERRY VH, 1983, J COMP NEUROL, V219, P356, DOI 10.1002/cne.902190309; POTTS RA, 1982, DEV BRAIN RES, V3, P481, DOI 10.1016/0165-3806(82)90013-X; PRINGLE N, 1989, EMBO J, V8, P1049, DOI 10.1002/j.1460-2075.1989.tb03472.x; PRINGLE N, 1992, IN PRESS DEVELOPMENT; PRUSS R, 1979, NATURE, V303, P390; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1983, J NEUROSCI, V3, P1289; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; RAFF MC, 1978, NATURE, V274, P813, DOI 10.1038/274813a0; RAFF MC, 1992, IN PRESS NATURE; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; Richardson WD, 1990, SEMIN NEUROSCI, V2, P445; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SARA VR, 1990, KAR INS NCS, P179; SARA VR, 1990, PHYSIOL REV, V70, P591, DOI 10.1152/physrev.1990.70.3.591; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHWARTZ LM, 1991, ABSTR SOC NEUROSCI, V17, P228; SMALL RK, 1987, NATURE, V328, P155, DOI 10.1038/328155a0; SMART I, 1961, J COMP NEUROL, V116, P349, DOI 10.1002/cne.901160307; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; STURROCK RR, 1979, NEUROPATH APPL NEURO, V5, P433, DOI 10.1111/j.1365-2990.1979.tb00642.x; SVRZIC D, 1990, BIOCHEM BIOPH RES CO, V172, P54, DOI 10.1016/S0006-291X(05)80172-X; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0; VAUGHN JE, 1969, Z ZELLFORSCH MIK ANA, V94, P293, DOI 10.1007/BF00319179; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; WILSON AC, 1987, TRENDS GENET, V3, P241, DOI 10.1016/0168-9525(87)90257-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYSOCKI LJ, 1978, P NATL ACAD SCI USA, V75, P2844, DOI 10.1073/pnas.75.6.2844	115	1173	1191	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					31	46		10.1016/0092-8674(92)90531-G	http://dx.doi.org/10.1016/0092-8674(92)90531-G			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623522				2022-12-28	WOS:A1992JC95700006
J	PUGLISI, JD; TAN, RY; CALNAN, BJ; FRANKEL, AD; WILLIAMSON, JR				PUGLISI, JD; TAN, RY; CALNAN, BJ; FRANKEL, AD; WILLIAMSON, JR			CONFORMATION OF THE TAR RNA-ARGININE COMPLEX BY NMR-SPECTROSCOPY	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROTEIN; SEQUENCE; BINDING; LOOP; TRANSACTIVATION; TRANSCRIPTION; INVITRO; BULGE	The messenger RNAs of human immunodeficiency virus-1 (HIV-1) have an RNA hairpin structure, TAR, at their 5' ends that contains a six-nucleotide loop and a three-nucleotide bulge. The conformations of TAR RNA and of TAR with an arginine analog specifically bound at the binding site for the viral protein, Tat, were characterized by nuclear magnetic resonance (NMR) spectroscopy. Upon arginine binding, the bulge changes conformation, and essential nucleotides for binding, U23 and A27.U38, form a base-triple interaction that stabilizes arginine hydrogen bonding to G26 and phosphates. Specificity in the arginine-TAR interaction appears to be derived largely from the structure of the RNA.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA; WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute			Williamson, James R/B-2891-2009; Williamson, James/AAL-2104-2021	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29135] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERKHOUT B, 1991, NUCLEIC ACIDS RES, V19, P6169, DOI 10.1093/nar/19.22.6169; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DAVIS PW, 1990, BIOPOLYMERS, V29, P109, DOI 10.1002/bip.360290116; DELLING U, 1991, P NATL ACAD SCI USA, V88, P6234, DOI 10.1073/pnas.88.14.6234; DELLING U, 1992, J VIROL, V66, P3018, DOI 10.1128/JVI.66.5.3018-3025.1992; Denoyelle S., SYNTHESIS SAR STUDY; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Frankel AD, 1992, CURR OPIN GENET DEV, V2, P293, DOI 10.1016/S0959-437X(05)80287-4; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; MARCINIAK RA, 1990, CELL, V63, P791, DOI 10.1016/0092-8674(90)90145-5; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PUGLISI JD, 1990, J MOL BIOL, V214, P437, DOI 10.1016/0022-2836(90)90192-O; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RIORDAN FA, IN PRESS J MOL BIOL; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VARANI G, 1989, BIOCHEMISTRY-US, V28, P7760, DOI 10.1021/bi00445a036; VARANI G, 1991, BIOCHEMISTRY-US, V30, P3280, DOI 10.1021/bi00227a016; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1986, HNMR PROTEINS NUCLEI; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	37	560	584	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					76	80		10.1126/science.1621097	http://dx.doi.org/10.1126/science.1621097			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621097				2022-12-28	WOS:A1992JC16500033
J	JONES, DT; TAYLOR, WR; THORNTON, JM				JONES, DT; TAYLOR, WR; THORNTON, JM			A NEW APPROACH TO PROTEIN FOLD RECOGNITION	NATURE			English	Article							SECONDARY STRUCTURE; MEAN FORCE; PREDICTION; POTENTIALS; FEATURES; MODELS; ENERGY	THE prediction of protein tertiary structure from sequence using molecular energy calculations has not yet been successful; an alternative strategy of recognizing known motifs 1 or folds 2-4 in sequences looks more promising. We present here a new approach to fold recognition, whereby sequences are fitted directly onto the backbone coordinates of known protein structures. Our method for protein fold recognition involves automatic modelling of protein structures using a given sequence, and is based on the frameworks of known protein folds. The plausibility of each model, and hence the degree of compatibility between the sequence and the proposed structure, is evaluated by means of a set of empirical potentials derived from proteins of known structure. The novel aspect of our approach is that the matching of sequences to backbone coordinates is performed in full three-dimensional space, incorporating specific pair interactions explicitly.	NATL INST MED RES,MATH BIOL LAB,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	JONES, DT (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,BIOMOLEC STRUCT & MODELLING UNIT,GOWER ST,LONDON WC1E 6BT,ENGLAND.			Thornton, Janet/0000-0003-0824-4096				BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; FINKELSTEIN AV, 1991, NATURE, V351, P497, DOI 10.1038/351497a0; HENDLICH M, 1990, J MOL BIOL, V216, P167, DOI 10.1016/S0022-2836(05)80068-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; NOVOTNY J, 1984, J MOL BIOL, V177, P787, DOI 10.1016/0022-2836(84)90049-4; ORENGO CA, 1990, J THEOR BIOL, V147, P517, DOI 10.1016/S0022-5193(05)80263-2; OVERINGTON J, 1990, P ROY SOC B-BIOL SCI, V241, P132, DOI 10.1098/rspb.1990.0077; PASTORE A, 1990, PROTEINS, V8, P133, DOI 10.1002/prot.340080204; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SIPPL MJ, 1990, J MOL BIOL, V213, P859, DOI 10.1016/S0022-2836(05)80269-4; TAYLOR WR, 1989, J MOL BIOL, V208, P1, DOI 10.1016/0022-2836(89)90084-3; TAYLOR WR, 1991, PROTEIN ENG, V4, P853, DOI 10.1093/protein/4.8.853; TAYLOR WR, 1984, J MOL BIOL, V173, P487, DOI 10.1016/0022-2836(84)90393-0; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0	19	985	1017	4	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					86	89		10.1038/358086a0	http://dx.doi.org/10.1038/358086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614539				2022-12-28	WOS:A1992JB34100061
J	HEALY, B				HEALY, B			RESEARCH OFFERS NEW HOPE FOR YOUNG PERSONS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					20	20						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608101				2022-12-28	WOS:A1992JA16500004
J	WOOLF, AD; WENGER, T; SMITH, TW; LOVEJOY, FH				WOOLF, AD; WENGER, T; SMITH, TW; LOVEJOY, FH			THE USE OF DIGOXIN-SPECIFIC FAB FRAGMENTS FOR SEVERE DIGITALIS INTOXICATION IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIBODY-FRAGMENTS; TOXICITY; REVERSAL; OVERDOSE; TACHYCARDIA; EXPERIENCE; INFANT	Background. Because life-threatening digitalis intoxication is unusual in children, treatment with digoxin-specific-antibody Fab fragments (Fab) has rarely been reported. We describe the efficacy of Fab in the treatment of children with severe digitalis intoxication. Methods. Twenty-nine children with intoxication due to digoxin (28) or digitoxin (1) received Fab at 21 participating hospitals between 1974 and 1986. Data were gathered about the patients' medical illnesses, doses and serum concentrations of digitalis, responses to Fab therapy, and outcomes. Results. In the infants and young children with acute digoxin intoxication, the digoxin doses ranged from 0.30 to 0.96 mg per kilogram of body weight; two adolescents had severe intoxication after doses of only 0.20 and 0.26 mg per kilogram. The serum digoxin concentrations ranged form 3.0 to >100 ng per milliliter (mean, 13.8). Atrioventricular block (present in 22 patients [76 percent]) was the most common sign of toxicity. All the patients in this series had severe disturbances of cardiac rhythm, hyperkalemia (mean serum potassium concentration, 5.4 mmol per liter), or both. In 27 patients (93 percent), digitalis toxicity resolved after the administration of Fab. Of the 19 patients for whom data were available on the timing of the response to Fab, 15 responded within 180 minutes. Three patients required retreatment with Fab. Seven died of complications unrelated to the administration of Fab. Conclusions. We recommend that Fab be used in the treatment ot digitalis poisoning in infants and young children who have ingested greater-than-or-equal-to 0.3 mg of digoxin per kilogram, who have underlying heart disease, or who have a serum digoxin concentration of greater-than-or-equal-to 6.4 nmol per liter (greater-than-or-equal-to 5.0 ng per milliliter) in the elimination phase; and who also have a life-threatening arrhythmia, hemodynamic instability, hyperkalemia, or rapidly progressive toxicity. Adolescents, who are more sensitive to the toxic effects of digoxin than younger children, may require treatment with Fab after ingesting lower doses.	HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; MASSACHUSETTS POISON CONTROL CTR,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; BURROUGHS WELLCOME CO,RES TRIANGLE PK,NC 27709	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Burroughs Wellcome Fund	WOOLF, AD (corresponding author), CHILDRENS HOSP MED CTR,DEPT MED,BOSTON,MA 02115, USA.							ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; AUTRET E, 1985, ARCH FR PEDIATR, V42, P803; CLARKE W, 1988, AM J EMERG MED, V6, P465, DOI 10.1016/0735-6757(88)90248-3; Colton T., 1974, STAT MED, V1; COOPER DM, 1987, CLEV CLIN J MED, V54, P43, DOI 10.3949/ccjm.54.1.43; DESANTOLA JR, 1986, AM J CARDIOL, V58, P1109, DOI 10.1016/0002-9149(86)90125-6; DOHERTY JE, 1985, CARDIOLOGY, V72, P225; DUKE M, 1972, AM J DIS CHILD, V124, P754, DOI 10.1001/archpedi.1972.02110170132023; FOWLER RS, 1964, J PEDIATR-US, V64, P188, DOI 10.1016/S0022-3476(64)80262-6; HASTREITER AR, 1984, PEDIATR CARDIOL, V5, P131, DOI 10.1007/BF02424966; HOUGEN TJ, 1979, CIRC RES, V44, P23, DOI 10.1161/01.RES.44.1.23; HURSTING MJ, 1987, CLIN CHEM, V33, P1652; HURSTING MJ, 1987, ARCH PATHOL LAB MED, V111, P693; Hussain M I, 1985, Indiana Med, V78, P780; KAUFMAN J, 1990, Pediatric Emergency Care, V6, P118, DOI 10.1097/00006565-199006000-00013; KEARNS GL, 1989, J CLIN PHARMACOL, V29, P901, DOI 10.1002/j.1552-4604.1989.tb03252.x; LEWANDER WJ, 1986, AM J DIS CHILD, V140, P770, DOI 10.1001/archpedi.1986.02140220052031; MARTINY SS, 1988, CRIT CARE MED, V16, P629, DOI 10.1097/00003246-198806000-00014; MCNAMARA DG, 1964, NEW ENGL J MED, V271, P1106, DOI 10.1056/NEJM196411192712108; MURPHY DJ, 1982, PEDIATRICS, V70, P472; NOLLET H, 1989, J CLIN PHARMACOL, V29, P41, DOI 10.1002/j.1552-4604.1989.tb03235.x; PRESTI S, 1985, PEDIATR CARDIOL, V6, P91, DOI 10.1007/BF02282744; ROSE SR, 1987, AM J EMERG MED, V5, P509, DOI 10.1016/0735-6757(87)90172-0; ROSSI R, 1984, EUR J PEDIATR, V142, P138, DOI 10.1007/BF00445597; SCHAUMANN W, 1986, EUR J CLIN PHARMACOL, V30, P527, DOI 10.1007/BF00542410; SMITH T W, 1988, New England Journal of Medicine, V318, P358; SMITH TW, 1988, J AM COLL CARDIOL, V12, P267, DOI 10.1016/0735-1097(88)90386-5; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; SMITH TW, 1982, NEW ENGL J MED, V307, P1357, DOI 10.1056/NEJM198211253072201; SMOLARZ A, 1985, J TOXICOL-CLIN TOXIC, V23, P327, DOI 10.3109/15563658508990641; SOYKA LF, 1981, PEDIATR CLIN N AM, V28, P203; SPIEGEL A, 1985, AM HEART J, V109, P1397, DOI 10.1016/0002-8703(85)90376-X; STOLSHEK BS, 1988, MED TOXICOL ADVERSE, V3, P161; WENGER T, 1986, J AM COLL CARDIOL, V7, pA74; WENGER TL, 1985, J AM COLL CARDIOL, V5, pA118, DOI 10.1016/S0735-1097(85)80471-X; WENGER TL, 1986, CIRCULATION, V74, P38; WIELAND JM, 1986, PACE, V9, P727, DOI 10.1111/j.1540-8159.1986.tb05422.x; ZALCBERG JR, 1985, PHARMACOL THERAPEUT, V28, P273, DOI 10.1016/0163-7258(85)90055-5; ZUCKER AR, 1982, PEDIATRICS, V70, P468; 1986, MED LETT DRUGS THER, V28, P87; 1990, AHFS DRUG INFORMATIO, V90, P1885	41	50	53	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1739	1744		10.1056/NEJM199206253262604	http://dx.doi.org/10.1056/NEJM199206253262604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1594015				2022-12-28	WOS:A1992HZ89400004
J	SMITH, LFP				SMITH, LFP			ROLES, RISKS, AND RESPONSIBILITIES IN MATERNITY CARE - TRAINEES BELIEFS AND THE EFFECTS OF PRACTICE OBSTETRIC TRAINING	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL STAFFING STRUCTURES; GENERAL-PRACTICE; LABOR WARD; REGION	Objectives-To document the content of practice obstetric vocational training, the beliefs of general practitioner trainees about the roles of midwives and general practitioners in maternity care, and the risks of providing such care; and to ascertain if undergoing such training affects their beliefs. Design-Confidential postal questionnaire survey. Subjects-Random one in four sample of all general practitioner trainees in the United Kingdom on vocational training schemes or in training practices in autumn 1990. Main outcome measures-Beliefs scored on seven point Likert scales and characteristics of trainer and training practice. Results-Of 1019 trainees sent questionnaires, 765 (75.1% response rate) replied; 638 (83.3%) had done some part of their practice year. Of their trainers, 224 (35.1%)provided full obstetric care. 749 (99%) and 364 (48%) trainees believed that midwives and general practitioners respectively have an important role in normal labour; 681 (91.7%) trainees believed that general practice intrapartum care is a high risk "specialty." Those trainees whose trainers provide full obstetric care were significantly more likely to believe that both midwives and general practitioners have an important role in abnormal labour and to see the provision of intrapartum care as an incentive to join a practice. Conclusion-In this series most general practitioner trainees believed that both midwives and general practitioners have important roles in maternity care. Exposure of trainees to the provision of full obstetric care while in their training practice resulted in a more positive attitude towards the provision of such care by general practitioners.			SMITH, LFP (corresponding author), UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,GEN PRACTICE UNIT,CANYNGE HALL,BRISTOL BS8 2PR,ENGLAND.							CAMPBELL R, 1987, WHERE BE BORN DEBATE; COUPLAND VA, 1987, BRIT MED J, V295, P1077, DOI 10.1136/bmj.295.6605.1077; CRAWLEY HS, 1990, BRIT MED J, V300, P911, DOI 10.1136/bmj.300.6729.911; ENNIS M, 1991, BRIT MED J, V303, P1442, DOI 10.1136/bmj.303.6815.1442; Flint C, 1989, Midwifery, V5, P11, DOI 10.1016/S0266-6138(89)80059-2; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; GRANT J, 1989, BRIT MED J, V299, P1263, DOI 10.1136/bmj.299.6710.1263; HARE MJ, 1990, BRIT MED J, V300, P857, DOI 10.1136/bmj.300.6728.857; KELLY DR, 1991, BRIT J GEN PRACT, V41, P492; MARSH GN, 1985, BRIT MED J, V290, P971, DOI 10.1136/bmj.290.6473.971; MCWHINNEY I, 1982, J FAM PRACTICE, V15, P847; REEVE H, 1989, BRIT MED J, V298, P1432, DOI 10.1136/bmj.298.6685.1432; ROBINSON S, 1988, MIDWIFE HLTH VISITOR, V21, P274; RONALDS C, 1981, 4TH NAT TRAIN C LOND; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; Smith H, 1989, Nurs Times, V85, P75; SMITH LFP, 1991, BRIT MED J, V302, P13, DOI 10.1136/bmj.302.6767.13; SMITH LFP, 1991, BRIT MED J, V303, P1443, DOI 10.1136/bmj.303.6815.1443; SMITH LFP, 1991, BRIT MED J, V303, P1447, DOI 10.1136/bmj.303.6815.1447; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; STYLES WM, 1991, BRIT J GEN PRACT, V41, P488; TAYLOR A, 1986, J ROY COLL GEN PRACT, V36, P157; Towler J, 1984, Midwives Chron, V97, P3; WHITFIELD MJ, 1966, BMJ-BRIT MED J, V1, P663, DOI 10.1136/bmj.1.5488.663; 1992, 2ND HOUS COMM SEL CO, V1; 1990, NHS REFORMS YOU	26	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1613	1615		10.1136/bmj.304.6842.1613	http://dx.doi.org/10.1136/bmj.304.6842.1613			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628091	Bronze, Green Published			2022-12-28	WOS:A1992JA43600026
J	FORSCHER, P; LIN, CH; THOMPSON, C				FORSCHER, P; LIN, CH; THOMPSON, C			NOVEL FORM OF GROWTH CONE MOTILITY INVOLVING SITE-DIRECTED ACTIN FILAMENT ASSEMBLY	NATURE			English	Article							LATEX BEADS; LIPID FLOW; MOVEMENTS; NEURONS	REGULATION of cytoskeletal structure and motility by extracellular signals is essential for all directed forms of cell movement and underlies the developmental process of axonal guidance in neuronal growth cones. Interaction with polycationic microbeads can trigger morphogenic changes in neurons and muscle cells normally associated with formation of pre- and postsynaptic specializations 1,2. Furthermore, when various types of microscopic particles are applied to the lamellar surface of a neuronal growth cone or motile cell they often exhibit retrograde movement at rates of 1-6-mu-m min-1 (refs 3-6). There is strong evidence that this form of particle movement results from translocation of membrane proteins associated with cortical F-actin networks, not from bulk retrograde lipid flow 4,5,7 and may be a mechanism behind processes such as cell locomotion, growth cone migration and capping of cell-surface antigens 6,8,9. Here we report a new form of motility stimulated by polycationic bead interactions with the growth-cone membrane surface. Bead binding rapidly induces intracellular actin filament assembly, coincident with a production of force sufficient to drive bead movements. These extracellular bead movements resemble intracellular movements of bacterial parasites known to redirect host cell F-actin assembly for propulsion. Our results suggest that site-directed actin filament assembly may be a widespread cellular mechanism for generating force at membrane-cytoskeletal interfaces.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510	Yale University	FORSCHER, P (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511, USA.			Smith, Peter/0000-0003-4400-6853; Forscher, Paul/0000-0003-1988-5155				BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1970, P NATL ACAD SCI USA, V65, P905, DOI 10.1073/pnas.65.4.905; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; FORSCHER P, 1987, J NEUROSCI, V7, P3600; FORSCHER P, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P459; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; LEE J, 1990, SCIENCE, V247, P1229, DOI 10.1126/science.2315695; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; PENG HB, 1981, NATURE, V292, P831, DOI 10.1038/292831a0; PENG HB, 1987, SYNAPSE, V1, P10, DOI 10.1002/syn.890010104; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979	13	132	132	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					515	518		10.1038/357515a0	http://dx.doi.org/10.1038/357515a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608453				2022-12-28	WOS:A1992HY05200069
J	KHAWAJA, HT; BRYAN, S; WEAVER, PC				KHAWAJA, HT; BRYAN, S; WEAVER, PC			TREATMENT OF NATAL CLEFT SINUS - A PROSPECTIVE CLINICAL AND ECONOMIC-EVALUATION	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,DEPT SURG,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND; BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND	Brunel University								ALLENMERSH TG, 1990, BRIT J SURG, V77, P123, DOI 10.1002/bjs.1800770203; GARDNER MJ, 1990, STATISTICS CONFIDENC; KRONBORG O, 1986, BRIT J SURG, V72, P303	3	30	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1282	1283		10.1136/bmj.304.6837.1282	http://dx.doi.org/10.1136/bmj.304.6837.1282			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606429	Green Published, Bronze			2022-12-28	WOS:A1992HV08600021
J	PRYCE, D; BEHRENS, R; DAVIDSON, R; CHIODINI, P; BRYCESON, A; MCLEOD, J				PRYCE, D; BEHRENS, R; DAVIDSON, R; CHIODINI, P; BRYCESON, A; MCLEOD, J			ONCHOCERCIASIS IN MEMBERS OF AN EXPEDITION TO CAMEROON - ROLE OF ADVICE BEFORE TRAVEL AND LONG-TERM FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article											PRYCE, D (corresponding author), HOSP TROP DIS,1ST FLOOR,QUEENS HOUSE,LONDON W1P 9LE,ENGLAND.							GILLES HM, 1984, RECENT ADV TROPICAL; MANSONBAHR PEC, 1987, MANSONS TROPICAL DIS; 1987, WHO TECH REP SER, P752	3	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1285	1286		10.1136/bmj.304.6837.1285-a	http://dx.doi.org/10.1136/bmj.304.6837.1285-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606433	Green Published, Bronze			2022-12-28	WOS:A1992HV08600025
J	MOORE, MJ; SHARP, PA				MOORE, MJ; SHARP, PA			SITE-SPECIFIC MODIFICATION OF PRE-MESSENGER-RNA - THE 2'-HYDROXYL GROUPS AT THE SPLICE SITES	SCIENCE			English	Article							POLYNUCLEOTIDE LIGASE; LARIAT FORMATION; GROUP-II; TETRAHYMENA; SEQUENCE; RIBOZYME; INTRONS; CLEAVAGE; INVITRO; DNA	A simple and efficient method for synthesizing long, site-specifically modified RNA molecules was developed whereby segments of RNA were joined with the use of bacteriophage T4 DNA ligase. A single hydrogen or O-methyl group was substituted for the 2'-hydroxyl group at either splice site of a nuclear pre-messenger RNA substrate. Splicing of the modified pre-messenger RNA's in vitro revealed that, although a 2'-hydroxyl is not absolutely required at either splice site, the 2'-hydroxyl at the 3' splice site is important for the second step of splicing. These results are compared to previous studies of analogous 2'-hydroxyl groups in the self-splicing Tetrahymena group I intron.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	MOORE, MJ (corresponding author), MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA.				NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA14051] Funding Source: Medline; NIGMS NIH HHS [R01 GM34277] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BASS BL, 1986, BIOCHEMISTRY-US, V25, P4473, DOI 10.1021/bi00364a001; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; Blackburn P, 1982, ENZYMES, VXV, P317; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; ENGLAND TE, 1978, BIOCHEMISTRY-US, V17, P2069, DOI 10.1021/bi00604a008; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; Engler M.J., 1982, ENZYMES, V15, P3, DOI [10.1016/S1874-6047(08)60273-5, DOI 10.1016/S1874-6047(08)60273-5]; FAREED GC, 1971, J BIOL CHEM, V246, P925; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; INOUE T, 1985, CELL, V43, P431, DOI 10.1016/0092-8674(85)90173-4; INOUE T, 1986, J MOL BIOL, V189, P143, DOI 10.1016/0022-2836(86)90387-6; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAY PS, 1987, NATURE, V327, P343, DOI 10.1038/327343a0; KLEPPE K, 1970, P NATL ACAD SCI USA, V67, P68, DOI 10.1073/pnas.67.1.68; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; MANIATIS T, 1987, NATURE, V325, P673, DOI 10.1038/325673a0; MEI HY, 1989, P NATL ACAD SCI USA, V86, P9727, DOI 10.1073/pnas.86.24.9727; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; NOBLE JCS, 1986, NUCLEIC ACIDS RES, V14, P1219; PERREAULT JP, 1990, NATURE, V344, P565, DOI 10.1038/344565a0; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; RICHARDS FM, 1971, ENZYMES, V4, P647; ROMANIUK E, 1982, EUR J BIOCHEM, V125, P639, DOI 10.1111/j.1432-1033.1982.tb06730.x; ROMANIUK PJ, 1983, METHOD ENZYMOL, V100, P52; RUBY SW, 1991, TRENDS GENET, V7, P79; RYMOND BC, 1985, NATURE, V317, P735, DOI 10.1038/317735a0; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; SANO H, 1974, BIOCHEMISTRY-US, V13, P5110, DOI 10.1021/bi00722a009; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SHABAROVA ZA, 1988, BIOCHIMIE, V70, P1323, DOI 10.1016/0300-9084(88)90003-X; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SUGINO A, 1977, J BIOL CHEM, V252, P3987; Takahashi K., 1982, ENZYMES, V15, p435 468; TSIAPALIS CM, 1970, BIOCHEM BIOPH RES CO, V39, P631, DOI 10.1016/0006-291X(70)90251-2; Uhlenbeck O.C., 1982, ENZYMES, V15, P31, DOI [10.1016/s1874-6047(08)60274-7, DOI 10.1016/S1874-6047(08)60274-7]; UHLENBECK OC, 1977, NUCLEIC ACIDS RES, V4, P85, DOI 10.1093/nar/4.1.85; USHER DA, 1970, NATURE, V228, P663, DOI 10.1038/228663a0; VANDERVEEN R, 1987, EMBO J, V6, P3827, DOI 10.1002/j.1460-2075.1987.tb02719.x; WANG XD, 1989, P NATL ACAD SCI USA, V86, P7795, DOI 10.1073/pnas.86.20.7795; WEISS B, 1968, J BIOL CHEM, V243, P4543; WEISS B, 1976, J MOL BIOL, V103, P669, DOI 10.1016/0022-2836(76)90226-6; WITTENBERG WL, 1985, BIOCHEMISTRY-US, V24, P2705, DOI 10.1021/bi00332a017; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	56	434	508	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 15	1992	256	5059					992	997		10.1126/science.1589782	http://dx.doi.org/10.1126/science.1589782			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589782				2022-12-28	WOS:A1992HU22400029
J	ARNAIZVILLENA, A; TIMON, M; CORELL, A; PEREZACIEGO, P; MARTINVILLA, JM; REGUEIRO, JR				ARNAIZVILLENA, A; TIMON, M; CORELL, A; PEREZACIEGO, P; MARTINVILLA, JM; REGUEIRO, JR			PRIMARY IMMUNODEFICIENCY CAUSED BY MUTATIONS IN THE GENE ENCODING THE CD3-GAMMA SUBUNIT OF THE LYMPHOCYTE-T RECEPTOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SURFACE EXPRESSION; FAMILIAL DEFECT; COMPLEX		UNIV VALLADOLID,SCH MED,DEPT PEDIAT,VALLADOLID,SPAIN	Universidad de Valladolid	ARNAIZVILLENA, A (corresponding author), UNIV COMPLUTENSE MADRID,HOSP 12 OCTUBRE,DEPT IMMUNOL,E-28041 MADRID,SPAIN.		Regueiro, José R./B-5499-2014; Martin-Villa, Jose M./K-2522-2019; Corell, Alfredo/E-1903-2011; Martin-Villa, Jose M. M/F-9234-2013; Corell, Alfredo/AAE-2133-2020	Regueiro, José R./0000-0001-8442-7762; Martin-Villa, Jose M./0000-0002-2436-8585; Martin-Villa, Jose M. M/0000-0002-2436-8585; Corell, Alfredo/0000-0001-5797-7814				ALARCON B, 1990, Immunodeficiency Reviews, V2, P1; ALARCON B, 1988, NEW ENGL J MED, V319, P1203, DOI 10.1056/NEJM198811033191806; ARNAIZVILLENA A, 1991, LAB INVEST, V64, P675; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CORELL A, 1990, MOL IMMUNOL, V27, P313, DOI 10.1016/0161-5890(90)90145-P; CORELL A, 1991, MOL IMMUNOL, V28, P533, DOI 10.1016/0161-5890(91)90168-J; CORELL J, 1990, MOL IMMUNOL, V27, P471; Davis R W, 1980, Methods Enzymol, V65, P404; GELFAND EW, 1990, NEW ENGL J MED, V322, P1741, DOI 10.1056/NEJM199006143222410; PEREZACIEGO P, 1991, J EXP MED, V174, P319, DOI 10.1084/jem.174.2.319; REGUEIRO JR, 1990, EUR J IMMUNOL, V20, P2411, DOI 10.1002/eji.1830201108; REGUEIRO JR, 1986, LANCET, V1, P1274; REGUEIRO JR, 1992, SCAND J IMMUNOL, V36, P363; REGUEIRO JR, 1987, SCAND J IMMUNOL, V26, P699, DOI 10.1111/j.1365-3083.1987.tb02306.x; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; TUNNACLIFFE A, 1987, EMBO J, V6, P2953, DOI 10.1002/j.1460-2075.1987.tb02600.x	16	179	183	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					529	533		10.1056/NEJM199208203270805	http://dx.doi.org/10.1056/NEJM199208203270805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635567				2022-12-28	WOS:A1992JJ45700005
J	HARRIS, JR; LIPPMAN, ME; VERONESI, U; WILLETT, W				HARRIS, JR; LIPPMAN, ME; VERONESI, U; WILLETT, W			BREAST-CANCER .3.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ADJUVANT TAMOXIFEN THERAPY; FIBROBLAST GROWTH-FACTOR; SUBCUTANEOUS MASTECTOMY; FACTOR RECEPTOR; P53 MUTATIONS; TUMOR-GROWTH; FACTOR-BETA; ESTROGEN; CARCINOMAS; SURVIVAL		BETH ISRAEL HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT RADIAT ONCOL,BOSTON,MA 02115; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; IST NAZL STUDIO & CURA TUMORI,I-20133 MILAN,ITALY; GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Georgetown University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Georgetown University; Georgetown University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HARRIS, JR (corresponding author), HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,DEPT RADIAT ONCOL,50 BINNEY ST,BOSTON,MA 02115, USA.							AGNANTIS NJ, 1986, ONCOLOGY, V43, P36, DOI 10.1159/000226101; Ayash L J, 1991, Oncology (Williston Park), V5, P25; BAGDADE JD, 1990, J CLIN ENDOCR METAB, V70, P1132, DOI 10.1210/jcem-70-4-1132; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; COSSMAN J, 1991, J NATL CANCER I, V83, P980, DOI 10.1093/jnci/83.14.980; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; CURTIS RE, 1992, NEW ENGL J MED, V326, P1745, DOI 10.1056/NEJM199206253262605; DERYNCK R, 1987, CANCER RES, V47, P707; DIFIORE P, IN PRESS GENE ONCOGE; DVIR A, 1991, J CELL BIOL, V113, P857, DOI 10.1083/jcb.113.4.857; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; ELDAR S, 1984, AM J SURG, V148, P692, DOI 10.1016/0002-9610(84)90352-0; ERVIN PR, 1989, SCIENCE, V244, P1585, DOI 10.1126/science.2662405; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FISHER B, 1989, NEW ENGL J MED, V320, P473, DOI 10.1056/NEJM198902233200801; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1988, J CLIN ONCOL, V6, P1076, DOI 10.1200/JCO.1988.6.7.1076; FISHER ER, 1975, CANCER, V36, P1, DOI 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FORMELLI F, 1991, ANN ONCOL, V2, P446; FORNANDER T, 1990, J CLIN ONCOL, V8, P1019, DOI 10.1200/JCO.1990.8.6.1019; FURLANETTO RW, 1984, CANCER RES, V44, P2122; GOLDMAN LD, 1973, PLAST RECONSTR SURG, V51, P501, DOI 10.1097/00006534-197305000-00002; GOODNIGHT JE, 1984, J SURG ONCOL, V26, P198, DOI 10.1002/jso.2930260313; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HENDERSON IC, 1978, CANCER TREAT REP, V62, P923; HOLMES FA, 1991, P AN M AM SOC CLIN, V10, P60; JONES RB, 1987, J CLIN ONCOL, V5, P172, DOI 10.1200/JCO.1987.5.2.172; JORDAN VC, 1990, CANCER TREAT REV, V17, P15; JORDAN VC, 1990, EUR J CANCER, V26, P718, DOI 10.1016/0277-5379(90)90125-D; JORDAN VC, 1976, EUR J CANCER, V12, P419, DOI 10.1016/0014-2964(76)90030-X; KEYHANIROFAGHA S, 1990, CANCER-AM CANCER SOC, V65, P1577, DOI 10.1002/1097-0142(19900401)65:7<1577::AID-CNCR2820650721>3.0.CO;2-D; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; LI F, 1991, J CANCER EPIDEMIOL B, V1, P91; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; LIPPMAN M, 1991, BREAST COMPREHENSIVE, P363; LIPPMAN M, 1991, J NIH RES, V3, P59; LIPPMAN ME, 1988, BREAST CANCER CELLUL; LIPPMAN ME, 1991, REGULATORY MECHANISM; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LYNCH HT, 1979, CANCER, V44, P1860, DOI 10.1002/1097-0142(197911)44:5<1860::AID-CNCR2820440545>3.0.CO;2-I; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MAROUN J, 1991, P AM ASSOC CANC RES, V2, P177; MEYER JS, 1980, CANCER RES, V40, P1890; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; OKA T, 1988, BREAST CANCER CELLUL, P343; OTT J, 1985, ANAL HUMAN GENETIC L; Peters W P, 1991, Important Adv Oncol, P135; PIKE MC, 1987, J CHRON DIS, V40, pS59, DOI 10.1016/S0021-9681(87)80009-7; PIKE MC, 1989, BRIT J CANCER, V60, P142, DOI 10.1038/bjc.1989.237; RATKO TA, 1989, CANCER RES, V49, P4472; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; ROSS R, 1989, LANCET, V1, P1179; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SAINSBURY JRC, 1987, LANCET, V1, P1398; Schmitt M, 1990, Blood Coagul Fibrinolysis, V1, P695; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; SILVESTRINI R, 1985, CANCER, V56, P1982, DOI 10.1002/1097-0142(19851015)56:8<1982::AID-CNCR2820560816>3.0.CO;2-I; SINGH L, 1988, BRIT J CANCER, V57, P612, DOI 10.1038/bjc.1988.139; SKOLNICK MH, 1990, SCIENCE, V250, P1715, DOI 10.1126/science.2270486; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SNYDERMAN RK, 1984, CANCER, V53, P803, DOI 10.1002/1097-0142(19840201)53:3+<803::AID-CNCR2820531332>3.0.CO;2-6; STEIN CA, 1989, J CLIN ONCOL, V7, P499, DOI 10.1200/JCO.1989.7.4.499; TANAKA NG, 1991, INT J RADIAT BIOL, V60, P79, DOI 10.1080/09553009114551601; THOR A, 1991, J NATL CANCER I, V83, P170, DOI 10.1093/jnci/83.3.170; THORPE SM, 1989, CANCER RES, V49, P6008; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WELLSTEIN A, 1991, JNCI-J NATL CANCER I, V83, P716, DOI 10.1093/jnci/83.10.716; 1988, BRIT J CANCER, V57, P604; 1985, LANCET, V1, P836; 1988, BRIT J CANCER, V57, P608; 1989, NEW ENGL J MED, V320, P491; 1992, LANCET, V339, P71	81	202	206	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					473	480		10.1056/NEJM199208133270706	http://dx.doi.org/10.1056/NEJM199208133270706			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625737				2022-12-28	WOS:A1992JH34000006
J	FEINBERG, WM; FOSSUM, K; MCBRIDE, R				FEINBERG, WM; FOSSUM, K; MCBRIDE, R			ASPIRIN TO PREVENT STROKE IN NONRHEUMATIC ATRIAL-FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									SPAF STAT COORDINATING CTR,SEATTLE,WA 98105		FEINBERG, WM (corresponding author), UNIV ARIZONA,HLTH SCI CTR,TUCSON,AZ 85724, USA.							ALBERS GW, 1991, ANN NEUROL, V30, P511, DOI 10.1002/ana.410300402; PETERSEN P, 1990, NEW ENGL J MED, V323, P482; SINGER DE, 1991, NEW ENGL J MED, V325, P131; 1991, CIRCULATION, V84, P527	4	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614485				2022-12-28	WOS:A1992JE38100033
J	TOKARS, JI; CHAMBERLAND, ME; SCHABLE, CA; CULVER, DH; JONES, M; MCKIBBEN, PS; BELL, DM				TOKARS, JI; CHAMBERLAND, ME; SCHABLE, CA; CULVER, DH; JONES, M; MCKIBBEN, PS; BELL, DM			A SURVEY OF OCCUPATIONAL BLOOD CONTACT AND HIV-INFECTION AMONG ORTHOPEDIC SURGEONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK; TRANSMISSION	Objective.-To study the seroprevalence of human immunodeficiency virus (HIV) among orthopedic surgeons, and correlate the results with occupational and nonoccupational risk factors. Orthopedic surgeons are one of several groups of health care workers at risk for occupationally acquired HIV infection; however, few HIV seroprevalence studies in health care workers, and none in surgeons, have been performed to assist in estimating the extent of occupational risk. Design.-A voluntary, anonymous HIV serosurvey at an annual meeting. To assess the representativeness of participants, a mail survey of orthopedic surgeons was conducted 5 months prior to the annual meeting. Setting.-The 1991 annual meeting of the American Academy of Orthopaedic Surgeons held in Anaheim, Calif. Participants.-United States or Canadian orthopedic surgeons in training, in practice, or retired from practice who attended the annual meeting. Main Outcome Measures.-Participants' HIV serostatus and reporting of occupational and nonoccupational risk factors for HIV infection. Results.-Of 7147 eligible orthopedists at the annual meeting, 3420 (47.9%) participated. Compared with the 10411 orthopedic surgeons responding to the mail survey, serosurvey participants had at least as many opportunities for occupational contact with blood and with HIV-infected patients. Among participants, 87.4% reported a blood-skin contact and 39.2% reported a percutaneous blood contact in the previous month. Among 3267 participants without reported nonoccupational risk factors for HIV infection, none was positive for HIV antibody (0%; upper limit of the 95% confidence interval [CI] = 0.09%); among 108 participants with reported nonoccupational HIV risk factors, two were positive for HIV antibody (1.9%; upper limit of the 95% CI = 5.7%). Conclusion.-Although these findings may not be generalizable to all orthopedic surgeons, we found no evidence of HIV infection among serosurvey participants without nonoccupational risk factors. The high rates of self-reported blood contact underscore the importance of compliance with infection control precautions and of development of new techniques and equipment to minimize the risk of exposures to blood during surgical procedures.	CTR DIS CONTROL,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA	TOKARS, JI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,MAILSTOP A-07,ATLANTA,GA 30333, USA.							BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JOHNSON GK, 1991, J MED VIROL, V33, P47, DOI 10.1002/jmv.1890330110; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; MARCUS R, 1989, B WORLD HEALTH ORGAN, V67, P577; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MCQUILLAN GM, 1989, AM J MED, V87, pS5; PANLILIO AL, 1991, JAMA-J AM MED ASSOC, V265, P1533, DOI 10.1001/jama.265.12.1533; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V267, P2899, DOI 10.1001/jama.267.21.2899; 1988, MMWR, V37, P387; 1991, MMWR, V40, P309; 1991, REDUCING RISK BLOOD; 1991, MMWR, V40, P1; 1987, MMWR S2S, V36, pS1; 1991, ADVISORY STATEMENT H; 1988, MMWR, V37, P377; 1989, RECOMMENDATIONS PREV; 1990, HIV AIDS SURVEILLANC, P1; 1989, MMWR, V38, P95; 1989, MMWR, V38, P1; 1990, MMWR, V39, P1	26	68	70	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					489	494		10.1001/jama.268.4.489	http://dx.doi.org/10.1001/jama.268.4.489			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619740				2022-12-28	WOS:A1992JD47200023
J	JOHNSTON, CC; MILLER, JZ; SLEMENDA, CW; REISTER, TK; HUI, S; CHRISTIAN, JC; PEACOCK, M				JOHNSTON, CC; MILLER, JZ; SLEMENDA, CW; REISTER, TK; HUI, S; CHRISTIAN, JC; PEACOCK, M			CALCIUM SUPPLEMENTATION AND INCREASES IN BONE-MINERAL DENSITY IN CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; MASS; ABSORPTION; FRACTURE; CARBONATE; SINGLE; RATES; CCM	Background. Increased dietary intake of calcium during childhood, usually as calcium in milk, is associated with increased bone mass in adulthood; the increase in mass is important in modifying the later risk of fracture. Whether the increase is due to the calcium content of milk, however, is not certain. Methods. We conducted a three-year, double-blind, placebo-controlled trial of the effect of calcium supplementation (1000 mg of calcium citrate malate per day) on bone mineral density in 70 pairs of identical twins (mean [+/-SD] age, 10+/-2 years; range, 6 to 14). In each pair, one twin served as a control for the other; 45 pairs completed the study. Bone mineral density was measured by photon absorptiometry at two sites in the radius (at base line, six months, and one, two, and three years) and at three sites in the hip and in the spine (at base line and three years). Results. The mean daily calcium intake of the twins given placebo was 908 mg, and that of the twins given calcium supplements was 1612 mg (894 mg from the diet and 718 mg from the supplement). Among the 22 twin pairs who were prepubertal throughout the study, the twins given supplements had significantly greater increases in bone mineral density at both radial sites (mean difference in the increase in bone mineral density: midshaft radius, 5.1 percent [95 percent confidence interval, 1.5 to 8.7 percent]; distal radius, 3.8 percent [95 percent confidence interval, 1.4 to 6.2 percent]) and in the lumbar spine (increase, 2.8 percent [95 percent confidence interval, 1.1 to 4.5 percent]) after three years; the differences in the increases at two of three femoral sites approached significance (Ward's triangle in the femoral neck, 2.9 percent; greater trochanter, 3.5 percent). Among the 23 pairs who went through puberty or were postpubertal, the twins given supplements received no benefit. Conclusions. In prepubertal children whose average dietary intake of calcium approximated the recommended dietary allowance, calcium supplementation enhanced the rate of increase in bone mineral density. If the gain persists, peak bone density should be increased and the risk of fracture reduced.	INDIANA UNIV,SCH MED,DEPT MED & MOLEC GENET,INDIANAPOLIS,IN 46202; REGENSTRIEF INST HLTH CARE,INDIANAPOLIS,IN	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc	JOHNSTON, CC (corresponding author), INDIANA UNIV,SCH MED,DEPT MED,EMERSON HALL,RM 421,545 BARNHILL DR,INDIANAPOLIS,IN 46202, USA.				NCRR NIH HHS [RR 750] Funding Source: Medline; NIA NIH HHS [AG-05793] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARTELS E, 1969, CLIN CHIM ACTA, V26, P1; CARROLL MD, 1983, DHHS PHS831681 PUBL; CHRISTIAN JC, 1972, METABOLISM, V21, P691, DOI 10.1016/0026-0495(72)90118-7; DAWSONHUGHES B, 1990, NEW ENGL J MED, V323, P878, DOI 10.1056/NEJM199009273231305; HALIOUA L, 1989, AM J CLIN NUTR, V49, P534, DOI 10.1093/ajcn/49.3.534; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; JIANG X, 1987, ANAL CHEM, V59, P2570, DOI 10.1021/ac00148a009; LAU KHW, 1987, CLIN CHEM, V33, P458; Leighton G, 1929, LANCET, V1, P40; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1979, AM J CLIN NUTR, V32, P540, DOI 10.1093/ajcn/32.3.540; MATKOVIC V, 1991, AM J CLIN NUTR, V54, pS245, DOI 10.1093/ajcn/54.1.245S; MILLER JZ, 1989, CLIN CHIM ACTA, V183, P107, DOI 10.1016/0009-8981(89)90326-4; MILLER JZ, 1991, J NUTR, V121, P265, DOI 10.1093/jn/121.2.265; MILLER JZ, 1988, AM J CLIN NUTR, V48, P1291, DOI 10.1093/ajcn/48.5.1291; Orr JB, 1928, LANCET, V1, P202; RECKER RR, 1977, ANN INTERN MED, V87, P649, DOI 10.7326/0003-4819-87-6-649; RIIS B, 1987, NEW ENGL J MED, V316, P173, DOI 10.1056/NEJM198701223160401; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA C, 1987, J CLIN INVEST, V80, P1261, DOI 10.1172/JCI113201; SLEMENDA CW, 1991, J BONE MINER RES, V6, P1227; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SMITH KT, 1987, CALCIFIED TISSUE INT, V41, P351, DOI 10.1007/BF02556676; WASNICH RD, 1989, J NUCL MED, V30, P1166; WEINSTEIN RS, 1988, NEW ENGL J MED, V319, P1698, DOI 10.1056/NEJM198812293192603; ZETTNER A, 1964, CLIN CHEM, V10, P869; 1980, 2 DEP AGR PREL REP; 1989, RECOMMENDED DIETARY	29	795	820	0	40	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					82	87		10.1056/NEJM199207093270204	http://dx.doi.org/10.1056/NEJM199207093270204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603140				2022-12-28	WOS:A1992JC21400004
J	FISHLEDER, AJ				FISHLEDER, AJ			PRENATAL HEMOGLOBINOPATHY SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FISHLEDER, AJ (corresponding author), CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					266	266						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608146				2022-12-28	WOS:A1992JB27900035
J	WILSON, DK; BOHREN, KM; GABBAY, KH; QUIOCHO, FA				WILSON, DK; BOHREN, KM; GABBAY, KH; QUIOCHO, FA			AN UNLIKELY SUGAR SUBSTRATE SITE IN THE 1.65 ANGSTROM STRUCTURE OF THE HUMAN ALDOSE REDUCTASE HOLOENZYME IMPLICATED IN DIABETIC COMPLICATIONS	SCIENCE			English	Article							HEXONATE DEHYDROGENASE; KIDNEY ALDOSE; INHIBITION; SORBINIL; ALDEHYDE; PROTEINS; NEUROPATHY; CRYSTALLIN; FEATURES; KINETICS	Aldose reductase, which catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds, is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney. A 1.65 angstrom refined structure of a recombinant human placenta aldose reductase reveals that the enzyme contains a parallel beta-8/alpha-8-barrel motif and establishes a new motif for NADP-binding oxidoreductases. The substrate-binding site is located in a large, deep elliptical pocket at the COOH-terminal end of the beta-barrel with a bound NADPH in an extended conformation. The highly hydrophobic nature of the active site pocket greatly favors aromatic and apolar substrates over highly polar monosaccharides. The structure should allow for the rational design of specific inhibitors that might provide molecular understanding of the catalytic mechanism, as well as possible therapeutic agents.	BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Bohren, Kurt/0000-0002-3183-4118	NIDDK NIH HHS [DK-39,044] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039044] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON S, 1985, SCIENCE, V230, P144, DOI 10.1126/science.230.4722.144; BHATNAGAR A, 1990, BIOCHEM PHARMACOL, V39, P1115, DOI 10.1016/0006-2952(90)90292-S; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOHREN KM, 1991, J BIOL CHEM, V266, P24031; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BOULTON AJM, 1990, DIABETOLOGIA, V33, P431, DOI 10.1007/BF00404095; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRUNGER AT, 1990, XPLOR SYSTEM CRYSTAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DVORNIK D, 1973, SCIENCE, V182, P1146, DOI 10.1126/science.182.4117.1146; EINSPAHR HM, 1989, P S PROTEIN CARBOHYD, V25; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; FELDMAN HB, 1977, BIOCHIM BIOPHYS ACTA, V480, P18; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KADOR PF, 1985, ANNU REV PHARMACOL, V25, P691, DOI 10.1146/annurev.pa.25.040185.003355; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; MARTYN CN, 1987, DIABETES, V36, P987, DOI 10.2337/diabetes.36.9.987; OBRIEN MM, 1982, J NEUROCHEM, V39, P810, DOI 10.1111/j.1471-4159.1982.tb07964.x; Pai EF, 1991, CURR OPIN STRUC BIOL, V1, P796, DOI 10.1016/0959-440X(91)90181-R; POULSOM R, 1986, BIOCHEM PHARMACOL, V35, P2955, DOI 10.1016/0006-2952(86)90492-2; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; QUIOCHO FA, 1989, PURE APPL CHEM, V61, P1293, DOI 10.1351/pac198961071293; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; ROSE IA, 1980, P NATL ACAD SCI-BIOL, V77, P2439, DOI 10.1073/pnas.77.5.2439; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SPIELBERG SP, 1991, ANN INTERN MED, V114, P720, DOI 10.7326/0003-4819-114-9-720; TOMAREV SI, 1984, FEBS LETT, V171, P297, DOI 10.1016/0014-5793(84)80508-6; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WATANABE K, 1988, P NATL ACAD SCI USA, V85, P11, DOI 10.1073/pnas.85.1.11; WERMUTH B, 1982, EUR J BIOCHEM, V127, P279, DOI 10.1111/j.1432-1033.1982.tb06867.x; WERMUTH B, 1992, ENZYMOLOGY CARBONYL, P261; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WINTERS CJ, 1990, BIOCHEMISTRY-US, V29, P1080, DOI 10.1021/bi00456a034	40	403	413	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					81	84		10.1126/science.1621098	http://dx.doi.org/10.1126/science.1621098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621098				2022-12-28	WOS:A1992JC16500034
J	BICK, D; FRANCO, B; SHERINS, RJ; HEYE, B; PIKE, L; CRAWFORD, J; MADDALENA, A; INCERTI, B; PRAGLIOLA, A; MEITINGER, T; BALLABIO, A				BICK, D; FRANCO, B; SHERINS, RJ; HEYE, B; PIKE, L; CRAWFORD, J; MADDALENA, A; INCERTI, B; PRAGLIOLA, A; MEITINGER, T; BALLABIO, A			INTRAGENIC DELETION OF THE KALIG-1 GENE IN KALLMANNS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							ISOLATED HYPOGONADOTROPIC HYPOGONADISM; DISTAL SHORT ARM; STEROID SULFATASE; X-CHROMOSOME; ANOSMIA; IDENTIFICATION; ICHTHYOSIS; DEFICIENCY; MIGRATION; LINKAGE		BAYLOR COLL MED,INST MOLEC GENET,1 BAYLOR PL,HOUSTON,TX 77030; GENET & IVF INST,FAIRFAX,VA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298; UNIV MUNICH,KINDER POLIKLIN,PADIATR GENET ABT,W-8000 MUNICH 2,GERMANY; MASSACHUSETTS GEN HOSP,CHILDRENS SERV,BOSTON,MA 02114	Baylor College of Medicine; Virginia Commonwealth University; University of Munich; Harvard University; Massachusetts General Hospital			Meitinger, Thomas/O-1318-2015; FRANCO, Brunella/S-2882-2018	FRANCO, Brunella/0000-0001-5588-4569; Meitinger, Thomas/0000-0002-8838-8403; BALLABIO, Andrea/0000-0003-1381-4604	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028333] Funding Source: NIH RePORTER; NICHD NIH HHS [1 RO1 HD-28333-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALVAREZBUYLLA A, 1990, EXPERIENTIA, V46, P879, DOI 10.1007/BF01939379; BALLABIO A, 1986, HUM GENET, V72, P237, DOI 10.1007/BF00291885; BALLABIO A, 1989, P NATL ACAD SCI USA, V86, P10001, DOI 10.1073/pnas.86.24.10001; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BERNATOWICZ LF, IN PRESS GENOMICS; BICK DP, 1992, PRENATAL DIAG, V12, P19, DOI 10.1002/pd.1970120104; De Morster G, 1954, SCHWEIZ ARCH NEUROL, V74, P309; DOBYNS WB, 1989, NEUROL CLIN, V7, P89, DOI 10.1016/S0733-8619(18)30830-2; FILIPPI G, 1986, CLIN GENET, V30, P276; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; HENKIN RI, 1966, J CLIN INVEST, V45, P1631, DOI 10.1172/JCI105470; Jones J R, 1976, Obstet Gynecol Annu, V5, P443; Kallmann FJ, 1944, AM J MENT DEF, V48, P203; KERTZMAN C, 1990, NEUROLOGY, V40, P1057, DOI 10.1212/WNL.40.7.1057; KLINGMULLER D, 1987, J CLIN ENDOCR METAB, V65, P581, DOI 10.1210/jcem-65-3-581; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; MEITINGER T, 1990, AM J HUM GENET, V47, P664; MEITINGER T, 1990, AM J HUM GENET, V47, P883; NAFTOLIN F, 1971, NATURE, V232, P496, DOI 10.1038/232496a0; RADOVICK S, 1991, P NATL ACAD SCI USA, V88, P3402, DOI 10.1073/pnas.88.8.3402; Sambrook J, 1989, MOL CLONING LABORATO; SANTEN RJ, 1973, J CLIN ENDOCR METAB, V36, P47, DOI 10.1210/jcem-36-1-47; SCHWANKHAUS JD, 1989, NEUROLOGY, V39, P223, DOI 10.1212/WNL.39.2.223; SCHWANZELFUKUDA M, 1989, MOL BRAIN RES, V6, P311, DOI 10.1016/0169-328X(89)90076-4; SCHWANZELFUKUDA M, 1989, NATURE, V338, P161, DOI 10.1038/338161a0; SUNOHARA N, 1986, ANN NEUROL, V19, P174, DOI 10.1002/ana.410190211; TUCK RR, 1983, J NEUROL NEUROSUR PS, V46, P671, DOI 10.1136/jnnp.46.7.671; TURNER RC, 1974, P ROY SOC MED, V67, P33, DOI 10.1177/003591577406700120; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WEGENKE JD, 1975, CLIN GENET, V7, P368; WHITE BJ, 1983, AM J MED GENET, V15, P417, DOI 10.1002/ajmg.1320150307; WOODSSAMUELS P, 1991, GENOMICS, V10, P94, DOI 10.1016/0888-7543(91)90489-2; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; 1983, SMELL IDENTIFICATION; 1990, LANCET, V336, P1035	37	152	158	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 25	1992	326	26					1752	1755		10.1056/NEJM199206253262606	http://dx.doi.org/10.1056/NEJM199206253262606			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ894	1594017				2022-12-28	WOS:A1992HZ89400006
J	LINDLEY, D				LINDLEY, D			LARGE, OIL-SOAKED ENDOWMENT HELPS STATE-UNIVERSITIES WEATHER CURRENT HARD TIMES	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					625	625		10.1038/357625a0	http://dx.doi.org/10.1038/357625a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614504	Bronze			2022-12-28	WOS:A1992JA43000021
J	LURIE, N; MOSCOVICE, IS; FINCH, M; CHRISTIANSON, JB; POPKIN, MK				LURIE, N; MOSCOVICE, IS; FINCH, M; CHRISTIANSON, JB; POPKIN, MK			DOES CAPITATION AFFECT THE HEALTH OF THE CHRONICALLY MENTALLY-ILL - RESULTS FROM A RANDOMIZED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERVICES	Objective.-To determine the effect on health outcomes of enrollment of chronically mentally ill Medicaid recipients in prepaid plans vs traditional fee-for-service Medicaid. Design.-A randomized controlled trial. Clients who were randomly assigned to prepaid care were then permitted to choose among four capitated health plans. Clients returned to fee-for-service care at the end of the demonstration. Setting.-The Medicaid Demonstration Project in Hennepin County, Minnesota, the urban center of which is Minneapolis. Patients.-Seven hundred thirty-nine Medicaid clients who were classified as having chronic mental illness on the basis of Medicaid claims. Clients were interviewed at baseline (time 1) and at two follow-up points. Data were available for 96% of participants at the end of the intervention (time 2). Average duration of follow-up was 11 months. A subset of 370 clients with schizophrenia was followed up 11 months after the return of the prepaid group to fee-for-service care (time 3). Main Outcome Measures.-General health status, physical functioning, social functioning, and psychiatric symptoms, assessed using the Schedule of Affective Disorders and Schizophrenia-Change version, the Global Assessment Scale, and indicators of community function. Results.-No significant differences between prepaid and fee-for-service groups in general health or psychiatric symptoms from baseline to time 2. After regression adjustment, 12% fewer clients in the prepaid group reported being victimized (P<.01). At the end of time 3, the regression-adjusted Global Assessment Scale scores had worsened by 7.6 points more in the prepaid group in comparison with the fee-for-service group (P<.02). Conclusion.-There was no consistent evidence of harmful effects of enrolling chronically mentally ill Medicaid clients in prepaid care, at least in the short run. The generalizability of these findings may be limited to plans that control utilization by methods similar to those used in this study setting. Longer-term outcome studies should be undertaken to clarify the strength of the findings.	HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55415; UNIV MINNESOTA,DEPT PSYCHIAT,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	LURIE, N (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DIV HLTH SERV RES & POLICY,420 DELAWARE ST SE,BOX 729,MINNEAPOLIS,MN 55455, USA.		Young, Alexander/A-1523-2009; Finch, Michael/AAN-7772-2021	Young, Alexander/0000-0002-9367-9213; Finch, Michael/0000-0001-7770-1102				[Anonymous], 1948, CONSTITUTION WHO; CAREY TS, 1991, HEALTH SERV RES, V26, P165; CHRISTIANSON J, 1987, SEP NAT I MENT HLTH; CHRISTIANSON JB, 1990, JUN ANN M ASS HLTH S; CHRISTIANSON JC, 1988, ADM MENT HLTH, V15, P201; Cohen J, 1977, STAT POWER ANAL BEHA, P19, DOI [10.1016/B978-0-12-179060-8.50007-4, DOI 10.1016/B978-0-12-179060-8.50007-4]; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; ENDICOTT J, 1979, ARCH GEN PSYCHIAT, V36, P706; FINK DJ, 1991, HOSP COMMUNITY PSYCH, V42, P363; Freund D A, 1986, Health Care Financ Rev, P21; Heinen L, 1990, Health Care Financ Rev, V11, P55; KANE RA, 1985, MEASURING SOCIAL FUN; Lehman A F, 1983, Eval Program Plann, V6, P143, DOI 10.1016/0149-7189(83)90028-9; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MSOCOVICE I, 1989, ADV HLTH EC HLTH SER, V10, P265; SCARLET LJ, 1990, HLTH AFFAIRS, V9, P7; SHCLESINGER M, 1987, MILBANK Q, V64, P189; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; STEWART AL, 1982, CONSTRUCTION SCORING; TAUBE CA, 1990, HEALTH AFFAIR, V9, P5, DOI 10.1377/hlthaff.9.1.5; WARE JE, 1986, LANCET, V1, P1017; WELLS KB, 1986, HEALTH SERV RES, V21, P453; 1986, REDUCING INTERVIEWER	24	80	80	1	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3300	3304		10.1001/jama.267.24.3300	http://dx.doi.org/10.1001/jama.267.24.3300			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HY944	1597911				2022-12-28	WOS:A1992HY94400028
J	MERGNY, JL; DUVALVALENTIN, G; NGUYEN, CH; PERROUAULT, L; FAUCON, B; ROUGEE, M; MONTENAYGARESTIER, T; BISAGNI, E; HELENE, C				MERGNY, JL; DUVALVALENTIN, G; NGUYEN, CH; PERROUAULT, L; FAUCON, B; ROUGEE, M; MONTENAYGARESTIER, T; BISAGNI, E; HELENE, C			TRIPLE HELIX SPECIFIC LIGANDS	SCIENCE			English	Article							COLI RNA-POLYMERASE; ANTINEOPLASTIC AGENTS; DNA; OLIGONUCLEOTIDES; SEQUENCES; PROMOTER; COMPLEX	A triple helix is formed upon binding of an oligodeoxynucleotide to the major groove of duplex DNA. A benzo[e]pyridoindole derivative (BePI) strongly stabilized this structure and showed preferential binding to a triplex rather than to a duplex. Energy transfer experiments suggest that BePI intercalates within the triple helix. Sequence-specific inhibition of transcription initiation of a specific gene by Escherichia coli RNA polymerase by a triplex-forming oligodeoxynucleotide is strongly enhanced when the triplex is stabilized by BePI. Upon irradiation with ultraviolet light, BePI induces covalent modifications of the target within the triple helix structure.	MUSEUM NATL HIST NAT, BIOPHYS LAB,CNRS,UA 481,INSERM,U201,43 RUE CUVIER, F-75005 PARIS, FRANCE; INST CURIE, SYNTH LAB, CNRS, URA 1387, F-91405 ORSAY, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Mergny, Jean-Louis/E-2860-2013; Nguyen, Chi/GZG-5146-2022; Nguyen, Chi/GWR-1592-2022	Mergny, Jean-Louis/0000-0003-3043-8401; 				BISAGNI E, 1988, J MED CHEM, V31, P398, DOI 10.1021/jm00397a023; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; COLLIER DA, 1991, NUCLEIC ACIDS RES, V19, P4219, DOI 10.1093/nar/19.15.4219; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; CROTHERS DM, 1971, BIOPOLYMERS, V10, P2147, DOI 10.1002/bip.360101110; DELOSSANTOS C, 1989, BIOCHEMISTRY-US, V28, P7282, DOI 10.1021/bi00444a021; DUVALVALENTIN G, 1988, NUCLEIC ACIDS RES, V16, P2031, DOI 10.1093/nar/16.5.2031; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; DUVALVALENTIN G, 1987, NUCLEIC ACIDS RES, V15, P575, DOI 10.1093/nar/15.2.575; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HELENE C, 1991, ANTI-CANCER DRUG DES, V6, P569; LEDOAN T, 1987, NUCLEIC ACIDS RES, V15, P8643, DOI 10.1093/nar/15.21.8643; LYAMICHEV VI, 1988, NUCLEIC ACIDS RES, V16, P2165, DOI 10.1093/nar/16.5.2165; MERGNY JL, 1991, NUCLEIC ACIDS RES, V19, P1521, DOI 10.1093/nar/19.7.1521; MONTENAYGARESTIER T, 1990, JERUS SYM Q, V23, P275; MORGAN JP, 1980, PHOTOCHEM PHOTOBIOL, V31, P101, DOI 10.1111/j.1751-1097.1980.tb03692.x; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; NGUYEN CH, 1990, J MED CHEM, V33, P1519, DOI 10.1021/jm00167a037; NGUYEN CH, 1987, J MED CHEM, V30, P1642, DOI 10.1021/jm00392a021; PERROUAULT L, 1990, NATURE, V344, P358, DOI 10.1038/344358a0; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POVSIC TJ, 1989, J AM CHEM SOC, V111, P3059, DOI 10.1021/ja00190a047; RAJAGOPAL P, 1989, BIOCHEMISTRY-US, V28, P7859, DOI 10.1021/bi00445a048; ROUGEE M, UNPUB; SARI MA, 1986, BIOCHEM BIOPH RES CO, V141, P643, DOI 10.1016/S0006-291X(86)80221-2; SCARIA PV, 1991, J BIOL CHEM, V266, P5417; SUN JS, 1989, P NATL ACAD SCI USA, V86, P9198, DOI 10.1073/pnas.86.23.9198	27	309	312	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 19	1992	256	5064					1681	1684		10.1126/science.256.5064.1681	http://dx.doi.org/10.1126/science.256.5064.1681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609278				2022-12-28	WOS:A1992HZ17400045
J	LOMAS, DA; EVANS, DL; FINCH, JT; CARRELL, RW				LOMAS, DA; EVANS, DL; FINCH, JT; CARRELL, RW			THE MECHANISM OF Z-ALPHA-1-ANTITRYPSIN ACCUMULATION IN THE LIVER	NATURE			English	Article							ALPHA-1-ANTITRYPSIN; PURIFICATION; DEFICIENCY; DAMAGE; PLASMA	MOST northern Europeans have only the normal M form of the plasma protease inhibitor alpha-1-antitrypsin, but some 4% are heterozygotes for the Z deficiency variant 1. For reasons that have not been well-understood, the Z mutation results in a blockage in the final stage of processing of antitrypsin in the liver 2 such that in the Z homozygote only 15% of the protein is secreted into the plasma.The 85% of the alpha-1-antitrypsin that is not secreted accumulates in the endoplasmic reticulum of the hepatocyte; much of it is degraded but the remainder aggregates to form insoluble intracellular inclusions. These inclusions are associated with hepatocellular damage, and 10% of newborn Z homozygotes develop liver disease which often leads to a fatal childhood cirrhosis. Here we demonstrate the molecular pathology underlying this accumulation and describe how the Z mutation in antitrypsin results in a unique molecular interaction between the reactive centre loop of one molecule and the gap in the A-sheet of another. This loop-sheet polymerization of Z antitrypsin occurs spontaneously at 37-degrees-C and is completely blocked by the insertion of a specific peptide into the A-sheet of the antitrypsin molecule. Z antitrypsin polymerized in vitro has identical properties and ultrastructure to the inclusions isolated from hepatocytes of a Z homozygote. The concentration and temperature dependence of this loop-sheet polymerization has implications for the management of the liver disease of the newborn Z homozygote.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	LOMAS, DA (corresponding author), UNIV CAMBRIDGE,DEPT HAEMATOL,CAMBRIDGE,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; CARLSON JA, 1989, J CLIN INVEST, V83, P1183, DOI 10.1172/JCI113999; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1986, J CLIN INVEST, V78, P1427, DOI 10.1172/JCI112731; COX DW, 1986, FEBS LETT, V205, P255, DOI 10.1016/0014-5793(86)80908-5; CURIEL DT, 1989, J BIOL CHEM, V264, P13939; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; EVANS DLI, 1991, THESIS U CAMBRIDGE; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; LAURELL CB, 1975, EUR J BIOCHEM, V57, P107, DOI 10.1111/j.1432-1033.1975.tb02281.x; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LE AQ, 1992, J BIOL CHEM, V267, P1072; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN P, 1991, J MOL BIOL, V221, P615, DOI 10.1016/0022-2836(91)80076-7	15	840	883	0	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					605	607		10.1038/357605a0	http://dx.doi.org/10.1038/357605a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608473				2022-12-28	WOS:A1992HZ11200059
J	PETERSON, M; MILLER, J				PETERSON, M; MILLER, J			ANTIGEN PRESENTATION ENHANCED BY THE ALTERNATIVELY SPLICED INVARIANT CHAIN GENE-PRODUCT P41	NATURE			English	Article							H-2-RESTRICTED T-CELLS; II MHC MOLECULES; B-CELL; RECOGNITION; HYBRIDOMAS; TRANSPORT; PEPTIDE; BINDING; ENCODES; REGIONS	DURING biosynthesis, class II molecules of the major histocompatibility complex are associated with a nonpolymorphic protein called invariant chain, Ii, which facilitates folding of class II molecules and their exit from the endoplasmic reticulum 1-4, interferes with their association with peptide 5,6 and directs their post-Golgi transport (refs 7-9). If Ii blocks class II loading with endogenous antigens in the endoplasmic reticulum and/or directs class II molecules to the exogenous antigen-loading compartment, then the co-expression of Ii should enhance the ability of class II molecules to present exogenous antigens to T cells. But data supporting a role for Ii in class II-restricted antigen presentation are controversial 1,10-13. Here we show that Ii can facilitate exogenous antigen presentation for a subset of antigens. Although all known functions of li have been ascribed to the principal form of Ii, p31, we find that in most cases antigen presentation is facilitated only by the alternatively spliced, minor form of Ii, p41.			PETERSON, M (corresponding author), UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, 920 E 58TH ST, CHICAGO, IL 60637 USA.							ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; EKHOLM R, 1990, INT REV CYTOL, V120, P243; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; JENSEN PE, 1988, J IMMUNOL, V141, P2545; JENSEN PE, 1990, J EXP MED, V171, P1779, DOI 10.1084/jem.171.5.1779; KAPPLER J, 1982, P NATL ACAD SCI-BIOL, V79, P3604, DOI 10.1073/pnas.79.11.3604; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LORENZ RG, 1988, J IMMUNOL, V141, P4124; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; OZAKI S, 1988, J IMMUNOL, V141, P71; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; ROSIONIEC E, 1989, J IMMUNOL, V143, P50; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SEKALY RP, 1988, P NATL ACAD SCI USA, V85, P1209, DOI 10.1073/pnas.85.4.1209; SETTE A, 1992, J IMMUNOL, V148, P844; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; YAMAMOTO K, 1985, J IMMUNOL, V134, P3461	35	124	125	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					596	598		10.1038/357596a0	http://dx.doi.org/10.1038/357596a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608470				2022-12-28	WOS:A1992HZ11200056
J	SUTHERLAND, VJ; COOPER, CL				SUTHERLAND, VJ; COOPER, CL			JOB STRESS, SATISFACTION, AND MENTAL-HEALTH AMONG GENERAL-PRACTITIONERS BEFORE AND AFTER INTRODUCTION OF NEW CONTRACT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WORK; CONSULTATION; QUALITY; DOCTORS; TIME	Objective - To compare measures of job stress, job satisfaction, and mental health among general practitioners before and after the introduction of the new contract in April 1990. Design - Cross sectional postal questionnaire survey in July 1990. Comparison of results with those obtained in previous survey in November 1987. Setting - General practice in United Kingdom. Subjects - 1500 general practitioners randomly selected from general medical services lists, 917 of whom (61%) returned questionnaires usable for statistical analysis. Main outcome measures - Aspects of job causing stress, job satisfaction (Warr, Cook, and Wall scale), and mental health (Crown-Crisp experiential index). Results - Compared with 1987, in 1990 doctors experienced more stress from night calls (mean score 3.83 in 1990 v 3.45 in 1987), emergencies during surgery hours (3.72 v 3.48), and interruption of family life by telephone (3.58 v 2.73; p<0.001 for all three variables). Scores for somatic anxiety and depression were higher in both men and women in 1990 (men: somatic anxiety 3.12 v 2.36; depression 3.80 v 2.94; women: somatic anxiety 3.56 v 2.65; depression 4.02 v 3.37; p<0.001). Job satisfaction had also decreased in 1990 (5.23 v 4.26; p<0.001). Conclusions - Doctors experienced more stress, less job satisfaction, and poorer mental health in 1990 than in 1987. These changes may have resulted from the introduction of the new contract.			SUTHERLAND, VJ (corresponding author), UNIV MANCHESTER, INST SCI & TECHNOL, MANCHESTER SCH MANAGEMENT, DEPT ORG PSYCHOL, POB 88, MANCHESTER M60 1QD, LANCS, ENGLAND.							ABROOK M, 1990, PRACTITIONER, V234, P992; COOPER CL, 1989, BRIT MED J, V298, P366, DOI 10.1136/bmj.298.6670.366; Crown S, 1979, MANUAL CROWN CRISP E; FRENCH JRP, 1973, FAILURE SUCCESS, P30; GROL R, 1985, FAM PRACT, V2, P128, DOI 10.1093/fampra/2.3.128; HOWIE JGR, 1989, BMJ-BRIT MED J, V298, P1008, DOI 10.1136/bmj.298.6679.1008; KARASEK RA, 1979, ADMIN SCI QUART, V24, P285, DOI 10.2307/2392498; KEELEY D, 1991, BMJ-BRIT MED J, V302, P1514, DOI 10.1136/bmj.302.6791.1514; LLOYD G, 1990, BRIT MED J, V300, P728, DOI 10.1136/bmj.300.6726.728; MACPHERSON G, 1989, BRIT MED J, V298, P1406, DOI 10.1136/bmj.298.6685.1406; MARSH G, 1976, TEAM CARE GENERAL PR; MORRELL D, 1989, BRIT MED J, V298, P1005, DOI 10.1136/bmj.298.6679.1005; MORRELL DC, 1986, BMJ-BRIT MED J, V292, P870, DOI 10.1136/bmj.292.6524.870; MYERSON S, 1990, PRACTITIONER, V234, P973; PORTER AMD, 1985, FAM PRACT, V2, P136, DOI 10.1093/fampra/2.3.136; PORTER AMD, 1987, STRESS HLTH PROFESSI, P45; SALES SM, 1971, J CHRON DIS, V23, P861, DOI 10.1016/0021-9681(71)90015-4; SCHEIBER SC, 1987, STRESS HLTH PROFESSI, P23; Selye H., 1979, STRESS DISTRESS; SMITH T, 1989, BRIT MED J, V298, P1405, DOI 10.1136/bmj.298.6685.1405; SUTHERLAND VJ, 1990, UNDERSTANDING STRESS, P165; VANSELL M, 1981, HUM RELAT, V34, P43, DOI 10.1177/001872678103400104; WARR P, 1979, J OCCUP PSYCHOL, V52, P129, DOI 10.1111/j.2044-8325.1979.tb00448.x	23	162	162	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 13	1992	304	6841					1545	1548		10.1136/bmj.304.6841.1545	http://dx.doi.org/10.1136/bmj.304.6841.1545			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628056	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800027
J	ZHENG, B; BRETT, SJ; TITE, JP; LIFELY, MR; BRODIE, TA; RHODES, J				ZHENG, B; BRETT, SJ; TITE, JP; LIFELY, MR; BRODIE, TA; RHODES, J			GALACTOSE OXIDATION IN THE DESIGN OF IMMUNOGENIC VACCINES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; T-CELL ACTIVATION; INFLUENZA-A VIRUS; IMMUNE-RESPONSE; ANTIGEN; RECOGNITION; VACCINATION; ANTIBODIES; RETROVIRUS; INDUCTION	Potent immunological adjuvants are urgently required to complement recombinant and synthetic vaccines. However, it has not been possible to derive new principles for the design of vaccine adjuvants from knowledge of the mechanism of immunogenicity. Carbonyl-amino condensations, which are essential to the inductive interaction between antigen-presenting cells and T helper cells, were tested as a target for the enhancement of immune responses. Enzymic oxidation of cell-surface galactose to increase amine-reactive carbonyl groups on murine lymphocytes and antigen-presenting cells provided a potent, noninflammatory method of enhancing the immunogenicity of viral, bacterial, and protozoal subunit vaccines in mice.	WELLCOME RES LABS,DEPT PHARMACOL,LANGLEY COURT,S EDEN PK RD,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,DEPT CELL BIOL,BECKENHAM BR3 3BS,KENT,ENGLAND; WELLCOME RES LABS,DEPT DRUG SAFETY EVALUAT,BECKENHAM BR3 3BS,KENT,ENGLAND	GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories; GlaxoSmithKline; Wellcome Research Laboratories								ADA GL, 1990, LANCET, V335, P523, DOI 10.1016/0140-6736(90)90748-T; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CHARLES IG, 1989, P NATL ACAD SCI USA, V86, P3554, DOI 10.1073/pnas.86.10.3554; CHEDID L, 1976, P NATL ACAD SCI USA, V73, P2472, DOI 10.1073/pnas.73.7.2472; FURUKAWA KS, 1989, J EXP MED, V169, P583; GAO XM, 1990, J IMMUNOL, V144, P2883; GAO XM, 1991, J IMMUNOL, V147, P3268; GAO XM, 1989, J IMMUNOL, V143, P3007; GLENNY AT, 1926, CHEM IND         JUN, P415; GREGORIADIS G, 1989, IMMUNOLOGICAL ADJUVA; HART MK, 1990, J IMMUNOL, V145, P2677; KOFF WC, 1989, AIDS, V3, pS125, DOI 10.1097/00002030-198901001-00018; LASKY LA, 1986, SCIENCE, V233, P209, DOI 10.1126/science.3014647; LIFELY MR, 1991, VACCINE, V9, P60, DOI 10.1016/0264-410X(91)90318-Z; LIN YL, 1981, J EXP MED, V154, P225, DOI 10.1084/jem.154.2.225; MURPHY VF, 1990, PARASITOLOGY, V100, P177, DOI 10.1017/S0031182000061175; NOVOGRODSKY A, 1973, P NATL ACAD SCI USA, V70, P1824, DOI 10.1073/pnas.70.6.1824; PLAYFAIR JHL, 1990, LANCET, V335, P1263, DOI 10.1016/0140-6736(90)91316-3; RHODES J, 1990, J IMMUNOL, V145, P463; RHODES J, 1989, J IMMUNOL, V143, P1482; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; SCHILD GC, 1990, LANCET, V335, P1081, DOI 10.1016/0140-6736(90)92645-X; SCHWARTZ RH, 1985, ANNU REV IMMUNOL, V3, P237, DOI 10.1146/annurev.iy.03.040185.001321; SPRINGER TA, 1990, NATURE, V345, P426; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; TAYLOR PM, 1987, IMMUNOGENETICS, V26, P267, DOI 10.1007/BF00346521; YAP KL, 1978, NATURE, V273, P238, DOI 10.1038/273238a0; ZHENG B, UNPUB	28	54	59	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1560	1563		10.1126/science.1598588	http://dx.doi.org/10.1126/science.1598588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598588				2022-12-28	WOS:A1992HY07500030
J	MILTON, RCD; MILTON, SCF; KENT, SBH				MILTON, RCD; MILTON, SCF; KENT, SBH			TOTAL CHEMICAL SYNTHESIS OF A D-ENZYME - THE ENANTIOMERS OF HIV-1 PROTEASE SHOW DEMONSTRATION OF RECIPROCAL CHIRAL SUBSTRATE-SPECIFICITY	SCIENCE			English	Article							PROTEINASE; PEPTIDES	The D and L forms of the enzyme HIV-1 protease have been prepared by total chemical synthesis. The two proteins had identical covalent structures. However, the folded protein-enzyme enantiomers showed reciprocal chiral specificity on peptide substrates. That is, each enzyme enantiomer cut only the corresponding substrate enantiomer. Reciprocal chiral specificity was also evident in the effect of enantiomeric inhibitors. These data imply that the folded forms of the chemically synthesized D- and L-enzyme molecules are mirror images of one another in all elements of the three-dimensional structure. Enantiomeric proteins are expected to display reciprocal chiral specificity in all aspects of their biochemical interactions.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BERGMAN DA, 1992, FEB LORN C VICT; BRUINS AP, 1987, ANAL CHEM, V59, P2642, DOI 10.1021/ac00149a003; CHAIT BT, UNPUB; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; FERSHT A, 1977, ENZYME STRUCTURE MEC, P75; FRUTON JS, 1972, MOL LIFE, P53; HENKLEIN P, IN PRESS SOLID PHASE; KENT SBH, 1988, ANNU REV BIOCHEM, V57, P957, DOI 10.1146/annurev.bi.57.070188.004521; KENT SBH, 1989, VIRAL PROTEINASES TH, P223; KENT SBH, IN PRESS INNOVATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSSLICH HG, 1989, P NATL ACAD SCI USA, V86, P807, DOI 10.1073/pnas.86.3.807; MACKAY AL, 1989, NATURE, V342, P133, DOI 10.1038/342133a0; MASON SF, 1991, CHIRALITY, V3, P223, DOI 10.1002/chir.530030403; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MIRSKY AE, 1936, P NATL ACAD SCI USA, V22, P438; PASTEUR L, 1960, SOC CHIM PARIS, P1; RICHARDS AD, 1989, FEBS LETT, V247, P113, DOI 10.1016/0014-5793(89)81251-7; RICHARDSON JS, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P5; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHNOLZER M, IN PRESS INT J PEPT; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	25	320	357	2	98	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1445	1448		10.1126/science.1604320	http://dx.doi.org/10.1126/science.1604320			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604320				2022-12-28	WOS:A1992HX33700036
J	GREAVES, I; GRANT, AJ; HEATH, DA; MICHAEL, J; ADU, D				GREAVES, I; GRANT, AJ; HEATH, DA; MICHAEL, J; ADU, D			HYPERCALCEMIA - CHANGING CAUSES OVER THE PAST 10 YEARS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham								FISKEN R A, 1980, QJM, V196, P405; FISKEN RA, 1981, LANCET, V1, P202; HEATH D, 1991, CLIN ENDOCRINOL, V34, P155, DOI 10.1111/j.1365-2265.1991.tb00286.x; MALLUCHE H, 1990, KIDNEY INT, V38, P193, DOI 10.1038/ki.1990.187	4	16	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1284	1284		10.1136/bmj.304.6837.1284	http://dx.doi.org/10.1136/bmj.304.6837.1284			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606431	Green Published, Bronze			2022-12-28	WOS:A1992HV08600023
J	VOLPE, JJ				VOLPE, JJ			MECHANISMS OF DISEASE - EFFECT OF COCAINE USE ON THE FETUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INFANT-DEATH-SYNDROME; CEREBRAL BLOOD-FLOW; ASPARTATE GLUTAMATERGIC AGONIST; MATERNAL COCAINE; AUTO-REGULATION; SEROTONERGIC NEURONS; INUTERO EXPOSURE; ABUSING MOTHERS; NEWBORN PIGLETS; PREGNANCY		HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	VOLPE, JJ (corresponding author), CHILDRENS HOSP MED CTR, DEPT NEUROL, FEGAN 11, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							AIZENMAN E, 1990, NEUROSCI LETT, V116, P168, DOI 10.1016/0304-3940(90)90404-W; ALBUQUERQUE M L C, 1992, Pediatric Research, V31, p57A; ALBUQUERQUE M L C, 1992, Pediatric Research, V31, p27A; ALBUQUERQUE ML, 1991, PEDIATR RES, V29, pA56; AMARO H, 1989, PEDIATRICS, V84, P144; AMBRE JJ, 1982, J ANAL TOXICOL, V6, P26, DOI 10.1093/jat/6.1.26; ANDAY E, 1992, Pediatric Research, V31, p192A; ANDAY EK, 1989, DEV PHARMACOL THERAP, V12, P137, DOI 10.1159/000480959; ANDERSONBROWN T, 1990, BRAIN RES, V537, P197, DOI 10.1016/0006-8993(90)90358-I; AZMITIA EC, 1987, NEUROSCIENCE, V20, P47, DOI 10.1016/0306-4522(87)90005-4; BADA HS, 1991, PEDIATR RES, V29, pA202; BARPELED O, 1991, NEUROSCI LETT, V127, P173, DOI 10.1016/0304-3940(91)90787-T; BAUCHNER H, 1988, J PEDIATR-US, V113, P831, DOI 10.1016/S0022-3476(88)80009-X; BELCHER HME, 1991, PEDIATR RES, V29, pA7; BILLMAN D, 1991, PEDIATR RES, V29, pA251; BINGOL N, 1987, J PEDIATR-US, V110, P93, DOI 10.1016/S0022-3476(87)80297-4; BLACK VD, 1991, PEDIATR RES, V29, pA253; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHANEY NE, 1988, J PEDIATR-US, V112, P134, DOI 10.1016/S0022-3476(88)80139-2; CHASNOFF I, 1992, Pediatric Research, V31, p9A; CHASNOFF IJ, 1986, J PEDIATR-US, V108, P456, DOI 10.1016/S0022-3476(86)80896-4; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHASNOFF IJ, 1989, AM J DIS CHILD, V143, P583, DOI 10.1001/archpedi.1989.02150170085028; CHASNOFF IJ, 1992, PEDIATRICS, V89, P284; CHASNOFF IJ, 1989, JAMA-J AM MED ASSOC, V261, P1741, DOI 10.1001/jama.261.12.1741; CHASNOFF IJ, 1987, NEUROTOXICOL TERATOL, V9, P291, DOI 10.1016/0892-0362(87)90017-1; CHASNOFF IJ, 1990, 19TH P ALB BIRTH DEF, P57; CHEN XL, 1990, 20TH ANN M SOC NEUR, V16, P580; CHOUTEAU M, 1988, OBSTET GYNECOL, V72, P351; CHOW MJ, 1985, CLIN PHARMACOL THER, V38, P318, DOI 10.1038/clpt.1985.179; DACKIS CA, 1985, NEUROSCI BIOBEHAV R, V9, P469, DOI 10.1016/0149-7634(85)90022-3; DIXON SD, 1989, J PEDIATR-US, V115, P770, DOI 10.1016/S0022-3476(89)80661-4; DOBERCZAK TM, 1988, J PEDIATR-US, V113, P354, DOI 10.1016/S0022-3476(88)80283-X; DOMINGUEZ R, 1991, AM J DIS CHILD, V145, P688, DOI 10.1001/archpedi.1991.02160060106030; DOWEDWARDS DL, 1989, ANN NY ACAD SCI, V562, P280, DOI 10.1111/j.1749-6632.1989.tb21026.x; DOWEDWARDS DL, 1990, DEV BRAIN RES, V57, P263, DOI 10.1016/0165-3806(90)90052-Z; DOWEDWARDS DL, 1991, NEUROTOXICOL TERATOL, V13, P347, DOI 10.1016/0892-0362(91)90082-8; DOWEDWARDS DL, 1990, BRAIN RES DEV BRAIN, V53, P263; DURAND DJ, 1990, J PEDIATR-US, V117, P909, DOI 10.1016/S0022-3476(05)80133-7; DUSICK A M, 1992, Pediatric Research, V31, p201A; ELBIZRI H, 1991, PEDIATR RES, V29, P187, DOI 10.1203/00006450-199102000-00017; ELLENHORN M, 1988, MED TOXICOLOGY DIAGN, P641; FANTEL AG, 1989, TERATOLOGY, V39, P243, DOI 10.1002/tera.1420390306; FANTEL AG, 1990, TERATOLOGY, V42, P35, DOI 10.1002/tera.1420420106; FARRAR HC, 1989, J PEDIATR-US, V115, P665, DOI 10.1016/S0022-3476(89)80640-7; FERRIERO DM, 1989, ANN NEUROL, V26, P458; FRANK D A, 1992, Pediatric Research, V31, p247A; FRANK DA, 1988, PEDIATRICS, V82, P888; FRANK DA, 1990, J PEDIATR-US, V117, P622, DOI 10.1016/S0022-3476(05)80702-4; FRIED PA, 1989, NEUROTOXICOLOGY, V10, P577; FULROTH R, 1989, AM J DIS CHILD, V143, P905, DOI 10.1001/archpedi.1989.02150200057018; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GELBARD HA, 1990, DEV BRAIN RES, V56, P137, DOI 10.1016/0165-3806(90)90173-V; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; GLEASON CA, 1992, PEDIATR RES, V31, P645, DOI 10.1203/00006450-199206000-00021; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; GRAHAM K, 1989, JAMA-J AM MED ASSOC, V262, P3328, DOI 10.1001/jama.262.23.3328; GRIFFIN ML, 1989, ARCH GEN PSYCHIAT, V46, P122; HADEED AJ, 1989, PEDIATRICS, V84, P205; HANDLER A, 1991, AM J EPIDEMIOL, V133, P818, DOI 10.1093/oxfordjournals.aje.a115961; HANS SL, 1989, ANN NY ACAD SCI, V562, P195, DOI 10.1111/j.1749-6632.1989.tb21018.x; HEIER LA, 1991, AM J NEURORADIOL, V12, P951; HOFKOSH D, 1992, Pediatric Research, V31, p11A; HOYME HE, 1990, PEDIATRICS, V85, P743; HUME RF, 1989, AM J OBSTET GYNECOL, V161, P685, DOI 10.1016/0002-9378(89)90380-3; HURD WW, 1991, OBSTET GYNECOL, V78, P249; HURT H, 1992, Pediatric Research, V31, p251A; HURT H, 1992, Pediatric Research, V31, p11A; HURT H, 1991, PEDIATR RES, V29, pA257; HUTCHINGS DE, 1986, HDB BEHAVIORAL TERAT, P141; INABA T, 1978, CLIN PHARMACOL THER, V23, P547; KAISER K M, 1992, Pediatric Research, V31, p251A; KANDALL SR, 1991, PEDIATR RES, V29, pA92; KATIKANENI L D, 1992, Pediatric Research, V31, p251A; KAUFMANN WE, 1990, 20TH ANN M SOC NEUR, V16, P305; KNAPP S, 1972, SCIENCE, V177, P1209, DOI 10.1126/science.177.4055.1209; KOREN G, 1989, LANCET, V2, P1440; KRAMER LD, 1990, J CHILD NEUROL, V5, P60, DOI 10.1177/088307389000500115; KUBAN KCK, 1985, ANN NEUROL, V17, P539, DOI 10.1002/ana.410170603; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; Lakoski J M, 1988, NIDA Res Monogr, V88, P78; LAUDER JM, 1976, BRAIN RES, V107, P638, DOI 10.1016/0006-8993(76)90153-0; LAUDER JM, 1985, DEV BRAIN RES, V20, P107, DOI 10.1016/0165-3806(85)90092-6; LEDERMAN RP, 1978, AM J OBSTET GYNECOL, V132, P495, DOI 10.1016/0002-9378(78)90742-1; LIEN R, 1992, Pediatric Research, V31, p349A; LIEN R, 1991, PEDIATR RES, V29, pA222; LIFSCHITZ MH, 1985, PEDIATRICS, V75, P269; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LITTLE BB, 1991, OBSTET GYNECOL, V77, P361; LITTLE BB, 1989, OBSTET GYNECOL, V73, P157; LIU JP, 1991, DEV BRAIN RES, V60, P59, DOI 10.1016/0165-3806(91)90155-C; LUTIGER B, 1991, TERATOLOGY, V44, P405, DOI 10.1002/tera.1420440407; MADDEN JD, 1986, PEDIATRICS, V77, P209; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; MCLENAN D, 1992, Pediatric Research, V31, p212A; MITTLEMAN RE, 1989, J FORENSIC SCI, V34, P807; MITTLEMAN RE, 1989, J FORENSIC SCI, V34, P481; MOORE TR, 1986, AM J OBSTET GYNECOL, V155, P883, DOI 10.1016/S0002-9378(86)80044-8; MUELENAER A, 1991, PEDIATR RES, V29, pA326; NEERHOF MG, 1989, AM J OBSTET GYNECOL, V161, P633, DOI 10.1016/0002-9378(89)90368-2; NEUSPIEL DR, 1991, NEUROTOXICOL TERATOL, V13, P229, DOI 10.1016/0892-0362(91)90015-O; NEUSPIEL DR, 1991, J DEV BEHAV PEDIATR, V12, P55; O'BRIEN T P, 1992, Pediatric Research, V31, p214A; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; OSTERLOH JD, 1989, AM J DIS CHILD, V143, P791, DOI 10.1001/archpedi.1989.02150190041017; OSTREA EM, 1992, PEDIATRICS, V89, P107; OSTREA EM, 1989, J PEDIATR-US, V115, P474, DOI 10.1016/S0022-3476(89)80860-1; RAUM WJ, 1990, DEV BRAIN RES, V53, P230, DOI 10.1016/0165-3806(90)90011-M; RICHARDSON GA, 1991, NEUROTOXICOL TERATOL, V13, P455, DOI 10.1016/0892-0362(91)90095-E; RIVKIN M, 1989, PEDIATRICS, V84, P1101; ROCKHOLD RW, 1991, BRAIN RES BULL, V27, P721, DOI 10.1016/0361-9230(91)90052-L; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; ROSENBERG PA, 1991, P NATL ACAD SCI USA, V88, P4865, DOI 10.1073/pnas.88.11.4865; ROSS SB, 1969, EUR J PHARMACOL, V7, P270, DOI 10.1016/0014-2999(69)90091-0; RUSH D, 1989, ANN NY ACAD SCI, V562, P74, DOI 10.1111/j.1749-6632.1989.tb21008.x; RYAN L, 1987, NEUROTOXICOL TERATOL, V9, P295, DOI 10.1016/0892-0362(87)90018-3; SALAMY A, 1990, J PEDIATR-US, V117, P627, DOI 10.1016/S0022-3476(05)80703-6; SCHREIBER MD, 1992, PEDIATR RES, V31, P121, DOI 10.1203/00006450-199202000-00006; SCHULTZ S, 1989, MMWR-MORBID MORTAL W, V38, P825; SCHUTZMAN DL, 1991, PEDIATRICS, V88, P825; SEGAL DS, 1989, 19TH ANN M SOC NEUR, V15, P519; SHANNON M, 1989, PEDIATRICS, V83, P337; SHEMER AV, 1991, DEV BRAIN RES, V59, P59, DOI 10.1016/0165-3806(91)90029-I; SHIH L, 1988, INT J PEDIATR OTORHI, V15, P245, DOI 10.1016/0165-5876(88)90079-1; SINGER L, 1992, Pediatric Research, V31, p260A; SINGER LT, 1991, J PEDIATR-US, V119, P667, DOI 10.1016/S0022-3476(05)82426-6; SOBRIAN SK, 1990, PHARMACOL BIOCHEM BE, V35, P617, DOI 10.1016/0091-3057(90)90299-W; SPEAR LP, 1989, ANN NY ACAD SCI, V562, P290, DOI 10.1111/j.1749-6632.1989.tb21027.x; SPIRES MC, 1989, PEDIATR NEUROL, V5, P324, DOI 10.1016/0887-8994(89)90028-3; STERK C, 1988, LANCET, V1, P1052; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; STREISSGUTH AP, 1991, AM J OBSTET GYNECOL, V164, P1239, DOI 10.1016/0002-9378(91)90691-J; TWEED A, 1986, PEDIATR RES, V20, P516, DOI 10.1203/00006450-198606000-00007; TWEED WA, 1983, PEDIATR RES, V17, P246, DOI 10.1203/00006450-198304000-00002; ULTMANN MH, 1987, INT J NEUROSCI, V32, P661, DOI 10.3109/00207458709043320; VANDEBOR M, 1990, PEDIATRICS, V85, P733; VANDYKE C, 1982, SCI AM, V246, P128, DOI 10.1038/scientificamerican0382-128; VOLPE JJ, 1987, MAJOR PROBLEMS CLIN, V22; WARD SLD, 1990, J PEDIATR-US, V117, P876; Whitaker-Azmitia P M, 1987, Brain Res, V430, P285; WHITAKERAZMITIA PM, 1986, NEUROSCI LETT, V67, P307, DOI 10.1016/0304-3940(86)90327-7; WHITAKERAZMITIA PM, 1989, BRAIN RES, V497, P80, DOI 10.1016/0006-8993(89)90972-4; WHITAKERAZMITIA PM, 1990, DEV BRAIN RES, V57, P181, DOI 10.1016/0165-3806(90)90044-Y; WILSON GS, 1989, ANN NY ACAD SCI, V562, P183, DOI 10.1111/j.1749-6632.1989.tb21017.x; WILSON RJ, 1990, SOC NEUR ABSTR, V16, P252; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; WYATT RJ, 1988, JAMA-J AM MED ASSOC, V259, P2996, DOI 10.1001/jama.1988.03720200018014; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	149	271	273	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					399	407						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625714				2022-12-28	WOS:A1992JG35600007
J	SOLOMON, SD; GERRITY, ET; MUFF, AM				SOLOMON, SD; GERRITY, ET; MUFF, AM			EFFICACY OF TREATMENTS FOR POSTTRAUMATIC-STRESS-DISORDER - AN EMPIRICAL REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							COMBAT VETERANS; PTSD; TRIAL; PSYCHOTHERAPY; DEPRESSION; ALPRAZOLAM; PREVALENCE; PHENELZINE; IMIPRAMINE; SURVIVORS	Objective.-The purpose of this article is to review the empirical evidence for the efficacy of a range of treatments for posttraumatic stress disorder (PTSD). Reviewed studies focused on rape victims, combat veterans, the tragically bereaved, torture victims, accident victims, victims of physical assault, and child abuse victims. Data Sources.-Peer-reviewed journals (Psych-Info, MEDLINE), book chapters (PILOTS database), active investigators, abstracts from the 1990 and 1991 International Society for Traumatic Stress Studies. Study Selection.-We identified 255 English-language reports of treatment for PTSD. We restricted our focus to randomized, clinical trials that included a systematic assessment of PTSD using DSM-III or DSM-III-R criteria (N=11). Data Extraction.-Studies were assessed according to methodological strength: random assignment to the treatment of interest, and either an alternative treatment or control group; sample selection; and inclusion of statistical tests of significance. Data Synthesis.-Drug studies show a modest but clinically meaningful effect on PTSD. Stronger effects were found for behavioral techniques involving direct therapeutic exposure, particularly in terms of reducing PTSD intrusive symptoms. However, severe complications have also been reported from the use of these techniques in patients suffering from other psychiatric disorders. Studies of cognitive therapy, psychodynamic therapy, and hypnosis suggest that these approaches may also hold promise. However, further research is needed before any of these approaches can be pronounced effective as lasting treatment of PTSD. Conclusions.-Further studies should specifically address combined treatment approaches, optimal treatment length and timing, effects of comorbidity, and unstudied traumatized populations.			SOLOMON, SD (corresponding author), NIMH,DIV APPL & SERV RES,VIOLENCE & TRAUMAT STRESS RES BRANCH,ROCKVILLE,MD 20857, USA.							ABUEG FR, IN PRESS POSTTRAUMAT; ALLODI FA, 1991, J NERV MENT DIS, V179, P4, DOI 10.1097/00005053-199101000-00002; BALLENGER JC, 1988, ARCH GEN PSYCHIAT, V45, P413; BECKER JV, 1984, WOMEN HEALTH, V9, P5, DOI 10.1300/J013v09n04_02; Becker R. E., 1987, SOCIAL SKILLS TRAINI; Bernstein D.A., 1973, PROGR RELAXATION TRA; BLEICH A, 1986, BRIT J PSYCHIAT, V149, P365, DOI 10.1192/bjp.149.3.365; BOUDEWYNS PA, 1990, BEHAV THER, V21, P63, DOI 10.1016/S0005-7894(05)80189-3; BRAUN P, 1990, J CLIN PSYCHIAT, V51, P236; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; BROM D, 1989, J CONSULT CLIN PSYCH, V57, P607, DOI 10.1037/0022-006X.57.5.607; CHARNEY DS, 1981, ARCH GEN PSYCHIAT, V38, P1160; CLARK DM, 1985, J BEHAV THER EXP PSY, V16, P23, DOI 10.1016/0005-7916(85)90026-6; COOPER NA, 1989, BEHAV THER, V20, P381, DOI 10.1016/S0005-7894(89)80057-7; DAVIDSON J, 1992, BRIT J PSYCHIAT, V160, P309, DOI 10.1192/bjp.160.3.309; DAVIDSON J, 1990, ARCH GEN PSYCHIAT, V47, P259; DAVIDSON JRT, 1989, PSYCHOPHARMACOL BULL, V25, P422; DAVIDSON JRT, 1991, J ABNORM PSYCHOL, V100, P346, DOI 10.1037/0021-843X.100.3.346; DYE E, 1991, PSYCHOTHER, V28, P103, DOI 10.1037/0033-3204.28.1.103; FEIGHNER JP, 1983, JAMA-J AM MED ASSOC, V249, P3057, DOI 10.1001/jama.249.22.3057; FOA EB, 1989, BEHAV THER, V20, P155, DOI 10.1016/S0005-7894(89)80067-X; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; FOA EB, 1987, SEP NAT I MENT HLTH; FRANK JB, 1988, AM J PSYCHIAT, V145, P1289; Friedman MJ, 1991, J TRAUMA STRESS, V4, P67; HOROWITZ M, 1974, ARCH GEN PSYCHIAT, V31, P768; Horowitz M.J., 2011, STRESS RESPONSE SYND; Jacobson E., 1938, J ABNORM PSYCHOL; JHOROWITZ MJ, 1980, SPECIALIZED TECHNIQU, P162; Keane T. M., 1985, BEHAV THERAPIST, V8, P9; KEANE TM, 1990, J APPL SOC PSYCHOL, V20, P1776, DOI 10.1111/j.1559-1816.1990.tb01511.x; KEANE TM, 1989, BEHAV THER, V20, P245, DOI 10.1016/S0005-7894(89)80072-3; Kilpatrick D. G., 1985, TRAUMA ITS WAKE, V1, P113; KILPATRICK DG, 1987, CRIME DELINQUENCY, V33, P479, DOI 10.1177/0011128787033004005; Kilpatrick DG, 1982, BEHAV MED ASSESSMENT, P473, DOI DOI 10.1007/978-1-4684-4070-6_19; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; KRYSTAL JH, 1989, BEHAV THER, V20, P177, DOI 10.1016/S0005-7894(89)80068-1; KUDLER HS, 1989, AM J PSYCHIAT, V146, P1645; MCDOUGLE CJ, 1991, J CLIN PSYCHOPHARM, V11, P325; MEICHENBAUM DH, 1974, COGNITIVE BEHAVIOR M; MOWRER OH, 1983, FLOODING IMPLOSIVE T; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; PENISTON E G, 1986, Clinical Biofeedback and Health, V9, P35; POTMAN RK, 1991, J CLIN POSYCHIATRY, V52, P47; REGIER DA, 1988, ARCH GEN PSYCHIAT, V45, P977; REIST C, 1989, AM J PSYCHIAT, V146, P513; ROTHBAUM BO, IN PRESS POSTTRAUMAT; Schwartz L. S., 1990, J TRAUMA STRESS, V3, P221; SHEEHAN DV, 1982, DRUG THER, V7, P179; SHESTATZKY M, 1988, PSYCHIAT RES, V24, P149, DOI 10.1016/0165-1781(88)90057-1; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; STEKETTE G, 1987, J ANXIETY DIORD, V1, P69, DOI DOI 10.1016/0887-6185(87)90024-7; VANDERKOLK BA, 1987, J AFFECT DISORDERS, V13, P203, DOI 10.1016/0165-0327(87)90024-3; VERELLEN P, 1990, J APPLIED SOCIAL PSY, V20, P1789; WIDOM CS, 1989, SCIENCE, V24, P117; WOLPE J, 1973, PRACTICE BEHAVIOR TH; WYATT RJ, 1971, ARCH GEN PSYCHIAT, V24, P145; 1987, DIAGNOSTIC STATISTIC, P247; 1980, DIAGNOSTIC STATISTIC, P236	59	245	248	2	47	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	1992	268	5					633	638		10.1001/jama.268.5.633	http://dx.doi.org/10.1001/jama.268.5.633			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JF473	1629993				2022-12-28	WOS:A1992JF47300030
J	GRUNFELD, C; FEINGOLD, KR				GRUNFELD, C; FEINGOLD, KR			SEMINARS IN MEDICINE OF THE BETH-ISRAEL-HOSPITAL, BOSTON - METABOLIC DISTURBANCES AND WASTING IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR-NECROSIS-FACTOR; RESTING ENERGY-EXPENDITURE; LIPOPROTEIN-LIPASE ACTIVITY; LOW-DENSITY LIPOPROTEINS; HIV-INFECTED PATIENTS; AIDS-RELATED COMPLEX; FACTOR-ALPHA; CANCER CACHEXIA; PARENTERAL-NUTRITION; WEIGHT-LOSS		UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GRUNFELD, C (corresponding author), VET AFFAIRS MED CTR, MED SERV, METAB SECT 111F, 4150 CLEMENT ST, SAN FRANCISCO, CA 94121 USA.				NIDDK NIH HHS [DK40990] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040990] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADI S, 1992, J CLIN INVEST, V89, P1603, DOI 10.1172/JCI115755; BARTHOLEYNS J, 1987, INFECT IMMUN, V55, P2230, DOI 10.1128/IAI.55.9.2230-2233.1987; BEISEL WR, 1975, ANNU REV MED, V26, P9, DOI 10.1146/annurev.me.26.020175.000301; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER B, 1988, AM J MED, V85, P287, DOI 10.1016/0002-9343(88)90575-X; BEUTLER BA, 1985, J IMMUNOL, V135, P3969; BRENNAN MF, 1977, CANCER RES, V37, P2359; BROZEK J, 1946, Am Rev Sov Med, V4, P70; BURT ME, 1983, J SURG RES, V34, P303, DOI 10.1016/0022-4804(83)90076-8; CERAMI A, 1985, IMMUNOL LETT, V11, P173, DOI 10.1016/0165-2478(85)90165-8; CHAJEKSHAUL T, 1989, BIOCHIM BIOPHYS ACTA, V1001, P316, DOI 10.1016/0005-2760(89)90116-1; CHLEBOWSKI RT, 1989, AM J GASTROENTEROL, V84, P1288; DEMPSEY DT, 1984, CANCER-AM CANCER SOC, V53, P1265, DOI 10.1002/1097-0142(19840315)53:6<1265::AID-CNCR2820530609>3.0.CO;2-2; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DICKMEYER MS, 1991, 7 P INT C AIDS, V1, P231; DWORKIN BM, 1990, 6 P INT C AIDS SAN F, V1, P218; EHNHOLM C, 1982, ARTERIOSCLEROSIS, V2, P68, DOI 10.1161/01.ATV.2.1.68; FEINGOLD KR, 1991, ARTERIOSCLER THROMB, V11, P495, DOI 10.1161/01.ATV.11.3.495; FEINGOLD KR, 1989, ENDOCRINOLOGY, V125, P267, DOI 10.1210/endo-125-1-267; FEINGOLD KR, 1990, AM J PHYSIOL, V259, pE177, DOI 10.1152/ajpendo.1990.259.2.E177; FEINGOLD KR, 1987, J CLIN INVEST, V80, P184, DOI 10.1172/JCI113046; FELIG P, 1970, NEW ENGL J MED, V282, P166; Fliederbaum J, 1979, Curr Concepts Nutr, V7, P11; FLORES EA, 1989, J CLIN INVEST, V83, P1614, DOI 10.1172/JCI114059; FREDRIX EWHM, 1991, CANCER RES, V51, P6138; FRIED JC, 1990, ARCH INTERN MED, V150, P406, DOI 10.1001/archinte.150.2.406; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GRUNFELD C, 1989, J LIPID RES, V30, P579; GRUNFELD C, 1989, CANCER RES, V49, P2554; GRUNFELD C, 1990, ENDOCRINOLOGY, V127, P46, DOI 10.1210/endo-127-1-46; GRUNFELD C, 1990, CANCER RES, V50, P4233; GRUNFELD C, 1991, BIOTHERAPY, V3, P143, DOI 10.1007/BF02172087; GRUNFELD C, 1991, TRENDS ENDOCRIN MET, V2, P213, DOI 10.1016/1043-2760(91)90027-K; GRUNFELD C, 1989, AM J MED, V86, P27, DOI 10.1016/0002-9343(89)90225-8; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; GRUNFELD C, 1991, AM J MED, V90, P154, DOI 10.1016/0002-9343(91)80154-E; GRUNFELD C, 1992, AM J CLIN NUTR, V55, P455, DOI 10.1093/ajcn/55.2.455; Grunfeld C, 1991, SEMIN GASTROINTEST D, V2, P25; HANSELL DT, 1986, ANN SURG, V203, P240, DOI 10.1097/00000658-198603000-00003; HARRIS HW, 1990, J CLIN INVEST, V86, P696, DOI 10.1172/JCI114765; HELLERSTEIN MK, 1989, J CLIN INVEST, V84, P228, DOI 10.1172/JCI114145; HELLERSTEIN MK, IN PRESS J CLIN ENDO; HEYMSFIELD SB, 1982, AM J CLIN NUTR, V36, P680, DOI 10.1093/ajcn/36.4.680; HOMMES MJT, 1990, METABOLISM, V39, P1186, DOI 10.1016/0026-0495(90)90092-Q; HOMMES MJT, 1991, AM J CLIN NUTR, V54, P311, DOI 10.1093/ajcn/54.2.311; KAUFMANN RL, 1976, J INFECT DIS, V133, P548, DOI 10.1093/infdis/133.5.548; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; KETTELHUT IC, 1988, J CLIN INVEST, V81, P1384, DOI 10.1172/JCI113467; Keys A, 1950, BIOL HUMAN STARVATIO; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KOTLER DP, 1989, ARCH INTERN MED, V149, P901, DOI 10.1001/archinte.149.4.901; KOTLER DP, 1990, AM J CLIN NUTR, V51, P7, DOI 10.1093/ajcn/51.1.7; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KOTLER DP, 1991, AM J CLIN NUTR, V53, P149, DOI 10.1093/ajcn/53.1.149; KOTLER DP, 1990, JPEN-PARENTER ENTER, V14, P454, DOI 10.1177/0148607190014005454; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; KRAMER SM, 1988, CANCER RES, V48, P920; KRAUSS RM, 1990, ENDOCRINOLOGY, V127, P1016, DOI 10.1210/endo-127-3-1016; KRENTZ AJ, 1991, CLIN RES, V39, pA220; LAHDEVIRTA J, 1988, AM J MED, V85, P289, DOI 10.1016/0002-9343(88)90576-1; LAMBERT M, 1990, AM J MED, V89, P748, DOI 10.1016/0002-9343(90)90216-Z; LANG CH, 1985, AM J PHYSIOL, V248, pR471, DOI 10.1152/ajpregu.1985.248.4.R471; LANGSTEIN HN, 1991, CANCER RES, V51, P2302; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; MAHONY SM, 1988, BRIT J CANCER, V58, P345, DOI 10.1038/bjc.1988.216; MARTIN Z, 1991, 7TH INT C AIDS FLOR, V1, P46; MASSARO ER, 1986, J INTERFERON RES, V6, P655, DOI 10.1089/jir.1986.6.655; MATTHYS P, 1991, EUR J CANCER, V27, P182, DOI 10.1016/0277-5379(91)90483-T; MELCHIOR JC, 1991, AM J CLIN NUTR, V53, P437, DOI 10.1093/ajcn/53.2.437; MELCHIOR JC, 1991, 7TH INT C AIDS FLOR, V1, P293; MICHIE HR, 1989, ANN SURG, V209, P19, DOI 10.1097/00000658-198901000-00002; MILDVAN D, 1992, LANCET, V339, P453, DOI 10.1016/0140-6736(92)91058-G; MILLER TL, 1991, GASTROENTEROLOGY, V100, P1296, DOI 10.1016/0016-5085(91)90745-7; MORI M, 1991, CANCER RES, V51, P6656; MULLEN BJ, 1990, P SOC EXP BIOL MED, V193, P318; MULLIGAN HD, 1991, BRIT J CANCER, V63, P719, DOI 10.1038/bjc.1991.162; MULLIGAN K, 1992, FASEB J, V6, pA1942; NIXON DW, 1988, METABOLISM, V37, P1059, DOI 10.1016/0026-0495(88)90068-6; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; OLSEN EA, 1988, J AM ACAD DERMATOL, V19, P286, DOI 10.1016/S0190-9622(88)70173-5; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; PATTON JS, 1987, J CLIN INVEST, V80, P1587, DOI 10.1172/JCI113245; POPP MB, 1981, SURGERY, V90, P195; REDDY MM, 1988, J ACQ IMMUN DEF SYND, V1, P436; SALBE AD, 1991, CLIN RES, V39, pA385; SCUDERI P, 1986, LANCET, V2, P1364; SEMB H, 1987, J BIOL CHEM, V262, P8390; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHERRY BA, 1989, FASEB J, V3, P1956, DOI 10.1096/fasebj.3.8.2721856; SOCHER SH, 1988, J NATL CANCER I, V80, P595, DOI 10.1093/jnci/80.8.595; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; STEIN TP, 1990, METABOLISM, V39, P876, DOI 10.1016/0026-0495(90)90136-Z; STOVROFF MC, 1988, CANCER RES, V48, P4567; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; TANG WW, 1989, WESTERN J MED, V151, P627; TENG MN, 1991, P NATL ACAD SCI USA, V88, P3535, DOI 10.1073/pnas.88.9.3535; TERKELTAUB R, 1984, J CLIN INVEST, V73, P1719, DOI 10.1172/JCI111380; TIERNEY AR, 1991, 7TH INT C AIDS FLOR, V1, P247; TRACEY KJ, 1989, CANCER CELL-MON REV, V1, P62; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TREDGET EE, 1988, AM J PHYSIOL, V255, pE760, DOI 10.1152/ajpendo.1988.255.6.E760; VONROENN JH, 1988, ANN INTERN MED, V109, P840, DOI 10.7326/0003-4819-109-10-840; WAAGE A, 1986, SCAND J IMMUNOL, V24, P739, DOI 10.1111/j.1365-3083.1986.tb02194.x; WILMORE DW, 1974, ANN SURG, V180, P653, DOI 10.1097/00000658-197410000-00031; WOLFE RR, 1985, AM J PHYSIOL, V248, pE732, DOI 10.1152/ajpendo.1985.248.6.E732; YARCHOAN R, 1986, LANCET, V1, P575	106	368	377	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					329	337						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1620172				2022-12-28	WOS:A1992JF65500006
J	KUMAGAI, A; DUNPHY, WG				KUMAGAI, A; DUNPHY, WG			REGULATION OF THE CDC25 PROTEIN DURING THE CELL-CYCLE IN XENOPUS EXTRACTS	CELL			English	Article							FISSION YEAST; MITOTIC CONTROL; STEP PURIFICATION; DNA-REPLICATION; MESSENGER-RNA; M-PHASE; MITOSIS; KINASE; INVITRO; ACTIVATION	The cdc25 protein is a highly specific tyrosine phosphatase that triggers mitosis by dephosphorylating the cdc2 protein kinase. Using Xenopus extracts, we have found that the cdc25 protein is active at a low level throughout interphase. Near the onset of mitosis, the cdc25 protein undergoes a marked elevation in phosphatase activity that coincides with an extensive phosphorylation of the protein in its N-terminal region. In vitro dephosphorylation of this hyperphosphorylated form of cdc25 reduces its phosphatase activity back to the interphase level. Moreover, treatment of interphase Xenopus extracts with okadaic acid, a phosphatase inhibitor that accelerates the entry into mitosis, elicits both the premature hyperphosphorylation of cdc25 and the stimulation of its cdc2-specific tyrosine phosphatase activity. These experiments demonstrate the existence of a cdc25 regulatory system consisting of both a stimulatory kinase that phosphorylates a putative regulatory domain of the cdc25 protein and an inhibitory serine/threonine phosphatase that counteracts this kinase activity.			KUMAGAI, A (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.							BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DUNPHY WG, 1988, J CELL BIOL, V106, P2047, DOI 10.1083/jcb.106.6.2047; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fleig U N, 1991, Semin Cell Biol, V2, P195; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HARLOW E, 1988, ANTIBODIES LABORATOR; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; JESSUS C, 1991, DEVELOPMENT, V111, P813; Johnson B.F, 1989, MOL BIOL FISSION YEA, P243; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1989, J CELL SCI, V92, P131; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; Nigg E A, 1991, Semin Cell Biol, V2, P261; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sambrook J, 1989, MOL CLONING LABORATO; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M	53	360	374	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					139	151		10.1016/0092-8674(92)90540-S	http://dx.doi.org/10.1016/0092-8674(92)90540-S			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623517				2022-12-28	WOS:A1992JC95700015
J	GOLDHABER, SZ; HAMILTON, MA				GOLDHABER, SZ; HAMILTON, MA			BEVERLY-HILLS, 90210 - THE LAP BELTS DONT SHOW ON TV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	GOLDHABER, SZ (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA 02115, USA.							GOLDBAUM GM, 1986, JAMA-J AM MED ASSOC, V255, P2459, DOI 10.1001/jama.255.18.2459; ORSAY EM, 1988, JAMA-J AM MED ASSOC, V260, P3598, DOI 10.1001/jama.260.24.3598	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					200	200						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608137				2022-12-28	WOS:A1992JB27900023
J	MILLER, LH				MILLER, LH			THE CHALLENGE OF MALARIA	SCIENCE			English	Editorial Material											MILLER, LH (corresponding author), NIAID,MALARIA RES LAB,BETHESDA,MD 20892, USA.							[Anonymous], 1991, MALARIA OBSTACLES OP; ANXOLABEHERE D, 1988, MOL BIOL EVOL, V5, P252; GREENBERG AE, 1989, B WORLD HEALTH ORGAN, V67, P189; Harrison G, 1978, MOSQUITOES MALARIA M; JAROLIM P, 1991, P NATL ACAD SCI USA, V88, P11022, DOI 10.1073/pnas.88.24.11022; KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830; Macdonald G., 1957, EPIDEMIOLOGY CONTROL; MILLER LH, 1986, SCIENCE, V234, P1349, DOI 10.1126/science.2431481; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; WARBURG A, 1991, PARASITOL TODAY, V7, P179, DOI 10.1016/0169-4758(91)90127-A; WELLEMS TE, 1991, P NATL ACAD SCI USA, V88, P3382, DOI 10.1073/pnas.88.8.3382; 1992, LANCET, V339, P649	12	38	40	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					36	37		10.1126/science.1621092	http://dx.doi.org/10.1126/science.1621092			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621092				2022-12-28	WOS:A1992JC16500022
J	KARAGAS, MR; STUKEL, TA; GREENBERG, ER; BARON, JA; MOTT, LA; STERN, RS				KARAGAS, MR; STUKEL, TA; GREENBERG, ER; BARON, JA; MOTT, LA; STERN, RS			RISK OF SUBSEQUENT BASAL-CELL CARCINOMA AND SQUAMOUS-CELL CARCINOMA OF THE SKIN AMONG PATIENTS WITH PRIOR SKIN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-TRANSPLANTATION; HEMOGLOBIN ADDUCTS; CLINICAL-TRIAL; BETA-CAROTENE; FOLLOW-UP; MELANOMA; SMOKERS; SMOKING; PREVENTION; NONSMOKERS	Objective.-The primary aims of this study were to assess risk of subsequent basal and squamous cell skin cancer among patients with a prior history of these tumors and to examine these risks in relation to patient characteristics and life-style factors. Design.-Follow-up of participants in a randomized trial of betacarotene as a possible skin cancer preventive agent. Setting.-Clinical centers in Los Angeles, Calif, San Francisco, Calif, Minneapolis, Minn, and Hanover, NH. Participants.-Patients (n=1805) who were diagnosed as having a basal or squamous cell skin cancer between January 1980 and February 1986 and were free of skin cancer at study entry. Main Outcome Measure.-Time from study entry to first new occurrence of basal and squamous cell skin cancer. Results.-The estimated risk of developing one or more new skin cancers was 35% at 3 years and 50% at 5 years. New skin cancers tended to be of the same cell type as the previous skin cancers. For both basal and squamous cell skin cancer, risk was higher among patients who were male, were over the age of 60 years, had more prior skin cancers, had severe actinic skin damage, or who burned easily with sun exposure. Compared with those who had never smoked, the rate of subsequent squamous cell skin cancer was higher among current smokers (rate ratio, 2.01; 95% confidence interval, 1.21 to 3.34) and former smokers (rate ratio, 1.62; 95% confidence interval, 1.07 to 2.47) and increased with both duration and amount smoked. There was no clear relationship between smoking and basal cell skin cancer; the rate appeared lower among heavy smokers but was unrelated to duration of smoking. Conclusions.-Persons with a prior nonmelanoma skin cancer had a substantial 5-year risk of developing another tumor of the same histologic type. Number of previous skin.cancers, solar damage, and skin sensitivity to sun exposure were particularly related to this risk. The increased risk of squamous cell skin cancer associated with cigarette smoking merits further study.	DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,NORRIS COTTON CANC CTR,HANOVER,NH 03756; HARVARD UNIV,BETH ISRAEL HOSP,BOSTON,MA 02215; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756	Dartmouth College; Norris Cotton Cancer Center; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	KARAGAS, MR (corresponding author), DARTMOUTH COLL,DEPT COMMUNITY & FAMILY MED,HINMAN BOX 7927,HANOVER,NH 03755, USA.			Stukel, Therese/0000-0002-2951-1360	NATIONAL CANCER INSTITUTE [P30CA023108, U01CA032934] Funding Source: NIH RePORTER; NCI NIH HHS [CA23108, CA32934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKIN M, 1980, BIOMETRICS, V36, P173, DOI 10.2307/2530509; AUBRY F, 1985, CANCER-AM CANCER SOC, V55, P907, DOI 10.1002/1097-0142(19850215)55:4<907::AID-CNCR2820550433>3.0.CO;2-5; BARTSCH H, 1990, JNCI-J NATL CANCER I, V82, P1826, DOI 10.1093/jnci/82.23.1826; CARMELLA SG, 1990, CANCER RES, V50, P5438; COX DR, 1984, ANAL SURVIVAL DATA, P91; Doll R, 1981, THE CAUSES OF CANCER; DUBIN N, 1990, INT J EPIDEMIOL, V19, P811, DOI 10.1093/ije/19.4.811; DZUBOW L, 1991, CANC SKIN, P74; ENGEL A, 1988, ARCH DERMATOL, V124, P72, DOI 10.1001/archderm.124.1.72; EPSTEIN E, 1973, ARCH DERMATOL, V108, P798, DOI 10.1001/archderm.108.6.798; GALLAGHER RP, 1990, J AM ACAD DERMATOL, V23, P413, DOI 10.1016/0190-9622(90)70234-9; GHADIALLY FN, 1963, CANCER, V126, P603; GILES GG, 1988, BRIT MED J, V296, P13, DOI 10.1136/bmj.296.6614.13; GLASS AG, 1989, JAMA-J AM MED ASSOC, V262, P2097, DOI 10.1001/jama.262.15.2097; GREEN A, 1990, INT J CANCER, V46, P356, DOI 10.1002/ijc.2910460303; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; GREENBERG ER, 1989, CONTROL CLIN TRIALS, V10, P153; HELLBERG D, 1988, AM J OBSTET GYNECOL, V158, P910, DOI 10.1016/0002-9378(88)90093-2; HERSEY P, 1983, MED J AUSTRALIA, V2, P425, DOI 10.5694/j.1326-5377.1983.tb122565.x; HOOVER R, 1973, LANCET, V2, P55; HOXTELL EO, 1977, ARCH DERMATOL, V113, P436, DOI 10.1001/archderm.113.4.436; Hunter David J., 1990, Annals of Epidemiology, V1, P13; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KRICKER A, 1991, INT J CANCER, V48, P650, DOI 10.1002/ijc.2910480504; LEE ET, 1980, STATISTICAL METHODS; MAHONY JF, 1982, MED J AUSTRALIA, V2, P426, DOI 10.5694/j.1326-5377.1982.tb132505.x; PETRAKIS NL, 1978, SCIENCE, V199, P303, DOI 10.1126/science.619458; ROBINSON JK, 1987, CANCER, V60, P118, DOI 10.1002/1097-0142(19870701)60:1<118::AID-CNCR2820600122>3.0.CO;2-1; SCHREIBER MM, 1990, J AM ACAD DERMATOL, V23, P1114, DOI 10.1016/0190-9622(90)70343-G; SCOTTO J, 1982, CANCER EPIDEMIOL, P996; SCOTTO J, 1981, NIH822433 US DEP HLT; SILVERST.H, 1970, BRIT J CANCER, V24, P235, DOI 10.1038/bjc.1970.27; STAEHELIN J, 1990, LANCET, V336, P502, DOI 10.1016/0140-6736(90)92047-L; THALL PF, 1988, BIOMETRICS, V44, P197, DOI 10.2307/2531907; URBACH F, 1972, ENV CANCER, P355; URBACH F, 1984, TOPICS PHOTOMEDICINE; VITALIANO PP, 1980, ARCH DERMATOL, V116, P454, DOI 10.1001/archderm.116.4.454; VITASA BC, 1990, CANCER, V65, P2811, DOI 10.1002/1097-0142(19900615)65:12<2811::AID-CNCR2820651234>3.0.CO;2-U; WEINSTOCK MA, 1991, ARCH DERMATOL, V127, P1194, DOI 10.1001/archderm.127.8.1194; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; 1986, SUGI SUPPLEMENTAL LI, P437	41	234	238	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3305	3310		10.1001/jama.267.24.3305	http://dx.doi.org/10.1001/jama.267.24.3305			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597912				2022-12-28	WOS:A1992HY94400029
J	LI, N; TUOMILEHTO, J; DOWSE, G; ALBERTI, KG; ZIMMET, P; MIN, Z; CHITSON, P; GAREEBOO, H; YOU, CH; FAREED, D				LI, N; TUOMILEHTO, J; DOWSE, G; ALBERTI, KG; ZIMMET, P; MIN, Z; CHITSON, P; GAREEBOO, H; YOU, CH; FAREED, D			ELECTROCARDIOGRAPHIC ABNORMALITIES AND ASSOCIATED FACTORS IN CHINESE LIVING IN BEIJING AND IN MAURITIUS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; RISK-FACTORS; CARDIOVASCULAR-DISEASES; INSULIN; MEN; CALIFORNIA; STROKE; HAWAII; JAPAN	Objective-To compare the prevalence of electrocardiographic abnormalities and to evaluate the association between these abnormalities and the levels of coronary heart disease among Chinese living in different environments. Design-Cross sectional surveys. Setting-Beijing, China, and the island of Mauritius. Subjects-Random samples of people aged 35-64 years in Beijing (621 men, 642 women) in 1984 and in Mauritius among Chinese (137 men, 130 women) and non-Chinese (1265 men, 1432 women) in 1987. Main outcome measures-Prevalence of electrocardiographic abnormalities suggesting coronary heart disease and of associated risk factors. Results-Prevalence of electrocardiographic abnormalities suggesting coronary heart disease was significantly lower in Beijing (4.0%) than in Mauritian Chinese (24.3%) and Mauritian non-Chinese (24-5%). Mean serum concentrations of total and non-high density lipoprotein cholesterol were lower in Beijing Chinese than in Mauritian Chinese, but smoking and hypertension were slightly more prevalent. Overall, men with electrocardiographic abnormalities had higher risk factor levels than those with a normal electrocardiogram regardless of ethnic origin. Conclusions-The prevalence of coronary heart disease and associated risk factors was different among Chinese living in two different environments: in Beijing in the People's Republic of China and in Mauritius. Chinese, who traditionally have a very low frequency of coronary heart disease, are by no means protected against coronary heart disease and other non-communicable diseases. Therefore, primary prevention of coronary heart disease is a major challenge for preventive medicine in China, as well as in many other developing countries.	NATL PUBL HLTH INST,DEPT EPIDEMIOL,ELIMAENKATU 25A 6TH FLOOR,SF-00510 HELSINKI,FINLAND; BEIJING HEART LUNG & BLOOD VESSEL MED CTR,BEIJING,PEOPLES R CHINA; INT DIABET INST,CAULFIELD,AUSTRALIA; MED SCH NEWCASTLE UPON TYNE,NEWCASTLE TYNE,ENGLAND; MINIST HLTH,NONCOMMUNICABLE DIS OFF,PORT LOUIS,MAURITIUS; WHO,PORT LOUIS,MAURITIUS	Finland National Institute for Health & Welfare; Newcastle University - UK; World Health Organization			Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776	NIDDK NIH HHS [DK-25446] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1988, BMJ, V297, P319; AUSTIN MA, 1987, AM J EPIDEMIOL, V125, P308, DOI 10.1093/oxfordjournals.aje.a114531; Brissonnette L G, 1985, World Health Stat Q, V38, P163; BYINGTON R, 1979, US DHEW NIH791610 PU, P340; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; GONG LS, 1989, NEW HORIZONS PREVENT, P163; HUGHES K, 1990, J EPIDEMIOL COMMUN H, V44, P29, DOI 10.1136/jech.44.1.29; HUGHES K, 1989, Annals Academy of Medicine Singapore, V18, P245; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; LEVY D, 1988, AM HEART J, V116, P266, DOI 10.1016/0002-8703(88)90099-3; LIAO YL, 1987, CIRCULATION, V75, P347, DOI 10.1161/01.CIR.75.2.347; LINDA MG, 1984, HUM BIOL, V56, P449; LUO C, 1986, TIANJIN MED MED J, V1, P10; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; NAN L, 1991, J HYPERTENS, V9, P859, DOI 10.1097/00004872-199109000-00014; ORCHARD TJ, 1983, AM J EPIDEMIOL, V118, P326, DOI 10.1093/oxfordjournals.aje.a113639; PAJAK A, 1988, World Health Statistics Quarterly, V41, P115; REAVEN GM, 1987, LANCET, V2, P435; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; ROSE G, 1977, LANCET, V1, P105; ROSE G, 1978, BRIT HEART J, V40, P636; SCHWARTZKOPFF W, 1990, ATHEROSCLEROSIS, V82, P253, DOI 10.1016/0021-9150(90)90047-M; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STAMLER J, 1989, INT J EPIDEMIOL, V18, pS3; TAO SC, 1989, INT J EPIDEMIOL, V18, pS159; TOBEY TA, 1981, METABOLISM, V30, P165, DOI 10.1016/0026-0495(81)90167-0; TREMBATH RC, 1987, BRIT MED J, V294, P1577, DOI 10.1136/bmj.294.6587.1577; Tuomilehto J, 1987, World Health Stat Q, V40, P171; UUSITUPA M, 1983, AM HEART J, V106, P753, DOI 10.1016/0002-8703(83)90099-6; VARTIAINEN E, 1991, PUBLIC HEALTH REP, V106, P41; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186; WU ZS, 1987, ACTA MED SCAND S, V728, P60; XIANG KS, 1989, DIABETES, V38, P17, DOI 10.2337/diabetes.38.1.17; YAO CH, 1985, CHINESE MED J-PEKING, V98, P439; YAO CH, 1988, CHINESE MED J-PEKING, V101, P901; YU YH, 1986, PREV MED, V15, P643; ZHANG HX, 1989, NEW HORIZONS PREVENT, P259; ZHONG XL, 1982, CHINESE MED J-PEKING, V95, P423; ZIMMET P, 1989, DIBETES MELLITUS PAT, P5; 1988, EUR HEART J S, V9, P1	48	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1596	1601		10.1136/bmj.304.6842.1596	http://dx.doi.org/10.1136/bmj.304.6842.1596			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628086	Green Published, Bronze			2022-12-28	WOS:A1992JA43600019
J	ORENTLICHER, D				ORENTLICHER, D			CORPORAL PUNISHMENT IN THE SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											ORENTLICHER, D (corresponding author), AMER MED ASSOC, ETH & HLTH POLICY COUNSEL, CHICAGO, IL 60610 USA.							BEHRMAN RE, 1992, NELSON TXB PEDIATRIC, P48; BELLAK L, 1974, AM J ORTHOPSYCHIAT, V44, P503, DOI 10.1111/j.1939-0025.1974.tb00904.x; BLOCK N, 1988, CHILDRENS LEGAL RIGH, V9, P21; Bongiovanni A. F., 1979, CORPORAL PUNISHMENT, P351; CLARKE JR, 1982, CHILD YOUTH SERVICES, V4, P47; Dubanoski R A, 1983, Child Abuse Negl, V7, P271; HARPER FV, 1986, LAW TORTS, P389; HOLMES SJ, 1988, PSYCHIATRY, V51, P24, DOI 10.1080/00332747.1988.11024377; HYMAN IA, 1979, CORPORAL PUNISHMENT, P394; JONES VF, 1990, COMPREHENSIVE CLASSR, P253; KAUFMAN J, 1987, AM J ORTHOPSYCHIAT, V57, P186, DOI 10.1111/j.1939-0025.1987.tb03528.x; LAMBERTH J, 1979, CORPORAL PUNISHMENT, P384; LARZELERE RE, 1986, J FAMILY VIOLENCE, V1, P27; MCCORD J, 1991, SOC PROBL, V38, P167, DOI 10.1525/sp.1991.38.2.03a00040; POOLE SR, 1991, PEDIATRICS, V88, P162; RADIN N, 1988, URBAN EDUC, V22, P476, DOI 10.1177/004208598802200407; ROHNER RP, 1991, J MARRIAGE FAM, V53, P681, DOI 10.2307/352743; RUDOLPH AM, 1991, RUDOLPHS PEDIATRICS, P30; RUST JO, 1983, J SCHOOL PSYCHOL, V21, P91, DOI 10.1016/0022-4405(83)90032-8; RUTTER M, 1980, PEDIATRICS, V65, P208, DOI 10.1542/peds.65.2.208; STRAUS MA, 1991, SOC PROBL, V38, P133, DOI 10.1525/sp.1991.38.2.03a00010; USHKOW MC, 1991, PEDIATRICS, V88, P173; WISE JH, 1979, CORPORAL PUNISHMENT, P373; 1980, AM J PUBLIC HEALTH, V70, P308; 1978, J LAW EDUC, V7, P1; 1985, 134TH P HOUS DEL ANN, P88; 1985, RESTATEMENT LAW 2ND; 1989, CORPORAL PUNISHMENT; 1987, 1986 ELEMENTARY SECO	29	9	9	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3205	3208						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX918	1593744				2022-12-28	WOS:A1992HX91800032
J	ALPHEY, L; JIMENEZ, J; WHITECOOPER, H; DAWSON, I; NURSE, P; GLOVER, DM				ALPHEY, L; JIMENEZ, J; WHITECOOPER, H; DAWSON, I; NURSE, P; GLOVER, DM			TWINE, A CDC25 HOMOLOG THAT FUNCTIONS IN THE MALE AND FEMALE GERMLINE OF DROSOPHILA	CELL			English	Article							FISSION YEAST; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; MITOTIC INDUCER; GENETIC-CONTROL; CELL-DIVISION; MELANOGASTER; ACTIVATION; EMBRYOS; MITOSIS	twine is the second homolog of the fission yeast gene cdc25 to be found in Drosophila. Both string and twine cDNAs can rescue a temperature-sensitive cdc25 mutation in fission yeast, but not a deletion. We detect the expression of string but not twine transcripts in the proliferating cells of newly cellularized embryos, in third instar larval brains, and in imaginal discs. Both genes are abundantly expressed in nurse cells during oogenesis, the maternal transcripts persisting throughout the syncytial stage of embryonic development. In the testis, twine transcripts are seen in the growing stage of premeiotic cysts. Analysis of a twine mutant suggests a requirement for the gene during oogenesis, during syncytial embryonic development, and for male meiosis. Meiosis does not occur in homozygous twine males, which produce cysts containing 16 rather than 64 spermatids.	FAC CIENCIAS MALAGA,DEPT BIOL CELULAR & GENET,UNIDAD GENET,E-29017 MALAGA,SPAIN; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT CELL BIOL,NEW HAVEN,CT 06536; UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,IMPERIAL CANC RES FUND,CELL CYCLE GRP,OXFORD OX1 3QU,ENGLAND	Universidad de Malaga; Yale University; University of Oxford	ALPHEY, L (corresponding author), UNIV DUNDEE,CELL CYCLE GENET GRP,CANC RES CAMPAIGN LABS,DUNDEE DD1 4HN,SCOTLAND.		jimenez, juan/AAB-5357-2019; White-Cooper, Helen/A-4633-2010; MARTINEZ, J JIMENEZ/I-7959-2017	jimenez, juan/0000-0002-3851-7393; White-Cooper, Helen/0000-0002-3373-8023; MARTINEZ, J JIMENEZ/0000-0002-3851-7393; Glover, David/0000-0003-0956-0103; Alphey, Luke/0000-0002-2916-3802				ASHBURNER M, 1990, GENETICS, V126, P679; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; DOREE M, 1990, CURR OPINC ELL BIOL, V2, P169; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FOE VE, 1989, DEVELOPMENT, V107, P1; FREEMAN M, 1986, CELL, V46, P457, DOI 10.1016/0092-8674(86)90666-5; FREEMAN M, 1987, GENE DEV, V1, P924, DOI 10.1101/gad.1.9.924; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GONZALEZ C, 1989, GENET RES, V54, P205, DOI 10.1017/S0016672300028664; GONZALEZ C, 1990, J CELL SCI, V96, P605; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GRALLERT B, 1990, MOL GEN GENET, V222, P473, DOI 10.1007/BF00633860; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JIMENEZ J, 1990, EMBO J, V9, P3565, DOI 10.1002/j.1460-2075.1990.tb07567.x; JIMENEZ J, 1991, TRENDS GENET, V7, P40, DOI 10.1016/0168-9525(91)90226-G; King R. C., 1970, OVARIAN DEV DROSOPHI; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEHNER CF, 1990, EMBO J, V9, P3573, DOI 10.1002/j.1460-2075.1990.tb07568.x; LINDSLEY DL, 1980, GENETICS BIOL DROS D, V2, P226; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MORENO S, 1991, NATURE, V351, P194, DOI 10.1038/351194b0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PINES J, 1990, New Biologist, V2, P389; PURO J, 1977, CHROMOSOMA, V63, P273, DOI 10.1007/BF00327454; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1989, CELL, V57, P295, DOI 10.1016/0092-8674(89)90967-7; RUSSELL P, 1987, CELL, V49, P569, DOI 10.1016/0092-8674(87)90459-4; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHUPBACH T, 1989, GENETICS, V121, P101; SHAMANSKI FL, 1991, CELL, V66, P1289, DOI 10.1016/0092-8674(91)90050-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041	55	182	185	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					977	988		10.1016/0092-8674(92)90616-K	http://dx.doi.org/10.1016/0092-8674(92)90616-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606618				2022-12-28	WOS:A1992HY79200009
J	ROSSITER, EJR				ROSSITER, EJR			REFLECTIONS OF A WHISTLE-BLOWER	NATURE			English	Editorial Material																		BRIGGS, 1981, NEW CONSIDERATIONS O; BRIGGS, 1980, RES VET SCI, V28, P199; BRIGGS, REPRODUCTION S, V4, P79; BRIGGS, 1980, B POST GRADUATE COMM, V36, P148; BRIGGS M, 1981, CONTRACEPTION, V23, P463, DOI 10.1016/0010-7824(81)90074-3; BRIGGS M, 1980, 10TH P WORLD C FERT, P79; BRIGGS M, 1980, B POST GRADUATE COMM, V36, P148	7	14	15	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					434	436		10.1038/357434a0	http://dx.doi.org/10.1038/357434a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608440				2022-12-28	WOS:A1992HY05200021
J	WALLER, PC; WOOD, SM; LANGMAN, MJS; BRECKENRIDGE, AM; RAWLINS, MD				WALLER, PC; WOOD, SM; LANGMAN, MJS; BRECKENRIDGE, AM; RAWLINS, MD			REVIEW OF COMPANY POSTMARKETING SURVEILLANCE STUDIES	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To review postmarketing surveillance studies sponsored by the pharmaceutical industry since the introduction of voluntary guidelines in 1987 and to evaluate their contribution to monitoring drug safety. Design - Retrospective analysis of the information submitted to the Medicines Control Agency on postmarketing surveillance studies. Setting - United Kingdom. Main outcome measures - Study designs, projected and actual sample sizes, provision of interim and final reports, number of suspected serious adverse reactions reported, identification of new drug safety hazards. Results - 31 studies had been conducted under the guidelines, of which 27 were prospective and four retrospective. Nine studies had at least one comparator group, the remainder were uncontrolled. The median projected sample size for the studies was 5600 patients. Only five studies had achieved at least 75% of the projected sample size. 11 studies had been abandoned, predominantly because of difficulties in recruitment, and 15 were ongoing. One study had identified an important new safety hazard. Conclusions - Company postmarketing surveillance studies have made only a limited contribution to the assessment of drug safety, principally because of weak study designs and difficulties in recruitment. The guidelines require modification to take this experience into account.	COMM SAFETY MED,ADVERSE REACT GRP,LONDON SW8 5BR,ENGLAND; COMM SAFETY MED,SUBCOMM SAFETY EFFICACY & ADVERSE REACT,LONDON SW8 5BR,ENGLAND		WALLER, PC (corresponding author), MED CONTROL AGCY,PHARMACOVIGILANCE UNIT,MARKET TOWERS,LONDON SW8 5NQ,ENGLAND.							RAWLINS MD, 1991, BRIT MED J, V302, P223, DOI 10.1136/bmj.302.6770.223; 1987, ADVERSE DRUG REACT, P62; 1988, BMJ, V296, P399	3	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1470	1472		10.1136/bmj.304.6840.1470	http://dx.doi.org/10.1136/bmj.304.6840.1470			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611368	Bronze, Green Published			2022-12-28	WOS:A1992HY55300020
J	HANSSON, BS; LJUNGBERG, H; HALLBERG, E; LOFSTEDT, C				HANSSON, BS; LJUNGBERG, H; HALLBERG, E; LOFSTEDT, C			FUNCTIONAL SPECIALIZATION OF OLFACTORY GLOMERULI IN A MOTH	SCIENCE			English	Article							PHEROMONE-SENSITIVE NEURONS; DROSOPHILA-MELANOGASTER; ANTENNAL LOBE; BULB; DEUTOCEREBRUM; PROJECTION; BRAIN	The specific function of the glomerular structures present in the antennal lobes or olfactory bulbs of organisms ranging from insects to humans has been obscure because of limitations in neuronal marking methods. By tracing individual neurons in the moth Agrotis segetum, it was determined that physiologically distinct types of pheromone receptor neurons project axons to different regions of the macroglomerular complex (MGC). Each glomerulus making up the MGC has a specific functional identity, initially processing information about one specific pheromone component. This indicates that, at least through the first stage of synapses, olfactory information moves through labeled lines.	UNIV LUND,DEPT ZOOL,S-22362 LUND,SWEDEN	Lund University	HANSSON, BS (corresponding author), UNIV LUND,DEPT ECOL,S-22362 LUND,SWEDEN.		Hansson, Bill/G-2774-2013; Löfstedt, Christer/G-2016-2014	Hansson, Bill/0000-0002-4811-1223; Löfstedt, Christer/0000-0002-3116-6922				ARNOLD G, 1987, CR ACAD SCI III-VIE, V305, P271; ASTIC L, 1987, BRAIN RES, V424, P144, DOI 10.1016/0006-8993(87)91204-2; BOECKH J, 1979, J COMP PHYSIOL, V132, P235, DOI 10.1007/BF00614495; BURROWS M, 1982, J COMP PHYSIOL A, V15, P447; Christensen T.A., 1987, P457; CHRISTENSEN TA, 1991, J COMP PHYSIOL A, V169, P259; HANSSON BS, 1991, J COMP NEUROL, V312, P264, DOI 10.1002/cne.903120209; HOSL M, 1990, J COMP PHYSIOL A, V167, P321, DOI 10.1007/BF00192567; JASTREBOFF PJ, 1984, P NATL ACAD SCI-BIOL, V81, P5250, DOI 10.1073/pnas.81.16.5250; Kaissling KE, 1974, BIOCH SENSORY FUNCTI, P243; LOFSTEDT C, 1982, J CHEM ECOL, V8, P1305, DOI 10.1007/BF00987764; MATSUMOTO SG, 1981, PROC R SOC SER B-BIO, V213, P249, DOI 10.1098/rspb.1981.0066; MELLON D, 1990, J COMP NEUROL, V296, P253, DOI 10.1002/cne.902960205; OBERMAYER M, 1980, NEUROANATOMICAL TECH, P406; PEDERSEN PE, 1986, J COMP NEUROL, V250, P93, DOI 10.1002/cne.902500109; RODRIGUES V, 1988, BRAIN RES, V453, P299, DOI 10.1016/0006-8993(88)90170-9; ROWELL CHF, 1963, Q J MICROSC SCI, V104, P81; SCHNEIDERMAN AM, 1982, NATURE, V298, P844, DOI 10.1038/298844a0; SHANBHAG SR, 1992, CELL TISSUE RES, V267, P273, DOI 10.1007/BF00302965; STOCKER RF, 1983, CELL TISSUE RES, V232, P237, DOI 10.1007/BF00213783; VANDERPERS JNC, 1978, J INSECT PHYSIOL, V24, P337, DOI 10.1016/0022-1910(78)90033-1	21	188	198	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1313	1315		10.1126/science.1598574	http://dx.doi.org/10.1126/science.1598574			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598574				2022-12-28	WOS:A1992HW13500031
J	LEDERMAN, LM				LEDERMAN, LM			THE ADVANCEMENT OF SCIENCE	SCIENCE			English	Editorial Material									AMER ASSOC ADV SCI,WASHINGTON,DC 20036; UNIV CHICAGO,DEPT PHYS,CHICAGO,IL 60637	University of Chicago	LEDERMAN, LM (corresponding author), UNIV CHICAGO,ENRICO FERMI INST,CHICAGO,IL 60637, USA.							ATKINSON RC, 1990, SCIENCE, V248, P425, DOI 10.1126/science.248.4954.425; BROMLEY DA, 1982, SCIENCE, V215, P1035, DOI 10.1126/science.215.4536.1035; GLASS B, 1971, SCIENCE, V171, P23, DOI 10.1126/science.171.3966.23; KULA W, 1985, MEASURES MAN; LEDERMAN LM, 1984, SCI AM, V251, P40, DOI 10.1038/scientificamerican1184-40; PASSELL P, 1992, NY TIMES        0209, pE5; Reich R., 1991, WORK NATIONS; TEICH AH, 1992, CHRONICLE HIGHE 0122, pA52; WEAVER W, 1951, SCIENCE, V114, P471; 1992, 1992 M AAAS CHIC; 1991, FEDERALLY FUNDED RES	11	10	10	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1119	1124		10.1126/science.256.5060.1119	http://dx.doi.org/10.1126/science.256.5060.1119			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589785				2022-12-28	WOS:A1992HV19200008
J	WATSON, AJM				WATSON, AJM			ABC OF COLORECTAL DISEASES - DIARRHEA	BRITISH MEDICAL JOURNAL			English	Article											WATSON, AJM (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1302	1304		10.1136/bmj.304.6837.1302	http://dx.doi.org/10.1136/bmj.304.6837.1302			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606437	Green Published, Bronze			2022-12-28	WOS:A1992HV08600032
J	KENDRICK, KM; LEVY, F; KEVERNE, EB				KENDRICK, KM; LEVY, F; KEVERNE, EB			CHANGES IN THE SENSORY PROCESSING OF OLFACTORY SIGNALS INDUCED BY BIRTH IN SHEEP	SCIENCE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL SLICES; MATERNAL-BEHAVIOR; BULB; RAT; NOREPINEPHRINE; PARTURITION; STIMULATION; ASPARTATE; OXYTOCIN	After giving birth, sheep and many other species form a selective bond with their offspring based on the sense of smell. Processing of olfactory signals is altered to allow the animals to perform this selective recognition. Lamb odors have little effect on either neurotransmitter release or electrical activity of neurons in the olfactory bulb before birth. However, after birth there is an increase in the number of mitral cells, the principal cells of the olfactory bulb, that respond to lamb odors, which is associated with increased cholinergic and noradrenergic neurotransmitter release. Selective recognition of lambs is accompanied by increased activity of a subset of mitral cells and release of glutamate and gamma-aminobutyric acid (GABA) from the dendrodendritic synapses between the mitral and granule cells. The relation between the release of each transmitter after birth also suggests an increased efficacy of glutamate-evoked GABA release.	INRA,COMPORTEMENT ANIM LAB,F-37380 NOUZILLY,FRANCE; UNIV CAMBRIDGE,SUBDEPT ANIM BEHAV,CAMBRIDGE CB3 8AA,ENGLAND	INRAE; University of Cambridge	KENDRICK, KM (corresponding author), AFRC,INST ANIM PHYSIOL & GENET RES,CAMBRIDGE CB2 4AT,ENGLAND.			Kendrick, Keith/0000-0002-0371-5904				ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BALDWIN BA, 1974, ANIM BEHAV, V22, P220, DOI 10.1016/S0003-3472(74)80072-2; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; FREEMAN WJ, 1982, PSYCHOPHYSIOLOGY, V19, P44, DOI 10.1111/j.1469-8986.1982.tb02598.x; GERVAIS R, 1984, ELECTROEN CLIN NEURO, V57, P462, DOI 10.1016/0013-4694(84)90076-2; GODFREY DA, 1980, NEUROSCIENCE, V5, P273, DOI 10.1016/0306-4522(80)90103-7; GRAY CM, 1986, BEHAV NEUROSCI, V100, P585, DOI 10.1037/0735-7044.100.4.585; HIGASHIMA M, 1988, EXP BRAIN RES, V72, P37, DOI 10.1007/BF00248498; KENDRICK KM, 1988, BRAIN RES, V439, P1, DOI 10.1016/0006-8993(88)91455-2; KENDRICK KM, 1988, BRAIN RES, V442, P171, DOI 10.1016/0006-8993(88)91447-3; KENDRICK KM, 1991, PHYSIOL BEHAV, V50, P595, DOI 10.1016/0031-9384(91)90551-X; KENDRICK KM, 1991, CURR SEP, V10, P96; KENDRICK KM, 1991, METHODS NEUROSCI, V4, P3; KENDRICK KM, 1991, MICRODIALYSIS NEUROS, P327; KEVERNE EB, 1982, NATURE, V296, P148, DOI 10.1038/296148a0; KEVERNE EB, 1983, SCIENCE, V219, P81, DOI 10.1126/science.6849123; LEVY F, 1983, PHYSIOL BEHAV, V31, P687, DOI 10.1016/S0031-9384(83)80004-3; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; PISSONNIER D, 1985, PHYSIOL BEHAV, V35, P361, DOI 10.1016/0031-9384(85)90309-9; Poindron P., 1980, ADV STUD BEHAV, V11, P75; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; Rozin P., 1976, NEURAL MECHANISMS LE, P3; SHEPHERD GM, 1972, PHYSIOL REV, V52, P864, DOI 10.1152/physrev.1972.52.4.864; SHIPLEY MT, 1985, BRAIN RES, V329, P294, DOI 10.1016/0006-8993(85)90537-2; SMITH FV, 1966, ANIM BEHAV, V14, P120, DOI 10.1016/S0003-3472(66)80019-2; STANTON PK, 1985, J NEUROSCI, V5, P2169; SULLIVAN RM, 1989, J NEUROSCI, V9, P3998; SULLIVAN RM, 1987, DEV BRAIN RES, V35, P301; TAYLOR JG, 1991, BIOL CYBERN, V64, P301, DOI 10.1007/BF00199593	30	206	207	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					833	836		10.1126/science.1589766	http://dx.doi.org/10.1126/science.1589766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589766				2022-12-28	WOS:A1992HT23500044
J	DUFFY, TP				DUFFY, TP			THE RED BARON	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DUFFY, TP (corresponding author), YALE UNIV, SCH MED,DEPT INTERNAL MED,HEMATOL SECT,WWW4, POB 3333, NEW HAVEN, CT 06510 USA.							ASHER R, 1951, LANCET, V260, P339; BEAN W. B., 1959, PERSPECTIVES IN BIOL AND MED, V2, P347; CLARKE E, 1958, AM J MED, V25, P6, DOI 10.1016/0002-9343(58)90192-X; HUMPHRIES SR, 1988, BRIT J PSYCHIAT, V152, P416, DOI 10.1192/bjp.152.3.416; LEATHERMAN JW, 1984, MEDICINE, V63, P343, DOI 10.1097/00005792-198411000-00002; Luce J M, 1978, Pharos Alpha Omega Alpha Honor Med Soc, V41, P19; SCHLESINGER RD, 1989, SOUTHERN MED J, V82, P210, DOI 10.1097/00007611-198902000-00016; SULLIVAN CA, 1991, CLIN PEDIATR, V30, P112, DOI 10.1177/000992289103000213	8	18	19	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					408	411		10.1056/NEJM199208063270608	http://dx.doi.org/10.1056/NEJM199208063270608			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625715				2022-12-28	WOS:A1992JG35600008
J	ANDERSEN, RM; LYTTLE, CS; KOHRMAN, CH; LEVEY, GS; CLEMENTS, MM				ANDERSEN, RM; LYTTLE, CS; KOHRMAN, CH; LEVEY, GS; CLEMENTS, MM			NATIONAL STUDY OF INTERNAL-MEDICINE MANPOWER .19. TRENDS IN INTERNAL-MEDICINE RESIDENCY TRAINING-PROGRAMS	ANNALS OF INTERNAL MEDICINE			English	Article						INTERNSHIP AND RESIDENCY; HEALTH MANPOWER; EDUCATION, MEDICAL; SPECIALTIES, MEDICAL	PRIMARY CARE	The National Study of Internal Medicine Manpower (NaSIMM) reports on the results of its 1989-1990 census of residency programs. The results are integrated into an organizational model identifying inputs, process, outputs, and environment of medical training programs. The number of residents entering internal medicine continues to grow at a relatively rapid pace. This growth is largely accounted for by foreign citizens who are graduates of foreign medical schools (AFMGs). Residents are spending an increasing proportion of their time in ambulatory care settings, but, thus far, this ambulatory care training has occurred primarily in hospital clinics and emergency rooms. The proportion of a program's residents entering general internal medicine was found in a multiple regression analysis to be negatively associated with the number of subspecialty programs located in the training hospital, the percent of AFMG residents in the program, and the presence of a preliminary track in the program.	UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA; MERCK & CO INC, MED & SCI AFFAIRS, RAHWAY, NJ 07065 USA	University of California System; University of California Los Angeles; Merck & Company								ANDERSEN RM, 1990, ANN INTERN MED, V113, P243, DOI 10.7326/0003-4819-113-3-243; ANDERSEN RM, 1989, ANN INTERN MED, V110, P922, DOI 10.7326/0003-4819-110-11-922; BABBOTT D, 1991, ANN INTERN MED, V114, P16, DOI 10.7326/0003-4819-114-1-16; CROWLEY AE, 1988, JAMA-J AM MED ASSOC, V260, P1049, DOI 10.1001/jama.1988.03410080019002; JACOBY I, 1991, JAMA-J AM MED ASSOC, V112, P1046; KASSLER WJ, 1991, ACAD MED, V66, P41, DOI 10.1097/00001888-199101000-00012; LEWIS CE, 1991, ANN INTERN MED, V114, P1, DOI 10.7326/0003-4819-114-1-1; LIPKIN M, 1990, ANN INTERN MED, V112, P371, DOI 10.7326/0003-4819-112-5-371; LYTTLE CS, 1991, ANN INTERN MED, V114, P36, DOI 10.7326/0003-4819-114-1-36; ROSS M, 1982, MED CARE, V20, P235, DOI 10.1097/00005650-198202000-00009; SCHWARTZ MD, 1991, ANN INTERN MED, V114, P6, DOI 10.7326/0003-4819-114-1-6; SCOTT WR, 1987, ORG RATIONAL NATURAL, P23; SIMMONDS AC, 1990, ACAD MED, V65, P640, DOI 10.1097/00001888-199010000-00009; TAYLOR AD, 1990, ACAD MED, V65, P216, DOI 10.1097/00001888-199003000-00018; Thompson, 1967, ORG ACTION; WEIL PA, 1978, ANN INTERN MED, V89, P702, DOI 10.7326/0003-4819-89-5-702; WITZBURG RA, 1988, J GEN INTERN MED, V3, P48, DOI 10.1007/BF02595756; 1990, NRMP DATA, P14; 1989, 1989 1990 DIRECTORY; 1988, GUIDE EVALUATION RES, P1; 1990, AHA GUIDE HLTH CARE	21	34	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					243	250		10.7326/0003-4819-117-3-243	http://dx.doi.org/10.7326/0003-4819-117-3-243			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616219				2022-12-28	WOS:A1992JF30400012
J	JACKMAN, WM; BECKMAN, KJ; MCCLELLAND, JH; WANG, XZ; FRIDAY, KJ; ROMAN, CA; MOULTON, KP; TWIDALE, N; HAZLITT, HA; PRIOR, MI; OREN, J; OVERHOLT, ED; LAZZARA, R				JACKMAN, WM; BECKMAN, KJ; MCCLELLAND, JH; WANG, XZ; FRIDAY, KJ; ROMAN, CA; MOULTON, KP; TWIDALE, N; HAZLITT, HA; PRIOR, MI; OREN, J; OVERHOLT, ED; LAZZARA, R			TREATMENT OF SUPRAVENTRICULAR TACHYCARDIA DUE TO ATRIOVENTRICULAR NODAL REENTRY BY RADIOFREQUENCY CATHETER ABLATION OF SLOW-PATHWAY CONDUCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PARKINSON-WHITE SYNDROME; RETROGRADE BLOCK; SURGICAL CURE; PRESERVATION; JUNCTION; ATRIUM	Background. Atrioventricular nodal reentrant tachycardia (AVNRT), the most common form of supraventricular tachycardia, results from conduction through a reentrant circuit comprising fast and slow atrioventricular nodal pathways. Antiarrhythmic-drug therapy is not consistently successful in controlling this rhythm disturbance. Catheter ablation of the fast pathway with radiofrequency current eliminates AVNRT, but it can produce heart block. We hypothesized that catheter ablation of the site of insertion of the slow pathway into the atrium would eliminate AVNRT while leaving normal (fast-pathway) atrioventricular nodal conduction intact. Methods and Results. Eighty patients with symptomatic AVNRT were studied. Retrograde slow-pathway conduction (in which the earliest retrograde atrial potential was recorded at the posterior septum, close to the coronary sinus) was present in 33 patients. The retrograde atrial potential was preceded by a potential consistent with activation of the atrial end of the slow pathway (A(SP)). In 46 of the 47 patients without retrograde slow-pathway cont duction, a potential with the same characteristics as the A(SP) potential was recorded during sinus rhythm. Radiofrequency current delivered through a catheter to the A(SP) site (in the posteroseptal right atrium or coronary sinus) abolished or modified slow-pathway conduction in 78 patients, eliminating AVNRT without affecting normal atrioventricular nodal conduction. In the single patient without A(SP), the application of radiofrequency current to the proximal coronary sinus ablated the fast pathway and AVNRT. Atrioventricular block occurred in one patient (1.3 percent) with left bundle-branch block, after inadvertent ablation of the right bundle branch. AVNRT has not recurred in any patient during a mean (+/-SD) follow-up of 15.5+/-11.3 months. Electrophysiologic study 4.3+/-3.3 months after ablation in 32 patients demonstrated normal atrioventricular nodal conduction without AVNRT. Conclusions. Catheter ablation of the atrial end of the slow pathway using radiofrequency current, guided by A(SP) potentials, can eliminate AVNRT with very little risk of atrioventricular block.			JACKMAN, WM (corresponding author), UNIV OKLAHOMA,HLTH SCI CTR,DEPT MED,POB 26901,RM 5SP300,OKLAHOMA CITY,OK 73190, USA.				NHLBI NIH HHS [R01-HL39670] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039670] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUERNFEIND RA, 1978, AM J CARDIOL, V42, P499, DOI 10.1016/0002-9149(78)90947-5; CALKINS H, 1991, NEW ENGL J MED, V324, P1612, DOI 10.1056/NEJM199106063242302; COX JL, 1987, CIRCULATION, V76, P1329, DOI 10.1161/01.CIR.76.6.1329; EPSTEIN LM, 1989, CIRCULATION, V80, P757, DOI 10.1161/01.CIR.80.4.757; GUIRAUDON GM, 1990, ANN THORAC SURG, V49, P565, DOI 10.1016/0003-4975(90)90302-M; HAISSAGUERRE M, 1989, NEW ENGL J MED, V320, P426, DOI 10.1056/NEJM198902163200704; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; JACKMAN WM, 1991, CIRCULATION, V83, P1562, DOI 10.1161/01.CIR.83.5.1562; JOHNSON DC, 1987, J THORAC CARDIOV SUR, V93, P913; JOSEPHSON ME, 1976, CIRCULATION, V54, P430, DOI 10.1161/01.CIR.54.3.430; KUNZE KP, 1988, DEUT MED WOCHENSCHR, V113, P1343, DOI 10.1055/s-2008-1067817; LEE MA, 1991, CIRCULATION, V83, P827, DOI 10.1161/01.CIR.83.3.827; MARQUEZMONTES J, 1983, CHEST, V83, P690, DOI 10.1378/chest.83.4.690; PORTILLO B, 1984, AM J CARDIOL, V53, P1570, DOI 10.1016/0002-9149(84)90581-2; PRITCHETT ELC, 1979, CIRCULATION, V60, P440, DOI 10.1161/01.CIR.60.2.440; ROSS DL, 1985, J AM COLL CARDIOL, V6, P1383, DOI 10.1016/S0735-1097(85)80229-1; SUNG RJ, 1981, CIRCULATION, V64, P1059, DOI 10.1161/01.CIR.64.5.1059; SUNG RJ, 1990, CARDIAC ELECTROPHYSI, P513; WU D, 1978, AM J CARDIOL, V41, P1045, DOI 10.1016/0002-9149(78)90856-1	19	921	957	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					313	318		10.1056/NEJM199207303270504	http://dx.doi.org/10.1056/NEJM199207303270504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1620170				2022-12-28	WOS:A1992JF65500004
J	COMETTA, A; BAUMGARTNER, JD; LEE, ML; HANIQUE, G; GLAUSER, MP				COMETTA, A; BAUMGARTNER, JD; LEE, ML; HANIQUE, G; GLAUSER, MP			PROPHYLACTIC INTRAVENOUS ADMINISTRATION OF STANDARD IMMUNE GLOBULIN AS COMPARED WITH CORE-LIPOPOLYSACCHARIDE IMMUNE GLOBULIN IN PATIENTS AT HIGH-RISK OF POSTSURGICAL INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GRAM-NEGATIVE BACTEREMIA; SALMONELLA-MINNESOTA; SEPTIC SHOCK; IGG ANTIBODY; BACTERIAL-INFECTIONS; ESCHERICHIA-COLI; ROUGH MUTANTS; IMMUNIZATION; PROTECTION; ENDOTOXIN	Background. Infections and their sequelae are a major cause of death among patients admitted to the surgical intensive care unit (ICU). Studies of passive immunotherapy with standard intravenous immune globulin and hyperimmune globulin directed against gram-negative core lipopolysaccharide to prevent gram-negative infections and their serious systemic complications have had equivocal results in such patients. Methods. We performed a double-blind study to assess the efficacy of standard immune globulin and core-lipopolysaccharide hyperimmune globulin in preventing infections in surgical patients at high risk. The patients received standard immune globulin (400 mg per kilogram of body weight), hyperimmune globulin (400 mg per kilogram), or placebo (25 percent albumin, 8 ml per kilogram) weekly, for a maximum of four doses while in the ICU. Results. A total of 352 patients were enrolled, and 329 could be evaluated. The number of patients in whom infections developed was significantly lower in the group receiving standard immune globulin than in the placebo group (36 of 109 vs. 53 of 112 patients, P = 0.03), as was the incidence of pneumonia (15 vs. 30 cases, P = 0.04), especially pneumonia due to gram-negative bacteria (5 vs. 16 cases, P = 0.02). The number of days spent in the ICU and the total days spent in the hospital were lower in the standard immune globulin group (medians of 2 and 7.5 days fewer; P = 0.02 and 0.06, respectively). In contrast, the hyperimmune globulin had no detectable prophylactic effect on infections (50 of 108 patients, with 25 cases of pneumonia). The rate of systemic infections and shock was similar in the three study groups, and hospital mortality did not differ significantly among them. Conclusions. Intravenous immune globulin given prophylactically to selected high-risk patients in the surgical ICU can reduce the incidence of infection. Core-lipopolysaccharide hyperimmune globulin is not effective in preventing gram-negative infections and their systemic complications.	CHU VAUDOIS,DEPT INTERNAL MED,DIV INFECT DIS,CH-1011 LAUSANNE,SWITZERLAND; BAXTER HLTHCARE CORP,HYLAND DIV,GLENDALE,CA; HOP ST LUC,SURG INTENS CARE UNIT,BRUSSELS,BELGIUM	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Baxter International Inc								BARTLETT JG, 1987, LABORATORY DIAGNOSIS; Baumgartner J D, 1991, Infect Dis Clin North Am, V5, P915; BAUMGARTNER JD, 1987, REV INFECT DIS, V9, P194; BAUMGARTNER JD, 1991, J INFECT DIS, V163, P769, DOI 10.1093/infdis/163.4.769; BAUMGARTNER JD, 1985, LANCET, V2, P59; BAUMGARTNER JD, 1989, J INFECT DIS, V160, P347, DOI 10.1093/infdis/160.2.347; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BRYAN CS, 1983, REV INFECT DIS, V5, P629; CALANDRA T, 1988, J INFECT DIS, V158, P312, DOI 10.1093/infdis/158.2.312; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; COX DR, 1978, STATISTICAL ANAL SER, P231; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DAVIS CE, 1978, J EXP MED, V147, P1007, DOI 10.1084/jem.147.4.1007; DEMARIA A, 1985, LANCET, V1, P1363; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARNER JS, 1988, AM J INFECT CONTROL, V16, P177; GLINZ W, 1985, INTENS CARE MED, V11, P288, DOI 10.1007/BF00273538; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HEUMANN D, 1991, J INFECT DIS, V163, P762, DOI 10.1093/infdis/163.4.762; Hodgin L A, 1976, Infection, V4, P5, DOI 10.1007/BF01638340; JOHNS M, 1983, J INFECT DIS, V147, P57, DOI 10.1093/infdis/147.1.57; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LAFORCE FM, 1981, AM J MED, V70, P664, DOI 10.1016/0002-9343(81)90593-3; LEE ET, 1980, STATISTICAL METHODS, P144; MARTIN MA, 1989, 29TH INT C ANT AG CH, P153; MCCABE WR, 1972, J IMMUNOL, V108, P601; MCCABE WR, 1972, NEW ENGL J MED, V287, P261, DOI 10.1056/NEJM197208102870601; MCCABE WR, 1988, J INFECT DIS, V158, P291, DOI 10.1093/infdis/158.2.291; MCCUTCHAN JA, 1983, SCHWEIZ MED WOCHEN S, V113, P40; MCGOWAN JE, 1975, J INFECT DIS, V132, P316, DOI 10.1093/infdis/132.3.316; RANSON JHC, 1976, SURG GYNECOL OBSTET, V143, P209; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WENZEL R, 1991, 31ST INT C ANT AG CH, P294; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; ZINNER SH, 1976, J INFECT DIS, V133, P37, DOI 10.1093/infdis/133.1.37; 1992, INFECT DIS, V165, P695; 1988, NEW ENGL J MED, V319, P902; 1987, NEW ENGL J MED, V317, P659	43	106	106	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					234	240						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614464				2022-12-28	WOS:A1992JE38100004
J	CALDWELLBROWN, D; STERN, RS; LIN, AN; CARTER, DM				CALDWELLBROWN, D; STERN, RS; LIN, AN; CARTER, DM			LACK OF EFFICACY OF PHENYTOIN IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANCHORING FIBRILS; COLLAGENASE	Background. Recessive dystrophic epidermolysis bullosa is an uncommon, severely disabling, heritable disorder characterized by abnormal fragility of the skin. Open trials have suggested that phenytoin is an effective treatment, and this therapy is now widely used. Methods. To determine the efficacy of phenytoin in the treatment of recessive dystrophic epidermolysis bullosa, we performed a randomized, double-blind, placebo-controlled, crossover trial in 36 patients. Each treatment was given for five to seven months, separated by a two-month period. We measured the total number of blisters and erosions on the entire body, the size of three plaques containing blisters and erosions, and the number of blisters and erosions in the three plaques at the beginning and end of each treatment period in each patient. Results. Twenty-two patients completed both courses of therapy, seven patients completed one course, and seven patients withdrew before completing a single course. There was no significant difference in disease activity between phenytoin treatment and placebo treatment, as measured by changes in the number of blisters and erosions on the entire body (7 percent decrease vs. 6 percent increase), in the area of three designated plaques (0.4 percent decrease vs. 0.2 percent increase), or in the number of blisters and erosions in the designated plaques (12 percent decrease vs. 31 percent increase). Conclusions. Phenytoin is not an effective treatment for patients with recessive dystrophic epidermolysis bullosa.	ROCKEFELLER UNIV,INVEST DERMATOL LAB,1230 YORK AVE,NEW YORK,NY 10021; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02215	Rockefeller University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School					NIA NIH HHS [AG00282, AG04993] Funding Source: Medline; FDA HHS [FD01261] Funding Source: Medline; FOOD AND DRUG ADMINISTRATION [R01FD001261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004993] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); FDA HHS; FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUER EA, 1980, NEW ENGL J MED, V303, P776, DOI 10.1056/NEJM198010023031402; BAUER EA, 1988, ARCH DERMATOL, V124, P734, DOI 10.1001/archderm.124.5.734; BAUER EA, 1978, J EXP MED, V148, P1378, DOI 10.1084/jem.148.5.1378; BRIGGAMAN RA, 1975, J INVEST DERMATOL, V65, P203, DOI 10.1111/1523-1747.ep12598208; COOPER TW, 1984, ARCH DERMATOL, V120, P490, DOI 10.1001/archderm.120.4.490; EISENBERG M, 1978, AUSTRALAS J DERMATOL, V19, P1, DOI 10.1111/j.1440-0960.1978.tb00177.x; KERO M, 1984, BRIT J DERMATOL, V110, P177, DOI 10.1111/j.1365-2133.1984.tb07464.x; KERO M, 1984, ACTA DERM-VENER    S, V110, P1; LIN AN, 1989, J PEDIATR-US, V114, P349, DOI 10.1016/S0022-3476(89)80550-5; TIDMAN MJ, 1985, J INVEST DERMATOL, V84, P374, DOI 10.1111/1523-1747.ep12265460; WINBERG JO, 1989, J INVEST DERMATOL, V92, P82, DOI 10.1111/1523-1747.ep13071274	11	31	37	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					163	167		10.1056/NEJM199207163270305	http://dx.doi.org/10.1056/NEJM199207163270305			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608407				2022-12-28	WOS:A1992JD31900005
J	FOX, RC; YOUZWYSHYN, GP; KRAUSE, DW				FOX, RC; YOUZWYSHYN, GP; KRAUSE, DW			POST-JURASSIC MAMMAL-LIKE REPTILE FROM THE PALEOCENE	NATURE			English	Article								MAMMAL-LIKE reptiles of the Order Therapsida document the emergence of mammals from more primitive synapsids1 and are of unique zoological and palaeontological interest on that account2. Therapsids, first appearing in the Early Permian3, were thought to become extinct in the Middle Jurassic4,5, soon after the Late Triassic origin of mammals6. Here, however, we report the discovery of a therapsid from the late Palaeocene, 100 million years younger7 than the youngest previous occurrence of the order. This discovery nearly doubles the stratigraphic range of therapsids and furnishes their first record from the Cenozoic. The documenting fossils, an incomplete dentary containing three teeth, and four isolated teeth from other, conspecific individuals (Fig. 1), are from the Paskapoo Formation, at Cochrane, Alberta, Canada, from beds yielding a diverse mammalian fauna of early Tiffanian age8. These specimens are catalogued in the collections of the University of Alberta Laboratory for Vertebrate Paleontology (UALVP) and provide the basis for a new taxon, as named and described below. Class Reptilia Subclass Synapsida Order Therapsida Suborder Cynodontia Chronoperatidae fam. nov. Type genus Chronoperates gen. nov. Chronoperates paradoxus gen. et sp. nov.	UNIV ALBERTA,DEPT ZOOL,EDMONTON T6G 2E9,ALBERTA,CANADA; SUNY STONY BROOK,DEPT ANAT SCI,STONY BROOK,NY 11794	University of Alberta; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	FOX, RC (corresponding author), UNIV ALBERTA,DEPT GEOL,VERTEBRATE PALEONTOL LAB,EDMONTON T6G 2E9,ALBERTA,CANADA.							BONAPARTE JF, 1975, J PALEONTOL, V49, P931; Carlson S., 1990, SKELETAL BIOMINERALI, V1, P531; Carroll RL, 1988, VERTEBRATE PALEONTOL; Cassiliano M.L., 1979, P150; CHARLESWORTH E, 1854, REP BR ASS ADV SCI, V25, P80; CLARK JM, 1989, SCIENCE, V244, P1064, DOI 10.1126/science.244.4908.1064; Clemens W.A., 1980, Zitteliana, V5, P51; CUI GH, 1987, VERTEBRAT PALASIATIC, V25, P245; Estes R., 1988, P119; FOX RC, 1990, DAWN AGE MAMMALS NO, P51; FRASER NC, 1985, NATURE, V314, P161, DOI 10.1038/314161a0; GAUTHIER J, 1988, PHYLOGENETIC RELATIO, P16; GOULD SJ, 1970, EARTH-SCI REV, V6, P77, DOI 10.1016/0012-8252(70)90027-9; Harland W. B., 1989, GEOLOGIC TIME SCALE; Hopson J.A., 1986, P83; HOPSON JA, 1987, AM BIOL TEACH, V49, P16, DOI 10.2307/4448410; LAURIN M, 1990, NATURE, V345, P249, DOI 10.1038/345249a0; PEYER BERNHARD, 1956, SCHWEIZ PALAEONTOL ABHANDL, V72, P1; Prothero D.R., 1981, Bulletin of the American Museum of Natural History, V167, P281; SHUBIN NH, 1991, SCIENCE, V251, P1063, DOI 10.1126/science.251.4997.1063; SIMPSON GEORGE GAYLORD, 1948, BULL AMER MUS NAT HIST, V91, P1; Simpson GG, 1926, AM J SCI, V12, P87; WILD R, 1978, Bollettino della Societa Paleontologica Italiana, V17, P176	23	15	15	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					233	235		10.1038/358233a0	http://dx.doi.org/10.1038/358233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630490				2022-12-28	WOS:A1992JD58700053
J	THEROUX, P; WATERS, D; LAM, J; JUNEAU, M; MCCANS, J				THEROUX, P; WATERS, D; LAM, J; JUNEAU, M; MCCANS, J			REACTIVATION OF UNSTABLE ANGINA AFTER THE DISCONTINUATION OF HEPARIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SUBCUTANEOUS HEPARIN; PLATELET-AGGREGATION; THROMBIN INHIBITION; VEIN THROMBOSIS; ASPIRIN; PREVENTION; HIRUDIN; INJURY; TRIAL	Heparin is an effective, widely used treatment for unstable angina. Among patients enrolled in a double-blind, randomized, placebo-controlled trial comparing intravenous heparin, aspirin, both treatments, and neither during the acute phase of unstable angina, we encountered patients in whom unstable angina was reactivated after heparin was discontinued. Methods. The study population included 403 of the original 479 patients in the trial who had completed six days of blinded therapy without refractory angina or myocardial infarction. After the discontinuation of therapy, clinical events, including reactivation of unstable angina and myocardial infarction occurring within 96 hours after hospitalization, were closely monitored. Results. Early reactivation occurred in 14 of the 107 patients who received heparin alone, as compared with only 5 patients in each of the other three study groups (P<0.01). These reactivations required urgent intervention (thrombolysis, angioplasty, or coronary-bypass surgery) in 11 patients treated with heparin alone, but in only 2 patients in the other groups combined (P<0.01). Four of the six patients who had a myocardial infarction during a reactivation of their disease were in the heparin group. Reactivations in this group occurred in a cluster a mean (+/-SD) of 9.5+/-5 hours after the discontinuation of the study drug but were randomly distributed over the initial 96 hours in the other three groups. Conclusions, Although heparin is beneficial in treating unstable angina, the disease process may be reactivated within hours of the discontinuation of this drug. Concomitant therapy with aspirin may prevent this withdrawal phenomenon.			THEROUX, P (corresponding author), MONTREAL HEART INST, 5000 BELANGER ST, MONTREAL H1T 1C8, QUEBEC, CANADA.							[Anonymous], 1988, LANCET, V2, P349; BAUER KA, 1985, J CLIN INVEST, V76, P826, DOI 10.1172/JCI112040; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; CINES DB, 1987, NEW ENGL J MED, V316, P581, DOI 10.1056/NEJM198703053161004; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; ENGELMAN L, 1988, BMDP STATISTICAL SOF, P831; FOLTS JD, 1976, CIRCULATION, V54, P365, DOI 10.1161/01.CIR.54.3.365; FRANCIS CW, 1983, J LAB CLIN MED, V102, P220; FUSTER V, 1988, CIRCULATION, V77, P1213, DOI 10.1161/01.CIR.77.6.1213; HALVERSTADT DB, 1977, UROLOGY, V6, P617; HERAS M, 1989, CIRCULATION, V79, P657, DOI 10.1161/01.CIR.79.3.657; HIRSCH J, 1987, HEMOSTASIS THROMBOSI, P1173; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; JANG IK, 1990, CIRCULATION, V81, P219, DOI 10.1161/01.CIR.81.1.219; LAGERSTEDT CI, 1985, LANCET, V2, P515; LEWIS HD, 1983, NEW ENGL J MED, V309, P396, DOI 10.1056/NEJM198308183090703; MARCINIAK E, 1977, LANCET, V2, P581; MARKWARDT F, 1985, BIOMED BIOCHIM ACTA, V44, P1007; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MOMBELLI G, 1984, CIRCULATION, V69, P684, DOI 10.1161/01.CIR.69.4.684; SERNERI GGN, 1990, LANCET, V335, P615; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TELFORD AM, 1981, LANCET, V1, P1225; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; TURPIE AGG, 1989, NEW ENGL J MED, V320, P352, DOI 10.1056/NEJM198902093200604; von Kaulla E, 1972, J Med, V3, P349; WALLENTIN L, 1990, LANCET, V336, P827; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198	30	423	428	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					141	145		10.1056/NEJM199207163270301	http://dx.doi.org/10.1056/NEJM199207163270301			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608405	Bronze			2022-12-28	WOS:A1992JD31900001
J	COX, DR				COX, DR			MEDICAL GENETICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											COX, DR (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.							BIESECKER L, 1992, AM J HUM GENET, V50, P438; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CHOWDHURY JR, 1991, SCIENCE, V254, P1802, DOI 10.1126/science.1722351; COLLINS FS, 1991, HOSP PRACT, V26, P93; CULVER K, 1991, P NATL ACAD SCI USA, V88, P3155, DOI 10.1073/pnas.88.8.3155; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; FROGUEL P, 1992, NATURE, V356, P162, DOI 10.1038/356162a0; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEXLER NS, 1991, HOSP PRACT, V26, P145	15	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					368	369						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613923				2022-12-28	WOS:A1992JC35200035
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY		UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605, USA.							BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; COOK SL, 1991, CIRCULATION, V84, P632, DOI 10.1161/01.CIR.84.2.632; DALEN JE, 1991, ARCH INTERN MED, V151, P1066, DOI 10.1001/archinte.151.6.1066; GROVER SA, 1982, JAMA-J AM MED ASSOC, V267, P816; HENNEKENS CH, 1988, NEW ENGL J MED, V318, P923; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; OLSON RE, 1989, ARCH INTERN MED, V149, P1501, DOI 10.1001/archinte.149.7.1501; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; SERRUYS PW, 1991, J AM COLL CARDIOL, V17, pB143; SERRUYS PW, 1991, NEW ENGL J MED, V324, P13, DOI 10.1056/NEJM199101033240103; SLOAN MA, 1992, AM J CARDIOL, V69, pA21, DOI 10.1016/0002-9149(92)91169-5; TOPOL EJ, 1991, CIRCULATION, V84, P632; 1992, LANCET, V339, P753; 1990, LANCET, V366, P71	15	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					338	340						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613912				2022-12-28	WOS:A1992JC35200022
J	LACHS, MS; NACHAMKIN, I; EDELSTEIN, PH; GOLDMAN, J; FEINSTEIN, AR; SCHWARTZ, JS				LACHS, MS; NACHAMKIN, I; EDELSTEIN, PH; GOLDMAN, J; FEINSTEIN, AR; SCHWARTZ, JS			SPECTRUM BIAS IN THE EVALUATION OF DIAGNOSTIC-TESTS - LESSONS FROM THE RAPID DIPSTICK TEST FOR URINARY-TRACT INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						URINARY TRACT INFECTIONS; DIPSTICK TEST; DIAGNOSTIC TESTS, ROUTINE; URINALYSIS; SPECTRUM BIAS	FACTORS AFFECTING SENSITIVITY; SPECIFICITY; BACTERIURIA; SCREENS	Objective: To determine if the leukocyte esterase and bacterial nitrite rapid dipstick test for urinary tract infection (UTI) is susceptible to spectrum bias (when a diagnostic test has different sensitivities or specificities in patients with different clinical manifestations of the disease for which the test is intended). Design: Cross-sectional study. Patients: A total of 366 consecutive adult patients in whom clinicians performed urinalysis to diagnose or exclude UTI. Setting: An urban emergency department and walk-in clinic. Measurements: After the patient encounter, but before dipstick test or culture was done, clinicians recorded the signs and symptoms that were the basis for suspecting UTI and for performing a urinalysis and an estimate of the probability of UTI based on the clinical evaluation. For all patients who received urinalysis, dipstick tests and culture were done in the clinical microbiology laboratory by medical technologists blinded to clinical evaluation. Sensitivity for the dipstick was calculated using a positive result in either leukocyte esterase or bacterial nitrite, or both, as the criterion for a positive dipstick, and greater than 10(5) CFU/mL for a positive culture. Results: In the 107 patients with a high (>50%) prior probability of UTI, who had many characteristic UTI symptoms, the sensitivity of the test was excellent (0.92; 95% CI, 0.82 to 0.98). In the 259 patients with a low (less-than-or-equal-to 50%) prior probability of UTI, the sensitivity of the test was poor (0.56; CI, 0.03 to 0.79). Conclusions: The leukocyte esterase and bacterial nitrite dipstick test for UTI is susceptible to spectrum bias, which may be responsible for differences in the test's sensitivity reported in previous studies. As a more general principle, diagnostic tests may have different sensitivities or specificities in different parts of the clinical spectrum of the disease they purport to identify or exclude, but studies evaluating such tests rarely report sensitivity and specificity in subgroups defined by clinical symptoms. When diagnostic tests are evaluated, information about symptoms in the patients recruited for study should be included, and analyses should be done within appropriate clinical subgroups so that clinicians may decide if reported sensitivities and specificities are applicable to their patients.	UNIV PENN, SCH MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania	LACHS, MS (corresponding author), YALE UNIV, SCH MED, 333 CEDAR ST, TMP B15, NEW HAVEN, CT 06510 USA.		Nachamkin, Irving/Q-3673-2019; Edelstein, Paul/I-5527-2019	Edelstein, Paul/0000-0002-4069-5279; Nachamkin, Irving/0000-0003-4811-9716				CHERNOW B, 1984, ANN EMERG MED, V13, P150, DOI 10.1016/S0196-0644(84)80603-4; DETRANO R, 1988, AM J MED, V84, P699, DOI 10.1016/0002-9343(88)90107-6; FLETCHER RH, 1986, ANN INTERN MED, V104, P66, DOI 10.7326/0003-4819-104-1-66; GARDNER S, 1989, CONFIDENCE INTERVAL; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; HLATKY MA, 1987, AM J CARDIOL, V59, P1195, DOI 10.1016/0002-9149(87)90875-7; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; KELLOGG JA, 1987, AM J MED, V83, P739, DOI 10.1016/0002-9343(87)90907-7; KOMAROFF AL, 1984, NEW ENGL J MED, V310, P368, DOI 10.1056/NEJM198402093100607; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; MALES BM, 1985, J CLIN MICROBIOL, V22, P531, DOI 10.1128/JCM.22.4.531-534.1985; PELS RJ, 1989, JAMA-J AM MED ASSOC, V262, P1220, DOI 10.1001/jama.1989.03430090082038; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705	15	211	211	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					135	140		10.7326/0003-4819-117-2-135	http://dx.doi.org/10.7326/0003-4819-117-2-135			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605428				2022-12-28	WOS:A1992JD12300008
J	RABY, KE; BARRY, J; CREAGER, MA; COOK, EF; WEISBERG, MC; GOLDMAN, L				RABY, KE; BARRY, J; CREAGER, MA; COOK, EF; WEISBERG, MC; GOLDMAN, L			DETECTION AND SIGNIFICANCE OF INTRAOPERATIVE AND POSTOPERATIVE MYOCARDIAL-ISCHEMIA IN PERIPHERAL VASCULAR-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC RISK; MORTALITY; DISEASE	Objective.-To determine the incidence and significance of intraoperative and postoperative myocardial ischemia and their relationship to preoperative ischemia and postoperative cardiac events in patients undergoing peripheral arterial surgery. Design.-Prospective cohort trial. Patients.-One hundred fifteen patients undergoing elective vascular surgery who met predefined eligibility criteria and were thought to have acceptable cardiac risk as assessed by independent cardiologists. Interventions.-Ambulatory electrocardiographic monitoring preoperatively, intraoperatively, and up to 72 hours postoperatively. Measurements.-Preoperative clinical characteristics and laboratory data were collected. Predefined adverse cardiac events were identified by an investigator who was "blinded" to monitoring results. Monitor recordings were interpreted for ST-segment depression by investigators blinded to patient information. Main Results.-Intraoperative ischemia was present in 21 patients (18%), and postoperative ischemia was present in 35 (30%). There were 16 postoperative cardiac events. The relative risk of suffering a cardiac event was 2.7 in patients with intraoperative ischemia and was 16 in patients with postoperative ischemia. Preoperative ischemia closely correlated with intraoperative and postoperative ischemia. Preoperative and postoperative ischemia preceded cardiac events in 14 of 16 patients. Conclusions.-Preoperative ischemia appears to identify high-risk patients, and subsequent perioperative monitoring detects silent ischemia that commonly precedes clinical events and that may be treatable with anti-ischemia therapy.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CLIN EPIDEMIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV VASC MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	RABY, KE (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC,75 FRANCIS ST,BOSTON,MA 02115, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002553, R01HL035295] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02553-01, R01 HL35295] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRY J, 1987, AM J CARDIOL, V60, P483, DOI 10.1016/0002-9149(87)90290-6; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; DEANFIELD JE, 1983, LANCET, V2, P753; DODDS TM, 1990, 12TH ANN SOC CARD AN; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; FLEISHER LA, 1991, AM HEART J, V122, P980, DOI 10.1016/0002-8703(91)90461-P; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JAMIESON WRE, 1982, CIRCULATION, V66, P92; KENNEDY HL, 1987, AM J CARDIOL, V59, P1190, DOI 10.1016/0002-9149(87)90874-5; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; LEVIN RI, 1988, AM J CARDIOL, V61, pB13; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MCCANN RL, 1989, J VASC SURG, V9, P583; OUYANG P, 1989, AM J CARDIOL, V64, P1113, DOI 10.1016/0002-9149(89)90862-X; PASTERNACK PF, 1989, J VASC SURG, V10, P617; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; SILICIANO D, 1990, ANESTH ANALG, V70, pS1; TISCHLER M D, 1991, Journal of the American College of Cardiology, V17, p264A; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P	22	166	174	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					222	227		10.1001/jama.268.2.222	http://dx.doi.org/10.1001/jama.268.2.222			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608141				2022-12-28	WOS:A1992JB27900029
J	ARIZA, J; GUDIOL, F; PALLARES, R; VILADRICH, PF; RUFI, G; CORREDOIRA, J; MIRAVITLLES, MR				ARIZA, J; GUDIOL, F; PALLARES, R; VILADRICH, PF; RUFI, G; CORREDOIRA, J; MIRAVITLLES, MR			TREATMENT OF HUMAN BRUCELLOSIS WITH DOXYCYCLINE PLUS RIFAMPIN OR DOXYCYCLINE PLUS STREPTOMYCIN - A RANDOMIZED, DOUBLE-BLIND-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							MELITENSIS	Objective: To compare the effectiveness of doxycycline-rifampin (DR) combination therapy with that of the classic doxycycline-streptomycin (DS) combination in patients with brucellosis. Design: A randomized, double-blind study, with a mean follow-up of 15.7 months. Setting: A 1000-bed teaching hospital in Barcelona, Spain. Patients: Ninety-five patients (68 men and 27 women; mean age, 39 years) diagnosed with brucellosis on the basis of both clinical and serologic findings; 81 of these patients had blood cultures positive for Brucella melitensis. Interventions: Forty-four patients received doxycycline, 100 mg every 12 hours, and rifampin, 15 mg/kg body weight per day in a single morning dose, for 45 days; 51 patients received the same dose of doxycycline for 45 days plus streptomycin, 1 g/d for 15 days. Main Outcome Measures: Therapeutic failure and relapse during the follow-up period. Results: The mean time to defervescence was 4.2 days for the DR group and 3.2 days for the DS group (P > 0.2). The actuarial probability of therapeutic failure or relapse at 12 months of follow-up (Kaplan-Meier) was 14.4% in the DR group and 5.9% in the DS group (difference, 8.5%; 95% Cl, -4.8% to 21.6%; P > 0.2). All three patients with spondylitis in the DR group failed therapy compared with one of four patients in the DS group. Excluding patients with spondylitis, the actuarial failure rate was 4.9% and 4.3% in the DR and DS groups, respectively, at 12 months of follow-up (difference, 0.6%; Cl, -8.1% to 9.4%; P > 0.2). Conclusions: Doxycycline-rifampin combination therapy for 45 days is as effective as the classic DS combination in most patients with brucellosis; however, DR therapy might be less effective in those patients with spondylitis.	UNIV BARCELONA, BARCELONA 7, SPAIN	University of Barcelona	ARIZA, J (corresponding author), HOSP BELLVITGE PRINCEPS ESPANYA, INFECT DIS SERV, FEIXA LLARGA SN, E-08097 BARCELONA, SPAIN.		PALLARES, Roman/B-5710-2008	PALLARES, Roman/0000-0003-3262-8508				ACOCELLA G, 1989, J ANTIMICROB CHEMOTH, V23, P433, DOI 10.1093/jac/23.3.433; ALTON GG, 1975, LABORATORY TECHNIQUE; ARIZA J, 1985, REV INFECT DIS, V7, P656; ARIZA J, 1983, MED CLIN-BARCELONA, V81, P870; ARIZA J, 1986, ANTIMICROB AGENTS CH, V30, P958, DOI 10.1128/AAC.30.6.958; ARIZA J, 1985, ANTIMICROB AGENTS CH, V28, P548, DOI 10.1128/AAC.28.4.548; BERTRAND A, 1979, NOUV PRESSE MED, V8, P3635; BERTRAND A, 1985, 1985 P INT M BRUC MA, P119; BERTRAND A, 1974, MED AFRIQUE NOIRE, V21, P449; BESSARD G, 1983, MED MALADIES INFECT, V13, P138, DOI 10.1016/S0399-077X(83)80112-7; BOSCH J, 1986, J ANTIMICROB CHEMOTH, V17, P459, DOI 10.1093/jac/17.4.459; CASTANEDA M, 1961, B WORLD HEALTH ORGAN, V24, P73; CASTILLO JDC, 1989, CHEMOTHERAPY, V35, P146; CISNEROS JM, 1990, ANTIMICROB AGENTS CH, V34, P881, DOI 10.1128/AAC.34.5.881; FARRELL ID, 1976, J CLIN PATHOL, V29, P1097, DOI 10.1136/jcp.29.12.1097; FOZ A, 1954, Rev Immunol Ther Antimicrob, V18, P288; GARRAFFO R, 1987, PATHOL BIOL, V35, P746; HALL WH, 1990, REV INFECT DIS, V12, P1060; HALL WH, 1970, APPL MICROBIOL, V20, P600, DOI 10.1128/AEM.20.4.600-604.1970; Jones LM, 1971, INT J SYST BACTERIOL, V21, P126; Kosmidis J, 1982, CHEMOTHERAPIA S4, V1, P107; MAGILL GB, 1953, ARCH INTERN MED, V91, P204, DOI 10.1001/archinte.1953.00240140064005; MORGAN WJB, 1969, VET REC, V85, P636, DOI 10.1136/vr.85.23.636; RICHARDSON M, 1962, J BACTERIOL, V84, P638, DOI 10.1128/JB.84.4.638-646.1962; RODRIGUEZ JAG, 1985, P S INT S BRUC MADR, P137; SERRE H, 1981, REV RHUM, V48, P143; SOLERA J, 1991, MED CLIN-BARCELONA, V96, P649; SPINK WW, 1960, J LAB CLIN MED, V55, P535; SPINK WW, 1960, JAMA-J AM MED ASSOC, V172, P697, DOI 10.1001/jama.1960.63020070004016; ZAPATA MR, 1985, 1985 P S INT S BRUC, P143; 1986, WHO TECHNICAL REPORT, V740, P56; 1971, WHO TECHNICAL REPORT, V464, P82	32	154	165	2	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					25	30		10.7326/0003-4819-117-1-25	http://dx.doi.org/10.7326/0003-4819-117-1-25			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596044				2022-12-28	WOS:A1992JA43500004
J	WEINBERG, RB				WEINBERG, RB			THE LAYING ON OF HANDS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material						PHYSICIANS ROLE; TEACHING; ETHICS, MEDICAL; COMMUNICATION		A physician is catapulted into a physical and spiritual crisis when his brother becomes gravely ill. Made worse by his own attempts to treat himself, he must place his trust in the hands of another physician. His encounter with his own profession teaches him the ancient wisdom in the words of his Oath.			WEINBERG, RB (corresponding author), BOWMAN GRAY SCH MED, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					83	84		10.7326/0003-4819-117-1-83	http://dx.doi.org/10.7326/0003-4819-117-1-83			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596051				2022-12-28	WOS:A1992JA43500014
J	CLARKE, M; KURINCZUK, JJ				CLARKE, M; KURINCZUK, JJ			HEALTH-SERVICES RESEARCH - A CASE OF NEED OR SPECIAL PLEADING	BRITISH MEDICAL JOURNAL			English	Article											CLARKE, M (corresponding author), UNIV LEICESTER,LEICESTER ROYAL INFIRM,DEPT EPIDEMIOL & PUBL HLTH,CLIN SCI BLDG,LEICESTER LE2 7LX,W YORKSHIRE,ENGLAND.							DIXON J, 1991, LANCET, V337, P891, DOI 10.1016/0140-6736(91)90213-9; MECHANIC D, 1978, MILBANK Q; PECKHAM M, 1991, LANCET, V338, P367, DOI 10.1016/0140-6736(91)90494-A; 1991, DIRECTORY TRAINING P; 1991, RES HLTH RES DEV STR; 1988, PRIORITIES MED RES, V1	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1675	1676		10.1136/bmj.304.6843.1675	http://dx.doi.org/10.1136/bmj.304.6843.1675			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633523	Bronze, Green Published			2022-12-28	WOS:A1992JB93900026
J	IRVING, MH; HULME, O				IRVING, MH; HULME, O			ABC OF COLORECTAL DISEASES - INTESTINAL STOMAS	BRITISH MEDICAL JOURNAL			English	Article											IRVING, MH (corresponding author), HOPE HOSP,DEPT SURG,SALFORD M6 8HD,LANCS,ENGLAND.								0	4	4	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1679	1681		10.1136/bmj.304.6843.1679	http://dx.doi.org/10.1136/bmj.304.6843.1679			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633524	Green Published, Bronze			2022-12-28	WOS:A1992JB93900029
J	TAYLOR, AF				TAYLOR, AF			MOVEMENT AND RESOLUTION OF HOLLIDAY JUNCTIONS BY ENZYMES FROM ESCHERICHIA-COLI	CELL			English	Review							ESCHERICHIA-COLI; RECOMBINATION				TAYLOR, AF (corresponding author), FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104, USA.							BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KOBAYASHI I, 1983, MOL GEN GENET, V191, P213, DOI 10.1007/BF00334816; LLOYD RG, 1991, J BACTERIOL, V173, P6837, DOI 10.1128/jb.173.21.6837-6843.1991; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LUISIDELUCA C, 1989, GENETICS, V122, P269; POTTER H, 1976, P NATL ACAD SCI USA, V73, P3000, DOI 10.1073/pnas.73.9.3000; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SMITH GR, 1989, CELL, V58, P807, DOI 10.1016/0092-8674(89)90929-X; SMITH GR, 1991, CELL, V64, P19, DOI 10.1016/0092-8674(91)90205-D; TAYLOR AF, 1990, J MOL BIOL, V211, P117, DOI 10.1016/0022-2836(90)90015-E; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TSANEVA IR, 1992, CELL, V69	17	19	19	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1063	1065		10.1016/0092-8674(92)90626-N	http://dx.doi.org/10.1016/0092-8674(92)90626-N			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617722				2022-12-28	WOS:A1992JA43100001
J	GLASS, RI; LIBEL, M; BRANDLINGBENNETT, AD				GLASS, RI; LIBEL, M; BRANDLINGBENNETT, AD			EPIDEMIC CHOLERA IN THE AMERICA	SCIENCE			English	Editorial Material									PAN AMER HLTH ORG,HLTH SITUAT & TREND ASSESSMENT PROGRAM,WASHINGTON,DC	Pan American Health Organization	GLASS, RI (corresponding author), CTR DIS CONTROL,NATL CTR INFECT DIS,VIRAL GASTROENTERITIS UNIT,ATLANTA,GA 30333, USA.							[Anonymous], 1991, Epidemiol Bull, V12, P1; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101; KAMAL AM, 1974, CHOLERA, P1; KOBLAVI S, 1990, RES MICROBIOL, V141, P645, DOI 10.1016/0923-2508(90)90059-Y; KOLVIN JL, 1982, J HYG-CAMBRIDGE, V89, P243, DOI 10.1017/S0022172400070777; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; MAKUKUTU CA, 1986, APPL ENVIRON MICROB, V52, P824, DOI 10.1128/AEM.52.4.824-831.1986; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; Pollitzer R., 1959, WHO MONOGRAPH SERIES, V43; WACHSMUTH IK, 1991, LANCET, V337, P1097	11	42	44	2	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1524	1525		10.1126/science.1598586	http://dx.doi.org/10.1126/science.1598586			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598586				2022-12-28	WOS:A1992HY07500019
J	BORN, RT; TOOTELL, RBH				BORN, RT; TOOTELL, RBH			SEGREGATION OF GLOBAL AND LOCAL MOTION PROCESSING IN PRIMATE MIDDLE TEMPORAL VISUAL AREA	NATURE			English	Article							MACAQUE MONKEY; CORTEX; NEURONS; DIRECTION; ANATOMY; FIELD; MT	THE early stages Of primate visual processing appear to be divided up into several component parts so that, for example, colour, form and motion are analysed by anatomically distinct streams 1-3. We have found that further subspecialization occurs within the motion processing stream. Neurons representing two different kinds of information about visual motion are segregated in columnar fashion within the middle temporal area of the owl monkey. These columns can be distinguished by labelling with 2-deoxyglucose in response to large-field random-dot patterns. Neurons in lightly labelled interbands have receptive fields with antagonistic surrounds: the response to a centrally placed moving stimulus is suppressed by motion in the surround. Neurons in more densely labelled bands have surrounds that reinforce the centre response so that they integrate motion cues over large areas of the visual field. Interband cells carry information about local motion contrast that may be used to detect motion boundaries or to indicate retinal slip during visual tracking. Band cells encode information about global motion that might be useful for orienting the animal in its environment.			BORN, RT (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,220 LONGWOOD AVE,BOSTON,MA 02115, USA.		Born, Richard/M-6454-2019	Born, Richard/0000-0003-4360-427X				ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BAKER JF, 1981, J NEUROPHYSIOL, V45, P397, DOI 10.1152/jn.1981.45.3.397; BORN RT, 1991, P NATL ACAD SCI USA, V88, P7066, DOI 10.1073/pnas.88.16.7066; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; FROST BJ, 1981, EXP BRAIN RES, V43, P173; FROST BJ, 1983, SCIENCE, V220, P744, DOI 10.1126/science.6836313; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; KAAS JH, 1992, INVEST OPHTH VIS SCI, V33, P1219; Krauzlis RJ, 1989, NEURAL COMPUT, V1, P116, DOI 10.1162/neco.1989.1.1.116; KUFFLER SW, 1953, J NEUROPHYSIOL, V16, P37, DOI 10.1152/jn.1953.16.1.37; LAGAE L, 1989, BRAIN RES, V496, P361, DOI 10.1016/0006-8993(89)91089-5; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MAUNSELL JHR, 1987, ANNU REV NEUROSCI, V10, P363, DOI 10.1146/annurev.ne.10.030187.002051; ROCKLAND KS, 1989, VISUAL NEUROSCI, V3, P155, DOI 10.1017/S0952523800004466; STERLING P, 1969, J NEUROPHYSIOL, V32, P1, DOI 10.1152/jn.1969.32.1.1; TANAKA K, 1986, J NEUROSCI, V6, P134; TOOTELL R B H, 1990, Investigative Ophthalmology and Visual Science, V31, P238; TOOTELL RBH, 1988, J NEUROSCI, V8, P1500; TOOTELL RBH, 1985, J NEUROSCI, V5, P2786; Treisman A, 1986, SCI AM, V255, P106; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WURTZ RH, 1990, COLD SPRING HARB SYM, V55, P45	22	288	288	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					497	499		10.1038/357497a0	http://dx.doi.org/10.1038/357497a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608448				2022-12-28	WOS:A1992HY05200063
J	HULL, MGR; EDDOWES, HA; FAHY, U; ABUZEID, MI; MILLS, MS; CAHILL, DJ; FLEMING, CF; WARDLE, PG; FORD, WCL; MCDERMOTT, A				HULL, MGR; EDDOWES, HA; FAHY, U; ABUZEID, MI; MILLS, MS; CAHILL, DJ; FLEMING, CF; WARDLE, PG; FORD, WCL; MCDERMOTT, A			EXPECTATIONS OF ASSISTED CONCEPTION FOR INFERTILITY	BRITISH MEDICAL JOURNAL			English	Article							INVITRO FERTILIZATION; PREGNANCY; RATES	Objective - To provide reliable prognostic information for couples seeking assisted conception. Design - Analysis of four years' practice (1988-91). Setting - Private university service finked with NHS reproductive medicine services. Patients - 804 couples with various causes of subfertility, median duration five years, median age of women 34 years. Interventions - 1280 completed cycles: 950 in vitro fertilisation, 144 gamete intrafallopian transfer, and 186 intrauterine insemination and superovulation. Main outcome measures - Pregnancy and birth rates per cycle and cumulative pregnancy and take home baby rates per couple. Results - In women under 40 years and men with normal sperm, whatever the cause of infertility, results with in vitro fertilisation improved steadily reaching a pregnancy rate per cycle of 30% (95% confidence interval 26% to 35%) during 1990-1 and birth rate per cycle of 29% (23% to 35%) in 1990. Pregnancy and birth rates for gamete intrafallopian transfer were 36% (28% to 44%) and 26% (17% to 37%) and for intrauterine insemination 18% (12% to 24%) and 16% (10% to 22%). After six cycles cumulative probability of pregnancy was 82% and cumulative take home baby rate 70%. Considering only in vitro fertilisation and gamete intrafallopian transfer after four cycles the pregnancy rate was 78% (66% to 91%). Conclusions - Conception is less likely in women over 40 and men with sperm dysfunction. For other couples the prognosis for a live birth is at least as good as for fertile couples if they persist with treatment.	UNIV BRISTOL,BUPA HOSP,IVF UNIT,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol			Cahilll, David/AAQ-6724-2020; Cahill, David/AAE-9893-2019					CHAFFKIN LM, 1991, FERTIL STERIL, V55, P252; CROSIGNANI PG, 1991, HUM REPROD, V6, P953, DOI 10.1093/oxfordjournals.humrep.a137468; DEMOUZON J, 1990, CONTRACEPT FERTIL S, V18, P589; DODSON WC, 1991, FERTIL STERIL, V55, P457; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HAAN G, 1991, HUM REPROD, V6, P939, DOI 10.1093/oxfordjournals.humrep.a137465; HULL MGR, 1990, BRIT MED BULL, V46, P580, DOI 10.1093/oxfordjournals.bmb.a072418; KOVACS GT, 1986, MED J AUSTRALIA, V144, P682, DOI 10.5694/j.1326-5377.1986.tb113694.x; MATTHEWS DE, 1988, USING UNDERSTANDING, P75; MILLS MS, IN PRESS HUM REPROD; NICE L, 1991, J REPR FERT ABSTR SE, V7, P48; TAN SL, 1990, LANCET, V335, P299, DOI 10.1016/0140-6736(90)90126-P; TIETZE C, 1956, FERTIL STERIL, V7, P88; TIETZE C, 1986, FERTIL STERIL, V13, P385; VESSEY MP, 1978, BRIT MED J, V1, P265, DOI 10.1136/bmj.1.6108.265; WARDLE PG, 1985, LANCET, V2, P236; 1990, WHO EURICPMCH122S RE	17	91	91	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1465	1469		10.1136/bmj.304.6840.1465	http://dx.doi.org/10.1136/bmj.304.6840.1465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611367	Green Published, Bronze			2022-12-28	WOS:A1992HY55300019
J	MISHRA, M; CHAMBERS, JB; JACKSON, G				MISHRA, M; CHAMBERS, JB; JACKSON, G			MURMURS IN PREGNANCY - AN AUDIT OF ECHOCARDIOGRAPHY	BRITISH MEDICAL JOURNAL			English	Article									LEWISHAM HOSP,CARDIOL,LONDON SE13 6LH,ENGLAND									ELKAYAM U, 1985, PRINCIPLES MED TREAT; MCFAUL PB, 1988, BRIT J OBSTET GYNAEC, V95, P861, DOI 10.1111/j.1471-0528.1988.tb06570.x; SUGRUE D, 1980, BRIT HEART J, V44, P499, DOI 10.1136/hrt.44.5.499; 1990, LANCET, V335, P88; 1990, DRUG THER B, V28, P90	5	23	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1413	1414		10.1136/bmj.304.6839.1413	http://dx.doi.org/10.1136/bmj.304.6839.1413			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628016	Green Published, Bronze			2022-12-28	WOS:A1992HX08200019
J	LEUTHER, KK; JOHNSTON, SA				LEUTHER, KK; JOHNSTON, SA			NONDISSOCIATION OF GAL4 AND GAL80 INVIVO AFTER GALACTOSE INDUCTION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-BINDING; YEAST; GENE; ACTIVATOR; TRANSCRIPTION; INVITRO; PROTEIN; VP16	Transcription of galactose-inducible genes in yeast is regulated by interaction between the activator protein GAL4 and the negative regulatory protein GAL80. It has been suggested that GAL80 binds to and represses GAL4 under uninduced conditions and dissociates from GAL4 on induction. However, the possibility that GAL80 remains associated with GAL4 after induction has not been ruled out. Experiments to discriminate between these two models were performed and revealed that GAL80 stays bound after induction.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; LANGDON SD, UNPUB; LEUTHER KK, UNPUB; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA J, 1988, CELL, V55, P443, DOI 10.1016/0092-8674(88)90030-X; MA J, 1987, CELL, V50, P137, DOI 10.1016/0092-8674(87)90670-2; MATSUMOTO K, 1980, J BACTERIOL, V141, P509; PARTHUN MR, 1990, J BIOL CHEM, V265, P209; SELLECK SB, 1987, MOL CELL BIOL, V7, P3260, DOI 10.1128/MCB.7.9.3260; TORCHIA TE, 1984, MOL CELL BIOL, V4, P1521, DOI 10.1128/MCB.4.8.1521; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YOCUM RR, 1984, GENE, V32, P75, DOI 10.1016/0378-1119(84)90034-9	14	128	132	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1333	1335		10.1126/science.1598579	http://dx.doi.org/10.1126/science.1598579			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598579				2022-12-28	WOS:A1992HW13500038
J	GUERRY, D; SCHUCHTER, LM				GUERRY, D; SCHUCHTER, LM			DISSEMINATED MELANOMA - IS THERE A NEW STANDARD THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MALIGNANT-MELANOMA				GUERRY, D (corresponding author), UNIV PENN,CTR CANC,PHILADELPHIA,PA 19104, USA.							AHMANN DL, 1989, CANCER, V63, P224, DOI 10.1002/1097-0142(19890115)63:2<224::AID-CNCR2820630203>3.0.CO;2-I; CASSILETH BR, 1986, J AM ACAD DERMATOL, V14, P555, DOI 10.1016/S0190-9622(86)70068-6; Chekhov AP, 1982, CHEKHOV 5 MAJOR PLAY; COCCONI G, 1992, NEW ENGL J MED, V327, P516, DOI 10.1056/NEJM199208203270803; FALKSON CI, 1991, J CLIN ONCOL, V9, P1403, DOI 10.1200/JCO.1991.9.8.1403; GELLER AC, 1992, J GEN INTERN MED, V7, P154, DOI 10.1007/BF02598004; KIRKWOOD J M, 1992, Current Opinion in Oncology, V4, P368, DOI 10.1097/00001622-199204000-00020; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; LEE JAH, 1990, MAYO CLIN PROC, V65, P1368, DOI 10.1016/S0025-6196(12)62148-X; MCCLAY EF, 1992, INT J CANCER, V50, P553; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; 1992, NATIONAL I HLTH CONS, V10	12	43	43	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 20	1992	327	8					560	561		10.1056/NEJM199208203270811	http://dx.doi.org/10.1056/NEJM199208203270811			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JJ457	1635572				2022-12-28	WOS:A1992JJ45700011
J	ROSENBERG, PS; LEVY, ME; BRUNDAGE, JF; PETERSEN, LR; KARON, JM; FEARS, TR; GARDNER, LI; GAIL, MH; GOEDERT, JJ; BLATTNER, WA; RYAN, CC; VERMUND, SH; BIGGAR, RJ				ROSENBERG, PS; LEVY, ME; BRUNDAGE, JF; PETERSEN, LR; KARON, JM; FEARS, TR; GARDNER, LI; GAIL, MH; GOEDERT, JJ; BLATTNER, WA; RYAN, CC; VERMUND, SH; BIGGAR, RJ			POPULATION-BASED MONITORING OF AN URBAN HIV AIDS EPIDEMIC - MAGNITUDE AND TRENDS IN THE DISTRICT-OF-COLUMBIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SHORT-TERM PROJECTIONS; UNITED-STATES; SENTINEL HOSPITALS; INFECTION; PREVALENCE; SPREAD; SIZE	Objective.-To assess the extent of the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) epidemic in the District of Columbia and demonstrate an approach to monitoring HIV infection and projecting AIDS incidence at a community level. Design.-Backcalculation methods to reconstruct HIV incidence from AIDS incidence in subgroups. Results were compared with directly measured HIV seroprevalence in selected sentinel populations: childbearing women, civilian applicants for military service, and hospital patients admitted for conditions unrelated to HIV infection. Results.-Between the start of the epidemic in 1980 and January 1, 1991, one in 57 District of Columbia men aged 20 to 64 years was diagnosed with AIDS. Unlike the plateau projected for the nation, AIDS incidence for the District of Columbia was projected to increase by 34% between 1990 and 1994. Models of HIV infection incidence suggested two broad epidemic waves of approximately equal size. The first occurred in men who have sex with men and peaked during the period from 1982 through 1983. The second began in the mid-1980s in injecting drug users and heterosexuals. We estimated that among District of Columbia residents aged 20 to 64 years, 0.3% of white women, 2.9% of white men, 1.6% of black women, and 4.9% of black men were living with HIV infection as of January 1, 1991. These estimates are broadly consistent with survey data: among black childbearing women in their 20s, HIV prevalence doubled to 2% between the fall of 1989 and the spring of 1991; from military applicant data, we estimated that over 5% of black men born from 1951 through 1967 were HIV-positive; in the sentinel hospital, HIV prevalence rates among male patients aged 25 to 34 years were 11.3% in white men and 16.9% in black men. Conclusion.-Backcalculation and surveys yielded quantitatively consistent estimates of HIV prevalence. Many injecting drug users and heterosexuals in the District of Columbia were infected after January 1, 1986. Similar monitoring of the epidemic in other localities is needed to focus efforts to reduce the incidence of HIV transmission.	NCI, ENVIRONM EPIDEMIOL BRANCH, VIRAL EPIDEMIOL SECT, ROCKVILLE, MD 20892 USA; WALTER REED ARMY MED CTR, DIV PREVENT MED, WASHINGTON, DC 20307 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, POPULAT STUDIES SECT, ATLANTA, GA 30333 USA; CTR DIS CONTROL, CTR INFECT DIS, DIV HIV AIDS, STAT & DATA MANAGEMENT BRANCH, ATLANTA, GA 30333 USA; DIST COLUMBIA COMMISS PUBL HLTH, AGCY HIV AIDS, WASHINGTON, DC USA; NIAID, DIV AIDS, VACCINE TRIALS EPIDEMIOL BRANCH, BETHESDA, MD 20892 USA; DIST COLUMBIA COMMISS PUBL HLTH, PREVENT HLTH SERV ADM, WASHINGTON, DC USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	ROSENBERG, PS (corresponding author), NCI, BIOSTAT BRANCH, EPIDEMIOL METHODS SECT, 6130 EXECUT BLVD, EPN 403, ROCKVILLE, MD 20892 USA.		Vermund, Sten/AAD-3592-2020; Brundage, John/Q-9244-2019	Vermund, Sten/0000-0001-7289-8698; 				BIGGAR RJ, 1990, AIDS, V4, P1059, DOI 10.1097/00002030-199011000-00002; BROOKMEYER R, 1991, SCIENCE, V253, P37, DOI 10.1126/science.2063206; BROOKMEYER R, 1990, BIOMETRICS, V46, P1151, DOI 10.2307/2532455; BROOKMEYER R, 1989, BIOMETRICS, V45, P325, DOI 10.2307/2532057; BROOKMEYER R, 1989, STAT MED, V8, P23, DOI 10.1002/sim.4780080105; BROOKMEYER R, 1986, LANCET, V2, P1320; BROOKMEYER R, 1988, J AM STAT ASSOC, V83, P301, DOI 10.2307/2288844; BRUNDAGE JF, 1990, J ACQ IMMUN DEF SYND, V3, P1168; CHU SY, 1992, AM J PUBLIC HEALTH, V82, P220, DOI 10.2105/AJPH.82.2.220; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DANGELO LJ, 1991, PEDIATRICS, V88, P982; DANGELO LJ, 1991, OCT INT C ANT AG CH; DAY NE, 1989, SHORT TERM PREDICTIO; DEGRUTTOLA V, 1989, STAT MED, V8, P35, DOI 10.1002/sim.4780080106; GAIL MH, 1988, J NATL CANCER I, V80, P900, DOI 10.1093/jnci/80.12.900; GAIL MH, 1990, J ACQ IMMUN DEF SYND, V3, P296; GARDNER LI, 1989, J ACQ IMMUN DEF SYND, V2, P521; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GREEN TA, 1992, J ACQ IMMUN DEF SYND, V5, P547; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HAHN RA, 1989, JAMA-J AM MED ASSOC, V261, P2677, DOI 10.1001/jama.261.18.2677; ISHAM V, 1989, SHORT TERM PREDICTIO; JACK N, 1992, 8TH INT C AIDS 3 STD; KARON JM, 1988, J ACQ IMMUN DEF SYND, V1, P542; KINGSLEY LA, 1991, AM J EPIDEMIOL, V134, P331, DOI 10.1093/oxfordjournals.aje.a116094; NOVICK LF, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.Suppl.15; PAPPAIOANOU M, 1990, PUBLIC HEALTH REP, V105, P147; Rosenberg Philip S., 1990, Annals of Epidemiology, V1, P105; ROSENBERG PS, 1991, J ACQ IMMUN DEF SYND, V4, P392; ROSENBERG PS, 1991, AM J EPIDEMIOL, V133, P276, DOI 10.1093/oxfordjournals.aje.a115872; ROSENBERG PS, 1991, APPL STAT-J ROY ST C, V40, P269; ROSENBERG PS, IN PRESS STAT MED; SELIK RM, 1990, J ACQ IMMUN DEF SYND, V3, P73; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; STLOUIS ME, 1990, PUBLIC HEALTH REP, V105, P140; TAYLOR JMG, 1989, STAT MED, V8, P45, DOI 10.1002/sim.4780080107; 1991, DIMENSION HIV AIDS E; 1991, HIV AIDS SURVEILLANC, P1; 1991, SAN FRANCISCO EPIDEM, V7, P31; 1992, COMPREHENSIVE HIV AI; 1987, MMWR S15, V36, P1; 1991, INDICES STATISTICAL, P80; 1990, MMWR, V39, P110; 1989, DISTRICT COLUMBIA CO	45	25	25	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					495	503						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619741				2022-12-28	WOS:A1992JD47200024
J	SHAPIRO, MF; HAYWARD, RA; GUILLEMOT, D; JAYLE, D				SHAPIRO, MF; HAYWARD, RA; GUILLEMOT, D; JAYLE, D			RESIDENTS EXPERIENCES IN, AND ATTITUDES TOWARD, THE CARE OF PERSONS WITH AIDS IN CANADA, FRANCE, AND THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS; RISK	Objective.-To evaluate resident physicians' experiences in, and attitudes toward, the care of persons with the acquired immunodeficiency syndrome (AIDS) in Canada, France, and the United States. Design.-Cross-sectional survey, using a self-administered, mailed questionnaire to residents in 1 0 American states, three French regions, and all 10 Canadian provinces, with follow-up surveys of nonresponders in France and the United States. Subjects.-Systematic samples of residents in the last year of internal medicine or family medicine residencies prior to subspecialization or entry into medical practice. Results.-While the majority of residents had provided inpatient and outpatient care to persons with AIDS, most believed that their training in ambulatory care of persons with AIDS had been deficient. The rate of blood-contaminated needle-sticks from human immunodeficiency virus-infected patients ranged from 4% for internal medicine residents in Canada to 14% in the United States (P<.05). The majority recognized an ethical obligation to treat AIDS, but 4% in France, 14% in Canada, and 23% in the United States indicated that they would not care for persons with AIDS if they had a choice (P<.001). A substantial minority of US physicians reported that a patient of theirs had been refused care by a medical specialist (19%) or a surgeon (39%), but less than 10% of French physicians reported such refusals (P<.001). Conclusion.-Concerns about caring for AIDS patients were common and many physicians reported that patients were refused care. While most residents acknowledged an obligation to treat human immunodeficiency virus infection, many did not, and viewpoints varied considerably across the countries studied. The lower level of reluctance to treat AIDS patients in France and Canada makes it clear that the higher rate in the United States is far from optimal and needs to be addressed.	UNIV MICHIGAN,DEPT MED,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; ASSOC PREVENT SIDA,PARIS,FRANCE; CTR REG INFORMAT & PREVENT SIDA,PARIS,FRANCE	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	SHAPIRO, MF (corresponding author), UNIV CALIF LOS ANGELES,DEPT MED,CTR GEN MED,8-552 LOUIS FACTOR BLDG,LOS ANGELES,CA 90024, USA.		Guillemot, Didier/AAN-3051-2020	Guillemot, Didier/0000-0002-8497-1765				[Anonymous], 1989, PRIVATE ACTS SOCIAL; CONNER G, 1990, PSYCHOL REP, V67, P1147; DOUGLAS CJ, 1985, HOSP COMMUNITY PSYCH, V36, P1309; EDMOND M, 1988, INFECT CONT HOSP EP, V9, P114, DOI 10.1086/645806; GERBERDING JL, 1987, J INFECT DIS, V156, P861, DOI 10.1093/infdis/156.6.861; GERBERDING JL, 1990, NEW ENGL J MED, V322, P1788, DOI 10.1056/NEJM199006213222506; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GOSTIN L, 1989, HASTINGS CENT REP, V19, P32, DOI 10.2307/3561948; HAYWARD RA, 1991, J GEN INTERN MED, V6, P18, DOI 10.1007/BF02599384; HAYWARD RA, 1991, ANN INTERN MED, V114, P23, DOI 10.7326/0003-4819-114-1-23; LINK RN, 1988, AM J PUBLIC HEALTH, V78, P455, DOI 10.2105/AJPH.78.4.455; MIZES JS, 1984, PUBLIC OPIN QUART, V48, P794, DOI 10.1086/268885; MORGAN DR, 1988, J HOSP INFECT, V12, P301, DOI 10.1016/0195-6701(88)90072-2; NORTHFELT DW, 1988, ANN INTERN MED, V109, P773, DOI 10.7326/0003-4819-109-10-773; PIOT P, 1988, SCIENCE, V239, P573, DOI 10.1126/science.3277271; POLLAK M, 1989, SCI SOC SANTE, V7, P111; Prual A, 1991, Int J STD AIDS, V2, P1; ZUGER A, 1987, JAMA-J AM MED ASSOC, V258, P1924, DOI 10.1001/jama.258.14.1924; 1989, HIV AIDS SURVEILLANC, P1; 1991, B EPIDEMIOL HEBDOMAD, V44, P187; 1991, MMWR SRR8, V40, P1	21	50	50	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					510	515		10.1001/jama.268.4.510	http://dx.doi.org/10.1001/jama.268.4.510			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JD472	1619743				2022-12-28	WOS:A1992JD47200026
J	LING, L				LING, L			EMERGENCY-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											LING, L (corresponding author), HENNEPIN CTY MED CTR,MINNEAPOLIS,MN 55415, USA.							AMITAI Y, 1992, AM J EMERG MED, V10, P18, DOI 10.1016/0735-6757(92)90118-H; ANDRULIS DP, 1991, ANN EMERG MED, V20, P980, DOI 10.1016/S0196-0644(05)82976-2; BAKER DW, 1991, JAMA-J AM MED ASSOC, V266, P1085, DOI 10.1001/jama.266.8.1085; BARTON C, 1991, ANN EMERG MED, V20, P722, DOI 10.1016/S0196-0644(05)80830-3; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1085; CALLAHAM M, 1991, JAMA-J AM MED ASSOC, V265, P1117, DOI 10.1001/jama.265.9.1117; GALLERY ME, 1992, ANN EMERG MED, V21, P58, DOI 10.1016/S0196-0644(05)82238-3; GOCHMAN RF, 1991, ANN EMERG MED, V20, P57; GOETTING MG, 1991, ANN EMERG MED, V20, P22, DOI 10.1016/S0196-0644(05)81112-6; HAMMOND JS, 1990, J TRAUMA, V30, P555, DOI 10.1097/00005373-199005000-00005; KIMURA A, 1991, TRAUMA, V31, P20; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; RHEE KJ, 1991, ANN EMERG MED, V20, P969, DOI 10.1016/S0196-0644(05)82974-9; SABIA P, 1991, CIRCULATION, V84, P1615, DOI 10.1161/01.CIR.84.4.1615; SHUMAN WP, 1988, RADIOLOGY, V168, P117, DOI 10.1148/radiology.168.1.3289085; SMILKSTEIN MJ, 1992, ANN EMERG MED, V20, P1058; WEARS RL, 1991, ANN EMERG MED, V20, P749, DOI 10.1016/S0196-0644(05)80836-4; WHITLEY TW, 1991, ANN EMERG MED, V20, P992, DOI 10.1016/S0196-0644(05)82978-6	18	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					351	352						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613915				2022-12-28	WOS:A1992JC35200026
J	PRESTWOOD, KM; BESDINE, RW				PRESTWOOD, KM; BESDINE, RW			GERIATRIC-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAGETS-DISEASE; BONE; STROKE; RISK				PRESTWOOD, KM (corresponding author), UNIV CONNECTICUT, CTR HLTH, TRAVELERS CTR AGING, FARMINGTON, CT 06032 USA.							ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; [Anonymous], 1991, JAMA, V265, P3255; CONNOLLY SJ, 1991, AM J CARDIOL, V18, P349; FANTL JA, 1991, JAMA-J AM MED ASSOC, V265, P609, DOI 10.1001/jama.265.5.609; FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495-199141020-00009; FORETTE F, 1982, CLIN EXP HYPERTENS A, V4, P1177, DOI 10.3109/10641968209060782; KANNEL WB, 1981, JAMA-J AM MED ASSOC, V245, P1225, DOI 10.1001/jama.245.12.1225; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; MALLETTE LE, 1989, ARCH INTERN MED, V149, P2765, DOI 10.1001/archinte.149.12.2765; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1989, LANCET, V1, P175; ROSENTHAL MJ, 1989, J AM GERIATR SOC, V37, P639, DOI 10.1111/j.1532-5415.1989.tb01255.x; ROWE JW, 1983, NEW ENGL J MED, V309, P1246, DOI 10.1056/NEJM198311173092011; STONE MD, 1990, J BONE MINER RES, V5, P1231; THIEBAUD D, 1988, AM J MED, V85, P207; WOLF PA, 1985, STROKE, V16, P359, DOI 10.1161/01.STR.16.3.359	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					360	362						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613920				2022-12-28	WOS:A1992JC35200031
J	REDDICK, RL; MCLENDON, WW				REDDICK, RL; MCLENDON, WW			PATHOLOGY AND LABORATORY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											REDDICK, RL (corresponding author), UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA.							ALTSHULER G, 1991, ARCH PATHOL LAB MED, V115, P701; HABER DA, 1992, BLOOD, V79, P295; HARDY K, 1992, ARCH PATHOL LAB MED, V116, P388; HINDKJAER J, 1991, BIOTECH FORUM EUROPE, V8, P752; HJELLE B, 1991, ARCH PATHOL LAB MED, V115, P440; KNECHT H, 1991, BLOOD, V78, P760; LARDELLI P, 1991, HUM PATHOL, V22, P685, DOI 10.1016/0046-8177(91)90290-6; LINDEMAN R, 1991, PATHOLOGY, V23, P158, DOI 10.3109/00313029109060817; NAEYE RL, 1991, DISORDERS PLACENTA F; NEGRIN RS, 1991, BLOOD, V77, P654; NUOVO GJ, 1991, AM J PATHOL, V139, P1239; ROALD B, 1991, PATHOL RES PRACT, V187, P917, DOI 10.1016/S0344-0338(11)81060-5; SILVERMAN LM, 1992, CLIN CHEM, V38, P7; TRAINOR KJ, 1991, BLOOD, V78, P192; TRAVERS H, 1991, ARCH PATHOL LAB MED, V115, P660; WEINSTEIN RS, 1990, HUM PATHOL, V21, P34, DOI 10.1016/0046-8177(90)90073-E; WILSON ML, 1992, J CLIN MICROBIOL, V30, P323, DOI 10.1128/JCM.30.2.323-329.1992; WRIGHT PA, 1990, J PATHOL, V162, P99, DOI 10.1002/path.1711620203; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	19	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					397	399						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613933				2022-12-28	WOS:A1992JC35200046
J	STOECKLE, MY; DOUGLAS, RG				STOECKLE, MY; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC,RAHWAY,NJ 07065	Merck & Company	STOECKLE, MY (corresponding author), CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021, USA.		Stoeckle, Mark/D-3729-2011	Stoeckle, Mark/0000-0002-8280-4795				BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1125, DOI 10.1001/jama.266.8.1125; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; FERNANDEZMARTIN J, 1991, ANTIMICROB AGENTS CH, V35, P2049, DOI 10.1128/AAC.35.10.2049; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; PALESTINE AG, 1991, ANN INTERN MED, V115, P665, DOI 10.7326/0003-4819-115-9-665; REDFIELD RR, 1991, NEW ENGL J MED, V324, P1677, DOI 10.1056/NEJM199106133242401; SAFRIN S, 1991, NEW ENGL J MED, V325, P551, DOI 10.1056/NEJM199108223250805; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1991, MMWR, V40, P1; 1991, MMWR, V40, P585; 1990, MMWR, V39, P1	17	0	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					366	368						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613922				2022-12-28	WOS:A1992JC35200034
J	WEI, ZM; LABY, RJ; ZUMOFF, CH; BAUER, DW; HE, SY; COLLMER, A; BEER, SV				WEI, ZM; LABY, RJ; ZUMOFF, CH; BAUER, DW; HE, SY; COLLMER, A; BEER, SV			HARPIN, ELICITOR OF THE HYPERSENSITIVE RESPONSE PRODUCED BY THE PLANT PATHOGEN ERWINIA-AMYLOVORA	SCIENCE			English	Article							SYRINGAE PV SYRINGAE; K+/H+ EXCHANGE; TOBACCO; TN5	A proteinaceous elicitor of the plant defense reaction known as the hypersensitive response was isolated from Erwinia amylovora, the bacterium that causes fire blight of pear, apple, and other rosaceous plants. The elicitor, named harpin, is an acidic, heat-stable, cell-envelope-associated protein with an apparent molecular weight of 44 kilodaltons. Harpin caused tobacco leaf lamina to collapse and caused an increase in the pH of bathing solutions of suspension-cultured tobacco cells. The gene encoding harpin (hrpN) was located in the 40-kilobase hrp gene cluster of E. amylovora, sequenced, and mutated with Tn5tac1. The hrpN mutants were not pathogenic to pear, did not elicit the hypersensitive response, and did not produce harpin.	CORNELL UNIV, DEPT PLANT PATHOL, ITHACA, NY 14853 USA	Cornell University				He, Sheng Yang/0000-0003-1308-498X				Aldwinkle H. S., 1979, Horticultural Reviews, V1, P423; ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; BAKER CJ, 1987, PHYTOPATHOLOGY, V77, P1268, DOI 10.1094/Phyto-77-1268; BAUER DW, 1991, MOL PLANT MICROBE IN, V4, P493, DOI 10.1094/MPMI-4-493; Beer S. V., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P53; BEER SV, 1989, PLANT PATHOGENIC B B, P675; CHOW WY, 1988, P NATL ACAD SCI USA, V85, P6468, DOI 10.1073/pnas.85.17.6468; DANIELS MJ, 1988, ANNU REV PHYTOPATHOL, V26, P285, DOI 10.1146/annurev.py.26.090188.001441; HUANG HC, 1991, MOL PLANT MICROBE IN, V4, P469, DOI 10.1094/MPMI-4-469; HUANG HC, 1988, J BACTERIOL, V170, P4748, DOI 10.1128/jb.170.10.4748-4756.1988; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; KLEMENT Z, 1963, NATURE, V199, P299, DOI 10.1038/199299b0; KLEMENT Z, 1964, PHYTOPATHOLOGY, V54, P474; LABY RJ, UNPUB; LABY RJ, 1991, THESIS CORNELL U; Lacy G. H., 1982, PHYTOPATHOGENIC PROK, V2, P149; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Sambrook J, 1989, MOL CLONING LABORATO; Steinberger E. M., 1988, Molecular Plant-Microbe Interactions, V1, P135, DOI 10.1094/MPMI-1-135; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; WEI ZM, 1992, J BACTERIOL, V174, P1875, DOI 10.1128/jb.174.6.1875-1882.1992; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132	25	653	803	3	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					85	88		10.1126/science.1621099	http://dx.doi.org/10.1126/science.1621099			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621099				2022-12-28	WOS:A1992JC16500035
J	REDFIELD, MM; NICHOLSON, WJ; EDWARDS, WD; TAJIK, AJ				REDFIELD, MM; NICHOLSON, WJ; EDWARDS, WD; TAJIK, AJ			VALVE DISEASE ASSOCIATED WITH ERGOT ALKALOID USE - ECHOCARDIOGRAPHIC AND PATHOLOGICAL CORRELATIONS	ANNALS OF INTERNAL MEDICINE			English	Note						ERGOT ALKALOIDS; HEART VALVE DISEASES; ECHOCARDIOGRAPHY; MIGRAINE; METHYSERGIDE		Five patients had valve disease that was associated with long-term ingestion (6 to 20 years) of ergotamine (n = 3) or methysergide (n = 2). Only one patient had vascular disease suggestive of ergotism. Two patients had involvement of three or four valves, and three had mitral valve disease. Valvular lesions in the patients were both stenotic and regurgitant. Echocardiographic findings suggestive of ergot valve disease included fixed tricuspid lesions in the absence of the carcinoid syndrome. When left-sided lesions predominated, echocardiographic findings were indistinguishable from those seen in chronic rheumatic disease. All patients underwent valve replacement. Gross pathologic findings included excised valves and chordae tendineae that were thickened and retracted but not calcified; these findings were often initially reported as consistent with rheumatic disease. Microscopic findings differed from those seen in rheumatic disease and resembled those associated with carcinoid lesions. Leaflets and chordae were coated by myofibroblasts in an avascular myxoid or collagenous matrix, but underlying valve architecture was intact. The pathologic process was similar for methysergide and ergotamine.	CARDIAC DIAGNOST ASSOCIATES, YORK, PA USA		REDFIELD, MM (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							BANA DS, 1974, AM HEART J, V88, P640, DOI 10.1016/0002-8703(74)90251-8; GRAHAM JR, 1967, AM J MED SCI, V254, P1; HAUCK AJ, 1990, ARCH PATHOL LAB MED, V114, P62; MASON JW, 1977, CIRCULATION, V56, P889, DOI 10.1161/01.CIR.56.5.889; MISCH KA, 1974, BRIT MED J, V2, P365, DOI 10.1136/bmj.2.5915.365; MUNROE DS, 1969, CAN MED ASSOC J, V101, P536; Seiler K, 1973, Vasa, V2, P366; SPIERINGS ELH, 1988, HEADACHE, V28, P278, DOI 10.1111/j.1526-4610.1988.hed2804278.x	8	116	118	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					50	52		10.7326/0003-4819-117-1-50	http://dx.doi.org/10.7326/0003-4819-117-1-50			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596047				2022-12-28	WOS:A1992JA43500009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			ACCELERATED APPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V57, P13234	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-28	WOS:A1992HY94400006
J	MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R				MISSIAEN, L; DESMEDT, H; DROOGMANS, G; CASTEELS, R			CA2+ RELEASE INDUCED BY INOSITOL 1,4,5-TRISPHOSPHATE IS A STEADY-STATE PHENOMENON CONTROLLED BY LUMINAL CA2+ IN PERMEABILIZED CELLS	NATURE			English	Article							SMOOTH-MUSCLE CELLS; CALCIUM RELEASE; CA-2+ RELEASE; RAT; STORES; TRISPHOSPHATE; PHOSPHATES; KINETICS; ENTRY	Low concentrations of inositol 1,4,5-trisphosphate (InsP3) evoke a very rapid mobilization of intracellular Ca2+ stores in many cell types, which can be followed by a further, much slower efflux 1-8. Two explanations have been suggested for this biphasic release. The first proposes that the Ca2+ stores vary in their sensitivity to InsP3, and each store releases either its entire contents or nothing 2,5,7 (all-or-none release); the second proposes instead that the stores are uniformly sensitive to the effects of InsP3, but that they can release only a fraction of their Ca2+ before their sensitivity is somehow attenuated 6,8-11 (steady-state release). Experiments using purified InsP3 receptor molecules reconstituted into lipid vesicles have shown heterogeneity of the receptors in their response to InsP3 under conditions in which the total Ca2+ level at both sides of the receptor is held constant 7. We now report that in permeabilized A7r5 smooth-muscle cells incubated in Ca2+-free medium, the amount of Ca-45(2+) remaining in the stores after the rapid transient phase of release is independent of their initial Ca2+ levels, indicating that partially depleted stores are less sensitive to InsP3. Moreover, if the stores are reloaded with Ca-40(2+) after the first stimulus, reapplication of the same low concentration of InsP3 will release further Ca-45(2+). This recovery of InsP3 sensitivity is almost complete. Under these conditions, Ca2+ release must thus occur by a steady-state mechanism, in which the decreasing Ca2+ content of the stores slows down further release.			MISSIAEN, L (corresponding author), CATHOLIC UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG, HERESTR 49, B-3000 LOUVAIN, BELGIUM.							BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MAEDA N, 1991, J BIOL CHEM, V266, P1109; MENNITI FS, 1991, J BIOL CHEM, V266, P13646; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1990, J PHYSIOL-LONDON, V427, P171, DOI 10.1113/jphysiol.1990.sp018166; MORRIS AJ, 1988, BIOCHEM J, V251, P157, DOI 10.1042/bj2510157; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NAKAGAWA T, 1991, P NATL ACAD SCI USA, V88, P6244, DOI 10.1073/pnas.88.14.6244; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PERES A, 1990, FEBS LETT, V275, P213, DOI 10.1016/0014-5793(90)81474-3; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; STERN MD, 1992, CELL CALCIUM, V13, P183, DOI 10.1016/0143-4160(92)90046-U; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040	32	250	252	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 18	1992	357	6379					599	602		10.1038/357599a0	http://dx.doi.org/10.1038/357599a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608471				2022-12-28	WOS:A1992HZ11200057
J	BROWN, R				BROWN, R			VIOLENCE AGAINST WOMEN - RELEVANCE FOR MEDICAL PRACTITIONERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOMESTIC VIOLENCE; SEXUAL ABUSE; VICTIMIZATION	Evidence collected over the last 20 years indicates that physical and sexual violence against women is an enormous problem. Much of this violence is perpetrated by women's intimate partners or in relationships that would presumably carry some protective aura (eg, father-daughter, boyfriend-girlfriend). This violence carries with it both short- and long-term sequelae for women and affects both their physical and psychological well-being. The high prevalence of violence against women brings them into regular contact with physicians; at least one in five women seen in emergency departments has symptoms relating to abuse. However, physicians frequently treat the injuries only symptomatically or fail to recognize the injuries as abuse. Even when recognized, physicians are often without resources to address the needs of abused women. This report documents the extent of violence against women and suggests paths that the physician community might take to address the needs of victims.			BROWN, R (corresponding author), AMER MED ASSOC,SCI & TECHNOL GRP,COUNCIL SCI AFFAIRS,515 N STATE ST,CHICAGO,IL 60610, USA.							BROWNE A, 1989, LAW SOC REV, V23, P75, DOI 10.2307/3053881; BROWNE A, 1986, PSYCHOL BULL, V99, P66, DOI 10.1037/0033-2909.99.1.66; BROWNE A, IN PRESS GENDER SOC; Browne A., 1987, BATTERED WOMEN KILL; Burge S K, 1989, Fam Med, V21, P368; CRAINE P, 1990, PSYCHIATRIC RESPONSE; FAGAN J, 1984, NATIONAL FAMILY VIOL, V1; FAGAN J, IN PRESS UNDERSTANDI; Finkelhor D., 1985, LICENSE RAPE SEXUAL; FORMAN BD, 1980, PSYCHOTHER-THEOR RES, V17, P304, DOI 10.1037/h0085927; GELLES RJ, 1988, J MARRIAGE FAM, V50, P841, DOI 10.2307/352652; Gelles RJ, 1990, PHYS VIOLENCE AM FAM, P151; GOLD ER, 1986, J CONSULT CLIN PSYCH, V54, P471, DOI 10.1037/0022-006X.54.4.471; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; Hotaling G T, 1986, Violence Vict, V1, P101; KILPATRICK DG, 1985, TRAUMA ITS WAKE; KOSS MP, 1990, AM PSYCHOL, V45, P374, DOI 10.1037/0003-066X.45.3.374; KOSS MP, 1988, PSYCHOL WOMEN QUART, V12, P1, DOI 10.1111/j.1471-6402.1988.tb00924.x; KOSS MP, 1990, J CONSULT CLIN PSYCH, V58, P147, DOI 10.1037/0022-006X.58.2.147; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; KOSS MP, 1988, RAPE SEXUAL ASSAULT, V2, P3; Koss MP, 1991, RAPE VICTIM CLIN COM, V2; Langan P., 1986, PREVENTING DOMESTIC; LENTZNER HR, 1980, INTIMATE VICTIMS STU; MAKEPEACE JM, 1986, FAM RELAT, V35, P383, DOI 10.2307/584365; MCLEER SV, 1987, ANN EMERG MED, V16, P1155, DOI 10.1016/S0196-0644(87)80476-6; MILLER BA, 1987, VIOLENCE VICTIMS, V2, P57; PATTEN SB, 1989, SOC WORK, V34, P197, DOI 10.1093/sw/34.3.197; RANDALL T, 1990, JAMA-J AM MED ASSOC, V264, P939, DOI 10.1001/jama.264.8.939; RESICK P, 1983, STEREOTYPING WOMEN I; RESICK PA, 1988, BEHAV THER, V19, P385, DOI 10.1016/S0005-7894(88)80011-X; RESICK PA, 1981, J CONSULT CLIN PSYCH, V49, P705, DOI 10.1037/0022-006X.49.5.705; Russell D., 1982, RAPE MARRIAGE; Russell D. E. H., 1986, SECRET TRAUMA INCEST; Saltzman L E, 1990, Atlanta Med, V64, P45; Schechter S., 1982, WOMEN MALE VIOLENCE; Searles P., 1987, WORN RIGHTS LAW REPO, V9, P25; SORENSON SB, 1990, J TRAUMA STRESS, V3, P1154; STARK E, 1979, INT J HEALTH SERV, V9, P461, DOI 10.2190/KTLU-CCU7-BMNQ-V2KY; Stark E., 1988, HDB FAMILY VIOLENCE, P293; STARK E, 1981, MONOGRAPH OFFICE DOM, V7; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; Tonry M.H., 1989, FAMILY VIOLENCE, P163, DOI DOI 10.1086/449154; Walker L., 1984, BATTERED WOMAN SYNDR; WHITE KN, 1989, TREATING CHILD ABUSE; 1987, DIAGNOSTIC STATISTIC; 1989, TECHNICAL B AM COLLE, V124; 1984, CRIMINAL VICTIMIZATI	49	243	244	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3184	3189						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HX918	1593741				2022-12-28	WOS:A1992HX91800029
J	BROWN, RN; LANE, RS				BROWN, RN; LANE, RS			LYME-DISEASE IN CALIFORNIA - A NOVEL ENZOOTIC TRANSMISSION CYCLE OF BORRELIA-BURGDORFERI	SCIENCE			English	Article							LIZARD SCELOPORUS-OCCIDENTALIS; IXODES-PACIFICUS ACARI; BLACK-LEGGED TICK; SURFACE PROTEIN; IXODIDAE; SPIROCHETE; RESERVOIRS; RODENTS; RABBITS; ISOLATE	Knowledge of zoonotic transmission cycles is essential for the development of effective strategies for disease prevention. The enzootiology of Lyme disease in California differs fundamentally from that reported from the eastern United States. Woodrats, not mice, serve as reservoir hosts, and Ixodes neotomae, a nonhuman-biting tick, maintains the agent of Lyme disease, Borrelia burgdorferi, in enzootic cycles. The western black-legged tick, Ixodes pacificus, is the primary vector to humans, but it appears to be an inefficient maintenance vector. Isolates of B. burgdorferi from California exhibit considerable antigenic heterogeneity, and some isolates differ strikingly from isolates recovered from this and other geographic regions.	UNIV CALIF BERKELEY, DEPT ENTOMOL SCI, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	BROWN, RN (corresponding author), UNIV CALIF BERKELEY, PARASITOL GRP, 218 WELLMAN HALL, BERKELEY, CA 94720 USA.				NIAID NIH HHS [AI22501] Funding Source: Medline; PHS HHS [U50/CCU906594] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON JF, 1989, J CLIN MICROBIOL, V27, P13, DOI 10.1128/JCM.27.1.13-20.1989; ANDERSON JF, 1991, SCAND J INFECT DIS, P23; BARBOUR AG, 1984, INFECT IMMUN, V45, P94, DOI 10.1128/IAI.45.1.94-100.1984; BARBOUR AG, 1985, J INFECT DIS, V152, P478, DOI 10.1093/infdis/152.3.478; BISSETT M, 1988, ANN NY ACAD SCI, V539, P369, DOI 10.1111/j.1749-6632.1988.tb31873.x; BISSETT ML, 1987, J CLIN MICROBIOL, V25, P2296, DOI 10.1128/JCM.25.12.2296-2301.1987; BOYCE WM, 1992, J MED ENTOMOL, V29, P496, DOI 10.1093/jmedent/29.3.496; BROWN R, UNPUB; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; DAMROW T, 1989, WESTERN J MED, V150, P580; DONAHUE JG, 1987, AM J TROP MED HYG, V36, P92, DOI 10.4269/ajtmh.1987.36.92; Furman D.P., 1984, Bulletin of the California Insect Survey, V25, P1; HUMBOLDT, 1991, CALIF MORBID, V47, P1; Ingles L.G., 1965, MAMMALS PACIFIC STAT; KELT DA, 1988, MAMMALIAN SPECIES, V324, P1; KURASHIGE S, 1990, J CLIN MICROBIOL, V28, P1362, DOI 10.1128/JCM.28.6.1362-1366.1990; LANE R S, 1990, Bulletin of the Society for Vector Ecology, V15, P25; LANE RS, 1991, J MED ENTOMOL, V28, P299, DOI 10.1093/jmedent/28.3.299; LANE RS, 1989, J WILDLIFE DIS, V25, P189, DOI 10.7589/0090-3558-25.2.189; LANE RS, 1991, J MED ENTOMOL, V28, P719, DOI 10.1093/jmedent/28.5.719; LANE RS, 1986, ZBL BAKT-INT J MED M, V263, P55; LANE RS, 1989, J CLIN MICROBIOL, V27, P2344, DOI 10.1128/JCM.27.10.2344-2349.1989; LANE RS, 1988, J WILDLIFE DIS, V24, P1; LANE RS, 1988, ANN NY ACAD SCI, V539, P192, DOI 10.1111/j.1749-6632.1988.tb31853.x; LANE RS, 1989, J MED ENTOMOL, V26, P272, DOI 10.1093/jmedent/26.4.272; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LANE RS, 1990, AM J TROP MED HYG, V42, P75, DOI 10.4269/ajtmh.1990.42.75; LANE RS, 1987, AM J TROP MED HYG, V37, P188, DOI 10.4269/ajtmh.1987.37.188; LEFEBVRE RB, 1990, J CLIN MICROBIOL, V28, P700, DOI 10.1128/JCM.28.4.700-707.1990; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; MATHER TN, 1987, AM J TROP MED HYG, V36, P609, DOI 10.4269/ajtmh.1987.36.609; MATHER TN, 1989, AM J EPIDEMIOL, V130, P143, DOI 10.1093/oxfordjournals.aje.a115306; ROSA PA, 1991, J CLIN MICROBIOL, V29, P524, DOI 10.1128/JCM.29.3.524-532.1991; SCHOELER B, UNPUB; SCHWAN TG, UNPUB; SINSKY RJ, 1989, J CLIN MICROBIOL, V27, P1723, DOI 10.1128/JCM.27.8.1723-1727.1989; TELFORD SR, 1989, AM J TROP MED HYG, V41, P482, DOI 10.4269/ajtmh.1989.41.482; WILSKE B, 1991, SCAND J INFECT DIS, P108	38	212	212	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1992	256	5062					1439	1442		10.1126/science.1604318	http://dx.doi.org/10.1126/science.1604318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604318				2022-12-28	WOS:A1992HX33700034
J	JONES, DJ				JONES, DJ			ABC OF COLORECTAL DISEASES - DIVERTICULAR-DISEASE	BRITISH MEDICAL JOURNAL			English	Article											JONES, DJ (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1435	1437		10.1136/bmj.304.6839.1435	http://dx.doi.org/10.1136/bmj.304.6839.1435			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628026	Green Published, Bronze			2022-12-28	WOS:A1992HX08200031
J	DIKSTEIN, R; HEFFETZ, D; BEN-NERIAH, Y; SHAUL, Y				DIKSTEIN, R; HEFFETZ, D; BEN-NERIAH, Y; SHAUL, Y			C-ABL HAS A SEQUENCE-SPECIFIC ENHANCER BINDING-ACTIVITY	CELL			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; B VIRUS ENHANCER; ACUTE LYMPHOBLASTIC-LEUKEMIA; PHILADELPHIA-CHROMOSOME; MOLECULAR-CLONING; GENE-PRODUCT; PROTEIN; KINASE; REGION; BCR	The enhancers of several distinct viruses contain a common functional element, termed EP. This element binds ubiquitous cellular proteins and generates specific complexes in gel retardation analysis. Ultraviolet cross-linking and Southwestern analysis showed that a 140 kd polypeptide is the major EP DNA-binding protein. Using a combination of DNA binding and immunological techniques, we have identified the c-abl protein in a nuclear complex that binds to the EP element. abl was found to have both a specific and high affinity DNA binding activity. The ability to bind DNA is abolished in the mutant abl protein, p210bcr-abl, consistent with its cytoplasmic localization in chronic myelogenous leukemia.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL	Hebrew University of Jerusalem	DIKSTEIN, R (corresponding author), WEIZMANN INST SCI, DEPT MOLEC GENET & VIROL, IL-76100 REHOVOT, ISRAEL.		Ben-Neriah, Yinon/L-6285-2019					ANAFI M, 1992, IN PRESS J BIOL CHEM, V267; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BEN-NERIAH Y, 1986, CURR TOP MICROBIOL, V132, P81; BENLEVY R, 1989, MOL CELL BIOL, V9, P1804, DOI 10.1128/MCB.9.4.1804; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLEVELAND DW, 1983, METHOD ENZYMOL, V96, P222; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DIKSTEIN R, 1990, MOL CELL BIOL, V10, P3683, DOI 10.1128/MCB.10.7.3683; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; OSTAPCHUK P, 1989, MOL CELL BIOL, V9, P2787, DOI 10.1128/MCB.9.7.2787; PAWSON T, 1988, ONCOGENE, V3, P491; PENDERGAST AM, 1987, MOL CELL BIOL, V7, P4280, DOI 10.1128/MCB.7.12.4280; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1984, CELL, V36, P349; WESTBROOK CA, 1988, BLOOD, V71, P697	29	70	71	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					751	757		10.1016/0092-8674(92)90287-M	http://dx.doi.org/10.1016/0092-8674(92)90287-M			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591775				2022-12-28	WOS:A1992HW83800006
J	BETTERIDGE, DJ; BHATNAGER, D; BING, RF; DURRINGTON, PN; EVANS, GR; FLAX, H; JAY, RH; LEWISBARNED, NL; MANN, J; MATTHEWS, DR; MILLER, JP; RECKLESS, JPD; STURLEY, R; TAYLOR, KG; WINDER, AF				BETTERIDGE, DJ; BHATNAGER, D; BING, RF; DURRINGTON, PN; EVANS, GR; FLAX, H; JAY, RH; LEWISBARNED, NL; MANN, J; MATTHEWS, DR; MILLER, JP; RECKLESS, JPD; STURLEY, R; TAYLOR, KG; WINDER, AF			TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA - UNITED-KINGDOM LIPID CLINICS STUDY OF PRAVASTATIN AND CHOLESTYRAMINE	BRITISH MEDICAL JOURNAL			English	Article							HMG-COA REDUCTASE; CORONARY ATHEROSCLEROSIS; LOVASTATIN; CHOLESTEROL; INHIBITORS; RHABDOMYOLYSIS; THERAPY; SERUM	Objective-To compare the efficacy and safety of cholestyramine, an anion exchange resin, and pravastatin, a new hydrophilic specific inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in the treatment of heterozygous familial hypercholesterolaemia. Design-Double blind, double dummy, placebo controlled study with three parallel groups. Setting-Six specialist lipid clinics in the United Kingdom. Patients-128 patients aged 18-70 with heterozygous familial hypercholesterolaemia diagnosed on strict biochemical and clinical findings. Main outcome measures-Total plasma cholesterol, triglyceride, and lipoprotein subfractions and biochemical and haematological safety parameters. Results-Pravastatin (40 mg/day) led to a 25% reduction in total plasma cholesterol concentration and a reduction in low density lipoprotein cholesterol concentration of 30%. Cholestyramine (24 g/day) led to similar reductions in concentrations of total cholesterol (23%) and low density lipoprotein cholesterol (31%). No consistent changes occurred in high density lipoprotein cholesterol values with either compound. Plasma triglyceride concentrations showed a small rise (18%) on resin therapy. No serious adverse drug reactions occurred during the study. Conclusions-Pravastatin seems to be a highly effective, well tolerated drug for severe hypercholesterolaemia. Patients chosen for this study were recruited on the basis that they could tolerate a full dose of cholestyramine, and in this situation cholestyramine was also highly effective in lowering plasma low density lipoprotein cholesterol concentrations.	MANCHESTER ROYAL INFIRM,CLIN BIOCHEM & METAB MED,MANCHESTER M13 9WL,LANCS,ENGLAND; MANCHESTER ROYAL INFIRM,MED,MANCHESTER M13 9WL,LANCS,ENGLAND; GLENFIELD GEN HOSP,LEICESTER,ENGLAND; DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND; RADCLIFFE INFIRM,DIABET RES LAB,OXFORD OX2 6HE,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND; ROYAL UNITED HOSP,BATH,AVON,ENGLAND; ROYAL FREE NATL HLTH SERV TRUST & SCH MED,CHEM PATHOL,LONDON,ENGLAND	University of Manchester; University of Manchester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Radcliffe Infirmary; University of Oxford; University of Oxford; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; University of London; University College London	BETTERIDGE, DJ (corresponding author), UNIV COLL & MIDDLESEX SCH MED,MIDDLESEX HOSP,DEPT MED,LONDON W1N 8AA,ENGLAND.							ALBERTS AW, 1988, AM J CARDIOL, V62, P10; AYANIAN JZ, 1988, ANN INTERN MED, V109, P682, DOI 10.7326/0003-4819-109-8-682; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1985, GOODMAN GILMANS PHAR, P827; BURSTEIN M, 1970, J LIPID RES, V11, P583; CORPIER CL, 1988, JAMA-J AM MED ASSOC, V260, P239, DOI 10.1001/jama.260.2.239; CURTIS LD, 1988, BRIT MED J, V297, P173, DOI 10.1136/bmj.297.6642.173; EAST C, 1988, NEW ENGL J MED, V318, P47; ENDO A, 1976, J ANTIBIOT, V29, P1346, DOI 10.7164/antibiotics.29.1346; FRICK MH, 1987, NEW ENGL J MED, V317, P1234; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; HOEG JM, 1987, JAMA-J AM MED ASSOC, V258, P3532, DOI 10.1001/jama.258.24.3532; HUNNINGHAKE DB, 1988, JAMA-J AM MED ASSOC, V259, P354, DOI 10.1001/jama.1988.03720030022020; HUNNINGHAKE DB, 1990, ATHEROSCLEROSIS, V85, P81, DOI 10.1016/0021-9150(90)90185-L; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; LAROSA JC, 1989, INT C S SERIES, V162; LAUGHLIN RC, 1962, JAMA-J AM MED ASSOC, V181, P339, DOI 10.1001/jama.1962.03050300059020a; MAHER VMG, 1990, Q J MED, V74, P165; OLIVER MF, 1978, BRIT HEART J, V40, P1069; REAVEN P, 1988, ANN INTERN MED, V109, P597, DOI 10.7326/0003-4819-109-7-597_2; REIHNER E, 1990, NEW ENGL J MED, V323, P224, DOI 10.1056/NEJM199007263230403; RUDLING MJ, 1990, P NATL ACAD SCI USA, V87, P3469, DOI 10.1073/pnas.87.9.3469; STANBURY JB, 1983, METABOLIC BASIS INHE, P672; TIKKANEN MJ, 1987, CIRCULATION, V76, P529, DOI 10.1161/01.CIR.76.3.529; TOBERT JA, 1987, CIRCULATION, V76, P534, DOI 10.1161/01.CIR.76.3.534; TOBERT JA, 1988, AM J CARDIOL, V62, P28; 1987, EUR HEART J, V877, P88; 1985, JAMA-J AM MED ASSOC, V253, P2080; 1988, ARCH INTERN MED, V148, P36; 1984, JAMA-J AM MED ASSOC, V251, P351; 1988, EUR HEART J, V9, P571	36	35	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1335	1338		10.1136/bmj.304.6838.1335	http://dx.doi.org/10.1136/bmj.304.6838.1335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611329	Green Published, Bronze			2022-12-28	WOS:A1992HW41700019
J	FISCHL, MA; DAIKOS, GL; UTTAMCHANDANI, RB; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; OLDHAM, SA; SALDANA, MJ; LAI, SH				FISCHL, MA; DAIKOS, GL; UTTAMCHANDANI, RB; POBLETE, RB; MORENO, JN; REYES, RR; BOOTA, AM; THOMPSON, LM; CLEARY, TJ; OLDHAM, SA; SALDANA, MJ; LAI, SH			CLINICAL PRESENTATION AND OUTCOME OF PATIENTS WITH HIV-INFECTION AND TUBERCULOSIS CAUSED BY MULTIPLE-DRUG-RESISTANT BACILLI	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; TUBERCULOSIS; OUTCOME ASSESSMENT (HEALTH CARE); DRUG RESISTANCE, MICROBIAL; MYCOBACTERIUM-TUBERCULOSIS; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; NON-HAITIAN PATIENTS; VIRUS-INFECTION; SYNDROME AIDS; FLORIDA	Objective: To determine the clinical manifestations of patients with human immunodeficiency virus (HIV) infection and tuberculosis caused by multiple-drug-resistant bacilli compared with those with single-drug-resistant or susceptible bacilli. Design: Descriptive, case-control, and cohort studies. Setting: A large urban teaching hospital. Patients: Sixty-two patients with tuberculosis caused by multiple-drug-resistant bacilli (cases) and 55 patients with tuberculosis caused by single-drug-resistant or susceptible bacilli (controls). Measurements: Characteristics of clinical presentation, radiographs, pathologic abnormalities, antituberculosis treatment, and clinical course. Results: Twenty cases (32%) had concomitant pulmonary and extrapulmonary disease at presentation compared with 9 controls (16%; odds ratio, 2.4; 95% Cl, 1.0 to 5.9). More cases had alveolar infiltrates (76%; odds ratio, 3.6; Cl, 1.2 to 11.4), interstitial infiltrates with a reticular pattern (67%; odds ratio, 7.8; Cl, 1.0 to 83.5), and cavitations (18%; odds ratio, 6.6; Cl, 0.8 to 315.3) on initial chest radiographs compared with controls (49%, 19%, and 3%, respectively). Pathologic specimens from cases showed extensive necrosis, poor granuloma formation, marked inflammatory changes with a predominance of neutrophils, and abundant acid-fast bacilli. Twenty-five cases received two or more effective antituberculosis drugs for more than 2 months. Only 2 cases had three consecutive negative cultures for Mycobacterium tuberculosis, one patient died within 1 day of the last negative culture, and the other had positive cultures 496 days later. The remaining 23 cases had persistently or intermittently positive cultures despite therapy. The clinical course of these cases suggested overwhelming miliary tuberculosis with involvement of the lungs (77%), pleura (15%), stool (34%), meninges (13%), bone marrow (16%), blood (10%), lymph nodes (10%), and skin (8%). The median survival time was 2.1 months for cases compared with 14.6 months for controls (P = 0.001, log-rank test). Conclusions: Tuberculosis caused by multiple-drug resistant bacilli in patients with HIV infection is associated with widely disseminated disease, poor treatment response with an inability to eradicate the organism, and substantial mortality.	UNIV MIAMI, SCH MED, DEPT MED, AIDS CLIN RES UNIT, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT PATHOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT RADIOL, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, COMPREHENS AIDS PROGRAM, MIAMI, FL 33101 USA	University of Miami; University of Miami; University of Miami; University of Miami	FISCHL, MA (corresponding author), UNIV MIAMI, SCH MED, DEPT MED, R-60A, POB 016960, MIAMI, FL 33101 USA.		Daikos, George L./ABD-8378-2021					BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; HANDWERGER S, 1987, CHEST, V91, P176, DOI 10.1378/chest.91.2.176; HILL AR, 1991, AM REV RESPIR DIS, V144, P1164, DOI 10.1164/ajrccm/144.5.1164; KRAMER F, 1990, AM J MED, V89, P451, DOI 10.1016/0002-9343(90)90375-N; LOUIE E, 1986, CHEST, V90, P542, DOI 10.1378/chest.90.4.542; MEHTA CR, 1991, STATXART USER MANUEL; MODILEVSKY T, 1989, ARCH INTERN MED, V149, P2201, DOI 10.1001/archinte.149.10.2201; PITCHENIK AE, 1984, ANN INTERN MED, V101, P641, DOI 10.7326/0003-4819-101-5-641; PITCHENIK AE, 1985, AM REV RESPIR DIS, V131, P393; RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1986, MMWR, V35, P587; 1987, MMWR, V36, P785; 1990, MMWR, V39, P718; 1991, MMWR, V40, P585; 1986, MMWR, V35, P74; 1991, MMWR, V40, P129; 1987, MMWR, V36, P133	25	221	225	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					184	190		10.7326/0003-4819-117-3-184	http://dx.doi.org/10.7326/0003-4819-117-3-184			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616212				2022-12-28	WOS:A1992JF30400002
J	KARP, JE; BRODER, S				KARP, JE; BRODER, S			ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER				KARP, JE (corresponding author), NCI,BETHESDA,MD 20892, USA.							ASHER AL, 1991, J IMMUNOL, V146, P3227; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KASTAN MB, 1991, CANCER RES, V51, P6304; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288; Wakefield L. M., 1990, TUMOR SUPPRESSOR GEN, P217; 1992, LANCET, V339, P71	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					391	393						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613930				2022-12-28	WOS:A1992JC35200043
J	SUGRUE, DD; RODEHEFFER, RJ; CODD, MB; BALLARD, DJ; FUSTER, V; GERSH, BJ				SUGRUE, DD; RODEHEFFER, RJ; CODD, MB; BALLARD, DJ; FUSTER, V; GERSH, BJ			THE CLINICAL COURSE OF IDIOPATHIC DILATED CARDIOMYOPATHY - A POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						CARDIOMYOPATHY, CONGESTIVE; REFERRAL AND CONSULTATION; SELECTION BIAS; VENTRICULAR FUNCTION, LEFT; AGE FACTORS	CONGESTIVE CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; MYOCARDIAL-DISEASE; NATURAL-HISTORY; PROGNOSIS; HEART; EPIDEMIOLOGY; SURVIVAL; ALCOHOLISM; FAILURE	Objective: To describe the prognosis of individuals with idiopathic dilated cardiomyopathy in a population-based sample and to compare this with the prognosis of patients in a previous referral center case series of idiopathic dilated cardiomyopathy. Design: Cohort study. Setting: Population-based in Olmsted County, Minnesota. Patients: Forty residents of Olmstead County, Minnesota with idiopathic dilated cardiomyopathy initially diagnosed between 1975 and 1984 who were followed through 1 July 1989 and 104 patients from a Mayo Clinic referral case series from 1960 to 1973. Measurements: Survival for the population-based cohort at 1 year and 5 years. Results: Survival at 1 year differed dramatically between the population-based cohort and the referral case series at 1 year (95% compared with 69%, respectively) and at 5 years (80% compared with 36%, respectively) (P < 0.001). Long-term survival for the population-based cohort was nonetheless impaired when compared with an age- and sex-matched cohort, that is, the 1980 Minnesota white population (8-year survival: observed, 58% compared with expected, 83%; P < 0.001). Among community patients, older age (adjusted Cox model hazard ratio for 10-year increase in age, 1.59; 95% CI, 1.08 to 2.35) and lower left ventricular ejection fraction (adjusted hazard ratio for 10% decrease, 1.90; CI, 1.04 to 3.50) were independently associated with impaired survival. Conclusions: These population-based data challenge the clinical perception of the clinical course of idiopathic dilated cardiomyopathy based on referral practice prognostic studies and suggest that the clinical course of this condition may be more favorable than previously recognized.	MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS, 200 SW 1ST ST, ROCHESTER, MN 55905 USA	Mayo Clinic			Ballard, David J/H-1062-2018; Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24326] Funding Source: Medline; NIAMS NIH HHS [AR-30582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ballard D J, 1989, Int J Technol Assess Health Care, V5, P249; BRIGDEN W, 1957, LANCET, V2, P1243; BRIGDEN W, 1957, LANCET, V2, P1179; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; CONVERT G, 1980, ARCH MAL COEUR VAISS, V73, P227; COUGHLIN SS, 1990, AM J EPIDEMIOL, V131, P48, DOI 10.1093/oxfordjournals.aje.a115484; COX DR, 1972, J R STAT SOC B, V34, P187; DELIUS W, 1976, DEUT MED WOCHENSCHR, V101, P635, DOI 10.1055/s-0028-1104150; DIAZ RA, 1987, BRIT HEART J, V58, P393; DODGE HT, 1974, MYOCARDIUM FAILURE I, P70; FIGULLA HR, 1985, CIRCULATION, V71, P1095, DOI 10.1161/01.CIR.71.6.1095; FOWLER NO, 1961, CIRCULATION, V23, P498, DOI 10.1161/01.CIR.23.4.498; FRANCIOSA JA, 1983, AM J CARDIOL, V51, P831, DOI 10.1016/S0002-9149(83)80141-6; FURBERG CD, 1985, AM J CARDIOL, V55, P1110, DOI 10.1016/0002-9149(85)90756-8; FUSTER V, 1981, AM J CARDIOL, V47, P525, DOI 10.1016/0002-9149(81)90534-8; GAVAZZI A, 1984, Giornale Italiano di Cardiologia, V14, P492; GOODWIN JF, 1961, BRIT MED J, V1, P69, DOI 10.1136/bmj.1.5219.69; HAMBY RI, 1970, AM J CARDIOL, V25, P625, DOI 10.1016/0002-9149(70)90610-7; HARVEY WP, 1964, PROG CARDIOVASC DIS, V7, P17, DOI 10.1016/S0033-0620(64)80028-1; HATLE L, 1976, ACTA MED SCAND, V199, P399; HATLE L, 1976, ACTA MED SCAND, V199, P407; HESS OM, 1976, SCHWEIZ MED WSCHR, V106, P1577; HUANG SK, 1983, AM J CARDIOL, V51, P507, DOI 10.1016/S0002-9149(83)80089-7; IKRAM H, 1987, BRIT HEART J, V57, P521; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEREN A, 1990, CIRCULATION, V81, P506, DOI 10.1161/01.CIR.81.2.506; KOIDE T, 1980, JPN HEART J, V21, P451; KUHN H, 1978, POSTGRAD MED J, V54, P451, DOI 10.1136/pgmj.54.633.451; KUHN H, 1982, Z KARDIOL, V71, P497; KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MASSUMI RA, 1965, CIRCULATION, V31, P19, DOI 10.1161/01.CIR.31.1.19; MATTINGLY T W, 1961, Mod Concepts Cardiovasc Dis, V30, P677; MELTON LJ, 1985, MAYO CLIN PROC, V60, P880, DOI 10.1016/S0025-6196(12)64794-6; OGASAWARA S, 1985, Heart and Vessels, V1, P78, DOI 10.1007/BF02066353; REGAN TJ, 1977, ANNU REV MED, V28, P393, DOI 10.1146/annurev.me.28.020177.002141; ROBERTS WC, 1987, AM J CARDIOL, V60, P1340, DOI 10.1016/0002-9149(87)90618-7; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; SCHWARZ F, 1984, CIRCULATION, V70, P923, DOI 10.1161/01.CIR.70.6.923; SEGAL JP, 1978, CURR PROB CARDIOLOGY, V3, P9; SEGEL LD, 1984, MED CLIN N AM, V68, P147, DOI 10.1016/S0025-7125(16)31247-0; SHAPIRO LM, 1983, BRIT HEART J, V50, P530; SHIREY EK, 1980, AM HEART J, V99, P198, DOI 10.1016/0002-8703(80)90766-8; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; UNVERFERTH DV, 1984, AM J CARDIOL, V54, P147, DOI 10.1016/0002-9149(84)90320-5; URBANOMARQUEZ A, 1989, NEW ENGL J MED, V320, P409, DOI 10.1056/NEJM198902163200701; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; 1980, BRIT HEART J, V44, P672; 1979, NOMENCLATURE CRITERI; 1986, SUGI LIBRARY USERS S, P437	50	148	151	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					117	123		10.7326/0003-4819-117-2-117	http://dx.doi.org/10.7326/0003-4819-117-2-117			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605426				2022-12-28	WOS:A1992JD12300004
J	FALIKBORENSTEIN, ZC; JORDAN, SC; SAUDUBRAY, JM; BRIVET, M; DEMAUGRE, F; EDMOND, J; CEDERBAUM, SD				FALIKBORENSTEIN, ZC; JORDAN, SC; SAUDUBRAY, JM; BRIVET, M; DEMAUGRE, F; EDMOND, J; CEDERBAUM, SD			RENAL TUBULAR-ACIDOSIS IN CARNITINE PALMITOYLTRANSFERASE TYPE-1 DEFICIENCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							PALMITOYL TRANSFERASE DEFICIENCY; OXIDATION		UNIV CALIF LOS ANGELES,SCH MED,MENTAL RETARDAT RES CTR,760 WESTWOOD PLAZA,LOS ANGELES,CA 90024; CEDARS SINAI MED CTR,AHMANSON DEPT PEDIAT,CTR MED GENET BIRTH DEFECT,LOS ANGELES,CA 90048; CEDARS SINAI MED CTR,AHMANSON DEPT PEDIAT,DIV PEDIAT NEPHROL,LOS ANGELES,CA 90048; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT,LOS ANGELES,CA 90024; HOP ENFANTS MALAD,GENET MED CLIN,PARIS,FRANCE; HOP BICETRE,BIOCHIM LAB,F-94270 LE KREMLIN BICETR,FRANCE; HOP NECKER ENFANTS MALAD,DEPT BIOCHEM,PARIS,FRANCE	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite			Jordan, Stan/AAI-1250-2021	Jordan, Stan/0000-0002-0456-8635	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD006576] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-06576, HD-11496] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BOUGNERES PF, 1981, J PEDIATR-US, V98, P742, DOI 10.1016/S0022-3476(81)80834-7; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; HALPERIN ML, 1990, MINER ELECTROL METAB, V16, P277; HOPPEL CL, 1990, FATTY ACID OXIDATION, P435; MCGARRY JD, 1989, DIABETES METAB REV, V5, P271, DOI 10.1002/dmr.5610050305; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; ROE CR, 1989, METABOLIC BASIS INHE, V1, P889; Stanley C A, 1987, Adv Pediatr, V34, P59; TANAKA K, 1990, FATTY ACID OXIDATION; TEIN I, 1989, J NEUROL SCI, V92, P229, DOI 10.1016/0022-510X(89)90139-1; WOELTJE KF, 1990, J BIOL CHEM, V265, P10720; WOELTJE KF, 1990, J BIOL CHEM, V265, P10714; WU PYK, 1986, PEDIATR RES, V20, P338, DOI 10.1203/00006450-198604000-00016	14	39	40	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					24	27		10.1056/NEJM199207023270105	http://dx.doi.org/10.1056/NEJM199207023270105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598098	Bronze			2022-12-28	WOS:A1992JA76100005
J	SPENCER, JA; EDWARDS, C				SPENCER, JA; EDWARDS, C			PHARMACY BEYOND THE DISPENSARY - GENERAL-PRACTITIONERS VIEWS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To ascertain general practitioners' attitudes to an extended role for community pharmacists. Design-Postal questionnaire to a 1 in 6 sample of general practitioners in the Northern, West Midlands, and Oxford regions (total sample size 1087). Main outcome measures-Attitudes towards specific extended roles, pharmacist prescribing of particular drugs, the role of the pharmacist, and the relationship between the professions. Results-744 questionnaires were returned in a usable form, an overall response rate of 68.4%. Attitudes varied, from a majority in favour of pharmacists reporting adverse drug reactions to a majority against their supervising repeat prescriptions (81% and 36% in agreement respectively). A similar range of attitudes was shown to pharmacist prescribing, from 84% in agreement with their prescribing nicotine chewing gum (deregulated since the survey) to 11% agreeing to their prescribing cimetidine. About half the respondents thought general practitioners should be allowed to dispense and a third that pharmacists "should stick to dispensing." 27% agreed that pharmacists were too influenced by commercial pressures to give unbiased advice. Conclusions-Most doctors would favour an extension of the activities of community pharmacists but worry about their role in screening and counselling patients and in prescribing. Despite relationships being generally felt to be good, there may be a need for better communication and cooperation locally and for proper evaluation of initiatives to extend the role of the pharmacist.	UNIV NEWCASTLE UPON TYNE,CLIN PHARM,NEWCASTLE TYNE NE2 4HH,ENGLAND	Newcastle University - UK	SPENCER, JA (corresponding author), UNIV NEWCASTLE UPON TYNE,PRIMARY HLTH CARE,NEWCASTLE TYNE NE2 4HH,ENGLAND.							BLENKINSOPP A, 1991, BRIT J GEN PRACT, V41, P116; BRADLEY CP, 1991, BRIT J GEN PRACT, V41, P436; CUNNINGHAMBURLEY S, 1988, FAM PRACT, V5, P122, DOI 10.1093/fampra/5.2.122; Drury M, 1991, Br J Gen Pract, V41, P91; Edwards C, 1981, J R Coll Gen Pract, V31, P674; ELLIOTTBINNS CP, 1986, J ROY COLL GEN PRACT, V36, P542; GOODBURN E, 1991, BMJ-BRIT MED J, V302, P440, DOI 10.1136/bmj.302.6774.440; LIKERT R, 1932, PSYCHOLOGY; MORLEY A, 1983, PHARM J, V231, P387; NEEDHAM A, 1988, J ROY COLL GEN PRACT, V38, P166; RAWLINS M, 1991, BMJ, V2, P427; ROBERTS D, 1988, J ROY COLL GEN PRACT, V38, P563; RYAN M, 1990, HEALTH POLICY, V16, P233, DOI 10.1016/0168-8510(90)90424-C; Shulman J I, 1981, J R Coll Gen Pract, V31, P429; TORY MP, 1990, PHARM J, V244, P255; 1986, PHARM REPORT COMMITT; 1991, WHICH WAY HLTH, P191; 1989, WORKING PATIENTS; 1987, PHARM CHARTER EXTEND; 1987, PROMOTING BETTER HLT; 1991, PHARM J, V246, P414; 1992, PHARM CARE FUTURE CO	23	65	65	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1670	1672		10.1136/bmj.304.6843.1670	http://dx.doi.org/10.1136/bmj.304.6843.1670			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633521	Green Published, Bronze			2022-12-28	WOS:A1992JB93900024
J	HINSHAW, JE; CARRAGHER, BO; MILLIGAN, RA				HINSHAW, JE; CARRAGHER, BO; MILLIGAN, RA			ARCHITECTURE AND DESIGN OF THE NUCLEAR-PORE COMPLEX	CELL			English	Article							LINKED N-ACETYLGLUCOSAMINE; ELECTRON-MICROSCOPE; RIBOSOMAL-SUBUNITS; TRANSPORT SIGNALS; SINGLE PARTICLES; SOFTWARE SYSTEM; PROTEIN IMPORT; ENVELOPE; IDENTIFICATION; BINDING	A three-dimensional analysis of the nuclear pore complex reveals the underlying, highly symmetric framework of this supramolecular assembly, how it is anchored in the nuclear membrane, and how it is built from many distinct, interconnected subunits. The arrangement of the subunits within the membrane pore creates a large central channel, through which active nucleocytoplasmic transport is known to occur, and eight smaller peripheral channels that are probable routes for passive diffusion of ions and small molecules.	UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	HINSHAW, JE (corresponding author), Scripps Res Inst, RES INST, DEPT CELL BIOL, LA JOLLA, CA 92037 USA.			Carragher, Bridget/0000-0002-0624-5020	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044932] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39155] Funding Source: Medline; NIGMS NIH HHS [GM44932] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AEBI U, 1990, EMSA B, V20, P69; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; AKEY CW, 1990, BIOPHYS J, V58, P341, DOI 10.1016/S0006-3495(90)82381-X; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; FELDHERR CM, 1990, ELECTRON MICROSC REV, V3, P73, DOI 10.1016/0892-0354(90)90014-J; FINCH JT, 1965, J MOL BIOL, V13, P1, DOI 10.1016/S0022-2836(65)80075-4; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1990, CELL, V60, P17, DOI 10.1016/0092-8674(90)90712-N; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FRANK J, 1990, Q REV BIOPHYS, V23, P281, DOI 10.1017/S0033583500005564; FRANK J, 1981, ULTRAMICROSCOPY, V6, P343, DOI 10.1016/S0304-3991(81)80236-7; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; FRANKE WW, 1970, J ULTRA MOL STRUCT R, V30, P288, DOI 10.1016/S0022-5320(70)80064-8; FRANKE WW, 1981, J CELL BIOL S, V91, pS39; FRANKE WW, 1974, CELL NUCLEUS, V1, P219; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; KESSEL RG, 1973, PROGR SURFACE MEMBRA, V6, P243; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; MILLIGAN RA, 1986, NUCLEOCYTOPLASMIC TR, P113; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PANDEY S, 1991, BIOCHIM BIOPHYS ACTA, V1063, P81, DOI 10.1016/0005-2736(91)90356-D; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; Ris H., 1989, I PHYS C SER, V98, P657; RIS H, 1991, EMSA B, V21, P54; SAXTON WO, 1979, ULTRAMICROSCOPY, V4, P343, DOI 10.1016/S0304-3991(79)80044-3; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEWART M, 1988, J CELL SCI, V90, P409; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; UNWIN PNT, 1982, J CELL BIOL, V93, P63, DOI 10.1083/jcb.93.1.63; UNWIN PNT, 1980, NATURE, V283, P545, DOI 10.1038/283545a0; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; VANHEEL M, 1981, ULTRAMICROSCOPY, V7, P113, DOI 10.1016/0304-3991(81)90001-2; WOZNIAK RW, 1989, J CELL BIOL, V108, P2083, DOI 10.1083/jcb.108.6.2083; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	51	373	379	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1133	1141		10.1016/0092-8674(92)90635-P	http://dx.doi.org/10.1016/0092-8674(92)90635-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617726				2022-12-28	WOS:A1992JA43100008
J	MALNATI, MS; MARTI, M; LAVAUTE, T; JARAQUEMADA, D; BIDDISON, W; DEMARS, R; LONG, EO				MALNATI, MS; MARTI, M; LAVAUTE, T; JARAQUEMADA, D; BIDDISON, W; DEMARS, R; LONG, EO			PROCESSING PATHWAYS FOR PRESENTATION OF CYTOSOLIC ANTIGEN TO MHC CLASS-II-RESTRICTED T-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; LYMPHOBLASTOID-CELLS; EXPRESSION; REGION; HEMAGGLUTININ; TRANSPORTERS; RECOGNITION; SEQUENCES	ANTIGENS presented to CD4+ T cells derive primarily from exogenous proteins that are processed into peptides capable of binding to class II major histocompatibility complex (MHC) molecules in an endocytic compartment 1-4. In contrast, antigens presented to CD8+ T cells derive mostly from proteins processed in the cytosol, and peptide loading onto class I MHC molecules in an early exocytic compartment is dependent on a transporter for antigen presentation encoded in the class II MHC region 5-11. Endogenous cytosolic antigen can also be presented by class II molecules 12,13. Here we show that, unlike class I-restricted recognition of antigen, HLA-DR1-restricted recognition of cytosolic antigen occurs in mutant cells without a transporter for antigen presentation. In contrast, DR1-restricted recognition of a short cytosolic peptide is dependent on such a transporter. Thus helper T-cell epitopes can be generated from cytosolic antigens by several mechanisms, one of which is distinct from the classical class I pathway.	NIAID,IMMUNOGENET LAB,12441 PARKLAWN DR,ROCKVILLE,MD 20852; HOSP GERMANS TRIAS & PUJOL,IMMUNOL UNIT,E-08916 BADALONA,SPAIN; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Hospital Germans Trias i Pujol; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Wisconsin System; University of Wisconsin Madison			Long, Eric O/G-5475-2011; Malnati, Mauro/AAN-4207-2020; Martí, Mercè/I-2164-2015	Long, Eric O/0000-0002-7793-3728; Martí, Mercè/0000-0002-1846-0043; Malnati, mauro/0000-0001-5355-1680				CEMANBOGNER S, IN PRESS J IMMUN; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; COX JH, 1991, J EXP MED, V174, P1629, DOI 10.1084/jem.174.6.1629; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GOULD K, 1989, J EXP MED, V170, P1051, DOI 10.1084/jem.170.3.1051; GOULD KG, 1987, J EXP MED, V166, P693, DOI 10.1084/jem.166.3.693; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; KARP DR, 1992, J EXP MED, V175, P415, DOI 10.1084/jem.175.2.415; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LONG EO, 1992, NEW BIOL, V4, P274; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UNANUE ER, 1987, SCIENCE, V236, P551, DOI 10.1126/science.2437650; WHITTON JL, 1989, J EXP MED, V170, P1033, DOI 10.1084/jem.170.3.1033	28	182	185	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					702	704		10.1038/357702a0	http://dx.doi.org/10.1038/357702a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614517				2022-12-28	WOS:A1992JA43000076
J	JOBBINS, J; BAGG, J; FINLAY, IG; ADDY, M; NEWCOMBE, RG				JOBBINS, J; BAGG, J; FINLAY, IG; ADDY, M; NEWCOMBE, RG			ORAL AND DENTAL DISEASE IN TERMINALLY ILL CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article									S GLAMORGAN HLTH AUTHOR,CARDIFF CF1 3NW,S GLAM,WALES; UNIV WALES COLL MED,ORAL MED & ORAL PATHOL,CARDIFF CF4 4XN,S GLAM,WALES; HOLME TOWER MARIE CURIE CTR,PENARTH,S GLAM,WALES; UNIV WALES COLL MED,PERIODONTOL,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,MED STAT,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University; Cardiff University			Newcombe, Robert G/B-4897-2009					Aldred M J, 1991, Spec Care Dentist, V11, P59; FINLAY IG, 1986, BRIT MED J, V292, P592, DOI 10.1136/bmj.292.6520.592; JANMOHAMED R, 1990, BRIT J CANCER, V61, P469, DOI 10.1038/bjc.1990.103; WALLACE TW, 1984, MICROBIOS, V41, P99; WRAY D, 1975, BRIT MED J, V2, P490, DOI 10.1136/bmj.2.5969.490	5	41	41	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1612	1612		10.1136/bmj.304.6842.1612	http://dx.doi.org/10.1136/bmj.304.6842.1612			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628090	Bronze, Green Published			2022-12-28	WOS:A1992JA43600025
J	MARZUK, PM; TARDIFF, K; HIRSCH, CS				MARZUK, PM; TARDIFF, K; HIRSCH, CS			THE EPIDEMIOLOGY OF MURDER-SUICIDE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HOMICIDE-SUICIDE; UNITED-STATES; ABNORMAL HOMICIDE; DEPRESSION; DEATH	Objective. - To review the epidemiology, patterns, and major determinants of murder-suicide and to discuss the clinical and research strategies for identifying the individuals at greatest risk for this type of violence. Data Sources. - Data were obtained from English-language articles based on searches using MEDLINE (from 1966), PsychINFO (from 1967), and EMBASE (from 1974) programs. In addition, relevant articles, books, and monographs identified from the reference list of retrieved articles were reviewed. Study Selection. - Case-control studies, descriptive epidemiologic surveys, and case series were chosen for review. Data Extraction. - Because of the limited scope of the pertinent research literature, all data relevant to the incidence, demographics, circumstances, and precipitants of murder-suicide were summarized by the authors. Data Synthesis. - Murder-suicide occurs with an annual incidence of 0.2 to 0.3 per 100 000 person-years and accounts for approximately 1000 to 1500 deaths yearly in the United States. The annual incidence of these events is relatively constant across industrialized nations and has not significantly changed over several decades. The principal perpetrators are young males with intense sexual jealousy, depressed mothers, or despairing elderly men with ailing spouses. The principal victims are female sexual partners or consanguineous relatives, usually young children. Clinical depression, specific motivations such as male sexual proprietariness or maternal salvation fantasies, and a history of previous suicide attempts are important in explaining underlying psychopathological mechanisms. Conclusions. - Murder-suicide occupies a distinct epidemiological domain that overlaps with suicide, domestic homicide, and mass murder. These events may be categorized into one of only several phenomenologic typologies that share similar demographics, motivations, and circumstances. Despite the disruption of families and communities caused by murder-suicide, there are no standardized operational definitions, validated taxonomic systems, or national surveillance networks for these events, all of which are needed to develop prevention strategies.	NYU, SCH MED, DEPT FORENS MED, NEW YORK, NY 10003 USA; OFF CHIEF MED EXAMINER, NEW YORK, NY USA; CORNELL UNIV, MED CTR, COLL MED, DEPT PUBL HLTH, NEW YORK, NY 10021 USA	New York University; Cornell University	MARZUK, PM (corresponding author), CORNELL UNIV, MED CTR,COLL MED,DEPT PSYCHIAT, PUBL HLTH RES PSYCHIAT SECT, 1300 YORK AVE, NEW YORK, NY 10021 USA.				NIDA NIH HHS [1 RO1 DAO6354-01] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ADELSON L, 1991, AM J FOREN MED PATH, V12, P16, DOI 10.1097/00000433-199103000-00003; ALLEN NH, 1983, SUICIDE LIFE-THREAT, V13, P155; BATT JC, 1948, J MENT SCI, V94, P782, DOI 10.1192/bjp.94.397.782; BERMAN AL, 1979, SUICIDE LIFE-THREAT, V9, P15; BLOM GE, 1991, CHILD PSYCHIAT HUM D, V21, P257, DOI 10.1007/BF00705930; BOURGET D, 1987, CAN J PSYCHIAT, V32, P222, DOI 10.1177/070674378703200313; BOURGET D, 1990, CAN J PSYCHIAT, V35, P233, DOI 10.1177/070674379003500306; BROWN GL, 1982, AM J PSYCHIAT, V139, P741; BROWNE WJ, 1975, HOSP COMMUNITY PSYCH, V26, P71; Buda M, 1990, SUICIDE LIFE CYCLE R, P17; CAVAN R, 1928, SUICIDE, P254; COID J, 1983, PSYCHOL MED, V13, P855, DOI 10.1017/S0033291700051576; COPELAND AR, 1985, J FORENSIC SCI SOC, V25, P181, DOI 10.1016/S0015-7368(85)72390-0; CURRENS S, 1991, MMWR-MORBID MORTAL W, V40, P659; Currens S., 1991, MMWR-MORBID MORTAL W, V40, p[652, 659]; DALY M, 1988, SCIENCE, V242, P519, DOI 10.1126/science.3175672; Daly M., 1988, HOMICIDE; DANTO BL, 1978, INT J OFFENDER THER, V22, P140, DOI 10.1177/0306624X7802200206; DIETZ PE, 1986, B NEW YORK ACAD MED, V62, P477; DIETZ PE, 1987, AM PSYCHIAT ASS ANN, V6, P465; DORBAN PT, 1979, BRIT J PSYCHIAT, V134, P560, DOI 10.1192/bjp.134.6.560; DORPAT TL, 1966, PSYCHIATRY DIGEST, P51; ENOCH MD, 1979, UNCOMMON PSYCHIATRIC; FEGGETTER G, 1980, BRIT J PSYCHIAT, V136, P552, DOI 10.1192/bjp.136.6.552; FINK WL, 1979, HOSP COMMUNITY PSYCH, V30, P558; FISHBAIN DA, 1986, AM J PSYCHIAT, V143, P1319; FISHBAIN DA, 1985, J FORENSIC SCI, V30, P1148; FISHBAIN DA, 1989, CLIN J PAIN, V5, P275, DOI 10.1097/00002508-198909000-00014; GOLDNEY RD, 1983, FORENSIC SCI INT, V21, P161, DOI 10.1016/0379-0738(83)90105-6; GOLDNEY RD, 1977, FORENSIC SCI, V9, P219, DOI 10.1016/0300-9432(77)90094-2; GOTTLIEB P, 1987, ACTA PSYCHIAT SCAND, V76, P514, DOI 10.1111/j.1600-0447.1987.tb02912.x; GOVE WR, 1973, AM J SOCIOL, V79, P45, DOI 10.1086/225505; GUDJONSSON GH, 1990, ACTA PSYCHIAT SCAND, V82, P49; HARDER T, 1967, ACTA PSYCHIAT SCAND, V43, P196, DOI 10.1111/j.1600-0447.1967.tb11026.x; HARTHANSON JP, 1974, FORENSIC SCI, V4, P107, DOI 10.1016/0300-9432(74)90091-0; HIROSE S, 1979, ACTA PSYCHIAT SCAND, V59, P211, DOI 10.1111/j.1600-0447.1979.tb06961.x; JASON J, 1983, AM J EPIDEMIOL, V117, P309, DOI 10.1093/oxfordjournals.aje.a113543; LECSO PA, 1989, J AM GERIATR SOC, V37, P167, DOI 10.1111/j.1532-5415.1989.tb05878.x; LESTER D, 1991, SOC PSYCH PSYCH EPID, V26, P83, DOI 10.1007/BF00791532; LESTER D, 1987, PSYCHOL REP, V61, P198, DOI 10.2466/pr0.1987.61.1.198; LESTER D, 1987, PSYCHOL REP, V60, P1130, DOI 10.2466/pr0.1987.60.3c.1130; LESTER D, 1974, PSYCHOL REP, V35, P238, DOI 10.2466/pr0.1974.35.1.238; LEVITON J, 1989, TIME            0717, P57; LEVITON J, 1989, TIME            0717, P31; LEW EO, 1988, AM J FOREN MED PATH, V9, P283, DOI 10.1097/00000433-198812000-00002; Lindqvist P, 1986, Int J Law Psychiatry, V8, P19, DOI 10.1016/0160-2527(86)90081-6; LINNOILA M, 1983, LIFE SCI, V33, P2609, DOI 10.1016/0024-3205(83)90344-2; Mann J. J., 1986, PSYCHOBIOLOGY SUICID; MARCIKIC M, 1990, AM J FOREN MED PATH, V11, P312, DOI 10.1097/00000433-199012000-00009; MERCY JA, 1989, AM J PUBLIC HEALTH, V79, P595, DOI 10.2105/AJPH.79.5.595; MYERS S, 1970, AM J DIS CHILD, V120, P534, DOI 10.1001/archpedi.1970.02100110082008; PALMER S, 1980, SUICIDE LIFE-THREAT, V10, P106; RESNICK PJ, 1969, AM J PSYCHIAT, V126, P325, DOI 10.1176/ajp.126.3.325; RESNICK PJ, 1970, AM J PSYCHIAT, V126, P1414, DOI 10.1176/ajp.126.10.1414; RODENBURG M, 1971, CAN PSYCHIAT ASSOC J, V16, P41, DOI 10.1177/070674377101600107; ROSENBAUM M, 1990, AM J PSYCHIAT, V147, P1036; ROSENBAUM M, 1986, AM J PSYCHIAT, V143, P367; ROSENBAUM M, 1983, ARCH GEN PSYCHIAT, V40, P979; SANTORO JP, 1985, AM J FOREN MED PATH, V6, P222, DOI 10.1097/00000433-198509000-00010; SELKIN J, 1976, SUICIDE LIFE-THREAT, V6, P79; SHEPHERD M, 1961, J MENT SCI, V107, P687, DOI 10.1192/bjp.107.449.687; SOMANDER LKH, 1991, CHILD ABUSE NEGLECT, V15, P45, DOI 10.1016/0145-2134(91)90089-V; TARDIFF K, 1985, HOSP COMMUNITY PSYCH, V36, P632; TEOH JI, 1972, PSYCHIATR, V35, P345, DOI 10.1080/00332747.1972.11023730; VANPRAAG HM, 1990, VIOLENCE SUICIDALITY; VIRKKUNEN M, 1974, PSYCHIAT QUART, V48, P276, DOI 10.1007/BF01584690; WEST DJ, 1967, MURDER SUICIDE; WILBANKS W, 1984, MURDER MIAMI; WILKEY I, 1982, MED SCI LAW, V22, P31, DOI 10.1177/002580248202200105; Wolfgang M. E., 1958, PATTERNS CRIMINAL HO; WOLFGANG MARVIN E., 1958, JOUR CLIN AND EXPTL PSYCHOPATH, V19, P208; WONG M, 1973, BRIT J PSYCHIAT, V123, P295, DOI 10.1192/bjp.123.3.295; 1987, DIAGNOSTIC STATISTIC; [No title captured]; 1991, VITAL STATISTICS US, P2	75	288	293	3	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1992	267	23					3179	3183		10.1001/jama.267.23.3179	http://dx.doi.org/10.1001/jama.267.23.3179			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX918	1593740				2022-12-28	WOS:A1992HX91800028
J	ATKINSON, C; HAYDEN, J				ATKINSON, C; HAYDEN, J			MANAGING CHANGE IN PRIMARY CARE - STRATEGIES FOR SUCCESS .3.	BRITISH MEDICAL JOURNAL			English	Article									UNIV MANCHESTER,DEPT POSTGRAD MED STUDIES,MANCHESTER M60 7LP,ENGLAND	University of Manchester	ATKINSON, C (corresponding author), UNIV MANCHESTER,HLTH SERV MANAGEMENT UNIT,MANCHESTER M13 9PL,LANCS,ENGLAND.							KOTTER JP, 1979, PLANNING MANAGING CH; Plant R., 1987, MANAGING CHANGE MAKI; 1984, RCGP23 ROYAL COLL GE	3	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1488	1490		10.1136/bmj.304.6840.1488	http://dx.doi.org/10.1136/bmj.304.6840.1488			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611374	Green Published, Bronze			2022-12-28	WOS:A1992HY55300027
J	GONNET, GH; COHEN, MA; BENNER, SA				GONNET, GH; COHEN, MA; BENNER, SA			EXHAUSTIVE MATCHING OF THE ENTIRE PROTEIN-SEQUENCE DATABASE	SCIENCE			English	Article								The entire protein sequence database has been exhaustively matched. Definitive mutation matrices and models for scoring gaps were obtained from the matching and used to organize the sequence database as sets of evolutionarily connected components. The methods developed are general and can be used to manage sequence data generated by major genome sequencing projects. The alignments made possible by the exhaustive matching are the starting point for successful de novo prediction of the folded structures of proteins, for reconstructing sequences of ancient proteins and metabolisms in ancient organisms, and for obtaining new perspectives in structural biochemistry.	SWISS FED INST TECHNOL, INST SCI COMPUTAT, UNIV STR 16, CH-8092 ZURICH, SWITZERLAND; SWISS FED INST TECHNOL, INST ORGAN CHEM, CH-8092 ZURICH, SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich								ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BENNER SA, 1989, ADV ENZYME REGUL, V28, P219, DOI 10.1016/0065-2571(89)90073-3; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BLUNDELL TL, 1987, NATURE, V326, P347, DOI 10.1038/326347a0; BRANT DA, 1965, J AM CHEM SOC, V87, P2788, DOI 10.1021/ja01091a002; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P99; DOOLITTLE RF, 1981, SCIENCE, V214, P149, DOI 10.1126/science.7280687; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; EDWARDS AWF, 1963, ANN HUM GENET, V27, P104; FARRIS JS, 1970, SYST ZOOL, V19, P83, DOI 10.2307/2412028; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; Flory PJ., 1953, PRINCIPLES POLYM CHE, V672; Gonnet G.H., 1984, HDB ALGORITHMS DATA; GONNET GH, 1991, 154 EIDG TH DEP INF; HEIN J, 1989, MOL BIOL EVOL, V6, P649; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NIERMANN T, 1990, PROTEIN ENG, V4, P137, DOI 10.1093/protein/4.2.137; RECHSTEINER MC, 1991, TRENDS BIOCHEM SCI, V16, P455, DOI 10.1016/0968-0004(91)90178-X; STACKHOUSE J, 1990, FEBS LETT, V262, P104, DOI 10.1016/0014-5793(90)80164-E; TAYLOR W, 1991, NATURE, V353, P388, DOI 10.1038/353388a0; TAYLOR WR, 1990, METHOD ENZYMOL, V183, P456; TAYLOR WR, 1987, COMPUT APPL BIOSCI, V3, P81; THORNTON JM, 1991, NATURE, V354, P105, DOI 10.1038/354105a0; YAGER TD, 1991, TRENDS BIOCHEM SCI, V16, P454, DOI 10.1016/0968-0004(91)90177-W; ZUCKERKANDL EMILE, 1964, PROTIDES BIOL FLUIDS, V12, P102; ZUCKERKANDL EMILE, 1965, P97	29	587	792	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 5	1992	256	5062					1443	1445		10.1126/science.1604319	http://dx.doi.org/10.1126/science.1604319			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604319				2022-12-28	WOS:A1992HX33700035
J	LOGIE, D				LOGIE, D			THE GREAT EXTERMINATOR OF CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									HLTH CTR,EARLSTON,BERWICK,SCOTLAND									Cornia Giovanni Andrea, 1988, ADJUSTMENT HUMAN FAC, V1; COSTELLO A, 1992, GUARDIAN        0113; GEORGE S, 1988, FATE WORSE DEBT; GILLEN D, 1991, BRIT MED J, V303, P1017; Holden, 1991, CHILDREN CITIES; KELLY R, 1991, GUARDIAN        1216; MAYO E, 1991, GUARDIAN        1114; SMITH T, 1992, BRIT MED J, V304, P388; VALLELY P, 1991, BAD SAMARITANS; 1990, BRAZIL BRIEFING; 1991, COMMENT 3RD WORLD DE, P3; 1990, CHILDREN ENV; 1991, STATE WORLDS CHILDRE; 1991, BANKING POOR, P19	14	10	10	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1423	1426		10.1136/bmj.304.6839.1423	http://dx.doi.org/10.1136/bmj.304.6839.1423			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628022	Green Published, Bronze			2022-12-28	WOS:A1992HX08200027
J	BETTS, PR; VOSS, LD; BAILEY, BJR				BETTS, PR; VOSS, LD; BAILEY, BJR			MEASURING THE HEIGHTS OF VERY YOUNG-CHILDREN	BRITISH MEDICAL JOURNAL			English	Article									SOUTHAMPTON GEN HOSP,WESSEX GROWTH STUDY,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,FAC MATH STUDIES,SOUTHAMPTON SO9 5NH,HANTS,ENGLAND	University of Southampton; University of Southampton	BETTS, PR (corresponding author), SOUTHAMPTON GEN HOSP,DEPT PAEDIAT & CHILD HLTH,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; VOSS LD, 1991, ARCH DIS CHILD, V66, P833, DOI 10.1136/adc.66.7.833; VOSS LD, 1990, ARCH DIS CHILD, V65, P1340, DOI 10.1136/adc.65.12.1340	3	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1351	1352		10.1136/bmj.304.6838.1351	http://dx.doi.org/10.1136/bmj.304.6838.1351			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611333	Bronze, Green Published			2022-12-28	WOS:A1992HW41700023
J	WILLIAMS, SM; PARRY, BR; SCHLUP, MMT				WILLIAMS, SM; PARRY, BR; SCHLUP, MMT			QUALITY-CONTROL - AN APPLICATION OF THE CUSUM	BRITISH MEDICAL JOURNAL			English	Article									UNIV OTAGO,SCH MED,DEPT SURG,DUNEDIN,NEW ZEALAND; UNIV OTAGO,SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND	University of Otago; University of Otago	WILLIAMS, SM (corresponding author), UNIV OTAGO,SCH MED,DEPT PREVENT & SOCIAL MED,BOX 913,DUNEDIN,NEW ZEALAND.		Williams, Sheila/L-4028-2019					COTTON PB, 1982, PRACTICAL GI ENDOSCO; Davies OL, 1978, DESIGN ANAL IND EXPT; GALLUS G, 1986, STAT MED, V5, P565, DOI 10.1002/sim.4780050603; KINSEY SE, 1989, BRIT MED J, V299, P775, DOI 10.1136/bmj.299.6702.775; NIX ABJ, 1987, STAT MED, V6, P425, DOI 10.1002/sim.4780060403; PARRY BR, 1991, AUST NZ J SURG, V61, P419, DOI 10.1111/j.1445-2197.1991.tb00254.x; SHAW CD, 1989, BRIT MED J, V299, P498, DOI 10.1136/bmj.299.6697.498; VAIRA D, 1989, GUT, V30, P939, DOI 10.1136/gut.30.7.939; van Dobben de Bruyn C., 1968, CUMULATIVE SUM TESTS; WILLIAMS CB, 1987, CURR OPIN GASTROEN, V3, P36, DOI 10.1097/00001574-198701000-00007	10	171	173	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1359	1361		10.1136/bmj.304.6838.1359	http://dx.doi.org/10.1136/bmj.304.6838.1359			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611337	Green Published, Bronze			2022-12-28	WOS:A1992HW41700029
J	MORGAN, TR				MORGAN, TR			PREDNISOLONE IN SEVERE ALCOHOLIC HEPATITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							THERAPY; ENCEPHALOPATHY; TRIAL				MORGAN, TR (corresponding author), VET AFFAIRS MED CTR,LONG BEACH,CA 90822, USA.			Poynard, Thierry/0000-0002-2050-640X				CARITHERS RL, 1989, ANN INTERN MED, V110, P685, DOI 10.7326/0003-4819-110-9-685; DEPEW W, 1980, GASTROENTEROLOGY, V78, P524; HELMAN RA, 1971, ANN INTERN MED, V74, P311, DOI 10.7326/0003-4819-74-3-311; LESESNE HR, 1978, GASTROENTEROLOGY, V74, P169; MADDREY WC, 1978, GASTROENTEROLOGY, V75, P193; RAMOND MJ, 1992, NEW ENGL J MED, V326, P507, DOI 10.1056/NEJM199202203260802	6	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					284	285						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614484				2022-12-28	WOS:A1992JE38100029
J	EVENS, RG				EVENS, RG			RADIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											EVENS, RG (corresponding author), WASHINGTON UNIV,SCH MED,EDWARD MALLINCKRODT INST RADIOL,ST LOUIS,MO 63110, USA.							BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BOTTOMLEY PA, 1991, RADIOLOGY, V181, P344, DOI 10.1148/radiology.181.2.1924769; CONOLEY PM, 1991, AM J ROENTGENOL, V157, P1337, DOI 10.2214/ajr.157.6.1950885; EVENS RG, 1991, AM J ROENTGENOL, V157, P603, DOI 10.2214/ajr.157.3.1872246; GELFAND DW, 1991, AM J ROENTGENOL, V156, P939, DOI 10.2214/ajr.156.5.1902013; GRENIER N, 1991, RADIOLOGY, V178, P217, DOI 10.1148/radiology.178.1.1984307; HACKNEY DB, 1991, RADIOLOGY, V181, P711, DOI 10.1148/radiology.181.3.1947086; MASARYK AM, 1991, RADIOLOGY, V179, P797, DOI 10.1148/radiology.179.3.2027995; NYBERG DA, 1991, RADIOLOGY, V178, P823, DOI 10.1148/radiology.178.3.1994425; PALMAZ JC, 1990, RADIOLOGY, V174, P969, DOI 10.1148/radiology.174.3.174-3-969; PARDO JV, 1991, NATURE, V349, P61, DOI 10.1038/349061a0; PARKER SH, 1991, RADIOLOGY, V180, P403, DOI 10.1148/radiology.180.2.1648757; SCHNALL MD, 1991, RADIOLOGY, V178, P797, DOI 10.1148/radiology.178.3.1994421; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; TESSLER FN, 1991, AJR AM J ROENTGENOL, V157, P292; WOLF SI, 1991, RADIOLOGY, V180, P65, DOI 10.1148/radiology.180.1.2052725; ZEMEL G, 1991, JAMA-J AM MED ASSOC, V266, P390, DOI 10.1001/jama.266.3.390	17	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					409	411						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613939				2022-12-28	WOS:A1992JC35200052
J	DEQUEKER, J; RICO, H				DEQUEKER, J; RICO, H			RHEUMATOID ARTHRITIS-LIKE DEFORMITIES IN AN EARLY 16TH-CENTURY PAINTING OF THE FLEMISH-DUTCH-SCHOOL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIQUITY	Hand deformities resembling those of rheumatoid arthritis have been depicted in a painting by an anonymous artist of the Flemish-Dutch School, mid-15th to early 16th century. The painting is presently in the Escorial Museum near Madrid, Spain. This observation, like other earlier observations of rheumatoid deformities in paintings of the Middle Ages, suggests that rheumatoid arthritis is not a modern disease; it had, indeed, appeared several centuries before Landre-Beauvais' description in 1800.	CATHOLIC UNIV LEUVEN,ARTHRIT & METAB BONE DIS RES UNIT,B-3000 LOUVAIN,BELGIUM; HOSP UNIV SAN CARLOS,SECTOR OSTEOPATIAS,MADRID,SPAIN	KU Leuven								ALARCONSEGOVIA D, 1985, ARTHRITIS RHEUM, V28, P600; APPELBOOM T, 1981, JAMA-J AM MED ASSOC, V245, P483, DOI 10.1001/jama.245.5.483; DEQUEKER J, 1977, BRIT MED J, V1, P1203, DOI 10.1136/bmj.1.6070.1203; DEQUEKER J, 1984, ARTHRITIS RHEUM, V27, P1196, DOI 10.1002/art.1780271019; DEQUEKER J, 1987, ART HIST ANTIQUITY R, P31; DEQUEKER J, 1988, JUL S HUM PAL CURR S; DEQUEKER JV, 1981, CAN MED ASSOC J, V124, P1597; Dieppe P., 1987, ART HIST ANTIQUITY R, P109; EHRLICH GE, 1987, JAMA-J AM MED ASSOC, V257, P892; EHRLICH GE, 1987, ART HIST ANTIQUITY R, P80; FRASER KJ, 1982, ANN RHEUM DIS, V41, P335, DOI 10.1136/ard.41.4.335; ORTNER DJ, 1981, AM J PHYS ANTHROPOL, V56, P23, DOI 10.1002/ajpa.1330560103; ORTNER DJ, 1987, ARCHEOLOGY HIST ANTI, P92; ROTHSCHILD BM, 1988, SCIENCE, V241, P1498, DOI 10.1126/science.3047874; SHORT CL, 1974, ARTHRITIS RHEUM, V17, P193, DOI 10.1002/art.1780170302	15	18	20	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					249	251		10.1001/jama.268.2.249	http://dx.doi.org/10.1001/jama.268.2.249			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	JB279	1608144				2022-12-28	WOS:A1992JB27900033
J	JUVELA, S				JUVELA, S			ALCOHOL-CONSUMPTION AS A RISK FACTOR FOR POOR OUTCOME AFTER ANEURYSMAL SUBARACHNOID HEMORRHAGE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GAMMA-GLUTAMYL-TRANSFERASE; CEREBRAL-ISCHEMIA; CIGARETTE-SMOKING; BLOOD-PRESSURE; LIVER-DISEASE; HEMORRHAGE; STROKE; POPULATION; QUESTIONNAIRE; HEART	Objective-To evaluate the effect of factors existing before aneurysmal subarachnoid haemorrhage on outcome of haemorrhage. Design-Prospective follow up study. Setting-Helsinki University Hospital. Patients-291 consecutive patients (149 men) aged 15 to 65 years admitted within 96 hours after the bleeding. Main outcome measures-Potential risk factors (baseline characteristics, health habits, and clinical variables) for poor outcome after haemorrhage (dependent state in the activities of daily living, or death) were studied using multiple logistic regression. Results-One year after haemorrhage, 179 (62%) patients were independent in the activities of daily living and 28 (10%) dependent; 84 (29%) had died. Risk of poor outcome was predicted, after adjustment for sex and age, by clinical condition at admission according to the Glasgow coma scale (p<0.0001); occurrence of rebleeding (relative risk 7.1, 95% confidence interval 2.8 to 18.0, p<0.0001) or delayed cerebral ischaemia (10.3, 4.2 to 25.4, p<0.0001); surgery on an aneurysm (0.13, 0.05 to 0.35, p<0.0001); and heavy consumption of alcohol (4-5, 1.8 to 11.0, p=0.0014). Heavy drinking remained a significant risk factor after additional adjustment for hypertension, body mass index, and presence of intracerebral haematoma. Heavy drinkers had a more unfavourable outcome after rebleeding and delayed ischaemia than did others with rebleeding or ischaemia. Those who had salicylates in urine on admission had delayed ischaemia with fixed neurological deficits less commonly than others. Conclusions-Heavy drinking impairs outcome mainly through severe rebleeding and delayed ischaemia and to a lesser extent through a poor initial condition and presence of intracerebral haematoma.			JUVELA, S (corresponding author), HELSINKI UNIV HOSP, DEPT NEUROSURG, TOPELIUKSENKATU 5, SF-00260 HELSINKI, FINLAND.			Juvela, Seppo/0000-0003-4944-4983				ADAMS HP, 1987, NEUROLOGY, V37, P1586, DOI 10.1212/WNL.37.10.1586; BELL BA, 1979, BRIT MED J, V1, P577, DOI 10.1136/bmj.1.6163.577; BERGLUND M, 1981, ARCH GEN PSYCHIAT, V38, P351; BERNADT MW, 1982, LANCET, V1, P325; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; CAMARGO CA, 1989, STROKE, V20, P1611, DOI 10.1161/01.STR.20.12.1611; COLDITZ GA, 1988, NEW ENGL J MED, V318, P937, DOI 10.1056/NEJM198804143181501; DIXON WJ, 1988, BMDP STATISTICAL SOF; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; ELLIOTT P, 1988, BRIT MED J, V297, P319; ETTINGER PO, 1978, AM HEART J, V95, P555, DOI 10.1016/0002-8703(78)90296-X; HASELAGER EM, 1977, LANCET, V1, P774; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HIJDRA A, 1988, STROKE, V19, P1250, DOI 10.1161/01.STR.19.10.1250; HILLBOM M, 1988, HAEMOSTASIS, V18, P170; HILLBOM M, 1982, NEUROLOGY, V32, P706, DOI 10.1212/WNL.32.7.706; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; JENNETT B, 1975, LANCET, V1, P480; JUVELA S, 1990, NEUROSURGERY, V27, P929, DOI 10.1227/00006123-199012000-00011; JUVELA S, 1992, NEUROSURGERY, V30, P7, DOI 10.1227/00006123-199201000-00002; JUVELA S, 1991, J NEUROSURG, V74, P386, DOI 10.3171/jns.1991.74.3.0386; Juvela S, 1991, THESIS U HELSINKI HE; KASSELL NF, 1982, NEUROSURGERY, V10, P514, DOI 10.1227/00006123-198204000-00019; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; KRISTENSON H, 1980, PREV MED, V9, P108, DOI 10.1016/0091-7435(80)90062-6; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MONTEIRO MG, 1985, DRUG ALCOHOL DEPEN, V16, P31, DOI 10.1016/0376-8716(85)90079-1; MORGAN MY, 1981, CLIN LAB HAEMATOL, V3, P35; OHMAN J, 1991, J NEUROSURG, V74, P14, DOI 10.3171/jns.1991.74.1.0014; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; PUDDEY IB, 1985, HYPERTENSION, V7, P707, DOI 10.1161/01.HYP.7.5.707; RAGNI MV, 1982, ALCOHOL CLIN EXP RES, V6, P267, DOI 10.1111/j.1530-0277.1982.tb04973.x; SACCO RL, 1984, NEUROLOGY, V34, P847, DOI 10.1212/WNL.34.7.847; SHAPER AG, 1991, BRIT MED J, V302, P1111, DOI 10.1136/bmj.302.6785.1111; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; TEASDALE G, 1974, LANCET, V2, P81	37	49	50	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 27	1992	304	6843					1663	1667		10.1136/bmj.304.6843.1663	http://dx.doi.org/10.1136/bmj.304.6843.1663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633519	Green Published, Bronze			2022-12-28	WOS:A1992JB93900021
J	ANSARI, A; JONES, CM; HENRY, ER; HOFRICHTER, J; EATON, WA				ANSARI, A; JONES, CM; HENRY, ER; HOFRICHTER, J; EATON, WA			THE ROLE OF SOLVENT VISCOSITY IN THE DYNAMICS OF PROTEIN CONFORMATIONAL-CHANGES	SCIENCE			English	Article							GEMINATE RECOMBINATION; GLASS-TRANSITION; CARBON-MONOXIDE; LIGAND-BINDING; HEME-PROTEINS; MYOGLOBIN; PHOTODISSOCIATION; SPECTROSCOPY; DIFFUSION; KINETICS	Nanosecond lasers were used to measure the rate of conformational changes ir myoglobin after ligand dissociation at ambient temperatures. At low solvent viscosities the rate is independent of viscosity, but at high viscosities it depends on approximately the inverse first power of the viscosity. Kramers theory for unimolecular rate processes can be used to explain this result if the friction term is modified to include protein as well as solvent friction. The theory and experiment suggest that the dominant factor in markedly reducing the rate of conformational changes in myoglobin at low temperatures (<200 K) is the very high viscosity (>10(7) centipoise) of the glycerol-water solvent. That is, at low temperatures conformational substates may not be "frozen" so much as "stuck."	NIDDKD,CHEM PHYS LAB,BLDG 2,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Henry, Eric R/J-3414-2013	Henry, Eric R/0000-0002-5648-8696				AGMON N, 1983, J CHEM PHYS, V79, P2042, DOI 10.1063/1.445988; ANGELL CA, 1976, ANN NY ACAD SCI, V279, P53, DOI 10.1111/j.1749-6632.1976.tb39693.x; ANSARI A, 1987, BIOPHYS CHEM, V26, P337, DOI 10.1016/0301-4622(87)80034-0; ANSARI A, 1986, BIOCHEMISTRY-US, V25, P3139, DOI 10.1021/bi00359a011; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; BEECE D, 1980, BIOCHEMISTRY-US, V19, P5147, DOI 10.1021/bi00564a001; CHRUNYK BA, 1990, BIOCHEMISTRY-US, V29, P2149, DOI 10.1021/bi00460a027; DEMCHENKO AP, 1989, BIOCHIM BIOPHYS ACTA, V998, P196, DOI 10.1016/0167-4838(89)90273-2; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; FRAUENFELDER H, 1990, J PHYS CHEM-US, V94, P1024, DOI 10.1021/j100366a002; GAVISH B, 1979, BIOCHEMISTRY-US, V18, P1269, DOI 10.1021/bi00574a023; GENBERG L, 1991, SCIENCE, V251, P1051, DOI 10.1126/science.1998121; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HASINOFF BB, 1977, ARCH BIOCHEM BIOPHYS, V183, P176, DOI 10.1016/0003-9861(77)90432-5; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HENRY ER, 1983, J MOL BIOL, V166, P443, DOI 10.1016/S0022-2836(83)80094-1; HENRY ER, 1983, BRUSSELS HEMOGLOBIN, P193; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOFRICHTER J, 1985, BIOCHEMISTRY-US, V24, P2667, DOI 10.1021/bi00332a012; HOFRICHTER J, 1991, BIOCHEMISTRY-US, V30, P6538; IBEN IET, 1989, PHYS REV LETT, V62, P1916, DOI 10.1103/PhysRevLett.62.1916; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KURIYAN J, 1986, J MOL BIOL, V192, P133, DOI 10.1016/0022-2836(86)90470-5; LAMBRIGHT DG, 1991, CHEM PHYS, V158, P249, DOI 10.1016/0301-0104(91)87069-8; MASTRO AM, 1984, J CELL BIOL, V99, pS180, DOI 10.1083/jcb.99.1.180s; MURRAY LP, 1988, BIOPHYS CHEM, V29, P63, DOI 10.1016/0301-4622(88)87025-X; NEWMAN AA, 1968, GLYCEROL; RASMUSSEN DH, 1971, J PHYS CHEM-US, V75, P967, DOI 10.1021/j100677a022; Rice SA., 1985, DIFFUSION LTD REACTI; Smoluchowski M., 1917, Z PHYS CHEM, V92, P129, DOI [10.1515/zpch-1918-9209, DOI 10.1515/ZPCH-1918-9209]; SRAJER V, 1991, BIOCHEMISTRY-US, V30, P4886, DOI 10.1021/bi00234a008; STEINBACH PJ, 1991, BIOCHEMISTRY-US, V30, P3988, DOI 10.1021/bi00230a026; WESTRICK JA, 1987, BIOCHEMISTRY-US, V26, P8313, DOI 10.1021/bi00399a043; XIE XL, 1991, BIOCHEMISTRY-US, V30, P3682, DOI 10.1021/bi00229a013	34	489	496	0	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1796	1798		10.1126/science.1615323	http://dx.doi.org/10.1126/science.1615323			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615323				2022-12-28	WOS:A1992JA43400029
J	MENDEL, D; ELLMAN, JA; CHANG, ZY; VEENSTRA, DL; KOLLMAN, PA; SCHULTZ, PG				MENDEL, D; ELLMAN, JA; CHANG, ZY; VEENSTRA, DL; KOLLMAN, PA; SCHULTZ, PG			PROBING PROTEIN STABILITY WITH UNNATURAL AMINO-ACIDS	SCIENCE			English	Article							LYSOZYME; PACKING; HYDROPHOBICITY	Unnatural amino acid mutagenesis, in combination with molecular modeling and simulation techniques, was used to probe the effect of side chain structure on protein stability. Specific replacements at position 133 in T4 lysozyme included (i) leucine (wt), norvaline, ethyl-glycine, and alanine to measure the cost of stepwise removal of methyl groups from the hydrophobic core, (ii) norvaline and O-methyl serine to evaluate the effects of side chain solvation, and (iii) leucine, S,S-2-amino-4-methylhexanoic acid, and S-2-amino-3-cyclopentylpropanoic acid to measure the influence of packing density and side chain conformational entropy on protein stability. All of these factors (hydrophobicity, packing, conformational entropy, and cavity formation) significantly influence protein stability and must be considered when analyzing any structural change to proteins.	UNIV CALIF BERKELEY, DEPT CHEM, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, CTR ADV MAT, BERKELEY, CA 94720 USA; UNIV CALIF SAN FRANCISCO, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco			Ellman, Jonathan A/C-7732-2013		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008388, R01GM029072] Funding Source: NIH RePORTER; NCRR NIH HHS [NIH-RR-1081] Funding Source: Medline; NIGMS NIH HHS [GM-08388-02, GM-29072] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P619, DOI 10.1002/bip.360260505; BEHE MJ, 1991, P NATL ACAD SCI USA, V88, P4195, DOI 10.1073/pnas.88.10.4195; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; DAOPIN S, 1991, ANNU REV BIOPHYS BIO, V30, P11521; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOERING TL, 1991, SCIENCE, V252, P1851, DOI 10.1126/science.1829548; ELLMAN J, 1991, METHOD ENZYMOL, V202, P301; ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVANS DA, 1990, J AM CHEM SOC, V112, P4011, DOI 10.1021/ja00166a045; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; HEUCKROTH RO, 1986, P NATL ACAD SCI USA, V85, P8795; HUANG C, 1991, MIDAS PLUS; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1991, J MOL BIOL, V219, P359, DOI 10.1016/0022-2836(91)90570-V; LYU PC, 1991, P NATL ACAD SCI USA, V88, P5317, DOI 10.1073/pnas.88.12.5317; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MENDEL D, 1991, J AM CHEM SOC, V113, P2758, DOI 10.1021/ja00007a063; NAEF R, 1985, HELV CHIM ACTA, V68, P135, DOI 10.1002/hlca.19850680117; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NOREN CJ, 1989, SCIENCE, V244, P182, DOI 10.1126/science.2649980; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SCHAFMEISTER C, 1991, LEAP; SEIBEL G, 1991, AMBER 30 REV A; SHARP KA, 1991, SCIENCE, V252, P106, DOI 10.1126/science.2011744; SHARP KA, 1991, BIOCHEMISTRY-US, V30, P9686, DOI 10.1021/bi00104a017; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441	33	136	137	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 26	1992	256	5065					1798	1802		10.1126/science.1615324	http://dx.doi.org/10.1126/science.1615324			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615324				2022-12-28	WOS:A1992JA43400030
J	NUSSE, R; VARMUS, HE				NUSSE, R; VARMUS, HE			WNT GENES	CELL			English	Review							PROTO-ONCOGENE INT-1; MAMMARY-TUMOR VIRUS; SEGMENT-POLARITY GENE; EMBRYONAL CARCINOMA-CELLS; FIBROBLAST GROWTH-FACTOR; NUCLEOTIDE-SEQUENCE; PATTERN-FORMATION; MURINE INT-1; DROSOPHILA-MELANOGASTER; PROVIRAL ACTIVATION		UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; Stanford University; University of California System; University of California San Francisco	NUSSE, R (corresponding author), STANFORD UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; ALI IU, 1989, ONCOGENE, V4, P89; ARIAS AM, 1988, DEVELOPMENT, V103, P157; BABU P, 1977, MOL GEN GENET, V151, P289, DOI 10.1007/BF00268792; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bittner JJ, 1936, SCIENCE, V84, P162, DOI 10.1126/science.84.2172.162; BLASBAND A, 1992, IN PRESS ONCOGENE; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUSSE U, 1990, NUCLEIC ACIDS RES, V18, P7439, DOI 10.1093/nar/18.24.7439; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAKRABARTI A, 1992, IN PRESS DEVELOPMENT; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; COHEN JC, 1979, CELL, V16, P333; COHEN SM, 1990, NATURE, V343, P173, DOI 10.1038/343173a0; DAVIS CA, 1988, GENE DEV, V2, P1736, DOI 10.1101/gad.2.12b.1736; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; EGHBALI B, 1991, P NATL ACAD SCI USA, V88, P10701, DOI 10.1073/pnas.88.23.10701; Forrester LM, 1992, CURR OPIN GENET DEV, V2, P38, DOI 10.1016/S0959-437X(05)80319-3; FRASER SE, 1985, NATURE, V317, P533, DOI 10.1038/317533a0; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; FUNG YKT, 1986, MOL CELL BIOL, V6, P1362; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HALLONET MER, 1990, DEVELOPMENT, V108, P19; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Hoffmann FM, 1992, CURR OPIN GENET DEV, V2, P45, DOI 10.1016/S0959-437X(05)80320-X; HOOPER JE, 1992, RESULTS PROBLEMS CEL; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KAMB A, 1989, P NATL ACAD SCI USA, V86, P4372, DOI 10.1073/pnas.86.12.4372; KIEFER P, 1991, MOL CELL BIOL, V11, P5929, DOI 10.1128/MCB.11.12.5929; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLINGENSMITH J, 1989, DEV BIOL, V134, P130, DOI 10.1016/0012-1606(89)90084-5; KLINGENSMITH J, 1991, CELL ACTIVATION GENE, P251; KORTEWEG R., 1936, GENETICA, V18, P350, DOI 10.1007/BF01507441; KOSTRIKEN R, 1992, DEV BIOL, V151, P225, DOI 10.1016/0012-1606(92)90229-A; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LAMMIE GA, 1991, ONCOGENE, V6, P439; Lane P. W., 1967, MOUSE NEWS LETT, V36, P40; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LUMSDEN A, 1990, NATURE, V347, P335, DOI 10.1038/347335a0; MASON JO, 1992, IN PRESS MOL BIOL CE; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; MOLVEN A, 1991, EMBO J, V10, P799, DOI 10.1002/j.1460-2075.1991.tb08012.x; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; OLSON DJ, 1992, DEV BIOL, V151, P204, DOI 10.1016/0012-1606(92)90227-8; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PERRIMON N, 1989, GENETICS, V121, P333; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; ROELINK H, 1991, GENE DEV, V5, P381, DOI 10.1101/gad.5.3.381; ROELINK H, 1992, ONCOGENE, V7, P487; RUANGVORAVAT CP, 1992, DEV DYNAM, V193, P70, DOI 10.1002/aja.1001930110; RUSSELL J, 1992, IN PRESS DEVELOPMENT; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; Sharma R. P., 1973, DROS INF SER, V50, P134; SIDOW A, 1992, IN PRESS P NATL ACAD; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; SLACK JMW, 1989, DEVELOPMENT, V107, P141; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STARNAUD R, 1989, ONCOGENE, V4, P1077; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; VANDEVIJVER MJ, 1989, CANCER CEL, V7, P385; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	129	885	948	1	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1073	1087		10.1016/0092-8674(92)90630-U	http://dx.doi.org/10.1016/0092-8674(92)90630-U			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617723				2022-12-28	WOS:A1992JA43100003
J	GERSHON, D				GERSHON, D			SAN-ANTONIO AIMS FOR SPOT ON HIGH-TECHNOLOGY MAP	NATURE			English	Editorial Material																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					638	638		10.1038/357638a0	http://dx.doi.org/10.1038/357638a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614512	Bronze			2022-12-28	WOS:A1992JA43000035
J	BARRY, W; HUDGINS, L; DONTA, ST; PESANTI, EL				BARRY, W; HUDGINS, L; DONTA, ST; PESANTI, EL			INTRAVENOUS IMMUNOGLOBULIN THERAPY FOR TOXIC SHOCK SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							STREPTOCOCCAL PYROGENIC TOXINS; SCARLET FEVER TOXIN	Staphylococcus aureus and group A Streptococcus pyogenes produce toxic shock syndrome characterized by hypotension and multisystem organ failure. While conventional therapy has consisted of antibiotics and intensive supportive care, some experimental evidence suggests that immunoglobulins directed against the toxins may be effective additional therapy. We report a case of "toxic strep syndrome" in which intravenous immunoglobulin was administered when signs and symptoms were worsening while the patient was receiving conventional therapy. Within hours of administration of the intravenous immunoglobulin, the patient experienced dramatic clinical improvement. This response suggests a possible therapeutic benefit of intravenous immunoglobulin in toxic shock syndrome.	VET AFFAIRS MED CTR,MED SERV,555 WILLARD AVE,NEWINGTON,CT 06111; UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06032	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Connecticut								BARTTER T, 1988, ARCH INTERN MED, V148, P1421, DOI 10.1001/archinte.148.6.1421; BERKMAN SA, 1990, ANN INTERN MED, V112, P278, DOI 10.7326/0003-4819-112-4-278; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; BOHACH GA, 1988, INFECT IMMUN, V56, P400, DOI 10.1128/IAI.56.2.400-404.1988; FAST DJ, 1989, INFECT IMMUN, V57, P291, DOI 10.1128/IAI.57.1.291-294.1989; JOHNSON LP, 1986, MOL GEN GENET, V203, P354, DOI 10.1007/BF00333979; LEE PK, 1991, INFECT IMMUN, V59, P879, DOI 10.1128/IAI.59.3.879-884.1991; MELISH ME, 1987, CLIN RES, V35, pA57; RICKETTS HT, 1911, INFECTION IMMUNITY S, P515; SCHLIEVERT PM, 1981, INFECT IMMUN, V31, P732, DOI 10.1128/IAI.31.2.732-736.1981; SCOTT DF, 1989, REV INFECT DIS, V11, pS214; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; STROMBERG A, 1991, J INFECT DIS, V164, P595, DOI 10.1093/infdis/164.3.595	13	163	166	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3315	3316		10.1001/jama.267.24.3315	http://dx.doi.org/10.1001/jama.267.24.3315			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597914				2022-12-28	WOS:A1992HY94400031
J	PORTINCASA, P; CONTI, G; RE, MC; CHEZZI, C				PORTINCASA, P; CONTI, G; RE, MC; CHEZZI, C			DETECTION OF IGA AND IGM ANTIBODIES TO HIV-1 IN NEONATES BY RADIOIMMUNE WESTERN BLOTTING	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; INFANTS BORN; INVITRO PRODUCTION; DIAGNOSIS; INFECTION; CHILDREN; TYPE-1; WOMEN	Objective - To detect infection with HIV-1 by IgA and IgM response at birth in children born to HIV-1 seropositive mothers. Design - Western blotting and radioimmune western blotting on stored sera from infected and uninfected babies born to HIV-1 seropositive mothers. Sera were pretreated to remove IgG. Setting - Parma and Bologna, Italy. Subjects - 12 infected and five uninfected babies born to HIV-1 seropositive mothers and three babies born to seronegative mothers. Main outcome measures - Effectiveness of western blotting and radioimmune western blotting in detecting antibodies to HIV-1 gene products. Results - With conventional western blotting we found IgA class antibodies to HIV-1 proteins in serum from three out of 12 infected children; in two of these three the serum was collected at age 3 months (positive controls). Radioimmune western blotting detected both IgA and IgM antibodies in serum from all infected children tested, whereas all serum from uninfected children born to seropositive and seronegative mothers showed no such antibodies. Conclusion - Although the technique should be tested on more patients, radioimmune western blotting seems to be a valuable tool for serological diagnosis of congenital HIV-1 infection at birth in neonates born to seropositive mothers.	UNIV BOLOGNA,OSPED S ORSOLA,FAC MED & CHIRURG,IST MICROBIOL,I-40138 BOLOGNA,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	PORTINCASA, P (corresponding author), UNIV PARMA,FAC MED & CHIRURG,IST MICROBIOL,I-43100 PARMA,ITALY.			Re, Maria Carla/0000-0003-1486-9033				AMADORI A, 1988, LANCET, V1, P852; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BORKOWSKY W, 1987, LANCET, V1, P1168; DEROSSI A, 1988, LANCET, V2, P278; HIGUCHI R, 1989, NATURE, V339, P237; HUTTO C, 1991, J PEDIATR-US, V118, P347, DOI 10.1016/S0022-3476(05)82145-6; JACKSON JB, 1988, J CLIN MICROBIOL, V26, P1416, DOI 10.1128/JCM.26.7.1416-1418.1988; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; LAURE F, 1988, LANCET, V2, P538; LEE FK, 1989, AIDS RES HUM RETROV, V5, P517, DOI 10.1089/aid.1989.5.517; MOK J, 1991, BRIT MED J, V302, P921, DOI 10.1136/bmj.302.6782.921; PAHWA S, 1986, JAMA-J AM MED ASSOC, V255, P2299, DOI 10.1001/jama.255.17.2299; PAHWA S, 1989, P NATL ACAD SCI USA, V86, P7532, DOI 10.1073/pnas.86.19.7532; PALOMBA E, 1990, LANCET, V336, P940, DOI 10.1016/0140-6736(90)92310-E; PORTINCASA P, 1991, EUR J EPIDEMIOL, V7, P705, DOI 10.1007/BF00218688; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; SCHUPBACH J, 1989, AIDS, V3, P583, DOI 10.1097/00002030-198909000-00005; WEIBLEN BJ, 1990, LANCET, V335, P988, DOI 10.1016/0140-6736(90)91061-E; WEIBLEN BJ, 1990, J IMMUNOL METHODS, V126, P199, DOI 10.1016/0022-1759(90)90151-K; WEINTRUB PS, 1991, AIDS, V5, P881, DOI 10.1097/00002030-199107000-00014; 1991, LANCET, V337, P253; 1989, MMWR S7, V38, P1	22	9	9	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1539	1542		10.1136/bmj.304.6841.1539	http://dx.doi.org/10.1136/bmj.304.6841.1539			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628052	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800023
J	MOORE, MS; BLOBEL, G				MOORE, MS; BLOBEL, G			THE 2 STEPS OF NUCLEAR IMPORT, TARGETING TO THE NUCLEAR-ENVELOPE AND TRANSLOCATION THROUGH THE NUCLEAR-PORE, REQUIRE DIFFERENT CYTOSOLIC FACTORS	CELL			English	Article							SIGNAL-BINDING PROTEINS; COMPLEX GLYCOPROTEINS; LOCALIZATION SIGNALS; TRANSPORT SIGNAL; LOCATION SIGNAL; T-ANTIGEN; IDENTIFICATION; SEQUENCE; INHIBITION; MIGRATION	We have isolated two cytosolic fractions from Xenopus oocytes that contain all of the activity necessary to support both steps of nuclear import in digitonin-permeabilized mammalian cells: binding at the nuclear envelope and translocation through the nuclear pore. The first cytosolic fraction (fraction A) interacts with an import-competent, but not a mutant, nuclear localization sequence-bearing conjugate and stimulates its accumulation at the nuclear envelope in an ATP-independent fashion. The second cytosolic fraction (fraction B) gives no discernible effect when added alone; but when added either together with fraction A, or after fraction A, stimulates the passage of the conjugate from the outer nuclear envelope to the interior of the nucleus in an ATP-dependent fashion.			MOORE, MS (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,NEW YORK,NY 10021, USA.				PHS HHS [1F326M137585-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; DAVIS LI, 1986, CELL, V45, P699, DOI 10.1016/0092-8674(86)90784-1; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1991, J CELL BIOL, V113, P705, DOI 10.1083/jcb.113.4.705; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KROHNE G, 1980, P NATL ACAD SCI-BIOL, V77, P1034, DOI 10.1073/pnas.77.2.1034; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LI RH, 1989, J CELL BIOL, V109, P2623, DOI 10.1083/jcb.109.6.2623; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; MATTAJ IW, 1985, CELL, V40, P111, DOI 10.1016/0092-8674(85)90314-9; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; MICHAUD N, 1991, J CELL BIOL, V112, P215, DOI 10.1083/jcb.112.2.215; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; NEWMEYER DD, 1990, J CELL BIOL, V110, P547, DOI 10.1083/jcb.110.3.547; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; REICHELT R, 1990, J CELL BIOL, V110, P883, DOI 10.1083/jcb.110.4.883; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; WALTER P, 1980, P NATL ACAD SCI-BIOL, V77, P7112, DOI 10.1073/pnas.77.12.7112; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; YONEDA Y, 1987, EXP CELL RES, V173, P586, DOI 10.1016/0014-4827(87)90297-7; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	46	259	259	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 12	1992	69	6					939	950		10.1016/0092-8674(92)90613-H	http://dx.doi.org/10.1016/0092-8674(92)90613-H			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606616				2022-12-28	WOS:A1992HY79200006
J	MUSIERFORSYTH, K; SCHIMMEL, P				MUSIERFORSYTH, K; SCHIMMEL, P			FUNCTIONAL CONTACTS OF A TRANSFER-RNA SYNTHETASE WITH 2'-HYDROXYL GROUPS IN THE RNA MINOR GROOVE	NATURE			English	Article							IDENTITY	THE functional analysis of determinants on RNA has been largely limited to molecules that contain naturally occurring ribonucleotides, so little is known about the role of 2'-hydroxyl groups in protein-RNA recognition. A single base pair (G3.U70) in the acceptor stem of tRNA(Ala) is the principal element for specific recognition by Escherichia coli alanine-tRNA synthetase 1,2. This tRNA synthetase aminoacylates small RNA helices that contain the G3.U70 base pair. Furthermore, removal of the G3 exocyclic 2-amino group that projects into the minor groove eliminates aminoacylation 3. This 2-amino group is flanked on either side by ribose 2'-hydroxyl groups that line the minor groove. Here we use chemical synthesis to construct 32 helices that make deoxy and O-methyl substitutions of individual and multiple 2'-hydroxyl groups near and beyond the G3.U70 base pair and find that functional 2'-hydroxyl contacts are clustered within a few angstroms of the critical 2-amino group. These contacts are highly specific and make a thermodynamically significant contribution to RNA recognition.			MUSIERFORSYTH, K (corresponding author), MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA.							BEVILACQUA PC, 1991, BIOCHEMISTRY-US, V30, P10632, DOI 10.1021/bi00108a005; CHOWRIRA BM, 1991, BIOCHEMISTRY-US, V30, P8518, DOI 10.1021/bi00099a003; DOCKBREGEON AC, 1988, NATURE, V335, P375, DOI 10.1038/335375a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; HALL KB, 1991, BIOCHEMISTRY-US, V30, P10606, DOI 10.1021/bi00108a002; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; JASIN M, 1985, J BIOL CHEM, V260, P2226; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MUSIERFORSYTH K, 1991, P NATL ACAD SCI USA, V88, P209, DOI 10.1073/pnas.88.1.209; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; PYLE AM, 1991, NATURE, V350, P628, DOI 10.1038/350628a0; SCARINGE SA, 1990, NUCLEIC ACIDS RES, V18, P5433, DOI 10.1093/nar/18.18.5433; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; WANG AHJ, 1982, NATURE, V299, P601, DOI 10.1038/299601a0	15	113	113	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1992	357	6378					513	515		10.1038/357513a0	http://dx.doi.org/10.1038/357513a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608452				2022-12-28	WOS:A1992HY05200068
J	LI, BQ; KAPLAN, D; KUNG, HF; KAMATA, T				LI, BQ; KAPLAN, D; KUNG, HF; KAMATA, T			NERVE GROWTH-FACTOR STIMULATION OF THE RAS-GUANINE NUCLEOTIDE EXCHANGE FACTOR AND GAP ACTIVITIES	SCIENCE			English	Article							GTPASE ACTIVATING PROTEIN; PC12 CELLS; TYROSINE PHOSPHORYLATION; BOVINE BRAIN; DIFFERENTIATION; MICROINJECTION; PURIFICATION; P21RAS; ONCOGENES; INDUCTION	The biological activity of Ras proteins is thought to be controlled by the guanine nucleotide exchange factor and the guanosine triphosphatase activating protein (GAP). Treatment of rat pheochromocytoma PC-12 cells with nerve growth factor (NGF) increased the amount of active Ras guanosine triphosphate complex and stimulated the activities of both the guanine nucleotide exchange factor and GAP. In PC-12 cells that overexpressed the tyrosine kinase encoded by the trk proto-oncogene (a component of the high-affinity NGF receptor), the NGF-induced activation of the regulatory proteins was potentiated. These results suggest that the NGF receptor system enhances the activities of both the guanine nucleotide exchange factor and GAP and that the activation of Ras might be controlled by the balance in activity between these two regulatory proteins.	NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LAB,EUKARYOT SIGNAL TRANSDUCT GRP,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74102, N01-CO-74101] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102, N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, UNPUB; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; KAMATA T, 1987, BIOCHEM BIOPH RES CO, V144, P19, DOI 10.1016/S0006-291X(87)80469-2; KAMATA T, 1984, NATURE, V310, P147, DOI 10.1038/310147a0; Kamata T., UNPUB; KAPLAN DE, UNPUB; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Li B. A., UNPUB; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SATOH T, 1987, MOL CELL BIOL, V7, P4553, DOI 10.1128/MCB.7.12.4553; SUBULESKI MJ, UNPUB; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	37	121	124	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1456	1459		10.1126/science.1604323	http://dx.doi.org/10.1126/science.1604323			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604323				2022-12-28	WOS:A1992HX33700039
J	MEAD, GM				MEAD, GM			CURRENT ISSUES IN CANCER .4. TESTICULAR CANCER AND RELATED NEOPLASMS	BRITISH MEDICAL JOURNAL			English	Article							GERM-CELL TUMORS; STAGE-I; CARCINOMA INSITU; SEMINOMA; CHEMOTHERAPY; TESTIS; ORCHIDECTOMY; RADIOTHERAPY; CARBOPLATIN; ETOPOSIDE				MEAD, GM (corresponding author), ROYAL S HANS HOSP,MED ONCOL,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							DEARNALEY DP, 1990, INT J RADIAT ONCOL, V18, P773, DOI 10.1016/0360-3016(90)90396-2; DEARNALEY DP, 1991, EUR J CANCER, V27, P684, DOI 10.1016/0277-5379(91)90166-B; DUCHESNE GM, 1990, CANCER, V65, P1115, DOI 10.1002/1097-0142(19900301)65:5<1115::AID-CNCR2820650513>3.0.CO;2-6; EINHORN LH, 1989, J CLIN ONCOL, V7, P387, DOI 10.1200/JCO.1989.7.3.387; FOSSA SD, 1989, INT J RADIAT ONCOL, V16, P383, DOI 10.1016/0360-3016(89)90334-9; FREEDMAN LS, 1987, LANCET, V2, P294; GERSHENSON DM, 1990, J CLIN ONCOL, V8, P715, DOI 10.1200/JCO.1990.8.4.715; GREGORY C, 1986, RADIOTHER ONCOL, V6, P285, DOI 10.1016/S0167-8140(86)80195-5; HORWICH A, 1991, J CLIN ONCOL, V9, P62, DOI 10.1200/JCO.1991.9.1.62; HORWICH A, 1989, J CLIN ONCOL, V7, P1150, DOI 10.1200/JCO.1989.7.8.1150; JANSEN RLH, 1991, EUR J CANCER, V27, P695, DOI 10.1016/0277-5379(91)90168-D; LEWIS CR, 1991, ANN ONCOL, V2, P203, DOI 10.1093/oxfordjournals.annonc.a057906; LOEHRER PJ, 1988, J NATL CANCER I, V80, P1373, DOI 10.1093/jnci/80.17.1373; MCKENDRICK JJ, 1991, CANCER, V67, P684, DOI 10.1002/1097-0142(19910201)67:3<684::AID-CNCR2820670326>3.0.CO;2-7; MEAD GM, 1992, J CLIN ONCOL, V10, P85, DOI 10.1200/JCO.1992.10.1.85; NICHOLS CR, 1991, J CLIN ONCOL, V9, P1163, DOI 10.1200/JCO.1991.9.7.1163; NICHOLS CR, 1990, CANCER, V65, P1641, DOI 10.1002/1097-0142(19900401)65:7<1641::AID-CNCR2820650731>3.0.CO;2-U; NICHOLS CR, 1989, J CLIN ONCOL, V7, P932, DOI 10.1200/JCO.1989.7.7.932; NICHOLS CR, 1990, NEW ENGL J MED, V322, P1425, DOI 10.1056/NEJM199005173222004; READ G, IN PRESS J CLIN ONCO; REINBERG Y, 1989, J UROLOGY, V142, P243, DOI 10.1016/S0022-5347(17)38720-7; ROTH BJ, 1988, J CLIN ONCOL, V6, P1239, DOI 10.1200/JCO.1988.6.8.1239; SENTURIA YD, 1987, BRIT J UROL, V60, P285, DOI 10.1111/j.1464-410X.1987.tb04970.x; Smith D B, 1991, Clin Oncol (R Coll Radiol), V3, P96, DOI 10.1016/S0936-6555(05)81173-2; VONDERMAASE H, 1986, BRIT MED J, V293, P1398, DOI 10.1136/bmj.293.6559.1398	25	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1426	1429		10.1136/bmj.304.6839.1426	http://dx.doi.org/10.1136/bmj.304.6839.1426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628023	Bronze, Green Published			2022-12-28	WOS:A1992HX08200028
J	BLACK, DL				BLACK, DL			ACTIVATION OF C-SRC NEURON-SPECIFIC SPLICING BY AN UNUSUAL RNA ELEMENT INVIVO AND INVITRO	CELL			English	Article							PRE-MESSENGER-RNA; GENE-EXPRESSION; RIBONUCLEOPROTEIN-PARTICLES; BINDING PROTEINS; POLYMERASE-II; SEX-LETHAL; INTRON; SITE; INITIATION; CONTAINS	A conserved positive-acting RNA sequence was found to be required for the neuron-specific splicing of the mouse c-src N1 exon. The sequence lies in the intron between exons N1 and 4, close to the N1 donor site. Normally, only the neural-specific splicing of exon N1 required this sequence. When the intron downstream of N1 was shortened, splicing at the constitutive exon 4 acceptor also became dependent on the activating sequence. The neuronal and nonneuronal patterns of src splicing were reconstituted in vitro. HeLa cell extracts spliced exon 4 to exon 3, skipping exon N1. Weri-1 retinoblastoma cell extracts spliced exon 4 to exon N1 as well as to exon 3. Both patterns of splicing were dependent on the activating sequence. A 123 nt RNA containing just the activating sequence specifically inhibited both patterns of src splicing, indicating that factors bound to the activator were required for its effects.			BLACK, DL (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NICHD NIH HHS [HD28063-1] Funding Source: Medline; NIGMS NIH HHS [GM39458] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039458] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BISHOP JM, 1985, RNA TUMOR VIRUSES S, V2, P249; BLACK DL, 1991, GENE DEV, V5, P389, DOI 10.1101/gad.5.3.389; CHEBLI K, 1989, MOL CELL BIOL, V9, P4852, DOI 10.1128/MCB.9.11.4852; COTE GJ, 1991, NUCLEIC ACIDS RES, V19, P3601, DOI 10.1093/nar/19.13.3601; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; Erlich H.A., 1989, PCR TECHNOLOGY; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KUO HC, 1991, SCIENCE, V251, P1045, DOI 10.1126/science.1825520; LASKI FA, 1989, GENE DEV, V3, P720, DOI 10.1101/gad.3.5.720; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maniatis T, 1989, DECONTAMINATION DILU; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; PAWSON T, 1988, ONCOGENE, V3, P491; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TSENG JC, 1991, MECH DEVELOP, V35, P65, DOI 10.1016/0925-4773(91)90042-5	51	150	152	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					795	807		10.1016/0092-8674(92)90291-J	http://dx.doi.org/10.1016/0092-8674(92)90291-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591778				2022-12-28	WOS:A1992HW83800010
J	BRIGGS, DEG				BRIGGS, DEG			CONODONTS - A MAJOR EXTINCT GROUP ADDED TO THE VERTEBRATES	SCIENCE			English	Editorial Material											BRIGGS, DEG (corresponding author), UNIV BRISTOL,DEPT GEOL,WILLS MEM BLDG,QUEENS RD,BRISTOL BS8 1RJ,ENGLAND.							ALDRIDGE RJ, 1986, LETHAIA, V19, P279, DOI 10.1111/j.1502-3931.1986.tb00741.x; ALDRIDGE RJ, IN PRESS FOSSIL RECO; BLIECK A, 1991, SPEC PAP PALAEONTOL, V44, P345; BRIGGS DEG, 1983, LETHAIA, V16, P1, DOI 10.1111/j.1502-3931.1983.tb01139.x; ELLIOTT DK, 1991, GEOLOGICAL SURVEY CA, V909, P93; SANSOM IJ, 1992, SCIENCE, V256, P1308, DOI 10.1126/science.1598573; SMITH MM, 1990, BIOL REV, V65, P277, DOI 10.1111/j.1469-185X.1990.tb01427.x; Sweet WC, 1988, CONODONTA MORPHOLOGY	8	40	40	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1285	1286		10.1126/science.1598571	http://dx.doi.org/10.1126/science.1598571			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598571				2022-12-28	WOS:A1992HW13500023
J	KOH, DR; FUNGLEUNG, WP; HO, A; GRAY, D; ACHAORBEA, H; MAK, TW				KOH, DR; FUNGLEUNG, WP; HO, A; GRAY, D; ACHAORBEA, H; MAK, TW			LESS MORTALITY BUT MORE RELAPSES IN EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS IN CD8-/- MICE	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SUPPRESSOR CELLS; T-CELLS; INVIVO; DEPLETION; ANTIBODY; INVITRO; EAE	Mice lacking in CD8 were generated from homologous recombination in embryonal stem cells at the CD8 locus and bred with the experimental allergic encephalomyelitis (EAE)-susceptible PL/J H-2u through four backcross generations to investigate the role of CD8+ T cells in this model of multiple sclerosis. The disease onset and susceptibility were similar to those of wild-type mice. However, the mutant mice had a milder acute EAE, reflected by fewer deaths, but more chronic EAE, reflected by a higher frequency of relapse. This suggests that CD8+ T lymphocytes may participate as both effectors and regulators in this animal model.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA; LUDWIG INST CANC RES,LAUSANNE BRANCH,CH-1066 EPALINGES,SWITZERLAND	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Ludwig Institute for Cancer Research	KOH, DR (corresponding author), UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,500 SHERBOURNE ST,TORONTO M4X 1K9,ONTARIO,CANADA.			Fung-Leung, Wai-Ping/0000-0001-7013-8855				ACHAORBEA H, 1989, ANNU REV IMMUNOL, V7, P371, DOI 10.1146/annurev.iy.07.040189.002103; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; ARNASON BG, 1962, J EXP MED, V116, P177, DOI 10.1084/jem.116.2.177; ARNON R, 1981, IMMUNOL REV, V55, P5, DOI 10.1111/j.1600-065X.1981.tb00337.x; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BROSTOFF SW, 1984, J IMMUNOL, V133, P1938; BROWN A, 1982, LAB INVEST, V46, P171; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUNGLEUNG WP, UNPUB; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KARPUS WJ, 1989, J IMMUNOL, V143, P3492; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; LEMIRE JM, 1986, J IMMUNOL, V137, P3169; LIDER O, 1989, J IMMUNOL, V142, P748; MASON D, 1991, IMMUNOL TODAY, V12, P57, DOI 10.1016/0167-5699(91)90158-P; MATHIESON PW, 1991, EUR J IMMUNOL, V21, P2105, DOI 10.1002/eji.1830210919; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOSSMANN TR, 1989, ADV IMMUNOL, V46, P111; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; POWELL MB, 1990, INT IMMUNOL, V2, P539, DOI 10.1093/intimm/2.6.539; RACKE MK, 1991, J IMMUNOL, V146, P3012; SAKAI K, 1986, J IMMUNOL, V137, P1527; SAMBHARA SR, 1991, SCIENCE, V252, P1424; SEDGWICK JD, 1988, EUR J IMMUNOL, V18, P495, DOI 10.1002/eji.1830180402; SEDGWICK JD, 1990, J IMMUNOL, V145, P2474; SRIRAM S, 1988, J NEUROIMMUNOL, V17, P147, DOI 10.1016/0165-5728(88)90022-7; SRIRAM S, 1988, J IMMUNOL, V141, P464; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0	33	319	332	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1210	1213		10.1126/science.256.5060.1210	http://dx.doi.org/10.1126/science.256.5060.1210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589800				2022-12-28	WOS:A1992HV19200038
J	ANDERSON, WF				ANDERSON, WF			HUMAN GENE-THERAPY	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; METASTATIC MELANOMA; ETHICAL ISSUES; STEM-CELLS; RETROVIRUS; EXPRESSION; INTERLEUKIN-2; IMMUNOTHERAPY; TRANSDUCTION; PRECURSORS	Human gene therapy is a procedure that is being used in an attempt to treat genetic and other diseases. Eleven clinical protocols are under way at the present time, each with scientific and clinical objectives. Human genetic engineering raises unique safety, social, and ethical concerns.			ANDERSON, WF (corresponding author), NHLBI, MOLEC HEMATOL BRANCH, BETHESDA, MD 20892 USA.							AEBERSOLD P, 1990, HUM GENE THER, V1, P373, DOI 10.1089/hum.1990.1.4-373; AEBERSOLD P, 1992, HUM GENE THER, V3, P167; AKHURST RJ, 1989, J INHERIT METAB DIS, V12, P191, DOI 10.1007/BF01799294; ANDERSON WF, 1984, SCIENCE, V226, P401, DOI 10.1126/science.6093246; ANDERSON WF, 1985, J MED PHILOS, V10, P275, DOI 10.1093/jmp/10.3.275; ANDERSON WF, 1989, J MED PHILOS, V14, P681, DOI 10.1093/jmp/14.6.681; ANDERSON WF, 1990, HASTINGS CENT REP, P21; ANDREWS RG, 1986, BLOOD, V67, P842; APPERLEY JF, 1990, BRIT J HAEMATOL, V75, P148, DOI 10.1111/j.1365-2141.1990.tb02641.x; ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; ASHER A, 1987, J IMMUNOL, V138, P963; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BERENSON RJ, 1991, BLOOD, V77, P1717; BERGER EM, IN PRESS LAW MED HLT; BEUTLER E, 1990, EXP HEMATOL, V18, P857; BLAESE M, UNPUB; BLAESE RM, 1990, HUM GENE THER, V1, P327; BLAESE RM, 1991, CLIN IMMUNOL IMMUNOP, V61, pS47, DOI 10.1016/S0090-1229(05)80037-6; BOGGS SS, 1990, INT J CELL CLONING, V8, P80, DOI 10.1002/stem.5530080202; BORDIGNON C, UNPUB; BRENNER M, UNPUB; CAPRON AM, 1985, GENETICS LAW, V3, P24; CORNETTA K, 1991, HUM GENE THER, V2, P5, DOI 10.1089/hum.1991.2.1-5; COURNOYER D, 1990, CLIN PHARMACOL THER, V47, P1, DOI 10.1038/clpt.1990.1; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; EGLITIS MA, 1985, SCIENCE, V230, P1395, DOI 10.1126/science.2999985; FISHER B, 1989, J CLIN ONCOL, V7, P1676; FLEISCHMAN RA, 1991, AM J MED SCI, V301, P353, DOI 10.1097/00000441-199105000-00011; FLETCHER J, 1974, ETHICS GENETIC CONTR, P14; FLETCHER JC, 1985, J MED PHILOS, V10, P293, DOI 10.1093/jmp/10.3.293; FLETCHER JC, 1983, VA LAW REV, V69, P515, DOI 10.2307/1072768; Fowler G, 1989, Theor Med, V10, P151, DOI 10.1007/BF00539880; FRIEDMANN T, 1989, SCIENCE, V244, P1275, DOI 10.1126/science.2660259; FRIEDMANN T, 1989, MOL BIOL MED, V6, P117; GRIFFITH KD, 1989, J NATL CANCER I, V81, P1709, DOI 10.1093/jnci/81.22.1709; HESDORFFER C, 1991, HEMATOL ONCOL CLIN N, V5, P423, DOI 10.1016/S0889-8588(18)30423-4; HOOSE B, 1990, HUM GENE THER, V1, P299, DOI 10.1089/hum.1990.1.3-299; JOYNER A, 1983, NATURE, V305, P556, DOI 10.1038/305556a0; JOYNER AL, 1983, MOL CELL BIOL, V3, P2191, DOI 10.1128/MCB.3.12.2191; JUENGST ET, 1991, J MED PHILOS, V16, P587, DOI 10.1093/jmp/16.6.587; KARLSSON S, 1991, BLOOD, V78, P2481; Karson E M, 1991, Biotechnology, V16, P189; KASS L, 1972, NEW GENETICS FUTURE, P61; KELLER G, 1985, NATURE, V318, P149, DOI 10.1038/318149a0; KOHN DB, 1989, CANCER INVEST, V7, P179, DOI 10.3109/07357908909038283; KOLBERG R, 1992, J NIH RES, V4, P43; LAPPE M, 1991, J MED PHILOS, V16, P621, DOI 10.1093/jmp/16.6.621; LEDLEY FD, 1991, HUM GENE THER, V2, P331, DOI 10.1089/hum.1991.2.4-331; LEDLEY FD, 1992, INT PED, V7, P7; LEHN PM, 1990, BONE MARROW TRANSPL, V5, P287; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MCLACHLIN JR, 1990, PROG NUCLEIC ACID RE, V38, P91; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MILLER AD, 1990, HUM GENE THER, V1, P5, DOI 10.1089/hum.1990.1.1-5; MILLER AD, 1983, P NATL ACAD SCI-BIOL, V80, P4709, DOI 10.1073/pnas.80.15.4709; MILLER AD, 1984, SCIENCE, V225, P630, DOI 10.1126/science.6377498; MILLER AD, 1990, BLOOD, V76, P271; MOEN RC, 1991, BLOOD CELLS, V17, P407; MORGAN RA, 1990, HUM GENE THER, V1, P135, DOI 10.1089/hum.1990.1.2-135; MULLIGAN RC, 1992, ETIOLOTY HUMAN DISEA, P143; NABEL EG, 1991, J AM COLL CARDIOL, V17, pB189; NIENHUIS AW, 1991, CANCER, V67, P2700, DOI 10.1002/1097-0142(19910515)67:10+<2700::AID-CNCR2820671705>3.0.CO;2-3; NIENHUIS AW, UNPUB; NOLAN K, 1991, J MED PHILOS, V16, P613, DOI 10.1093/jmp/16.6.613; PARKMAN R, 1991, CURR OPIN IMMUNOL, V3, P547, DOI 10.1016/0952-7915(91)90019-W; PORTER J, 1990, HUM GENE THER, V1, P419, DOI 10.1089/hum.1990.1.4-419; RAMSEY P, 1972, NEW GENETICS FUTURE, P175; RIDDELL SR, 1992, HUM GENE THER, V3, P319, DOI 10.1089/hum.1992.3.3-319; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SANTANA VM, 1991, HUM GENE THER, V2, P257, DOI 10.1089/hum.1991.2.3-257; TAUER CA, 1990, HUM GENE THER, V1, P411, DOI 10.1089/hum.1990.1.4-411; TEMIN HM, 1990, J MED VIROL, V31, P13, DOI 10.1002/jmv.1890310105; TEMIN HM, 1990, HUM GENE THER, V1, P111, DOI 10.1089/hum.1990.1.2-111; VANBEUSECHEM VW, IN PRESS P NATL ACAD; WALTERS L, 1991, HUM GENE THER, V2, P115, DOI 10.1089/hum.1991.2.2-115; WALTERS L, 1986, NATURE, V320, P225, DOI 10.1038/320225a0; WEATHERALL DJ, 1989, BRIT MED J, V298, P691, DOI 10.1136/bmj.298.6675.691; WILLIAMS DA, 1990, HUM GENE THER, V1, P229, DOI 10.1089/hum.1990.1.3-229; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIS RC, 1984, J BIOL CHEM, V259, P7842; WILSON JM, 1992, HUM GENE THER, V3, P179, DOI 10.1089/hum.1992.3.2-179; WU GY, 1991, BIOTHERAPY, V3, P87, DOI 10.1007/BF02175102; ZIMMERMAN BK, 1991, J MED PHILOS, V16, P593, DOI 10.1093/jmp/16.6.593; 1991, HUM GENE THER, V2, P137; 1990, HUM GENE THER, V1, P441; 1992, HUM GENE THER, V3, P57; 1991, HUM GENE THER, V2, P359; 1982, SPLICING LIFE; 1990, HUM GENE THER, V1, P73	91	748	1169	4	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					808	813		10.1126/science.1589762	http://dx.doi.org/10.1126/science.1589762			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589762				2022-12-28	WOS:A1992HT23500035
J	GARCIA, KC; RONCO, PM; VERROUST, PJ; BRUNGER, AT; AMZEL, LM				GARCIA, KC; RONCO, PM; VERROUST, PJ; BRUNGER, AT; AMZEL, LM			3-DIMENSIONAL STRUCTURE OF AN ANGIOTENSIN-II FAB COMPLEX AT 3 ANGSTROM - HORMONE RECOGNITION BY AN ANTIIDIOTYPIC ANTIBODY	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; INTERNAL IMAGE; NETWORK; PEPTIDE	The elucidation of bioactive conformations of small peptide hormones remains an elusive goal to structural chemists because of the inherent flexibility of these molecules. Angiotensin II (AII), the major effector of the renin-angiotensin system, is an octapeptide hormone for which no clear structural models exist. Peptide hormones such as AII share the property that they bind to their receptors with high affinities, in spite of the fact that they must overcome an extremely large conformational entropy barrier to bind in one conformation. A "surrogate system" that consists of a high-affinity monoclonal antibody (MAb) and AII has been used to study a bound conformation of AII. The crystallographic structure of the complex reveals a structure of AII that is compatible with predicted bioactive conformations of AII derived from structure-activity studies and theoretical calculations. In the complex, the deeply bound hormone is folded into a compact structure in which two turns bring the amino and carboxyl termini close together. The antibody of this complex (MAb 131) has the unusual property that it was not generated against AII, but rather against an anti-idiotypic antibody reactive with a MAb to AII, which renders this antibody an anti-anti-idiotypic antibody. The high affinity for AII of the original MAb to AII was passed on to MAb 131 through a structural determinant on the anti-idiotypic antibody. Strikingly, the conformation of AII in this complex is highly similar to complementarity determining region loops of antibodies, possibly indicating that a true molecular mimic of bound AII was present on the anti-idiotypic antibody against which MAb 131 was elicited.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOPHYS & BIOPHYS CHEM,BALTIMORE,MD 21205; HOP TENON,INSERM,U64,F-75790 PARIS 20,FRANCE; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Johns Hopkins University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Howard Hughes Medical Institute; Yale University; Yale University			Ronco, Pierre/AAC-8390-2022	Brunger, Axel/0000-0001-5121-2036; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM44692] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044692] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUMELAS A, 1985, P NATL ACAD SCI USA, V82, P1881, DOI 10.1073/pnas.82.7.1881; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1990, XPLOR MANUAL VERSION; BUDISAVLJEVIC M, 1990, J IMMUNOL, V145, P1440; BUDISAVLJEVIC M, 1988, J IMMUNOL, V140, P3059; CARSON MJ, COMMUNICATION; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CORVOL P, 1989, CLIN EXP HYPERTENS A, V11, P463; COURAUD PO, 1986, J IMMUNOL, V136, P3365; COURAUD PO, 1987, J IMMUNOL, V138, P1164; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EPP D, 1979, EUR J BIOCHEM, V45, P513; FESIK SW, 1991, BIOCHEMISTRY-US, V30, P6574, DOI 10.1021/bi00240a030; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GARCIA KC, 1992, SCIENCE, V257, P528, DOI 10.1126/science.1636087; GARCIA KC, 1989, J BIOL CHEM, V264, P20463; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JORGENSEN WL, 1991, SCIENCE, V254, P954, DOI 10.1126/science.1719636; LARAGAH JH, 1973, HDB PHYSL, V8, P831; LENKINSKI RE, 1981, J INORG BIOCHEM, V15, P95, DOI 10.1016/S0162-0134(00)80295-0; LENKINSKI RE, 1985, PEPTIDES ANAL SYNTHE, V7, P301; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MARSHALL GR, 1974, RECENT ADV RENAL PHY, P215; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; PHILLIPS MI, 1978, NEUROENDOCRINOLOGY, V25, P354, DOI 10.1159/000122756; REICHMAN L, 1988, NATURE, V332, P327; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VALLOTTON MB, 1974, HDB EXPT PHARM, V37, P185; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WEINSTOCK J, 1991, J MED CHEM, V34, P1514, DOI 10.1021/jm00108a043; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; WUTHRICH K, 1991, SCIENCE, V254, P953, DOI 10.1126/science.1948082	42	168	174	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					502	507		10.1126/science.1636085	http://dx.doi.org/10.1126/science.1636085			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636085				2022-12-28	WOS:A1992JE75500019
J	KATAN, LL				KATAN, LL			MULTIPLICITY OF MIGRANTS	NATURE			English	Editorial Material											KATAN, LL (corresponding author), IFPS LTD,POB 1704,MALDON CM9 8RX,ESSEX,ENGLAND.								0	8	8	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					183	183		10.1038/358183a0	http://dx.doi.org/10.1038/358183a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630481				2022-12-28	WOS:A1992JD58700017
J	OROURKE, AM; MESCHER, MF				OROURKE, AM; MESCHER, MF			CYTOTOXIC LYMPHOCYTE-T ACTIVATION INVOLVES A CASCADE OF SIGNALING AND ADHESION EVENTS	NATURE			English	Article							RECEPTOR-MEDIATED ACTIVATION; TYROSINE PHOSPHORYLATION; CLASS-I; CELLS; CD8; BINDING; RECOGNITION; LFA-1	IN addition to the antigen-specific T-cell receptor (TCR), T cells bear an array of 'accessory' molecules that can contribute to stable adhesion to the antigen-bearing cell1 and provide costimulatory signals1-7. For several of these2-7, T-cell adhesion to the ligand can be activated by TCR-dependent signalling (a signal from the TCR primes the coreceptor to bind to its ligand). It is unclear whether the individual coreceptors share common mechanisms of priming and cosignalling, and perhaps act in a redundant manner, or whether they act in a distinct way and contribute uniquely to the activation process. We report here the use of isolated alloantigen, class I proteins and fibronectin ligands to show that coreceptors on cytotoxic T lymphocytes are activated sequentially and deliver distinct biochemical signals on binding to their ligands. TCR engagement activates CD8 by a protein tyrosine kinase-dependent pathway, and CD8 then acts as a signal for initiation of polyphosphoinositide hydrolysis on binding to class I. In contrast, activated adhesion to fibronectin does not initiate polyphosphoinositide hydrolysis, but amplifies hydrolysis once it has been initiated. Thus, cytotoxic T-lymphocyte activation involves a TCR-initiated cascade of adhesion and signalling events leading to response.			OROURKE, AM (corresponding author), MED BIOL INST,DIV MEMBRANE BIOL,11077 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Mescher, Matthew/B-8068-2009					BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; JUNE CH, 1990, J IMMUNOL, V144, P1591; KANE KP, 1989, J IMMUNOL, V142, P4153; KANE KP, 1990, J IMMUNOL, V144, P824; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; OROURKE AM, 1988, J BIOL CHEM, V263, P18594; PANACCIO M, 1987, P NATL ACAD SCI USA, V84, P6874, DOI 10.1073/pnas.84.19.6874; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SHIMIZU Y, 1990, J IMMUNOL, V145, P59; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SIU G, 1989, J IMMUNOL, V143, P3813; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; VANSEVENTER GA, 1991, J EXP MED, V174, P901, DOI 10.1084/jem.174.4.901; VANSEVENTER GA, 1990, J IMMUNOL, V144, P4579; VEILLETTE A, 1989, J EXP MED, V170, P1671, DOI 10.1084/jem.170.5.1671; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	23	103	104	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					253	255		10.1038/358253a0	http://dx.doi.org/10.1038/358253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630493				2022-12-28	WOS:A1992JD58700059
J	PELLEGRINO, ED				PELLEGRINO, ED			ETHICS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											PELLEGRINO, ED (corresponding author), GEORGETOWN UNIV, WASHINGTON, DC 20057 USA.		Mueller, Daniel/L-4159-2016	Mueller, Daniel/0000-0003-4978-4400				BROCK D, 1991, HASTINGS CENT REP, V2, pS5; Buchanan Allen E., 1989, DECIDING OTHERS ETHI; DOUKAS DJ, 1991, J FAM PRACTICE, V32, P145; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; GRIFFITH DB, 1991, ISSUES LAW MED, V7, P283; Kamisar Yale, 1991, Georgia Law Rev, V25, P1203; Lambert P, 1990, Law Med Health Care, V18, P202, DOI 10.1111/j.1748-720X.1990.tb00023.x; LAPUMA J, 1991, JAMA-J AM MED ASSOC, V266, P199; LO B, 1990, NEW ENGL J MED, V322, P1228, DOI 10.1056/NEJM199004263221711; LYNN J, 1992, JAMA-J AM MED ASSOC, V267, P2082, DOI 10.1001/jama.267.15.2082; MCCLOSKEY EL, 1991, J CLIN ETHIC, V62, P172; Olick R S, 1991, J Clin Ethics, V2, P181; Pellegrino E., 1988, PATIENTS GOOD RESTOR; Robertson John A, 1991, Georgia Law Rev, V25, P1139; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SINGER PA, 1992, CAN MED ASSOC J, V146, P127; SINGER PA, 1992, ARCH INTERN MED, V152, P22, DOI 10.1001/archinte.152.1.22; Swisher K N, 1991, J Clin Ethics, V2, P199; Weiss S M, 1991, J Clin Ethics, V2, P196; WHITE ML, 1991, JAMA-J AM MED ASSOC, V266, P410, DOI 10.1001/jama.1991.03470030110035; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	23	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					354	355		10.1001/jama.268.3.354	http://dx.doi.org/10.1001/jama.268.3.354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613917				2022-12-28	WOS:A1992JC35200028
J	PELICCI, G; LANFRANCONE, L; GRIGNANI, F; MCGLADE, J; CAVALLO, F; FORNI, G; NICOLETTI, I; GRIGNANI, F; PAWSON, T; PELICCI, PG				PELICCI, G; LANFRANCONE, L; GRIGNANI, F; MCGLADE, J; CAVALLO, F; FORNI, G; NICOLETTI, I; GRIGNANI, F; PAWSON, T; PELICCI, PG			A NOVEL TRANSFORMING PROTEIN (SHC) WITH AN SH2 DOMAIN IS IMPLICATED IN MITOGENIC SIGNAL TRANSDUCTION	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; PHOSPHOTYROSINE-CONTAINING PROTEINS; I PHOSPHATIDYLINOSITOL KINASE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; VIRAL ONCOGENE; GROWTH; COLLAGEN; SRC; GAP	A new SH2-containing sequence, SHC, was isolated by screening cDNA libraries with SH2 representative DNA probes. The SHC cDNA is predicted to encode overlapping proteins of 46.8 and 51.7 kd that contain a single C-terminal SH2 domain, and an adjacent glycine/proline-rich motif with regions of homology with the alpha-1 chain of collagen, but no identifiable catalytic domain. Anti-SHC antibodies recognized three proteins of 46, 52, and 66 kd in a wide range of mammalian cell lines. These SHC proteins complexed with and were phosphorylated by activated epidermal growth factor receptor. The physical association of SHC proteins with activated receptors was recreated in vitro by using a bacterially expressed SHC SH2 domain. NIH 3T3 mouse fibroblasts that constitutively overexpressed SHC acquired a transformed phenotype in culture and formed tumors in nude mice. These results suggest that the SHC gene products couple activated growth factor receptors to a signaling pathway that regulates the proliferation of mammalian cells.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; UNIV TURIN, IST MICROBIOL, I-10126 TURIN, ITALY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Turin	PELICCI, G (corresponding author), UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY.		Pelicci, Giuliana/AAA-8921-2022; Pawson, Tony J/E-4578-2013; Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Grignani, Francesco/AAC-2565-2022; Cavallo, Federica/C-5666-2011	Pelicci, Giuliana/0000-0003-0986-8255; Lanfrancone, Luisa/0000-0002-4523-3815; Cavallo, Federica/0000-0003-4571-1060				ALCALAY M, 1990, ONCOGENE, V5, P267; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; EYRE DR, 1980, SCIENCE, V207, P1315, DOI 10.1126/science.7355290; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAY ED, 1981, J CELL BIOL, V91, P205; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; KOCH CA, 1991, SCIENCE, V252, P669; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LETWIN K, 1988, ONCOGENE, V3, P621; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P77, DOI 10.1056/NEJM197907123010204; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; REEDIJK M, 1992, IN PRESS EMBO J, V11; Sambrook J, 1989, MOL CLONING LABORATO; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TAINSKY MA, 1987, MOL CELL BIOL, V7, P1280, DOI 10.1128/MCB.7.3.1280; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; [No title captured]	57	1255	1293	1	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					93	104		10.1016/0092-8674(92)90536-L	http://dx.doi.org/10.1016/0092-8674(92)90536-L			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623525				2022-12-28	WOS:A1992JC95700011
J	REEVE, HK				REEVE, HK			QUEEN ACTIVATION OF LAZY WORKERS IN COLONIES OF THE EUSOCIAL NAKED MOLE-RAT	NATURE			English	Article							POLISTES-FUSCATUS; HYMENOPTERA; VESPIDAE; WASPS	EVOLUTIONARY ConfliCtS of interest are expected to arise in genetically diverse social groups 1. In eusocial insect societies, a potential conflict exists between the queen and her workers over how active the workers should be 2-5, and evidence exists that queen aggression increases activity levels of her lazier workers 2,3. Here I provide evidence that queen aggression (shoving) in laboratory colonies of the eusocial mammal, the naked mole-rat (Heterocephalus glaber), is a convergently evolved manifestation of queen-worker conflict over worker activity. Queen-initiated shoves activate inherently lazy workers, which tend to be larger and/or less related to the queen than are infrequently shoved, industrious workers. In addition, queen removal selectively depresses the activity of workers that are larger and less related to her. Finally, queen shoving and worker inactivity are pronounced when colonies are satiated but not when colonies are hungry, indicating that the underlying 'work-conflict' is highly context specific.	CORNELL UNIV,NEUROBIOL & BEHAV SECT,ITHACA,NY 14853	Cornell University								Braude S.H., 1991, P185; Brett R.A., 1991, P97; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Jarvis J.U.M., 1991, P384; Jarvis J.U.M., 1991, P66; JARVIS JUM, 1981, SCIENCE, V212, P571, DOI 10.1126/science.7209555; Lacey E.A., 1991, P209; Lacey E.A., 1991, P275; Reeve H., 1991, BIOL NAKED MOLE RAT, P337; REEVE HK, 1987, BEHAVIOUR, V102, P147, DOI 10.1163/156853986X00090; REEVE HK, 1983, BEHAV ECOL SOCIOBIOL, V13, P63, DOI 10.1007/BF00295077; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; REEVE HK, 1991, THESIS CORNELL U; SCHMIDHEMPEL P, 1990, AM NAT, V135, P501, DOI 10.1086/285059; West-Eberhard M.J., 1981, P3	15	136	142	2	85	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 9	1992	358	6382					147	149		10.1038/358147a0	http://dx.doi.org/10.1038/358147a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC583	1614546				2022-12-28	WOS:A1992JC58300050
J	MANN, GV				MANN, GV			LIPID-LEVELS AND AFFLUENT DIETS	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter																		MANN GV, 1955, NEW ENGL J MED, V253, P349, DOI 10.1056/NEJM195509012530901; MCMURRY MP, 1991, NEW ENGL J MED, V325, P1704, DOI 10.1056/NEJM199112123252405; WALKER WJ, 1953, AM J MED, V14, P654, DOI 10.1016/0002-9343(53)90383-0	3	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					52	52						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598109				2022-12-28	WOS:A1992JA76100020
J	OLINER, JD; KINZLER, KW; MELTZER, PS; GEORGE, DL; VOGELSTEIN, B				OLINER, JD; KINZLER, KW; MELTZER, PS; GEORGE, DL; VOGELSTEIN, B			AMPLIFICATION OF A GENE ENCODING A P53-ASSOCIATED PROTEIN IN HUMAN SARCOMAS	NATURE			English	Article							MALIGNANT FIBROUS HISTIOCYTOMA; GLI GENE; DNA; P53; TRANSLOCATION	DESPITE extensive data linking mutations in the p53 gene to human tumorigenesis 1, little is known about the cellular regulators and mediators of p53 function. MDM2 is a strong candidate for one such cellular protein; the MDM2 gene was originally identified by virtue of its amplification in a spontaneously transformed derivative of mouse BALB/c cells 2 and the MDM2 protein subsequently shown to bind to p53 in rat cells transfected with p53 genes 3,4. To determine whether MDM2 plays a role in human cancer, we have cloned the human MDM2 gene. Here we show that recombinant-derived human MDM2 protein binds human p53 in vitro, and we use MDM2 clones to localize the human MDM2 gene to chromosome 12q13-14. Because this chromosomal position appears to be altered in many sarcomas 5-7, we looked for changes in human MDM2 in such cancers. The gene was amplified in over a third of 47 sarcomas, including common bone and soft tissue forms. These results are consistent with the hypothesis that MDM2 binds to p53, and that amplification of MDM2 in sarcomas leads to escape from p53-regulated growth control. This mechanism of tumorigenesis parallels that for virally-induced tumours 8,9, in which viral oncogene products bind to and functionally inactivate p53.	JOHNS HOPKINS ONCOL CTR,424 N BOND ST,BALTIMORE,MD 21231; UNIV MICHIGAN,CTR CANC,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR CANC,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109; UNIV PENN,DEPT HUMAN GENET,PHILADELPHIA,PA 19104	Johns Hopkins University; Johns Hopkins Medicine; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Pennsylvania								BRODEUR GM, 1986, CANCER GENET CYTOGEN, V19, P101, DOI 10.1016/0165-4608(86)90377-8; DASMAHAPATRA B, 1987, NUCLEIC ACIDS RES, V15, P3933, DOI 10.1093/nar/15.9.3933; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1986, P NATL ACAD SCI USA, V83, P1031, DOI 10.1073/pnas.83.4.1031; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LAW ML, 1986, ANN HUM GENET, V50, P131, DOI 10.1111/j.1469-1809.1986.tb01031.x; MALAWER MM, 1985, CANCER PRINCIPLES PR, P1293; MANDAHL N, 1989, GENE CHROMOSOME CANC, V1, P9, DOI 10.1002/gcc.2870010104; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; MOMAND J, INPRESS CELL; OCHMAN H, 1985, PCR TECHNOLOGY PRINC, P105; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; TANAKA K, 1990, FEBS LETT, V271, P41, DOI 10.1016/0014-5793(90)80367-R; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P291, DOI 10.1016/0165-4608(86)90011-7; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEISS SW, 1978, CANCER-AM CANCER SOC, V41, P2250, DOI 10.1002/1097-0142(197806)41:6<2250::AID-CNCR2820410626>3.0.CO;2-W; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286	31	1863	1933	1	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					80	83		10.1038/358080a0	http://dx.doi.org/10.1038/358080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614537	Green Submitted			2022-12-28	WOS:A1992JB34100059
J	MEADOR, CK				MEADOR, CK			THE PERSON WITH THE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					35	35						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608104				2022-12-28	WOS:A1992JA16500007
J	TCHENG, JE; JACKMAN, JD; NELSON, CL; GARDNER, LH; SMITH, LR; RANKIN, JS; CALIFF, RM; STACK, RS				TCHENG, JE; JACKMAN, JD; NELSON, CL; GARDNER, LH; SMITH, LR; RANKIN, JS; CALIFF, RM; STACK, RS			OUTCOME OF PATIENTS SUSTAINING ACUTE ISCHEMIC MITRAL REGURGITATION DURING MYOCARDIAL-INFARCTION	ANNALS OF INTERNAL MEDICINE			English	Article						MYOCARDIAL INFARCTION; MITRAL VALVE INSUFFICIENCY; HEART CATHETERIZATION; CORONARY ARTERY BYPASS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY	CORONARY-ARTERY DISEASE; VALVE REPAIR; WALL MOTION; ANGIOPLASTY; REPLACEMENT; TRIAL; RECONSTRUCTION; STREPTOKINASE; THROMBOLYSIS; THERAPY	Objective: To describe outcomes of patients sustaining an acute myocardial infarction complicated by mitral regurgitation managed with contemporary reperfusion therapies. Design: Inception cohort case study. Long-term follow-up was obtained in 99% of all patients. Setting: University referral center. Patients: A series of 1480 consecutive patients presenting between April 1986 and March 1989 who had emergency cardiac catheterization within 6 hours of infarction. Fifty patients were found to have moderately severe or severe mitral regurgitation. Outcome Measures: Mortality; follow-up cardiac catheterization in patients with regurgitation. Results: Acute ischemic moderately severe to severe (3 + or 4 +) mitral regurgitation was associated with a mortality of 24% at 30 days (95% Cl, 12% to 36%), 42% at 6 months (Cl, 28% to 56%), and 52% at 1 year (Cl, 38% to 66%); multivariable analysis identified 3 + or 4 + mitral regurgitation as a possible independent predictor of mortality (P = 0.06). Patients with mitral regurgitation tended to be female, older, and to have cerebrovascular disease, diabetes, and pre-existing symptomatic coronary artery disease. A physical examination did not identify 50% of patients with moderately severe to severe regurgitation. Acute reperfusion with thrombolysis or angioplasty did not reliably reverse valvular incompetence. In this observational study, the greatest in-hospital and 1-year mortalities were seen in patients reperfused with emergency balloon angioplasty, whereas patients managed medically or with coronary bypass surgery had lower mortalities. Conclusions: Moderately severe to severe (3 + or 4 +) mitral regurgitation complicating acute myocardial infarction portends a grave prognosis. Acute reperfusion does not reduce mortality to levels experienced by patients with lesser degrees of mitral regurgitation nor does it reliably restore valvular competence.			TCHENG, JE (corresponding author), DUKE UNIV, MED CTR, BOX 3275, DURHAM, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045702, P50HL017670, P01HL036587] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45702, HL-36587, HL-17670] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELL WW, 1987, J THORAC CARDIOV SUR, V93, P665; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BARZILAI B, 1988, AM J CARDIOL, V61, P220, DOI 10.1016/0002-9149(88)90919-8; BONCHEK LI, 1984, J THORAC CARDIOV SUR, V88, P122; BURCH GE, 1963, ARCH INTERN MED, V112, P112, DOI 10.1001/archinte.1963.03860010138015; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; COHN LH, 1988, ANN THORAC SURG, V45, P284, DOI 10.1016/S0003-4975(10)62463-0; CONNOLLY MW, 1986, J THORAC CARDIOV SUR, V91, P379; DAVID TE, 1986, CIRCULATION, V74, P116; DESERVI S, 1988, EUR HEART J, V9, P5, DOI 10.1093/eurheartj/9.suppl_F.5; ESTES EH, 1966, AM HEART J, V71, P356, DOI 10.1016/0002-8703(66)90475-3; HEIKKILA J, 1967, BRIT HEART J, V29, P162; HEUSER RR, 1987, ANN INTERN MED, V107, P852, DOI 10.7326/0003-4819-107-6-852; HICKEY MS, 1988, CIRCULATION, V78, P51; Kay G L, 1987, Cardiovasc Clin, V17, P41; KAY GL, 1986, CIRCULATION, V74, P88; LOPERFIDO F, 1986, AM J CARDIOL, V58, P692, DOI 10.1016/0002-9149(86)90339-5; MAGOVERN JA, 1985, ANN THORAC SURG, V39, P346, DOI 10.1016/S0003-4975(10)62628-8; MAISEL AS, 1986, AM HEART J, V112, P705, DOI 10.1016/0002-8703(86)90464-3; OKEEFE JH, 1989, AM J CARDIOL, V64, P1221, DOI 10.1016/0002-9149(89)90558-4; ONEILL W, 1986, NEW ENGL J MED, V314, P812, DOI 10.1056/NEJM198603273141303; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PHILLIPS JH, 1963, ANN INTERN MED, V59, P508, DOI 10.7326/0003-4819-59-4-508; Rankin J S, 1989, Semin Thorac Cardiovasc Surg, V1, P149; RANKIN JS, 1989, CIRCULATION, V79, P116; RANKIN JS, 1988, J THORAC CARDIOV SUR, V95, P165; RANKIN JS, 1986, TXB SURGERY, P2344; REINFELD HB, 1985, CATHETER CARDIO DIAG, V11, P273, DOI 10.1002/ccd.1810110307; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SAND ME, 1987, J THORAC CARDIOV SUR, V94, P208; SHAWL FA, 1989, J AM COLL CARDIOL, V14, P986, DOI 10.1016/0735-1097(89)90477-4; SHEEHAN FH, 1983, CIRCULATION, V68, P756, DOI 10.1161/01.CIR.68.4.756; SHEEHAN FH, 1983, CIRCULATION, V68, P550, DOI 10.1161/01.CIR.68.3.550; SMITH LR, 1991, CIRCULATION, V84, P245; TOPOL EJ, 1987, J AM COLL CARDIOL, V10, pB65, DOI 10.1016/S0735-1097(87)80430-8	37	170	177	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					18	24		10.7326/0003-4819-117-1-18	http://dx.doi.org/10.7326/0003-4819-117-1-18			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596043				2022-12-28	WOS:A1992JA43500003
J	PIMENTA, PFP; TURCO, SJ; MCCONVILLE, MJ; LAWYER, PG; PERKINS, PV; SACKS, DL				PIMENTA, PFP; TURCO, SJ; MCCONVILLE, MJ; LAWYER, PG; PERKINS, PV; SACKS, DL			STAGE-SPECIFIC ADHESION OF LEISHMANIA PROMASTIGOTES TO THE SANDFLY MIDGUT	SCIENCE			English	Article							MAJOR PROMASTIGOTES; TRYPANOSOMA-CRUZI; LIPOPHOSPHOGLYCAN; METACYCLOGENESIS; IDENTIFICATION; GLYCOCONJUGATE; ATTACHMENT; GUT	Although leishmaniasis is transmitted to humans almost exclusively by the bite of infected phlebotomine sandflies, little is known about the molecules controlling the survival and development of Leishmania parasites in their insect vectors. Adhesion of Leishmania promastigotes to the midgut epithelial cells of the sandfly was found to be an inherent property of noninfective-stage promastigotes, which was lost during their transformation to metacyclic forms, thus permitting the selective release of infective-stage parasites for subsequent transmission by bite. Midgut attachment and release was found to be controlled by specific developmental modifications in terminally exposed saccharides on lipophosphoglycan, the major surface molecule on Leishmania promastigotes.	NIAID,PARASIT DIS LAB,BLDG 4,ROOM 126,BETHESDA,MD 20892; WALTER REED ARMY MED CTR,DEPT ENTOMOL,WASHINGTON,DC 20307; UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536; UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Army; Walter Reed National Military Medical Center; University of Kentucky; University of Dundee			Pimenta, Paulo/AAH-1502-2020					BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; COOMBS G, 1991, BIOCH PARASITIC PROT; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; HANDMAN E, 1984, EMBO J, V3, P2301, DOI 10.1002/j.1460-2075.1984.tb02130.x; HENDRY KAK, 1988, PARASITOL RES, V74, P403, DOI 10.1007/BF00535138; HOWARD RJ, 1982, J PROTOZOOL, V29, P114, DOI 10.1111/j.1550-7408.1982.tb02891.x; IBRAHIM EAR, 1984, TROPENMED PARASITOL, V35, P151; KARP CL, 1991, J IMMUNOL, V147, P680; KILLICKKENDRICK R, 1979, BIOL KINETOPLASTIDA, V2, pCH8; LAWYER PG, 1990, AM J TROP MED HYG, V43, P31, DOI 10.4269/ajtmh.1990.43.31; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, UNPUB; Molyneux DH, 1987, LEISHMANIASES BIOL M, V1, P121; ORLANDI P, 1987, J BIOL CHEM, V262, P10382; PEREIRA MEA, 1981, SCIENCE, V211, P597, DOI 10.1126/science.7006082; PIMENTA PFP, 1985, J SUBMICR CYTOL PATH, V17, P413; PIMENTA PFP, 1991, EXP PARASITOL, V72, P191, DOI 10.1016/0014-4894(91)90137-L; PIMENTA PFP, UNPUB; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SACKS DL, 1985, J IMMUNOL, V135, P564; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SACKS DL, UNPUB; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; WALLBANKS KR, 1986, TROP MED PARASITOL, V37, P409; WARBURG A, 1989, J PROTOZOOL, V36, P613, DOI 10.1111/j.1550-7408.1989.tb01104.x	26	204	207	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 26	1992	256	5065					1812	1815		10.1126/science.1615326	http://dx.doi.org/10.1126/science.1615326			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA434	1615326				2022-12-28	WOS:A1992JA43400034
J	WILBERS, D; VEENSTRA, G; VANDEWIEL, HBM; SCHULTZ, WCMW				WILBERS, D; VEENSTRA, G; VANDEWIEL, HBM; SCHULTZ, WCMW			SEXUAL CONTACT IN THE DOCTOR-PATIENT-RELATIONSHIP IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article							THERAPISTS; ATTITUDES	Objective - To obtain data on sexual contact between doctors and their patients. Design - Anonymous questionnaire with 17 items sent to all working gynaecologists (n=595) and all ear, nose, and throat specialists (n=380) in the Netherlands. Results - Response rate was 74%; a total 64 doctors gave a reason for not completing the questionnaire. 201 (59%) male gynaecologists and 128 (56%) male ear nose, and throat specialists indicated that sexual feelings are acceptable in the doctor-patient relationship; 286 (85%) and 186 (81%), respectively, had felt sexually attracted to a patient at some time, as had 14 (27%) female gynaecologists. More than half (59%) of the doctors who indicated that sexual feelings are unacceptable in the doctor-patient relationship had experienced these feelings, and 91% of this group had a negative attitude towards these feelings. 4% of respondents in each group had had actual sexual contact with patients. Most gynaecologists were in favour of having more attention paid to sexual problems during training; having their professional society take an official viewpoint; subsequent public support of this viewpoint; and taking on an impartial counsellor for the patients as well as the doctors. Conclusion - Sexuality exists in the doctor-patient relationship. Gynaecologists have a higher risk of having sexual contact with their patients than do ear, nose, and throat specialists but compensate for this greater risk by a higher state of recognition and acknowledgement.	UNIV GRONINGEN HOSP,DEPT OBSTET & GYNAECOL,POB 30001,9700 RB GRONINGEN,NETHERLANDS	University of Groningen				van de Wiel, Harry/0000-0001-7179-6649				BOUHOUTSOS J, 1983, PROF PSYCHOL-RES PR, V14, P185, DOI 10.1037/0735-7028.14.2.185; BURGESS AW, 1981, AM J PSYCHIAT, V138, P1335; BUTLER S, 1977, PSYCHOTHER-THEOR RES, V14, P139, DOI 10.1037/h0086521; FELDMANSUMMERS S, 1984, J CONSULT CLIN PSYCH, V52, P1054, DOI 10.1037/0022-006X.52.6.1054; FISHER N, 1990, J ROY SOC MED, V83, P681, DOI 10.1177/014107689008301103; GARTRELL N, 1986, AM J PSYCHIAT, V143, P1125; GUTHEIL TG, 1989, AM J PSYCHIAT, V146, P597; HENDERIKX W, 1984, LICHAMELIJK CONTACT; HOLROYD JC, 1977, AM PSYCHOL, V32, P843, DOI 10.1037/0003-066X.32.10.843; KARDENER SH, 1974, AM J PSYCHIAT, V131, P1134; KARDENER SH, 1973, AM J PSYCHIAT, V130, P1077, DOI 10.1176/ajp.130.10.1077; Pope KS, 1989, SEXUAL EXPLOITATION; SCHULTZ WCM, 1991, THESIS STATE U GRONI; SMITH S, 1989, SEXUAL EXPLOITATION; TWENLOW SW, 1989, SEXUAL EXPLOITATION	15	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1531	1534		10.1136/bmj.304.6841.1531	http://dx.doi.org/10.1136/bmj.304.6841.1531			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HZ178	1628050	Bronze, Green Published			2022-12-28	WOS:A1992HZ17800020
J	WISTROM, J; JERTBORN, M; EKWALL, E; NORLIN, K; SODERQUIST, B; STROMBERG, A; LUNDHOLM, R; HOGEVIK, H; LAGERGREN, L; ENGLUND, G; NORRBY, SR				WISTROM, J; JERTBORN, M; EKWALL, E; NORLIN, K; SODERQUIST, B; STROMBERG, A; LUNDHOLM, R; HOGEVIK, H; LAGERGREN, L; ENGLUND, G; NORRBY, SR			EMPIRIC TREATMENT OF ACUTE DIARRHEAL DISEASE WITH NORFLOXACIN - A RANDOMIZED, PLACEBO-CONTROLLED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIARRHEA; NORFLOXACIN; CAMPYLOBACTER INFECTIONS; SALMONELLA INFECTIONS; DYSENTERY	QUINOLONE RESISTANCE; ADULTS; SALMONELLA	Objective: To evaluate the clinical and microbiologic efficacy and safety of norfloxacin for acute diarrhea. Design: Double-blind, placebo-controlled, randomized clinical multicenter trial. Setting: Six departments of infectious disease. Participants: Patients 12 years of age or older with a history of acute diarrhea lasting 5 or fewer days. Eighty-five percent of patients (511/598) were evaluable for efficacy. Of these evaluable patients, 70% had traveled abroad within the previous 6 weeks. Interventions: Patients received either norfloxacin, 400 mg, or placebo twice daily for 5 days. Measurements: Enteric pathogens were isolated in 51 % of the evaluable patients: Campylobacter species in 29%, Salmonella species in 16%, Shigella species in 3.5%, and other pathogens in 2.6%. Results: Norfloxacin had a favorable overall effect compared with placebo (cure rate, 63% compared with 51 %; P = 0.003). There were statistically favorable effects in culture-positive patients, patients with salmonellosis, and severely ill patients but not in culture-negative patients or patients with campylobacteriosis or shigellosis. A significant difference was noted between norfloxacin and placebo in median time to cure among all evaluable patients (3 compared with 4 days, P = 0.02) and in patients with campylobacteriosis (3 compared with 5 days, P = 0.05). Culture-positive, but not culture-negative patients, in the norfloxacin group had significantly fewer loose stools per day compared with patients in the placebo group from day 2 onward (P less-than-or-equal-to 0.01). Norfloxacin was significantly less effective than placebo in eliminating Salmonella species on days 12 to 17 (18% compared with 49%, P = 0.006), whereas the opposite was true for Campylobacter species (70% compared with 50%, P = 0.03). In six of nine patients tested, norfloxacin-resistant Campylobacter species (MIC, greater-than-or-equal-to 32-mu-g/mL) appeared after norfloxacin treatment. Conclusion: Empiric treatment reduced the intensity and, to some extent, the duration of symptoms of acute diarrhea. The effect was restricted to patients who had bacterial enteropathogens or who were severely ill. The clinical usefulness of this treatment is limited by the fact that norfloxacin seems to delay the elimination of salmonella and to induce resistance in campylobacter.	OSTRA HOSP, DEPT INFECT DIS, S-41685 GOTHENBURG, SWEDEN; ROSLAGSTULL HOSP, S-11489 STOCKHOLM, SWEDEN; LASARETTET, DEPT INFECT DIS, S-22185 LUND, SWEDEN; OREBRO MED CTR HOSP, DEPT INFECT DIS, S-70185 OREBRO, SWEDEN; ASTRA ARCUS AB, S-15185 SODERTALJE, SWEDEN; UMEA UNIV, REG HOSP UMEA, DEPT CLIN BACTERIOL, S-90185 UMEA, SWEDEN; DANDERYD HOSP, DEPT INFECT DIS, S-18288 DANDERYD, SWEDEN	Sahlgrenska University Hospital; Umea University; Danderyds Hospital	WISTROM, J (corresponding author), UMEA UNIV, REG HOSP UMEA, DEPT INFECT DIS, S-90185 UMEA, SWEDEN.			Soderquist, Bo/0000-0001-5939-2932				ASPERILLA MO, 1990, REV INFECT DIS, V12, P873; CARLSTEDT G, 1990, SCAND J INFECT DIS, V22, P553, DOI 10.3109/00365549009027095; DUPONT HL, 1987, AM J MED, V82, P79, DOI 10.1016/0002-9343(87)90624-3; ENDTZ HP, 1991, J ANTIMICROB CHEMOTH, V27, P199, DOI 10.1093/jac/27.2.199; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GOOTZ TD, 1991, ANTIMICROB AGENTS CH, V35, P840, DOI 10.1128/AAC.35.5.840; GOTUZZO E, 1989, ANTIMICROB AGENTS CH, V33, P1101, DOI 10.1128/AAC.33.7.1101; LOLEKHA S, 1988, SCAND J INFECT DIS, P35; MANDAL BK, 1991, J INFECTION, V22, P1, DOI 10.1016/0163-4453(91)90758-K; MURRAY BE, 1989, EUR J CLIN MICROBIOL, V8, P1093, DOI 10.1007/BF01975176; NEILL MA, 1991, ANN INTERN MED, V114, P195, DOI 10.7326/0003-4819-114-3-195; NEU HC, 1987, LANCET, V2, P1319; PICHLER HET, 1987, AM J MED, V82, P329; PIDDOCK LJV, 1990, LANCET, V335, P1459, DOI 10.1016/0140-6736(90)91484-R; ROGERIE F, 1986, ANTIMICROB AGENTS CH, V29, P883, DOI 10.1128/AAC.29.5.883; WALDVOGEL FA, 1989, EUR J CLIN MICROBIOL, V8, P1075, DOI 10.1007/BF01975174; WISTROM J, 1989, J ANTIMICROB CHEMOTH, V23, P905, DOI 10.1093/jac/23.6.905; 1990, LANCET, V336, P282	18	97	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					202	208		10.7326/0003-4819-117-3-202	http://dx.doi.org/10.7326/0003-4819-117-3-202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616214				2022-12-28	WOS:A1992JF30400005
J	BRETSCHER, PA; WEI, GJ; MENON, JN; BIELEFELDTOHMANN, H				BRETSCHER, PA; WEI, GJ; MENON, JN; BIELEFELDTOHMANN, H			ESTABLISHMENT OF STABLE, CELL-MEDIATED-IMMUNITY THAT MAKES SUSCEPTIBLE MICE RESISTANT TO LEISHMANIA-MAJOR	SCIENCE			English	Article							EXPERIMENTAL CUTANEOUS LEISHMANIASIS; IMMUNOLOGICAL REGULATION; T-CELLS; BALB/C MICE; INTERFERON-GAMMA; INDUCTION; INFECTION; TROPICA; SUBSETS	Cell-mediated, but not antibody-mediated, immune responses protect humans against certain pathogens that produce chronic diseases such as leishmaniasis. Effective vaccination against such pathogens must therefore produce an immunological "imprint" so that stable, cell-mediated immunity is induced in all individuals after natural infection. BALB/c mice "innately susceptible" to Leishmania major produce antibodies after substantial infection. In the present study, "susceptible" mice injected with a small number of parasites mounted a cell-mediated response and acquired resistance to a larger, normally pathogenic, challenge. This vaccination strategy may be applicable in diseases in which protection is dependent on cell-mediated immunity.			BRETSCHER, PA (corresponding author), UNIV SASKATCHEWAN, DEPT MICROBIOL, SASKATOON S7N 0W0, SASKATCHEWAN, CANADA.		Bielefeldt-Ohmann, Helle/A-3686-2010					BEHFOROUZ NC, 1986, J IMMUNOL, V136, P3067; BLACKWELL JM, 1985, CURR TOP MICROBIOL, V122, P97; BRETSCHER PA, 1979, EUR J IMMUNOL, V9, P311, DOI 10.1002/eji.1830090412; BRETSCHER PA, 1974, CELL IMMUNOL, V13, P171, DOI 10.1016/0008-8749(74)90237-8; BRETSCHER PA, 1991, RES IMMUNOL, V142, P45, DOI 10.1016/0923-2494(91)90011-7; BRETSCHER PA, 1981, FED PROC, V40, P1473; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; ELLNER JJ, 1989, TXB INTERNAL MED, P569; FINKELMAN FD, 1991, TODAY A, V62; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HOWARD JG, 1981, J EXP MED, V153, P557, DOI 10.1084/jem.153.3.557; HOWARD JG, 1986, INT REV EXP PATHOL, V28, P79; HOWARD JG, 1980, PARASITE IMMUNOL, V2, P303, DOI 10.1111/j.1365-3024.1980.tb00061.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGRANGE PH, 1974, J EXP MED, V139, P528, DOI 10.1084/jem.139.3.528; LIEW FY, 1982, J IMMUNOL, V128, P1917; LIU HP, 1987, BIOCHEMISTRY-US, V26, P731; MENON JN, UNPUB; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MORHART M, UNPUB; NASSERI M, 1979, INFECT IMMUN, V26, P611, DOI 10.1128/IAI.26.2.611-614.1979; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PARISH CR, 1972, J EXP MED, V135, P298, DOI 10.1084/jem.135.2.298; PEARSON RD, 1983, REV INFECT DIS, V5, P907; POND L, 1989, J IMMUNOL, V143, P4232; PRESTON PM, 1976, CLIN EXP IMMUNOL, V23, P126; RAMSHAW IA, 1977, EUR J IMMUNOL, V7, P180, DOI 10.1002/eji.1830070313; RAMSHAW IA, 1977, CELL IMMUNOL, V31, P364, DOI 10.1016/0008-8749(77)90038-7; SADICK MD, 1987, J IMMUNOL, V139, P1303; SHEARER GM, IN PRESS PROG CLIN I; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; STUMPF R, 1977, EUR J IMMUNOL, V7, P74, DOI 10.1002/eji.1830070205; TITUS RG, 1985, J IMMUNOL, V135, P2108; TUTTOSI S, 1992, J IMMUNOL, V148, P397	34	471	478	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 24	1992	257	5069					539	542		10.1126/science.1636090	http://dx.doi.org/10.1126/science.1636090			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636090				2022-12-28	WOS:A1992JE75500032
J	DAOPIN, S; PIEZ, KA; OGAWA, Y; DAVIES, DR				DAOPIN, S; PIEZ, KA; OGAWA, Y; DAVIES, DR			CRYSTAL-STRUCTURE OF TRANSFORMING GROWTH-FACTOR-BETA-2 - AN UNUSUAL FOLD FOR THE SUPERFAMILY	SCIENCE			English	Article							DEOXYRIBONUCLEIC-ACID CLONING; MESSENGER RIBONUCLEIC-ACID; X-RAY-DIFFRACTION; FACTOR-BETA; EMBRYO CHONDROCYTES; IDENTIFICATION; PURIFICATION	The transforming growth factors-beta (TGF-beta-1 through -beta-5) are a family of homodimeric cytokines that regulate proliferation and function in many cell types. Family members have 66 to 80% sequence identity and nine strictly conserved cysteines. A crystal structure of a member of this family, TGF-beta-2, has been determined at 2.1 angstrom (angstrom) resolution and refined to an R factor of 0.172. The monomer lacks a well-defined hydrophobic core and displays an unusual elongated nonglobular fold with dimensions of approximately 60 angstrom by 20 angstrom by 15 angstrom. Eight cysteines form four intrachain disulfide bonds, which are clustered in a core region forming a network complementary to the network of hydrogen bonds. The dimer is stabilized by the ninth cysteine, which forms an interchain disulfide bond, and by two identical hydrophobic interfaces. Sequence profile analysis of other members of the TGF-beta superfamily, including the activins, inhibins, and several developmental factors, imply that they also adopt the TGF-beta fold.	NIDDKD,MOLEC BIOL LAB,BETHESDA,MD 20892; NIH,FOGARTY INT CTR,BETHESDA,MD 20892; CELTRIX PHARMACEUT INC,SANTA CLARA,CA 95052	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC)								ARCHER S, COMMUNICATION; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BHAT TN, BROOKHAVEN PROTEIN D; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHEIFETZ S, 1991, J BIOL CHEM, V266, P20767; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FROLIK CA, 1983, P NATL ACAD SCI-BIOL, V80, P3676, DOI 10.1073/pnas.80.12.3676; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; Hendrickson W. A., 1970, Acta Crystallographica, Section B (Structural Crystallography and Crystal Chemistry), Vb26, P136, DOI 10.1107/S0567740870002078; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P747, DOI 10.1210/mend-2-8-747; JAKOWLEW SB, 1988, MOL ENDOCRINOL, V2, P1186, DOI 10.1210/mend-2-12-1186; JOHNSON CK, 1970, ORTEP FORTRAN THERMA; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KONDAIAH P, 1990, J BIOL CHEM, V265, P1089; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; OGAWA Y, 1992, J BIOL CHEM, V267, P2325; OGAWA Y, COMMUNICATION; PIEZ KA, 1990, TRANSFORMING GROWTH, P593; QIAN SW, IN PRESS P NATL ACAD; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; ROBERTS AB, 1983, BIOCHEMISTRY-US, V22, P5692, DOI 10.1021/bi00294a002; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; SPORN MB, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; TENDIJKE P, 1988, P NATL ACAD SCI USA, V85, P4715; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANN M, 1987, EMBO J, V6, P1633, DOI 10.1002/j.1460-2075.1987.tb02411.x	40	394	436	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					369	373		10.1126/science.1631557	http://dx.doi.org/10.1126/science.1631557			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631557	Green Submitted			2022-12-28	WOS:A1992JD67400028
J	HEALY, B				HEALY, B			IS THIS YOUR FATHERS NIH - AND OTHER STRATEGIC QUESTIONS	SCIENCE			English	Article											HEALY, B (corresponding author), NIH,BETHESDA,MD 20892, USA.							BUSH V, 1990, SCI ENDLESS FRONTIER; GARMENT S, 1991, SCANDAL CRISIS MISTR, P165; 1990, FORTUNE, V122, P190; 1991, WORLD FACT BOOK 1991; 1953, NY TIMES        0224, P8; 1967, ADM RES GRANTS PUBLI, P59; 1992, CONSUM REP, V51, P38	7	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 17	1992	257	5068					312	&		10.1126/science.1631548	http://dx.doi.org/10.1126/science.1631548			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631548				2022-12-28	WOS:A1992JD67400006
J	MELLO, CC; DRAPER, BW; KRAUSE, M; WEINTRAUB, H; PRIESS, JR				MELLO, CC; DRAPER, BW; KRAUSE, M; WEINTRAUB, H; PRIESS, JR			THE PIE-1 AND MEX-1 GENES AND MATERNAL CONTROL OF BLASTOMERE IDENTITY IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; GERM-LINE; CELLULAR INTERACTIONS; GLP-1; SEGREGATION; GRANULES; LIN-12; MUSCLE; NOTCH; LOCUS	During C. elegans embryogenesis an 8-cell stage blastomere, called MS, undergoes a reproducible cleavage pattern, producing pharyngeal cells, body wall muscles, and cell deaths. We show here that maternal-effect mutations in the pie-1 and mex-1 genes cause additional 8-cell stage blastomeres to adopt a fate very similar to that of the wild-type MS blastomere. In pie-1 mutants one additional posterior blastomere adopts an MS-like fate, and in mex-1 mutants four additional anterior blastomeres adopt an MS-like fate. We propose that maternally provided pie-1(+) and mex-1(+) gene products may function in the early embryo to localize or regulate factors that determine the fate of the MS blastomere.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	MELLO, CC (corresponding author), FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Krause, Michael/0000-0001-6127-3940; Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALBERTSON DG, 1984, DEV BIOL, V101, P61, DOI 10.1016/0012-1606(84)90117-9; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; COWAN AE, 1985, CELL, V41, P923, DOI 10.1016/S0092-8674(85)80073-8; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; EPSTEIN HF, 1982, MUSCLE DEV MOL CELLU, P7; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOSSETT LA, 1982, CELL, V30, P193, DOI 10.1016/0092-8674(82)90025-3; GREENWALD IS, 1985, CELL, V45, P583; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; HORVITZ HR, 1982, NEUROSCI COMMENT, V1, P56; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHIERENBERG E, 1984, DEV BIOL, V101, P240, DOI 10.1016/0012-1606(84)90136-2; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; STJOHNSTON D, 1992, CELL, V68, P201; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WOLF N, 1983, J EMBRYOL EXP MORPH, V73, P297; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0; YAMAGUCHI Y, 1983, DEV GROWTH DIFFER, V25, P121; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	36	207	217	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					163	176		10.1016/0092-8674(92)90542-K	http://dx.doi.org/10.1016/0092-8674(92)90542-K			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623520				2022-12-28	WOS:A1992JC95700017
J	TOPPER, JN; BENNETT, JL; CLAYTON, DA				TOPPER, JN; BENNETT, JL; CLAYTON, DA			A ROLE FOR RNASE MRP IN MITOCHONDRIAL RNA PROCESSING	CELL			English	Editorial Material							DNA-REPLICATION; ORI SEQUENCES; NUCLEAR GENE; HEAVY-STRAND; YEAST; INITIATION; GENOME; CONTAINS; INVITRO; CELLS				TOPPER, JN (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT DEV BIOL,STANFORD,CA 94305, USA.				NIGMS NIH HHS [GM33088] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033088, R37GM033088] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BALDACCI G, 1984, EMBO J, V3, P2115, DOI 10.1002/j.1460-2075.1984.tb02099.x; BENNETT JL, 1990, MOL CELL BIOL, V10, P2191, DOI 10.1128/MCB.10.5.2191; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1985, EMBO J, V4, P1559, DOI 10.1002/j.1460-2075.1985.tb03817.x; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; DEZAMAROCZY M, 1984, GENE, V32, P439, DOI 10.1016/0378-1119(84)90019-2; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FAUGERONFONTY G, 1984, GENE, V32, P459, DOI 10.1016/0378-1119(84)90020-9; FISHER RP, 1985, J BIOL CHEM, V260, P1330; FLORY PJ, 1973, J MOL BIOL, V74, P81, DOI 10.1016/0022-2836(73)90100-9; GILLUM AM, 1979, J MOL BIOL, V135, P353, DOI 10.1016/0022-2836(79)90441-8; GOLD HA, 1989, SCIENCE, V245, P1377, DOI 10.1126/science.2476849; KARWAN R, 1991, GENE DEV, V5, P1264, DOI 10.1101/gad.5.7.1264; KISS T, 1992, CELL, V69, P11; MORALES MJ, 1989, NUCLEIC ACIDS RES, V17, P6865, DOI 10.1093/nar/17.17.6865; STOHL LL, 1992, IN PRESS MOL CELL BI, V12; TAPPER DP, 1983, METHOD ENZYMOL, V97, P426; TOPPER JN, 1990, NUCLEIC ACIDS RES, V18, P793, DOI 10.1093/nar/18.4.793; TOPPER JN, 1990, J BIOL CHEM, V265, P13254; TOPPER JN, 1988, EUKARYOTIC DNA REPLI, P207; YUAN Y, 1989, J BIOL CHEM, V264, P14835; YUAN Y, 1991, BIOCHIM BIOPHYS ACTA, V1089, P33, DOI 10.1016/0167-4781(91)90081-V; YUAN Y, 1991, MOL CELL BIOL, V11, P5266, DOI 10.1128/MCB.11.10.5266; ZIERLER MK, 1985, J BIOL CHEM, V260, P974	28	62	64	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					16	20		10.1016/0092-8674(92)90529-L	http://dx.doi.org/10.1016/0092-8674(92)90529-L			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623519				2022-12-28	WOS:A1992JC95700004
J	NAKAYAMA, K; LOH, DY				NAKAYAMA, K; LOH, DY			NO REQUIREMENT FOR P56(LCK) IN THE ANTIGEN-STIMULATED CLONAL DELETION OF THYMOCYTES	SCIENCE			English	Article							T-CELL-RECEPTOR; TYROSINE PHOSPHORYLATION; KINASE-ACTIVITY; HERBIMYCIN-A; INHIBITION; ACTIVATION; CD4; IA	Activation of protein-tyrosine kinases (PTKs) is required for signal transduction during T cell activation, although the pathway used during thymic selection is unknown. An in vitro system was established in which T cell receptor transgenic thymocytes underwent clonal deletion in response to peptide antigen. The effects of two PTK-specific inhibitors, herbimycin A and genistein, on the clonal deletion of immature thymocytes and the activation of mature thymocytes were examined. Clonal deletion occurred while T cell activation was inhibited and when no p56lck activity was evident. Thus, p56lck is not required for the antigen-stimulated step of clonal deletion of immature thymocytes, and negative selection proceeds via a distinct pathway.	WASHINGTON UNIV,SCH MED,DEPT MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)								AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; IWABUCHI K, IN PRESS P NATL ACAD; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOH DY, 1991, NEW BIOL, V3, P924; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NAKAYAMA K, UNPUB; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARK DJ, 1991, J BIOL CHEM, V266, P16277; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SETTE A, 1989, J IMMUNOL, V142, P35; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; TANTI JF, 1991, J BIOL CHEM, V266, P2099; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484	27	50	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					94	96		10.1126/science.1621101	http://dx.doi.org/10.1126/science.1621101			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621101				2022-12-28	WOS:A1992JC16500038
J	FARNAN, I; GRANDINETTI, PJ; BALTISBERGER, JH; STEBBINS, JF; WERNER, U; EASTMAN, MA; PINES, A				FARNAN, I; GRANDINETTI, PJ; BALTISBERGER, JH; STEBBINS, JF; WERNER, U; EASTMAN, MA; PINES, A			QUANTIFICATION OF THE DISORDER IN NETWORK-MODIFIED SILICATE-GLASSES	NATURE			English	Article							BOND-ANGLE DISTRIBUTION; VITREOUS SILICA; O-17 NMR; TEMPERATURE; DYNAMICS; SOLIDS; NUCLEI; TIME	Local order in silicate glasses has been observed by many experimental techniques to be similar to that in crystalline materials. Details of the intermediate-range order are more elusive, but essential for understanding the lack of long-range symmetry in glasses and the effect of composition on glass structure. Two-dimensional O-17 dynamic-angle-spinning nuclear magnetic resonance experiments reveal intermediate-range order in the distribution of inter-tetrahedral (Si-O-Si) bond angles and a high degree of order in the disposition of oxygen atoms around the network-modifying cations.	LAWRENCE BERKELEY LAB,DIV MAT SCI,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	FARNAN, I (corresponding author), STANFORD UNIV,DEPT GEOL,STANFORD,CA 94305, USA.		Baltisberger, Jay/C-8340-2019; Farnan, Ian/M-3881-2014; Grandinetti, Philip J/F-1084-2010	Baltisberger, Jay/0000-0003-2305-0046; Farnan, Ian/0000-0001-7844-5112; Grandinetti, Philip J/0000-0003-0102-316X; Stebbins, Jonathan/0000-0002-2384-6637				CHMELKA BF, 1989, NATURE, V339, P42, DOI 10.1038/339042a0; COHEN MH, 1957, SOLID STATE PHYS, V5, P321, DOI 10.1016/S0081-1947(08)60105-8; Dupree R, 1984, NATURE, V308, P523, DOI 10.1038/308523a0; DUPREE R, 1984, J NON-CRYST SOLIDS, V68, P399, DOI 10.1016/0022-3093(84)90020-6; EASTMAN MA, IN PRESS J MAGN RESO; ECKERSLEY MC, 1988, NATURE, V335, P525, DOI 10.1038/335525a0; ENGELHARDT G, 1984, CHEM PHYS LETT, V108, P271, DOI 10.1016/0009-2614(84)87063-3; FARNAN I, 1990, J AM CHEM SOC, V112, P32, DOI 10.1021/ja00157a008; GASKELL PH, 1991, NATURE, V350, P675, DOI 10.1038/350675a0; GEISSBERGER AE, 1983, J NON-CRYST SOLIDS, V54, P121, DOI 10.1016/0022-3093(83)90087-X; GLADDEN LF, 1986, PHILOS MAG B, V53, pL81, DOI 10.1080/01418638608244284; GREAVES GN, 1981, NATURE, V293, P611, DOI 10.1038/293611a0; GREAVES GN, 1990, GLASS SCI TECHNOLO B, V4, P1; HUANG CD, 1991, J CHEM PHYS, V95, P3634, DOI 10.1063/1.460814; Kirkpatrick R. J., 1986, STRUCTURE BONDING NO; LLOR A, 1988, CHEM PHYS LETT, V152, P248, DOI 10.1016/0009-2614(88)87362-7; MELMAN H, 1991, J NON-CRYST SOLIDS, V134, P107, DOI 10.1016/0022-3093(91)90017-Z; MOZZI RL, 1969, J APPL CRYSTALLOGR, V2, P164, DOI 10.1107/S0021889869006868; MUELLER KT, 1990, J MAGN RESON, V86, P470, DOI 10.1016/0022-2364(90)90025-5; MUELLER KT, IN PRESS J PHYS CHEM; NEWTON MD, 1980, PHYS CHEM MINER, V6, P221, DOI 10.1007/BF00309858; PETTIFER RF, 1988, J NON-CRYST SOLIDS, V106, P408, DOI 10.1016/0022-3093(88)90299-2; SAMOSON A, 1988, MOL PHYS, V65, P1013, DOI 10.1080/00268978800101571; SCHWEINSBERG H, 1974, ACTA CRYSTALLOGR B, V30, P2206, DOI 10.1107/S0567740874006753; SOULES TF, 1979, J CHEM PHYS, V71, P4570, DOI 10.1063/1.438210; SPEARING DR, IN PRESS PHYS CHEM M; STEBBINS JF, 1991, NATURE, V351, P638, DOI 10.1038/351638a0; STEBBINS JF, 1988, J NON-CRYST SOLIDS, V106, P359, DOI 10.1016/0022-3093(88)90289-X; TESAR AA, 1987, J CHEM PHYS, V87, P2986, DOI 10.1063/1.453034; TOSSELL JA, 1988, PHYS CHEM MINER, V15, P564, DOI 10.1007/BF00311027; VESSAL B, 1992, NATURE, V356, P504, DOI 10.1038/356504a0; XUE X, 1991, T AM GEOPHYS UN, V72, P572	32	231	231	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					31	35		10.1038/358031a0	http://dx.doi.org/10.1038/358031a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614527				2022-12-28	WOS:A1992JB34100043
J	EDDY, DM				EDDY, DM			COST-EFFECTIVENESS ANALYSIS - WILL IT BE ACCEPTED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CANCER		DUKE UNIV,DURHAM,NC 27706	Duke University								EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P132, DOI 10.1001/jama.268.1.132; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1674; Rawls J., 1971, THEORY JUSTICE	7	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					132	136		10.1001/jama.268.1.132	http://dx.doi.org/10.1001/jama.268.1.132			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608100				2022-12-28	WOS:A1992JA16500033
J	TSANEVA, IR; MULLER, B; WEST, SC				TSANEVA, IR; MULLER, B; WEST, SC			ATP-DEPENDENT BRANCH MIGRATION OF HOLLIDAY JUNCTIONS PROMOTED BY THE RUVA AND RUVB PROTEINS OF ESCHERICHIA-COLI	CELL			English	Article							STRAND EXCHANGE-REACTIONS; ESCHERICHIA-COLI; RECA PROTEIN; DNA-REPAIR; ENZYMATIC FORMATION; K-12 REVEALS; RECOMBINATION; PURIFICATION; RESOLUTION; MOLECULES	The RuvA and RuvB proteins of E. coli, which are induced as part of the cellular response to DNA damage, act together to promote the branch migration of Holliday junctions. Addition of purified RuvA and RuvB to a RecA-mediated recombination reaction stimulates the rate of strand exchange and the formation of heteroduplex DNA. Stimulation does not occur via interaction with RecA; instead, RuvA and RuvB act directly upon recombination intermediates (Holliday junctions) made by RecA. We show that RuvAB-mediated branch migration requires ATP and can bypass UV-induced DNA lesions. At high RuvB concentrations, the requirement for RuvA is overcome, indicating that the RuvB ATPase provides the motor force for branch migration. RuvA protein provides specificity by binding to the Holliday junction, thereby reducing the requirement for RuvB by 50-fold. The newly discovered biochemical properties of RuvA, RuvB, and RuvC are incorporated into a model for the postreplicational repair of DNA following UV irradiation.			TSANEVA, IR (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418; Muller, Berndt/0000-0003-1279-5421				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; CLARK AJ, 1988, RECOMBINATION GENETI, P155; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; CONNOLLY B, 1990, P NATL ACAD SCI USA, V87, P8476, DOI 10.1073/pnas.87.21.8476; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; GRIFFIN TJ, 1990, J BACTERIOL, V172, P6291, DOI 10.1128/jb.172.11.6291-6299.1990; HAHN TR, 1988, J BIOL CHEM, V263, P7431; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LIVNEH Z, 1982, P NATL ACAD SCI-BIOL, V79, P3171, DOI 10.1073/pnas.79.10.3171; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1987, J GEN MICROBIOL, V133, P2531; LOVETT ST, 1989, P NATL ACAD SCI USA, V86, P2627, DOI 10.1073/pnas.86.8.2627; LUISIDELUCA C, 1989, GENETICS, V122, P269; MULLER B, 1990, CELL, V60, P329, DOI 10.1016/0092-8674(90)90747-3; MULLER B, 1991, J BIOL CHEM, V266, P19028; MULLER B, 1992, IN PRESS EMBO J; OTSUJI N, 1974, J BACTERIOL, V117, P337, DOI 10.1128/JB.117.2.337-344.1974; PARSONS CA, 1992, IN PRESS P NATL ACAD; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHARPLES GJ, 1990, MOL GEN GENET, V221, P219, DOI 10.1007/BF00261724; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; SHURVINTON CE, 1982, MOL GEN GENET, V185, P352, DOI 10.1007/BF00330811; STACEY KA, 1976, MOL GEN GENET, V143, P223, DOI 10.1007/BF00266925; TAKAHAGI M, 1991, J BACTERIOL, V173, P5747, DOI 10.1128/jb.173.18.5747-5753.1991; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; TSANEVA IR, 1992, IN PRESS MOL GEN GEN; UMEZU K, 1990, P NATL ACAD SCI USA, V87, P5363, DOI 10.1073/pnas.87.14.5363; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEST SC, 1982, MOL GEN GENET, V187, P209, DOI 10.1007/BF00331119; WEST SC, 1983, CELL, V32, P817, DOI 10.1016/0092-8674(83)90068-5; WEST SC, 1981, NATURE, V294, P659, DOI 10.1038/294659a0; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P6149, DOI 10.1073/pnas.78.10.6149; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	44	240	240	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 26	1992	69	7					1171	1180		10.1016/0092-8674(92)90638-S	http://dx.doi.org/10.1016/0092-8674(92)90638-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617728				2022-12-28	WOS:A1992JA43100011
J	CULLITON, BJ				CULLITON, BJ			SW MEDICAL-CENTER, FAMOUS AND FAVORED, IS THRIVING	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					627	628		10.1038/357627a0	http://dx.doi.org/10.1038/357627a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614506				2022-12-28	WOS:A1992JA43000023
J	ALLEN, S; TICE, J; VANDEPERRE, P; SERUFILIRA, A; HUDES, E; NSENGUMUREMYI, F; BOGAERTS, J; LINDAN, C; HULLEY, S				ALLEN, S; TICE, J; VANDEPERRE, P; SERUFILIRA, A; HUDES, E; NSENGUMUREMYI, F; BOGAERTS, J; LINDAN, C; HULLEY, S			EFFECT OF SEROTESTING WITH COUNSELING ON CONDOM USE AND SEROCONVERSION AMONG HIV DISCORDANT COUPLES IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; HETEROSEXUAL TRANSMISSION; SEXUAL PARTNERS; UNITED-STATES; RISK; INFECTION; AIDS; MEN; ALCOHOL; FEMALE	Objective-To determine whether HIV testing and counselling increased condom use and decreased heterosexual transmission of HIV in discordant couples. Design-Prospective study. Setting-Kigali, the capital of Rwanda. Subjects-Cohabiting couples with discordant HIV serology results. Main outcome measures-Condom use in the couple and HIV seroconversion in the negative partners. Results-60 HIV discordant couples were identified, of whom 53 were followed for an average of 2.2 years. The proportion of discordant couples using condoms increased from 4% to 57% after one year of follow up. During follow up two of the 23 HIV negative men and six of the 30 HIV negative women seroconverted (seroconversion rates of 4 and 9 per 100 person years). The rate among women was less than half that estimated for similar women in discordant couples whose partners had not been serotested. Condom use was less common among those who seroconverted (100% v 5%, p=0.01 in men; 67% v 25%, p=0.14 in women). Conclusions-Roughly one in seven cohabiting couples in Kigali have discordant HIV serological results. Confidential HIV serotesting with counselling caused a large increase in condom use and was associated with a lower rate of new HIV infections. HIV testing is a promising intervention for preventing the spread of HIV in African cities.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; PROJET SAN FRANCISCO,KIGALI,RWANDA; MINISTRY HLTH,KIGALI,RWANDA; NATL AIDS CONTROL PROGRAM,KIGALI,RWANDA; CTR HOSP KIGALI,KIGALI,RWANDA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Van de Perre, Philippe/B-9692-2008	Van de Perre, Philippe/0000-0002-3912-0427; Tice, Jeffrey/0000-0002-9857-2028	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23980] Funding Source: Medline; NIMH NIH HHS [MH-42459] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1991, J INFECT DIS, V164, P67, DOI 10.1093/infdis/164.1.67; CAMERON DW, 1989, LANCET, V2, P403; CARAEL M, 1988, AIDS, V2, P201; CHIN J, 1989, B WORLD HEALTH ORGAN, V87, P1; Cochran W.G, 1957, STAT METHODS, V6th ed; FELDBLUM PJ, 1988, AM J PUBLIC HEALTH, V78, P52, DOI 10.2105/AJPH.78.1.52; FISCHL MA, 1987, JAMA-J AM MED ASSOC, V257, P640, DOI 10.1001/jama.257.5.640; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HIRA SK, 1990, J ACQ IMMUN DEF SYND, V3, P83; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; JOHNSON AM, 1989, AIDS, V3, P367, DOI 10.1097/00002030-198906000-00005; Johnson NL, 1969, DISTRIBUTIONS STAT D; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAMENGA M, 1989, 5 INT C AIDS MONTR; KING R, 1991, LANCET, V338, P1278, DOI 10.1016/0140-6736(91)92149-V; KREISS J, 1985, ANN INTERN MED, V102, P632; LAGA M, 1989, AIDS, V3, P361, DOI 10.1097/00002030-198906000-00004; LARSON A, 1989, REV INFECT DIS, V11, P716; LAURIAN Y, 1989, NEW ENGL J MED, V320, P183; Laurian Y., 1989, New England Journal of Medicine, V321, P268; LAWRENCE DN, 1989, AM J HEMATOL, V30, P68, DOI 10.1002/ajh.2830300204; MANN J, 1987, NEW ENGL J MED, V316, P345; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; PADIAN N, 1987, JAMA-J AM MED ASSOC, V258, P788, DOI 10.1001/jama.258.6.788; PADIAN NS, 1990, J INFECT DIS, V161, P883, DOI 10.1093/infdis/161.5.883; PERRONI L, 1989, 5 INT C AIDS MONTR; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; PETERMAN TA, 1989, JAMA-J AM MED ASSOC, V262, P502; ROBERTSON JA, 1988, DRUG ALCOHOL DEPEN, V22, P75, DOI 10.1016/0376-8716(88)90039-7; RYDER RW, 1990, AIDS, V4, P725, DOI 10.1097/00002030-199008000-00002; Sheehan A, 1990, Nursing (Lond), V4, P13; SILVESTRE AJ, 1989, AIDS, V3, P647, DOI 10.1097/00002030-198910000-00005; SMILEY ML, 1988, AM J HEMATOL, V28, P27, DOI 10.1002/ajh.2830280106; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; STEIN ZA, 1990, AM J PUBLIC HEALTH, V80, P460, DOI 10.2105/AJPH.80.4.460; 1989, BMJ, V298, P411	38	369	375	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1605	1609		10.1136/bmj.304.6842.1605	http://dx.doi.org/10.1136/bmj.304.6842.1605			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628088	Bronze, Green Published			2022-12-28	WOS:A1992JA43600021
J	FULTZ, PN; NARA, P; BARRESINOUSSI, F; CHAPUT, A; GREENBERG, ML; MUCHMORE, E; KIENY, MP; GIRARD, M				FULTZ, PN; NARA, P; BARRESINOUSSI, F; CHAPUT, A; GREENBERG, ML; MUCHMORE, E; KIENY, MP; GIRARD, M			VACCINE PROTECTION OF CHIMPANZEES AGAINST CHALLENGE WITH HIV-1 INFECTED PERIPHERAL-BLOOD MONONUCLEAR-CELLS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RETROVIRUS; SECRETIONS; MACAQUES; ANTIBODY; TYPE-1; WOMEN; AIDS	Because human immunodeficiency virus (HIV) can be transmitted as cell-free virus or as infected cells (cell-associated virus), vaccines must protect against infection by both viral forms. Vaccine-mediated protection of nonhuman primates against low doses of cell-free HIV-1, HIV-2, or simian immunodeficiency virus (SIV) has been demonstrated. It is now shown that multiple immunizations of chimpanzees with HIV-1 antigens protected against infection with cell-associated virus. Protection can persist for extended periods (one animal had not been exposed to viral antigens for 1 year before challenge). These results show that it is possible to elicit long-lasting protective immunity against cell-associated HIV-1.	NCI,FREDERICK CANC RES FACIL,FREDERICK,MD 21701; INST PASTEUR,F-75724 PARIS 15,FRANCE; NYU MED CTR,EXPTL MED & SURG PRIMATES LAB,NEW YORK,NY 10016; TRANSGENE SA,F-67082 STRASBOURG,FRANCE; DUKE UNIV,MED CTR,DURHAM,NC 27710	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; New York University; Transgene SA; Duke University	FULTZ, PN (corresponding author), UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294, USA.		Barre-Sinoussi, Françoise/G-8355-2011; Dr. Peter L. Nara, M.Sc./I-7432-2019; Kieny, Marie-Paule/Q-1238-2019; Kieny, Marie-Paule/N-3914-2017	Kieny, Marie-Paule/0000-0002-5943-6488				BELO M, 1991, AIDS, V5, P169, DOI 10.1097/00002030-199102000-00006; BERMAN PW, 1990, NATURE, V345, P622, DOI 10.1038/345622a0; BORZY MS, 1988, J ACQ IMMUN DEF SYND, V1, P419; CARLSON JR, 1990, AIDS RES HUM RETROV, V6, P1239, DOI 10.1089/aid.1990.6.1239; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; CULMANN B, 1991, J IMMUNOL, V146, P1560; DESROSIERS RC, 1989, P NATL ACAD SCI USA, V86, P6353, DOI 10.1073/pnas.86.16.6353; EMINI EA, 1990, J VIROL, V64, P3674, DOI 10.1128/JVI.64.8.3674-3678.1990; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; FULTZ PN, UNPUB; GIRARD M, 1991, P NATL ACAD SCI USA, V88, P542, DOI 10.1073/pnas.88.2.542; HADIDA F, 1992, J CLIN INVEST, V89, P53, DOI 10.1172/JCI115585; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JOHNSON PR, 1992, P NATL ACAD SCI USA, V89, P2175, DOI 10.1073/pnas.89.6.2175; LANGLOIS AJ, 1992, SCIENCE, V255, P292, DOI 10.1126/science.1549775; LAURE F, 1988, LANCET, V2, P538; LEVY JA, 1985, ANN INTERN MED, V103, P694, DOI 10.7326/0003-4819-103-5-694; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; NARA PL, 1987, AIDS RES HUM RETROV, V3, P283, DOI 10.1089/aid.1987.3.283; PUTKONEN P, 1991, AIDS RES HUM RETROV, V7, P271, DOI 10.1089/aid.1991.7.271; SHAFFERMAN A, 1991, P NATL ACAD SCI USA, V88, P7126, DOI 10.1073/pnas.88.16.7126; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; STOTT EJ, 1990, LANCET, V336, P1538, DOI 10.1016/0140-6736(90)93310-L; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; VOGT MW, 1986, LANCET, V1, P525; WOFSY CB, 1986, LANCET, V1, P527	27	154	159	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1687	1690		10.1126/science.256.5064.1687	http://dx.doi.org/10.1126/science.256.5064.1687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609280				2022-12-28	WOS:A1992HZ17400047
J	BACHVAROVA, RF				BACHVAROVA, RF			A MATERNAL TAIL OF POLY(A) - THE LONG AND THE SHORT OF IT	CELL			English	Review							MESSENGER-RNA TRANSLATION; POLYADENYLATION; MATURATION				BACHVAROVA, RF (corresponding author), CORNELL UNIV, MED CTR, COLL MED, DEPT CELL BIOL, NEW YORK, NY 10021 USA.							AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AHRINGER J, 1992, IN PRESS EMBO J; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PARIS J, 1991, GENE DEV, V5, P1697, DOI 10.1101/gad.5.9.1697; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; Sachs A, 1990, CURR OPIN CELL BIOL, V2, P1092, DOI 10.1016/0955-0674(90)90161-7; SALLEIS FJ, 1992, IN PRESS GENES DEV, V6; STJOHNSTON D, 1992, CELL, V68, P201; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; VARNUM SM, 1992, IN PRESS DEV BIOL; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	17	155	157	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					895	897		10.1016/0092-8674(92)90606-D	http://dx.doi.org/10.1016/0092-8674(92)90606-D			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606613	hybrid			2022-12-28	WOS:A1992HY79200001
J	PRYLE, BJ; GRECH, H; STODDART, PA; CARSON, R; OMAHONEY, T; REYNOLDS, F				PRYLE, BJ; GRECH, H; STODDART, PA; CARSON, R; OMAHONEY, T; REYNOLDS, F			TOXICITY OF NORPETHIDINE IN SICKLE-CELL CRISIS	BRITISH MEDICAL JOURNAL			English	Article							MEPERIDINE; CANCER		ST THOMAS HOSP,DEPT ANAESTHESIA,LONDON SE1 7EH,ENGLAND; ST THOMAS HOSP,DEPT HAEMATOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; MITCHELL A, 1991, BRIT MED J, V303, P249, DOI 10.1136/bmj.303.6796.249-a; REYNOLDS F, 1968, BRIT J PHARMACOL, V20, P704; SZETO HH, 1977, ANN INTERN MED, V86, P738, DOI 10.7326/0003-4819-86-6-738; Tang R, 1980, HOSP FORMUL, V15, P764	5	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1478	1479		10.1136/bmj.304.6840.1478	http://dx.doi.org/10.1136/bmj.304.6840.1478			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611370	Green Published, Bronze			2022-12-28	WOS:A1992HY55300023
J	KANG, SM; TRAN, AC; GRILLI, M; LENARDO, MJ				KANG, SM; TRAN, AC; GRILLI, M; LENARDO, MJ			NF-KAPPA-B SUBUNIT REGULATION IN NONTRANSFORMED CD4+ LYMPHOCYTES-T	SCIENCE			English	Article							ANTIGEN-PRESENTING CELLS; HUMAN INTERLEUKIN-2 GENE; DNA-BINDING SUBUNIT; PROTEIN-BINDING; REL ONCOGENE; EXPRESSION; ENHANCER; ACTIVATION; IDENTIFICATION; TRANSCRIPTION	Regulation of interleukin-2 (IL-2) gene expression by the p50 and p65 subunits of the DNA binding protein NF-kappa-B was studied in nontransformed CD4+ T lymphocyte clones. A homodimeric complex of the NF-kappa-B p50 subunit was found in resting T cells. The amount of p50-p50 complex decreased after full antigenic stimulation, whereas the amount of the NF-kappa-B p50-p65 heterodimer was increased. Increased expression of the IL-2 gene and activity of the IL-2 kappa-B DNA binding site correlated with a decrease in the p50-p50 complex. Overexpression of p50 repressed IL-2 promoter expression. The switch from p50-p50 to p50-p65 complexes depended on a protein that caused sequestration of the p50-p50 complex in the nucleus.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			grilli, mariagrazia/ABF-1542-2020	grilli, mariagrazia/0000-0001-9165-5827				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAUERLE PA, 1988, SCIENCE, V242, P540; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BOURS V, 1992, MOL CELL BIOL, V12, P682; BRABLETZ T, 1991, NUCLEIC ACIDS RES, V19, P61, DOI 10.1093/nar/19.1.61; BRORSON KA, 1991, J IMMUNOL, V147, P3601; CHIU JJS, UNPUB; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; EMMEL EA, 1989, SCIENCE, V246, P617; FATHMAN CG, 1989, FUNDAMENTAL IMMUNOLO, P803; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, IN PRESS INT REV CYT; GRILLI MG, 1991, CYTOKINE, V3, P372; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAZAN U, 1990, P NATL ACAD SCI USA, V87, P7861, DOI 10.1073/pnas.87.20.7861; HECHT TT, 1983, J IMMUNOL, V131, P1049; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; JAMIESON C, 1991, J IMMUNOL, V147, P416; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; Kang S.-G., UNPUB; KANG SM, IN PRESS MOL CELL BI; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENARDO M, UNPUB; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUELLER DL, 1990, J IMMUNOL, V144, P3701; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; RADLER-POHL A, 1990, New Biologist, V2, P566; RANDAK C, 1990, EMBO J, V9, P2529, DOI 10.1002/j.1460-2075.1990.tb07433.x; RONCHESE F, 1987, NATURE, V329, P254, DOI 10.1038/329254a0; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P675; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHIBUYA H, 1989, NUCLEIC ACIDS RES, V17, P9173, DOI 10.1093/nar/17.22.9173; SHIBUYA H, 1989, INT IMMUNOL, V1, P143; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THOMPSON CC, 1991, SCIENCE, V253, P672; URBAN MB, 1991, NEW BIOL, V3, P279; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WEAVER CT, 1988, P NATL ACAD SCI USA, V85, P8181, DOI 10.1073/pnas.85.21.8181; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x	66	313	330	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1452	1456		10.1126/science.1604322	http://dx.doi.org/10.1126/science.1604322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604322				2022-12-28	WOS:A1992HX33700038
J	MOUTQUIN, JM; EFFER, SB; MILNER, RA; MOHIDE, PT; SAUVE, RS; SINCLAIR, JC; RAND, C; WESTFALL, L; WHITFIELD, M; JANSEN, P; JANG, Q; DALTON, ME; HARDIE, M; DUDLEY, D; BELCHER, J; PARNES, S; DUBE, MS; YEN, M; HUNTER, D; SAIGAL, S; HUNTER, V; ROSENBLOOM, D; DEMIANCZUK, N; CORNET, A; PARNES, S; DUBE, M; TIERNEY, M; VINCER, M; NWAESEI, CG; ZIMMER, P; RENO, M; MITCHELL, BF; ROBERTSON, C; PHELAN, V				MOUTQUIN, JM; EFFER, SB; MILNER, RA; MOHIDE, PT; SAUVE, RS; SINCLAIR, JC; RAND, C; WESTFALL, L; WHITFIELD, M; JANSEN, P; JANG, Q; DALTON, ME; HARDIE, M; DUDLEY, D; BELCHER, J; PARNES, S; DUBE, MS; YEN, M; HUNTER, D; SAIGAL, S; HUNTER, V; ROSENBLOOM, D; DEMIANCZUK, N; CORNET, A; PARNES, S; DUBE, M; TIERNEY, M; VINCER, M; NWAESEI, CG; ZIMMER, P; RENO, M; MITCHELL, BF; ROBERTSON, C; PHELAN, V			TREATMENT OF PRETERM LABOR WITH THE BETA-ADRENERGIC AGONIST RITODRINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MIMETIC AGENT; HYDROCHLORIDE; MORTALITY	Background. Beta-adrenergic agonists are commonly used to arrest premature labor. Although treatment of preterm labor with these agents can delay delivery by 24 to 48 hours, the potential risks and benefits to the mother and infant before and after delivery have not been adequately assessed. Methods. We randomly assigned 708 women with preterm labor at six hospitals to receive an intravenous infusion of either the beta-adrenergic agonist ritodrine (n = 352) or placebo (n = 356). Assignment was made with stratification according to four categories of gestational age (20 to 23 weeks, 24 to 27 weeks, 28 to 31 weeks, and 32 to 35 weeks). The primary objective was to assess the effect of ritodrine on perinatal mortality. Secondary objectives were the evaluation of the causes of perinatal death, the extent to which delivery was delayed with ritodrine, and the effects on birth weight, maternal morbidity, neonatal morbidity, and infant morbidity at 18 months of postnatal age, corrected for preterm delivery. Results. Among the 771 infants born to the women in the study (including 63 pairs of twins), there were 23 deaths (6.1 percent) in the ritodrine group and 25 deaths (6.4 percent) in the placebo group (event-rate difference, -0.3 percent; 95 percent confidence interval, -3.7 percent to 3.1 percent). There was no difference between the groups in the extent of delay of delivery, the incidence of delivery before 37 weeks' gestation, the proportion of babies weighing less than 2500 g, or measures of neonatal morbidity. Maternal morbidity (such as chest pain and cardiac arrhythmias) occurred more frequently but not exclusively in the ritodrine group. One infant born to a woman in the ritodrine group and five infants born to women in the placebo group had cerebral palsy (P = 0.09). There was a slight but not significant trend toward an improved score on the Bayley Psychomotor Development Index at 18 months of age among the infants of the ritodrine-treated women. Conclusions. We found that the use of ritodrine in the treatment of preterm labor had no significant beneficial effect on perinatal mortality, the frequency of prolongation of pregnancy to term, or birth weight.	OTTAWA CIVIC HOSP,OTTAWA K1Y 4E9,ONTARIO,CANADA; GRACE MATERN HOSP,HALIFAX,NS,CANADA; BRITISH COLUMBIA CHILDRENS HOSP,VANCOUVER,BC,CANADA; UNIV LAVAL,DEPT OBSTET & GYNECOL,QUEBEC CITY G1K 7P4,QUEBEC,CANADA; UNIV BRITISH COLUMBIA,DEPT OBSTET & GYNECOL,VANCOUVER V6T 1W5,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT HLTH CARE & EPIDEMIOL,VANCOUVER V6T 1W5,BC,CANADA; MCMASTER UNIV,DEPT OBSTET & GYNECOL,HAMILTON L8S 4L8,ONTARIO,CANADA; UNIV CALGARY,DEPT PEDIAT,CALGARY T2N 1N4,ALBERTA,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA; GRACE HOSP,VANCOUVER,BC,CANADA; UNIV ALBERTA HOSP,EDMONTON T6G 2B7,ALBERTA,CANADA; OTTAWA GEN HOSP,OTTAWA K1H 8L6,ONTARIO,CANADA	University of Ottawa; Ottawa Hospital Research Institute; Dalhousie University; BC Childrens Hospital; University of British Columbia; Laval University; University of British Columbia; University of British Columbia; McMaster University; University of Calgary; McMaster University; McMaster University; University of British Columbia; University of Alberta; University of Ottawa; Ottawa Hospital Research Institute	MOUTQUIN, JM (corresponding author), ST FRANCOIS DASSISE HOSP,DEPT OBSTET & GYNECOL,10 LESPINAY ST,QUEBEC CITY G1L 3L5,QUEBEC,CANADA.							ARMITAGE P, 1986, 13TH P INT BIOM C SE; BARDEN TP, 1980, OBSTET GYNECOL, V56, P1; Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BOYLAN P, 1983, AM J OBSTET GYNECOL, V145, P781, DOI 10.1016/0002-9378(83)90678-6; CREASY RK, 1980, AM J OBSTET GYNECOL, V137, P212, DOI 10.1016/0002-9378(80)90777-2; CROWLEY P, 1989, EFFECTIVE CARE PREGN, V1, P746; CSAPO AI, 1977, AM J OBSTET GYNECOL, V129, P482, DOI 10.1016/0002-9378(77)90084-9; IRETON H, 1974, MINNESOTA CHILD DEV; KING JF, 1988, BRIT J OBSTET GYNAEC, V95, P211, DOI 10.1111/j.1471-0528.1988.tb06860.x; LEVENO KJ, 1990, OBSTET GYNECOL, V76, P12; MERKATZ IR, 1980, OBSTET GYNECOL, V56, P7; PAPAGEORGIOU AN, 1989, PEDIATRICS, V83, P493; SCHENKEN RS, 1980, AM J OBSTET GYNECOL, V137, P773, DOI 10.1016/0002-9378(80)90884-4; WESSELIU.A, 1971, BMJ-BRIT MED J, V3, P144	14	263	265	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					308	312						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1620169				2022-12-28	WOS:A1992JF65500003
J	DONIACH, T; PHILLIPS, CR; GERHART, JC				DONIACH, T; PHILLIPS, CR; GERHART, JC			PLANAR INDUCTION OF ANTEROPOSTERIOR PATTERN IN THE DEVELOPING CENTRAL-NERVOUS-SYSTEM OF XENOPUS-LAEVIS	SCIENCE			English	Article							NEURAL INDUCTION; POSITIONAL INFORMATION; PROSPECTIVE AREAS; HOMEOBOX GENE; EXPRESSION; EMBRYOS; ANTERIOR; ECTODERM; MARKER; MOUSE	It has long been thought that anteroposterior (A-P) pattern in the vertebrate central nervous system is induced in the embryo's dorsal ectoderm exclusively by signals passing vertically from underlying, patterned dorsal mesoderm. Explants from early gastrulae of the frog Xenopus laevis were prepared in which vertical contact between dorsal ectoderm and mesoderm was prevented but planar contact was maintained. In these, four position-specific neural markers (engrailed-2, Krox-20, XIHbox 1, and XIHbox 6) were expressed in the ectoderm in the same A-P order as in the embryo. Thus, planar signals alone, following a path available in the normal embryo, can induce A-P neural pattern.	BOWDOIN COLL,DEPT BIOL,BRUNSWICK,ME 04011	Bowdoin College	DONIACH, T (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,301 LSA,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019363, R37GM019363] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19363] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA ARI, 1990, DEVELOPMENT, V108, P595; BALAK K, 1987, DEV BIOL, V119, P540, DOI 10.1016/0012-1606(87)90057-1; BOLCE ME, IN PRESS DEVELOPMENT; DEROBERTIS EM, 1989, CELL, V57, P189, DOI 10.1016/0092-8674(89)90954-9; DIXON JE, 1989, DEVELOPMENT, V106, P749; FROHMAN MA, 1990, DEVELOPMENT, V110, P589; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HEMMATIBRIVANLOU A, 1991, DEVELOPMENT, V111, P715; Holtfreter J., 1955, ANAL DEV, P230; HOLTFRETER J, 1933, ARCH ENTWICKLUNGSMEC, V129, P669; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; KELLER R, 1992, DEV DYNAM, V193, P218, DOI 10.1002/aja.1001930303; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KELLER R, 1988, DEVELOPMENT, V103, P193; KELLER RE, 1976, DEV BIOL, V51, P118, DOI 10.1016/0012-1606(76)90127-5; KELLER RE, 1975, DEV BIOL, V42, P222, DOI 10.1016/0012-1606(75)90331-0; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; LONDON C, 1988, DEV BIOL, V129, P380, DOI 10.1016/0012-1606(88)90385-5; Mangold O, 1933, NATURWISSENSCHAFTEN, V21, P761, DOI 10.1007/BF01503740; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NIEUWKOOP PD, 1952, J EXP ZOOL, V120, P1, DOI 10.1002/jez.1401200102; OLIVER G, 1988, EMBO J, V7, P3199, DOI 10.1002/j.1460-2075.1988.tb03187.x; PAPALOPULU N, 1991, DEVELOPMENT, V113, P1145; ROBERTS SA, UNPUB; SATER AK, UNPUB; SAVAGE R, 1989, DEV BIOL, V133, P157, DOI 10.1016/0012-1606(89)90307-2; SERVETNICK M, 1991, DEV BIOL, V147, P73, DOI 10.1016/S0012-1606(05)80008-9; SHARPE CR, 1987, CELL, V50, P749, DOI 10.1016/0092-8674(87)90333-3; SHARPE CR, 1990, DEVELOPMENT, V109, P765; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; Spemann H, 1988, EMBRYONIC DEV INDUCT; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; WILSON P, 1991, DEVELOPMENT, V112, P289; WOLPERT L, 1989, DEVELOPMENT, V107, P3; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	41	155	158	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					542	545		10.1126/science.1636091	http://dx.doi.org/10.1126/science.1636091			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636091				2022-12-28	WOS:A1992JE75500033
J	FLORIG, HK				FLORIG, HK			CONTAINING THE COSTS OF THE EMF PROBLEM	SCIENCE			English	Article							ELECTRICAL WIRING CONFIGURATIONS; BRAIN-TISSUE INVITRO; ELF 1-120 HZ; ELECTROMAGNETIC-FIELDS; CHILDHOOD-CANCER; MAGNETIC-FIELDS; CALCIUM-IONS; RF FIELDS; EXPOSURE; CELLS				FLORIG, HK (corresponding author), RESOURCES FUTURE INC,1616 P ST NW,WASHINGTON,DC 20036, USA.							ADAIR RK, 1991, PHYS REV A, V43, P1039, DOI 10.1103/PhysRevA.43.1039; ADEY WR, 1981, PHYSIOL REV, V61, P435, DOI 10.1152/physrev.1981.61.2.435; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; BALCERKUBICZEK EK, 1991, RADIAT RES, V126, P65, DOI 10.2307/3578172; BARRY RE, 1991, SEP COMP C ROCK MOUN; BERNHARDT J, 1979, RADIAT ENVIRON BIOPH, V16, P309, DOI 10.1007/BF01340569; BLACKMAN CF, 1985, BIOELECTROMAGNETICS, V6, P1, DOI 10.1002/bem.2250060102; BLANK M, 1988, BIOELECTROCH BIOENER, V19, P569, DOI 10.1016/0302-4598(88)80035-7; BOSTROM A, 1991, 13TH ANN M BIOEL SOC; COLE P, 1991, COMMUNICATION   0114; COOPER MS, 1984, J THEOR BIOL, V111, P123, DOI 10.1016/S0022-5193(84)80200-3; DAVIS MK, 1988, LANCET, V2, P365; FISHER A, 1989, J POLICY ANAL MANAG, V8, P88, DOI 10.2307/3324426; FITZSIMMONS R, 1991, 13TH ANN M BIOEL SOC; FLORIG HK, 1991, DEC ANN M SOC RISK A; FRANCESCHI C, 1991, 1991 ANN REV RES BIO; FULTON JP, 1980, AM J EPIDEMIOL, V111, P292, DOI 10.1093/oxfordjournals.aje.a112899; FURBY L, 1988, J ENVIRON MANAGE, V27, P69; FURBY L, 1988, J ENVIRON PSYCHOL, V8, P19, DOI 10.1016/S0272-4944(88)80021-5; GIBNEY KB, 1991, JUN RIGHT WAY ASS C; GOODMAN R, 1988, P NATL ACAD SCI USA, V85, P3928, DOI 10.1073/pnas.85.11.3928; GOODMAN R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P216, DOI 10.1016/0167-4781(89)90105-X; GORDON I, 1990, 242 U MELB STAT CONS; GRAHAM C, 1990, DE90006671 NAT TECHN; GROTA LJ, 1991, 13TH ANN M BIOEL SOC; JOHN EM, 1991, AM J EPIDEMIOL, V133, P123, DOI 10.1093/oxfordjournals.aje.a115851; KUNREUTHER H, 1987, J ENVIRON ECON MANAG, V14, P371, DOI 10.1016/0095-0696(87)90027-1; LEDNEV VV, 1991, BIOELECTROMAGNETICS, V12, P71, DOI 10.1002/bem.2250120202; LIBOFF AR, 1984, SCIENCE, V223, P818, DOI 10.1126/science.6695183; LONDON SJ, 1991, AM J EPIDEMIOL, V134, P923, DOI 10.1093/oxfordjournals.aje.a116176; LOVELY RH, 1988, ELECTROMAGNETIC FIEL, P327; LUBEN RA, 1982, P NATL ACAD SCI-BIOL, V79, P4180, DOI 10.1073/pnas.79.13.4180; LYLE DB, 1991, BIOELECTROMAGNETICS, V12, P145, DOI 10.1002/bem.2250120303; MALTIN L, COMMUNICATION; MATANOSKI G, 1991, 13TH ANN M BIOEL SOC; MCLEAN JRN, 1991, BIOELECTROMAGNETICS, V12, P273, DOI 10.1002/bem.2250120503; MIZUSHIMA Y, 1975, EXPERIENTIA, V21, P1411; MORGAN MG, 1985, RISK ANAL, V5, P139, DOI 10.1111/j.1539-6924.1985.tb00161.x; MORGAN MG, 1986, SCIENCE, V232, P917, DOI 10.1126/science.3704631; MORGAN MG, 1988, PUBLIC UTILITIES FOR, V121, P49; MURTHY KK, 1991, 1991 ANN REV RES BIO; PILLA AA, 1992, CHARGE FIELD EFFECTS, V3, P231; POOL R, 1990, SCIENCE, V249, P1096, DOI 10.1126/science.2204111; POOLE C, 1991, CANCER CAUSES CONTRO, V2; Portney KE, 1991, HAZARDOUS WASTE TREA; RAYNER S, 1988, NONIONIZING RAD, P39; REESE JA, 1988, BIOELECTROMAGNETICS, V9, P237, DOI 10.1002/bem.2250090305; SANGHVI AP, 1990, EL6791 EL POW RES I; SAVITZ DA, 1987, J OCCUP ENVIRON MED, V29, P47; SAVITZ DA, 1988, AM J EPIDEMIOL, V128, P21, DOI 10.1093/oxfordjournals.aje.a114943; SAVITZ DA, 1989, EPIDEMIOL REV, V11, P59, DOI 10.1093/oxfordjournals.epirev.a036045; SMITH SD, 1987, BIOELECTROMAGNETICS, V8, P215, DOI 10.1002/bem.2250080302; SULZMAN FM, 1987, EFFECTS ELECTROMAGNE; Susskind L., 1987, BREAKING IMPASSE; TENFORDE TS, 1991, BIOELECTROCH BIOENER, V25, P1, DOI 10.1016/0302-4598(91)87015-9; THERIAULT GP, 1991, NIOSH91111 PUBL, P91; TOMENIUS L, 1986, BIOELECTROMAGNETICS, V7, P191, DOI 10.1002/bem.2250070209; TRAVIS CC, 1987, ENVIRON SCI TECHNOL, V21, P415, DOI 10.1021/es00159a001; TSONG TY, 1988, ANNU REV PHYSIOL, V50, P273; WALBORG EF, 1991, EXTREMELY LOW FREQUE; WALLECZEK J, 1990, FEBS LETT, V271, P157, DOI 10.1016/0014-5793(90)80396-Z; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273, DOI 10.1093/oxfordjournals.aje.a112681; WERTHEIMER N, 1980, AM J EPIDEMIOL, V111, P461, DOI 10.1093/oxfordjournals.aje.a112924; WILSON BW, 1981, BIOELECTROMAGNETICS, V2, P371, DOI 10.1002/bem.2250020408; Wilson R., 1982, RISK BENEFIT ANAL; ZAFFANELLA LE, 1985, ENV HLTH PERSPECT, V62, P297; 1991, 1991 P AM LAW FILM A; 1990, MICROW NEWS, V10, P5; 1991, MICROW NEWS, V11, P6; 1987, MAGNETIC FIELDS; 1987, MICROW NEWS, V7, P1; 1991, STATISTICAL YB ELECT; 1991, MICROW NEWS, V11, P7; 1987, BIOL EFFECTS POWERLI; 1991, ELECTRIC SUPPLY DEMA; 1991, NIOSH91111 NAT I OCC; 1989, OTABPE53 US C OFF TE	78	30	30	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					468	&		10.1126/science.1636078	http://dx.doi.org/10.1126/science.1636078			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JE755	1636078				2022-12-28	WOS:A1992JE75500005
J	LAU, J; ANTMAN, EM; JIMENEZSILVA, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC				LAU, J; ANTMAN, EM; JIMENEZSILVA, J; KUPELNICK, B; MOSTELLER, F; CHALMERS, TC			CUMULATIVE METAANALYSIS OF THERAPEUTIC TRIALS FOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CLINICAL-TRIALS; CORONARY HEART-DISEASE; SCIENTIFIC DISCIPLINE; THROMBOLYTIC THERAPY; PUBLICATION BIAS; MORTALITY; STREPTOKINASE; INTRACORONARY; LONG; REHABILITATION	Background. The large volume of published randomized, controlled trials has led to a need for meta-analyses to track therapeutic advances. Performing a new meta-analysis whenever the results of a new trial of a particular therapy are published permits the study of trends in efficacy and makes it possible to determine when a new treatment appears to be significantly effective or deleterious. We describe the use of such a procedure, cumulative meta-analysis, to assess therapeutic trials among patients with myocardial infarction. Methods. We performed cumulative meta-analyses of clinical trials that evaluated 15 treatments and preventive measures for acute myocardial infarction. Results. An example of this method is its application to the use of intravenous streptokinase as thrombolytic therapy for acute infarction. Thirty-three trials evaluating this therapy were performed between 1959 and 1988. We found that a consistent, statistically significant reduction in total mortality (odds ratio, 0.74; 95 percent confidence interval, 0.59 to 0.92) was achieved in 1973, after only eight trials involving 2432 patients had been completed. The results of the 25 subsequent trials, which enrolled an additional 34,542 patients through 1988, had little or no effect on the odds ratio establishing efficacy, but simply narrowed the 95 percent confidence interval. In particular, two very large trials, the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico trial in 1986 (11,712 patients) and the Second International Study of Infarct Survival trial in 1988 (17,187 patients) did not modify the already established evidence of efficacy. We used a similar approach to study the accumulating evidence of efficacy (or lack of efficacy) of 14 other therapies and preventive measures for myocardial infarction. Conclusions. Cumulative meta-analysis of therapeutic trials facilitates the determination of clinical efficacy and harm and may be helpful in tracking trials, planning future trials, and making clinical recommendations for therapy.	HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, TECHNOL ASSESSMENT GRP, BOSTON, MA 02115 USA; DEPT VET AFFAIRS MED CTR, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC, BOSTON, MA 02115 USA; NEW ENGLAND MED CTR, CTR CARDIOVASC HLTH SERV RES, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Tufts Medical Center; Tufts University; Harvard University; Harvard Medical School					AHRQ HHS [P0RT-1-PO1-HS 06341-02, R01 HS-05936] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 1980, LANCET, V1, P1172; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1988, BRIT MED J, V296, P320; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; ARMITAGE P, 1989, J CLIN EPIDEMIOL, V42, P293, DOI 10.1016/0895-4356(89)90033-4; BABER NJ, 1982, PRIM CARDIOL S, V1, P31; BABER NS, 1983, CIRCULATION, V67, P71; BABER NS, 1982, BRIT MED J, V284, P1749, DOI 10.1136/bmj.284.6331.1749; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; CANNER PL, 1987, STAT MED, V6, P255, DOI 10.1002/sim.4780060310; CANNER PL, 1983, ISRAEL J MED SCI, V19, P413; CHALMERS I, 1991, OXFORD DATABASE PERI; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; CHALMERS TC, 1987, STAT MED, V6, P733, DOI 10.1002/sim.4780060704; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; COLLINS R, 1988, NEW ENGL J MED, V318, P1162, DOI 10.1056/NEJM198805053181805; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; EMERSON JD, 1990, CONTROL CLIN TRIALS, V11, P339, DOI 10.1016/0197-2456(90)90175-2; ERKELENS DW, 1990, CARDIOLOGY, V77, P33; FURBERG CD, 1983, CIRCULATION, V67, P83; FURBERG CD, 1984, AM J CARDIOL, V53, P626, DOI 10.1016/0002-9149(84)90042-0; HELD PH, 1990, CIRCULATION, V82, P1668, DOI 10.1161/01.CIR.82.5.1668; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HINE LK, 1989, ARCH INTERN MED, V149, P2694, DOI 10.1001/archinte.149.12.2694; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HONAN MB, 1990, J AM COLL CARDIOL, V16, P359, DOI 10.1016/0735-1097(90)90586-E; KAPLAN K, 1986, ARCH INTERN MED, V146, P593, DOI 10.1001/archinte.146.3.593; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAU J, IN PRESS CONTROLLED; LEIZOROVICZ A, 1983, EUR J CLIN PHARMACOL, V24, P333, DOI 10.1007/BF00610050; LOELIGER EA, 1981, ACTA MED SCAND, P305; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MACMAHON S, 1987, ACUTE CORONARY CARE, P51; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARDER VJ, 1984, AM J MED, V77, P921, DOI 10.1016/0002-9343(84)90543-6; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; NAYLOR CD, 1990, JAMA-J AM MED ASSOC, V264, P697, DOI 10.1001/jama.264.6.697; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; PATEL B, 1987, AM J CARDIOL, V59, P501, DOI 10.1016/0002-9149(87)91156-8; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; STAMPFER MJ, 1982, NEW ENGL J MED, V307, P1180, DOI 10.1056/NEJM198211043071904; TEO KK, 1991, BMJ-BRIT MED J, V303, P1499, DOI 10.1136/bmj.303.6816.1499; THACKER SB, 1988, JAMA-J AM MED ASSOC, V259, P1685, DOI 10.1001/jama.259.11.1685; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; Topol E J, 1989, Cardiol Clin, V7, P827; YUSUF S, 1985, EUR HEART J, V6, P556, DOI 10.1093/oxfordjournals.eurheartj.a061905; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1988, LANCET, V1, P1088; YUSUF S, 1985, ACUTE CORONARY CARE, P73; 1982, LANCET, V1, P1159	62	897	911	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					248	254		10.1056/NEJM199207233270406	http://dx.doi.org/10.1056/NEJM199207233270406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614465				2022-12-28	WOS:A1992JE38100006
J	LEWIS, VA; HYNES, GM; DONG, Z; SAIBIL, H; WILLISON, K				LEWIS, VA; HYNES, GM; DONG, Z; SAIBIL, H; WILLISON, K			T-COMPLEX POLYPEPTIDE-1 IS A SUBUNIT OF A HETEROMERIC PARTICLE IN THE EUKARYOTIC CYTOSOL	NATURE			English	Article							GENE; PROTEINS; TCP-1; PLANT	THE murine t-complex encodes t-complex polypeptide-1 (TCP1)1, which is constitutively expressed in almost all cells, and upregulated during spermatogenesis2,3. Mammalian sequences have >96% identity with each other, and >60% identity with Drosophila melanogaster and yeast orthologues4-9. TCP1 is essential in yeast9, and is postulated to be the cytosolic mammalian equivalent of groEL10,11. We report here that, in the native state, murine and human TCP1 is distributed throughout the cytosol as an 800K-950K hetero-oligomeric particle in association with four to six unidentified proteins and two Hsp70 heat-shock proteins. Negative-stain electron microscopy indicates that the structure is two stacked rings, 12-16 nm in diameter. Therefore, despite similarities with the chaperonin 60 proteins, these data indicate that TCP1 is biochemically and structurally unique. We suggest that TCP1 may represent one of a family of molecules in the eukaryotic cytosol involved in protein folding and regulated in part by their heteromeric associations.	UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND	University of London; Birkbeck University London	LEWIS, VA (corresponding author), INST CANC RES,CHESTER BEATTY LABS,FULHAM RD,LONDON SW3 6JB,ENGLAND.							AHMAD S, 1990, BIOCHIM BIOPHYS ACTA, V1087, P253, DOI 10.1016/0167-4781(90)90214-M; CORBETT J, IN PRESS METHODS MOL; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, SCIENCE, V60, P321; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUTCHINSON EG, 1989, EMBO J, V8, P1485, DOI 10.1002/j.1460-2075.1989.tb03532.x; KIM YS, 1971, J BIOL CHEM, V246, P5466; KIRCHHOFF C, 1990, NUCLEIC ACIDS RES, V18, P4248; LINQUIST S, 1988, ANNU REV GENET, V22, P631; MAEKAWA M, 1989, BIOL REPROD, V40, P843, DOI 10.1095/biolreprod40.4.843; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MORITA T, 1991, BIOCHIM BIOPHYS ACTA, V1129, P96, DOI 10.1016/0167-4781(91)90219-C; PHIPPS BM, 1991, EMBO J, V10, P1711, DOI 10.1002/j.1460-2075.1991.tb07695.x; SILVER LM, 1979, CELL, V17, P275, DOI 10.1016/0092-8674(79)90153-3; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1988, GENE, V68, P267, DOI 10.1016/0378-1119(88)90029-7; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WILLISON KR, 1990, GENET RES, V56, P193, DOI 10.1017/S0016672300035291; WILLISON KR, 1986, CELL, V44, P727, DOI 10.1016/0092-8674(86)90839-1; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	27	281	286	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					249	252		10.1038/358249a0	http://dx.doi.org/10.1038/358249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630492				2022-12-28	WOS:A1992JD58700058
J	SCHWENK, TL				SCHWENK, TL			FAMILY MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											SCHWENK, TL (corresponding author), UNIV MICHIGAN, SCH MED, ANN ARBOR, MI 48104 USA.							ABRUTYN E, 1991, J AM GERIATR SOC, V39, P388, DOI 10.1111/j.1532-5415.1991.tb02905.x; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; BALLOR DL, 1991, INT J OBESITY, V15, P717; BEITMAN BD, 1991, JAMA-J AM MED ASSOC, V265, P1545, DOI 10.1001/jama.265.12.1545; BLACK ER, 1991, J GEN INTERN MED, V6, P394, DOI 10.1007/BF02598159; BLUMENTHAL JA, 1991, JAMA-J AM MED ASSOC, V266, P2098, DOI 10.1001/jama.266.15.2098; CARUTHERS BS, 1991, J FAM PRACTICE, V32, P590; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; GERBERT B, 1991, JAMA-J AM MED ASSOC, V266, P2837, DOI 10.1001/jama.266.20.2837; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KLINKMAN MS, 1992, J FAM PRACTICE, V34, P205; MANSON JE, 1991, JAMA-J AM MED ASSOC, V266, P521, DOI 10.1001/jama.266.4.521; Marsland D W, 1976, J Fam Pract, V3, P37; MITCHELL H, 1991, LANCET, V337, P265, DOI 10.1016/0140-6736(91)90870-U; RENNARD S, 1991, JAMA-J AM MED ASSOC, V266, P3133; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SHAW KN, 1991, AM J DIS CHILD, V145, P151, DOI 10.1001/archpedi.1991.02160020041012; SMITH MA, 1991, J FAM PRACTICE, V33, P281; SOTSKY SM, 1991, AM J PSYCHIAT, V148, P997; SPACH DH, 1992, JAMA-J AM MED ASSOC, V267, P679, DOI 10.1001/jama.267.5.679; STAMM WE, 1992, AM J MED, V91, P19; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; ZAZOVE P, 1992, J FAM PRACTICE, V34, P320; 1991, US PHS913042 US DEP; 1992, 920019 US DEP HLTH H	30	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					356	358						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613918				2022-12-28	WOS:A1992JC35200029
J	KARLHOFER, FM; RIBAUDO, RK; YOKOYAMA, WM				KARLHOFER, FM; RIBAUDO, RK; YOKOYAMA, WM			MHC CLASS-I ALLOANTIGEN SPECIFICITY OF LY-49+ IL-2-ACTIVATED NATURAL-KILLER-CELLS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; EXPRESSION; ANTIGEN; IDENTIFICATION; RECEPTOR; GENE; MOLECULES; SUSCEPTIBILITY; RECOGNITION; RESISTANCE	THE molecular basis of target cell recognition by CD3- natural killer (NK) cells is poorly understood, despite the ability of NK cells to lyse specific tumour cells 1,2. In general, target cell major histocompatibility complex (MHC) class I antigen expression correlates with resistance to NK cell-mediated lysis 3-9, possibly because NK cell-surface molecules engage MHC class I antigens and consequently deliver inhibitory signals 3,4. Natural killer cell allospecificity involves the MHC class I peptide-binding cleft 10, and further understanding of this allospecificity should provide insight into the molecular mechanisms of NK cell recognition. The Ly-49 cell surface molecule is expressed by 20% of CD3- NK cells 11 in C57BL/6 mice (H-2b). Here we show that C57BL/6-derived, interleukin-2-activated NK cells expressing Ly-49 do not lyse target cells displaying H-2d or H-2k despite efficient spontaneous lysis by Ly-49- effector cells. This preferential resistance correlates with expression of target cell MHC class I antigens. Transfection and expression of H-2D(d), but not H-2K(d) or H-2L(d), renders a susceptible target (H-2b) resistant to Ly-49+ effector cells. The transfected resistance is abrogated by monoclonal antibodies directed against Ly-49 or the alpha-1/alpha-2 domains of H-2D(d), suggesting that Ly-49 specifically interacts with the peptide-binding domains of the MHC class I alloantigen, H-2D(d) Inas-much as Ly49+ effector cells cannot be stimulated to lyse H-2D(d) targets, our results indicate that NK cells may possess inhibitory receptors that specifically recognize MHC class I antigens.	SAN FRANCISCO GEN HOSP, MED SERV, SAN FRANCISCO, CA 94110 USA; NIAID, IMMUNOL LAB, BETHESDA, MD 20892 USA	San Francisco General Hospital Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	KARLHOFER, FM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, ROSALIND RUSSELL ARTHRITIS RES LAB, SAN FRANCISCO, CA 94143 USA.		Ribaudo, Randall/AAH-7094-2021					BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CICCONE E, 1990, P NATL ACAD SCI USA, V87, P9794, DOI 10.1073/pnas.87.24.9794; COCHET M, 1986, IMMUNOGENETICS, V24, P267, DOI 10.1007/BF00364531; EVANS GA, 1982, NATURE, V300, P755, DOI 10.1038/300755a0; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HERBERMAN RB, 1982, NK CELLS OTHER NATUR; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; HUNZIKER W, 1990, NATURE, V345, P628, DOI 10.1038/345628a0; HYMAN R, 1976, IMMUNOGENETICS, V3, P75, DOI 10.1007/BF01576940; KARLHOFER FM, 1991, J IMMUNOL, V146, P3662; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KOO GC, 1984, HYBRIDOMA, V3, P301, DOI 10.1089/hyb.1984.3.301; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1986, J IMMUNOL, V137, P3874; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORETTA A, 1990, J EXP MED, V172, P1589, DOI 10.1084/jem.172.6.1589; NAGASAWA R, 1987, J IMMUNOL, V138, P815; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; QUILLET A, 1988, J IMMUNOL, V141, P17; RUBOCKI RJ, 1991, J IMMUNOL, V146, P2352; SPRINGER TA, 1980, MONOCLONAL ANTIBODIE, P185; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; STURMHOFEL K, 1990, EUR J IMMUNOL, V20, P171, DOI 10.1002/eji.1830200125; SUZUKI N, 1990, J EXP MED, V172, P457, DOI 10.1084/jem.172.2.457; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1989, J IMMUNOL, V143, P1379; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229	34	738	748	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 2	1992	358	6381					66	70		10.1038/358066a0	http://dx.doi.org/10.1038/358066a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614533				2022-12-28	WOS:A1992JB34100055
J	OREILLY, SE; CONNORS, JM				OREILLY, SE; CONNORS, JM			CURRENT ISSUES IN CANCER .8. NON-HODGKINS-LYMPHOMA .1. CHARACTERIZATION AND TREATMENT	BRITISH MEDICAL JOURNAL			English	Article							LARGE-CELL LYMPHOMA; DIFFUSE HISTIOCYTIC LYMPHOMA; NODULAR MIXED LYMPHOMA; STAGE-I; RADIATION-THERAPY; M-BACOD; CHEMOTHERAPY; RADIOTHERAPY; REMISSION; SURVIVAL				OREILLY, SE (corresponding author), BRITISH COLUMBIA CANC AGCY,VANCOUVER V5Z 4E6,BC,CANADA.		Connors, Joseph/AAF-5284-2019	Connors, Joseph/0000-0002-1361-7531				[Anonymous], 1982, CANCER, V49, P2112; ARMITAGE JO, 1984, J CLIN ONCOL, V2, P898, DOI 10.1200/JCO.1984.2.8.898; BAGLEY CM, 1972, ANN INTERN MED, V76, P227, DOI 10.7326/0003-4819-76-2-227; CABANILLAS F, 1985, HEMATOL ONCOL, V3, P25, DOI 10.1002/hon.2900030104; CARBONE PP, 1971, CANCER RES, V31, P1860; COIFFIER B, 1989, BLOOD, V74, P558; COLTMAN CA, 1986, UPDATE TREATMENT DIF, P71; CONNORS JM, 1987, ANN INTERN MED, V107, P25, DOI 10.7326/0003-4819-107-1-25; CONNORS JM, 1988, P AN M AM SOC CLIN, V7, P224; GLICK JH, 1981, BLOOD, V58, P920; GOSPODAROWICZ MK, 1984, INT J RADIAT ONCOL, V10, P489, DOI 10.1016/0360-3016(84)90028-2; GREER JP, 1984, J CLIN ONCOL, V2, P7; HOSKINS PJ, 1991, J CLIN ONCOL, V9, P220, DOI 10.1200/JCO.1991.9.2.220; JAGANNATH S, 1986, J CLIN ONCOL, V4, P859, DOI 10.1200/JCO.1986.4.6.859; JONES SE, 1973, CANCER-AM CANCER SOC, V32, P682, DOI 10.1002/1097-0142(197309)32:3<682::AID-CNCR2820320322>3.0.CO;2-M; KLASA RJ, 1992, P AN M AM SOC CLIN, V11, P328; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LANDBERG TG, 1979, CANCER, V44, P831, DOI 10.1002/1097-0142(197909)44:3<831::AID-CNCR2820440307>3.0.CO;2-S; LEVITT SH, 1985, HEMATOL ONCOL, V3, P33, DOI 10.1002/hon.2900030105; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LONGO DL, 1984, ANN INTERN MED, V100, P651, DOI 10.7326/0003-4819-100-5-651; LOWENBRAUN S, 1970, CANCER-AM CANCER SOC, V25, P1018, DOI 10.1002/1097-0142(197005)25:5<1018::AID-CNCR2820250505>3.0.CO;2-A; LUCE JK, 1971, CANCER, V28, P306, DOI 10.1002/1097-0142(197108)28:2<306::AID-CNCR2820280208>3.0.CO;2-N; MCLAUGHLIN P, 1987, J CLIN ONCOL, V5, P867, DOI 10.1200/JCO.1987.5.6.867; MILLER TP, 1984, HODGKINS DISEASE NON, P33; MONFARDINI S, 1980, INT J RADIAT ONCOL, V6, P125, DOI 10.1016/0360-3016(80)90027-9; NISSEN NI, 1983, CANCER, V52, P1, DOI 10.1002/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SKARIN A, 1983, P AN M AM SOC CLIN, V2, P220; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; VOKES EE, 1985, J CLIN ONCOL, V3, P1309, DOI 10.1200/JCO.1985.3.10.1309; WEINBERG RA, 1987, SCI AM, V12, P1; WEISENBURGER DD, 1982, CANCER, V49, P2112; YOUNG RC, 1987, P AN M AM SOC CLIN, V6, pA790	34	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1682	1686		10.1136/bmj.304.6843.1682	http://dx.doi.org/10.1136/bmj.304.6843.1682			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633525	Green Published, Bronze			2022-12-28	WOS:A1992JB93900030
J	ROBEY, EA; RAMSDELL, F; KIOUSSIS, D; SHA, W; LOH, D; AXEL, R; FOWLKES, BJ				ROBEY, EA; RAMSDELL, F; KIOUSSIS, D; SHA, W; LOH, D; AXEL, R; FOWLKES, BJ			THE LEVEL OF CD8 EXPRESSION CAN DETERMINE THE OUTCOME OF THYMIC SELECTION	CELL			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; NEGATIVE SELECTION; POSITIVE SELECTION; ANTIGEN RECEPTOR; LYMPHOCYTES-T; KINASE P56LCK; TOLERANCE; DELETION; SELF	During thymic development, thymocytes that can recognize major histocompatability complex (MHC) molecules on thymic epithelial cells are selected to survive and mature (positive selection), whereas thymocytes that recognize MHC on hematopoietic cells are destroyed (negative selection). It is not known how MHC recognition can mediate both death and survival. One model to explain this paradox proposes that thymocytes whose T cell antigen receptors (TCRs) recognize MHC with high affinity are eliminated by negative selection, whereas low affinity TCR-MHC interactions are sufficient to mediate positive selection. Here we report that, while the expression of a 2C TCR transgene leads to positive selection of thymocytes in H-2b mice, expression of both a CD8 transgene and a 2C TCR transgene causes negative selection. This observation indicates that quantitative differences in TCR-MHC recognition are a critical determinant of T cell fate, a finding predicted by the affinity model for thymic selection.	WASHINGTON UNIV, DEPT IMMUNOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; NIAID, CELLULAR & MOLEC IMMUNOL LAB, BETHESDA, MD 20892 USA; NATL INST MED RES, GENE STRUCT & EXPRESS LAB, LONDON NW7 1AA, ENGLAND; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; COLUMBIA UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10032 USA	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); MRC National Institute for Medical Research; Columbia University; Columbia University; Howard Hughes Medical Institute				Axel, Richard/0000-0002-3141-4076				ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BERG LJ, 1989, NATURE, V340, P559, DOI 10.1038/340559a0; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GAO EK, 1990, J EXP MED, V171, P1101, DOI 10.1084/jem.171.4.1101; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1989, IMMUNOL TODAY, V10, P234, DOI 10.1016/0167-5699(89)90260-0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; LEE NA, 1992, IN PRESS J EXP MED; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; MAGE MG, 1984, METHOD ENZYMOL, V108, P118; MARRACK P, 1988, CELL, V53, P627, DOI 10.1016/0092-8674(88)90578-8; MARRACK P, 1989, NATURE, V338, P503, DOI 10.1038/338503a0; MARRACK P, 1987, SCIENCE, V238, P1073, DOI 10.1126/science.3317824; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; PARNES JR, 1989, ADV IMMUNOL, V44, P265; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; RAMSDELL F, 1989, J IMMUNOL, V143, P1467; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPRENT J, 1988, IMMUNOL REV, V101, P173, DOI 10.1111/j.1600-065X.1988.tb00737.x; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZUNIGAPFLUCKER JC, 1990, J EXP MED, V171, P427, DOI 10.1084/jem.171.2.427	38	146	147	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 26	1992	69	7					1089	1096		10.1016/0092-8674(92)90631-L	http://dx.doi.org/10.1016/0092-8674(92)90631-L			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JA431	1617724				2022-12-28	WOS:A1992JA43100004
J	MILLER, DJ; MACEK, MB; SHUR, BD				MILLER, DJ; MACEK, MB; SHUR, BD			COMPLEMENTARITY BETWEEN SPERM SURFACE BETA-1,4-GALACTOSYL-TRANSFERASE AND EGG-COAT ZP3 MEDIATES SPERM EGG BINDING	NATURE			English	Article							O-LINKED OLIGOSACCHARIDES; ZONA PELLUCIDA; MOUSE SPERM; ACROSOME REACTION; RECEPTOR ACTIVITY; GALACTOSYLTRANSFERASE; IDENTIFICATION; PROTEIN; FERTILIZATION; GLYCOPROTEINS	DESPITE its importance, the molecular basis of mammalian gamete recognition has remained unclear. The enzyme beta-1,4-galactosyltransferase (Gal-transferase) has been viewed traditionally as a biosynthetic component of the Golgi complex, but is also found on the surface of many cells where it can bind its specific glycoside substrate on adjacent cell surfaces or in the extracellular matrix 1-3. In mouse it has been suggested that Gal-transferase on the sperm head mediates fertilization by binding oligosaccharide residues in the egg coat, or zona pellucida 4-9, and that the ability of the zona pellucida to bind sperm is conferred by oligosaccharides of the ZP3 glycoprotein 10,13. However, it has not been confirmed that Gal-transferase and ZP3 are in fact complementary gamete receptors whose interaction mediates sperm-eg binding. Here we show that mouse sperm Gal-transferase specifically recognizes those oligosaccharides on ZP3 that have sperm-binding activity, but does not interact with other zona pellucida glycoproteins. In contrast, all zona pellucida glycoproteins are recognized by non-sperm Gal-transferase, demonstrating a more stringent substrate specificity for the sperm enzyme. This interaction is required for sperm-egg binding because blocking or removing the binding site for Gal-transferase on ZP3 inhibits its ability to bind sperm. After the release of the sperm acrosome, the transferase relocalizes to a new membrane domain where it can no longer bind to ZP3, which is consistent with the inability of acrosome-reacted sperm to bind ZP3 or to initiate binding to the zona pellucida. Following fertilization, ZP3 is modified by egg cortical granule secretions so that it loses sperm receptor activity, which can be accounted for by a selective loss of its binding site for sperm Gal-transferase. These results show that sperm surface beta-1,4-galactosyltransferase and the egg-coat glycoprotein ZP3 are complementary adhesion molecules that mediate primary gamete binding in the mouse.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Miller, David J/ABC-2156-2020	Miller, David J/0000-0001-7147-5546				BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; BEER D, 1985, HELV CHIM ACTA, V68, P2254, DOI 10.1002/hlca.19850680821; BEGOVAC PC, 1991, J CELL BIOL, V113, P637, DOI 10.1083/jcb.113.3.637; BENAU DA, 1988, BIOL REPROD, V39, P235, DOI 10.1095/biolreprod39.2.235; BERGER T, 1989, J REPROD FERTIL, V86, P559, DOI 10.1530/jrf.0.0860559; BLEIL JD, 1988, DEV BIOL, V128, P376, DOI 10.1016/0012-1606(88)90299-0; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BLEIL JD, 1986, J CELL BIOL, V102, P1363, DOI 10.1083/jcb.102.4.1363; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; ENDO Y, 1987, DEV BIOL, V119, P210, DOI 10.1016/0012-1606(87)90222-3; FAYRER-HOSKEN R A, 1987, Biology of Reproduction, V36, P53; FAYRERHOSKEN RA, 1991, MOL REPROD DEV, V28, P74, DOI 10.1002/mrd.1080280112; FLORMAN HM, 1984, DEV BIOL, V106, P243, DOI 10.1016/0012-1606(84)90079-4; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; HUMPHREYSBEHER MG, 1990, FERTIL STERIL, V54, P133; JONES R, 1988, DEVELOPMENT, V102, P781; LAMBERT CC, 1989, DEVELOPMENT, V105, P415; LEYTON L, 1989, J CELL BIOL, V108, P2163, DOI 10.1083/jcb.108.6.2163; LEYTON L, 1989, CELL, V57, P1123, DOI 10.1016/0092-8674(89)90049-4; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; LOPEZ LC, 1987, J CELL BIOL, V105, P1663, DOI 10.1083/jcb.105.4.1663; MACEK MB, 1991, DEV BIOL, V147, P440, DOI 10.1016/0012-1606(91)90301-I; MILLER DJ, 1992, COMP SPERMATOLOGY 20, P569; MORI E, 1991, BIOCHEMISTRY-US, V30, P2078, DOI 10.1021/bi00222a012; NEILL JM, 1988, GAMETE RES, V20, P459, DOI 10.1002/mrd.1120200407; NETER J, 1974, APPLIED LINEAR STATI; PASSANITI A, 1990, CANCER RES, V50, P7261; PRODY GA, 1985, J EXP ZOOL, V235, P335, DOI 10.1002/jez.1402350304; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH S, 1973, Q REV BIOL, V48, P541, DOI 10.1086/407816; RUIZBRAVO N, 1986, DEV BIOL, V118, P202, DOI 10.1016/0012-1606(86)90088-6; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; SHUR BD, 1982, J CELL BIOL, V95, P574, DOI 10.1083/jcb.95.2.574; SHUR BD, 1988, J BIOL CHEM, V263, P17706; SULLIVAN R, 1989, BIOCHEM BIOPH RES CO, V162, P184, DOI 10.1016/0006-291X(89)91979-7; WASSARMAN PM, 1988, ANNU REV BIOCHEM, V57, P415, DOI 10.1146/annurev.bi.57.070188.002215	39	417	429	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					589	593		10.1038/357589a0	http://dx.doi.org/10.1038/357589a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608469	Bronze			2022-12-28	WOS:A1992HZ11200054
J	KEMP, IW; CLARKE, K; KINLEN, LJ				KEMP, IW; CLARKE, K; KINLEN, LJ			ESOPHAGEAL CANCER AND DISTILLERIES IN SCOTLAND	BRITISH MEDICAL JOURNAL			English	Article									UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN EPIDEMIOL GRP,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	KEMP, IW (corresponding author), UNIV EDINBURGH,SCH MED,DEPT PUBL HLTH SCI,EDINBURGH EH8 9AJ,SCOTLAND.							BRESLOW NE, 1987, IARC SCI PUBL, V82, P96; KEMP JW, 1985, ATLAS CANCER SCOTLAN; MUIR CS, 1987, IARC SCI PUBLICATION, V88; PATHAN AH, 1985, ABERDEEN POSTGRADUAT, V19, P8	4	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1543	1544		10.1136/bmj.304.6841.1543	http://dx.doi.org/10.1136/bmj.304.6841.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628054	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800025
J	PHILPOTT, KL; VINEY, JL; KAY, G; RASTAN, S; GARDINER, EM; CHAE, S; HAYDAY, AC; OWEN, MJ				PHILPOTT, KL; VINEY, JL; KAY, G; RASTAN, S; GARDINER, EM; CHAE, S; HAYDAY, AC; OWEN, MJ			LYMPHOID DEVELOPMENT IN MICE CONGENITALLY LACKING T-CELL RECEPTOR-ALPHA-BETA EXPRESSING CELLS	SCIENCE			English	Article							DENDRITIC EPIDERMAL-CELLS; MONOCLONAL-ANTIBODIES; LYMPHOCYTES-T; GAMMA-CHAIN; ANTIGEN; COMPLEX; DIFFERENTIATION; RECOGNITION; SPECIFICITY; COMMITMENT	Vertebrate T cells express either an alpha-beta or gamma-delta T cell receptor (TCR). The developmental relatedness of the two cell types is unresolved. Alpha-beta+ T cells respond to specific pathogens by collaborating with immunoglobulin-producing B cells in distinct lymphoid organs such as the spleen and Peyer's patches. The precise influence of alpha-beta+ T cells on B cell development is poorly understood. To investigate the developmental effects of alpha-beta+ T cells on B cells and gamma-delta+ T cells, mice homozygous for a disrupted TCR-alpha gene were generated. The homozygotes showed elimination of alpha-beta+ T cells and the loss of thymic medullae. Despite this, gamma-delta+ T cells developed in normal numbers, and there was an increase in splenic B cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; MRC,CLIN RES CTR,COMPARAT BIOL SECT,HARROW HA1 3UJ,MIDDX,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Cancer Research UK; Medical Research Council Clinical Trials Unit; Yale University			Kay, Graham F/A-4130-2011		NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG LJ, 1989, CELL, V58, P1035, DOI 10.1016/0092-8674(89)90502-3; BONNEVILLE M, 1989, NATURE, V342, P931, DOI 10.1038/342931a0; BORN W, 1990, SCIENCE, V249, P67, DOI 10.1126/science.1695022; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; BUTCHER EC, 1989, FUNDAMENTAL IMMUNOLO, P117; CARBONE A, 1991, IMMUNOL REV, V120, P35; CARDING SR, 1990, GENE DEV, V4, P1304, DOI 10.1101/gad.4.8.1304; CEBRA JJ, 1983, ANN NY ACAD SCI, V409, P25, DOI 10.1111/j.1749-6632.1983.tb26857.x; CEBRA JJ, 1982, RECENT ADV MUCOSAL I, P155; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; Cobbold S P, 1983, Mol Biol Med, V1, P285; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; GLICK B, 1956, POULTRY SCI, V35, P224, DOI 10.3382/ps.0350224; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HAYDAY AC, UNPUB; HAYDAY AC, IN PRESS ENCY IMMUNO; HOCHSTENBACH F, 1989, NATURE, V340, P562, DOI 10.1038/340562a0; IKEDA RM, 1978, ANIMAL MODELS COMP D, P201; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; JANIS EM, 1989, SCIENCE, V244, P713, DOI 10.1126/science.2524098; KAWANISHI H, 1983, J EXP MED, V157, P433, DOI 10.1084/jem.157.2.433; Kay G., UNPUB; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KUBO RT, 1989, J IMMUNOL, V142, P2736; KUZIEL WA, 1987, NATURE, V328, P263, DOI 10.1038/328263a0; LEDBETTER JA, 1980, J EXP MED, V152, P280, DOI 10.1084/jem.152.2.280; MACKAY CR, 1990, RES IMMUNOL, V141, P611, DOI 10.1016/0923-2494(90)90067-9; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MATIS LA, 1987, NATURE, V330, P262, DOI 10.1038/330262a0; MILLER JF, 1961, LANCET, V2, P748; MIXTER PF, 1991, J IMMUNOL, V147, P4109; MONGINI PKA, 1983, J EXP MED, V157, P69, DOI 10.1084/jem.157.1.69; PHILPOTT KL, UNPUB; PORTOLES P, 1989, J IMMUNOL, V142, P4169; RAFF MC, 1985, CELL, V42, P61, DOI 10.1016/S0092-8674(85)80101-X; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; STINGL G, 1987, P NATL ACAD SCI USA, V84, P4586, DOI 10.1073/pnas.84.13.4586; STROBER W, 1985, ADV HOST DEFENSE MEC, V4, P1; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0	46	344	353	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1448	1452		10.1126/science.1604321	http://dx.doi.org/10.1126/science.1604321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604321				2022-12-28	WOS:A1992HX33700037
J	USHEVA, A; MALDONADO, E; GOLDRING, A; LU, H; HOUBAVI, C; REINBERG, D; ALONI, Y				USHEVA, A; MALDONADO, E; GOLDRING, A; LU, H; HOUBAVI, C; REINBERG, D; ALONI, Y			SPECIFIC INTERACTION BETWEEN THE NONPHOSPHORYLATED FORM OF RNA POLYMERASE-II AND THE TATA-BINDING PROTEIN	CELL			English	Article							MAJOR LATE PROMOTER; C-TERMINAL DOMAIN; LARGEST SUBUNIT; TRANSCRIPTION INITIATION; ACCURATE TRANSCRIPTION; INVITRO TRANSCRIPTION; COMPLEXES; INVIVO; GENE; ADENOVIRUS-2	Fractionation of a transcription-competent HeLa cell extract on a column containing one copy of the heptamer repeat (YSPTSPS) present in the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II resulted in the loss of transcriptional activity. Fractionation of the extracts on columns containing mutations of the heptamer repeat was without effect. Such transcriptionally inactive extracts regained their ability to specifically transcribe different class II promoters upon the addition of human TFIID, recombinant yeast TATA-binding protein (TBP), or proteins bound to the column. Fractionation of RNA polymerase II on columns containing human or yeast TBP resulted in the specific retention of the nonphosphorylated form of RNA polymerase II. The phosphorylated form of the enzyme was unable to interact with TBP. The specific interaction of RNA polymerase II with TBP was mediated by the CTD of RNA polymerase II.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Weizmann Institute of Science; Rutgers State University New Brunswick; Rutgers State University Medical Center				Reinberg, Danny/0000-0003-4288-2016	NCI NIH HHS [CA 14995] Funding Source: Medline; NIGMS NIH HHS [GM 37120] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHEARN JM, 1987, J BIOL CHEM, V265, P425; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARCAMO J, 1990, GENE DEV, V4, P1611, DOI 10.1101/gad.4.9.1611; CHO KWY, 1985, J BIOL CHEM, V260, P5204; CHRISTMANN JL, 1981, J BIOL CHEM, V256, P1798; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; DAHMUS ME, 1983, J BIOL CHEM, V258, P2303; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FIRE A, 1984, J BIOL CHEM, V259, P2509; FLORES O, 1992, J BIOL CHEM, V267, P2786; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE A, 1992, IN PRESS CELL, V69; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; MOYLE M, 1989, MOL CELL BIOL, V9, P5750, DOI 10.1128/MCB.9.12.5750; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; REINBERG D, 1987, J BIOL CHEM, V262, P3322; Roeder R.G., 1976, RNA POLYMERASE, P285; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHWARTZ LB, 1975, J BIOL CHEM, V250, P3221; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	49	215	217	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					871	881		10.1016/0092-8674(92)90297-P	http://dx.doi.org/10.1016/0092-8674(92)90297-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591781				2022-12-28	WOS:A1992HW83800016
J	VETTER, NJ; LEWIS, PA; LLEWELLYN, L				VETTER, NJ; LEWIS, PA; LLEWELLYN, L			SUPPORTING ELDERLY DEPENDENT PEOPLE AT HOME	BRITISH MEDICAL JOURNAL			English	Article							CARE	Objective-To clarify the relation between the dependency of elderly people and the assistance they receive from others by using a detailed but simple measure of dependency. Design - Secondary analysis of data from a survey of people aged 70 and over. Setting-Two general practices in south Wales. Subjects - 1280 people aged 70 and over. Main outcome measures-Dependency on others to perform essential functions; detailed data on who assists with those functions. Results-Increasing dependency was associated with increased use of more than one member of the family or friends and an increase in the provision of statutory services. Conclusion-The complexity of the relation between dependency and those who care for dependent people has previously been underestimated. The presence of providers of statutory services at the household of elderly dependent people suggests that these services can be developed further to help those caring for elderly people at home.	UNIV WALES COLL MED,DEPT PUBL HLTH MED,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	VETTER, NJ (corresponding author), UNIV WALES COLL MED,DEPT EPIDEMIOL & COMMUNITY MED,CARDIFF CF4 4XN,S GLAM,WALES.							BOYDEN PGK, 1979, NZ MED J, V89, P265; BRODY EM, 1981, GERONTOLOGIST, V21, P471, DOI 10.1093/geront/21.5.471; ISAACS B, 1971, BRIT MED J, V4, P282, DOI 10.1136/bmj.4.5782.282; JONES DA, 1984, SOC SCI MED, V19, P511, DOI 10.1016/0277-9536(84)90046-7; NISSEL M, 1984, AGEING SOC, V4, P185; SALVAGE AV, 1988, AGE AGEING, V17, P270, DOI 10.1093/ageing/17.4.270; Vetter N J, 1990, Int Disabil Stud, V12, P22; VETTER NJ, 1984, BRIT MED J, V288, P369, DOI 10.1136/bmj.288.6414.369; 1980, EXPERIENCE CARING EL	9	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1290	1292		10.1136/bmj.304.6837.1290	http://dx.doi.org/10.1136/bmj.304.6837.1290			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	HV086	1606435	Green Published, Bronze			2022-12-28	WOS:A1992HV08600027
J	BUZSAKI, G; HORVATH, Z; URIOSTE, R; HETKE, J; WISE, K				BUZSAKI, G; HORVATH, Z; URIOSTE, R; HETKE, J; WISE, K			HIGH-FREQUENCY NETWORK OSCILLATION IN THE HIPPOCAMPUS	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; PATTERNED STIMULATION; THETA-RHYTHM; CA1 REGION; NEURONS; INTERNEURONS; INDUCTION; ORIGIN	Pyramidal cells in the CA1 hippocampal region displayed transient network oscillations (200 hertz) during behavioral immobility, consummatory behaviors, and slow-wave sleep. Simultaneous, multisite recordings revealed temporal and spatial coherence of neuronal activity during population oscillations. Participating pyramidal cells discharged at a rate lower than the frequency of the population oscillation, and their action potentials were phase locked to the negative phase of the simultaneously recorded oscillatory field potentials. In contrast, interneurons discharged at population frequency during the field oscillations. Thus, synchronous output of cooperating CA1 pyramidal cells may serve to induce synaptic enhancement in target structures of the hippocampus.	UNIV MICHIGAN,CTR INTEGRATED SENSORS & CIRCUITS,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	BUZSAKI, G (corresponding author), RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,197 UNIV AVE,NEWARK,NJ 07102, USA.			Buzsaki, Gyorgy/0000-0002-3100-4800	NINDS NIH HHS [NS02383, NS27058] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027058] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUDRY M, 1991, LONG TERM POTENTIATI; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Bush PC, 1991, NEURAL COMPUT, V3, P19, DOI 10.1162/neco.1991.3.1.19; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, J NEUROSCI METH, V28, P209, DOI 10.1016/0165-0270(89)90038-1; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1982, J NEUROPHYSIOL, V48, P597, DOI 10.1152/jn.1982.48.3.597; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CHRISTIAN EP, 1988, J NEUROPHYSIOL, V59, P110, DOI 10.1152/jn.1988.59.1.110; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; FINCH DM, 1983, BRAIN RES, V271, P201, DOI 10.1016/0006-8993(83)90283-4; FOX SE, 1981, EXP BRAIN RES, V41, P299; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; JEFFERYS JGR, 1982, NATURE, V300, P448, DOI 10.1038/300448a0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; KRUGER GJ, 1991, TRENDS NEUROSCI, V7, P1001; KUPERSTEIN M, 1986, EXP BRAIN RES, V61, P438; LACAILLE JC, 1990, NEUROSCIENCE, V36, P349, DOI 10.1016/0306-4522(90)90431-3; LARSON J, 1986, SCIENCE, V232, P985, DOI 10.1126/science.3704635; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; PERKEL DH, 1967, BIOPHYS J, V7, P327; ROSE GM, 1986, NEUROSCI LETT, V69, P244, DOI 10.1016/0304-3940(86)90487-8; SEJNOWSKI TJ, 1988, SCIENCE, V241, P1299, DOI 10.1126/science.3045969; SUZUKI SS, 1987, ELECTROENCEPHALOGR C, V67, P438; TAMAMAKI N, 1988, BRAIN RES, V452, P255, DOI 10.1016/0006-8993(88)90030-3; TAYLOR CP, 1982, SCIENCE, V218, P810, DOI 10.1126/science.7134978; TRAUB RD, 1989, SCIENCE, V243, P1319, DOI 10.1126/science.2646715; TRAUB RD, 1985, NEUROSCIENCE, V15, P947, DOI 10.1016/0306-4522(85)90245-3; WISE KD, 1991, SCIENCE, V254, P1335, DOI 10.1126/science.1962192	34	843	858	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 15	1992	256	5059					1025	1027		10.1126/science.1589772	http://dx.doi.org/10.1126/science.1589772			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HU224	1589772				2022-12-28	WOS:A1992HU22400040
J	IRWIN, CE; SHAFER, MA				IRWIN, CE; SHAFER, MA			ADOLESCENT MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											IRWIN, CE (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143, USA.				PHS HHS [MCJ000978] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLUM R, 1988, J ADOLESC HLTH S, V6, pS1; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; DANGELO LJ, 1991, PEDIATRICS, V88, P982; Feldman SS, 1990, THRESHOLD DEV ADOLES; HECHINGER F, 1992, FATEFUL CHOICES HLTH, P217; IRWIN CE, 1992, ADOLESCENTS AT RISK, P35; MOSCICKI AB, 1990, PEDIATR RES, V28, P507, DOI 10.1203/00006450-199011000-00018; SONENSTEIN FL, 1991, FAM PLANN PERSPECT, V23, P162, DOI 10.2307/2135739; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2581, DOI 10.1001/jama.266.18.2581; WILLIAM T, 1988, FORGOTTEN HALF PATHW; 1990, PHS9150213 US DEP HL; 1991, VITAL STATISTICS U A, V2; 1991, OTAH466 OFF TECHN AS; 1992, MMWR, V40, P886; 1991, MMWR, V39, P929; 1991, SEXUALLY TRANSMITTED, P18; 1990, HLTH YOUTH 2000 NATI; 1989, TURNING POINTS PREPA; 1990, CODE BLUE UNITING HL; 1992, HIV AIDS SURVEILLANC, P1; 1991, OTAH468 OFF TECHN AS; 1991, OTAH467 OFF TECHN AS; 1991, RHETORIC NEW AM AGEN; 1988, ADOLESCENT HLTH UPDA, P1	24	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					333	335						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613909				2022-12-28	WOS:A1992JC35200019
J	STOECKLE, JD; GOODSON, JG				STOECKLE, JD; GOODSON, JG			GENERAL INTERNAL-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											STOECKLE, JD (corresponding author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA.							[Anonymous], 1991, JAMA, V265, P3255; CASSEL CK, 1992, ANN INTERN MED, V116, P163, DOI 10.7326/0003-4819-116-2-163; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FURSTER V, 1992, NEW ENGL J MED, V326, P310; Goldfield N, 1991, QRB Qual Rev Bull, V17, P343; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; IRWIN H, 1991, AUST J COMMUN, V18, P11; LACROIX AZ, 1991, NEW ENGL J MED, V324, P1619, DOI 10.1056/NEJM199106063242303; LLEVENS RM, 1992, AM J PREV MED, V8, P70; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; ORNISH D, 1990, D ORNISHS PROGRAM RE; RIDKER PM, 1991, ANN INTERN MED, V114, P835, DOI 10.7326/0003-4819-114-10-835; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STOECKLE JD, 1992, ANN INTERN MED, V116, P407, DOI 10.7326/0003-4819-116-5-407; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WENNBERG JE, 1990, HEALTH SERV RES, V25, P709	23	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					358	360						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613919				2022-12-28	WOS:A1992JC35200030
J	FISHER, RF; LONG, SR				FISHER, RF; LONG, SR			RHIZOBIUM - PLANT SIGNAL EXCHANGE	NATURE			English	Review							LEGUMINOSARUM BIOVAR VICIAE; HOST-SPECIFIC NODULATION; NOD GENE-EXPRESSION; BRADYRHIZOBIUM-JAPONICUM; NUCLEOTIDE-SEQUENCE; SYM PLASMID; EFFICIENT NODULATION; INDUCE EXPRESSION; STRAIN NGR234; ROOT EXUDATE	Initial stages in the Rhizobium-legume symbiosis can be thought of as a reciprocal molecular conversation: transmission of a gene inducer from legume host to bacterium, with ensuing bacterial synthesis of a morphogen that is transmitted to the plant, switching the developmental fate of the legume root. These signal molecules have a key role in determining bacterium-host specificity and the purified Nod factor compounds provide useful new tools to probe plant cell function.			FISHER, RF (corresponding author), STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030962] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBAUM ER, 1988, J BACTERIOL, V170, P12; BAEY N, 1991, MOL GEN GENET, V228, P113; BAKER ME, 1989, MOL ENDOCRINOL, V3, P881, DOI 10.1210/mend-3-5-881; BANFALVI Z, 1988, MOL GEN GENET, V214, P420, DOI 10.1007/BF00330475; BARNETT MJ, 1990, J BACTERIOL, V172, P3695, DOI 10.1128/jb.172.7.3695-3700.1990; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BULAWA CE, 1991, NATURE, V353, P710, DOI 10.1038/353710b0; BURN J, 1987, GENE DEV, V1, P456, DOI 10.1101/gad.1.5.456; BURN JE, 1989, MOL MICROBIOL, V3, P1567, DOI 10.1111/j.1365-2958.1989.tb00142.x; CERVANTES E, 1989, MOL MICROBIOL, V3, P745, DOI 10.1111/j.1365-2958.1989.tb00223.x; CREMERS HCJC, 1989, PLANT MOL BIOL, V13, P163, DOI 10.1007/BF00016135; DAVIS EO, 1990, MOL MICROBIOL, V4, P921, DOI 10.1111/j.1365-2958.1990.tb00665.x; DAVIS EO, 1988, MOL GEN GENET, V212, P531, DOI 10.1007/BF00330860; DAVIS EO, 1990, MOL MICROBIOL, V4, P933, DOI 10.1111/j.1365-2958.1990.tb00666.x; DEBELLE F, 1986, NUCLEIC ACIDS RES, V14, P7453, DOI 10.1093/nar/14.18.7453; DEBRUIJN FJ, 1991, CURR OPIN BIOTECH, V2, P184, DOI 10.1016/0958-1669(91)90008-S; DEHO C, 1991, PL J, V2, P117; DJORDJEVIC MA, 1985, MOL GEN GENET, V200, P463, DOI 10.1007/BF00425732; DJORDJEVIC MA, 1987, ANNU REV PHYTOPATHOL, V25, P145, DOI 10.1146/annurev.py.25.090187.001045; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; DUSHA I, 1989, MOL GEN GENET, V219, P89, DOI 10.1007/BF00261162; ECONOMOU A, 1990, EMBO J, V9, P349, DOI 10.1002/j.1460-2075.1990.tb08117.x; ERHARDT DW, 1992, SCIENCE, V256, P998; EVANS IJ, 1986, GENE, V43, P95, DOI 10.1016/0378-1119(86)90012-0; FAUCHER C, 1989, MOL PLANT MICROBE IN, V2, P291, DOI 10.1094/MPMI-2-291; FISHER RF, 1987, GENETICS, V117, P191; FISHER RF, 1988, GENE DEV, V2, P282, DOI 10.1101/gad.2.3.282; FISHER RF, 1992, UNPUB J MOL BIOL; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; GOTTFERT M, 1990, P NATL ACAD SCI USA, V87, P2680, DOI 10.1073/pnas.87.7.2680; GOTTFERT M, 1988, J PLANT PHYSIOL, V132, P394, DOI 10.1016/S0176-1617(88)80051-8; GOTTFERT M, 1986, J MOL BIOL, V191, P411, DOI 10.1016/0022-2836(86)90136-1; GOTTFERT M, 1990, MOL PLANT MICROBE IN, V3, P308, DOI 10.1094/MPMI-3-308; GYORGYPAL Z, 1991, MOL PLANT MICROBE IN, V4, P356, DOI 10.1094/MPMI-4-356; GYORGYPAL Z, 1988, MOL GEN GENET, V212, P85, DOI 10.1007/BF00322448; HARBORNE JB, SECONDARY PLANT PROD, P329; HARTWIG UA, 1990, PLANT PHYSIOL, V92, P116, DOI 10.1104/pp.92.1.116; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HIRSCH AM, 1989, P NATL ACAD SCI USA, V86, P1244, DOI 10.1073/pnas.86.4.1244; HONIG GF, 1987, NUCLEIC ACIDS RES, V15, P9677; HONMA M, 1987, P NATL ACAD SCI USA, V84, P8556; HONMA MA, 1990, J BACTERIOL, V172, P901, DOI 10.1128/jb.172.2.901-911.1990; HORVATH B, 1987, EMBO J, V6, P841, DOI 10.1002/j.1460-2075.1987.tb04829.x; INNES RW, 1985, MOL GEN GENET, V201, P426, DOI 10.1007/BF00331334; KAPE R, 1991, APPL ENVIRON MICROB, V57, P316, DOI 10.1128/AEM.57.1.316-319.1991; KEEN NT, 1988, ANNU REV MICROBIOL, V42, P421, DOI 10.1146/annurev.mi.42.100188.002225; KOBLIKA BK, 1988, SCIENCE, V240, P1310; KONDOROSI E, 1989, EMBO J, V8, P1331, DOI 10.1002/j.1460-2075.1989.tb03513.x; KONDOROSI E, 1991, MOL MICROBIOL, V5, P3035, DOI 10.1111/j.1365-2958.1991.tb01863.x; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LEWIN A, 1987, PLANT MOL BIOL, V8, P447, DOI 10.1007/BF00017990; LEWIN A, 1990, MOL PLANT MICROBE IN, V3, P317, DOI 10.1094/MPMI-3-317; Long S. R., 1988, MOL GENETICS PLANT M; LONG SR, 1990, NATURE, V344, P712, DOI 10.1038/344712a0; LONG SR, 1989, CELL, V56, P203, DOI 10.1016/0092-8674(89)90893-3; LONG SR, 1991, CURR PLANT SCI BIOT, V10, P127; LONG SR, 1992, BIOL NITROGEN FIXATI, P500; MAILLET F, 1990, J MOL MICROBIOL, V4, P1; MANE C, 1992, MOL MICROBIOL, V6, P843; MCIVER J, 1989, Molecular Plant-Microbe Interactions, V2, P97, DOI 10.1094/MPMI-2-097; MORRIS RO, 1986, ANNU REV PLANT PHYS, V37, P509, DOI 10.1146/annurev.pp.37.060186.002453; MULLIGAN JT, 1985, P NATL ACAD SCI USA, V82, P6609, DOI 10.1073/pnas.82.19.6609; MULLIGAN JT, 1989, GENETICS, V122, P7; NAYUDU M, 1987, MOL GEN GENET, V206, P326, DOI 10.1007/BF00333591; NIEUWKOOP AJ, 1987, J BACTERIOL, V169, P2631, DOI 10.1128/jb.169.6.2631-2638.1987; PARNISKE M, 1991, Z NATURFORSCH C, V46, P318; PETERS NK, 1986, SCIENCE, V233, P917; PHILLIPS DA, 1991, RECENT ADV PHYTOCHEM, V26, P1; REDMOND JW, 1986, NATURE, V323, P632, DOI 10.1038/323632a0; ROCHE P, 1991, CELL, V67, P1131, DOI 10.1016/0092-8674(91)90290-F; ROLFE B G, 1988, Biofactors, V1, P3; ROSSEN L, 1985, EMBO J, V4, P3369, DOI 10.1002/j.1460-2075.1985.tb04092.x; ROSTAS K, 1986, P NATL ACAD SCI USA, V83, P1757, DOI 10.1073/pnas.83.6.1757; RUSHING B, 1990, NUCLEIC ACIDS RES, V19, P921; SADOWSKY MJ, 1991, P NATL ACAD SCI USA, V88, P637, DOI 10.1073/pnas.88.2.637; SCHULTZE M, 1992, P NATL ACAD SCI USA, V89, P192, DOI 10.1073/pnas.89.1.192; SCHWEDOCK J, 1990, NATURE, V348, P644, DOI 10.1038/348644a0; SCHWEDOCK J, 1989, Molecular Plant-Microbe Interactions, V2, P181, DOI 10.1094/MPMI-2-181; SCOTT KF, 1986, NUCLEIC ACIDS RES, V14, P2905, DOI 10.1093/nar/14.7.2905; SHARMA SB, 1990, GENE DEV, V4, P344, DOI 10.1101/gad.4.3.344; SHEARMAN CA, 1986, EMBO J, V5, P647, DOI 10.1002/j.1460-2075.1986.tb04262.x; SHEN WH, 1988, P NATL ACAD SCI USA, V85, P3417, DOI 10.1073/pnas.85.10.3417; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; SPAINK HP, 1987, NATURE, V328, P337, DOI 10.1038/328337a0; SPAINK HP, 1989, PLANT MOL BIOL, V12, P59, DOI 10.1007/BF00017448; STACEY G, 1991, CURR PLANT SCI BIOT, V10, P156; STACHEL SE, 1986, P NATL ACAD SCI USA, V83, P379, DOI 10.1073/pnas.83.2.379; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; SWANSON JA, IN PRESS GENETICS; TRUCHET G, 1989, MOL GEN GENET, V219, P65, DOI 10.1007/BF00261158; TRUCHET G, 1991, NATURE, V351, P670, DOI 10.1038/351670a0; TRUCHET G, 1980, DIFFERENTIATION, V16, P163, DOI 10.1111/j.1432-0436.1980.tb01072.x; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VANCE CP, 1983, ANNU REV MICROBIOL, V37, P399, DOI 10.1146/annurev.mi.37.100183.002151; VANCE CP, 1980, PHYSIOL PLANT PATHOL, V17, P167, DOI 10.1016/0048-4059(80)90049-1; WANG SP, 1990, MOL GEN GENET, V223, P329, DOI 10.1007/BF00265071; WANG SP, 1991, J BACTERIOL, V173, P3356, DOI 10.1128/jb.173.11.3356-3365.1991; YAO PY, 1969, AUST J BIOL SCI, V22, P413; YOUNG JPW, 1989, TRENDS ECOL EVOL, V4, P331; ZAAT SAJ, 1988, PLANT PHYSIOL, V86, P1298, DOI 10.1104/pp.86.4.1298	101	507	526	4	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					655	660		10.1038/357655a0	http://dx.doi.org/10.1038/357655a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614514				2022-12-28	WOS:A1992JA43000059
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SILICONE BREAST IMPLANT DECISION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-28	WOS:A1992HY94400005
J	OGILVYSTUART, AL; RYDER, WDJ; GATTAMANENI, HR; CLAYTON, PE; SHALET, SM				OGILVYSTUART, AL; RYDER, WDJ; GATTAMANENI, HR; CLAYTON, PE; SHALET, SM			GROWTH-HORMONE AND TUMOR RECURRENCE	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA	Objective-To determine whether using growth hormone to treat radiation induced growth hormone deficiency causes tumour recurrence. Design-Comparison of tumour recurrence rates in children treated with growth hormone for radiation induced deficiency and an untreated population. Computed tomograms from children with brain tumours were reviewed when starting growth hormone and subsequently. Setting-North West region. Patients-207 children treated for brain tumour, 47 of whom received growth hormone and 161 children with acute lymphoblastic leukaemia 15 of whom received growth hormone. Main outcome measures-Tumour recurrence and changes in appearances on computed tomography. Results-Among children with brain tumour, five (11%) who received growth hormone had recurrences compared with 42 (26%) who did not receive growth hormone. Also adjusting for other variables that might affect tumour recurrence the estimated relative risk of recurrence was 0.82 (95% confidence interval 0.28 to 2.37). The only child with acute lymphoblastic leukaemia who relapsed while taking growth hormone had relapsed previously before starting treatment. Two of the five children with brain tumours who relapsed had abnormal appearances on computed tomography when growth hormone was started. 14 other children who remained relapse free and had follow up computed tomography showed no deterioration in radiological appearance during treatment. Conclusions-In this population growth hormone did not increase the risk of tumour recurrence but continued surveillance is essential. Abnormal results on computed tomography are not a contraindication to treatment with growth hormone.	CHRISTIE HOSP & HOLT RADIUM INST,DEPT ENDOCRINOL,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT RADIOTHERAPY,MANCHESTER M20 9BX,LANCS,ENGLAND; CHRISTIE HOSP & HOLT RADIUM INST,DEPT STAT,MANCHESTER M20 9BX,LANCS,ENGLAND	Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital; Christie NHS Foundation Trust; Christie Hospital				Clayton, Peter/0000-0003-1225-4537				ARSLANIAN SA, 1985, AM J DIS CHILD, V139, P347, DOI 10.1001/archpedi.1985.02140060029020; BENTLEY HP, 1974, NATURE, V252, P747, DOI 10.1038/252747a0; BUCHANAN CR, 1991, BRIT MED J, V302, P824, DOI 10.1136/bmj.302.6780.824; CLAYTON PE, 1991, J PEDIATR-US, V118, P226, DOI 10.1016/S0022-3476(05)80487-1; CLAYTON PE, 1987, LANCET, V1, P711; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P112; DELEMARREVANDEWAAL HA, 1988, LANCET, V1, P1159; ESTROV Z, 1991, J CLIN ONCOL, V9, P394, DOI 10.1200/JCO.1991.9.3.394; EZZAT S, 1991, J CLIN ENDOCR METAB, V72, P245, DOI 10.1210/jcem-72-2-245; FISHER DA, 1988, LANCET, V1, P1159; MOON HD, 1950, CANCER RES, V10, P297; RODENS KP, 1987, ACTA ENDOCR-COP    S, V283, P188; ROGERS PC, 1977, LANCET, V2, P434; WATANABE S, 1988, LANCET, V1, P1159	15	95	96	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1601	1605		10.1136/bmj.304.6842.1601	http://dx.doi.org/10.1136/bmj.304.6842.1601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628087	Green Published, Bronze			2022-12-28	WOS:A1992JA43600020
J	POTTS, M; ANGELONI, SV; EBEL, RE; BASSAM, D				POTTS, M; ANGELONI, SV; EBEL, RE; BASSAM, D			MYOGLOBIN IN A CYANOBACTERIUM	SCIENCE			English	Article							AMINO-ACID-SEQUENCE; NITROGEN-FIXATION; PROTEINS	Myoglobin was found in the nitrogen-fixing cyanobacterium Nostoc commune. This cyanobacterial myoglobin, referred to as cyanoglobin, was shown to be a soluble hemoprotein of 12.5 kilodaltons with an amino acid sequence that is related to that of myoglobins from two lower eukaryotes, the ciliated protozoa Paramecium caudatum and Tetrahymena pyriformis. Cyanoglobin is encoded by the glbNgene, which is positioned between nifU and nifH-two genes essential for nitrogen fixation-in the genome of Nostoc. Cyanoglobin was detected in Nostoc cells only when they were starved for nitrogen and incubated microaerobically.			POTTS, M (corresponding author), VIRGINIA POLYTECH INST & STATE UNIV,DEPT BIOCHEM,BLACKSBURG,VA 24061, USA.							Bothe H., 1982, biology of cyanobacteria [edited by Carr, N.G.; Whitton, B.A.], P87; CARPENTER EJ, 1976, SCIENCE, V191, P1278, DOI 10.1126/science.1257749; DEFRANCESCO N, 1988, J BACTERIOL, V170, P3297, DOI 10.1128/jb.170.7.3297-3300.1988; GALLON JR, 1974, CAN J MICROBIOL, V20, P1633, DOI 10.1139/m74-254; Haselkorn R, 1992, BIOL NITROGEN FIXATI, P166; IWAASA H, 1990, J BIOL CHEM, V265, P8603; IWAASA H, 1989, J MOL BIOL, V208, P355, DOI 10.1016/0022-2836(89)90395-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MULLIGAN ME, 1989, J BIOL CHEM, V264, P19200; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2441; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Schopf JW, 1982, BIOL CYANOBACTERIA, P543; STEWART WDP, 1978, ENDEAVOUR, V2, P170, DOI 10.1016/0160-9327(78)90097-2; WAKABAYASHI S, 1986, NATURE, V322, P481, DOI 10.1038/322481a0; Wolk C. P., 1982, biology of cyanobacteria [edited by Carr, N.G.; Whitton, B.A.], P359	18	98	103	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 19	1992	256	5064					1690	1692		10.1126/science.256.5064.1690	http://dx.doi.org/10.1126/science.256.5064.1690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ174	1609281				2022-12-28	WOS:A1992HZ17400048
J	HAASS, C; KOO, EH; MELLON, A; HUNG, AY; SELKOE, DJ				HAASS, C; KOO, EH; MELLON, A; HUNG, AY; SELKOE, DJ			TARGETING OF CELL-SURFACE BETA-AMYLOID PRECURSOR PROTEIN TO LYSOSOMES - ALTERNATIVE PROCESSING INTO AMYLOID-BEARING FRAGMENTS	NATURE			English	Article							ALZHEIMERS-DISEASE; IDENTIFICATION; RECEPTOR	PROGRESSIVE cerebral deposition of the amyloid beta-peptide is an early and invariant feature of Alzheimer's disease. The beta-peptide is released by proteolytic cleavages from the beta-amyloid precursor protein (beta-APP) 1, a membrane-spanning glycoprotein expressed in most mammalian cells. Normal secretion of beta-APP involves a cleavage in the beta-peptide region 2,3, releasing the soluble extramembranous portion 4,5 and retaining a 10K C-terminal fragment in the membrane 6. Because this secretory pathway precludes beta-amyloid formation, we searched for an alternative proteolytic processing pathway that can generate beta-peptide-bearing fragments from full-length beta-APP. Incubation of living human endothelial cells with a beta-APP antibody revealed reinternalization of mature PAPP from the cell surface and its targeting to endosomes/lysosomes. After cell-surface biotinylation, full-length biotinylated beta-APP was recovered inside the cells. Purification of lysosomes directly demonstrated the presence of mature beta-APP and an extensive array of beta-peptide-containing proteolytic products. Our results define a second processing pathway for beta-APP and suggest that it may be responsible for generating amyloid-bearing fragments in Alzheimer's disease.	HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, NEUROSCI PROGRAM, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV NEUROL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HAASS, C (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA.							BASKIN F, 1991, J NEUROSCI RES, V29, P127, DOI 10.1002/jnr.490290115; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BUKTENICA S, 1987, J BIOL CHEM, V262, P9469; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; DICE JF, 1990, CRIT REV THER DRUG, V7, P211; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; HAASS C, 1991, J NEUROSCI, V11, P3783; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAMAOKA A, 1992, P NATL ACAD SCI USA, V89, P1345, DOI 10.1073/pnas.89.4.1345; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	26	825	843	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 11	1992	357	6378					500	503		10.1038/357500a0	http://dx.doi.org/10.1038/357500a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608449				2022-12-28	WOS:A1992HY05200064
J	GAVISH, M; WANG, JL; EISENSTEIN, M; LAHAV, M; LEISEROWITZ, L				GAVISH, M; WANG, JL; EISENSTEIN, M; LAHAV, M; LEISEROWITZ, L			THE ROLE OF CRYSTAL POLARITY IN ALPHA-AMINO-ACID CRYSTALS FOR INDUCED NUCLEATION OF ICE	SCIENCE			English	Article							CONSISTENT FORCE-FIELD; WATER; CRYSTALLIZATION; DENSITIES; PEPTIDES	The hydrophobic faces of single crystals of a series of pairs of racemic and chiral-resolved hydrophobic alpha-amino acids were used as a substrate, onto which water vapor has been cooled to freezing. The morphologies and molecular packing arrangements within each crystal pair are similar but only one of each pair exhibits a polar axis, parallel to the hydrophobic face exposed to water. Those crystals that have a polar axis induce a freezing point higher by 4-degrees to 5-degrees-C than the corresponding crystals that do not have a polar axis. The results are interpreted in terms of an electric field mechanism that helps align the water molecules into ice-like clusters en route to crystallization.	WEIZMANN INST SCI, DEPT MAT & INTERFACES, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								BARTHAKUR N, 1963, NATURE, V200, P866, DOI 10.1038/200866a0; BENEDETTI E, 1973, ACTA CRYSTALLOGR B, V29, P730, DOI 10.1107/S0567740873003250; Blair D. N., 1973, Journal of Applied Meteorology, V12, P1012, DOI 10.1175/1520-0450(1973)012<1012:CCTOGU>2.0.CO;2; COLL M, 1986, ACTA CRYSTALLOGR C, V42, P599, DOI 10.1107/S0108270186095240; CORRIN ML, 1968, J PHYS CHEM-US, V72, P643, DOI 10.1021/j100848a043; DAVIS BL, 1975, J APPL METEOROL, V14, P891, DOI 10.1175/1520-0450(1975)014<0891:AEFTUN>2.0.CO;2; DESTRO R, 1988, J PHYS CHEM-US, V92, P966, DOI 10.1021/j100315a022; DEVRIES AL, 1984, PHILOS T R SOC B, V304, P575; DIBLASIO B, 1975, ACTA CRYSTALLOGR B, V31, P601, DOI 10.1107/S0567740875003342; DONOHUE J, 1950, J AM CHEM SOC, V72, P949, DOI 10.1021/ja01158a079; EISENSTEIN M, 1988, ACTA CRYSTALLOGR B, V44, P412, DOI 10.1107/S0108768188002356; FEENEY RE, 1986, ANNU REV BIOPHYS BIO, V15, P59; GAVISH M, 1990, SCIENCE, V250, P973, DOI 10.1126/science.250.4983.973; GRAYER S, 1990, THESIS WEIZMANN I SC; GRAYER S, 1986, THESIS WEIZMANN I SC; GREEN RL, 1985, NATURE, V317, P645, DOI 10.1038/317645a0; HAGLER AT, 1974, J AM CHEM SOC, V96, P5319, DOI 10.1021/ja00824a004; HIRSHFELD FL, 1977, THEOR CHIM ACTA, V44, P129, DOI 10.1007/BF00549096; HIRSHFELD FL, 1977, ISRAEL J CHEM, V16, P226; HIRSHFELD FL, 1971, ACTA CRYSTALL B-STRU, VB 27, P769, DOI 10.1107/S0567740871002905; JACQUEMAIN D, 1991, J AM CHEM SOC, V113, P7684, DOI 10.1021/ja00020a034; LIFSON S, 1979, J AM CHEM SOC, V101, P5111, DOI 10.1021/ja00512a001; LINDOW SE, 1983, ANNU REV PHYTOPATHOL, V21, P363, DOI 10.1146/annurev.py.21.090183.002051; MALLIKARJUNAN M, 1969, ACTA CRYSTALL B-STRU, VB 25, P296, DOI 10.1107/S0567740869002147; MATHIESON AM, 1952, ACTA CRYSTALLOGR, V5, P332; MATHIESON AM, 1953, ACTA CRYSTALLOGR, V6, P399; MIZUNO H, 1989, PROTEINS, V5, P47, DOI 10.1002/prot.340050107; MOSTAD A, 1972, ACTA CHEM SCAND, V26, P3819, DOI 10.3891/acta.chem.scand.26-3819; MOSTAD A, 1973, ACTA CHEM SCAND, V27, P401, DOI 10.3891/acta.chem.scand.27-0401; PARUNGO FP, 1965, J ATMOS SCI, V22, P309, DOI 10.1175/1520-0469(1965)022<0309:MSAINO>2.0.CO;2; PARUNGO FP, 1967, J ATMOS SCI, V24, P274, DOI 10.1175/1520-0469(1967)024<0274:AAAIN>2.0.CO;2; POWER BA, 1962, NATURE, V194, P1170, DOI 10.1038/1941170a0; SIMPSON HJ, 1966, ACTA CRYSTALLOGR, V20, P550, DOI 10.1107/S0365110X66001221; STOREY KB, 1990, SCI AM, V263, P92, DOI 10.1038/scientificamerican1290-92; TORII K, 1970, ACTA CRYSTALL B-STRU, VB 26, P1317, DOI 10.1107/S0567740870004065; TORII K, 1971, ACTA CRYSTALL B-STRU, VB 27, P2237, DOI 10.1107/S0567740871005612; TORII K, 1973, ACTA CRYSTALLOGR B, V29, P2799, DOI 10.1107/S0567740873007569; VONNEGUT B, 1947, J APPL PHYS, V18, P593, DOI 10.1063/1.1697813; WANG JC, UNPUB; WEISSBUCH I, 1990, J AM CHEM SOC, V112, P7718, DOI 10.1021/ja00177a036; ZHU SB, 1991, J CHEM PHYS, V94, P1403, DOI 10.1063/1.459998	41	138	144	3	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 8	1992	256	5058					815	818		10.1126/science.1589763	http://dx.doi.org/10.1126/science.1589763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589763				2022-12-28	WOS:A1992HT23500037
J	HARRIS, JR; LIPPMAN, ME; VERONESI, U; WILLETT, W				HARRIS, JR; LIPPMAN, ME; VERONESI, U; WILLETT, W			MEDICAL PROGRESS .1. BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ORAL-CONTRACEPTIVE USE; PREMENOPAUSAL WOMEN; UNITED-STATES; DIETARY-FAT; SCREENING TRIAL; AMERICAN-WOMEN; RISK-FACTORS; PAST DECADE; BODY SIZE; AGE		HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT RADIAT ONCOL, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT RADIAT ONCOL, BOSTON, MA 02115 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT MED, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PHARMACOL, WASHINGTON, DC 20007 USA; IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Georgetown University; Georgetown University; Georgetown University; Fondazione IRCCS Istituto Nazionale Tumori Milan; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	HARRIS, JR (corresponding author), HARVARD UNIV, SCH MED, JOINT CTR RADIAT THERAPY, DEPT RADIAT ONCOL, 50 BINNEY ST, BOSTON, MA 02115 USA.							ADAMI HO, 1981, CANCER, V48, P1688, DOI 10.1002/1097-0142(19811001)48:7<1688::AID-CNCR2820480736>3.0.CO;2-W; ANDERSON DE, 1974, CANCER, V34, P1090, DOI 10.1002/1097-0142(197410)34:4<1090::AID-CNCR2820340419>3.0.CO;2-J; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BAINES CJ, 1990, AM J ROENTGENOL, V155, P743, DOI 10.2214/ajr.155.4.2119103; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BLOT WJ, 1987, J NATL CANCER I, V78, P451; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOYLE P, 1988, CANCER PREVENTION VI; BUELL P, 1973, J NATL CANCER I, V51, P1479, DOI 10.1093/jnci/51.5.1479; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; CHAMBERLAIN J, 1988, LANCET, V2, P411; CHEN J, 1990, DIET LIFE STYLE MORT, P750; CHILVERS C, 1989, LANCET, V1, P973; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CONE TE, 1961, J PEDIATR-US, V59, P736, DOI 10.1016/S0022-3476(61)80012-7; DEWAARD F, 1988, INT J CANCER, V41, P666, DOI 10.1002/ijc.2910410505; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EPHROSS SA, 1990, AM J EPIDEMIOL, V132, P790; EVELETH PB, 1976, 8 INT BIOL PROGR, P260; EWERTZ M, 1990, INT J CANCER, V46, P597, DOI 10.1002/ijc.2910460408; FISHER B, 1980, CANCER RES, V40, P3863; FRISCH RE, 1985, BRIT J CANCER, V52, P885, DOI 10.1038/bjc.1985.273; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GARFINKEL L, 1988, PREV MED, V17, P686, DOI 10.1016/0091-7435(88)90086-2; GLASS A, 1988, J NATL CANCER I, V80, P1076; GLASS AG, 1990, J NATL CANCER I, V82, P693, DOI 10.1093/jnci/82.8.693; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; HENDERSON IC, 1980, NEW ENGL J MED, V302, P17, DOI 10.1056/NEJM198001033020104; HENDERSON IC, 1980, NEW ENGL J MED, V302, P78, DOI 10.1056/NEJM198001103020203; HESTON JF, 1986, NCI MONOGRAPH, V70; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HOWARD J, 1987, CA-CANCER J CLIN, V37, P33, DOI 10.3322/canjclin.37.1.33; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; Ip C, 1990, Prog Clin Biol Res, V346, P107; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KAMPERT JB, 1988, AM J EPIDEMIOL, V128, P962; KATSOUYANNI K, 1988, CANCER-AM CANCER SOC, V61, P181, DOI 10.1002/1097-0142(19880101)61:1<181::AID-CNCR2820610130>3.0.CO;2-J; KVALE G, 1988, J EPIDEMIOL COMMUN H, V42, P30, DOI 10.1136/jech.42.1.30; LILIENFELD AM, 1956, CANCER, V9, P927, DOI 10.1002/1097-0142(195609/10)9:5<927::AID-CNCR2820090510>3.0.CO;2-3; LONDON S, 1988, CANCER, V31, P19; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; LONGNECKER MP, 1988, JAMA-J AM MED ASSOC, V260, P652; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; MCGREGOR DH, 1977, J NATL CANCER I, V59, P799, DOI 10.1093/jnci/59.3.799; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; MEYER F, 1986, J NATL CANCER I, V77, P613, DOI 10.1093/jnci/77.3.613; MICOZZI MS, 1985, YEARB PHYS ANTHROPOL, V28, P175; MILLER AB, 1991, BREAST DISEASES, P215; MILLER BA, 1991, CANCER CAUSE CONTROL, V2, P67, DOI 10.1007/BF00053123; MILLER DR, 1989, AM J EPIDEMIOL, V129, P269, DOI 10.1093/oxfordjournals.aje.a115132; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MOOLGAVKAR S, 1989, JNCI-J NATL CANCER I, V65, P559; MOORE JW, 1982, INT J CANCER, V29, P17, DOI 10.1002/ijc.2910290105; MOORE JW, 1986, INT J CANCER, V38, P625, DOI 10.1002/ijc.2910380502; MORRISON, 1989, JNCI-J NATL CANCER I, V81, P1513, DOI 10.1093/jnci/81.19.1513-a; MORRISON AS, 1988, JNCI-J NATL CANCER I, V80, P1540, DOI 10.1093/jnci/80.19.1540; MORRISON AS, 1991, J NATL CANCER I, V83, P226, DOI 10.1093/jnci/83.4.226; MOSKOWITZ M, 1986, RADIOLOGY, V161, P37, DOI 10.1148/radiology.161.1.3532183; MUIR CS, 1987, IARC SCI PUBLICATION, V88; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; OTTMAN R, 1983, LANCET, V2, P556; PAFFENBARGER RS, 1987, AM J CLIN NUTR, V45, P312, DOI 10.1093/ajcn/45.1.312; PIKE MC, 1983, NATURE, V303, P767, DOI 10.1038/303767a0; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; ROBERTS MM, 1990, LANCET, V335, P241; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; RUTQVIST LE, 1990, INT J CANCER, P76; Shapiro S, 1985, Natl Cancer Inst Monogr, V67, P65; SHAPIRO S, 1989, CANCER, V63, P1873, DOI 10.1002/1097-0142(19890515)63:10<1873::AID-CNCR2820631002>3.0.CO;2-6; STEPHEN AM, 1990, AM J CLIN NUTR, V52, P457, DOI 10.1093/ajcn/52.3.457; SWANSON CA, 1988, CANCER RES, V48, P5363; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; THOMAS DB, 1990, BRIT J CANCER, V61, P110; TRETLI S, 1990, BRIT J CANCER, V62, P299, DOI 10.1038/bjc.1990.282; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; TRICHOPOULOS D, 1983, INT J CANCER, V31, P701, DOI 10.1002/ijc.2910310604; VALAORAS VG, 1969, INT J CANCER, V4, P350, DOI 10.1002/ijc.2910040312; VANDERMAAS PJ, 1988, COSTS EFFECTS MASS S; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; WALD N, 1991, BRIT MED J, V302, P845, DOI 10.1136/bmj.302.6780.845; WELSCH CW, 1992, CANCER RES, V52, pS2040; WHITE E, 1987, AM J PUBLIC HEALTH, V77, P495, DOI 10.2105/AJPH.77.4.495; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P731, DOI 10.1093/oxfordjournals.aje.a114156; WYSHAK G, 1982, NEW ENGL J MED, V306, P1033, DOI 10.1056/NEJM198204293061707; WYSOWSKI DK, 1987, AM J EPIDEMIOL, V125, P791, DOI 10.1093/oxfordjournals.aje.a114596; 1990, DHHS PHS901101 NAT C; 1991, LANCET, V337, P1575; 1991, BREAST CANCER SCREEN	101	598	636	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					319	328		10.1056/NEJM199207303270505	http://dx.doi.org/10.1056/NEJM199207303270505			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1620171				2022-12-28	WOS:A1992JF65500005
J	FRANK, AL				FRANK, AL			OCCUPATIONAL AND ENVIRONMENTAL MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FRANK, AL (corresponding author), UNIV KENTUCKY,COLL MED,LEXINGTON,KY 40506, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					385	386						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613929				2022-12-28	WOS:A1992JC35200042
J	LAFFEL, G; BERWICK, DM				LAFFEL, G; BERWICK, DM			QUALITY IN HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	LAFFEL, G (corresponding author), BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA.							AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BRENNAN TA, 1991, JAMA-J AM MED ASSOC, V265, P3265, DOI 10.1001/jama.265.24.3265; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; Dick R.S., 1991, COMPUTER BASED PATIE; Field MJ, 1990, CLIN PRACTICE GUIDEL; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; GUERRIERE MRJ, 1991, ANN INTERN MED, V115, P906, DOI 10.7326/0003-4819-115-11-906; HAND R, 1991, JAMA-J AM MED ASSOC, V266, P3429, DOI 10.1001/jama.266.24.3429; Kleefield S, 1991, QRB Qual Rev Bull, V17, P138; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lehr H, 1991, QRB Qual Rev Bull, V17, P326; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; NELSON E C, 1989, Medical Care (Philadelphia), V27, pS77, DOI 10.1097/00005650-198903001-00007; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; SALIVE ME, 1990, HEALTH SERV RES, V25, P697; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; STAFFORD RS, 1991, JAMA-J AM MED ASSOC, V265, P59, DOI 10.1001/jama.265.1.59; WARE JE, 1991, CANCER, V67, P774, DOI 10.1002/1097-0142(19910201)67:3+<774::AID-CNCR2820671404>3.0.CO;2-I; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011	29	22	22	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					407	409		10.1001/jama.268.3.407	http://dx.doi.org/10.1001/jama.268.3.407			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613938				2022-12-28	WOS:A1992JC35200051
J	OTT, JE				OTT, JE			ADMINISTRATIVE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE				OTT, JE (corresponding author), GEORGE WASHINGTON UNIV,HLTH CARE SYST,WASHINGTON,DC 20052, USA.							BERWICK DM, 1989, MED CARE, V27, P763, DOI 10.1097/00005650-198908000-00001; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BROWN M, 1991, HLTH CARE MANAGE REV, V15, P87; COUCH JB, 1988, ANN INTERN MED, V109, P771, DOI 10.7326/0003-4819-109-10-771; HOY EW, 1991, HEALTH AFFAIR, V10, P18, DOI 10.1377/hlthaff.10.4.18; KECKLEY PH, 1991, HLTH CARE MARKET, V6, P1; Kindig D A, 1991, Health Care Manage Rev, V16, P11; LIPSON EH, 1991, J HLTH CARE BENEFITS, V1, P4; MATURI R, 1992, MANAGED CARE WE 0127, P1; Nash D B, 1991, Front Health Serv Manage, V8, P3; OTT JE, 1991, PAYING DOCTOR HLTH P, P83; RELMAN AS, 1988, NEW ENGL J MED, V319, P1990; ROBERTS SS, 1987, INTERNIST, V28, P10; WENNBERG JE, 1990, NEW ENGL J MED, V323, P1202, DOI 10.1056/NEJM199010253231710; 1992, 1991 HLTH CARE BENEF, V2, P1	15	1	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					332	333						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613908				2022-12-28	WOS:A1992JC35200018
J	FRIEDERICH, E; VANCOMPERNOLLE, K; HUET, C; GOETHALS, M; FINIDORI, J; VANDEKERCKHOVE, J; LOUVARD, D				FRIEDERICH, E; VANCOMPERNOLLE, K; HUET, C; GOETHALS, M; FINIDORI, J; VANDEKERCKHOVE, J; LOUVARD, D			AN ACTIN-BINDING SITE CONTAINING A CONSERVED MOTIF OF CHARGED AMINO-ACID-RESIDUES IS ESSENTIAL FOR THE MORPHOGENIC EFFECT OF VILLIN	CELL			English	Article							F-ACTIN; MICROVILLUS CYTOSKELETON; INTESTINAL MICROVILLI; EPITHELIAL-CELLS; PROTEINS; SEQUENCE; ORGANIZATION; MICROFILAMENTS; POLYMERIZATION; NUCLEATION	The actin-binding protein villin induces microvillus growth and reorganization of the cytoskeleton in cells that do not normally produce this protein. Transfection of mutagenized villin cDNAs into CV-1 cells was used to show that a conserved, COOH-terminally located cluster of charged amino acid residues (KKEK) is crucial for the morphogenic activity of villin in vivo. In vitro experiments with a 22 amino acid synthetic peptide corresponding to this region of villin provide evidence that this motif is part of an F-actin-binding site that induces G-actin to polymerize. Chemical cross-linking of actin to this peptide, the effects of amino acid substitutions in peptides, and the behavior of villin variants further corroborate the participation of the KKEK sequence in actin contacts.	STATE UNIV GHENT,FYSIOL SCHEIKUNDE LAB,B-9000 GHENT,BELGIUM	Ghent University	FRIEDERICH, E (corresponding author), INST PASTEUR,DEPT BIOL MOLEC,CNRS,URA 1149,UNITE BIOL MEMBRANES,F-75724 PARIS 15,FRANCE.							AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P723; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAUW G, 1987, P NATL ACAD SCI USA, V84, P4806, DOI 10.1073/pnas.84.14.4806; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; BRETSCHER A, 1980, CELL, V20, P839, DOI 10.1016/0092-8674(80)90330-X; BRETSCHER A, 1979, P NATL ACAD SCI USA, V76, P2321, DOI 10.1073/pnas.76.5.2321; BROWN SS, 1979, J CELL BIOL, V80, P499, DOI 10.1083/jcb.80.2.499; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COUDRIER E, 1981, J MOL BIOL, V152, P49, DOI 10.1016/0022-2836(81)90095-4; COUDRIER E, 1983, EMBO J, V2, P469, DOI 10.1002/j.1460-2075.1983.tb01446.x; CRAIG SW, 1980, CELL, V22, P739, DOI 10.1016/0092-8674(80)90550-4; ETO M, 1991, J BIOL CHEM, V266, P18233; EZZEL RM, 1989, J CELL BIOL, V109, pA37; FINIDORI J, 1992, J CELL BIOL, V116, P1145, DOI 10.1083/jcb.116.5.1145; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; GLENNEY JR, 1981, CELL, V24, P471, DOI 10.1016/0092-8674(81)90338-X; GLENNEY JR, 1981, J BIOL CHEM, V256, P8156; GLENNEY JR, 1981, P NATL ACAD SCI-BIOL, V78, P2810, DOI 10.1073/pnas.78.5.2810; HESTERBERG LK, 1983, J BIOL CHEM, V258, P365; HESTERBERG LK, 1983, J BIOL CHEM, V258, P359; HUYLEBROECK D, 1988, GENE, V66, P163, DOI 10.1016/0378-1119(88)90354-X; JANMEY PA, 1988, J BIOL CHEM, V263, P16738; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOOSEKER MS, 1980, J CELL BIOL, V87, P809, DOI 10.1083/jcb.87.3.809; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; REGGIO H, 1983, METHOD ENZYMOL, V98, P379; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; SAFER D, 1991, J BIOL CHEM, V266, P4029; SMABROOK J, 1989, MOL CLONING LABORATO; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; WALSH TP, 1984, BIOCHEMISTRY-US, V23, P2613, DOI 10.1021/bi00307a012; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E; YONEZAWA N, 1989, EUR J BIOCHEM, V183, P235, DOI 10.1111/j.1432-1033.1989.tb14918.x	45	153	153	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 10	1992	70	1					81	92		10.1016/0092-8674(92)90535-K	http://dx.doi.org/10.1016/0092-8674(92)90535-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623524				2022-12-28	WOS:A1992JC95700010
J	GALAN, JE; PACE, J; HAYMAN, MJ				GALAN, JE; PACE, J; HAYMAN, MJ			INVOLVEMENT OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN THE INVASION OF CULTURED-MAMMALIAN-CELLS BY SALMONELLA-TYPHIMURIUM	NATURE			English	Article							ESCHERICHIA-COLI; IDENTIFICATION; INFECTION; CLONING	SALMONELLA infection continues to be a major world-wide health problem 1. One essential pathogenic feature common to all Salmonella is their ability to penetrate the cells of the intestinal epithelium which are normally non-phagocytic 2. The internalization of Salmonella into mammalian cells is thought to be a receptor-mediated phenomenon and the invasion of cultured epithelial cells depends on several Salmonella genes, but nothing is known about the host determinants participating in this interaction 3-6. Protein tyrosine phosphorylation follows stimulation of many cell-surface receptors to initiate signal transduction pathways that stimulate cellular responses 7. We report here that invasion of cultured Henle-407 cells by Salmonella typhimurium induces the tyrosine phosphorylation of the epidermal growth factor (EGF) receptor. In contrast, an isogenic strain of S. typhimurium that is defective in invasion owing to a mutation in the invA gene is unable to induce such phosphorylation. Addition of EGF to cultured Henle-407 cells allowed the internalization of the invasion-defective S. typhimurium invA mutant although it did not cause the internalization of an adherent, but non-invasive, strain of Escherichia coli. This result indicates that stimulation of the EGF receptor is involved in the invasion of cultured Henle-407 cells by S. typhimurium.			GALAN, JE (corresponding author), SUNY STONY BROOK,SCH MED,DEPT MICROBIOL,STONY BROOK,NY 11794, USA.							CHALKER RB, 1988, REV INFECT DIS, V10, P111; CHENEY CP, 1980, INFECT IMMUN, V28, P1019; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GALAN JE, IN PRESS J BACT; GINOCCHIO C, IN PRESS P NATN ACAD; HOISETH SK, 1981, NATURE, V291, P238, DOI 10.1038/291238a0; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KAMPS MP, 1988, ONCOGENE, V2, P305; LEE EB, 1990, ONCOGENE, V5, P1165; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; RIJKEN PJ, 1991, J CELL SCI, V100, P491; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; Todaro G J, 1990, Semin Cancer Biol, V1, P257; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	19	182	186	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 18	1992	357	6379					588	589		10.1038/357588a0	http://dx.doi.org/10.1038/357588a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HZ112	1608468				2022-12-28	WOS:A1992HZ11200053
J	UDAKA, K; TSOMIDES, TJ; EISEN, HN				UDAKA, K; TSOMIDES, TJ; EISEN, HN			A NATURALLY-OCCURRING PEPTIDE RECOGNIZED BY ALLOREACTIVE CD8+ CYTOTOXIC LYMPHOCYTES-T IN ASSOCIATION WITH A CLASS-I MHC PROTEIN	CELL			English	Article							CELL RECEPTOR; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; HISTOCOMPATIBILITY ANTIGENS; TRANSGENIC MICE; VIRAL PEPTIDES; CLONE; GENE; DETERMINANT; EXPRESSION	The antigenic structures that initiate T cell responses to foreign (allogeneic) cells have long attracted considerable interest. We have purified and sequenced a peptide from mouse spleen that is recognized in association with the class I MHC protein H-2L(d) by 2C, an alloreactive CD8+ T cell clone. The peptide (LSP-FPFDL) greatly enhances the susceptibility of L(d+) cells to lysis by 2C, and this activity is completely blocked by a clonotypic antibody against the 2C T cell receptor. Thus, this study characterizes the naturally occurring peptide moiety of an MHC-I/peptide complex recognized by alloreactive CD8+ T cells. The peptide, which occurs in the thymus of MHC-disparate mice, can be used to study T cell development in mice expressing transgenes for the 2C T cell receptor.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NCI NIH HHS [R35-CA42504, CA14051, CA09255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042504, P30CA014051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BEVAN MJ, 1977, P NATL ACAD SCI USA, V74, P2094, DOI 10.1073/pnas.74.5.2094; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARBONE FR, 1990, J EXP MED, V171, P377, DOI 10.1084/jem.171.2.377; ERARD F, 1985, EUR J IMMUNOL, V15, P798, DOI 10.1002/eji.1830150811; EVANS GA, 1982, P NATL ACAD SCI-BIOL, V79, P1994, DOI 10.1073/pnas.79.6.1994; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GOVERMAN J, 1990, CELL, V60, P929, DOI 10.1016/0092-8674(90)90341-B; HANSEN TH, 1988, J IMMUNOL, V140, P3522; HEATH WR, 1991, P NATL ACAD SCI USA, V88, P5101, DOI 10.1073/pnas.88.12.5101; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KOURILSKY P, 1989, ADV IMMUNOL, V45, P107, DOI 10.1016/S0065-2776(08)60693-8; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LURQUIN C, 1989, CELL, V58, P293, DOI 10.1016/0092-8674(89)90844-1; MARYANSKI JL, 1982, EUR J IMMUNOL, V12, P401, DOI 10.1002/eji.1830120508; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MESCHER MF, 1983, METHOD ENZYMOL, V92, P86; MOORE KW, 1982, SCIENCE, V215, P679, DOI 10.1126/science.7058332; MULLBACHER A, 1991, J IMMUNOL, V147, P1765; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OZATO K, 1982, TRANSPLANTATION, V34, P113, DOI 10.1097/00007890-198209000-00001; PANINABORDIGNON P, 1991, SCIENCE, V252, P1548, DOI 10.1126/science.1710827; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; PUNT JA, 1991, J EXP MED, V174, P775, DOI 10.1084/jem.174.4.775; REDDEHASE MJ, 1989, NATURE, V337, P651, DOI 10.1038/337651a0; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; RUDENSKY AY, 1991, NATURE, V353, P660, DOI 10.1038/353660a0; SAITO H, 1984, NATURE, V309, P757, DOI 10.1038/309757a0; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SCHULZ M, 1991, EUR J IMMUNOL, V21, P1181, DOI 10.1002/eji.1830210513; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TSOMIDES TJ, 1991, J BIOL CHEM, V266, P3357; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; VANBLEEK GM, 1990, NATURE, V348, P213; VANMEERWIJK JPM, 1991, J EXP MED, V174, P815, DOI 10.1084/jem.174.4.815	51	287	296	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					989	998		10.1016/0092-8674(92)90617-L	http://dx.doi.org/10.1016/0092-8674(92)90617-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606619				2022-12-28	WOS:A1992HY79200010
J	MITSUHASHI, M; KELLER, C; AKITAYA, T				MITSUHASHI, M; KELLER, C; AKITAYA, T			GENE MANIPULATION ON PLASTIC PLATES	NATURE			English	Article							HYBRIDIZATION	Oligonucleotide-immobilized plastic plates provide a rapid and easy-to-use tool for use in mRNA research, including the long-term storage, amplification and detection of the specific message, in vitro synthesis of both strands of sense and antisense mRNA, and ligation of cDNA to other DNA molecules.			MITSUHASHI, M (corresponding author), HITACHI CHEM RES CTR,DIV MED SCI,1003 HLTH SCI RD W,IRVINE,CA 92715, USA.							ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; Melton D. A., 1984, NUCLEIC ACIDS RES, V7, P1175; Sambrook J, 1989, MOL CLONING LABORATO; WHITE BA, 1982, J BIOL CHEM, V257, P8569	6	27	60	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					519	520		10.1038/357519a0	http://dx.doi.org/10.1038/357519a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608454				2022-12-28	WOS:A1992HY05200070
J	SANSOM, IJ; SMITH, MP; ARMSTRONG, HA; SMITH, MM				SANSOM, IJ; SMITH, MP; ARMSTRONG, HA; SMITH, MM			PRESENCE OF THE EARLIEST VERTEBRATE HARD TISSUES IN CONODONTS	SCIENCE			English	Article								From histological investigations into the microstructure of conodont elements, a number of tissue types characteristic of the phosphatic skeleton of vertebrates have been identified. These include cellular bone, two forms of hypermineralized enamel homologs, and globular calcified cartilage. The presence of cellular bone in conodont elements provides unequivocal evidence for their vertebrate affinities. Furthermore, the identification of vertebrate hard tissues in the oral elements of conodonts extends the earliest occurrence of vertebrate hard tissues back by around 40 million years, from the Middle Ordovician (475 million years ago) to the Late Cambrian (515 million years ago).	UNIV BIRMINGHAM,SCH EARTH SCI,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,DIV ANAT & CELL BIOL,LONDON SE1 9RT,ENGLAND	University of Birmingham; University of London; King's College London	SANSOM, IJ (corresponding author), UNIV DURHAM,DEPT GEOL SCI,SOUTH RD,DURHAM DH1 3LE,ENGLAND.		Sansom, Ivan/B-4078-2009	Smith, Paul/0000-0002-5141-1577				ALDRIDGE RJ, 1986, LETHAIA, V19, P279, DOI 10.1111/j.1502-3931.1986.tb00741.x; ANDRES D, 1988, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V200, P105; Barnes C.R., 1973, Life Sci Contr R Ont Mus, VNo. 90, P1; BARSKOV IS, 1982, PALEONTOL J, P82; BENGTSON S, 1976, Lethaia, V9, P185, DOI 10.1111/j.1502-3931.1976.tb00966.x; BRIGGS DEG, 1987, LETHAIA, V20, P381, DOI 10.1111/j.1502-3931.1987.tb00799.x; BRIGGS DEG, 1983, LETHAIA, V16, P1, DOI 10.1111/j.1502-3931.1983.tb01139.x; Denison R H, 1963, Clin Orthop Relat Res, V31, P141; Dzik J., 1986, PROBLEMATIC FOSSIL T, P240; Fahraeus L.E., 1987, P105; Gross W., 1954, Senckenbergiana Lethaea, V35, P73; HALSTEAD LB, 1982, PROBLEMS PHYLOGENETI, P159; JANVIER P, 1981, Journal of Vertebrate Paleontology, V1, P121; JEPPSSON L, 1979, LETHAIA, V12, P153, DOI 10.1111/j.1502-3931.1979.tb00994.x; KREJSA RJ, 1990, LETHAIA, V23, P359, DOI 10.1111/j.1502-3931.1990.tb01369.x; Lindstrom M, 1964, CONODONTS; MULLER KJ, 1981, TREATISE INVERTE W S, V2, pW78; ORVIG T, 1989, ZOOL SCR, V18, P427, DOI 10.1111/j.1463-6409.1989.tb00138.x; ORVIG T, 1968, CURRENT PROBLEMS LOW, P374; Pander C. H., 1856, AKAD WISS, V10, P1; Pietzner H., 1968, Palaeontographica A, V128, P115; Schmidt H., 1964, Palaeontologische Zeitschrift, V38, P105; Smith M.M., 1989, Historical Biology, V3, P97; SMITH MM, 1990, BIOL REV, V65, P277, DOI 10.1111/j.1469-185X.1990.tb01427.x; SMITH MM, 1991, SCIENCE, V251, P301, DOI 10.1126/science.251.4991.301; STEWART GA, 1956, J PALEONTOL, V30, P261; Sweet WC, 1988, CONODONTA MORPHOLOGY; Szaniawski H., 1987, P35; TILLIER S, 1986, RECHERCHE, V17, P1574; TILLIER S, 1986, CR ACAD SCI II, V303, P627; 1968, ODONT REVY S13, V19, P1	31	135	145	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 29	1992	256	5061					1308	1311		10.1126/science.1598573	http://dx.doi.org/10.1126/science.1598573			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598573				2022-12-28	WOS:A1992HW13500029
J	FRANKS, P; CLANCY, CM; NUTTING, PA				FRANKS, P; CLANCY, CM; NUTTING, PA			GATEKEEPING REVISITED - PROTECTING PATIENTS FROM OVERTREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							FEE-FOR-SERVICE; RANDOMIZED CONTROLLED TRIAL; PREPAID GROUP-PRACTICE; PRIMARY CARE; FINANCIAL INCENTIVES; AMBULATORY CARE; PHYSICIAN SPECIALTY; HEALTH-INSURANCE; MEDICAL-CARE; HOSPITALIZED-PATIENTS		AGCY HLTH CARE POLICY & RES, ROCKVILLE, MD 20852 USA	Agency for Healthcare Research & Quality	FRANKS, P (corresponding author), UNIV ROCHESTER, DEPT FAMILY MED, 885 SOUTH AVE, ROCHESTER, NY 14620 USA.							AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; ALPERT JJ, 1976, PEDIATRICS, V57, P917; BERTAKIS KD, 1987, J FAM PRACTICE, V24, P305; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BOMBARDIER C, 1977, NEW ENGL J MED, V297, P699, DOI 10.1056/NEJM197709292971305; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; BROOK RH, 1990, MED CARE, V28, P392, DOI 10.1097/00005650-199005000-00002; BROOK RH, 1988, LANCET, V1, P750; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; CLANCY CM, 1989, ARCH INTERN MED, V149, P917, DOI 10.1001/archinte.149.4.917; CLARK RA, 1983, J AM ACAD DERMATOL, V9, P787, DOI 10.1016/S0190-9622(83)70193-3; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; CUNNINGHAM AS, 1989, AM J DIS CHILD, V143, P786, DOI 10.1001/archpedi.1989.02150190036016; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; DIETRICH AJ, 1984, AM J PUBLIC HEALTH, V74, P223, DOI 10.2105/AJPH.74.3.223; DIETRICH AJ, 1988, JAMA-J AM MED ASSOC, V259, P3145; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P1196, DOI 10.1001/jama.262.9.1196; EISENBERG L, 1988, AM J MED, V84, P483; ELLENBERG JH, 1980, JAMA-J AM MED ASSOC, V243, P1337, DOI 10.1001/jama.243.13.1337; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; EPSTEIN AM, 1986, NEW ENGL J MED, V314, P1089, DOI 10.1056/NEJM198604243141706; FRANKS P, 1987, J FAM PRACTICE, V24, P152; FREUND DA, 1988, ANN ALLERGY, V60, P3; FYRO K, 1987, ACTA PAEDIATR SCAND, V76, P107, DOI 10.1111/j.1651-2227.1987.tb10424.x; GARG ML, 1979, SOC SCI MED-MED ECON, V13, P187, DOI 10.1016/0160-7995(79)90043-1; GORDIS L, 1973, NEW ENGL J MED, V289, P331, DOI 10.1056/NEJM197308162890701; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; Hartley R M, 1987, Am J Med, V82, P513, DOI 10.1016/0002-9343(87)90452-9; HARTLEY RM, 1987, AM J PUBLIC HEALTH, V77, P565, DOI 10.2105/AJPH.77.5.565; HAYES TM, 1984, BRIT MED J, V289, P728, DOI 10.1136/bmj.289.6447.728; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; Higgins W, 1991, Fam Med, V23, P292; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1992, MED CARE, V30, P136, DOI 10.1097/00005650-199202000-00005; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HOCHHEISER LI, 1971, NEW ENGL J MED, V285, P148, DOI 10.1056/NEJM197107152850305; HORNBROOK MC, 1985, MED CARE, V23, P484, DOI 10.1097/00005650-198505000-00011; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; JACOBS I, 1988, LANCET, V1, P268; JOHNSON AN, 1989, INQUIRY-J HEALTH CAR, V26, P388; JOHNSON HA, 1991, JAMA-J AM MED ASSOC, V265, P2229, DOI 10.1001/jama.265.17.2229; KAHN KL, 1988, ANN INTERN MED, V109, P664, DOI 10.7326/0003-4819-109-8-664; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KEMPER KJ, 1988, NEW ENGL J MED, V318, P1033, DOI 10.1056/NEJM198804213181605; KRAHN M, 1991, ANN INTERN MED, V115, P248, DOI 10.7326/0003-4819-115-4-248; Langwell K M, 1990, Health Care Financ Rev, V12, P71; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LERMAN C, 1991, AM J OBSTET GYNECOL, V165, P658, DOI 10.1016/0002-9378(91)90304-A; LEVINSON DF, 1987, NEW ENGL J MED, V317, P1729, DOI 10.1056/NEJM198712313172708; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MANU P, 1983, SOC SCI MED, V17, P1339, DOI 10.1016/0277-9536(83)90193-4; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MCDONALD IG, 1988, J CLIN EPIDEMIOL, V41, P151, DOI 10.1016/0895-4356(88)90089-3; MELTON LJ, 1984, DIABETES CARE, V7, P12, DOI 10.2337/diacare.7.1.12; MENKEN M, 1985, JAMA-J AM MED ASSOC, V253, P1926; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; MORREIM EH, 1989, JAMA-J AM MED ASSOC, V262, P390, DOI 10.1001/jama.262.3.390; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; NELSON LM, 1988, J CLIN EPIDEMIOL, V41, P187, DOI 10.1016/0895-4356(88)90093-5; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OBER KP, 1987, AM J MED, V82, P1009, DOI 10.1016/0002-9343(87)90165-3; Payer L., 1988, MED CULTURE VARIETIE; PAYNE BC, 1984, HEALTH SERV RES, V19, P307; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; REAGAN MD, 1987, NEW ENGL J MED, V317, P1731, DOI 10.1056/NEJM198712313172709; Restuccia J D, 1986, Health Care Financ Rev, V8, P47; REYNOLDS RA, 1987, JAMA-J AM MED ASSOC, V257, P2776, DOI 10.1001/jama.257.20.2776; RHEE S, 1981, MED CARE, V19, P14, DOI 10.1097/00005650-198101000-00003; Roos N P, 1979, Inquiry, V16, P73; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; SINGH BM, 1984, BRIT MED J, V289, P726, DOI 10.1136/bmj.289.6447.726; SIU AL, 1988, JAMA-J AM MED ASSOC, V259, P1343, DOI 10.1001/jama.259.9.1343; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; Somers A R, 1983, Inquiry, V20, P301; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z; SPIEGEL JS, 1983, NEW ENGL J MED, V308, P1208, DOI 10.1056/NEJM198305193082007; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEPHENS GG, 1989, J FAM PRACTICE, V28, P701; STRAUSS MJ, 1986, MED CARE, V24, P915, DOI 10.1097/00005650-198610000-00005; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WAGNER EH, 1990, MED CARE, V28, P191, DOI 10.1097/00005650-199003000-00001; WARE JE, 1986, LANCET, V1, P1017; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WEINER JP, 1983, AM J PUBLIC HEALTH, V73, P666, DOI 10.2105/AJPH.73.6.666; WEISMAN CS, 1989, MED CARE, V27, P16, DOI 10.1097/00005650-198901000-00002; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WILSON P, 1984, HEALTH SERV RES, V19, P333; WINSLOW CM, 1988, JAMA-J AM MED ASSOC, V260, P505, DOI 10.1001/jama.260.4.505; WINSLOW CM, 1988, NEW ENGL J MED, V318, P721, DOI 10.1056/NEJM198803243181201; WOOLF SH, 1990, ARCH INTERN MED, V150, P2451, DOI 10.1001/archinte.150.12.2451; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; 1977, REPORT MED INSURANCE	109	265	266	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	1992	327	6					424	429		10.1056/NEJM199208063270613	http://dx.doi.org/10.1056/NEJM199208063270613			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JG356	1625720				2022-12-28	WOS:A1992JG35600013
J	SIBER, GR				SIBER, GR			IMMUNE GLOBULIN TO PREVENT NOSOCOMIAL INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											SIBER, GR (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BAKER CJ, 1992, NEW ENGL J MED, V327, P213, DOI 10.1056/NEJM199207233270401; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; BUSSEL JB, 1990, REV INFECT DIS, V12, pS457; CLAPP DW, 1989, J PEDIATR-US, V115, P973, DOI 10.1016/S0022-3476(89)80753-X; FANAROFF A, 1992, Pediatric Research, V31, p202A; GIVNER LB, 1990, PEDIATRICS, V86, P955; KINNEY J, 1991, AM J DIS CHILD, V145, P1233, DOI 10.1001/archpedi.1991.02160110025013; MAGNY JF, 1991, PEDIATRICS, V88, P437; Siber G R, 1992, Curr Clin Top Infect Dis, V12, P208; 1992, NEW ENGL J MED, V327, P234	10	20	24	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	1992	327	4					269	271		10.1056/NEJM199207233270409	http://dx.doi.org/10.1056/NEJM199207233270409			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JE381	1614468				2022-12-28	WOS:A1992JE38100009
J	YAFFE, MB; FARR, GW; MIKLOS, D; HORWICH, AL; STERNLICHT, ML; STERNLICHT, H				YAFFE, MB; FARR, GW; MIKLOS, D; HORWICH, AL; STERNLICHT, ML; STERNLICHT, H			TCP1 COMPLEX IS A MOLECULAR CHAPERONE IN TUBULIN BIOGENESIS	NATURE			English	Article							HEAT-SHOCK PROTEIN; HUMAN ALPHA-TUBULIN; BETA-TUBULIN; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CELLS; MICROTUBULES; EXPRESSION; COLOCALIZATION; OVEREXPRESSION	A ROLE in folding of newly translated proteins in the cytosol of eukaryotes has been proposed for t-complex polypeptide-1 (TCP1), although its molecular targets have not yet been identified1-3. Tubulin is a major cytosolic protein whose assembly into microtubules is critical to many cellular processes4-8. Although numerous studies have focused on the expression of tubulin9-20, little is known about the processes where by newly translated tubulin subunits acquire conformations that enable them to form alpha-beta-heterodimers. We examined the biogenesis of alpha- and beta-tubulin in rabbit reticulocyte lysate, and report here that newly translated tubulin subunits entered a 900K complex in a protease-sensitive conformation. Addition of Mg-ATP, but not nonhydrolysable analogues, released the tubulin subunits as assembly-competent protein with a conformation that was relatively protease-resistant. The 900K complex purified from reticulocyte lysate contained as its major constituent a 58K protein that cross-reacted with a monoclonal antiserum against mouse TCP1. We conclude that TCP1 functions as a cytosolic chaperone in the biogenesis of tubulin.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT SURG,BOSTON,MA 02146; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510	Case Western Reserve University; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Yale University; Yale University								AHMAD S, 1990, MOL CELL BIOL, V10, P5160, DOI 10.1128/MCB.10.10.5160; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOLLAG DM, 1990, EUR J CELL BIOL, V51, P295; BROWN HR, 1983, ARCH BIOCHEM BIOPHYS, V220, P46, DOI 10.1016/0003-9861(83)90385-5; BURKE D, 1989, MOL CELL BIOL, V9, P1049, DOI 10.1128/MCB.9.3.1049; CARON JM, 1985, NATURE, V317, P648, DOI 10.1038/317648a0; CLEVELAND DW, 1978, CELL, V15, P1021, DOI 10.1016/0092-8674(78)90286-6; COIAS R, 1988, EUR J BIOCHEM, V175, P467, DOI 10.1111/j.1432-1033.1988.tb14218.x; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; Dustin P., 1984, MICROTUBULES; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRASSO JA, 1986, ANAT REC, V156, P397; GUPTA RS, 1990, BIOCHEM INT, V20, P833; HUFFAKER TC, 1988, J CELL BIOL, V106, P1997, DOI 10.1083/jcb.106.6.1997; ISAACS WB, 1989, CELLULAR MOL BIOL MU, P137; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SANCHEZ ER, 1988, MOL ENDOCRINOL, V2, P756, DOI 10.1210/mend-2-8-756; SKOUFIAS DA, 1990, J CELL BIOL, V111, P1929, DOI 10.1083/jcb.111.5.1929; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; VALLEE R, 1991, NATURE, V352, P187; WEINSTEIN B, 1990, MOL CELL BIOL, V10, P5295, DOI 10.1128/MCB.10.10.5295; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; WU J, 1987, GENE, V61, P51, DOI 10.1016/0378-1119(87)90364-7; YAFFE MB, 1988, J BIOL CHEM, V263, P16023; YAFFE MB, 1988, BIOCHEMISTRY-US, V27, P1869, DOI 10.1021/bi00406a012; YAFFE MB, 1989, J BIOL CHEM, V264, P19045; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0	33	397	405	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 16	1992	358	6383					245	248		10.1038/358245a0	http://dx.doi.org/10.1038/358245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD587	1630491				2022-12-28	WOS:A1992JD58700057
J	CHRISTMAN, BW; MCPHERSON, CD; NEWMAN, JH; KING, GA; BERNARD, GR; GROVES, BM; LOYD, JE				CHRISTMAN, BW; MCPHERSON, CD; NEWMAN, JH; KING, GA; BERNARD, GR; GROVES, BM; LOYD, JE			AN IMBALANCE BETWEEN THE EXCRETION OF THROMBOXANE AND PROSTACYCLIN METABOLITES IN PULMONARY-HYPERTENSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIRCULATION; SCLERODERMA; REGRESSION; SEROTONIN; THERAPY; DISEASE; HUMANS	Background. Constriction of small pulmonary arteries and arterioles and focal vascular injury are features of pulmonary hypertension. Because thromboxane A2 is both a vasoconstrictor and a potent stimulus for platelet aggregation, it may be an important mediator of pulmonary hypertension. Its effects are antagonized by prostacyclin, which is released by vascular endothelial cells. We tested the hypothesis that there may be an imbalance between the release of thromboxane A2 and prostacyclin in pulmonary hypertension, reflecting platelet activation and an abnormal response of the pulmonary vascular endothelium. Methods. We used radioimmunoassays to measure the 24-hour urinary excretion of two stable metabolites of thromboxane A2 and a metabolite of prostacyclin in 20 patients with primary pulmonary hypertension, 14 with secondary pulmonary hypertension, 9 with severe chronic obstructive pulmonary disease (COPD) but no clinical evidence of pulmonary hypertension, and 23 normal controls. Results. The 24-hour excretion of 11-dehydro-thromboxane B2 (a stable metabolite of thromboxane A2) was increased in patients with primary pulmonary hypertension and patients with secondary pulmonary hypertension, as compared with normal controls (3224+/-482, 5392+/-1640, and 1145+/-221 pg per milligram of creatinine, respectively; P<0.05), whereas the 24-hour excretion of 2,3-dinor-6-keto-prostaglandin F1-alpha (a stable metabolite of prostacyclin) was decreased (369+/-106, 304+/-76, and 644+/-124 pg per milligram of creatinine, respectively; P<0.05). The rate of excretion of all metabolites in the patients with COPD but no clinical evidence of pulmonary hypertension was similar to that in the normal controls. Conclusions. An increase in the release of the vasoconstrictor thromboxane A2, suggesting the activation of platelets, occurs in both the primary and secondary forms of pulmonary hypertension. By contrast, the release of prostacyclin is depressed in these patients. Whether the imbalance in the release of these mediators is a cause or a result of pulmonary hypertension is unknown, but it may play a part in the development and maintenance of both forms of the disorder.	UNIV COLORADO, HLTH SCI CTR, DIV CARDIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHRISTMAN, BW (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, CTR LUNG RES, DIV PULM & CRIT CARE MED, NASHVILLE, TN 37232 USA.				NHLBI NIH HHS [HL 41952, HL 43167, HL 39952] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043167, R01HL039952, R01HL041952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADESCH DB, 1989, AM J RESP CELL MOL, V1, P489, DOI 10.1165/ajrcmb/1.6.489; BARST RJ, 1985, AM REV RESPIR DIS, V131, P171; CATELLA F, 1987, THROMB RES, V47, P647, DOI 10.1016/0049-3848(87)90103-4; CHRISTMAN BW, 1989, BIOMED ENVIRON MASS, V18, P258, DOI 10.1002/bms.1200180409; Ciabattoni G, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P598; COHEN M, 1986, J AM COLL CARDIOL, V7, P172, DOI 10.1016/S0735-1097(86)80277-7; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; EDWARDS BS, 1987, J AM COLL CARDIOL, V10, P1233, DOI 10.1016/S0735-1097(87)80123-7; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FUSTER V, 1984, CIRCULATION, V70, P580, DOI 10.1161/01.CIR.70.4.580; Groves BM, 1990, PULMONARY CIRCULATIO, P359; HART CM, 1989, CLIN CHEST MED, V10, P59; HEATH D, 1958, CIRCULATION, V18, P533, DOI 10.1161/01.CIR.18.4.533; HENRIKSSON P, 1986, BRIT HEART J, V55, P543; HERVE P, 1990, AM J MED, V89, P117, DOI 10.1016/0002-9343(90)90111-P; KAHALEH MB, 1982, ANN INTERN MED, V96, P610, DOI 10.7326/0003-4819-96-5-610; NAIR SS, 1980, ARCH INTERN MED, V140, P109, DOI 10.1001/archinte.140.1.109; PATRONO C, 1986, J CLIN INVEST, V77, P590, DOI 10.1172/JCI112341; PIETRA GG, 1989, CIRCULATION, V80, P1198, DOI 10.1161/01.CIR.80.5.1198; REEVES JT, 1986, AM REV RESPIR DIS, V134, P342; RICH S, 1986, J AM COLL CARDIOL, V8, P1307, DOI 10.1016/S0735-1097(86)80301-1; RICH S, 1987, CHEST, V91, P356, DOI 10.1378/chest.91.3.356; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; Siegel S., 1988, NONPARAMETRIC STAT B; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TURNERSTOKES L, 1982, CLIN RHEUM DIS, V8, P229; UNGERER RG, 1983, AM J MED, V75, P65, DOI 10.1016/0002-9343(83)91169-5; VESTERQVIST O, 1987, THROMB RES, V45, P393, DOI 10.1016/0049-3848(87)90228-3; VOELKEL NF, 1989, PULMONARY VASCULAR P, V38, P513; WAGENVOORT CA, 1970, CIRCULATION, V42, P1163, DOI 10.1161/01.CIR.42.6.1163; WEIR EK, 1989, AM REV RESPIR DIS, V140, P1623, DOI 10.1164/ajrccm/140.6.1623; YOUNG RH, 1978, AM J MED, V64, P998, DOI 10.1016/0002-9343(78)90455-2	33	892	929	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					70	75		10.1056/NEJM199207093270202	http://dx.doi.org/10.1056/NEJM199207093270202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603138				2022-12-28	WOS:A1992JC21400002
J	KARLIN, S; BRENDEL, V				KARLIN, S; BRENDEL, V			CHANCE AND STATISTICAL SIGNIFICANCE IN PROTEIN AND DNA-SEQUENCE ANALYSIS	SCIENCE			English	Article							MARKOV-CHAIN ANALYSIS; EPSTEIN-BARR VIRUS; ESCHERICHIA-COLI; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE-SEQUENCES; GROWTH-FACTOR; LYTIC ORIGIN; GENOME; IDENTIFICATION; METHYLATION	Statistical approaches help in the determination of significant configurations in protein and nucleic acid sequence data. Three recent statistical methods are discussed: (i) score-based sequence analysis that provides a means for characterizing anomalies in local sequence text and for evaluating sequence comparisons; (ii) quantile distributions of amino acid usage that reveal general compositional biases in proteins and evolutionary relations; and (iii) r-scan statistics that can be applied to the analysis of spacings of sequence markers.			KARLIN, S (corresponding author), STANFORD UNIV, DEPT MATH, STANFORD, CA 94305 USA.				NHGRI NIH HHS [HG00335-04] Funding Source: Medline; NIGMS NIH HHS [GM10452-29] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERS DG, 1991, J VIROL, V65, P931, DOI 10.1128/JVI.65.2.931-937.1991; ARRATIA R, 1989, ANN PROBAB, V17, P9, DOI 10.1214/aop/1176991491; ARRATIA R, 1985, ADV MATH, V55, P13, DOI 10.1016/0001-8708(85)90003-9; ARRATIA R, 1991, ANNU REV BIOPHYS BIO, V11, P806; Arratia R., 1990, STAT SCI, P403, DOI [10.1214/ss/1177012015, DOI 10.1214/SS/1177012015]; ASMUSSEN S, 1982, ADV APPL PROBAB, V14, P143, DOI 10.2307/1426737; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2247, DOI 10.1093/nar/19.suppl.2247; BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BELL G, 1989, COMPUTERS DNA, V7; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BEUTLER E, 1989, P NATL ACAD SCI USA, V86, P192, DOI 10.1073/pnas.86.1.192; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP YM, 1975, MULTIVARIATE ANAL TH; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLAISDELL BE, 1985, J MOL EVOL, V21, P278, DOI 10.1007/BF02102360; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENDEL V, 1992, MATH COMPUT MODEL, V16, P37, DOI 10.1016/0895-7177(92)90150-J; BRENDEL V, 1991, P NATL ACAD SCI USA, V88, P1536, DOI 10.1073/pnas.88.4.1536; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; BURGE C, 1992, P NATL ACAD SCI USA, V89, P1358, DOI 10.1073/pnas.89.4.1358; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHURCHILL GA, 1990, NUCLEIC ACIDS RES, V18, P589, DOI 10.1093/nar/18.3.589; CRESSIE N, 1977, AUSTR J STATIST, V19, P132; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEMBO A, 1991, ANN PROBAB, V19, P1737, DOI 10.1214/aop/1176990232; DEMBO A, 1991, ANN PROBAB, V19, P1756, DOI 10.1214/aop/1176990233; DEMBO A, 1992, ANN APPL PROBAB, V2, P304; DONOFRIO G, 1991, J MOL EVOL, V32, P504, DOI 10.1007/BF02102652; Doolittle R.F., 1990, MOL EVOLUTION COMPUT, V183; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1984, NATURE, V307, P558, DOI 10.1038/307558a0; DOOLITTLE RF, 1986, URFS ORFS, P55; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; Feller W., 1968, INTRO PROBABILITY TH, V2; GALAMBOS J, 1992, ASYMPTOTIC THEORY EX, V24, P113; GLAZ J, 1989, J AM STAT ASSOC, V84, P560; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HAMMERSCHMIDT W, 1988, CELL, V55, P427, DOI 10.1016/0092-8674(88)90028-1; HAMZEH FM, 1990, J VIROL, V64, P6184, DOI 10.1128/JVI.64.12.6184-6195.1990; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HOLST L, 1980, J APPL PROBAB, V17, P284, DOI 10.2307/3212948; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HOWARD B H, 1990, New Biologist, V2, P759; IGLEHART DL, 1972, ANN MATH STAT, V43, P627, DOI 10.1214/aoms/1177692642; IKEMURA T, 1990, GENOMICS, V8, P207, DOI 10.1016/0888-7543(90)90273-W; INMAN RB, 1966, J MOL BIOL, V18, P464, DOI 10.1016/S0022-2836(66)80037-2; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JOSSE J, 1961, J BIOL CHEM, V236, P864; JUKES TH, 1986, J MOL EVOL, V24, P39, DOI 10.1007/BF02099949; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KARLIN S, 1992, NUCLEIC ACIDS RES, V20, P1363, DOI 10.1093/nar/20.6.1363; KARLIN S, 1990, METHOD ENZYMOL, V183, P388; KARLIN S, 1991, NUCLEIC ACIDS RES, V19, P4241, DOI 10.1093/nar/19.15.4241; KARLIN S, 1990, P NATL ACAD SCI USA, V87, P2264, DOI 10.1073/pnas.87.6.2264; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KARLIN S, 1990, ANN STAT, V18, P571, DOI 10.1214/aos/1176347616; KARLIN S, 1991, ANNU REV BIOPHYS BIO, V20, P175, DOI 10.1146/annurev.bb.20.060191.001135; KARLIN S, 1981, 2ND COURSE STOCHASTI, pCH13; KARLIN S, UNPUB; KARLIN S, 1989, MATH METHODS DNA SEQ, P133; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOZHUKHIN CG, 1991, COMPUT APPL BIOSCI, V7, P39; KRAWIEC S, 1990, MICROBIOL REV, V54, P502, DOI 10.1128/MMBR.54.4.502-539.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDER E S, 1988, Genomics, V2, P231; LEHNINGER AL, 1975, BIOCHEMISTRY-US, P861; LEUNG MY, 1991, J MOL BIOL, V221, P1367, DOI 10.1016/0022-2836(91)90938-3; MARMUR J, 1962, J MOL BIOL, V5, P109, DOI 10.1016/S0022-2836(62)80066-7; MASSE MJO, 1992, P NATL ACAD SCI USA, V89, P5246, DOI 10.1073/pnas.89.12.5246; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MCMACKEN R, 1987, ESCHERICHIA COLI SAL, P564; MIKOLAS GLG, 1985, MOL EVOLUTIONARY GEN, P241; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOUCHIROND D, 1988, J MOL EVOL, V28, P7; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAKASHIMA H, 1986, J BIOCHEM-TOKYO, V99, P153, DOI 10.1093/oxfordjournals.jbchem.a135454; NAUS JI, 1979, INT STAT REV, V47, P47; NEY P, 1987, ANN PROBAB, V15, P561, DOI 10.1214/aop/1176992159; NUSSINOV R, 1987, J THEOR BIOL, V125, P219, DOI 10.1016/S0022-5193(87)80043-7; NUSSINOV R, 1981, J BIOL CHEM, V256, P8458; OHNO S, 1988, P NATL ACAD SCI USA, V85, P9630, DOI 10.1073/pnas.85.24.9630; PHILLIPS GJ, 1987, NUCLEIC ACIDS RES, V15, P2611, DOI 10.1093/nar/15.6.2611; REICH JG, 1984, NUCLEIC ACIDS RES, V12, P5529, DOI 10.1093/nar/12.13.5529; RUDD KE, 1991, NUCLEIC ACIDS RES, V19, P637, DOI 10.1093/nar/19.3.637; Sankoff D., 1983, TIME WARPS STRING ED; SCHACHTEL GA, 1991, J MOL EVOL, V33, P483, DOI 10.1007/BF02102801; SCHILDKRAUT CL, 1962, J MOL BIOL, V4, P430; SCHLEIF R, 1988, SCIENCE, V241, P1182, DOI 10.1126/science.2842864; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SHAPIRO HS, 1976, CRC HDB BIOCH MOL BI, V3, P241; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; STERNBERG N, 1985, J BACTERIOL, V164, P490, DOI 10.1128/JB.164.1.490-493.1985; STORMO GD, 1988, ANNU REV BIOPHYS BIO, V17, P241; STUCKLE EE, 1990, NUCLEIC ACIDS RES, V18, P6641, DOI 10.1093/nar/18.22.6641; SUEOKA N, 1961, COLD SPRING HARB SYM, V26, P35, DOI 10.1101/SQB.1961.026.01.009; VANHEEL M, 1991, J MOL BIOL, V220, P877, DOI 10.1016/0022-2836(91)90360-I; VINGRON M, 1989, COMPUT APPL BIOSCI, V5, P115; VONHEIJNE G, 1987, SEQUENCE AMA; WALLENSTEIN S, 1987, STAT MED, V6, P197, DOI 10.1002/sim.4780060212; Waterman M.S, 1989, MATH METHODS DNA SEQ; WATERMAN MS, 1987, P NATL ACAD SCI USA, V84, P1239, DOI 10.1073/pnas.84.5.1239; WATERMAN MS, 1984, B MATH BIOL, V46, P515; WILLIAMS ML, 1990, J ACQ IMMUN DEF SYND, V3, P192; ZUKER M, 1991, J MOL BIOL, V221, P403, DOI 10.1016/0022-2836(91)80062-Y; ZYSKIND JW, 1990, BACTERIAL CHROMOSOME, P269; [No title captured]	116	148	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 3	1992	257	5066					39	49		10.1126/science.1621093	http://dx.doi.org/10.1126/science.1621093			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621093				2022-12-28	WOS:A1992JC16500024
J	ANDERSON, C				ANDERSON, C			TEXAS-A-AND-M STRUGGLES TO GAIN THE RESPECT THAT ITS RESEARCHERS HAVE ALREADY WON	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					634	635		10.1038/357634a0	http://dx.doi.org/10.1038/357634a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614510				2022-12-28	WOS:A1992JA43000030
J	SWAFFIELD, JC; BROMBERG, JF; JOHNSTON, SA				SWAFFIELD, JC; BROMBERG, JF; JOHNSTON, SA			ALTERATIONS IN A YEAST PROTEIN RESEMBLING HIV TAT-BINDING PROTEIN RELIEVE REQUIREMENT FOR AN ACIDIC ACTIVATION DOMAIN IN GAL4	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; TRANSCRIPTION; ENZYMES; CELLS; CDNA	THE acidic transcriptional activation motif functions in all eukaryotes 1-4, which suggests that it makes contact with some universal component of the transcriptional apparatus. Transcriptional activation by the yeast regulatory protein GAL4 requires an acidic region at its carboxyl terminus. Here we implement a selection scheme to determine whether GAL4 can still function when this C-terminal domain has been deleted. It can, when accompanied by a mutation in the SUG1 gene which is an essential gene in yeast. Analysis of mutant SUG1 in combination with various alleles of GAL4 indicates that SUG1 acts through a transcriptional pathway that depends on GAL4, but requires a region of GAL4 other than the C-terminal acidic activation domain. The predicted amino-acid sequence of SUG1 closely resembles that of two human proteins, TBP1 and MSS1, which modulate expression mediated by the human immunodeficiency virus tat gene.	UNIV TEXAS,SW MED CTR,DEPT MED,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7582; EAKE KA, 1988, MOL CELL BIOL, V8, P4098; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; JOHNSTON M, 1988, GENETICS, V120, P63; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; MATSUMOTO K, 1980, J BACTERIOL, V141, P508, DOI 10.1128/JB.141.2.508-527.1980; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3	19	182	184	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					698	700		10.1038/357698a0	http://dx.doi.org/10.1038/357698a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614516				2022-12-28	WOS:A1992JA43000074
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PARALLEL TRACK POLICY ISSUED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							FED REGISTER, V57, P13250	1	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 24	1992	267	24					3262	3262		10.1001/jama.267.24.3262	http://dx.doi.org/10.1001/jama.267.24.3262			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY944	1597900				2022-12-28	WOS:A1992HY94400007
J	KATZ, Y; BOULOS, M; SINGER, P; ROSENBERG, B				KATZ, Y; BOULOS, M; SINGER, P; ROSENBERG, B			CARDIAC-ARREST ASSOCIATED WITH FLUMAZENIL	BRITISH MEDICAL JOURNAL			English	Letter							DEATH				KATZ, Y (corresponding author), RAMBAM MED CTR,POB 9602,IL-31096 HAIFA,ISRAEL.							BURR W, 1989, BRIT MED J, V298, P1713, DOI 10.1136/bmj.298.6689.1713-a; GELLER E, 1988, Resuscitation, V16, pS49, DOI 10.1016/0300-9572(88)90005-6; GELLER E, 1988, Resuscitation, V16, pS57, DOI 10.1016/0300-9572(88)90006-8; LIM AG, 1989, BRIT MED J, V299, P858, DOI 10.1136/bmj.299.6703.858-c; LOUIS M, 1984, Anesthesiology (Hagerstown), V61, pA61, DOI 10.1097/00000542-198409001-00061; ROUILLER M, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P1, DOI 10.1016/S0750-7658(87)80001-1; SHORT TG, 1988, BRIT MED J, V296, P1070, DOI 10.1136/bmj.296.6628.1070-e	7	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1415	1415		10.1136/bmj.304.6839.1415-b	http://dx.doi.org/10.1136/bmj.304.6839.1415-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628018	Bronze, Green Published			2022-12-28	WOS:A1992HX08200022
J	GLENN, JS; WATSON, JA; HAVEL, CM; WHITE, JM				GLENN, JS; WATSON, JA; HAVEL, CM; WHITE, JM			IDENTIFICATION OF A PRENYLATION SITE IN DELTA-VIRUS LARGE ANTIGEN	SCIENCE			English	Article							GENOME REPLICATION; MOLECULAR-CLONING; HEPATITIS; RNA; PROTEINS; AGENT; SERUM; LIVER; CELLS; HETEROGENEITY	During replication, hepatitis delta virus (HDV) switches from production of small to large delta antigen. Both antigen isoforms have an HDV genome binding domain and are packaged into hepatitis B virus (HBV)-derived envelopes but differ at their carboxyl termini. The large antigen was shown to contain a terminal CXXX box and undergo prenylation. The large, but not the small, antigen formed secreted particles when expressed singly with HBV surface antigen. Mutation of Cys211 in the CXXX box of the large antigen abolished both prenylation and particle formation, suggesting that this site is important for virion morphogenesis.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	GLENN, JS (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA.							BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BERGMANN KF, 1986, J INFECT DIS, V154, P702, DOI 10.1093/infdis/154.4.702; BONINO F, 1986, J VIROL, V58, P945, DOI 10.1128/JVI.58.3.945-950.1986; BONINO F, 1984, INFECT IMMUN, V43, P1000, DOI 10.1128/IAI.43.3.1000-1005.1984; BRUSS V, 1991, J VIROL, V65, P3813, DOI 10.1128/JVI.65.7.3813-3820.1991; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHAO YC, 1991, HEPATOLOGY, V13, P345, DOI 10.1016/0270-9139(91)92451-D; DENY P, 1991, J GEN VIROL, V72, P735, DOI 10.1099/0022-1317-72-3-735; ELLENS H, 1989, METHOD CELL BIOL, V31, P155; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLENN J, UNPUB; GLENN JS, 1991, J VIROL, V65, P2357, DOI 10.1128/JVI.65.5.2357-2361.1991; GLENN JS, 1990, J VIROL, V64, P3104, DOI 10.1128/JVI.64.6.3104-3107.1990; GLENN JS, 1992, THESIS U CALIFORNIA; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOOFNAGLE JH, 1989, JAMA-J AM MED ASSOC, V261, P1321, DOI 10.1001/jama.261.9.1321; IMAZEKI F, 1990, J VIROL, V64, P5594, DOI 10.1128/JVI.64.11.5594-5599.1990; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; KUO MYP, 1988, J VIROL, V62, P1855, DOI 10.1128/JVI.62.6.1855-1861.1988; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; RAMIG RF, 1990, VIROLOGY, P112; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RIZZETTO M, 1980, J INFECT DIS, V141, P590, DOI 10.1093/infdis/141.5.590; RIZZETTO M, 1980, P NATL ACAD SCI-BIOL, V77, P6124, DOI 10.1073/pnas.77.10.6124; RYU WS, IN PRESS J VIROL; RYU WS, UNPUB; SALDANHA JA, 1990, J GEN VIROL, V71, P1603, DOI 10.1099/0022-1317-71-7-1603; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SUREAU C, COMMUNICATION; WANG CJ, 1991, J VIROL, V65, P6630, DOI 10.1128/JVI.65.12.6630-6636.1991; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; XIA YP, 1990, VIROLOGY, V178, P331, DOI 10.1016/0042-6822(90)90415-N	39	230	245	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 29	1992	256	5061					1331	1333		10.1126/science.1598578	http://dx.doi.org/10.1126/science.1598578			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HW135	1598578				2022-12-28	WOS:A1992HW13500037
J	JANSSEN, RS; STLOUIS, ME; SATTEN, GA; CRITCHLEY, SE; PETERSEN, LR; STAFFORD, RS; WARD, JW; HANSON, DL; OLIVO, N; SCHABLE, CA; DONDERO, TJ				JANSSEN, RS; STLOUIS, ME; SATTEN, GA; CRITCHLEY, SE; PETERSEN, LR; STAFFORD, RS; WARD, JW; HANSON, DL; OLIVO, N; SCHABLE, CA; DONDERO, TJ			HIV-INFECTION AMONG PATIENTS IN UNITED-STATES ACUTE CARE HOSPITALS - STRATEGIES FOR THE COUNSELING AND TESTING OF HOSPITAL PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SENTINEL HOSPITALS; RISK; SURVEILLANCE; EPIDEMIOLOGY; EMERGENCY; WORKERS	Background. Routine, voluntary testing of hospital patients for the human immunodeficiency virus (HIV) has been proposed in order to identify those with early HIV infection in a setting where there is ready access to counseling, appropriate clinical referral, evaluation, and therapy. We studied the pattern of HIV infection among patients in 20 U.S. hospitals, in order to evaluate possible national strategies for the routine, voluntary HIV counseling and testing of hospital patients. Methods. Blood specimens remaining after clinical use from a systematically selected sample of patients at 20 hospitals in 15 U.S. cities were tested anonymously for antibody to HIV type 1 (HIV-1). Multivariate regression was used to determine which variables best predicted HIV seroprevalence in individual hospitals. Using these data, we estimated the number of HIV-positive patients in all U.S. hospitals and considered the efficiency of routine counseling and testing in different subgroups of patients and hospitals. Results. From September 1989 through October 1991, 9286 of 195,829 specimens (4.7 percent) were positive for HIV-1 in the 20 hospitals. The seroprevalence of HIV at these institutions ranged from 0.2 percent to 14.2 percent. Among HIV-positive patients, 32 percent had symptomatic HIV infection or the acquired immunodeficiency syndrome (AIDS) at the time of admission or evaluation. In the 20 hospitals, HIV seroprevalence was 10.4 times (95 percent confidence interval, 8.8 to 12.0) the AIDS-diagnosis rate (the annual number of patients with new diagnoses of AIDS per 1000 discharges in 1990). In a multivariate model that included 13 hospital-specific variables, only the AIDS-diagnosis rate was associated with the hospital-specific HIV-seroprevalence rate (P<0.001). Using these data and the AIDS-diagnosis rates for all U.S. acute care hospitals, we estimated that 225,000 HIV-positive persons were hospitalized (95 percent confidence interval, 190,000 to 260,000) in all 5558 such hospitals in 1990, including 163,000 persons presenting with conditions other than HIV or AIDS (95 percent confidence interval, 130,000 to 196,000). In 1990, in 593 U.S. hospitals with AIDS-diagnosis rates of 1.0 or more per 1000 discharges, HIV testing of patients 15 to 54 years old (3 million patients, or 12.0 percent of all patients in U.S. acute care hospitals) would have identified an estimated 68 percent of all HIV-positive patients (110,000 patients) who were admitted with conditions other than symptomatic HIV infection or AIDS. Conclusions. We estimate that about 225,000 HIV-positive persons were hospitalized in 1990, of whom only one third were admitted for symptomatic HIV infection or AIDS. Routine, voluntary HIV testing of patients 15 to 54 years old in hospitals with 1 or more patients with newly diagnosed AIDS per 1000 discharges per year could potentially have identified as many as 110,000 patients with HIV infection that was previously unrecognized.	CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AID,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,AIDS SURVEILLANCE BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL,DIV HUMAN IMMUNODEFICIENCY VIRUS AIDS,LAB INVEST BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Stafford, Randall/F-3974-2017	Stafford, Randall/0000-0003-1805-1271; Satten, Glen/0000-0001-7275-5371				ANGELL M, 1991, NEW ENGL J MED, V324, P1498, DOI 10.1056/NEJM199105233242110; BERKELMAN RL, 1989, AM J MED, V86, P761, DOI 10.1016/0002-9343(89)90470-1; BRENNAN TA, 1991, NEW ENGL J MED, V324, P1504, DOI 10.1056/NEJM199105233242112; CASTRO KG, 1988, JAMA-J AM MED ASSOC, V259, P1338, DOI 10.1001/jama.259.9.1338; Centers for Disease Control (CDC), 1986, MMWR Morb Mortal Wkly Rep, V35, P334; FARIZO KM, 1992, JAMA-J AM MED ASSOC, V267, P1798, DOI 10.1001/jama.267.13.1798; GORDIN FM, 1990, J INFECT DIS, V161, P14, DOI 10.1093/infdis/161.1.14; HARRIS RL, 1990, INFECT CONT HOSP EP, V11, P628; HENRY K, 1992, PUBLIC HEALTH REP, V107, P138; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; KELEN GD, 1989, JAMA-J AM MED ASSOC, V262, P516, DOI 10.1001/jama.262.4.516; KELEN GD, 1988, NEW ENGL J MED, V318, P1645, DOI 10.1056/NEJM198806233182503; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; LOMBARDO JM, 1991, ARCH INTERN MED, V151, P965, DOI 10.1001/archinte.151.5.965; MARCUS R, 1990, 6TH INT C AIDS SAN F, V1, P276; RHAME FS, 1989, NEW ENGL J MED, V320, P1248, DOI 10.1056/NEJM198905113201905; RISI GF, 1989, SOUTHERN MED J, V82, P1079, DOI 10.1097/00007611-198909000-00005; STLOUIS ME, 1990, NEW ENGL J MED, V323, P213, DOI 10.1056/NEJM199007263230401; STLOUIS ME, 1990, PUBLIC HEALTH REP, V105, P140; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1990, MMWR MORB MORT SRR8, V39; 1991, MMWR MORB MOTAL WKLY, V40, P1; 1992, HIV AIDS SURVEIL JAN; 1987, MMWR MORB MORTAL S1S, V36, pS1; 1989, MMWR MORB MORTAL SS7, V38; 1991, AHA ANN SURVEY HOSPI; 1990, NATIONAL HLTH INTERV; 1990, MMWR MORB MORT SRR16, V39, P1; 1989, MMWR MORB MORTAL SS5, V38; 1990, SAS STAT USERS GUIDE, V2; 1986, MMWR MORB MOTAL WKLY, V35, P152	31	109	109	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	1992	327	7					445	452		10.1056/NEJM199208133270701	http://dx.doi.org/10.1056/NEJM199208133270701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JH340	1625734				2022-12-28	WOS:A1992JH34000001
J	AUSTIN, SC; STOLLEY, PD; LASKY, T				AUSTIN, SC; STOLLEY, PD; LASKY, T			THE HISTORY OF MALARIOTHERAPY FOR NEUROSYPHILIS - MODERN PARALLELS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS TRIALS; THERAPY; DESIGN		UNIV MARYLAND, SCH MED, DEPT EPIDEMIOL & PREVENT MED, 600 REDWOOD ST, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore			Lasky, Tamar/AAR-3410-2021					Bennett AE, 1938, ARCH NEURO PSYCHIATR, V40, P1141, DOI 10.1001/archneurpsyc.1938.02270120091006; Bierman W, 1942, Bull N Y Acad Med, V18, P65; Bunker HA, 1926, ARCH NEURO PSYCHIATR, V16, P182, DOI 10.1001/archneurpsyc.1926.02200260054004; BUNKER HA, 1928, B N Y ACAD MED 2, V4, P307; BYAR DP, 1990, NEW ENGL J MED, V323, P1343, DOI 10.1056/NEJM199011083231912; CLANCY FJ, 1927, NW MED, V26, P427; Dattner B, 1944, MANAGEMENT NEUROSYPH; DELANEY M, 1989, J INFECT DIS, V159, P416, DOI 10.1093/infdis/159.3.416; EDGAR H, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350178; FONG Theodore C. C., 1937, Southern Medical Journal, V30, P1084, DOI 10.1097/00007611-193711000-00012; GREEN SB, 1990, CONTROL CLIN TRIALS, V11, P80, DOI 10.1016/0197-2456(90)90002-J; KOLMER JA, 1926, PRINCIPLES PRACTICE; KRAUSS William, 1932, Southern Medical Journal, V25, P537, DOI 10.1097/00007611-193205000-00021; KUPPER WH, 1939, MALARIAL THERAPY GEN; Levi Jeffrey, 1991, BIOMEDICAL POLITICS, p[9, 14]; MERIGAN TC, 1990, NEW ENGL J MED, V323, P1341, DOI 10.1056/NEJM199011083231911; MOORE JE, 1946, PENICILLIN SYPHILIS; Moore JE, 1933, MODERN TREATMENT SYP, DOI [10.1001/jama.1943.02840480071034, DOI 10.1001/JAMA.1943.02840480071034]; O Leary PA, 1927, J AMER MED ASSOC, V89, P95, DOI 10.1001/jama.1927.02690020019007; PARRAN T, 1937, SHADOW LAND; PILCZ A, 1905, JB PSYCHIAT NEUROL, V25, P141; Rudolf G.d.M., 1927, THERAPEUTIC MALARIA; Schamberg J F, 1928, Bull N Y Acad Med, V4, P329; Schonbauer L, 1950, LEBENSERINNERUNGEN; Stone C W, 1928, Bull N Y Acad Med, V4, P322; Vedder Edward Bright, 1918, SYPHILIS PUBLIC HLTH; Wagner-Jauregg, 1922, J NERV MENT DIS, V55, P369, DOI 10.1097/00005053-192205000-00001; WAGNERJAUREGG J, 1965, NOBEL LECT PHYSL MED, P159; WHITROW M, 1990, MED HIST, V34, P294, DOI 10.1017/S0025727300052431	29	53	54	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	1992	268	4					516	519		10.1001/jama.268.4.516	http://dx.doi.org/10.1001/jama.268.4.516			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD472	1619744				2022-12-28	WOS:A1992JD47200027
J	FINKEL, MS; ODDIS, CV; JACOB, TD; WATKINS, SC; HATTLER, BG; SIMMONS, RL				FINKEL, MS; ODDIS, CV; JACOB, TD; WATKINS, SC; HATTLER, BG; SIMMONS, RL			NEGATIVE INOTROPIC EFFECTS OF CYTOKINES ON THE HEART MEDIATED BY NITRIC-OXIDE	SCIENCE			English	Article							MYOCARDIAL INJURY; REPERFUSION; DYSFUNCTION; NEUTROPHIL; ISCHEMIA; CELLS	The direct effects of pro-inflammatory cytokines on the contractility of mammalian heart were studied. Tumor necrosis factor-alpha, interleukin-6, and interleukin-2 inhibited contractility of isolated hamster papillary muscles in a concentration-dependent, reversible manner. The nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine (L-NMMA) blocked these negative inotropic effectS. L-Arginine reversed the inhibition by L-NMMA. Removal of the endocardial endothelium did not alter these responses. These findings demonstrate that the direct negative inotropic effect of cytokines is mediated through a myocardial nitric oxide synthase. The regulation of pro-inflammatory cytokines and myocardial nitric oxide synthase may provide new therapeutic strategies for the treatment of cardiac disease.	UNIV PITTSBURGH, SCH MED, DEPT NEUROBIOL ANAT & CELL SCI, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15213 USA; UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	FINKEL, MS (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT MED, PITTSBURGH, PA 15213 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-37753] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; DEAGOSTINI AI, 1990, J CELL BIOL, V111, P1293, DOI 10.1083/jcb.111.3.1293; ENGLER R, 1987, CIRC RES, V61, P20, DOI 10.1161/01.RES.61.1.20; FINKEL MS, 1992, J CARDIOVASC PHARM, V19, P610, DOI 10.1097/00005344-199204000-00019; GARMAN RD, 1987, P NATL ACAD SCI USA, V84, P7629, DOI 10.1073/pnas.84.21.7629; GO LO, 1988, AM J PHYSIOL, V255, pH1188, DOI 10.1152/ajpheart.1988.255.5.H1188; GREEN SJ, 1991, J LEUKOCYTE BIOL, V50, P93, DOI 10.1002/jlb.50.1.93; GROSS SS, 1991, BIOCHEM BIOPH RES CO, V178, P823, DOI 10.1016/0006-291X(91)90965-A; HATTIER BG, 1991, 20TH ANN M KEYST S M; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; LI LM, 1991, CANCER RES, V51, P2531; LUCCHESI BR, 1989, J MOL CELL CARDIOL, V21, P1241, DOI 10.1016/0022-2828(89)90670-6; MONCADA S, 1991, J CARDIOVASC PHARM, V17, pS1, DOI 10.1097/00005344-199117003-00002; MULLANE KM, 1988, ANN NY ACAD SCI, V524, P103; NALDINI A, 1987, J IMMUNOL, V139, P1880; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; SHAH AM, 1991, J CARDIOVASC PHARM, V17, pS251, DOI 10.1097/00005344-199117003-00046; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; VANDAMME J, 1987, J EXP MED, V165, P914, DOI 10.1084/jem.165.3.914; WESTLIN W, 1989, CIRCULATION, V80, P1828, DOI 10.1161/01.CIR.80.6.1828	20	1423	1519	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 17	1992	257	5068					387	389		10.1126/science.1631560	http://dx.doi.org/10.1126/science.1631560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JD674	1631560				2022-12-28	WOS:A1992JD67400034
J	REIBER, GE; PECORARO, RE; KOEPSELL, TD				REIBER, GE; PECORARO, RE; KOEPSELL, TD			RISK-FACTORS FOR AMPUTATION IN PATIENTS WITH DIABETES-MELLITUS - A CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETES-MELLITUS; AMPUTATION; PATIENT EDUCATION; DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES	PERIPHERAL VASCULAR-DISEASE; LOWER-EXTREMITY AMPUTATIONS; FOLLOW-UP; LIMB AMPUTATION; MORTALITY; PREVENTION; FRAMINGHAM; SMOKING; HEALTH	Objective: To identify and quantify risk factors for lower extremity amputation in persons with diabetes mellitus. Design: Case-control study. Setting: A Veterans Affairs medical center. Patients: Eighty patients having amputation associated with diabetes and 236 diabetic controls without limb lesions were enrolled before surgery from the 21 167 inpatient care and outpatient surgical patients seen at the Seattle Veterans Affairs Medical Center during a 30-month period. Measurements: Selected vascular, neuropathic, environmental, health care, self care, nutritional, metabolic, lifestyle, and psychosocial risk factors were measured in all patients before surgery. Results: Statistically significant risk factors identified from analysis included insufficient mean below-knee and foot cutaneous circulation (odds ratio, 161; 95% CI, 55.1 to 469); ankle-arm blood pressure index < 0.45 (odds ratio, 55.8; CI, 14.9 to 209); absence of lower leg vibratory perception (odds ratio, 15.5; CI, 8.3 to 28.7); low levels of high-density lipoprotein (HDL) subfraction 3 less-than-or-equal-to 0.7-mu-mol/L (odds ratio, 4.9; CI, 2.9 to 8.3); and no previous outpatient diabetes education (odds ratio, 3.2; CI, 1.6 to 6.6). A logistic regression analysis done to control for the potentially confounding effects of age; race; socioeconomic status; diabetes duration, type, and severity confirmed these findings and added a statistically significant interaction between foot transcutaneous oxygen tension and peripheral vascular disease history. Clinical interventions to alter these risk factors were identified, including aggressive treatment of infection, diabetes education, protective footwear, and preventive footcare. Conclusions: Multiple risk factors exist along the continuum of conditions and events leading to lower extremity amputation in diabetes. Modification of certain risk factors by patients and health professionals may reduce the risk for amputation and thus decrease the human and dollar costs that accompany limb loss in this prevalent chronic disease.			REIBER, GE (corresponding author), VET ADM MED CTR, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.							[Anonymous], 1985, DIABETOLOGIA, V28, P615, DOI [10.1007/BF00290267, DOI 10.1007/BF00290267]; Bachorik P S, 1986, Methods Enzymol, V129, P78; BAGDADE JD, 1974, DIABETES, V23, P9, DOI 10.2337/diab.23.1.9; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; Davis W, 1980, IARC SCI PUBL, V32, P192; DAVIS WK, 1988, DIABETES CARE, V11, P538, DOI 10.2337/diacare.11.7.538; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FELGAL DW, 1989, RISK FACTORS AMPUTAT; FRONEK A, 1985, NONINVASIVE DIAGNOSI, P697; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; GOODSON WH, 1979, SURG GYNECOL OBSTET, V149, P600; GORDON T, 1972, J AMER MED ASSOC, V221, P661, DOI 10.1001/jama.221.7.661; HAUSER CJ, 1987, ARCH SURG-CHICAGO, V122, P1128; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; HOWARD BV, 1987, J LIPID RES, V28, P613; KLEIN BEK, 1984, OPHTHALMOLOGY, V91, P10; KNIGHTON DR, 1986, ANN SURG, V204, P322, DOI 10.1097/00000658-198609000-00011; KREINES K, 1985, DIABETES CARE, V8, P235, DOI 10.2337/diacare.8.3.235; LABBE RF, 1989, SEMIN HEMATOL, V26, P40; LEVIN ME, 1988, DIABETIC FOOT, P1; LIEDBERG E, 1983, ACTA ORTHOP SCAND, V54, P383, DOI 10.3109/17453678308996589; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MANTEL N, 1959, J NATL CANCER I, V22, P719; MATTOCK MB, 1982, ATHEROSCLEROSIS, V45, P67, DOI 10.1016/0021-9150(82)90172-1; Miller A D, 1985, J Med Soc N J, V82, P723; MOST RS, 1983, DIABETES CARE, V6, P87, DOI 10.2337/diacare.6.1.87; NELSON RG, 1988, DIABETES CARE, V11, P8, DOI 10.2337/diacare.11.1.8; OGBUAWA O, 1982, SOUTHERN MED J, V75, P285, DOI 10.1097/00007611-198203000-00010; osmer D. W, 1989, APPL LOGISTIC REGRES, P38; PECORARO R, 1990, WOUNDS, V2, P65; PECORARO R E, 1988, Diabetes Research and Clinical Practice, V5, pS398; PECORARO RE, 1991, PROG CLIN BIOL RES, V365, P27; PECORARO RE, 1990, DIABETES CARE, V13, P513, DOI 10.2337/diacare.13.5.513; PECORARO RE, 1979, DIABETES, V28, P1120, DOI 10.2337/diabetes.28.12.1120; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; REIBER GE, 1990, DIABETES, V39, pA18; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; RUTKOW IM, 1986, J BONE JOINT SURG AM, V68A, P716, DOI 10.2106/00004623-198668050-00011; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P171; SHOPLAND DR, 1987, PUBLIC HEALTH REP, V102, P68; SKYLER JS, 1980, DIABETES CARE, V3, P369, DOI 10.2337/diacare.3.2.369; STEWART AL, 1980, R23742HEW RAND, P20; Warnick G R, 1986, Methods Enzymol, V129, P101; WEST KM, 1978, EPIDEMIOLOGY DIABETE, P391; WHEELOCK FC, 1984, MANAGEMENT DIABETIC, P188; WYSS CR, 1984, SURGERY, V95, P339; 1990, 1990 CTR DIS CONTR D, P24; 1980, DHEW NIH801527 PUBL, P52; 1987, DHHS NIH871587 PUBL; 1963, 15 US BUR CENS WORK, P1; 1982, DHHS PHS825017 DEP H; 1980, DHHS PHS801260 DEP H, P235	54	332	341	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					97	105		10.7326/0003-4819-117-2-97	http://dx.doi.org/10.7326/0003-4819-117-2-97			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605439				2022-12-28	WOS:A1992JD12300001
J	RYAN, JB; MCBRIDE, JT				RYAN, JB; MCBRIDE, JT			SPORTS MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REHABILITATION; KNEE		FITZSIMONS ARMY MED CTR,AURORA,CO 80045		RYAN, JB (corresponding author), LETTERMAN ARMY INST RES,SAN FRANCISCO,CA 94129, USA.							ANDERSON WA, 1991, PHYSICIAN SPORTSMED, V19, P91; ARNOCZKY SP, 1988, J BONE JOINT SURG AM, V70A, P1209, DOI 10.2106/00004623-198870080-00012; ARNOCZKY SP, 1990, CLIN ORTHOP RELAT R, V252, P121; CASE J G, 1991, Athletic Training, V26, P22; COX JS, 1990, AM J SPORT MED, V18, P568, DOI 10.1177/036354659001800602; DICK R W, 1991, Athletic Training, V26, P138; ENSTROM B, 1991, AM J SPORTS MED, V19, P372; HANKS GA, 1990, AM J SPORT MED, V18, P606, DOI 10.1177/036354659001800609; HENNING CE, 1991, AM J SPORT MED, V19, P626, DOI 10.1177/036354659101900613; IRELAND ML, 1991, OCT ORTH GUILD WASH; KAUFMAN KR, 1991, AM J SPORT MED, V19, P305, DOI 10.1177/036354659101900317; LOOSLI AR, 1992, AM J SPORT MED, V20, P35, DOI 10.1177/036354659202000110; OHKOSHI Y, 1991, AM J SPORT MED, V19, P605, DOI 10.1177/036354659101900609; PERRY PJ, 1990, AM J SPORT MED, V18, P422, DOI 10.1177/036354659001800416; QUADAGNO D, 1991, PHYSICIAN SPORTSMED, V19, P121; SHELBOURNE KD, 1990, AM J SPORT MED, V18, P292, DOI 10.1177/036354659001800313; STEADMAN JR, 1989, CLIN SPORT MED, V8, P605; Stone K. R., 1990, CLIN ORTHOP RELAT R, V252, P129; WARREN RF, 1990, CLIN ORTHOP RELAT R, V252, P55; WILSON C A, 1991, Athletic Training, V26, P170	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					411	412						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613940				2022-12-28	WOS:A1992JC35200053
J	STANLEY, CA; HALE, DE; BERRY, GT; DELEEUW, S; BOXER, J; BONNEFONT, JP				STANLEY, CA; HALE, DE; BERRY, GT; DELEEUW, S; BOXER, J; BONNEFONT, JP			A DEFICIENCY OF CARNITINE ACYLCARNITINE TRANSLOCASE IN THE INNER MITOCHONDRIAL-MEMBRANE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DEHYDROGENASE-DEFICIENCY; LIVER-MITOCHONDRIA; TRANSPORT; HYPERORNITHINEMIA; HOMOCITRULLINURIA; HYPERAMMONEMIA; HYPOGLYCEMIA; FIBROBLASTS; CARRIER; MUSCLE		CHILDRENS HOSP PHILADELPHIA,DIV METAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PEDIAT,PHILADELPHIA,PA 19104; HOP NECKER ENFANTS MALAD,GENET MED CLIN,PARIS,FRANCE	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	STANLEY, CA (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV ENDOCRINE DIABET,34TH ST & CIV CTR BLVD,PHILADELPHIA,PA 19104, USA.			STANLEY, CHARLES/0000-0003-4881-9392; BONNEFONT, Jean-Paul/0000-0002-4235-1197; Berry, Gerard/0000-0001-5299-3313	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS017752] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00240] Funding Source: Medline; NINDS NIH HHS [NS 17752] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CORR PB, 1989, J CLIN INVEST, V83, P927, DOI 10.1172/JCI113978; DEMAUGRE F, 1988, PEDIATR RES, V24, P308, DOI 10.1203/00006450-198809000-00006; DEMAUGRE F, 1991, J CLIN INVEST, V87, P859, DOI 10.1172/JCI115090; GORDON BA, 1987, CLIN INVEST MED, V10, P329; HALE DE, 1985, PEDIATR RES, V19, P666, DOI 10.1203/00006450-198507000-00006; HALE DE, 1990, PROG CLIN BIOL RES, V321, P303; INDIVERI C, 1990, BIOCHIM BIOPHYS ACTA, V1020, P81, DOI 10.1016/0005-2728(90)90096-M; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P231, DOI 10.1016/0005-2736(91)90235-Z; INOUE I, 1988, BIOCHIM BIOPHYS ACTA, V964, P90, DOI 10.1016/0304-4165(88)90071-2; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGARRY JD, 1976, J LIPID RES, V17, P277; MURTHY MSR, 1986, BIOCHEM J, V236, P143, DOI 10.1042/bj2360143; PANDE SV, 1980, J BIOL CHEM, V255, P2994; PARVIN R, 1977, ANAL BIOCHEM, V79, P190, DOI 10.1016/0003-2697(77)90393-1; SCHMIDTSOMMERFE.E, IN PRESS PROGR CLIN; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; SHIH VE, 1982, CLIN CHIM ACTA, V118, P149, DOI 10.1016/0009-8981(82)90002-X; Stanley C A, 1987, Adv Pediatr, V34, P59; STANLEY CA, 1983, PEDIATR RES, V17, P877, DOI 10.1203/00006450-198311000-00008; STANLEY CA, 1991, ANN NEUROL, V30, P709, DOI 10.1002/ana.410300512; STANLEY CA, 1976, PEDIATRICS, V57, P702; STANLEY CA, IN PRESS J INHERIT M; TEIN I, 1991, ANN NEUROL, V30, P415, DOI 10.1002/ana.410300315; TREEM WR, 1991, PEDIATRICS, V87, P328; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; VICI CD, 1991, J PEDIATR-US, V118, P744, DOI 10.1016/S0022-3476(05)80039-3; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090	28	142	146	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	1992	327	1					19	23		10.1056/NEJM199207023270104	http://dx.doi.org/10.1056/NEJM199207023270104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA761	1598097	Bronze			2022-12-28	WOS:A1992JA76100004
J	MACMILLAN, L; PRINGLE, M				MACMILLAN, L; PRINGLE, M			MANAGING CHANGE IN PRIMARY CARE .6. PRACTICE MANAGERS AND PRACTICE MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article									DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND									DORNAN M, 1991, BRIT MED J, V303, P146, DOI 10.1136/bmj.303.6795.146; PRINGLE M, 1991, MANAGING CHANGE GENE	2	1	1	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1672	1674		10.1136/bmj.304.6843.1672	http://dx.doi.org/10.1136/bmj.304.6843.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633522	Bronze, Green Published			2022-12-28	WOS:A1992JB93900025
J	CULLITON, BJ				CULLITON, BJ			SAN-ANTONIO FILLS RESEARCH PARK BY MAKING OFFERS THAT SCIENTISTS CANNOT REFUSE	NATURE			English	Editorial Material																		GERSHON D, 1992, NATURE, V357, P638, DOI 10.1038/357638a0	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					631	631		10.1038/357631a0	http://dx.doi.org/10.1038/357631a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614509	Bronze			2022-12-28	WOS:A1992JA43000027
J	ROBERTS, DJ; CRAIG, AG; BERENDT, AR; PINCHES, R; NASH, G; MARSH, K; NEWBOLD, CI				ROBERTS, DJ; CRAIG, AG; BERENDT, AR; PINCHES, R; NASH, G; MARSH, K; NEWBOLD, CI			RAPID SWITCHING TO MULTIPLE ANTIGENIC AND ADHESIVE PHENOTYPES IN MALARIA	NATURE			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; HUMAN CEREBRAL MALARIA; PLASMODIUM-FALCIPARUM; PARASITIZED ERYTHROCYTES; MEMBRANE GLYCOPROTEIN; CONTINUOUS CULTURE; CYTOADHERENCE; EXPRESSION; SEQUESTRATION; RECEPTOR	ADHESION of parasitized erythrocytes to post-capillary venular endothelium 1 or uninfected red cells 2-4 is strongly implicated in the pathogenesis of severe Plasmodium falciparum malaria. Neoantigens at the infected red-cell surface adhere to a variety of host receptors 5-9, demonstrate serological diversity in field isolates 10,11 and may also be a target of the host-protective immune response 12. Here we use sequential cloning of P. falciparum by micromanipulation to investigate the ability of a parasite to switch antigenic and cytoadherence phenotypes. Our data show that antigens at the parasitized cell surface undergo clonal variation in vitro in the absence of immune pressure at the rate of 2% per generation with concomitant modulations of the adhesive phenotype. A clone has the potential to switch at high frequency to a variety of antigenic and adhesive phenotypes, including a new type of cytoadherence behaviour, 'auto-agglutination' of infected erythrocytes. This rapid appearance of antigenic and functional heterogeneity has important implications for pathogenesis and acquired immunity.	UNIV BIRMINGHAM,DEPT HAEMATOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	ROBERTS, DJ (corresponding author), JOHN RADCLIFFE HOSP,INST MOLEC MED,MOLEC PARASITOL GRP,OXFORD OX3 9DU,ENGLAND.		Nash, Gerard B/E-4182-2010	Nash, Gerard B/0000-0002-5935-2831; Craig, Alister/0000-0003-0914-6164; Newbold, Chris/0000-0002-9274-3789	Wellcome Trust [061524] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAERENDT AR, 1992, CELL, V8, P71; BAIRD JK, 1991, AM J TROP MED HYG, V45, P65, DOI 10.4269/ajtmh.1991.45.65; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BARNWELL JW, 1983, INFECT IMMUN, V40, P985, DOI 10.1128/IAI.40.3.985-994.1983; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BIGGS BA, 1991, P NATL ACAD SCI USA, V88, P9171, DOI 10.1073/pnas.88.20.9171; BIGGS BA, IN PRESS J IMMUN; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0; CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N; DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; HANDUNNETTI SM, 1987, J EXP MED, V165, P1269, DOI 10.1084/jem.165.5.1269; HAYNES JD, 1976, NATURE, V263, P767, DOI 10.1038/263767a0; JENSEN JB, 1978, AM J TROP MED HYG, V27, P1274, DOI 10.4269/ajtmh.1978.27.1274; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MAGOWAN C, 1988, J EXP MED, V168, P1307, DOI 10.1084/jem.168.4.1307; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MCLEAN SA, 1982, EXP PARASITOL, V54, P296, DOI 10.1016/0014-4894(82)90038-8; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; SINNIS P, 1988, GENOMICS, V3, P287, DOI 10.1016/0888-7543(88)90117-6; TANDON NN, 1989, J BIOL CHEM, V264, P7570; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835	30	524	530	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					689	692		10.1038/357689a0	http://dx.doi.org/10.1038/357689a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614515	Green Accepted			2022-12-28	WOS:A1992JA43000071
J	LEFEBVRE, DL; GIAID, A; BENNETT, H; LARIVIERE, R; ZINGG, HH				LEFEBVRE, DL; GIAID, A; BENNETT, H; LARIVIERE, R; ZINGG, HH			OXYTOCIN GENE-EXPRESSION IN RAT UTERUS	SCIENCE			English	Article							HUMAN PARTURITION; LOCALIZATION; INITIATION; LACTATION; RECEPTORS; ELEMENT; LABOR	The neurohypophyseal hormone oxytocin (OT) is the most potent uterotonic agent known and is used to induce labor. Yet, endogenous circulating OT appears not to participate in the induction of labor. As shown here, the finding of OT messenger RNA and peptide in the uterus suggests a solution for this paradox. During gestation, rat uterus OT messenger RNA increased more than 150-fold and, at term, exceeded hypothalamic OT messenger RNA by 70-fold. Thus, during parturition, OT may act primarily as a local mediator and not as a circulating hormone.	MCGILL UNIV,ROYAL VICTORIA HOSP,MOLEC ENDOCRINOL LAB,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,MONTREAL GEN HOSP,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,ROYAL VICTORIA HOSP,ENDOCRINE LAB,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital; McGill University; McGill University; Royal Victoria Hospital			Zingg, Hans/GPS-9984-2022					AKERLUND M, 1987, BRIT J OBSTET GYNAEC, V94, P1040, DOI 10.1111/j.1471-0528.1987.tb02287.x; ALE CC, 1961, J ENDOCRINOL, V22, P107; AYAD VJ, 1991, J ENDOCRINOL, V128, P187, DOI 10.1677/joe.0.1280187; BARASH I, 1988, ENDOCRINOLOGY, V122, P1151, DOI 10.1210/endo-122-3-1151; CHARD T, 1989, AM J PERINAT, V6, P145, DOI 10.1055/s-2007-999566; CIAROCHI FF, 1985, PEPTIDES, V6, P903, DOI 10.1016/0196-9781(85)90321-3; COLLINS S, 1990, J BIOL CHEM, V265, P19330; DEGEEST K, 1985, J PERINAT MED, V13, P3, DOI 10.1515/jpme.1985.13.1.3; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; FUCHS AR, 1982, SCIENCE, V215, P1396, DOI 10.1126/science.6278592; FUCHS AR, 1984, BRIT J OBSTET GYNAEC, V91, P948, DOI 10.1111/j.1471-0528.1984.tb03671.x; GIRALDI A, 1990, DAN MED BULL, V37, P377; GOEDERT M, 1987, EMBO J, V6, P3627, DOI 10.1002/j.1460-2075.1987.tb02694.x; GOREWIT RC, 1979, P SOC EXP BIOL MED, V160, P80, DOI 10.3181/00379727-160-40394; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; HCIBBAR R, 1992, 39TH P ANN M SOC GYN, P251; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IVELL R, 1984, P NATL ACAD SCI-BIOL, V81, P2006, DOI 10.1073/pnas.81.7.2006; KUMARESAN P, 1979, J ENDOCRINOL INVEST, V2, P65, DOI 10.1007/BF03349277; LEFEBVRE D, UNPUB; LEFEBVRE DL, 1991, MOL ENDOCRINOL, V5, P645, DOI 10.1210/mend-5-5-645; LEFEBVRE DL, 1992, ENDOCRINOLOGY, V130, P1185, DOI 10.1210/en.130.3.1185; MARTINI L, 1977, CLIN NEUROENDOCRINOL, P569; PHELAN JP, 1978, AM J OBSTET GYNECOL, V130, P365; SELLERS SM, 1981, BRIT J OBSTET GYNAEC, V88, P725, DOI 10.1111/j.1471-0528.1981.tb01273.x; SHUKOVSKI L, 1991, J ENDOCRINOL, V128, P305, DOI 10.1677/joe.0.1280305; SILVERMAN AJ, 1983, ANNU REV NEUROSCI, V6, P357, DOI 10.1146/annurev.ne.06.030183.002041; SOLOFF MS, 1979, SCIENCE, V204, P1313, DOI 10.1126/science.221972; WALLACE JM, 1991, J ENDOCRINOL, V128, P253, DOI 10.1677/joe.0.1280253; WILSON L, 1990, AM J OBSTET GYNECOL, V163, P1875, DOI 10.1016/0002-9378(90)90767-2; ZINGG HH, 1988, MOL BRAIN RES, V4, P1, DOI 10.1016/0169-328X(88)90011-3; ZINGG HH, 1984, ENDOCRINOLOGY, V115, P90, DOI 10.1210/endo-115-1-90; ZINGG HH, 1986, J BIOL CHEM, V261, P2956	33	181	182	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 12	1992	256	5063					1553	1555		10.1126/science.1598587	http://dx.doi.org/10.1126/science.1598587			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY075	1598587				2022-12-28	WOS:A1992HY07500028
J	COHN, M; STEWART, P				COHN, M; STEWART, P			PREVALENCE OF POTENTIAL PATHOGENS IN CERVICAL CANAL BEFORE TERMINATION OF PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							THERAPEUTIC-ABORTION; INFECTION		NO GEN HOSP,DEPT OBSTET & GYNAECOL,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	Northern General Hospital								AGRESTI A, 1990, CATEGORICAL DATA ANA, P332; FRANK PI, 1985, J ROY COLL GEN PRACT, V35, P175; HEISTERBERG L, 1988, DAN MED BULL, V35, P64; QVIGSTAD E, 1983, BRIT J VENER DIS, V59, P189; RIDGWAY GL, 1983, BRIT MED J, V286, P1478, DOI 10.1136/bmj.286.6376.1478-a	5	14	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1479	1479		10.1136/bmj.304.6840.1479	http://dx.doi.org/10.1136/bmj.304.6840.1479			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611371	Green Published, Bronze			2022-12-28	WOS:A1992HY55300024
J	WILLIAMS, C				WILLIAMS, C			CURRENT ISSUES IN CANCER .5. OVARIAN AND CERVICAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article							UTERINE CERVIX; CARCINOMA; IRRADIATION; RADIATION; FAILURES; SURGERY				WILLIAMS, C (corresponding author), ROYAL S HANS HOSP,MED ONCOL,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							AVERETTE HE, 1969, AM J OBSTET GYNECOL, V105, P79, DOI 10.1016/0002-9378(69)90160-4; BUXTON EJ, 1989, J NATL CANCER I, V81, P359, DOI 10.1093/jnci/81.5.359; COPPLESON M, 1992, GYNECOL ONCOL, P571; CUCKLE HS, 1990, OVARIAN CANCER BIOL, P229; CULLHED S, 1978, ACTA OBSTET GYNECO S, V78, P1; DEMBO AJ, 1979, CANCER TREAT REP, V63, P249; Early Breast Cancer Trialists' Collaborative Group, 1992, LANCET, V339, P1; HEINTZ APM, 1988, GYNECOL ONCOL, V30, P347, DOI 10.1016/0090-8258(88)90249-1; JAMPOLIS S, 1975, RADIOLOGY, V115, P681, DOI 10.1148/15.3.681; LYNCH HT, 1986, AM J MED, V81, P1073, DOI 10.1016/0002-9343(86)90411-0; MACK TM, 1992, GYNECOLOGIC ONCOLOGY; MORLEY GW, 1976, AM J OBSTET GYNECOL, V126, P785, DOI 10.1016/0002-9378(76)90668-2; MORROW CP, 1992, GYNECOL ONCOL, P897; NEWTON M, 1975, AM J OBSTET GYNECOL, V123, P534; NG ABP, 1992, GYNECOL ONCOL, P277; PEREZ CA, 1980, CANCER, V45, P2759, DOI 10.1002/1097-0142(19800601)45:11<2759::AID-CNCR2820451110>3.0.CO;2-0; PICKEL, 1990, OVARIAN CANCER BIOL; PONDER BAJ, 1991, BRIT J CANCER, V64, P203, DOI 10.1038/bjc.1991.275; RICHARDSON GS, 1985, NEW ENGL J MED, V312, P415, DOI 10.1056/NEJM198502143120706; Smith J P, 1975, Natl Cancer Inst Monogr, V42, P149; 1991, BMJ, V303, P884; 1992, LANCET, V339, P71; 1977, 17TH ANN REP	23	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1501	1504		10.1136/bmj.304.6840.1501	http://dx.doi.org/10.1136/bmj.304.6840.1501			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611377	Green Published, Bronze			2022-12-28	WOS:A1992HY55300031
J	NEESER, M; RUEDIN, P; RESTELLINI, JP				NEESER, M; RUEDIN, P; RESTELLINI, JP			THIRST STRIKE - HYPERNATREMIA AND ACUTE PRERENAL FAILURE IN A PRISONER WHO REFUSED TO DRINK	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OSMOREGULATION; ABNORMALITIES		UNIV GENEVA, MED CTR, INST MED LEGALE, DIV PRISON MED, CH-1211 GENEVA 4, SWITZERLAND; HOP CANTONAL GENEVA, DIV NEPHROL, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva; University of Geneva								HAMMOND DN, 1986, NEW ENGL J MED, V315, P433, DOI 10.1056/NEJM198608143150706; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; POLLOCK AS, 1980, AM J PHYSIOL, V239, pF195, DOI 10.1152/ajprenal.1980.239.3.F195; ROBERTSON GL, 1984, KIDNEY INT, V25, P460, DOI 10.1038/ki.1984.39; ROBERTSON GL, 1982, AM J MED, V72, P339, DOI 10.1016/0002-9343(82)90825-7	5	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 23	1992	304	6838					1352	1352		10.1136/bmj.304.6838.1352	http://dx.doi.org/10.1136/bmj.304.6838.1352			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611334	Green Published, Bronze			2022-12-28	WOS:A1992HW41700024
J	FISHER, EA; DESNICK, RJ; GORDON, RE; ENG, CM; GRIEPP, R; GOLDMAN, ME				FISHER, EA; DESNICK, RJ; GORDON, RE; ENG, CM; GRIEPP, R; GOLDMAN, ME			FABRY DISEASE - AN UNUSUAL CAUSE OF SEVERE CORONARY-DISEASE IN A YOUNG MAN	ANNALS OF INTERNAL MEDICINE			English	Note						FABRYS DISEASE; CORONARY DISEASE; ANGINA PECTORIS; GLYCOSPHINGOLIPIDS; CORONARY ARTERY BYPASS		Fabry disease is an X-linked recessive disease resulting from deficient activity of alpha-galactosidse A. This deficiencY leads to the accumulation of glycosphingolipids in the lysosomes of vascular endothelial and smooth muscle cells. In classically affected men, skin manifestations begin by adolescence, and, with advancing age, vascular deposition in small vessels throughout the body leads to end-organ involvement of the kidney, heart, and brain. We report the case of a patient who had clinically significant coronary artery disease as the initial presentation of end-organ involvement and who was treated with bypass surgery.	MT SINAI MED CTR, DIV CARDIOL, BOX 1030, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai				Fisher, Edward/0000-0001-9802-143X	NCRR NIH HHS [RR-71] Funding Source: Medline; NICHD NIH HHS [5 T32HD07150] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKER AE, 1975, AM J CARDIOL, V36, P829, DOI 10.1016/0002-9149(75)90468-3; DESNICK RJ, 1976, CIRCULATION, V54, P818, DOI 10.1161/01.CIR.54.5.818; Desnick RJBD., 1989, METABOLIC BASIS INHE, V6, P1751; FERRANS VJ, 1969, AM J CARDIOL, V24, P95, DOI 10.1016/0002-9149(69)90055-1; GOLDMAN ME, 1986, J AM COLL CARDIOL, V7, P1157, DOI 10.1016/S0735-1097(86)80238-8; MOSSARD JM, 1972, ARCH MAL COEUR VAISS, V65, P495; VONSCHEIDT W, 1991, NEW ENGL J MED, V324, P395, DOI 10.1056/NEJM199102073240607; 1984, NEW ENGL J MED, V310, P106	8	28	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1992	117	3					221	223		10.7326/0003-4819-117-3-221	http://dx.doi.org/10.7326/0003-4819-117-3-221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF304	1616216				2022-12-28	WOS:A1992JF30400008
J	AVORN, J; SOUMERAI, SB; EVERITT, DE; ROSSDEGNAN, D; BEERS, MH; SHERMAN, D; SALEMSCHATZ, SR; FIELDS, D				AVORN, J; SOUMERAI, SB; EVERITT, DE; ROSSDEGNAN, D; BEERS, MH; SHERMAN, D; SALEMSCHATZ, SR; FIELDS, D			A RANDOMIZED TRIAL OF A PROGRAM TO REDUCE THE USE OF PSYCHOACTIVE-DRUGS IN NURSING-HOMES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EDUCATIONAL OUTREACH; HIP FRACTURE; MEDICATION; CARE; POLICY; RISK	Background. Although psychoactive medications have substantial side effects in the elderly, these drugs are used frequently in nursing homes. Few interventions have succeeded in changing this situation, and little is known about the clinical effects of such interventions. Methods. We studied six matched pairs of nursing homes; at one randomly selected nursing home in each pair, physicians, nurses, and aides participated in an educational program in geriatric psychopharmacology. At base line we determined the type and quantity of drugs received by all residents (n = 823), and a blinded observer performed standardized clinical assessments of the residents who were taking psychoactive medications. After the five-month program, drug use and patient status were reassessed. Results. Scores on an index of psychoactive-drug use, measuring both the magnitude and the probable inappropriateness of medication use, declined significantly more in the nursing homes in which the program was carried out (experimental nursing homes) than in the control nursing homes (decrease, 27 percent vs. 8 percent; P = 0.02). The use of antipsychotic drugs was discontinued in more residents in the experimental nursing homes than in the control nursing homes (32 percent vs. 14 percent); the comparable figures for the discontinuation of long-acting benzodiazepines were 20 percent vs. 9 percent, and for antihistamine hypnotics, 45 percent vs. 21 percent. In the experimental nursing homes residents who were initially taking antipsychotic drugs showed less deterioration on several measures of cognitive function than similar residents in the control facilities, but they were more likely to report depression. Those who were initially taking benzodiazepines or antihistamine hypnotic agents reported less anxiety than controls but had more loss ot memory. Most other measures of clinical status remained unchanged in both groups. Conclusions. An educational program targeted to physicians, nurses, and aides can reduce the use of psychoactive drugs in nursing homes without adversely affecting the overall behavior and level of functioning of the residents.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, PROGRAM ANAL CLIN STRATEGIES, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT SOCIAL MED, BOSTON, MA 02115 USA; BROCKTON W ROXBURY VET AFFAIRS MED CTR, CTR GERIATR RES EDUC & CLIN, BOSTON, MA USA; HARVARD GERIATR RES & TRAINING CTR, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Geriatric Research Education & Clinical Center; Harvard University; Harvard University; Harvard Medical School								Albert MS., 1984, NEUROPSYCHOLOGY MEMO, P236; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; AVORN J, 1990, HEALTH AFFAIR, V9, P6, DOI 10.1377/hlthaff.9.3.6; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; Cochran W.G, 1957, STAT METHODS, V6th ed; DAVIS K, 1986, OUR AGING SOC PARADO, P299; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; DONNER A, 1987, STAT MED, V6, P43, DOI 10.1002/sim.4780060106; ERMAN MK, 1987, PSYCHIAT CLIN N AM, V10, P525; EVERITT DE, 1991, J AM GERIATR SOC, V39, P792, DOI 10.1111/j.1532-5415.1991.tb02702.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; HESBACHER PT, 1980, J CLIN PSYCHIAT, V41, P6; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MORRIS JN, 1987, HEALTH SERV RES, V22, P117; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, AM J PUBLIC HEALTH, V77, P1448, DOI 10.2105/AJPH.77.11.1448; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; Schaffner W, 1979, QRB Qual Rev Bull, V5, P28; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; 1984, JAMA-J AM MED ASSOC, V251, P2410	27	280	282	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	1992	327	3					168	173		10.1056/NEJM199207163270306	http://dx.doi.org/10.1056/NEJM199207163270306			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD319	1608408				2022-12-28	WOS:A1992JD31900006
J	HARKEN, AH; HARKEN, DE				HARKEN, AH; HARKEN, DE			CARDIOTHORACIC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	HARKEN, AH (corresponding author), UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80262, USA.							CLARKE DR, 1989, CARDIAC SURGEY STATE, V2, P1; COX JL, 1991, JAMA-J AM MED ASSOC, V266, P1976, DOI 10.1001/jama.266.14.1976; LIM CS, 1991, CIRCULATION, V83, P2007, DOI 10.1161/01.CIR.83.6.2007; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928	4	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					337	338						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613911				2022-12-28	WOS:A1992JC35200021
J	STRANDJORD, TP; HODSON, WA				STRANDJORD, TP; HODSON, WA			NEONATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											STRANDJORD, TP (corresponding author), UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA.							CARLO WA, 1990, J PEDIATR-US, V117, P765, DOI 10.1016/S0022-3476(05)83341-4; CHASNOFF IJ, 1992, PEDIATRICS, V89, P284; CLARK RH, 1992, PEDIATRICS, V89, P5; CONNOR E, 1991, JAMA-J AM MED ASSOC, V266, P3474, DOI 10.1001/jama.266.24.3474; CONNOR E, 1991, SEMIN PEDIATR INFECT, V2, P285; DUNN MS, 1991, PEDIATRICS, V87, P377; HALL SB, 1992, AM REV RESPIR DIS, V145, P24, DOI 10.1164/ajrccm/145.1.24; HIFI Study Group, 1989, N Engl J Med, V320, P88; HOEKSTRA RE, 1991, PEDIATRICS, V88, P10; HUSSON RN, 1990, PEDIATRICS, V86, P1; KESZLER M, 1991, J PEDIATR-US, V119, P85, DOI 10.1016/S0022-3476(05)81046-7; LIECHTY EA, 1991, PEDIATRICS, V88, P19; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; MAYES LC, 1992, JAMA-J AM MED ASSOC, V89, P337; PHIBBS RH, 1991, PEDIATRICS, V88, P1; ZUCKERMAN B, 1992, PEDIATRICS, V89, P337	16	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					377	378						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613925				2022-12-28	WOS:A1992JC35200037
J	MEIER, UT; BLOBEL, G				MEIER, UT; BLOBEL, G			NOPP140 SHUTTLES ON TRACKS BETWEEN NUCLEOLUS AND CYTOPLASM	CELL			English	Article							NUCLEAR LOCATION SIGNAL; CASEIN KINASE-II; GEL-ELECTROPHORESIS; SEQUENCE REQUIREMENTS; BINDING-PROTEINS; T-ANTIGEN; SPECIFICITY DETERMINANTS; PRECURSOR PARTICLES; SYNTHETIC PEPTIDES; TRANSPORT SIGNALS	Nopp140 is a nucleolar phosphoprotein of 140 kd that we originally identified and purified as a nuclear localization signal (NLS)-binding protein. Molecular characterization revealed a 10-fold repeated motif of highly conserved acidic serine clusters that contain an abundance of phosphorylation consensus sites for casein kinase II (CK II). Indeed, Nopp140 is one of the most phosphorylated proteins in the cell, and NLS binding was dependent on phosphorylation. Nopp140 was shown to shuttle between the nucleolus and the cytoplasm. Shuttling is likely to proceed on tracks that were revealed by immunoelectron microscopy. These tracks extend from the dense fibrillar component of the nucleolus across the nucleoplasm to some nuclear pore complexes. We suggest that Nopp140 functions as a chaperone for import into and/or export from the nucleolus.			MEIER, UT (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; ADAM SA, 1991, CELL, V66, P837, DOI 10.1016/0092-8674(91)90431-W; AHN YS, 1985, BIOCHEMISTRY-US, V24, P7296, DOI 10.1021/bi00346a041; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BACHMANN M, 1989, MOL CELL BIOCHEM, V85, P103, DOI 10.1007/BF00577106; BANVILLE D, 1982, EXP CELL RES, V137, P437, DOI 10.1016/0014-4827(82)90046-5; BENDITT JO, 1989, P NATL ACAD SCI USA, V86, P9327, DOI 10.1073/pnas.86.23.9327; BLOBEL G, 1985, P NATL ACAD SCI USA, V82, P8527, DOI 10.1073/pnas.82.24.8527; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CLARK TG, 1977, CELL, V12, P883, DOI 10.1016/0092-8674(77)90152-0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; COTTEN M, 1986, BIOCHEMISTRY-US, V25, P5063, DOI 10.1021/bi00366a014; DANG CV, 1989, J BIOL CHEM, V264, P18019; DWORETZKY SI, 1988, J CELL BIOL, V107, P1279, DOI 10.1083/jcb.107.4.1279; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUKUI Y, 1978, J CELL BIOL, V76, P146, DOI 10.1083/jcb.76.1.146; GOLDFARB DS, 1988, CELL BIOL INT REP, V12, P809, DOI 10.1016/0309-1651(88)90090-2; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOLDSTEIN L, 1981, J CELL BIOL, V88, P516, DOI 10.1083/jcb.88.3.516; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; HUANG S, 1991, Genes and Development, V5, P2288, DOI 10.1101/gad.5.12a.2288; HUGLE B, 1985, CELL, V41, P615, DOI 10.1016/S0092-8674(85)80034-9; IMAMOTOSONOBE N, 1990, J BIOL CHEM, V265, P16504; JOCKUSCH BM, 1974, EXP CELL RES, V89, P241, DOI 10.1016/0014-4827(74)90787-3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANFORD RE, 1986, CELL, V46, P575, DOI 10.1016/0092-8674(86)90883-4; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; Le Stourgeon WM, 1978, CELL NUCLEUS, V6, P305; LEE WC, 1989, P NATL ACAD SCI USA, V86, P8808, DOI 10.1073/pnas.86.22.8808; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MADSEN P, 1986, J CELL BIOL, V103, P2083, DOI 10.1083/jcb.103.6.2083; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Maniatis T, 1989, MOL CLONING; MANSOUR SL, 1988, EMBO J, V7, P2035, DOI 10.1002/j.1460-2075.1988.tb03043.x; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MARSHAK DR, 1991, METHOD ENZYMOL, V200, P134; MEGGIO F, 1988, BIOCHIM BIOPHYS ACTA, V971, P227, DOI 10.1016/S0005-2728(88)80111-7; MEIER UT, 1990, J CELL BIOL, V111, P2235, DOI 10.1083/jcb.111.6.2235; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NICCHITTA CV, 1991, CELL, V65, P587, DOI 10.1016/0092-8674(91)90091-C; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; NIKKODEM V, 1979, ANAL BIOCHEM, V97, P382; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PFAFF M, 1988, BIOCHIM BIOPHYS ACTA, V969, P100, DOI 10.1016/0167-4889(88)90093-6; PFEIFLE J, 1981, BIOCHIM BIOPHYS ACTA, V670, P274, DOI 10.1016/0005-2795(81)90020-9; PFEIFLE J, 1984, EUR J BIOCHEM, V39, P417; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PRESTAYKO AW, 1974, BIOCHEMISTRY-US, V13, P1945, DOI 10.1021/bi00706a026; RECHSTEINER M, 1979, CELL, V16, P901, DOI 10.1016/0092-8674(79)90105-3; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEER U, 1984, P NATL ACAD SCI-BIOL, V81, P1431, DOI 10.1073/pnas.81.5.1431; SCHNELL DJ, 1990, J CELL BIOL, V111, P1825, DOI 10.1083/jcb.111.5.1825; SCHUURMAN R, 1991, BIOTECHNIQUES, V10, P185; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SILVER P, 1989, J CELL BIOL, V109, P983, DOI 10.1083/jcb.109.3.983; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCHAJ U, 1991, J CELL BIOL, V113, P1243, DOI 10.1083/jcb.113.6.1243; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOKUYASU KT, 1973, J CELL BIOL, V57, P551, DOI 10.1083/jcb.57.2.551; WANG TC, 1981, EXP CELL RES, V134, P409, DOI 10.1016/0014-4827(81)90440-7; WARNER JR, 1989, MICROBIOL REV, V53, P256, DOI 10.1128/MMBR.53.2.256-271.1989; WEHNER JM, 1977, NATURE, V266, P842, DOI 10.1038/266842a0; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	78	350	354	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					127	138						12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623516				2022-12-28	WOS:A1992JC95700014
J	LEHMANN, KG; FRANCIS, CK; DODGE, HT				LEHMANN, KG; FRANCIS, CK; DODGE, HT			MITRAL REGURGITATION IN EARLY MYOCARDIAL-INFARCTION - INCIDENCE, CLINICAL DETECTION, AND PROGNOSTIC IMPLICATIONS	ANNALS OF INTERNAL MEDICINE			English	Article						MITRAL VALVE INSUFFICIENCY; MYOCARDIAL INFARCTION; VENTRICULAR FUNCTION, LEFT RADIONUCLEOTIDE; VENTRICULOGRAPHY	PAPILLARY-MUSCLE DYSFUNCTION; PLASMINOGEN-ACTIVATOR; VENTRICULAR-FUNCTION; LEAFLET CLOSURE; RUPTURE; ECHOCARDIOGRAPHY; THROMBOLYSIS; ADVANTAGES; MECHANISM; TRIAL	Objective: To investigate mitral regurgitation occurring early in the course of acute myocardial infarction with respect to its incidence, the impact of infarct size and location, the accuracy of clinical detection, the contribution of global and regional left ventricular performance, and its influence on prognosis. Design: Prospective observational study derived from patients entering Phase I of the Thrombolysis in Myocardial Infarction (TIMI) trial. Setting: Multicenter trial involving 13 university-affiliated medical centers. Patients: A total of 206 patients studied within 7 hours of symptom onset during their first myocardial infarction. Measurements: Contrast left ventriculography was used to document mitral regurgitation. Results: Mitral regurgitation was present in 27 patients (13%). Although the presence of regurgitation correlated with the site of infarction (20 of 27 had anterior infarctions) and the number of akinetic chords, it was not statistically related to the peak creatine kinase value or to left ventricular chamber size or filling pressure. A murmur of mitral regurgitation was heard in only 2 patients (1 incorrectly). The presence of early mitral regurgitation predicted cardiovascular mortality at 1 year by univariate (relative risk, 12.2; 95% Cl, 3.5 to 42; P < 0.0001) and multivariate (relative risk, 7.5; Cl, 2.0 to 28.6; P = 0.0008) analyses. Conclusions: Mitral regurgitation in early myocardial infarction is generally clinically "silent," is more common in anterior infarction, is associated with regional dysfunction but not early ventricular dilation or peak enzyme release, and is an important predictor of cardiovascular mortality.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	Yale University; University of Washington; University of Washington Seattle								AHNVE S, 1986, AM J CARDIOL, V58, P872, DOI 10.1016/S0002-9149(86)80002-9; BARBOUR DJ, 1986, J AM COLL CARDIOL, V8, P558, DOI 10.1016/S0735-1097(86)80182-6; BARZILAI B, 1988, AM J CARDIOL, V61, P220, DOI 10.1016/0002-9149(88)90919-8; BARZILAI B, 1990, AM J CARDIOL, V65, P1169, DOI 10.1016/0002-9149(90)90968-7; BERGER P B, 1991, Journal of the American College of Cardiology, V17, p247A; BLUMLEIN S, 1986, CIRCULATION, V74, P306, DOI 10.1161/01.CIR.74.2.306; BRAND FR, 1967, CIRCULATION, V36, pII75; BRAUNWALD E, 1988, HEART DISEASE TXB CA, P1042; BURCH GE, 1968, AM HEART J, V75, P399, DOI 10.1016/0002-8703(68)90097-5; BURCH GE, 1985, ARCH INTERN MED, V312, P932; CHENG TO, 1969, AM J MED, V47, P924, DOI 10.1016/0002-9343(69)90206-X; FORRESTER JS, 1971, CIRCULATION, V44, P877, DOI 10.1161/01.CIR.44.5.877; GAHL K, 1977, BRIT HEART J, V39, P13; GODLEY RW, 1981, CIRCULATION, V63, P565, DOI 10.1161/01.CIR.63.3.565; Gross L., 1921, BLOOD SUPPLY HEART I; HEIKKILA J, 1967, BRIT HEART J, V29, P162; HICKEY MS, 1988, CIRCULATION, V78, P51; HIRAKAWA S, 1977, AM J PHYSIOL, V233, pH384, DOI 10.1152/ajpheart.1977.233.3.H384; IZUMI S, 1987, CIRCULATION, V76, P777, DOI 10.1161/01.CIR.76.4.777; KINNEY EL, 1985, AM HEART J, V109, P87, DOI 10.1016/0002-8703(85)90420-X; MAISEL AS, 1986, AM HEART J, V112, P705, DOI 10.1016/0002-8703(86)90464-3; MILLER GE, 1968, J THORAC CARDIOV SUR, V56, P611, DOI 10.1016/S0022-5223(19)42786-4; MITTAL AK, 1971, CIRCULATION, V44, P174, DOI 10.1161/01.CIR.44.2.174; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MUKHARJI J, 1984, AM J CARDIOL, V54, P31, DOI 10.1016/0002-9149(84)90299-6; NAJAFI H, 1975, ANN THORAC SURG, V20, P529, DOI 10.1016/S0003-4975(10)64252-X; NISHIMURA RA, 1983, AM J CARDIOL, V51, P373, DOI 10.1016/S0002-9149(83)80067-8; OGAWA S, 1979, AM HEART J, V97, P312, DOI 10.1016/0002-8703(79)90430-7; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PERLOFF JK, 1972, CIRCULATION, V46, P227, DOI 10.1161/01.CIR.46.2.227; PHILLIPS JH, 1963, ANN INTERN MED, V59, P508, DOI 10.7326/0003-4819-59-4-508; PINSON CW, 1984, J THORAC CARDIOV SUR, V88, P663; RADFORD MJ, 1979, CIRCULATION, V60, pI39; REPLOGLE RL, 1989, CIRCULATION, V79, P122; ROBERTS WC, 1972, CIRCULATION, V46, P138, DOI 10.1161/01.CIR.46.1.138; SANDLER H, 1968, AM HEART J, V75, P325, DOI 10.1016/0002-8703(68)90089-6; SHEEHAN FH, 1987, CIRCULATION, V75, P817, DOI 10.1161/01.CIR.75.4.817; SHEEHAN FH, 1986, CIRCULATION, V74, P293, DOI 10.1161/01.CIR.74.2.293; SPALTEHOLZ W, 1924, ARTERIENDIE HERZWAND; TEI C, 1983, CIRCULATION, V68, P183, DOI 10.1161/01.CIR.68.1.183; TSAKIRIS AG, 1970, MAYO CLIN PROC, V45, P275; WEI JY, 1979, ANN INTERN MED, V90, P149, DOI 10.7326/0003-4819-90-2-149; WILLIAMS DO, 1986, CIRCULATION, V73, P338, DOI 10.1161/01.CIR.73.2.338; ZELDIS SM, 1980, CATHETER CARDIO DIAG, V6, P225, DOI 10.1002/ccd.1810060303	44	149	152	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					10	17		10.7326/0003-4819-117-1-10	http://dx.doi.org/10.7326/0003-4819-117-1-10			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596042				2022-12-28	WOS:A1992JA43500002
J	GERSHON, D				GERSHON, D			HOUSTON BREEDS BIOTECHNOLOGY HOT SHOTS	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					629	629		10.1038/357629a0	http://dx.doi.org/10.1038/357629a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614507				2022-12-28	WOS:A1992JA43000024
J	GALE, R; JACKSON, G; NICHOLLS, M				GALE, R; JACKSON, G; NICHOLLS, M			HOW TO RUN AN INDUCTION MEETING FOR HOUSE OFFICERS	BRITISH MEDICAL JOURNAL			English	Article									LEWISHAM HOSP,LEWISHAM POSTGRAD CTR,LONDON SE13 6LH,ENGLAND; SE THAMES REG HLTH AUTHOR,LONDON WC1N 3EJ,ENGLAND	University of London									0	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1619	1620		10.1136/bmj.304.6842.1619	http://dx.doi.org/10.1136/bmj.304.6842.1619			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628093	Bronze, Green Published			2022-12-28	WOS:A1992JA43600030
J	RAMSAY, MEB; RAO, M; BEGG, NT				RAMSAY, MEB; RAO, M; BEGG, NT			SYMPTOMS AFTER ACCELERATED IMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION; DIPHTHERIA; TETANUS	Objective - To document the incidence of symptoms after accelerated immunisation with diphtheria-tetanus-pertussis vaccine. Design - Controlled study of children immunised with adsorbed diphtheria-tetanus-pertussis vaccine at accelerated and standard schedules. Setting - Colchester and north Hertfordshire. Subjects - 107 children scheduled to receive immunisation at 2, 3, and 4 months of age and 115 children scheduled to receive immunisation at 3, 4 1/2 to 5, and 8 1/2 to 11 months of age. Main outcome measures - Parentally recorded symptoms, axillary temperatures, and size of local redness and swelling at the injection site during the seven days after immunisation. Results - In general symptoms occurred less frequently with the accelerated schedule. Proportions of parents reporting axillary temperatures greater than 37.2-degrees-C or local redness or swelling greater than 2.5 cm after the third dose of vaccine were significantly reduced in the accelerated schedule group. Conclusion - Immunisation at 2, 3, and 4 months of age is likely to cause fewer reactions than immunisation at 3, 4 1/2 to 5, and 8 1/2 to 11 months of age.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,DIV IMMUNISAT,LONDON NW9 5EQ,ENGLAND; NE ESSEX HLTH AUTHOR,PUBL HLTH MED,COLCHESTER CO4 5JR,ENGLAND	Public Health England			Ramsay, Mary Elizabeth/S-8281-2016	Ramsay, Mary Elizabeth/0000-0002-7156-7640				BARRAFF LJ, 1984, PEDIATRICS, V73, P31; BEGG NT, 1989, PUBLIC HEALTH, V103, P81, DOI 10.1016/S0033-3506(89)80021-6; JONES AE, 1989, VACCINE, V7, P300, DOI 10.1016/0264-410X(89)90189-8; PECKHAM C, 1989, NATIONAL IMMUNISATIO; POLLOCK TM, 1984, LANCET, V2, P146, DOI 10.1016/S0140-6736(84)91057-2; WAIGHT PA, 1983, ARCH DIS CHILD, V58, P921, DOI 10.1136/adc.58.11.921; 1990, IMMUNISATION INFECTI; 1988, IMMUNISATION INFECTI	8	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 13	1992	304	6841					1534	1536		10.1136/bmj.304.6841.1534	http://dx.doi.org/10.1136/bmj.304.6841.1534			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HZ178	1628051	Green Published, Bronze			2022-12-28	WOS:A1992HZ17800021
J	DHANARAJ, V; DEALWIS, CG; FRAZAO, C; BADASSO, M; SIBANDA, BL; TICKLE, IJ; COOPER, JB; DRIESSEN, HPC; NEWMAN, M; AGUILAR, C; WOOD, SP; BLUNDELL, TL; HOBART, PM; GEOGHEGAN, KF; AMMIRATI, MJ; DANLEY, DE; OCONNOR, BA; HOOVER, DJ				DHANARAJ, V; DEALWIS, CG; FRAZAO, C; BADASSO, M; SIBANDA, BL; TICKLE, IJ; COOPER, JB; DRIESSEN, HPC; NEWMAN, M; AGUILAR, C; WOOD, SP; BLUNDELL, TL; HOBART, PM; GEOGHEGAN, KF; AMMIRATI, MJ; DANLEY, DE; OCONNOR, BA; HOOVER, DJ			X-RAY ANALYSES OF PEPTIDE-INHIBITOR COMPLEXES DEFINE THE STRUCTURAL BASIS OF SPECIFICITY FOR HUMAN AND MOUSE RENINS	NATURE			English	Article							HUMAN RENAL RENIN; 3-DIMENSIONAL STRUCTURE; SEQUENCE-ANALYSIS; GLAND RENIN; RESOLUTION	X-ray analyses have defined the three-dimensional structures of crystals of mouse and human renins complexed with peptide inhibitors at resolutions of 1.9 and 2.8 angstrom, respectively. The exquisite specificity of renin arises partly from ordered loop regions at the periphery of the binding cleft. Although the pattern of main-chain hydrogen bonding in other aspartic proteinase inhibitor complexes is conserved in renins, differences in the positions of secondary structure elements (particularly helices) also lead to improved specificity in renins for angiotensinogen substrates.	UNIV LONDON BIRKBECK COLL,MOLEC BIOL LAB,LONDON WC1E 7HX,ENGLAND; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,IMPERIAL CANC RES FUND,STRUCT MOLEC BIOL UNIT,LONDON WC1E 7HX,ENGLAND; PFIZER INC,DEPT MOLEC GENET & PROT CHEM,GROTON,CT 06340; PFIZER INC,DEPT MED CHEM,DIV CENT RES,GROTON,CT 06340	University of London; Birkbeck University London; Cancer Research UK; University of London; Birkbeck University London; Pfizer; Pfizer			Wood, Stephen P/B-1438-2009; Frazao, Carlos/C-1965-2008	Tickle, Ian/0000-0003-2977-0650; Frazao, Carlos/0000-0002-7725-1671				AKAHANE K, 1985, HYPERTENSION, V7, P3, DOI 10.1161/01.HYP.7.1.3; BADASSO M, 1992, J MOL BIOL, V223, P447, DOI 10.1016/0022-2836(92)90663-5; BLUNDELL T, 1983, NATURE, V304, P273, DOI 10.1038/304273a0; CARLSON W, 1985, HYPERTENSION, V7, P13, DOI 10.1161/01.HYP.7.1.13; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; CUMIN F, 1987, BIOCHIM BIOPHYS ACTA, V913, P10, DOI 10.1016/0167-4838(87)90226-3; DODSON EJ, 1985, MOL REPLACEMENT, P33; DRIESSEN H, 1989, J APPL CRYSTALLOGR, V22, P510, DOI 10.1107/S0021889889004097; DRIESSEN HPC, 1992, ACTA CRYSTALLOGR B, V47, P987; GREEN DW, 1990, BIOCHEMISTRY-US, V29, P3126, DOI 10.1021/bi00464a032; GREENLEE WJ, 1990, MED RES REV, V10, P173, DOI 10.1002/med.2610100203; HOBART PM, 1984, P NATL ACAD SCI-BIOL, V81, P5026, DOI 10.1073/pnas.81.16.5026; HOLZMAN TF, 1991, J PROTEIN CHEM, V10, P553, DOI 10.1007/BF01025483; HUTCHINS C, 1991, CRIT REV BIOCHEM MOL, V26, P77, DOI 10.3109/10409239109081721; IMAI T, 1983, P NATL ACAD SCI-BIOL, V80, P7405, DOI 10.1073/pnas.80.24.7405; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LIM LW, 1989, J MOL BIOL, V210, P239, DOI 10.1016/0022-2836(89)90305-7; MORNON JP, 1982, J MOL BIOL, V155, P539, DOI 10.1016/0022-2836(82)90487-9; NAVIA MA, 1984, J BIOL CHEM, V259, P2714; NEWMAN M, 1991, J MOL BIOL, V221, P1295, DOI 10.1016/0022-2836(91)80127-G; POE M, 1984, ANAL BIOCHEM, V140, P459, DOI 10.1016/0003-2697(84)90194-5; RAHUEL J, 1991, J STRUCT BIOL, V107, P227, DOI 10.1016/1047-8477(91)90048-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALI A, 1989, EMBO J, V8, P2179, DOI 10.1002/j.1460-2075.1989.tb08340.x; SALI A, 1992, PROTEINS, V12, P158, DOI 10.1002/prot.340120209; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SIBANDA BL, 1984, FEBS LETT, V174, P102, DOI 10.1016/0014-5793(84)81086-8; SIBANDA BL, 1986, THESIS U LONDON; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SKEGGS LT, 1968, J EXP MED, V120, P13; Tigerstedt R., 1898, SKAND ARCH PHYSIOL, V8, P223, DOI [10.1111/j.1748-1716.1898.tb00272.x, DOI 10.1111/J.1748-1716.1898.TB00272.X]; VEERAPANDIAN B, 1990, J MOL BIOL, V216, P1017, DOI 10.1016/S0022-2836(99)80017-5; VEERAPANDIAN B, 1992, PROTEIN SCI, V1, P322	36	131	134	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					466	472		10.1038/357466a0	http://dx.doi.org/10.1038/357466a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608447				2022-12-28	WOS:A1992HY05200052
J	LUCK, CA				LUCK, CA			VALUE OF ROUTINE ULTRASOUND SCANNING AT 19 WEEKS - A 4 YEAR STUDY OF 8849 DELIVERIES	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS	Objective - To evaluate the effectiveness of routine ultrasound scanning at 19 weeks' gestation in an unselected population in terms of accuracy of detection of fetal structural abnormality and the effect on obstetric and neonatal care. Design - Prospective study over four years. Scans performed by radiographers with overall supervision by a radiologist. Setting - Ultrasound department of district general hospital. Subjects - All pregnant women were offered scans; 8523 of 8849 (96%) accepted. Main outcome measures - Information obtained from hospital records, genetic analysis, and post-mortem findings. Results - 166 fetal anomalies occurred; 140 were detected at 19 weeks (sensitivity 85%; specificity 99.9%). In 27 cases fetuses were shown to have severely crippling or lethal abnormalities; termination of pregnancy was requested in 25. Early diagnosis influenced timing and place of delivery in babies with severe cardiac or gastrointestinal anomalies. Conclusion - Scanning at 19 weeks with availability of termination can reduce perinatal morbidity and mortality. Scanning can be performed in a general ultrasound department with adequate counselling facilities and close cooperation between radiographers, midwives, obstetricians, paediatricians, and the radiologist.			LUCK, CA (corresponding author), HEATHERWOOD HOSP,ASCOT SL5 8AA,BERKS,ENGLAND.							BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P573, DOI 10.1016/0002-9378(87)90053-6; CAMPBELL S, 1983, CLIN OBSTET GYNAECOL, V10, P475; CAMPBELL S, 1984, PRENATAL DIAGNOSIS, P325; CHERVENAK FA, 1991, ULTRASOUND OBST GYN, V1, P18, DOI 10.1046/j.1469-0705.1991.01010018.x; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; CRAWFORD DC, 1988, AM J OBSTET GYNECOL, V159, P352, DOI 10.1016/S0002-9378(88)80083-8; HANSMANN M, 1991, ULTRASOUND OBST GYN, V1, P305, DOI 10.1046/j.1469-0705.1991.01050305.x; HECHER K, 1991, ULTRASOUND OBST GYN, V1, P426, DOI 10.1046/j.1469-0705.1991.01060426.x; MCNAY M, 1991, BRIT MED SOC ULTRASO, V63, P23; THOMSON P, 1991, TIMES           1202, P15; 1984, WORKING PARTY REPORT, P10; 1989, REPORT PRENATAL DIAG, P14	12	157	160	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1474	1478		10.1136/bmj.304.6840.1474	http://dx.doi.org/10.1136/bmj.304.6840.1474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611369	Green Published			2022-12-28	WOS:A1992HY55300022
J	KITAMURA, D; KUDO, A; SCHAAL, S; MULLER, W; MELCHERS, F; RAJEWSKY, K				KITAMURA, D; KUDO, A; SCHAAL, S; MULLER, W; MELCHERS, F; RAJEWSKY, K			A CRITICAL ROLE OF LAMBDA-5 PROTEIN IN B-CELL DEVELOPMENT	CELL			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; LIGHT CHAIN GENES; LYMPHOCYTES-PRE-B; HEAVY-CHAINS; TRANSGENIC MICE; STEM-CELLS; MU; ANTIBODIES; MOUSE; VPREB	The lambda-5 gene is a homolog of immunoglobulin J(lambda)-C(lambda) genes, expressed specifically in immature B-lineage cells. Lambda-5-encoded molecules form membrane complexes with mu or D(mu) proteins in association with an additional protein specifically expressed in immature B cells that is encoded by the V(pre-B) gene. We have generated mice in which the lambda-5 gene is inactivated by targeted gene disruption in embryonic stem cells. In these mice, B cell development in the bone marrow is blocked at the pre-B cell stage. However, the blockade is leaky, allowing B cells to populate the peripheral immune system at a low rate. These cells are allelically excluded and able to respond to antigen.	UNIV COLOGNE, INST GENET, W-5000 COLOGNE 41, GERMANY; BASEL INST IMMUNOL, CH-4058 BASEL, SWITZERLAND	University of Cologne			Muller, Werner/B-9044-2008; Kudo, Akira/C-7340-2015	Muller, Werner/0000-0002-1297-9725; Kudo, Akira/0000-0001-6289-3391				ALT F, 1981, CELL, V27, P381, DOI 10.1016/0092-8674(81)90421-9; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CHERAYIL BJ, 1991, J EXP MED, V173, P111, DOI 10.1084/jem.173.1.111; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COFFMAN RL, 1983, J MOL CELL IMMUNOL, V1, P31; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; FORSTER I, 1987, EUR J IMMUNOL, V17, P521, DOI 10.1002/eji.1830170414; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; Forster I, 1989, Int Immunol, V1, P321, DOI 10.1093/intimm/1.4.321; Grutzmann R., 1981, THESIS U COLOGNE COL; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; IMANISHI T, 1973, EUR J IMMUNOL, V3, P323, DOI 10.1002/eji.1830030602; ISCOVE NN, 1978, J EXP MED, V147, P923, DOI 10.1084/jem.147.3.923; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KENDALL C, 1983, J IMMUNOL METHODS, V56, P329, DOI 10.1016/S0022-1759(83)80022-2; Kerr W G, 1989, Int Immunol, V1, P355, DOI 10.1093/intimm/1.4.355; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KUBAGAWA H, 1989, P NATL ACAD SCI USA, V86, P2356, DOI 10.1073/pnas.86.7.2356; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; KUDO A, 1989, PROGR IMMUNOLOGY, V7, P339; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MULLER CE, 1983, THESIS U COLOGNE COL; MULLER W, 1989, EUR J IMMUNOL, V19, P923, DOI 10.1002/eji.1830190520; MULLER W, 1991, EUR J IMMUNOL, V21, P921, DOI 10.1002/eji.1830210410; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; NISHIMOTO N, 1991, P NATL ACAD SCI USA, V88, P6284, DOI 10.1073/pnas.88.14.6284; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OPITZ HG, 1982, IMMUNOBIOLOGY, V160, P438, DOI 10.1016/S0171-2985(82)80007-7; OSMOND DG, 1991, CURR OPIN IMMUNOL, V3, P179, DOI 10.1016/0952-7915(91)90047-5; PILLAI S, 1987, NATURE, V329, P172, DOI 10.1038/329172a0; PILLAI S, 1988, CURR TOP MICROBIOL, V137, P136; RETH M, 1987, EMBO J, V6, P3299, DOI 10.1002/j.1460-2075.1987.tb02649.x; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; RETH MG, 1984, NATURE, V312, P418, DOI 10.1038/312418a0; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; SAKAGUCHI N, 1986, NATURE, V324, P579, DOI 10.1038/324579a0; SAKAGUCHI N, 1986, EMBO J, V5, P2139, DOI 10.1002/j.1460-2075.1986.tb04477.x; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SEEMANN G, 1981, THESIS U COLOGNE COL; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TSUBATA T, 1991, EUR J IMMUNOL, V21, P1359, DOI 10.1002/eji.1830210605; TSUBATA T, 1990, J EXP MED, V172, P973, DOI 10.1084/jem.172.3.973; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0	54	543	547	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 29	1992	69	5					823	831		10.1016/0092-8674(92)90293-L	http://dx.doi.org/10.1016/0092-8674(92)90293-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591779				2022-12-28	WOS:A1992HW83800012
J	KERN, SE; PIETENPOL, JA; THIAGALINGAM, S; SEYMOUR, A; KINZLER, KW; VOGELSTEIN, B				KERN, SE; PIETENPOL, JA; THIAGALINGAM, S; SEYMOUR, A; KINZLER, KW; VOGELSTEIN, B			ONCOGENIC FORMS OF P53 INHIBIT P53-REGULATED GENE-EXPRESSION	SCIENCE			English	Article							WILD-TYPE P53; BREAST-CANCER; LUNG-CANCER; CELL-LINE; MUTATIONS; TRANSFORMATION; SARCOMAS; PROTEIN; IDENTIFICATION; ABNORMALITIES	Mutant forms of the gene encoding the tumor suppressor p53 are found in numerous human malignancies, but the physiologic function of p53 and the effects of mutations on this function are unknown. The p53 protein binds DNA in a sequence-specific manner and thus may regulate gene transcription. Cotransfection experiments showed that wild-type p53 activated the expression of genes adjacent to a p53 DNA binding site. The level of activation correlated with DNA binding in vitro. Oncogenic forms of p53 lost this activity. Moreover, all mutants inhibited the activity of coexpressed wild-type p53, providing a basis for the selection of such mutants during tumorigenesis.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,BALTIMORE,MD 21231; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21231	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University				Thiagalingam, Sam/0000-0001-5211-266X	NATIONAL CANCER INSTITUTE [T32CA009243, R37CA035494, R01CA035494, P30CA006973] Funding Source: NIH RePORTER; NCI NIH HHS [CA35494, CA06973, CA09243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KERN S, UNPUB; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Miller J.H., 1972, EXPT MOL GENETICS; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MURAKAMI Y, 1990, ONCOGENE, V5, P5; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STEINMEYER K, 1988, ONCOGENE, V3, P501; STRATTON MR, 1990, ONCOGENE, V5, P1297; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1990, J CLIN INVEST, V86, P363, DOI 10.1172/JCI114710; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	49	1033	1064	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 8	1992	256	5058					827	830		10.1126/science.1589764	http://dx.doi.org/10.1126/science.1589764			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HT235	1589764				2022-12-28	WOS:A1992HT23500042
J	SHORS, TJ; WEISS, C; THOMPSON, RF				SHORS, TJ; WEISS, C; THOMPSON, RF			STRESS-INDUCED FACILITATION OF CLASSICAL-CONDITIONING	SCIENCE			English	Article							NICTITATING-MEMBRANE RESPONSE; INESCAPABLE SHOCK; CEREBELLAR NUCLEI; HIPPOCAMPECTOMY DISRUPTS; SYNAPTIC TRANSMISSION; LEARNED HELPLESSNESS; EYELID RESPONSES; RABBIT; LESIONS; RATS	Stress has been shown to impair subsequent learning. To determine whether stress would impair classical conditioning, rats were exposed to inescapable, low-intensity tail shock and subsequently classically conditioned under freely moving conditions with a brief periorbital shock unconditioned stimulus and a white noise conditioned stimulus. Unexpectedly stressed rats exhibited significantly more conditioned eyeblink responses and the magnitude of their individual responses was also enhanced. These results stand in contrast to the learning deficits typically observed and suggest that stress can enhance the acquisition of discrete conditioned responses.	UNIV SO CALIF,DEPT PSYCHOL,LOS ANGELES,CA 90089; UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089	University of Southern California; University of Southern California	SHORS, TJ (corresponding author), PRINCETON UNIV,DEPT PSYCHOL,GREEN HALL,PRINCETON,NJ 08544, USA.				NATIONAL INSTITUTE ON AGING [F32AG005514, F32AG005500] Funding Source: NIH RePORTER; NIA NIH HHS [AG05500, AG00093, AG05514] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS R M, 1989, Society for Neuroscience Abstracts, V15, P890; ANISMAN H, 1975, PSYCHOL REV, V82, P359; ANISMAN H, 1979, J COMP PHYSIOL PSYCH, V93, P610, DOI 10.1037/h0077603; BAUDRY M, 1991, LONG TERM POTENTIATI; BERGER TW, 1986, BEHAV NEUROSCI, V100, P802, DOI 10.1037/0735-7044.100.6.802; BERGER TW, 1983, BEHAV BRAIN RES, V8, P49, DOI 10.1016/0166-4328(83)90171-7; BERGER TW, 1984, SCIENCE, V224, P627, DOI 10.1126/science.6324350; BERGER TW, 1980, BRAIN RES, V183, P265, DOI 10.1016/0006-8993(80)90463-1; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; CHEN JS, 1977, ANIM LEARN BEHAV, V5, P377, DOI 10.3758/BF03209583; CLARK GA, 1984, BRAIN RES, V291, P125, DOI 10.1016/0006-8993(84)90658-9; DESS NK, 1989, LEARN MOTIV, V20, P1, DOI 10.1016/0023-9690(89)90028-3; GILBERT P, 1975, NATURE, V254, P688, DOI 10.1038/254688a0; GLASER HI, 1976, J EXP PSYCHOL ANIM B, V2, P201; Ito M, 1984, CEREBELLUM NEURAL CO; KESSLER M, 1991, BRAIN RES, V560, P337, DOI 10.1016/0006-8993(91)91255-Y; LANDFIELD PW, 1988, LONG TERM POTENTIATI; LAVOND DG, 1984, BRAIN RES, V305, P323, DOI 10.1016/0006-8993(84)90438-4; MAIER SF, 1976, J EXP PSYCHOL GEN, V105, P3, DOI 10.1037/0096-3445.105.1.3; MAIER SF, 1979, PSYCHOL LEARNING MOT, V13; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MCCORMICK DA, 1982, P NATL ACAD SCI-BIOL, V79, P2731, DOI 10.1073/pnas.79.8.2731; MINOR TR, 1984, J EXP PSYCHOL ANIM B, V10, P543, DOI 10.1037/0097-7403.10.4.543; MOYER JR, 1990, BEHAV NEUROSCI, V104, P243, DOI 10.1037/0735-7044.104.2.243; ORR WB, 1985, BEHAV NEUROSCI, V99, P35, DOI 10.1037/0735-7044.99.1.35; OVERMIER JB, 1967, J COMP PHYSIOL PSYCH, V63, P28, DOI 10.1037/h0024166; OVERMIER JB, 1983, LEARN MOTIV, V14, P324, DOI 10.1016/0023-9690(83)90020-6; ROSELLINI RA, 1984, J EXP PSYCHOL ANIM B, V10, P346; ROSELLINI RA, 1978, ANIM LEARN BEHAV, V6, P155, DOI 10.3758/BF03209594; SCHMAJUK NA, 1990, PHYSIOL BEHAV, V48, P755, DOI 10.1016/0031-9384(90)90221-O; SHORS T J, 1991, Society for Neuroscience Abstracts, V17, P915; SKELTON RW, 1988, BEHAV NEUROSCI, V102, P586, DOI 10.1037/0735-7044.102.4.586; SOLOMON PR, 1986, BEHAV NEUROSCI, V100, P729, DOI 10.1037/0735-7044.100.5.729; THOMPSON RF, 1990, PHILOS T ROY SOC B, V329, P161, DOI 10.1098/rstb.1990.0161; TOCCO G, 1991, BRAIN RES, V559, P168, DOI 10.1016/0006-8993(91)90302-C; TOCCO G, 1992, BRAIN RES, V573, P228, DOI 10.1016/0006-8993(92)90767-4; WEISS C, 1992, NEUROBIOL AGING, V13, P319, DOI 10.1016/0197-4580(92)90045-Y; WEISS JM, 1971, J COMP PHYSIOL PSYCH, V77, P14, DOI 10.1037/h0031582; WEISZ DJ, 1984, BEHAV BRAIN RES, V12, P145, DOI 10.1016/0166-4328(84)90037-8; YEO CH, 1985, EXP BRAIN RES, V60, P87, DOI 10.1007/BF00237022	40	255	261	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 24	1992	257	5069					537	539		10.1126/science.1636089	http://dx.doi.org/10.1126/science.1636089			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	JE755	1636089				2022-12-28	WOS:A1992JE75500031
J	LIVORNESE, LL; DIAS, S; SAMEL, C; ROMANOWSKI, B; TAYLOR, S; MAY, P; PITSAKIS, P; WOODS, G; KAYE, D; LEVISON, ME; JOHNSON, CC				LIVORNESE, LL; DIAS, S; SAMEL, C; ROMANOWSKI, B; TAYLOR, S; MAY, P; PITSAKIS, P; WOODS, G; KAYE, D; LEVISON, ME; JOHNSON, CC			HOSPITAL-ACQUIRED INFECTION WITH VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM TRANSMITTED BY ELECTRONIC THERMOMETERS	ANNALS OF INTERNAL MEDICINE			English	Article						ENTEROCOCCUS-FAECIUM; GROSS INFECTION; DRUG RESISTANCE, MICROBIAL; VANCOMYCIN; THERMOMETERS	TRANSFERABLE RESISTANCE; ENDOCARDITIS; FAECALIS; INVITRO	Objectives: To describe an epidemic of vancomycin-resistant Enterococcus faecium causing bacteremia and bacteriuria, to identify the source of infection, to delineate risk factors associated with acquisition of the organism, and to determine antibiotic sensitivities for the organism. Design: Investigation of an epidemic, including a case-control study. Setting: Medical-surgical intensive care unit and ward in a university medical center. Patients: Nine patients infected or colonized with vancomycin-resistant Enterococcus faecium and 20 noninfected controls. Measurements: Clinical data, environmental surveillance cultures, and in-vitro microbiologic studies. Results: Colonization or infection by vancomycin-resistant E. faecium was associated with an increased duration of treatment with ceftazidime, 13.2 compared with 4.6 days, and a greater number of nonisolated days of hospitalization in the intensive care unit, 19.9 compared with 6.4 days for infected and noninfected patients, respectively (P < 0.05). Environmental surveillance cultures recovered the organism repeatedly from the rectal probe handles of three electronic thermometers used exclusively on nonisolated patients in the intensive care unit. Restriction endonuclease analysis of plasmid DNA showed that all clinical and environmental isolates were identical. Infection control measures, including isolation of colonized or infected patients and removal of the rectal thermometer probes suspected to be responsible for transmission, resulted in termination of the outbreak. In-vitro, time-kill studies showed that the combination of ciprofloxacin, rifampin, and gentamicin resulted in bactericidal activity against the organism. Conclusions: This nosocomial outbreak of infection due to a highly vancomycin-resistant strain of Enterococcus is the first epidemic in which an electronic thermometer has been implicated as the vehicle of transmission for an infectious agent.	DEPT VET AFFAIRS, PHILADELPHIA, PA USA; MED COLL PENN, PHILADELPHIA, PA 19129 USA	Drexel University								BENNETT PM, 1986, J ANTIMICROB CHEMOTH, V18, P421, DOI 10.1093/jac/18.3.421; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BROOKS S, 1990, INFECT CONT HOSP EP, V11, P574; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P2017, DOI 10.1021/bi00222a002; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P2291, DOI 10.1128/AAC.34.12.2291; ELIOPOULOS GM, 1989, REV INFECT DIS, V11, pS1210; FERNANDEZGUERRERO M, 1987, ANTIMICROB AGENTS CH, V31, P430, DOI 10.1128/AAC.31.3.430; French G L, 1981, J Hosp Infect, V2, P389, DOI 10.1016/0195-6701(81)90074-8; HERMAN DJ, 1991, ANTIMICROB AGENTS CH, V35, P215, DOI 10.1128/AAC.35.2.215; Im S W, 1981, J Hosp Infect, V2, P171, DOI 10.1016/0195-6701(81)90026-8; KAPLAN AH, 1988, J CLIN MICROBIOL, V26, P1216, DOI 10.1128/JCM.26.6.1216-1218.1988; KARANFIL LV, 1992, INFECT CONT HOSP EP, V13, P195, DOI 10.1086/646509; KREISWIRTH BN, 1991, 31ST INT C ANT AG CH, P131; LECLERCQ R, 1988, NEW ENGL J MED, V319, P157, DOI 10.1056/NEJM198807213190307; MANDELL GL, 1970, ARCH INTERN MED, V125, P258, DOI 10.1001/archinte.125.2.258; MCALLISTER TA, 1986, LANCET, V1, P1262; NICAS TI, 1989, ANTIMICROB AGENTS CH, V33, P1121, DOI 10.1128/AAC.33.7.1121; RHINEHART E, 1990, NEW ENGL J MED, V323, P1814, DOI 10.1056/NEJM199012273232606; SAHM DF, 1989, ANTIMICROB AGENTS CH, V33, P71, DOI 10.1128/AAC.33.1.71; SCHOENKNECHT FD, 1985, MANUAL CLIN MICROBIO, P1000; SHLAES DM, 1989, J ANTIMICROB CHEMOTH, V23, P503, DOI 10.1093/jac/23.4.503; SHLAES DM, 1989, ANTIMICROB AGENTS CH, V33, P198, DOI 10.1128/AAC.33.2.198; SMITH L, 1981, INFECT CONT HOSP EP, V2, P315, DOI 10.1017/S0195941700055363; SMITH SM, 1988, DIAGN MICR INFEC DIS, V9, P239, DOI 10.1016/0732-8893(88)90115-0; UTTLEY AHC, 1988, LANCET, V1, P57; WASHINGTON JA, 1985, MANUAL CLIN MICROBIO, P972; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687	27	379	387	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1992	117	2					112	116		10.7326/0003-4819-117-2-112	http://dx.doi.org/10.7326/0003-4819-117-2-112			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JD123	1605425				2022-12-28	WOS:A1992JD12300003
J	TAYLOR, TC; KAHN, RA; MELANCON, P				TAYLOR, TC; KAHN, RA; MELANCON, P			2 DISTINCT MEMBERS OF THE ADP-RIBOSYLATION FACTOR FAMILY OF GTP-BINDING PROTEINS REGULATE CELL-FREE INTRA-GOLGI TRANSPORT	CELL			English	Article							ADENYLATE-CYCLASE; VESICULAR TRANSPORT; MOLECULAR-WEIGHT; BOVINE BRAIN; YEAST; PURIFICATION; SECRETION; COMPARTMENTS; LOCALIZATION; EXPRESSION	We have used an intra-Golgi transport assay to identify GTP-binding proteins involved in regulation of protein traffic. Two soluble proteins of 20 kd were purified by their ability to mediate GTP-gamma-S-dependent inhibition of transport. These GTP-dependent Golgi binding factors, or GGBFs, exhibit a 3-fold difference in activity and are differentiated by their hydrophobicity, isoelectric points, and apparent size. Removal of 80% of GGBFs from cytosol abolishes GTP-gamma-S sensitivity but does not affect inhibition by aluminum fluoride. We demonstrate that GGBFs are members of the ADP-ribosylation factor (ARF) family. Recombinant ARF1 exhibits GGBF activity and myristoylation is required. The distinct biochemical properties of GGBFs indicate that members of the ARF family may have related but distinct functions in intracellular transport.	NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, BIOL CHEM LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAYLOR, TC (corresponding author), UNIV COLORADO, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.		Kahn, Richard/ABD-2666-2020; Melancon, Paul/P-1304-2018	Kahn, Richard/0000-0002-0259-0601; Melancon, Paul/0000-0002-8085-3032	NIGMS NIH HHS [GM43378] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1992, IN PRESS J BIOL CHEM; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BOMAN AL, 1992, IN PRESS NATURE; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARY DO, 1990, J BIOL CHEM, V265, P10109; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; GODA Y, 1989, FASEB J, V3, P2488, DOI 10.1096/fasebj.3.13.2680705; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1992, IN PRESS J BIOL CHEM; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG L, 1984, ANAL BIOCHEM, V140, P264, DOI 10.1016/0003-2697(84)90163-5; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LENHARD JM, 1992, IN PRESS J BIOL CHEM; LEWIS JM, 1991, CELL REGUL, V2, P1097, DOI 10.1091/mbc.2.12.1097; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; Melancon P, 1991, Trends Cell Biol, V1, P165, DOI 10.1016/0962-8924(91)90018-5; MELANCON P, 1989, SECRETION ITS CONTRO, P175; MELMAN I, 1992, CELL, V68, P829; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; NISHIKAWA S, 1991, BIOCHIM BIOPHYS ACTA, V1093, P135, DOI 10.1016/0167-4889(91)90114-D; OKA T, 1991, J CELL BIOL, V114, P671, DOI 10.1083/jcb.114.4.671; ORCI L, 1991, CELL, V64, P1183; Penefsky H S, 1979, Methods Enzymol, V56, P527; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; WATTENBERG BW, 1986, J BIOL CHEM, V261, P2208; WEISS O, 1989, J BIOL CHEM, V264, P21066	54	124	124	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 10	1992	70	1					69	79		10.1016/0092-8674(92)90534-J	http://dx.doi.org/10.1016/0092-8674(92)90534-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	JC957	1623523				2022-12-28	WOS:A1992JC95700009
J	EISENBERG, MJ; LONDON, MJ; LEUNG, JM; BROWNER, WS; HOLLENBERG, M; TUBAU, JF; TATEO, IM; SCHILLER, NB; MANGANO, DT				EISENBERG, MJ; LONDON, MJ; LEUNG, JM; BROWNER, WS; HOLLENBERG, M; TUBAU, JF; TATEO, IM; SCHILLER, NB; MANGANO, DT			MONITORING FOR MYOCARDIAL-ISCHEMIA DURING NONCARDIAC SURGERY - A TECHNOLOGY-ASSESSMENT OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY AND 12-LEAD ELECTROCARDIOGRAPHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY; PERIPHERAL VASCULAR-SURGERY; TWO-DIMENSIONAL ECHOCARDIOGRAPHY; WALL-MOTION ABNORMALITIES; CARDIAC SURGICAL PROCEDURES; CORONARY-ARTERY DISEASE; INTRAOPERATIVE DETECTION; RISK; INFARCTION; ANGIOPLASTY	Objective.-Transesophageal echocardiography (TEE) and 12-lead electrocardiography (ECG) are sophisticated techniques that are increasingly being used to monitor for myocardial ischemia during noncardiac surgery. We examined whether the routine use of these techniques has incremental clinical value in identifying patients at high risk for perioperative ischemic outcomes when compared with preoperative clinical data and intraoperative monitoring using continuous two-lead bipolar ECG. Design.-Cohort study. Setting.-Veterans Affairs medical center. Patients.-A total of 332 men undergoing noncardiac surgery who had or were at high risk for coronary artery disease. Interventions.-TEE, 12-lead ECG, and two-lead ECG were performed continuously during noncardiac surgery (47% vascular, 53% nonvascular). Monitoring results were not available to anesthesiologists or surgeons, and data were blindly analyzed after surgery. Main Outcome Measure.-Perioperative ischemic outcomes (cardiac death, nonfatal myocardial infarction, unstable angina). Results.-In a subset of 285 patients who were adequately studied by all three techniques, 111 patients (39%) were identified as having intraoperative myocardial ischemia (by one or more monitoring techniques). By univariate analysis, intraoperative ischemia was associated with all perioperative cardiac outcomes, including ischemic outcomes, congestive heart failure, and ventricular tachycardia (P less-than-or-equal-to .02 for each of the three monitoring techniques). However, when monitoring results for TEE and 12-lead ECG were added to a multivariate model that included preoperative clinical data and continuous two-lead ECG results, the incremental value of TEE was small (odds ratio, 2.6; 95% confidence interval [CI], 1.2 to 5.7; P=.02) and that of 12-lead ECG was not significant (odds ratio, 1.5; 95% CI, 0.6 to 3.8). Furthermore, when the multivariate analysis was repeated with only ischemic outcomes, neither TEE nor 12-lead ECG retained significant associations (odds ratio, 2.2; 95% CI, 0.5 to 9.4, and odds ratio, 1.1; 95% CI, 0.2 to 6.1, respectively). Conclusion.-When compared with preoperative clinical data and intraoperative monitoring using two-lead ECG, routine monitoring for myocardial ischemia with TEE or 12-lead ECG during noncardiac surgery has little incremental clinical value in identifying patients at high risk for perioperative ischemic outcomes.	UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT SURG, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco				Tice, Jeffrey/0000-0002-9857-2028	NHLBI NIH HHS [HL 07192, R01-HL36744] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036744, T32HL007192] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEAUPRE PN, 1984, AM HEART J, V107, P1021, DOI 10.1016/0002-8703(84)90844-5; BLACKBURN H, 1960, CIRCULATION, V21, P1160, DOI 10.1161/01.CIR.21.6.1160; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; CHAITMAN BR, 1978, CIRCULATION, V57, P71, DOI 10.1161/01.CIR.57.1.71; CHUNG F, 1991, CAN J ANAESTH, V38, P98, DOI 10.1007/BF03009170; CLEMENTS FM, 1987, ANESTH ANALG, V66, P249; COHEN M, 1987, J AM COLL CARDIOL, V10, P17, DOI 10.1016/S0735-1097(87)80154-7; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; GEWERTZ BL, 1987, J VASC SURG, V5, P607, DOI 10.1067/mva.1987.avs0050607; GIANNUZZI P, 1989, EUR HEART J, V10, P880, DOI 10.1093/oxfordjournals.eurheartj.a059396; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HAGGMARK S, 1989, ANESTHESIOLOGY, V70, P19; HAUSER AM, 1985, J AM COLL CARDIOL, V5, P193, DOI 10.1016/S0735-1097(85)80036-X; KREMER P, 1983, CIRCULATION, V68, P332; KREMER P, 1982, AM J CARDIOL, V49, P956, DOI 10.1016/0002-9149(82)92230-5; KRUCOFF MW, 1987, J ELECTROCARDIOL, V20, P15; LEUNG JM, 1989, ANESTHESIOLOGY, V71, P16, DOI 10.1097/00000542-198907000-00004; LONDON MJ, 1988, ANESTHESIOLOGY, V69, P232, DOI 10.1097/00000542-198808000-00013; LONDON MJ, 1990, ANESTHESIOLOGY, V73, P644, DOI 10.1097/00000542-199010000-00010; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MATSUMOTO M, 1980, AM J CARDIOL, V46, P95, DOI 10.1016/0002-9149(80)90611-6; MCCANN RL, 1989, J VASC SURG, V9, P583, DOI 10.1067/mva.1989.vs0090583; PASTERNACK PF, 1989, J VASC SURG, V10, P617, DOI 10.1067/mva.1989.15572; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; ROIZEN MF, 1984, J VASC SURG, V1, P300, DOI 10.1067/mva.1984.avs0010300; ROY WL, 1979, ANESTHESIOLOGY, V51, P393, DOI 10.1097/00000542-197911000-00005; SHIVELY B, 1986, J AM COLL CARDIOL, V7, pA2; SLOGOFF S, 1985, ANESTHESIOLOGY, V62, P107, DOI 10.1097/00000542-198502000-00002; SMITH JS, 1985, CIRCULATION, V72, P1015, DOI 10.1161/01.CIR.72.5.1015; TOPOL EJ, 1984, J AM COLL CARDIOL, V4, P1123, DOI 10.1016/S0735-1097(84)80131-X; VONKNORRING J, 1986, SURGERY, V99, P610; WOHLGELERNTER D, 1986, J AM COLL CARDIOL, V7, P1245, DOI 10.1016/S0735-1097(86)80143-7; 1989, PHS891232 DEP HLTH H; 1978, MANUAL OPERATIONS, V2	36	102	105	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 8	1992	268	2					210	216		10.1001/jama.268.2.210	http://dx.doi.org/10.1001/jama.268.2.210			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB279	1608139				2022-12-28	WOS:A1992JB27900027
J	AGY, MB; FRUMKIN, LR; COREY, L; COOMBS, RW; WOLINSKY, SM; KOEHLER, J; MORTON, WR; KATZE, MG				AGY, MB; FRUMKIN, LR; COREY, L; COOMBS, RW; WOLINSKY, SM; KOEHLER, J; MORTON, WR; KATZE, MG			INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	SCIENCE			English	Article							PERSISTENT INFECTION; RHESUS-MONKEYS; HIV INFECTION; MOLECULAR CLONE; CD4 RECEPTOR; T-CELL; AIDS; CHIMPANZEES; MACAQUES; RETROVIRUSES	After observations that Macaca nemestrina were exceptionally susceptible to simian immunodeficiency virus and human immunodeficiency virus type-2 (HIV-2), studies of HIV-1 replication were initiated. Several strains of HIV-1, including a recent patient isolate, replicated in vitro in peripheral blood mononuclear cells (PBMCs) and in CD4-positive M. nemestrina lymphocytes in a CD4-dependent fashion. Eight animals were subsequently inoculated with either cell-associated or cell-free suspensions of HIV-1. All animals had HIV-1 isolated by cocultivation, had HIV-1 DNA in their PBMCs as shown by polymerase chain reaction, and experienced sustained seroconversion to a broad spectrum of HIV-1 proteins. Macaca nemestrina is an animal model of HIV-1 infections that provides opportunities for evaluating the pathogenesis of acute HIV-1 replication and candidate vaccines and therapies.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT LAB MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MICROBIOL,SEATTLE,WA 98195; UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Northwestern University			Wolinsky, Steven/B-2893-2012; Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436; Wolinsky, Steven/0000-0002-9625-6697	NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [AI27757, AI26503] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGY MB, 1990, VIROLOGY, V177, P251, DOI 10.1016/0042-6822(90)90478-A; AGY MB, 1991, VIROLOGY, V183, P170, DOI 10.1016/0042-6822(91)90130-4; AGY MB, UNPUB; ALTER HJ, 1984, SCIENCE, V226, P549, DOI 10.1126/science.6093251; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; BENVENISTE RE, 1988, J VIROL, V62, P2091, DOI 10.1128/JVI.62.6.2091-2101.1988; CASTRO BA, 1991, VIROLOGY, V184, P219, DOI 10.1016/0042-6822(91)90838-3; CHAFFEE S, 1988, J EXP MED, V168, P605, DOI 10.1084/jem.168.2.605; CHALIFOUX LV, 1987, AM J PATHOL, V128, P104; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; DEMATO JJ, 1988, LAB MED, V19, P753; DORMONT D, 1989, INTERVIROLOGY, V30, P59, DOI 10.1159/000150125; EHRNST A, 1988, J MED VIROL, V26, P23, DOI 10.1002/jmv.1890260105; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FRANCHINI G, 1990, J VIROL, V64, P4462, DOI 10.1128/JVI.64.9.4462-4467.1990; FULTZ PN, 1986, J VIROL, V58, P116, DOI 10.1128/JVI.58.1.116-124.1986; FULTZ PN, 1989, AIDS RES HUM RETROV, V5, P397, DOI 10.1089/aid.1989.5.397; FURTADO MR, 1991, VIROLOGY, V185, P258, DOI 10.1016/0042-6822(91)90773-5; GAJDUSEK DC, 1985, LANCET, V1, P55; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; KESTLER H, 1990, SCIENCE, V248, P1109, DOI 10.1126/science.2160735; KINNEYTHOMAS E, 1988, AIDS, V2, P25; KOEHLER JA, UNPUB; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; Kraiselburd E N, 1990, P R Health Sci J, V9, P161; LEVY JA, 1985, VIROLOGY, V147, P441, DOI 10.1016/0042-6822(85)90146-1; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LINSLEY PS, 1988, J VIROL, V62, P3695, DOI 10.1128/JVI.62.10.3695-3702.1988; LUSSO P, 1988, J IMMUNOL, V141, P2467; MCCLURE MO, 1987, NATURE, V330, P487, DOI 10.1038/330487a0; MORROW WJW, 1989, AIDS RES HUM RETROV, V5, P233, DOI 10.1089/aid.1989.5.233; MORTON WR, UNPUB; NAIDU YM, 1988, J VIROL, V62, P4691, DOI 10.1128/JVI.62.12.4691-4696.1988; NARA P, 1989, J MED PRIMATOL, V18, P343; NARA PL, 1987, J VIROL, V61, P3173, DOI 10.1128/JVI.61.10.3173-3180.1987; NICOL I, 1989, INTERVIROLOGY, V30, P258, DOI 10.1159/000150101; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SCHNEIDER J, 1988, AIDS, V2, P1, DOI 10.1097/00002030-198802000-00001; STAHLHENNIG C, 1990, AIDS, V4, P611, DOI 10.1097/00002030-199007000-00001; TRAUNECKER A, 1988, NATURE, V331, P84, DOI 10.1038/331084a0; WAINHOBSON S, 1991, SCIENCE, V252, P961, DOI 10.1126/science.2035026; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992	47	161	172	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 3	1992	257	5066					103	106		10.1126/science.1621083	http://dx.doi.org/10.1126/science.1621083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JC165	1621083				2022-12-28	WOS:A1992JC16500041
J	CHRISTMAN, K; MUSS, HB; CASE, LD; STANLEY, V				CHRISTMAN, K; MUSS, HB; CASE, LD; STANLEY, V			CHEMOTHERAPY OF METASTATIC BREAST-CANCER IN THE ELDERLY - THE PIEDMONT-ONCOLOGY-ASSOCIATION EXPERIENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED TRIAL; CLINICAL ONCOLOGY; CYCLOPHOSPHAMIDE; 5-FLUOROURACIL; METHOTREXATE; AGE; VINCRISTINE; DOXORUBICIN; TOXICITY; PROGRAM	Objective.-To determine the effect of age on treatment outcome in women with metastatic breast cancer treated with chemotherapy. Design.-Case-comparison study of patients with metastatic breast cancer treated in five clinical trials of the Piedmont Oncology Association. Setting.-University and private practice physicians participating in the Piedmont Oncology Association clinical tri,als in the southeastern United States. Patients.-Seventy patients 70 years of age or older were compared with 60 patients aged 50 through 69 years and 40 patients less than 50 years of age. All patients were ambulatory or capable of self-care, with adequate hematologic, renal, and hepatic function. Interventions.-Treatment with multidrug chemotherapy regimens. Main Outcome Measures.-Response to treatment, time to disease progression, survival, and toxic effects. Results.-Pretreatment characteristics including race, performance status; disease-free interval, prior therapy, sites of metastatic disease, and number and dominant sites of metastases were similar for the three age groups. The response rates for the younger-than-50, 50-through-69, and 70-or-older age groups were 40%, 31%, and 29%, respectively (P=.53). There were no significant differences in time to disease progression or survival for patients in the three age groups. Estimates for time to progression and survival were 9.1 and 17.9 months, 6.2 and 12.8 months, and 7.2 and 14.2 months, respectively. Toxic effects, dose delivery, and dose delays were also similar for all three age groups. Conclusions.-Women 70 years of age or older who were enrolled in these trials were similar to their younger counterparts in response rates, time to disease progression, survival, and toxic effects. Women in this age group should not be excluded, based on age alone, from clinical trials involving chemotherapy for advanced breast cancer.	WAKE FOREST UNIV,CTR COMPREHENS CANC,MED CTR BLVD,WINSTON SALEM,NC 27157; PIEDMONT ONCOL ASSOC,WINSTON SALEM,NC	Wake Forest University					NATIONAL CANCER INSTITUTE [U10CA045808, U10CA037378, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45808, CA-37378, CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDUCCI L, 1989, SEMIN ONCOL, V16, P76; BALDWIN JG, 1988, ARCH INTERN MED, V148, P2544, DOI 10.1001/archinte.148.12.2544; BEGG CB, 1980, CANCER CLIN TRIALS, V3, P369; BEGG CB, 1989, CANCER ELDERLY APPRO; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BORING CC, 1991, CA-CANCER J CLIN, V41, P19, DOI 10.3322/canjclin.41.1.19; COX DR, 1972, J R STAT SOC B, V34, P187; GARBER JE, 1989, HEMATOL ONCOL CLIN N, V3, P807, DOI 10.1016/S0889-8588(18)30532-X; GELMAN RS, 1984, J CLIN ONCOL, V2, P1404, DOI 10.1200/JCO.1984.2.12.1404; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; HAYWARD JL, 1977, CANCER, V39, P1289, DOI 10.1002/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F; HENDERSON IC, 1991, BREAST DIS, P604; HOAGLAND HC, 1982, SEMIN ONCOL, V9, P95; HOST H, 1986, CANCER, V58, P996; Hryniuk W M, 1986, NCI Monogr, P87; HUNTER CP, 1987, CANCER TREAT REP, V71, P559; KERR IG, 1989, CANC AGING PROGR RES, P139; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOR V, 1985, J AM GERIATR SOC, V33, P585, DOI 10.1111/j.1532-5415.1985.tb06313.x; MUSS HB, 1991, NEW ENGL J MED, V325, P1342, DOI 10.1056/NEJM199111073251904; MUSS HB, 1982, CANCER, V50, P2269, DOI 10.1002/1097-0142(19821201)50:11<2269::AID-CNCR2820501107>3.0.CO;2-L; MUSS HB, 1981, CANCER, V47, P2295, DOI 10.1002/1097-0142(19810501)47:9<2295::AID-CNCR2820470932>3.0.CO;2-8; MUSS HB, 1978, CANCER, V42, P2141, DOI 10.1002/1097-0142(197811)42:5<2141::AID-CNCR2820420509>3.0.CO;2-3; NERENZ DR, 1986, HEALTH SERV RES, V20, P961; SHANK W, 1991, P AN M AM SOC CLIN, V10, P326; STEWART JA, 1989, SEMIN ONCOL, V16, P41; YANCIK R, 1989, CANCER, V63, P976, DOI 10.1002/1097-0142(19890301)63:5<976::AID-CNCR2820630532>3.0.CO;2-A; ZEKAN PJ, 1984, CANCER, V54, P2338, DOI 10.1002/1097-0142(19841201)54:11<2338::AID-CNCR2820541105>3.0.CO;2-4	28	172	173	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					57	62		10.1001/jama.268.1.57	http://dx.doi.org/10.1001/jama.268.1.57			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608114				2022-12-28	WOS:A1992JA16500023
J	CRANE, TS				CRANE, TS			THE PROBLEM OF PHYSICIAN SELF-REFERRAL UNDER THE MEDICARE AND MEDICAID ANTIKICKBACK STATUTE - THE HANLESTER NETWORK CASE AND THE SAFE HARBOR REGULATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FINANCIAL INCENTIVES	Dramatic changes have taken place in the legal and ethical status of physician self-referral. In July 1991, the US Department of Health and Human Services issued the 'safe harbor' regulation, which permits self-referral only under very narrow constraints. In September 1991, the Department of Health and Human Services Departmental Appeals Board ruled in the landmark Hanlester Network case that joint venture profit distributions are illegal under the antikickback statute when intended to influence investors' reason or judgment in referring Medicare or Medicaid patients. Following this principle on remand in March 1992, the Administrative Law Judge precedentially held that profit distributions violated the statute. Before this remand decision, the Departmental Appeals Board ruling and the safe harbor regulation started the pendulum swinging against self-referral as seen, for example, in the December 1991 revised American Medical Association ethical guidelines. To help providers operate in this new legal and ethical climate, legislation is needed to authorize case-by-case safe harbors.	US DEPT HHS,DIV INSPECTOR GEN,OFF GEN COUNSEL,WASHINGTON,DC 20201									ARQUIT KJ, 1992, JAN NAT HLTH LAW ASS; Freudenheim Milt, 1991, N Y Times Web, P10; Gray BH, 1986, PROFIT ENTERPRISE HL; Gray Bradford H., 1991, PROFIT MOTIVE PATIEN, P111; GREENBERG DS, 1991, LANCET, V338, P1067, DOI 10.1016/0140-6736(91)91914-G; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1989, NEW ENGL J MED, V321, P86, DOI 10.1056/NEJM198907133210205; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; HIMMELSTEIN L, 1992, LEGAL TIMES, V14, P1; HIMMELSTEIN L, 1992, LEGAL TIMES, V14, P18; KELLY TL, 1992, DIMENS HLTH CARE, V92, P1; KUSSEROW RP, 1992, COMMUNICATION   0313; PERRY L, 1989, MOD HEALTHCARE  0630, P25; RELMAN AS, 1991, NEW ENGL J MED, V325, P854, DOI 10.1056/NEJM199109193251205; RELMAN AS, 1985, NEW ENGL J MED, V313, P749, DOI 10.1056/NEJM198509193131209; Starr P, 1982, SOCIAL TRANSFORMATIO; THORNTON DM, 1991, COMMUNICATION   0806; 1991, 39862 INT REV SERV G; FED REGISTER, V56, P35968; 1989, FINANCIAL ARRANGEMEN; FED REGISTER, V56, P35971; 1984, COMP LABORATORY UTIL; FED REGISTER, V56, P35958; FED REGISTER, V56, P35966; 1983, 205200411 DEPT HLTH; 1981, UTILIZATION MEDICAID; FED REGISTER, V56, P35959; FED REGISTER, V56, P35973; 1991, REPORT AM MED ASS CO; 1992, HLTH LAWYERS NEWS RE, V20, P1; 1992, 9270 INT REV SERV AD; 1992, EXEMPT ORG EXAMINATI; FED REGISTER, V56, P35978; FED REGISTER, V54, P3090; 1992, JAMA-J AM MED ASSOC, V267, P2366; FED REGISTER, V56, P35969; 1992, PRESIDENTS COMPREHEN, P68; FED REGISTER, V56, P35984; FED REGISTER, V56, P35967; FED REGISTER, V56, P35954; FED REGISTER, V56, P35964; FED REGISTER, V56, P35987; 1991, JOINT VENTURES HLTH, V2; FED REGISTER, V56, P35952	44	30	30	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1992	268	1					85	91		10.1001/jama.268.1.85	http://dx.doi.org/10.1001/jama.268.1.85			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA165	1608118				2022-12-28	WOS:A1992JA16500028
J	HOBBS, FDR; DRURY, M				HOBBS, FDR; DRURY, M			MANAGING CHANGE IN PRIMARY CARE .5. MEETINGS AND CHAIRMANSHIP	BRITISH MEDICAL JOURNAL			English	Editorial Material							GENERAL-PRACTICE				HOBBS, FDR (corresponding author), UNIV BIRMINGHAM,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,ENGLAND.							FULLARD E, 1987, BRIT MED J, V294, P1080, DOI 10.1136/bmj.294.6579.1080; GRANT GB, 1985, LANCET, V1, P1030; JARMAN B, 1987, BRIT MED J, V294, P1005, DOI 10.1136/bmj.294.6578.1005; MANT D, 1989, BRIT MED J, V298, P1360, DOI 10.1136/bmj.298.6684.1360; MARSH G, 1976, TEAM CARE GENERAL PR; 1986, NEIGHBOURHOOD LIVING; 1974, 1974 DEP HLTH SOC SE; 1991, BR J GEN PRAC, V41, P31	8	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 20	1992	304	6842					1616	1618		10.1136/bmj.304.6842.1616	http://dx.doi.org/10.1136/bmj.304.6842.1616			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA436	1628092	Bronze, Green Published			2022-12-28	WOS:A1992JA43600027
J	FREEMAN, M; KLAMBT, C; GOODMAN, CS; RUBIN, GM				FREEMAN, M; KLAMBT, C; GOODMAN, CS; RUBIN, GM			THE ARGOS GENE ENCODES A DIFFUSIBLE FACTOR THAT REGULATES CELL FATE DECISIONS IN THE DROSOPHILA EYE	CELL			English	Article							SEGMENT POLARITY GENE; NERVOUS-SYSTEM; RECEPTOR; HOMOLOG; MELANOGASTER; WINGLESS; CLONING; EMBRYOS; PROTEIN; DIFFERENTIATION	The argos gene encodes a protein that is required for viability and that regulates the determination of cells in the Drosophila eye. A developmental analysis of argos mutant eyes indicates that the mystery cells, which are usually nonneuronal, are transformed into extra photoreceptors, and that supernumerary cone cells and pigment cells are also recruited. Clonal analysis indicates that argos acts nonautonomously and can diffuse over the range of several cell diameters. Conceptual translation of the argos gene suggests that it encodes a secreted protein.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Rubin, Gerald/0000-0001-8762-8703; Freeman, Matthew/0000-0003-0410-5451				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMAYA E, 1991, CELL, V66, P257; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CAMPOS AR, 1992, DEVELOPMENT, V114, P355; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; DANIELS SB, 1985, GENETICS, V109, P95; FISCHERVIZE JA, 1992, IN PRESS DEVELOPMENT; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GELBART WM, 1989, DEVELOPMENT, V107, P65; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HEBERLEIN U, 1991, DEVELOPMENT, V112, P703; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HORTSCH M, 1990, NEURON, V4, P697, DOI 10.1016/0896-6273(90)90196-M; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; LAWRENCE PA, 1979, DEV BIOL, V71, P142, DOI 10.1016/0012-1606(79)90088-5; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAY RP, 1991, DEVELOPMENT, V113, P35; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBERTSON HM, 1988, GENETICS, V118, P461; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wieschaus E., 1986, P199; WOLFF T, 1991, DEVELOPMENT, V113, P825	59	218	222	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					963	975		10.1016/0092-8674(92)90615-J	http://dx.doi.org/10.1016/0092-8674(92)90615-J			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606617				2022-12-28	WOS:A1992HY79200008
J	HUARTE, J; STUTZ, A; OCONNELL, ML; GUBLER, P; BELIN, D; DARROW, AL; STRICKLAND, S; VASSALLI, JD				HUARTE, J; STUTZ, A; OCONNELL, ML; GUBLER, P; BELIN, D; DARROW, AL; STRICKLAND, S; VASSALLI, JD			TRANSIENT TRANSLATIONAL SILENCING BY REVERSIBLE MESSENGER-RNA DEADENYLATION	CELL			English	Article							XENOPUS OOCYTE MATURATION; MOUSE OOCYTES; PLASMINOGEN-ACTIVATOR; MEIOTIC MATURATION; POLY(A) ADDITION; RICH SEQUENCES; CYTOPLASMIC POLYADENYLATION; SPISULA OOCYTES; DEGRADATION; FERTILIZATION	Tissue-type plasminogen activator (tPA) mRNA is stored, stable and untranslated, in the cytoplasm of fully grown primary mouse oocytes. Dormancy is associated with an unusually short poly(A) tail, and poly(A) tail elongation controls tPA mRNA translational activation during meiotic maturation. Here we show that the nuclear transcript of this mRNA is extensively polyadenylated and that primary oocytes contain a deadenylating activity capable of silencing the cytoplasmic message. The sequence determinants that control deadenylation and polyadenylation overlap; this AU-rich region thus serves as an adenylation control element (ACE). The translation of a reporter mRNA in primary oocytes is prevented upon inclusion of an ACE in its 3' untranslated region. Therefore, the stage-specific regulation of poly(A) tail length accounts for the regulated synthesis of tPA in oocytes, and reversible deadenylation provides a mechanism for the translational control of dormant mRNAs.	SUNY STONY BROOK, DEPT PHARMACOL, STONY BROOK, NY 11794 USA; UNIV GENEVA, SCH MED, DEPT PATHOL, CH-1211 GENEVA 4, SWITZERLAND	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Geneva	HUARTE, J (corresponding author), UNIV GENEVA, SCH MED, INST HISTOL & EMBRYOL, CH-1211 GENEVA 4, SWITZERLAND.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017875, R01HD025922] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-25922, HD-17875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTABA AR, 1987, EMBO J, V6, P3065, DOI 10.1002/j.1460-2075.1987.tb02613.x; BACHVAROVA R, 1985, DEV BIOL, V108, P325, DOI 10.1016/0012-1606(85)90036-3; BAER BW, 1980, P NATL ACAD SCI-BIOL, V77, P1890, DOI 10.1073/pnas.77.4.1890; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Davidson E. H., 1986, GENE ACTIVITY EARLY; DELEON V, 1983, DEV BIOL, V98, P400, DOI 10.1016/0012-1606(83)90369-X; FENG P, 1990, J BIOL CHEM, V265, P2022; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FOX CA, 1990, GENE DEV, V4, P2287, DOI 10.1101/gad.4.12b.2287; HAN J, 1991, J IMMUNOL, V146, P1843; HUARTE J, 1985, CELL, V43, P551, DOI 10.1016/0092-8674(85)90184-9; HUARTE J, 1987, GENE DEV, V1, P1201, DOI 10.1101/gad.1.10.1201; KONECKI DS, 1982, NUCLEIC ACIDS RES, V10, P6763, DOI 10.1093/nar/10.21.6763; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MCGREW LL, 1990, EMBO J, V9, P3743, DOI 10.1002/j.1460-2075.1990.tb07587.x; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NEVINS JR, 1978, CELL, V15, P1477, DOI 10.1016/0092-8674(78)90071-5; PARIS J, 1990, MOL CELL BIOL, V10, P5634, DOI 10.1128/MCB.10.11.5634; PAYNTON BV, 1988, DEV BIOL, V129, P304, DOI 10.1016/0012-1606(88)90377-6; RICHTER JD, 1991, BIOESSAYS, V13, P179, DOI 10.1002/bies.950130406; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; ROSENTHAL ET, 1983, J MOL BIOL, V166, P309, DOI 10.1016/S0022-2836(83)80087-4; ROSENTHAL ET, 1987, DEV BIOL, V121, P237, DOI 10.1016/0012-1606(87)90155-2; SALES FJ, 1992, IN PRESS GENES DEV; Sambrook J, 1989, MOL CLONING LABORATO; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STRICKLAND S, 1988, SCIENCE, V241, P680, DOI 10.1126/science.2456615; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; VARNUM SM, 1990, GENE DEV, V4, P2278, DOI 10.1101/gad.4.12b.2278; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	35	208	209	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 12	1992	69	6					1021	1030		10.1016/0092-8674(92)90620-R	http://dx.doi.org/10.1016/0092-8674(92)90620-R			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HY792	1606611				2022-12-28	WOS:A1992HY79200013
J	DIRICK, L; MOLL, T; AUER, H; NASMYTH, K				DIRICK, L; MOLL, T; AUER, H; NASMYTH, K			A CENTRAL ROLE FOR SWI6 IN MODULATING CELL-CYCLE START-SPECIFIC TRANSCRIPTION IN YEAST	NATURE			English	Article							HO GENE; CEREVISIAE; SEQUENCE	MOST genes involved in DNA replication in the yeast Saccharomyces cerevisiae are transcribed transiently during late G1 as cells become committed to a new cell cycle at Start 1. Their promoters all contain one or more versions of an 8-base-pair motif (ACGCGTNA) containing an MluI restriction enzyme site and called the MluI cell-cycle box (MCB) 2. MCBs are both necessary and sufficient for the late G1-specific transcription of the TMP1 thymidylate synthase and POL1 DNA polymerase genes 3,4. A different late G1-specific 8-base-pair transcription element called the SCB (CACGAAAA; ref. 5) is bound by a factor containing the Swi4 and Swi6 proteins 6,7. We describe here the formation in vitro of complexes on TMP1 MCBs that contain the Swi6 protein and, we suggest, a protein of relative molecular mass 120,000 (p120) that is distinct from Swi4. Transcription due to SCBs and MCBs occurs in the absence of Swi6 but it is no longer correctly regulated in the cell cycle. We suggest that Swi6 is an essential regulatory subunit of two different Start-dependent transcription factors. One factor (SBF) contains Swi4 and binds to SCBs, whereas the other (MBF) contains the protein p120 and binds MCBs.	INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Auer, Herbert/AAV-2332-2020	Nasmyth, Kim/0000-0001-7030-4403				AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; ANDREWS BJ, 1990, J BIOL CHEM, V265, P14057; ANDREWS BJ, 1989, NATURE, V342, P803; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GORDON CB, 1991, P NATL ACAD SCI USA, V88, P6058, DOI 10.1073/pnas.88.14.6058; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; Maxam A M, 1980, Methods Enzymol, V65, P499; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MOLL T, IN PRESS J CELL SCI; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PIZZAGALLI A, 1988, P NATL ACAD SCI USA, V85, P3772, DOI 10.1073/pnas.85.11.3772; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STURM R, 1987, GENE DEV, V1, P1147, DOI 10.1101/gad.1.10.1147; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000	26	163	165	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 11	1992	357	6378					508	513		10.1038/357508a0	http://dx.doi.org/10.1038/357508a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HY052	1608451				2022-12-28	WOS:A1992HY05200067
J	PICCIRILLI, JA; MCCONNELL, TS; ZAUG, AJ; NOLLER, HF; CECH, TR				PICCIRILLI, JA; MCCONNELL, TS; ZAUG, AJ; NOLLER, HF; CECH, TR			AMINOACYL ESTERASE-ACTIVITY OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							SELF-SPLICING RNA; GROUP-I INTRON; BINDING-SITE; ENDORIBONUCLEASE ACTIVITY; THERMOPHILA RIBOZYME; KINETIC DESCRIPTION; RIBONUCLEASE-P; CATALYSIS; CLEAVAGE; SUBSTRATE	Several classes of ribozymes (catalytic RNA's) catalyze reactions at phosphorus centers, but apparently no reaction at a carbon center has been demonstrated. The active site of the Tetrahymena ribozyme was engineered to bind an oligonucleotide derived from the 3' end of N-formyl-methionyl-tRNA(fMet). This ribozyme catalyzes the hydrolysis of the aminoacyl ester bond to a modest extent, 5 to 15 times greater than the uncatalyzed rate. Catalysis involves binding of the oligonucleotide to the internal guide sequence of the ribozyme and requires Mg2+ and sequence elements of the catalytic core. The ability of RNA to catalyze reactions with aminoacyl esters expands the catalytic versatility of RNA and suggests that the first aminoacyl tRNA synthetase could have been an RNA molecule.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV CALIF SANTA CRUZ,SINSHEIMER LABS,SANTA CRUZ,CA 95064	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of California System; University of California Santa Cruz								ALTMAN S, 1990, J BIOL CHEM, V265, P20053; BARFOD ET, 1989, MOL CELL BIOL, V9, P3657, DOI 10.1128/MCB.9.9.3657; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; Benkovic S. J, 1973, ENZYMES, P201; Benkovic S. J., 1978, TRANSITION STATES BI, P493; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BUERGI HB, 1973, J AM CHEM SOC, V95, P5605; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; DAVIES RW, 1982, NATURE, V300, P719, DOI 10.1038/300719a0; DESLONGC.P, 1972, CAN J CHEMISTRY, V50, P3405, DOI 10.1139/v72-549; DOUDNA JA, 1989, P NATL ACAD SCI USA, V86, P7402, DOI 10.1073/pnas.86.19.7402; DOWNS WD, 1990, BIOCHEMISTRY-US, V29, P5605, DOI 10.1021/bi00475a027; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FORSTER AC, 1990, SCIENCE, V249, P784; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; GROSSHANS CA, 1989, BIOCHEMISTRY-US, V28, P6888, DOI 10.1021/bi00443a017; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1990, NATURE, V344, P405, DOI 10.1038/344405a0; HERSCHLAG D, UNPUB; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LERNER RA, 1988, BIOESSAYS, V9, P107, DOI 10.1002/bies.950090402; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; Monro RE., 1971, METHOD ENZYMOL, V20, P472; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; ORGEL LE, 1986, J THEOR BIOL, V123, P127, DOI 10.1016/S0022-5193(86)80149-7; PACE NR, 1985, ORIGINS LIFE EVOL B, V16, P97, DOI 10.1007/BF01809465; PACE NR, 1990, J BIOL CHEM, V265, P3587; PICCIRILLI JA, UNPUB; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTZ PG, 1990, CHEM ENG NEWS, V68, P26, DOI 10.1021/cen-v068n022.p026; SYMONS RH, 1991, CRIT REV PLANT SCI, V10, P189, DOI 10.1080/07352689109382312; SZOSTAK JW, 1986, NATURE, V322, P83, DOI 10.1038/322083a0; TAIJI M, 1985, BIOCHEMISTRY-US, V24, P5776, DOI 10.1021/bi00342a013; VISSER CM, 1984, ORIGINS LIFE EVOL B, V14, P291, DOI 10.1007/BF00933670; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; WARING RB, 1986, NATURE, V321, P133, DOI 10.1038/321133a0; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WESTHEIMER FH, 1986, NATURE, V319, P534, DOI 10.1038/319534a0; White H. I., 1982, PYRIDINE NUCLEOTIDE; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Woese C.R., 1967, MOL BASIS GENETIC EX, P186; WOLFENDEN R, 1963, BIOCHEMISTRY-US, V2, P1090, DOI 10.1021/bi00905a031; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	61	165	176	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 5	1992	256	5062					1420	1424		10.1126/science.1604316	http://dx.doi.org/10.1126/science.1604316			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX337	1604316				2022-12-28	WOS:A1992HX33700027
J	CHOPIN, K				CHOPIN, K			LETTER FROM POLAND - TOO MANY ADVISERS, NOT ENOUGH AID	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRISTOL,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol									0	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1429	1432		10.1136/bmj.304.6839.1429	http://dx.doi.org/10.1136/bmj.304.6839.1429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628024	Green Published, Bronze			2022-12-28	WOS:A1992HX08200029
J	HANSMA, HG; VESENKA, J; SIEGERIST, C; KELDERMAN, G; MORRETT, H; SINSHEIMER, RL; ELINGS, V; BUSTAMANTE, C; HANSMA, PK				HANSMA, HG; VESENKA, J; SIEGERIST, C; KELDERMAN, G; MORRETT, H; SINSHEIMER, RL; ELINGS, V; BUSTAMANTE, C; HANSMA, PK			REPRODUCIBLE IMAGING AND DISSECTION OF PLASMID DNA UNDER LIQUID WITH THE ATOMIC FORCE MICROSCOPE	SCIENCE			English	Article							SCANNING TUNNELING MICROSCOPY; NUCLEIC-ACIDS; WATER; RESOLUTION; SURFACE; IMAGES; AIR	Reproducible images of uncoated DNA in the atomic force microscope (AFM) have been obtained by imaging plasmid DNA on mica in n-propanol. Specially sharpened AFM tips give images with reproducible features several nanometers in size along the DNA. Plasmids can be dissected in propanol by increasing the force applied by the AFM tip at selected locations.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; DIGITAL INSTRUMENTS INC,SANTA BARBARA,CA 93117	University of Oregon	HANSMA, HG (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106, USA.			Bustamante, Carlos/0000-0002-2970-0073	NIGMS NIH HHS [GM32543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032543, R37GM032543] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKAMA Y, 1990, J VAC SCI TECHNOL A, V8, P429, DOI 10.1116/1.576413; ALBRECHT TR, 1988, J VAC SCI TECHNOL A, V6, P271, DOI 10.1116/1.575441; ALLEN MJ, IN PRESS ULTRAMICROS; BEEBE TP, 1989, SCIENCE, V243, P370, DOI 10.1126/science.2911747; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BINNIG G, 1987, EUROPHYS LETT, V3, P1281, DOI 10.1209/0295-5075/3/12/006; BUSTAMANTE C, 1992, BIOCHEMISTRY-US, V31, P22, DOI 10.1021/bi00116a005; CLEMMER CR, 1991, SCIENCE, V251, P640, DOI 10.1126/science.1992517; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; DRISCOLL RJ, 1990, NATURE, V346, P294, DOI 10.1038/346294a0; DUNLAP DD, 1989, NATURE, V342, P204, DOI 10.1038/342204a0; HANSMA HG, 1991, J VAC SCI TECHNOL B, V9, P1282, DOI 10.1116/1.585221; HECKL WM, 1991, P NATL ACAD SCI USA, V88, P8003, DOI 10.1073/pnas.88.18.8003; HECKL WM, IN PRESS ULTRAMICROS; HECKL WM, 1992, NONLINEAR OPTICS, V1, P53; HENDERSON E, IN PRESS NUCLEIC ACI; HOH JH, 1991, SCIENCE, V253, P1405, DOI 10.1126/science.1910206; Israelachvili JN, 1985, INTERMOLECULAR SURFA; JEFFREY GA, 1991, HYDROGEN BONDONG BIO; KELLER D, IN PRESS SURF SCI; KOLLER T, 1974, BIOPOLYMERS, V13, P995, DOI 10.1002/bip.1974.360130514; KUNISADA T, 1983, PLASMID, V9, P8, DOI 10.1016/0147-619X(83)90027-6; LEE G, 1989, SCIENCE, V244, P475, DOI 10.1126/science.2470146; LEE KL, 1989, J VAC SCI TECHNOL B, V7, P1941, DOI 10.1116/1.584652; LINDSAY SM, 1989, SCIENCE, V244, P1063, DOI 10.1126/science.2727694; LIU CY, 1991, LANGMUIR, V7, P1138, DOI 10.1021/la00054a020; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHNEIR J, 1986, PHYS REV B, V34, P4979, DOI 10.1103/PhysRevB.34.4979; VASILE MJ, 1991, REV SCI INSTRUM, V62, P2167, DOI 10.1063/1.1142334; VESENKA J, IN PRESS ULTRAMICROS; WEISENHORN AL, 1989, APPL PHYS LETT, V54, P2651, DOI 10.1063/1.101024; WEISENHORN AL, 1991, LANGMUIR, V7, P8, DOI 10.1021/la00049a003	33	484	497	0	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 22	1992	256	5060					1180	1184		10.1126/science.256.5060.1180	http://dx.doi.org/10.1126/science.256.5060.1180			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HV192	1589799				2022-12-28	WOS:A1992HV19200028
J	WAUD, DR				WAUD, DR			PHARMACEUTICAL PROMOTIONS - A FREE LUNCH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											WAUD, DR (corresponding author), UNIV MASSACHUSETTS,SCH MED,DEPT PHARMACOL,S7-137,55 LAKE AVE N,WORCESTER,MA 01655, USA.							GOLDFINGER SE, 1990, ANN INTERN MED, V112, P624	1	68	68	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 30	1992	327	5					351	353		10.1056/NEJM199207303270511	http://dx.doi.org/10.1056/NEJM199207303270511			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JF655	1620175				2022-12-28	WOS:A1992JF65500011
J	PARRILLO, JE				PARRILLO, JE			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAM-NEGATIVE BACTEREMIA; SEPTIC SHOCK; ENDOTOXIN; IMPACT; UNIT				PARRILLO, JE (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,CHICAGO,IL 60612, USA.							COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HOLLENBERG SM, 1991, CHEST, V100, P1133, DOI 10.1378/chest.100.4.1133; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEE L, 1988, CIRCULATION, V78, P1345, DOI 10.1161/01.CIR.78.6.1345; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; MUNDTH ED, 1976, CIRCULATION, V53, P176; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; NATANSON C, 1990, AM J PHYSIOL, V259, pH1440, DOI 10.1152/ajpheart.1990.259.5.H1440; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PARRILLO JE, 1985, JAMA-J AM MED ASSOC, V254, P2288, DOI 10.1001/jama.1985.03360160120029; PARRILLO JE, 1990, ANN INTERN MED, V113, P27; REYNOLDS HN, 1988, JAMA-J AM MED ASSOC, V260, P3446, DOI 10.1001/jama.260.23.3446; VANDEVENTER SJH, 1988, LANCET, V1, P605; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1992	268	3					340	342						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC352	1613913				2022-12-28	WOS:A1992JC35200023
J	WOEBER, KA				WOEBER, KA			CURRENT CONCEPTS - THYROTOXICOSIS AND THE HEART	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LEFT-VENTRICULAR FUNCTION; ATRIAL-FIBRILLATION; THYROID-HORMONE; ELDERLY PATIENTS; RAT-HEART; HYPERTHYROIDISM; STATE; CARDIOMYOPATHY; DYSFUNCTION; DISEASE				WOEBER, KA (corresponding author), UNIV CALIF SAN FRANCISCO, MT ZION MED CTR, DEPT MED, 1600 DIVISADERO ST, SAN FRANCISCO, CA 94115 USA.							ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; BAYER MF, 1991, MED CLIN N AM, V75, P1; BILEZIKIAN JP, 1983, ENDOCR REV, V4, P378, DOI 10.1210/edrv-4-4-378; CALLAS G, 1974, ANAT REC, V178, P539, DOI 10.1002/ar.1091780303; CAVALIERI RR, 1991, MED CLIN N AM, V75, P27, DOI 10.1016/S0025-7125(16)30470-9; CHANNICK BJ, 1981, NEW ENGL J MED, V305, P497, DOI 10.1056/NEJM198108273050906; CHAUDHURY S, 1987, MOL ENDOCRINOL, V1, P83, DOI 10.1210/mend-1-1-83; DAVIES AB, 1985, BRIT MED J, V291, P773, DOI 10.1136/bmj.291.6498.773; DEGROOT WJ, 1970, AM HEART J, V79, P265, DOI 10.1016/0002-8703(70)90318-2; FELDMAN T, 1986, J AM COLL CARDIOL, V7, P967, DOI 10.1016/S0735-1097(86)80213-3; FORFAR JC, 1979, AM J CARDIOL, V44, P9, DOI 10.1016/0002-9149(79)90243-1; FORFAR JC, 1982, NEW ENGL J MED, V307, P1165, DOI 10.1056/NEJM198211043071901; FREEDBERG AS, 1970, J PHYSIOL-LONDON, V207, P357, DOI 10.1113/jphysiol.1970.sp009066; GILADI M, 1991, INT J CARDIOL, V30, P309, DOI 10.1016/0167-5273(91)90008-D; GLIKSON M, 1991, POSTGRAD MED J, V67, P81, DOI 10.1136/pgmj.67.783.81; GOLDMAN S, 1983, NEW ENGL J MED, V308, P780; IKRAM H, 1985, Q J MED, V54, P19; ISLEY WL, 1990, AM J MED, V89, P122, DOI 10.1016/0002-9343(90)90114-S; IWASAKI T, 1989, CARDIOLOGY, V76, P10, DOI 10.1159/000174467; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KIM D, 1987, J CLIN INVEST, V80, P88, DOI 10.1172/JCI113068; KLEIN I, 1986, J CLIN INVEST, V77, P1694, DOI 10.1172/JCI112488; LEVEY GS, 1990, AM J MED, V88, P642, DOI 10.1016/0002-9343(90)90533-J; Levine SA, 1924, BOSTON MED SURG J, V190, P233, DOI 10.1056/NEJM192402141900703; LEVY EG, 1991, MED CLIN N AM, V75, P151, DOI 10.1016/S0025-7125(16)30476-X; LIGGETT SB, 1989, J CLIN INVEST, V83, P803, DOI 10.1172/JCI113961; Likoff WB, 1943, AM J MED SCI, V206, P425; LOELIGER EA, 1964, THROMB DIATH HAEMOST, V10, P267; MAGNER JA, 1988, WESTERN J MED, V149, P86; MERILLON JP, 1981, BRIT HEART J, V46, P137; MINTZ G, 1991, J CLIN ENDOCR METAB, V73, P146, DOI 10.1210/jcem-73-1-146; NAKAZAWA HK, 1982, AM J MED, V72, P903, DOI 10.1016/0002-9343(82)90850-6; NOAH MS, 1988, INT J CARDIOL, V19, P217, DOI 10.1016/0167-5273(88)90082-4; OSTRANDER LD, 1965, CIRCULATION, V31, P888, DOI 10.1161/01.CIR.31.6.888; PETERSEN P, 1988, STROKE, V19, P15, DOI 10.1161/01.STR.19.1.15; PRESTI CF, 1989, AM HEART J, V117, P976, DOI 10.1016/0002-8703(89)90642-X; ROHRER D, 1988, J BIOL CHEM, V263, P6941; RONNOVJE.V, 1973, BMJ-BRIT MED J, V1, P41, DOI 10.1136/bmj.1.5844.41; ROTI E, 1988, ARCH INTERN MED, V148, P1919, DOI 10.1001/archinte.148.9.1919; SANDLER G, 1959, Q J MED, V28, P347; Saphir O, 1942, ARCH PATHOL, V33, P88; SHENFIELD GM, 1981, CLIN PHARMACOKINET, V6, P275, DOI 10.2165/00003088-198106040-00003; SIMONE JV, 1965, NEW ENGL J MED, V273, P1057, DOI 10.1056/NEJM196511112732001; SPENCER CA, 1990, J CLIN ENDOCR METAB, V70, P453, DOI 10.1210/jcem-70-2-453; SUMMERS VK, 1961, ACTA MED SCAND, V169, P661; TAJIRI J, 1986, JPN HEART J, V27, P183	47	225	232	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	1992	327	2					94	98						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JC214	1603141				2022-12-28	WOS:A1992JC21400006
J	FARMER, G; BARGONETTI, J; ZHU, H; FRIEDMAN, P; PRYWES, R; PRIVES, C				FARMER, G; BARGONETTI, J; ZHU, H; FRIEDMAN, P; PRYWES, R; PRIVES, C			WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO	NATURE			English	Article							PROTEIN; REPLICATION; ONCOGENE; ANTIGEN; MUTANT	THE p53 protein is an important determinant in human cancer and regulates the growth of cells in culture 1-3. It is known to be a sequence-specific DNA-binding protein 4,5 with a powerful activation domain 6-8, but it has not been established whether it regulates transcription directly. Here we show that intact purified wild-type human and murine p53 proteins strongly activate transcription in vitro. This activation depends on the ability of p53 to bind to a template bearing a p53-binding sequence. By contrast, tumour-derived mutant p53 proteins cannot activate transcription from the template at all, and when complexed to wild-type p53, these mutants block transcriptional activation by the wild-type protein. Moreover, the simian virus 40 large T antigen inhibits wild-type p53 from activating transcription. Our results support a model in which p53 directly activates transcription but this activity can be inhibited by mutant p53 and SV40 large T antigen through interaction with wild-type p53.			FARMER, G (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.			Bargonetti, Jill/0000-0003-2692-0991				BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MURAKAMI Y, 1990, ONCOGENE, V5, P5; OROURKE RW, 1990, ONCOGENE, V5, P1829; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SOUSSI T, 1990, ONCOGENE, V5, P945; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4750; ZAMBETTI GP, IN PRESS GENES DEV; ZHU H, 1991, NEW BIOL, V3, P455	31	648	663	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 2	1992	358	6381					83	86		10.1038/358083a0	http://dx.doi.org/10.1038/358083a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JB341	1614538				2022-12-28	WOS:A1992JB34100060
J	LITWIN, MA; WILLIAMS, CM				LITWIN, MA; WILLIAMS, CM			CUTANEOUS PNEUMOCYSTIS-CARINII INFECTION MIMICKING KAPOSI-SARCOMA	ANNALS OF INTERNAL MEDICINE			English	Note						SARCOMA, KAPOSIS PNEUMOCYSTIS-CARINII; ACQUIRED IMMUNODEFICIENCY SYNDROME; SKIN DISEASES, INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS	ACQUIRED IMMUNODEFICIENCY SYNDROME; MANIFESTATION	Extrapulmonary Pneumocystis carinii infection is rare in patients with the acquired immunodeficiency syndrome (AIDS). We report a case of cutaneous P. carinii that was clinically indistinguishable from the lesions of Kaposi sarcoma in a patient with AIDS. This case is the first report of disseminated cutaneous P. carinii simulating wide-spread Kaposi sarcoma without obvious pulmonary involvement. Only two cases of cutaneous pneumocystosis have recently been noted in a location other than the external auditory canal. We stress the importance of biopsy in obtaining the correct diagnosis of cutaneous lesions in patients with AIDS.	GEORGE WASHINGTON UNIV, MED CTR, DEPT DERMATOL, 2150 PENNSYLVANIA AVE NW, WASHINGTON, DC 20037 USA	George Washington University								BREDA SD, 1988, ANN OTO RHINOL LARYN, V97, P427, DOI 10.1177/000348948809700418; COULMAN CU, 1987, ANN INTERN MED, V106, P396, DOI 10.7326/0003-4819-106-3-396; DAVEY RT, 1989, ANN INTERN MED, V111, P681, DOI 10.7326/0003-4819-111-8-681; GHERMAN CR, 1988, AM J MED, V85, P250, DOI 10.1016/S0002-9343(88)80354-1; HENNESSEY NP, 1991, ARCH DERMATOL, V127, P1699, DOI 10.1001/archderm.127.11.1699; KWOK S, 1982, NEW ENGL J MED, V307, P184; RAVIGLIONE MC, 1989, ANN INTERN MED, V111, P339, DOI 10.7326/0003-4819-111-4-339; SCHINELLA RA, 1987, ANN INTERN MED, V106, P399, DOI 10.7326/0003-4819-106-3-399; TELZAK EE, 1990, REV INFECT DIS, V12, P380	9	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1992	117	1					48	49		10.7326/0003-4819-117-1-48	http://dx.doi.org/10.7326/0003-4819-117-1-48			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JA435	1596046				2022-12-28	WOS:A1992JA43500008
J	CHAUHAN, AJ; MCLINDON, JP; DILLON, P; SAWYER, JPC; GRAY, L; LEAHY, BC				CHAUHAN, AJ; MCLINDON, JP; DILLON, P; SAWYER, JPC; GRAY, L; LEAHY, BC			REGULAR BALLOON INFLATION FOR PATIENTS WITH CHRONIC-BRONCHITIS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article											CHAUHAN, AJ (corresponding author), TRAFFORD GEN HOSP,DEPT MED,MANCHESTER M31 3SL,ENGLAND.							BELMAN MJ, 1980, AM REV RESPIR DIS, V121, P273; BELMAN MJ, 1991, CHEST, V99, P566, DOI 10.1378/chest.99.3.566; GUYATT GH, 1991, RESP MED, V85, P17, DOI 10.1016/S0954-6111(06)80164-2; SINCLAIR DJM, 1980, BRIT MED J, V1, P519	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 27	1992	304	6843					1668	1669		10.1136/bmj.304.6843.1668-a	http://dx.doi.org/10.1136/bmj.304.6843.1668-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	JB939	1633520	Green Published, Bronze			2022-12-28	WOS:A1992JB93900023
J	OBERG, A				OBERG, A			SPACE SCIENCE IN TEXAS MEANS BASIC RESEARCH AS WELL AS SUPPORT FOR MANNED FLIGHTS	NATURE			English	Editorial Material																		1992, NATURE, V357, P184	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 25	1992	357	6380					637	638		10.1038/357637a0	http://dx.doi.org/10.1038/357637a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	JA430	1614511				2022-12-28	WOS:A1992JA43000034
J	CHOPIN, K				CHOPIN, K			POLLUTION MOST FOUL .2.	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRISTOL,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol								KABALA SJ, 1990, ENV CRISIS CENTRAL E; NORSKABOROWKA I, 1990, LANCET, V335, P1392	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 6	1992	304	6840					1495	1497		10.1136/bmj.304.6840.1495	http://dx.doi.org/10.1136/bmj.304.6840.1495			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HY553	1611376	Green Published, Bronze			2022-12-28	WOS:A1992HY55300029
J	MARSH, RL; OLSON, JM; GUZIK, SK				MARSH, RL; OLSON, JM; GUZIK, SK			MECHANICAL PERFORMANCE OF SCALLOP ADDUCTOR MUSCLE DURING SWIMMING	NATURE			English	Article								MECHANICAL performance of skeletal muscle has long been the subject of intense interest 1, but the details of in vivo performance of individual skeletal muscles during normal locomotion remain largely unknown. Performance in vitro has been described with considerable precision under simplified loading conditions 2. The force production and shortening velocity of most muscles, however, probably change continuously during natural movements. Therefore, modelling in vivo performance on the basis of in vitro contractile properties 3 is subject to large degrees of uncertainty. Designing in vitro experiments that effectively examine the limits of mechanical performance requires increasing knowledge of precisely how muscles are used during normal movements. We report here measurements of the mechanical performance of the adductor muscle in scallops during jet-propulsion swimming. Swimming in scallops is powered solely by the striated portion of the single adductor muscle. Exploiting this simple locomotor morphology with simultaneous high-resolution measurements of pressure and flow rate, we have recorded nearly instantaneous measurements of the performance of a single skeletal muscle during normal locomotion.			MARSH, RL (corresponding author), NORTHEASTERN UNIV,DEPT BIOL,360 HUNTINGTON AVE,BOSTON,MA 02115, USA.			Marsh, Richard/0000-0002-4264-9890				BENNETCLARK HC, 1975, J EXP BIOL, V63, P53; DANIEL TL, 1984, AM ZOOL, V24, P121; DAVIES CTM, 1989, EUR J APPL PHYSIOL O, V58, P838, DOI 10.1007/BF02332216; GADE G, 1978, J COMP PHYSIOL, V124, P121; HILL AV, 1920, J PHYSIOL-LONDON, V53, pR88; LOWY J, 1954, J PHYSIOL-LONDON, V124, P100, DOI 10.1113/jphysiol.1954.sp005088; MELLON D, 1969, Z VERGL PHYSIOL, V62, P318; MOORE J D, 1971, Journal of Experimental Marine Biology and Ecology, V6, P179, DOI 10.1016/0022-0981(71)90017-7; TRUEMAN ER, 1953, J EXP BIOL, V30, P453; VANLEEUWEN JL, 1991, J THEOR BIOL, V149, P229, DOI 10.1016/S0022-5193(05)80279-6; WANG CY, 1979, J BIOMECH, V12, P9, DOI 10.1016/0021-9290(79)90003-4; WILKENS LA, 1981, PROC R SOC SER B-BIO, V211, P341, DOI 10.1098/rspb.1981.0011; Woledge RC., 1985, ENERGETIC ASPECTS MU; Yonge C. M., 1936, Mem Mus Hist Nat Belg (2), V3, P77; [No title captured]	15	81	81	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 4	1992	357	6377					411	413		10.1038/357411a0	http://dx.doi.org/10.1038/357411a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HX172	1594046				2022-12-28	WOS:A1992HX17200065
J	KENNY, N; HILL, J				KENNY, N; HILL, J			GONAD PROTECTION IN YOUNG ORTHOPEDIC PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective - To determine whether gonad shields are correctly positioned on the pelvic radiographs of children with slipped capital femoral epiphysis. Design - Retrospective study of radiographs taken of children treated by in situ pinning of slipped capital femoral epiphysis between 1 january 1983 and 31 December 1988. Setting - Three teaching hospitals in north west England. Patients - 32 patients with complete set of radiographs. Results - An average of 10.8 anteroposterior pelvic radiographs plus 8.9 lateral hip radiographs had been performed per patient. Gonad shields had been completely omitted in 137 (40%) anteroposterior pelvic radiographs performed on the 32 patients at the time of completion of the study. In 100 (29%) the gonad shields were adequately protecting the gonads, but in 109(31%) the gonad shields were not protecting the gonads due to incorrect positioning of the shield. The incorrect positioning of the gonad shields was more commonly found in girls than boys (64 v 45; p < 0.012), presumably because of the difficulty in determining gonadal position in relation to surface landmarks. Absence of gonad shields was also more commonly seen in girls (82 v 55; p < 0.005), but this is not easily explained. Conclusions - Gonad shields are not protecting the gonads in a large percentage of anteroposterior pelvic radiographs (71%) because they have been omitted or inadequately placed. This avoidable excess radiation exposure to the gonads, combined with the inability to shield the gonads in lateral hip radiographs and the large number of radiographs performed, results in the gonads receiving a higher dose of radiation than may otherwise be the case, and may increase the potential for disease in the future offspring of these patients.	ROYAL PRESTON HOSP,RADIOL & NUCL MED,PRESTON PR2 4HT,LANCS,ENGLAND	Royal Preston Hospital	KENNY, N (corresponding author), ANCOATS HOSP,MANCHESTER M4 6EB,ENGLAND.							[Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1977, ANN ICRP, V1, P228; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KENDALL GM, 1980, NRPBR104; MCKINNEY PA, 1991, BRIT MED J, V302, P681, DOI 10.1136/bmj.302.6778.681; RICHARDSON RB, 1990, BRIT J RADIOL, V63, P235, DOI 10.1259/0007-1285-63-748-235; RUSSELL JGB, 1986, BRIT J RADIOL, V59, P630, DOI 10.1259/0007-1285-59-702-630; WALL BF, 1980, NRPBR105; 1990, PATIENT DOSE REDUCTI; 1989, WORKING PATIENTS; 1991, BRIT J RADIOL, V64, P53; 1991, WHICH            JAN, P40; 1991, ANN ICRP, V21, P1	13	23	23	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 30	1992	304	6839					1411	1413		10.1136/bmj.304.6839.1411	http://dx.doi.org/10.1136/bmj.304.6839.1411			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX082	1628015	Green Published, Bronze			2022-12-28	WOS:A1992HX08200018
J	GRUSS, P; WALTHER, C				GRUSS, P; WALTHER, C			PAX IN DEVELOPMENT	CELL			English	Review							GENES; CONSERVATION; DROSOPHILA; NOTOCHORD; PROTEINS; DOMAIN; BOX				GRUSS, P (corresponding author), MAX PLANCK INST BIOPHYS CHEM,DEPT MOLEC CELL BIOL,W-3400 GOTTINGEN,GERMANY.							BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; DEUTSCH U, 1991, SEMIN DEV BIOL, V2, P413; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; LUFKIN T, 1991, CELL, V66, P1105, DOI 10.1016/0092-8674(91)90034-V; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MOASE CE, 1991, DEVELOPMENT, V113, P1049; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PUSCHEL AW, 1991, DEVELOPMENT, V112, P279; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREISMAN J, 1989, CELL, V59, P553; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435	25	401	405	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 29	1992	69	5					719	722		10.1016/0092-8674(92)90281-G	http://dx.doi.org/10.1016/0092-8674(92)90281-G			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	HW838	1591773				2022-12-28	WOS:A1992HW83800002
J	RUBENS, RD				RUBENS, RD			CURRENT ISSUES IN CANCER .3. MANAGEMENT OF EARLY BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							RADIATION-THERAPY; MASTECTOMY; EXPERIENCE; PROGNOSIS				RUBENS, RD (corresponding author), GUYS HOSP,DEPT CLIN ONCOL,LONDON SE1 9RT,ENGLAND.							AMALRIC R, 1982, CANCER-AM CANCER SOC, V49, P30, DOI 10.1002/1097-0142(19820101)49:1<30::AID-CNCR2820490107>3.0.CO;2-L; ANDERSSON M, 1991, J NATL CANCER I, V83, P1013, DOI 10.1093/jnci/83.14.1013; ATKINS H, 1972, BRIT MED J, V2, P423, DOI 10.1136/bmj.2.5811.423; BADWE RA, 1991, LANCET, V337, P1261, DOI 10.1016/0140-6736(91)92927-T; BONADONNA G, 1990, J NATL CANCER I, V82, P1539, DOI 10.1093/jnci/82.19.1539; CALLE R, 1978, CANCER-AM CANCER SOC, V42, P2045, DOI 10.1002/1097-0142(197810)42:4<2045::AID-CNCR2820420455>3.0.CO;2-8; COLEMAN RE, 1988, J NUCL MED, V29, P1045; DAVIES GC, 1980, ANN SURG, V192, P148, DOI 10.1097/00000658-198008000-00002; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FENTIMAN IS, 1991, EUR J CANCER, V27, P447, DOI 10.1016/0277-5379(91)90383-O; FENTIMAN IS, 1990, DETECTION TREATMENT, P79; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; GOLDHIRSCH A, 1991, EUR J CANCER, V27, P389, DOI 10.1016/0277-5379(91)90552-O; HAYWARD JL, 1984, SURGERY, V95, P270; HOLDENER EE, 1984, RECENT RES CANCER, P188; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; OREILLY SM, 1990, BRIT J CANCER, V61, P671, DOI 10.1038/bjc.1990.152; OREILLY SM, 1990, J CLIN ONCOL, V8, P2040, DOI 10.1200/JCO.1990.8.12.2040; PIERQUIN B, 1980, INT J RADIAT ONCOL, V6, P17, DOI 10.1016/0360-3016(80)90197-2; RAMIREZ AJ, 1989, BRIT MED J, V298, P291, DOI 10.1136/bmj.298.6669.291; STEWART JF, 1983, EUR J CANCER CLIN ON, V19, P1381, DOI 10.1016/0277-5379(93)90007-R; VERONESI U, 1986, EUR J CANCER CLIN ON, V22, P1085, DOI 10.1016/0277-5379(86)90011-8; 1992, LANCET, V339, P71	25	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 23	1992	304	6838					1361	1364		10.1136/bmj.304.6838.1361	http://dx.doi.org/10.1136/bmj.304.6838.1361			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HW417	1611338	Green Published, Bronze			2022-12-28	WOS:A1992HW41700030
J	CROFT, P; COGGON, D; CRUDDAS, M; COOPER, C				CROFT, P; COGGON, D; CRUDDAS, M; COOPER, C			OSTEOARTHRITIS OF THE HIP - AN OCCUPATIONAL-DISEASE IN FARMERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To test the hypothesis that farmers are at high risk of hip osteoarthritis and to investigate possible causes for such a hazard. Design-Cross sectional survey. Setting-Five rural general practices. Subjects-167 male farmers aged 60-76 and 83 controls from mainly sedentary jobs. All those without previous hip replacement underwent radiography of the hip. Main outcome measures-Hip replacement for osteoarthritis or radiological evidence of hip osteoarthritis. Results-Prevalence of hip osteoarthritis was higher in farmers than controls and especially in those who had farmed for over 10 years (odds ratio 9.3, 95% confidence interval 1.9 to 44.5). The excess could not be attributed to any one type of farming, and heavy lifting seems the likely explanation. Conclusions-Manual handling in agriculture should be limited where possible. Consideration should be given to making hip osteoarthritis a prescribed industrial disease in farmers. There may be wider implications for the prevention of hip osteoarthritis in the general population.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND; UNIV MANCHESTER,AFRC,EPIDEMIOL RES UNIT,MANCHESTER M13 9PT,LANCS,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,DEPT MED,RHEUMATOL UNIT,BRISTOL BS2 8HW,AVON,ENGLAND	University of Southampton; University of Manchester; Bristol Royal Infirmary					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AXMACHER B, 1988, PROGR OCCUPATIONAL E, P203; CROFT P, 1990, AM J EPIDEMIOL, V132, P514, DOI 10.1093/oxfordjournals.aje.a115687; CROFT P, 1992, SCAND J WORK ENV HEA, V18, P59, DOI 10.5271/sjweh.1608; CROFT P, IN PRESS BR J RHEUMA; FRANK O, 1968, Z RHEUMAFORSCH, V27, P371; FRANKEL S, 1990, EPIDEMIOLOGICALLY BA; HAGGLUND G, 1984, CLIN ORTHOPAEDICS, V191, P81; JACOBSSON B, 1987, INT ORTHOP, V11, P311, DOI 10.1007/BF00271306; LINDBERG H, 1984, CLIN ORTHOP RELAT R, V191, P159; LOUYOT P, 1966, REV RHUM, V33, P625; ORDEBERG G, 1984, CLIN ORTHOPAEDICS, V191, P95; THELIN A, 1990, AM J IND MED, V18, P339, DOI 10.1002/ajim.4700180316; Typpti T., 1985, ANN CHIR GYNAEC S201, V74, P1; VANSAASE JLCM, 1989, ANN RHEUM DIS, V48, P271, DOI 10.1136/ard.48.4.271; VINGARD E, 1991, SCAND J WORK ENV HEA, V17, P104, DOI 10.5271/sjweh.1727; VINGARD E, 1991, WORK SPORTS OVERWEIG; WALSH K, 1991, SCAND J WORK ENV HEA, V17, P420, DOI 10.5271/sjweh.1680; WILCOCK GK, 1979, INT J EPIDEMIOL, V8, P247, DOI 10.1093/ije/8.3.247; 1986, OCCUPATIONAL MORTALI; 1979, DHEW PHS791161 PUBL	20	157	158	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 16	1992	304	6837					1269	1272		10.1136/bmj.304.6837.1269	http://dx.doi.org/10.1136/bmj.304.6837.1269			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HV086	1606427	Green Published, Bronze			2022-12-28	WOS:A1992HV08600017
